diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/adnexa_uterine_other.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/adnexa_uterine_other.json index 6f3a8b3e4..335292e91 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/adnexa_uterine_other.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/adnexa_uterine_other.json @@ -269,6 +269,6 @@ } ] } ], "involved_tables" : [ "seer_mets_48348", "neoadjuvant_therapy_37302", "nodes_pos_fpa", "grade_post_therapy_clin_69737", "neoadj_tx_clinical_response_31723", "histology", "nodes_exam_76029", "schema_selection_adnexa_uterine_other", "tumor_size_summary_63115", "combined_grade_56638", "behavior", "nodes_dcc", "grade_clinical_standard_non_ajcc_32473", "grade_pathological_standard_non_ajcc_5627", "adnexa_uterine_other_97891", "derived_grade_standard_non_ajcc_63932", "type_of_reporting_source_76696", "tumor_size_pathological_25597", "tumor_size_clinical_60979", "neoadj_tx_treatment_effect_18122", "primary_site", "ss2018_adnexa_uterine_other_values_44976", "grade_post_therapy_path_75348", "year_dx_validation", "summary_stage_rpa", "extension_bcn" ], - "last_modified" : "2025-09-19T18:55:02.447Z", + "last_modified" : "2025-11-14T20:05:07.419Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/adrenal_gland.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/adrenal_gland.json index eae701aaa..589aaa5a0 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/adrenal_gland.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/adrenal_gland.json @@ -269,6 +269,6 @@ } ] } ], "involved_tables" : [ "grade_clinical_26293", "neoadjuvant_therapy_37302", "grade_post_therapy_clin_53870", "tumor_size_pathological_43328", "nodes_pos_fpa", "neoadj_tx_clinical_response_31723", "histology", "nodes_exam_76029", "combined_grade_56638", "behavior", "derived_ss2018_adrenal_gland_258", "grade_pathological_38051", "tumor_size_clinical_48894", "schema_selection_adrenal_gland", "eod_mets_13303", "seer_primary_tumor_44962", "type_of_reporting_source_76696", "ss2018_adrenal_gland_including_net_adrenal_70096", "neoadj_tx_treatment_effect_18122", "primary_site", "derived_grade_24813", "year_dx_validation", "summary_stage_rpa", "tumor_size_summary_47973", "grade_post_therapy_path_93034", "eod_regional_nodes_22383" ], - "last_modified" : "2025-09-19T18:54:59.410Z", + "last_modified" : "2025-11-14T20:05:12.348Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/ampulla_vater.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/ampulla_vater.json index 37df9c4f0..b536cf34a 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/ampulla_vater.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/ampulla_vater.json @@ -269,6 +269,6 @@ } ] } ], "involved_tables" : [ "grade_post_therapy_clin_61658", "neoadjuvant_therapy_37302", "grade_clinical_6485", "nodes_pos_fpa", "extension_bde", "neoadj_tx_clinical_response_31723", "histology", "nodes_exam_76029", "mets_har", "tumor_size_summary_63115", "derived_ss2018_ampulla_of_vater_2679", "combined_grade_56638", "behavior", "grade_post_therapy_path_40048", "ss2018_ampulla_of_vater_including_net_96311", "schema_selection_ampulla_vater", "type_of_reporting_source_76696", "tumor_size_pathological_25597", "tumor_size_clinical_60979", "neoadj_tx_treatment_effect_18122", "primary_site", "grade_pathological_84704", "nodes_dbo", "year_dx_validation", "derived_grade_69945", "summary_stage_rpa" ], - "last_modified" : "2025-09-19T18:54:43.340Z", + "last_modified" : "2025-11-14T20:05:36.777Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/anus.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/anus.json index 06acb29f8..b77bfae62 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/anus.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/anus.json @@ -270,6 +270,6 @@ } ] } ], "involved_tables" : [ "grade_post_therapy_path_3704", "grade_pathological_93273", "neoadjuvant_therapy_37302", "tumor_size_pathological_43328", "eod_mets_41985", "nodes_pos_fpa", "neoadj_tx_treatment_effect_90678", "ss2018_anus_55561", "neoadj_tx_clinical_response_31723", "grade_post_therapy_clin_93593", "derived_grade_97763", "histology", "nodes_exam_76029", "combined_grade_56638", "behavior", "nodes_dab", "tumor_size_clinical_48894", "derived_ss2018_anus_8409", "type_of_reporting_source_76696", "grade_clinical_88426", "schema_selection_anus", "extension_baa", "primary_site", "year_dx_validation", "summary_stage_rpa", "tumor_size_summary_47973" ], - "last_modified" : "2025-09-19T18:54:46.939Z", + "last_modified" : "2025-11-14T20:05:37.199Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/anus_v9_2023.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/anus_v9_2023.json index 55aff05c1..d0acbd42d 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/anus_v9_2023.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/anus_v9_2023.json @@ -291,6 +291,6 @@ } ] } ], "involved_tables" : [ "grade_post_therapy_path_3704", "grade_pathological_93273", "neoadjuvant_therapy_37302", "tumor_size_pathological_43328", "nodes_pos_fpa", "neoadj_tx_treatment_effect_90678", "ss2018_anus_55561", "eod_mets_14084", "neoadj_tx_clinical_response_31723", "grade_post_therapy_clin_93593", "p16_anus_2709", "derived_grade_97763", "histology", "nodes_exam_76029", "eod_regional_nodes_30921", "combined_grade_56638", "behavior", "tumor_size_clinical_48894", "derived_ss2018_anus_8409", "type_of_reporting_source_76696", "grade_clinical_88426", "primary_site", "eod_primary_tumor_v9_58724", "schema_selection_anus_v9_2023", "year_dx_validation", "summary_stage_rpa", "tumor_size_summary_47973" ], - "last_modified" : "2025-09-19T18:54:43.666Z", + "last_modified" : "2025-11-14T20:05:52.007Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/appendix.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/appendix.json index 1987c82a1..b416b93cf 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/appendix.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/appendix.json @@ -302,6 +302,6 @@ } ] } ], "involved_tables" : [ "neoadjuvant_therapy_37302", "nodes_dfc", "mets_hcf", "nodes_pos_fpa", "extension_bfg", "neoadj_tx_clinical_response_31723", "histology", "nodes_exam_76029", "derived_grade_21657", "derived_ss2018_appendix_76889", "tumor_size_summary_63115", "combined_grade_56638", "behavior", "ss2018_appendix_including_netl_54459", "grade_clinical_29193", "cea_pretx_lab_value_33864", "type_of_reporting_source_76696", "tumor_size_pathological_25597", "tumor_size_clinical_60979", "cea_pretx_interpretation_99474", "neoadj_tx_treatment_effect_18122", "schema_selection_appendix", "primary_site", "grade_post_therapy_clin_45036", "grade_post_therapy_path_28874", "year_dx_validation", "summary_stage_rpa", "grade_pathological_57271" ], - "last_modified" : "2025-09-19T18:55:04.288Z", + "last_modified" : "2025-11-14T20:05:04.624Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/appendix_v9_2023.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/appendix_v9_2023.json index 30b7d0b5a..138fa388f 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/appendix_v9_2023.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/appendix_v9_2023.json @@ -322,6 +322,6 @@ } ] } ], "involved_tables" : [ "neoadjuvant_therapy_37302", "eod_mets_89986", "nodes_pos_fpa", "histologic_subtype_8603", "neoadj_tx_clinical_response_31723", "histology", "nodes_exam_76029", "derived_grade_21657", "derived_ss2018_appendix_76889", "tumor_size_summary_63115", "combined_grade_56638", "behavior", "eod_regional_nodes_62689", "ss2018_appendix_including_netl_54459", "grade_clinical_29193", "cea_pretx_lab_value_33864", "type_of_reporting_source_76696", "tumor_size_pathological_25597", "schema_selection_appendix_v9_2023", "tumor_size_clinical_60979", "cea_pretx_interpretation_99474", "neoadj_tx_treatment_effect_18122", "primary_site", "grade_post_therapy_clin_45036", "grade_post_therapy_path_28874", "year_dx_validation", "summary_stage_rpa", "grade_pathological_57271", "eod_primary_tumor_93243" ], - "last_modified" : "2025-09-19T18:54:37.404Z", + "last_modified" : "2025-11-14T20:05:05.005Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/bile_ducts_distal.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/bile_ducts_distal.json index e619dd0a9..aad33daea 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/bile_ducts_distal.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/bile_ducts_distal.json @@ -289,6 +289,6 @@ } ] } ], "involved_tables" : [ "grade_post_therapy_clin_61658", "neoadjuvant_therapy_37302", "tumor_size_pathological_43328", "mets_hcq", "nodes_dfn", "grade_clinical_6485", "nodes_pos_fpa", "neoadj_tx_clinical_response_31723", "histology", "nodes_exam_76029", "combined_grade_56638", "extension_bfs", "behavior", "tumor_size_clinical_48894", "grade_post_therapy_path_40048", "derived_ss2018_extrahepatic_bile_ducts_37420", "bileductsdistal_bileductsperihilar_cysticduct_24541", "schema_selection_bile_ducts_distal", "type_of_reporting_source_76696", "neoadj_tx_treatment_effect_18122", "primary_site", "ss2018_extrahepatic_bile_ducts_65728", "grade_pathological_84704", "year_dx_validation", "derived_grade_69945", "summary_stage_rpa", "tumor_size_summary_47973" ], - "last_modified" : "2025-09-19T18:54:39.980Z", + "last_modified" : "2025-11-14T20:05:37.676Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/bile_ducts_intrahepat.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/bile_ducts_intrahepat.json index 06815b112..710615eb2 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/bile_ducts_intrahepat.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/bile_ducts_intrahepat.json @@ -235,7 +235,7 @@ }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", "start" : 2018, - "end" : 2025 + "end" : 2023 } ] }, { "key" : "prim_scleros_cholangitis", @@ -322,6 +322,6 @@ } ] } ], "involved_tables" : [ "tumor_growth_pattern_31889", "ss2018_intrahepatic_bile_ducts_51957", "grade_post_therapy_clin_61658", "neoadjuvant_therapy_37302", "tumor_size_pathological_43328", "grade_clinical_6485", "nodes_pos_fpa", "neoadj_tx_clinical_response_31723", "fibrosis_score_38658", "histology", "nodes_exam_76029", "combined_grade_56638", "behavior", "nodes_dew", "tumor_size_clinical_48894", "grade_post_therapy_path_40048", "type_of_reporting_source_76696", "primary_scleros_cholangitis_86402", "extension_bfa", "neoadj_tx_treatment_effect_18122", "mets_hbz", "primary_site", "derived_ss2018_intrahepatic_bile_ducts_29879", "grade_pathological_84704", "year_dx_validation", "derived_grade_69945", "summary_stage_rpa", "schema_selection_bile_ducts_intrahepat", "tumor_size_summary_47973" ], - "last_modified" : "2025-09-19T18:54:40.214Z", + "last_modified" : "2025-11-14T20:05:38.083Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/bile_ducts_perihilar.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/bile_ducts_perihilar.json index 3eb27d8ff..074a34992 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/bile_ducts_perihilar.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/bile_ducts_perihilar.json @@ -306,6 +306,6 @@ } ] } ], "involved_tables" : [ "grade_post_therapy_clin_61658", "neoadjuvant_therapy_37302", "extension_bft", "mets_hcr", "grade_clinical_6485", "nodes_pos_fpa", "nodes_dfo", "neoadj_tx_clinical_response_31723", "schema_selection_bile_ducts_perihilar", "histology", "nodes_exam_76029", "tumor_size_summary_63115", "combined_grade_56638", "behavior", "grade_post_therapy_path_40048", "derived_ss2018_extrahepatic_bile_ducts_37420", "bileductsdistal_bileductsperihilar_cysticduct_24541", "type_of_reporting_source_76696", "primary_scleros_cholangitis_86402", "tumor_size_pathological_25597", "tumor_size_clinical_60979", "neoadj_tx_treatment_effect_18122", "primary_site", "ss2018_extrahepatic_bile_ducts_65728", "grade_pathological_84704", "year_dx_validation", "derived_grade_69945", "summary_stage_rpa" ], - "last_modified" : "2025-09-19T18:54:40.428Z", + "last_modified" : "2025-11-14T20:05:38.451Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/biliary_other.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/biliary_other.json index 87df5faa7..edd5fbd54 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/biliary_other.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/biliary_other.json @@ -269,6 +269,6 @@ } ] } ], "involved_tables" : [ "seer_mets_48348", "neoadjuvant_therapy_37302", "nodes_pos_fpa", "grade_post_therapy_clin_69737", "neoadj_tx_clinical_response_31723", "histology", "nodes_exam_76029", "derived_ss2018_biliary_other_47058", "tumor_size_summary_63115", "combined_grade_56638", "behavior", "schema_selection_biliary_other", "extension_bcx", "grade_clinical_standard_non_ajcc_32473", "grade_pathological_standard_non_ajcc_5627", "derived_grade_standard_non_ajcc_63932", "type_of_reporting_source_76696", "nodes_dcl", "tumor_size_pathological_25597", "tumor_size_clinical_60979", "neoadj_tx_treatment_effect_18122", "primary_site", "grade_post_therapy_path_75348", "year_dx_validation", "summary_stage_rpa", "adnexa_uterine_other_36223" ], - "last_modified" : "2025-09-19T18:54:37.674Z", + "last_modified" : "2025-11-14T20:05:07.711Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/bladder.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/bladder.json index be771d8a9..cd54228f6 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/bladder.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/bladder.json @@ -269,6 +269,6 @@ } ] } ], "involved_tables" : [ "neoadjuvant_therapy_37302", "nodes_pos_fpa", "derived_ss2018_bladder_71090", "neoadj_tx_clinical_response_31723", "grade_post_therapy_path_55848", "histology", "nodes_exam_76029", "tumor_size_summary_63115", "combined_grade_56638", "behavior", "derived_grade_84046", "schema_selection_bladder", "nodes_dck", "type_of_reporting_source_76696", "tumor_size_pathological_25597", "tumor_size_clinical_60979", "neoadj_tx_treatment_effect_18122", "primary_site", "grade_pathological_59975", "extension_bcb", "grade_post_therapy_clin_68213", "year_dx_validation", "ss2018_bladder_57733", "summary_stage_rpa", "eod_mets_91004", "grade_clinical_91989" ], - "last_modified" : "2025-09-19T18:55:10.354Z", + "last_modified" : "2025-11-14T20:05:38.836Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/bone_appendicular_skeleton.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/bone_appendicular_skeleton.json index 29bee4549..e95d9c5fc 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/bone_appendicular_skeleton.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/bone_appendicular_skeleton.json @@ -234,7 +234,7 @@ }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", "start" : 2018, - "end" : 2025 + "end" : 2023 } ] } ], "outputs" : [ { @@ -287,6 +287,6 @@ } ] } ], "involved_tables" : [ "derived_ss2018_bone_34531", "neoadjuvant_therapy_37302", "tumor_size_pathological_43328", "ss2018_validation", "nodes_dbh", "nodes_pos_fpa", "neoadj_tx_clinical_response_31723", "ajcc_path_grade_3_70197", "histology", "nodes_exam_76029", "post_neoadj_chemo_percent_necrosis_15912", "neoadj_tx_treatment_effect_4391", "combined_grade_56638", "derived_grade_8564", "mets_hav", "seer_primary_tumor_38025", "grade_post_therapy_clin_4232", "grade_post_therapy_path_25809", "tumor_size_clinical_48894", "ajcc_grade_3_94758", "type_of_reporting_source_76696", "primary_site", "year_dx_validation", "summary_stage_rpa", "schema_selection_bone_appendicular_skeleton", "tumor_size_summary_47973" ], - "last_modified" : "2025-09-19T18:54:45.439Z", + "last_modified" : "2025-11-14T20:06:13.985Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/bone_pelvis.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/bone_pelvis.json index 35da1f0bb..300101d95 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/bone_pelvis.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/bone_pelvis.json @@ -234,7 +234,7 @@ }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", "start" : 2018, - "end" : 2025 + "end" : 2023 } ] } ], "outputs" : [ { @@ -287,6 +287,6 @@ } ] } ], "involved_tables" : [ "derived_ss2018_bone_34531", "neoadjuvant_therapy_37302", "tumor_size_pathological_43328", "ss2018_validation", "nodes_dbh", "nodes_pos_fpa", "neoadj_tx_clinical_response_31723", "ajcc_path_grade_3_70197", "histology", "nodes_exam_76029", "post_neoadj_chemo_percent_necrosis_15912", "neoadj_tx_treatment_effect_4391", "combined_grade_56638", "derived_grade_8564", "mets_hav", "grade_post_therapy_clin_4232", "grade_post_therapy_path_25809", "tumor_size_clinical_48894", "ajcc_grade_3_94758", "type_of_reporting_source_76696", "primary_site", "year_dx_validation", "summary_stage_rpa", "schema_selection_bone", "tumor_size_summary_47973", "eod_primary_tumor_42615" ], - "last_modified" : "2025-09-19T18:54:58.521Z", + "last_modified" : "2025-11-14T20:06:13.639Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/bone_spine.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/bone_spine.json index 49e181ddb..52a9327ea 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/bone_spine.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/bone_spine.json @@ -234,7 +234,7 @@ }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", "start" : 2018, - "end" : 2025 + "end" : 2023 } ] } ], "outputs" : [ { @@ -287,6 +287,6 @@ } ] } ], "involved_tables" : [ "derived_ss2018_bone_34531", "neoadjuvant_therapy_37302", "ss2018_validation", "nodes_dbh", "schema_selection_bone_spine", "nodes_pos_fpa", "neoadj_tx_clinical_response_31723", "ajcc_path_grade_3_70197", "histology", "nodes_exam_76029", "post_neoadj_chemo_percent_necrosis_15912", "eod_primary_tumor_72332", "neoadj_tx_treatment_effect_4391", "tumor_size_summary_63115", "combined_grade_56638", "derived_grade_8564", "mets_hav", "grade_post_therapy_clin_4232", "grade_post_therapy_path_25809", "ajcc_grade_3_94758", "type_of_reporting_source_76696", "tumor_size_pathological_25597", "tumor_size_clinical_60979", "primary_site", "year_dx_validation", "summary_stage_rpa" ], - "last_modified" : "2025-09-19T18:54:56.802Z", + "last_modified" : "2025-11-14T20:05:19.396Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/brain.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/brain.json index a50017eb9..331bb87b4 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/brain.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/brain.json @@ -333,6 +333,6 @@ } ] } ], "involved_tables" : [ "derived_ss2018_brain_35480", "neoadjuvant_therapy_37302", "mgmt_17454", "grade_post_therapy_path_86055", "chromosome_1p_status_40269", "nodes_exam_dna_95635", "neoadj_tx_clinical_response_31723", "histology", "chromosome_19q_status_72683", "tumor_size_summary_63115", "combined_grade_56638", "behavior", "grade_clinical_19997", "nodes_dna", "mets_haw", "summary_stage_benign_3306", "type_of_reporting_source_76696", "tumor_size_pathological_25597", "tumor_size_clinical_60979", "grade_pathological_11803", "derived_grade_12594", "schema_selection_brain", "neoadj_tx_treatment_effect_18122", "extension_bcc", "primary_site", "grade_post_therapy_clin_26948", "year_dx_validation", "brain_molecular_markers_75370", "ss2018_brain_67865", "nodes_pos_dna_91511" ], - "last_modified" : "2025-09-19T18:54:34.315Z", + "last_modified" : "2025-11-14T20:05:14.975Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/brain_v9_2023.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/brain_v9_2023.json index 4e8a6908d..a42e721e2 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/brain_v9_2023.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/brain_v9_2023.json @@ -356,6 +356,6 @@ } ] } ], "involved_tables" : [ "derived_ss2018_brain_35480", "neoadjuvant_therapy_37302", "mgmt_17454", "schema_selection_brain_v9_2023", "eod_primary_tumor_84520", "chromosome_1p_status_40269", "nodes_exam_dna_95635", "grade_post_therapy_path_yp_3519", "grade_pathological_53280", "neoadj_tx_clinical_response_31723", "eod_mets_28878", "histology", "chromosome_19q_status_72683", "grade_clinical_78613", "grade_post_therapy_clin_yc_55565", "tumor_size_summary_63115", "combined_grade_56638", "behavior", "nodes_dna", "brain_primary_tumor_location_69074", "summary_stage_benign_3306", "type_of_reporting_source_76696", "tumor_size_pathological_25597", "tumor_size_clinical_60979", "brain_molecular_markers_v9_48556", "neoadj_tx_treatment_effect_18122", "derived_grade_96207", "primary_site", "year_dx_validation", "ss2018_brain_67865", "nodes_pos_dna_91511" ], - "last_modified" : "2025-09-19T18:54:37.085Z", + "last_modified" : "2025-11-14T20:05:54.312Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/breast.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/breast.json index 5cfec31d6..45edbf98a 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/breast.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/breast.json @@ -384,7 +384,7 @@ }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", "start" : 2018, - "end" : 2025 + "end" : 2023 } ] }, { "key" : "multigene_signature_method", @@ -401,7 +401,7 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 } ] }, { "key" : "multigene_signature_result", @@ -418,7 +418,7 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 } ] }, { "key" : "response_neoadjuv_therapy", @@ -457,7 +457,7 @@ "key" : "rcb_class", "name" : "RCB Class", "naaccr_item" : 1179, - "naaccr_xml_id" : "rcbClass", + "naaccr_xml_id" : "residualCancerBurdenClass", "default" : "8", "table" : "rcb_class_750", "used_for_staging" : false, @@ -490,7 +490,7 @@ }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", "start" : 2018, - "end" : 2025 + "end" : 2023 } ] }, { "key" : "oncotype_dx_risk_level_dcis", @@ -511,7 +511,7 @@ }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", "start" : 2018, - "end" : 2025 + "end" : 2023 } ] }, { "key" : "er_allred_score", @@ -719,6 +719,6 @@ } ] } ], "involved_tables" : [ "neoadjuvant_therapy_37302", "her2_ish_sp_copy_no_95955", "er_percent_positive_61867", "oncotype_dx_recur_score_73667", "grade_post_therapy_clin_88214", "her2_ish_summary_40783", "grade_pathological_47031", "schema_selection_breast", "ss2018_breast_69079", "neoadj_tx_clinical_response_31723", "histology", "sentinel_nodes_pos_95909", "rcb_class_750", "nodes_exam_76029", "nodes_pos_fab", "er_summary_44166", "her2_summary_30512", "her2_ish_dp_copy_no_89821", "tumor_size_clinical_breast_34385", "combined_grade_breast_8723", "her2_ish_dual_probe_ration_4635", "nodes_daj", "type_of_reporting_source_76696", "her2_ihc_summary_57693", "pr_allred_score_83938", "sentinel_nodes_exam_7235", "summary_stage_rpa", "extension_bak", "tumor_size_pathological_breast_85445", "pr_summary_49534", "oncotype_dx_risk_level_11033", "multigene_signature_result_37000", "derived_ss2018_breast_7622", "ki67_8355", "oncotype_dx_recurrence_score_dcis_70549", "grade_post_therapy_path_47044", "response_to_neoadjuvant_therapy_57695", "er_allred_score_36612", "grade_clinical_91491", "pr_percent_positive_94563", "mets_hau", "behavior", "neoadj_tx_treatment_effect_34708", "multigene_signature_method_85043", "behavior_with_primary_tumor_for_ss2018_t_69793", "derived_grade_76001", "primary_site", "number_of_positive_ipsilateral_level_i_ii_axillary_lymph_nodes_79439", "tumor_size_summary_breast_14624", "year_dx_validation", "oncotype_dx_risk_level_dcis_53080", "residual_cancer_burden_62520" ], - "last_modified" : "2025-09-19T18:54:57.644Z", + "last_modified" : "2025-11-14T20:06:13.255Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/buccal_mucosa.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/buccal_mucosa.json index 6a7ac50cb..0e01ca14d 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/buccal_mucosa.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/buccal_mucosa.json @@ -250,10 +250,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] }, { "key" : "ln_size_of_mets", @@ -272,10 +272,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] }, { "key" : "seer_ssf1", @@ -339,6 +339,6 @@ } ] } ], "involved_tables" : [ "extranodal_extension_head_and_neck_pathological_87046", "eod_primary_tumor_50451", "grade_post_therapy_clin_61658", "neoadjuvant_therapy_37302", "tumor_size_pathological_43328", "grade_clinical_6485", "nodes_pos_fpa", "schema_selection_buccal_mucosa", "neoadj_tx_clinical_response_31723", "histology", "nodes_exam_76029", "combined_grade_56638", "behavior", "derived_ss2018_buccal_mucosa_61240", "nodes_daa", "tumor_size_clinical_48894", "seer_mets_lip_lower_28596", "grade_post_therapy_path_40048", "type_of_reporting_source_76696", "neoadj_tx_treatment_effect_18122", "p16_hpv_human_papilloma_virus_status_head_and_neck_509", "primary_site", "extranodal_extension_head_and_neck_clinical_79321", "grade_pathological_84704", "year_dx_validation", "derived_grade_69945", "summary_stage_rpa", "tumor_size_summary_47973", "ln_size_70140", "ss2018_buccal_mucosa_94903" ], - "last_modified" : "2025-09-19T18:54:54.380Z", + "last_modified" : "2025-11-14T20:06:03.569Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/cervical_lymph_nodes_occult_head_neck.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/cervical_lymph_nodes_occult_head_neck.json index e8e207a7f..a6757da28 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/cervical_lymph_nodes_occult_head_neck.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/cervical_lymph_nodes_occult_head_neck.json @@ -271,10 +271,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] }, { "key" : "ln_size_of_mets", @@ -293,10 +293,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] }, { "key" : "ln_hn_1_2_3", @@ -313,10 +313,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] }, { "key" : "ln_hn_4_5", @@ -333,10 +333,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] }, { "key" : "ln_hn_6_7", @@ -353,10 +353,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] }, { "key" : "ln_hn_other", @@ -373,10 +373,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] } ], "outputs" : [ { @@ -429,6 +429,6 @@ } ] } ], "involved_tables" : [ "extranodal_extension_head_and_neck_pathological_87046", "neoadjuvant_therapy_37302", "lymph_nodes_head_and_neck_levels_i_iii_19222", "occult_head_and_neck_lymph_nodes_10277", "nodes_pos_fpa", "eod_regional_nodes_77237", "neoadj_tx_clinical_response_31723", "histology", "nodes_exam_76029", "tumor_size_summary_63115", "combined_grade_56638", "behavior", "grade_post_therapy_clin_95734", "grade_clinical_standard_94331", "lymph_nodes_head_and_neck_other_31141", "derived_grade_standard_1196", "lymph_nodes_head_and_neck_levels_vi_vii_32325", "eod_primary_tumor_85962", "type_of_reporting_source_76696", "tumor_size_pathological_25597", "tumor_size_clinical_60979", "neoadj_tx_treatment_effect_18122", "primary_site", "eod_mets_98654", "extranodal_extension_head_and_neck_clinical_79321", "grade_pathological_standard_94268", "year_dx_validation", "ss2018_cervical_lymph_nodes_and_unknown_primary_tumor_8991", "derived_ss2018_cervical_lymph_nodes_and_unknown_primary_tumors_of_head_and_neck_49724", "lymph_nodes_head_and_neck_levels_iv_v_55093", "summary_stage_rpa", "grade_post_therapy_path_32110", "ln_size_70140", "schema_selection_cervical_lymph_nodes_occult_head_and_neck" ], - "last_modified" : "2025-09-19T18:55:11.528Z", + "last_modified" : "2025-11-14T20:06:15.667Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/cervix.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/cervix.json index 865b36611..41f7d3873 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/cervix.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/cervix.json @@ -377,6 +377,6 @@ } ] } ], "involved_tables" : [ "lymph_nodes_distant_assessment_method_24499", "grade_post_therapy_clin_61658", "neoadjuvant_therapy_37302", "nodes_dbc", "mets_han", "tumor_size_pathological_43328", "grade_clinical_6485", "nodes_pos_fpa", "ln_status_para_aortic_41020", "neoadj_tx_clinical_response_31723", "histology", "nodes_exam_76029", "extension_bbk", "combined_grade_56638", "behavior", "figo_stage_cervix_46535", "tumor_size_clinical_48894", "grade_post_therapy_path_40048", "derived_ss2018_cervix_8763", "type_of_reporting_source_76696", "neoadj_tx_treatment_effect_18122", "lymph_nodes_assessment_method_pelvic_33476", "primary_site", "schema_selection_cervix", "lymph_nodes_distant_mediastinal_scalene_90567", "ss2018_cervix_64954", "ln_status_pelvic_31753", "grade_pathological_84704", "year_dx_validation", "lymph_nodes_assessment_method_para_aortic_56026", "derived_grade_69945", "summary_stage_rpa", "tumor_size_summary_47973" ], - "last_modified" : "2025-09-19T18:55:08.355Z", + "last_modified" : "2025-11-14T20:05:20.221Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/cervix_9th_2021.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/cervix_9th_2021.json index df9dbbc8a..c91f4ebec 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/cervix_9th_2021.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/cervix_9th_2021.json @@ -234,10 +234,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2021, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] }, { "key" : "p16", @@ -405,6 +405,6 @@ } ] } ], "involved_tables" : [ "lymph_nodes_distant_assessment_method_24499", "grade_post_therapy_clin_61658", "neoadjuvant_therapy_37302", "schema_selection_cervix_9th_2021", "tumor_size_pathological_43328", "grade_clinical_6485", "nodes_pos_fpa", "ln_status_para_aortic_41020", "neoadj_tx_clinical_response_31723", "eod_regional_nodes_92760", "histology", "nodes_exam_76029", "eod_primary_tumor_97833", "combined_grade_56638", "behavior", "figo_stage_cervix_46535", "tumor_size_clinical_48894", "grade_post_therapy_path_40048", "derived_ss2018_cervix_8763", "type_of_reporting_source_76696", "neoadj_tx_treatment_effect_18122", "lymph_nodes_assessment_method_pelvic_33476", "primary_site", "lymph_nodes_distant_mediastinal_scalene_90567", "ss2018_cervix_64954", "ln_status_pelvic_31753", "eod_mets_24606", "grade_pathological_84704", "year_dx_validation", "lymph_nodes_assessment_method_para_aortic_56026", "derived_grade_69945", "summary_stage_rpa", "p16_19452", "tumor_size_summary_47973" ], - "last_modified" : "2025-09-19T18:55:04.013Z", + "last_modified" : "2025-11-14T20:06:12.012Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/cervix_sarcoma.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/cervix_sarcoma.json index 26843c6e6..ee8be087c 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/cervix_sarcoma.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/cervix_sarcoma.json @@ -234,10 +234,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] }, { "key" : "num_pos_pelvic_nodes", @@ -365,6 +365,6 @@ } ] } ], "involved_tables" : [ "neoadjuvant_therapy_37302", "tumor_size_pathological_43328", "number_of_postive_pelvic_nodes_94512", "grade_clinical_83264", "nodes_pos_fpa", "peritoneal_cytology_with_primary_tumor_for_ss2018_t_88427", "neoadj_tx_clinical_response_31723", "histology", "nodes_exam_76029", "figo_stage_corpus_sarcoma_78807", "combined_grade_56638", "behavior", "peritoneal_cytology_38674", "number_of_positive_para_aortic_nodes_62533", "tumor_size_clinical_48894", "eod_mets_79894", "grade_pathological_4783", "derived_ss2018_cervix_8763", "grade_post_therapy_path_87571", "type_of_reporting_source_76696", "eod_regional_nodes_10020", "derived_grade_10693", "neoadj_tx_treatment_effect_18122", "eod_primary_tumor_4717", "primary_site", "ss2018_cervix_64954", "number_of_examined_para_aortic_nodes_38078", "grade_post_therapy_clin_21162", "schema_selection_cervix_sarcoma", "number_of_examined_pelvic_nodes_60771", "year_dx_validation", "summary_stage_rpa", "tumor_size_summary_47973" ], - "last_modified" : "2025-09-19T18:55:02.131Z", + "last_modified" : "2025-11-14T20:05:52.450Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/cns_other.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/cns_other.json index 8fd61ff3e..6353563d3 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/cns_other.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/cns_other.json @@ -330,6 +330,6 @@ } ] } ], "involved_tables" : [ "neoadjuvant_therapy_37302", "mgmt_17454", "grade_post_therapy_path_86055", "chromosome_1p_status_40269", "nodes_exam_dna_95635", "neoadj_tx_clinical_response_31723", "schema_selection_cns_other", "histology", "chromosome_19q_status_72683", "tumor_size_summary_63115", "combined_grade_56638", "behavior", "grade_clinical_19997", "nodes_dna", "mets_haw", "derived_ss2018_cns_other_22397", "summary_stage_benign_3306", "type_of_reporting_source_76696", "tumor_size_pathological_25597", "tumor_size_clinical_60979", "grade_pathological_11803", "derived_grade_12594", "neoadj_tx_treatment_effect_18122", "extension_bcd", "ss2018_cns_other_67712", "primary_site", "grade_post_therapy_clin_26948", "year_dx_validation", "brain_molecular_markers_75370", "nodes_pos_dna_91511" ], - "last_modified" : "2025-09-19T18:54:53.868Z", + "last_modified" : "2025-11-14T20:05:15.319Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/cns_other_v9_2023.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/cns_other_v9_2023.json index 035f05169..88bba34b0 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/cns_other_v9_2023.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/cns_other_v9_2023.json @@ -330,6 +330,6 @@ } ] } ], "involved_tables" : [ "neoadjuvant_therapy_37302", "mgmt_17454", "chromosome_1p_status_40269", "nodes_exam_dna_95635", "grade_post_therapy_path_yp_3519", "grade_pathological_53280", "neoadj_tx_clinical_response_31723", "histology", "chromosome_19q_status_72683", "grade_clinical_78613", "grade_post_therapy_clin_yc_55565", "tumor_size_summary_63115", "combined_grade_56638", "behavior", "eod_primary_tumor_40607", "nodes_dna", "derived_ss2018_cns_other_22397", "summary_stage_benign_3306", "eod_mets_24042", "type_of_reporting_source_76696", "tumor_size_pathological_25597", "tumor_size_clinical_60979", "brain_molecular_markers_v9_48556", "neoadj_tx_treatment_effect_18122", "derived_grade_96207", "ss2018_cns_other_67712", "primary_site", "year_dx_validation", "nodes_pos_dna_91511", "schema_selection_cns_other_v9_2023" ], - "last_modified" : "2025-09-19T18:54:59.718Z", + "last_modified" : "2025-11-14T20:05:54.894Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/colon_rectum.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/colon_rectum.json index a98f2b629..1c938b92f 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/colon_rectum.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/colon_rectum.json @@ -265,10 +265,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] }, { "key" : "perineural_invasion", @@ -423,6 +423,6 @@ } ] } ], "involved_tables" : [ "tumor_size_summary_full_15510", "nras_mutational_analysis_16621", "perineural_invasion_27557", "neoadjuvant_therapy_37302", "braf_mutational_analysis_37823", "kras_79447", "derived_grade_46639", "grade_post_therapy_path_41285", "ss2018_colon_and_rectum_including_net_40538", "grade_pathological_31963", "grade_post_therapy_clin_41222", "nodes_pos_fpa", "neoadj_tx_treatment_effect_90678", "mets_hae", "tumor_deposits_40070", "neoadj_tx_clinical_response_31723", "histology", "nodes_exam_76029", "schema_selection_colon", "nodes_dan", "derived_ss2018_colon_and_rectum_35271", "combined_grade_56638", "behavior", "tumor_size_pathological_full_93442", "circumferential_resection_margin_77909", "tumor_size_clinical_full_19656", "extension_bao", "cea_pretx_lab_value_33864", "type_of_reporting_source_76696", "cea_pretx_interpretation_99474", "primary_site", "microsatellite_instability_7008", "year_dx_validation", "grade_clinical_73056", "summary_stage_rpa" ], - "last_modified" : "2025-09-19T18:55:06.288Z", + "last_modified" : "2025-11-14T20:06:08.332Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/conjunctiva.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/conjunctiva.json index 82ba702e2..0081ee20a 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/conjunctiva.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/conjunctiva.json @@ -269,6 +269,6 @@ } ] } ], "involved_tables" : [ "neoadjuvant_therapy_37302", "tumor_size_pathological_43328", "derived_grade_46639", "grade_post_therapy_path_41285", "grade_pathological_31963", "grade_post_therapy_clin_41222", "eod_regional_nodes_58339", "nodes_pos_fpa", "schema_selection_conjunctiva", "neoadj_tx_clinical_response_31723", "histology", "nodes_exam_76029", "extension_bbj", "ss2018_conjunctiva_16779", "combined_grade_56638", "behavior", "eod_mets_56430", "tumor_size_clinical_48894", "type_of_reporting_source_76696", "neoadj_tx_treatment_effect_18122", "primary_site", "year_dx_validation", "grade_clinical_73056", "summary_stage_rpa", "derived_ss2018_conjunctiva_74486", "tumor_size_summary_47973" ], - "last_modified" : "2025-09-19T18:55:00.998Z", + "last_modified" : "2025-11-14T20:05:06.841Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/corpus_adenosarcoma.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/corpus_adenosarcoma.json index ae3eae8a3..4e9171c3f 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/corpus_adenosarcoma.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/corpus_adenosarcoma.json @@ -226,10 +226,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] }, { "key" : "num_pos_pelvic_nodes", @@ -357,6 +357,6 @@ } ] } ], "involved_tables" : [ "peritoneal_cytology_with_primary_tumor_for_ss2018_t_19664", "neoadjuvant_therapy_37302", "number_of_postive_pelvic_nodes_94512", "nodes_pos_fpa", "derived_ss2018_corpus_sarcoma_68247", "nodes_dfh", "eod_mets_26533", "neoadj_tx_clinical_response_31723", "histology", "nodes_exam_76029", "grade_post_therapy_clin_72770", "grade_post_therapy_path_48957", "tumor_size_summary_63115", "extension_bfl", "combined_grade_56638", "peritoneal_cytology_38674", "number_of_positive_para_aortic_nodes_62533", "ss2018_corpus_sarcoma_75896", "schema_selection_corpus_adenosarcoma", "figo_stage_corpus_adenosarcoma_24886", "derived_grade_91894", "type_of_reporting_source_76696", "tumor_size_pathological_25597", "tumor_size_clinical_60979", "grade_clinical_24620", "grade_pathological_40052", "neoadj_tx_treatment_effect_18122", "primary_site", "number_of_examined_para_aortic_nodes_38078", "number_of_examined_pelvic_nodes_60771", "year_dx_validation", "summary_stage_rpa" ], - "last_modified" : "2025-09-19T18:55:10.656Z", + "last_modified" : "2025-11-14T20:05:26.876Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/corpus_carcinoma.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/corpus_carcinoma.json index 5bf3c2562..90b1f1ca6 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/corpus_carcinoma.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/corpus_carcinoma.json @@ -233,10 +233,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] }, { "key" : "num_pos_pelvic_nodes", @@ -385,6 +385,6 @@ } ] } ], "involved_tables" : [ "ss2018_corpus_carcinoma_and_carcinosarcoma_28794", "neoadjuvant_therapy_37302", "derived_ss2018_corpus_carcinoma_and_carcinosarcoma_56302", "number_of_postive_pelvic_nodes_94512", "grade_clinical_83264", "nodes_pos_fpa", "nodes_dbd", "schema_selection_corpus_carcinoma", "neoadj_tx_clinical_response_31723", "histology", "nodes_exam_76029", "tumor_size_summary_63115", "combined_grade_56638", "figo_stage_corpus_carcinoma_and_carcinosarcoma_69186", "behavior", "microsatellite_instability_35598", "peritoneal_cytology_38674", "extension_bbl", "number_of_positive_para_aortic_nodes_62533", "peritoneal_cytology_with_primary_tumor_for_ss2018_t_66387", "grade_pathological_4783", "grade_post_therapy_path_87571", "type_of_reporting_source_76696", "tumor_size_pathological_25597", "tumor_size_clinical_60979", "derived_grade_10693", "neoadj_tx_treatment_effect_18122", "primary_site", "number_of_examined_para_aortic_nodes_38078", "grade_post_therapy_clin_21162", "eod_mets_30426", "number_of_examined_pelvic_nodes_60771", "year_dx_validation", "summary_stage_rpa" ], - "last_modified" : "2025-09-19T18:55:08.042Z", + "last_modified" : "2025-11-14T20:05:04.219Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/corpus_sarcoma.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/corpus_sarcoma.json index 2a2fab490..5e7733df1 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/corpus_sarcoma.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/corpus_sarcoma.json @@ -226,10 +226,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] }, { "key" : "num_pos_pelvic_nodes", @@ -357,6 +357,6 @@ } ] } ], "involved_tables" : [ "neoadjuvant_therapy_37302", "tumor_size_pathological_43328", "number_of_postive_pelvic_nodes_94512", "grade_clinical_83264", "nodes_pos_fpa", "derived_ss2018_corpus_sarcoma_68247", "nodes_dfh", "eod_mets_26533", "peritoneal_cytology_with_primary_tumor_for_ss2018_t_88427", "neoadj_tx_clinical_response_31723", "histology", "nodes_exam_76029", "extension_bfm", "figo_stage_corpus_sarcoma_78807", "combined_grade_56638", "peritoneal_cytology_38674", "number_of_positive_para_aortic_nodes_62533", "ss2018_corpus_sarcoma_75896", "schema_selection_corpus_sarcoma", "tumor_size_clinical_48894", "grade_pathological_4783", "grade_post_therapy_path_87571", "type_of_reporting_source_76696", "derived_grade_10693", "neoadj_tx_treatment_effect_18122", "primary_site", "number_of_examined_para_aortic_nodes_38078", "grade_post_therapy_clin_21162", "number_of_examined_pelvic_nodes_60771", "year_dx_validation", "summary_stage_rpa", "tumor_size_summary_47973" ], - "last_modified" : "2025-09-19T18:54:38.258Z", + "last_modified" : "2025-11-14T20:05:35.245Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/cutaneous_carcinoma_head_neck.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/cutaneous_carcinoma_head_neck.json index 7a674fb17..7abc357fa 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/cutaneous_carcinoma_head_neck.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/cutaneous_carcinoma_head_neck.json @@ -250,10 +250,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] }, { "key" : "high_risk_features", @@ -270,10 +270,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] } ], "outputs" : [ { @@ -326,6 +326,6 @@ } ] } ], "involved_tables" : [ "nodes_pos_fah", "neoadjuvant_therapy_37302", "tumor_size_pathological_43328", "derived_grade_46639", "grade_post_therapy_path_41285", "eod_regional_nodes_7080", "grade_pathological_31963", "grade_post_therapy_clin_41222", "summary_stage_rac", "neoadj_tx_clinical_response_31723", "histology", "nodes_exam_76029", "combined_grade_56638", "behavior", "tumor_size_clinical_48894", "derived_ss2018_skin_except_eyelid_95559", "type_of_reporting_source_76696", "high_risk_features_73750", "schema_selection_cutaneous_squamous_cell_carcinoma_head_and_neck", "eod_mets_3742", "neoadj_tx_treatment_effect_18122", "primary_site", "ss2018_skin_other_56341", "perineural_invasion_84622", "year_dx_validation", "grade_clinical_73056", "ln_size_70140", "tumor_size_summary_47973", "seer_primary_tumor_9084" ], - "last_modified" : "2025-09-19T18:55:04.556Z", + "last_modified" : "2025-11-14T20:06:07.898Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/cystic_duct.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/cystic_duct.json index 32f644e31..2cfa94842 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/cystic_duct.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/cystic_duct.json @@ -289,6 +289,6 @@ } ] } ], "involved_tables" : [ "extension_bfw", "grade_post_therapy_clin_61658", "neoadjuvant_therapy_37302", "grade_clinical_6485", "nodes_pos_fpa", "neoadj_tx_clinical_response_31723", "histology", "nodes_exam_76029", "mets_hcv", "tumor_size_summary_63115", "combined_grade_56638", "behavior", "grade_post_therapy_path_40048", "derived_ss2018_extrahepatic_bile_ducts_37420", "bileductsdistal_bileductsperihilar_cysticduct_24541", "type_of_reporting_source_76696", "tumor_size_pathological_25597", "tumor_size_clinical_60979", "neoadj_tx_treatment_effect_18122", "primary_site", "schema_selection_cystic_duct", "ss2018_extrahepatic_bile_ducts_65728", "grade_pathological_84704", "nodes_dfr", "year_dx_validation", "derived_grade_69945", "summary_stage_rpa" ], - "last_modified" : "2025-09-19T18:54:40.693Z", + "last_modified" : "2025-11-14T20:05:39.294Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/digestive_other.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/digestive_other.json index 3fd874b66..b059dffc3 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/digestive_other.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/digestive_other.json @@ -269,6 +269,6 @@ } ] } ], "involved_tables" : [ "seer_mets_48348", "neoadjuvant_therapy_37302", "schema_selection_digestive_other", "nodes_pos_fpa", "derived_ss2018_digestive_other_3351", "grade_post_therapy_clin_69737", "neoadj_tx_clinical_response_31723", "histology", "nodes_exam_76029", "tumor_size_summary_63115", "combined_grade_56638", "behavior", "grade_clinical_standard_non_ajcc_32473", "grade_pathological_standard_non_ajcc_5627", "derived_grade_standard_non_ajcc_63932", "type_of_reporting_source_76696", "ss2018_digestive_other_9136", "tumor_size_pathological_25597", "tumor_size_clinical_60979", "neoadj_tx_treatment_effect_18122", "primary_site", "extension_bcg", "grade_post_therapy_path_75348", "year_dx_validation", "nodes_dbx", "summary_stage_rpa" ], - "last_modified" : "2025-09-19T18:54:53.698Z", + "last_modified" : "2025-11-14T20:05:45.613Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/endocrine_other.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/endocrine_other.json index 8dbc7c4fe..69c1f499d 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/endocrine_other.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/endocrine_other.json @@ -269,6 +269,6 @@ } ] } ], "involved_tables" : [ "seer_mets_48348", "neoadjuvant_therapy_37302", "ss2018_endocrine_other_54817", "nodes_pos_fpa", "grade_post_therapy_clin_69737", "neoadj_tx_clinical_response_31723", "histology", "derived_ss2018_endocrine_other_15778", "nodes_exam_76029", "tumor_size_summary_63115", "combined_grade_56638", "schema_selection_endocrine_other", "behavior", "nodes_dcd", "grade_clinical_standard_non_ajcc_32473", "grade_pathological_standard_non_ajcc_5627", "derived_grade_standard_non_ajcc_63932", "type_of_reporting_source_76696", "tumor_size_pathological_25597", "tumor_size_clinical_60979", "neoadj_tx_treatment_effect_18122", "primary_site", "grade_post_therapy_path_75348", "year_dx_validation", "summary_stage_rpa", "extension_bco" ], - "last_modified" : "2025-09-19T18:54:56.500Z", + "last_modified" : "2025-11-14T20:05:08.091Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/esophagus_gejunction.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/esophagus_gejunction.json index b70625f7c..821321566 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/esophagus_gejunction.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/esophagus_gejunction.json @@ -321,6 +321,6 @@ } ] } ], "involved_tables" : [ "tumor_size_summary_full_15510", "derived_ss2018_esophagus_32092", "neoadjuvant_therapy_37302", "esophagusgejunction_egj_stomach_57130", "nodes_pos_fpa", "neoadj_tx_treatment_effect_90678", "extension_bbb", "neoadj_tx_clinical_response_31723", "histology", "nodes_exam_76029", "combined_grade_56638", "behavior", "grade_post_therapy_path_92197", "tumor_size_pathological_full_93442", "nodes_dat", "ss2018_esophagus_excluding_gist_57104", "tumor_size_clinical_full_19656", "schema_selection_esophagus_gejunction", "grade_pathological_19694", "histology_discriminator_for_8020_3_93311", "type_of_reporting_source_76696", "mets_hbg", "primary_site", "derived_grade_32209", "grade_clinical_8742", "year_dx_validation", "summary_stage_rpa", "her2_overall_summary_copy_71435", "grade_post_therapy_clin_30400" ], - "last_modified" : "2025-09-19T18:54:48.415Z", + "last_modified" : "2025-11-14T20:05:35.813Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/esophagus_including_ge_junction_squamous.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/esophagus_including_ge_junction_squamous.json index 391e4082c..a3590059b 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/esophagus_including_ge_junction_squamous.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/esophagus_including_ge_junction_squamous.json @@ -338,6 +338,6 @@ } ] } ], "involved_tables" : [ "tumor_size_summary_full_15510", "derived_ss2018_esophagus_32092", "neoadjuvant_therapy_37302", "esophagusgejunction_egj_stomach_57130", "nodes_pos_fpa", "neoadj_tx_treatment_effect_90678", "extension_bbb", "neoadj_tx_clinical_response_31723", "histology", "nodes_exam_76029", "esoph_tumor_epicenter_18976", "combined_grade_56638", "behavior", "grade_post_therapy_path_92197", "nodes_dat", "tumor_size_pathological_full_93442", "ss2018_esophagus_excluding_gist_57104", "tumor_size_clinical_full_19656", "grade_pathological_19694", "histology_discriminator_for_8020_3_93311", "type_of_reporting_source_76696", "schema_selection_esophagus_including_ge_junction_squamous", "mets_hbg", "primary_site", "derived_grade_32209", "grade_clinical_8742", "year_dx_validation", "summary_stage_rpa", "her2_overall_summary_copy_71435", "grade_post_therapy_clin_30400" ], - "last_modified" : "2025-09-19T18:55:01.813Z", + "last_modified" : "2025-11-14T20:05:50.072Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/eye_other.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/eye_other.json index 00b4ca526..3e95bf54a 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/eye_other.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/eye_other.json @@ -269,6 +269,6 @@ } ] } ], "involved_tables" : [ "seer_mets_48348", "neoadjuvant_therapy_37302", "derived_ss2018_eye_other_38179", "nodes_pos_fpa", "grade_post_therapy_clin_69737", "neoadj_tx_clinical_response_31723", "histology", "nodes_exam_76029", "tumor_size_summary_63115", "combined_grade_56638", "behavior", "seer_primary_tumor_eyeother_64077", "grade_clinical_standard_non_ajcc_32473", "grade_pathological_standard_non_ajcc_5627", "schema_selection_eye_other", "ss2018_eye_other_36531", "derived_grade_standard_non_ajcc_63932", "type_of_reporting_source_76696", "tumor_size_pathological_25597", "tumor_size_clinical_60979", "seer_regional_nodes_eyeother_16963", "neoadj_tx_treatment_effect_18122", "primary_site", "grade_post_therapy_path_75348", "year_dx_validation", "summary_stage_rpa" ], - "last_modified" : "2025-09-19T18:55:11.222Z", + "last_modified" : "2025-11-14T20:05:45.989Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/fallopian_tube.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/fallopian_tube.json index 1215e1bca..36144a220 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/fallopian_tube.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/fallopian_tube.json @@ -233,10 +233,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] }, { "key" : "ca125_pretx_interpretation", @@ -270,10 +270,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] } ], "outputs" : [ { @@ -326,6 +326,6 @@ } ] } ], "involved_tables" : [ "residual_tumor_volume_post_cytoreduction_90653", "grade_post_therapy_path_91649", "neoadjuvant_therapy_37302", "eod_regional_nodes_53169", "nodes_pos_fpa", "mets_hah", "neoadj_tx_clinical_response_31723", "histology", "nodes_exam_76029", "grade_clinical_69174", "tumor_size_summary_63115", "combined_grade_56638", "behavior", "derived_grade_40528", "ss2018_fallopian_tube_83058", "type_of_reporting_source_76696", "tumor_size_pathological_25597", "tumor_size_clinical_60979", "primary_site", "figo_stage_30513", "derived_ss2018_fallopian_tube_71863", "schema_selection_fallopian_tube", "grade_pathological_42127", "grade_post_therapy_clin_54917", "year_dx_validation", "ca_125_pretx_interpretation_51295", "summary_stage_rpa", "eod_primary_tumor_19089", "neoadj_tx_treatment_effect_61650" ], - "last_modified" : "2025-09-19T18:54:50.094Z", + "last_modified" : "2025-11-14T20:05:16.198Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/floor_mouth.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/floor_mouth.json index 17451ae78..9517dc7ad 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/floor_mouth.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/floor_mouth.json @@ -250,10 +250,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] }, { "key" : "ln_size_of_mets", @@ -272,10 +272,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] }, { "key" : "seer_ssf1", @@ -339,6 +339,6 @@ } ] } ], "involved_tables" : [ "extranodal_extension_head_and_neck_pathological_87046", "grade_post_therapy_clin_61658", "neoadjuvant_therapy_37302", "tumor_size_pathological_43328", "grade_clinical_6485", "nodes_pos_fpa", "ss2018_floor_of_mouth_27181", "neoadj_tx_clinical_response_31723", "histology", "ss2018_floor_mouth_83713", "nodes_exam_76029", "combined_grade_56638", "schema_selection_floor_mouth", "behavior", "nodes_daa", "tumor_size_clinical_48894", "seer_mets_lip_lower_28596", "grade_post_therapy_path_40048", "type_of_reporting_source_76696", "neoadj_tx_treatment_effect_18122", "p16_hpv_human_papilloma_virus_status_head_and_neck_509", "primary_site", "extranodal_extension_head_and_neck_clinical_79321", "grade_pathological_84704", "year_dx_validation", "derived_grade_69945", "eod_primary_tumor_98910", "summary_stage_rpa", "tumor_size_summary_47973", "ln_size_70140" ], - "last_modified" : "2025-09-19T18:54:47.241Z", + "last_modified" : "2025-11-14T20:06:04.642Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/gallbladder.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/gallbladder.json index d40c55655..0d32033bb 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/gallbladder.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/gallbladder.json @@ -269,6 +269,6 @@ } ] } ], "involved_tables" : [ "ss2018_gallbladder_15174", "grade_post_therapy_clin_61658", "neoadjuvant_therapy_37302", "grade_clinical_6485", "nodes_pos_fpa", "neoadj_tx_clinical_response_31723", "histology", "nodes_exam_76029", "extension_bbd", "schema_selection_gallbladder", "tumor_size_summary_63115", "combined_grade_56638", "behavior", "nodes_dav", "derived_ss2018_gallbladder_56868", "grade_post_therapy_path_40048", "mets_hbe", "type_of_reporting_source_76696", "tumor_size_pathological_25597", "tumor_size_clinical_60979", "neoadj_tx_treatment_effect_18122", "primary_site", "grade_pathological_84704", "year_dx_validation", "derived_grade_69945", "summary_stage_rpa" ], - "last_modified" : "2025-09-19T18:54:50.408Z", + "last_modified" : "2025-11-14T20:05:39.759Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/genital_female_other.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/genital_female_other.json index 11d201d04..a554d1f3d 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/genital_female_other.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/genital_female_other.json @@ -269,6 +269,6 @@ } ] } ], "involved_tables" : [ "seer_mets_48348", "neoadjuvant_therapy_37302", "ss2018_genital_female_other_5962", "nodes_pos_fpa", "grade_post_therapy_clin_69737", "schema_selection_genital_female_other", "neoadj_tx_clinical_response_31723", "histology", "nodes_exam_76029", "derived_ss2018_genital_female_other_6389", "tumor_size_summary_63115", "combined_grade_56638", "behavior", "nodes_dcb", "grade_clinical_standard_non_ajcc_32473", "grade_pathological_standard_non_ajcc_5627", "derived_grade_standard_non_ajcc_63932", "type_of_reporting_source_76696", "tumor_size_pathological_25597", "tumor_size_clinical_60979", "neoadj_tx_treatment_effect_18122", "primary_site", "grade_post_therapy_path_75348", "year_dx_validation", "summary_stage_rpa", "extension_bcm" ], - "last_modified" : "2025-09-19T18:55:05.123Z", + "last_modified" : "2025-11-14T20:05:08.341Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/genital_male_other.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/genital_male_other.json index 9d0c24e75..35d6d848a 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/genital_male_other.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/genital_male_other.json @@ -269,6 +269,6 @@ } ] } ], "involved_tables" : [ "seer_mets_48348", "neoadjuvant_therapy_37302", "nodes_pos_fpa", "grade_post_therapy_clin_69737", "neoadj_tx_clinical_response_31723", "histology", "nodes_exam_76029", "tumor_size_summary_63115", "combined_grade_56638", "behavior", "nodes_dca", "grade_clinical_standard_non_ajcc_32473", "grade_pathological_standard_non_ajcc_5627", "derived_grade_standard_non_ajcc_63932", "type_of_reporting_source_76696", "tumor_size_pathological_25597", "tumor_size_clinical_60979", "neoadj_tx_treatment_effect_18122", "derived_ss2018_genital_male_other_41924", "primary_site", "grade_post_therapy_path_75348", "year_dx_validation", "extension_bcl", "summary_stage_rpa", "schema_selection_genital_male_other", "ss2018_genital_male_other_44390" ], - "last_modified" : "2025-09-19T18:54:38.558Z", + "last_modified" : "2025-11-14T20:05:08.714Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/gist.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/gist.json index 1a07b4d12..b3970ba62 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/gist.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/gist.json @@ -305,6 +305,6 @@ } ] } ], "involved_tables" : [ "kit_gene_immunohistochemistry_33220", "nodes_dfd", "neoadjuvant_therapy_37302", "grade_clinical_21060", "derived_grade_gist_82068", "primary_peritoneum_tumor_19475", "grade_post_therapy_path_83202", "tumor_size_pathological_full_62176", "nodes_pos_fpa", "mets_hch", "neoadj_tx_clinical_response_31723", "ss2018_gist_23534", "histology", "nodes_exam_76029", "grade_pathological_68805", "extension_bfh", "derived_ss2018_gist_48315", "grade_post_therapy_clin_93998", "neoadj_tx_treatment_effect_4391", "combined_grade_56638", "behavior", "tumor_size_clinical_full_74867", "type_of_reporting_source_76696", "tumor_size_summary_full_31213", "schema_selection_gist_appendix", "primary_site", "year_dx_validation", "summary_stage_rpa" ], - "last_modified" : "2025-09-19T18:55:08.878Z", + "last_modified" : "2025-11-14T20:05:11.315Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/gum.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/gum.json index 541a67b59..07e5b15ef 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/gum.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/gum.json @@ -250,10 +250,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] }, { "key" : "ln_size_of_mets", @@ -272,10 +272,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] }, { "key" : "seer_ssf1", @@ -339,6 +339,6 @@ } ] } ], "involved_tables" : [ "extranodal_extension_head_and_neck_pathological_87046", "grade_post_therapy_clin_61658", "neoadjuvant_therapy_37302", "tumor_size_pathological_43328", "grade_clinical_6485", "nodes_pos_fpa", "neoadj_tx_clinical_response_31723", "schema_selection_gum_lower", "histology", "nodes_exam_76029", "extension_bdl", "combined_grade_56638", "behavior", "ss2018_gum_75440", "nodes_daa", "tumor_size_clinical_48894", "seer_mets_lip_lower_28596", "grade_post_therapy_path_40048", "type_of_reporting_source_76696", "derived_ss2018_gum_32702", "neoadj_tx_treatment_effect_18122", "p16_hpv_human_papilloma_virus_status_head_and_neck_509", "primary_site", "extranodal_extension_head_and_neck_clinical_79321", "grade_pathological_84704", "year_dx_validation", "derived_grade_69945", "summary_stage_rpa", "tumor_size_summary_47973", "ln_size_70140" ], - "last_modified" : "2025-09-19T18:55:05.398Z", + "last_modified" : "2025-11-14T20:05:17.778Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/heart_mediastinum_pleura.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/heart_mediastinum_pleura.json index b8ffead06..6576afc53 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/heart_mediastinum_pleura.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/heart_mediastinum_pleura.json @@ -226,10 +226,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] } ], "outputs" : [ { @@ -282,6 +282,6 @@ } ] } ], "involved_tables" : [ "ss2018_soft_tissue_heart_mediastinum_pleura_63956", "neoadjuvant_therapy_37302", "grade_post_therapy_path_36935", "nodes_pos_fpa", "derived_ss2018_heart_mediastinum_and_pleura_70478", "schema_selection_soft_tissue_heart_and_mediastinum", "neoadj_tx_clinical_response_31723", "grade_post_therapy_clin_1647", "histology", "nodes_exam_76029", "bone_invasion_96628", "neoadj_tx_treatment_effect_4391", "tumor_size_summary_63115", "seer_regional_nodes_67072", "combined_grade_56638", "grade_pathological_40399", "type_of_reporting_source_76696", "tumor_size_pathological_25597", "derived_grade_71227", "tumor_size_clinical_60979", "grade_clinical_41135", "primary_site", "seer_primary_tumor_72151", "year_dx_validation", "summary_stage_rpa", "eod_mets_76404" ], - "last_modified" : "2025-09-19T18:54:39.224Z", + "last_modified" : "2025-11-14T20:05:20.628Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/hemeretic.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/hemeretic.json index 745cd8f08..8090db317 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/hemeretic.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/hemeretic.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "HemeRetic", "title" : "HemeRetic", - "notes" : "9724, 9727, 9740-9742, 9749, 9762-9809, 9811-9820, 9831-9920, 9931-9993 \n* C700-C729, C751-C753 for 9749, 9766 (2018-2022 only) (See **Note 2**)\n\nC000-C440, C442-C689, C691-C694, C698-C809: 9591 and Schema Discriminator 1: 1, 2 \n\nC000-C699, C739-C750, C754-C809: 9751, 9755-9759 \n\nC000-C440, C442-C689, C691-C694, C698-C809: 9930 \n\n**Note 1:** **Sources used in the development of this schema**\n* SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998) (https://seer.cancer.gov/archive/manuals/EOD10Dig.3rd.pdf)\n* SEER Summary Staging Manual-2000: Codes and Coding Instructions (https://seer.cancer.gov/tools/ssm/ssm2000/)\n* Collaborative Stage Data Collection System, version 02.05: https://cancerstaging.org/cstage/Pages/default.aspx \n* Chapter 83 *Leukemia*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois.\n\n**Note 2:** **Histologies moved to Brain, CNS, Intracranial Gland** \n* For the histologies and primary sites listed below, these have moved to the Brain, CNS Other, and Intracranial Gland schemas starting with 2023 diagnoses.\n* If you have one of these cases for 2018-2022, then this is the appropriate schema. If you have one of these cases diagnosed on January 1, 2023, forward, see the appropriate schema\n * **9749, 9766** \n * **Brain**: C700, C710-C719\n * **CNS Other**: C701, C709, C720-C725, C728-C729\n * **Intracranial Gland**: C751-C753\n\n**Note 3:** **Other EOD Schemas with the listed histologies**\n* **Brain**: 9751, 9755-9759 (C700, C710-C719)\n* **CNS Other**: 9751, 9755-9759 (C701, C709, C720-C725, C728-C729)\n* **Intracranial Gland**: 9751, 9755-9759 (C751-C753)\n* **Lymphoma**: 9591 and Schema Discriminator 1: 3, 9 (C000-C440, C442-C689, C691-C694, C698-C809)\n* **Lymphoma Ocular Adnexa**: 9930 (C441, C690, C695-C696)\n\n**Note 4:** **Summary Stage** \n* Summary Stage is the only applicable staging system for this site/histology/schema.\n\n**Note 5:** **Histologies and Primary Sites** \n* See list of specific histologies below, effective for cases diagnosed 2010 and forward. \n* All primary sites (C000-C809) are included unless otherwise specified. \n\n**Note 6:** **Schema includes the preferred terms based on the 2024 WHO Classification of Tumours, Haematolymphoid tumors, 5th edition**\n\n* 9591 Splenic B-cell lymphoma/leukemia, unclassifiable (except C441, C690, C695-C696)\n* 9724: Systemic EBV-positive T-cell lymphoma of childhood (SEBVTCL)\n* 9727: Blastic plasmacytoid dendritic cell neoplasm (BPDC)\n* 9740: Mast cell sarcoma (MSC)\n* 9741: Systemic mastocytosis with an associated hematological neoplasm (SM-AHN)\n* 9742: Mast cell leukemia (MCL)\n* 9749: Erdheim-Chester disease (ECD) (2021+ only) (except C700-C729, C751-C753 for 1/1/2023+)\n* 9750: ALK-positive histiocytosis\n* 9751: Langerhans cell histiocytosis, disseminated (except C700-C729, C751-C753)\n* 9755: Histiocytic sarcoma (except C700-C729, C751-C753)\n* 9756: Langerhans cell sarcoma (LCS) (except C700-C729, C751-C753)\n* 9757: Interdigitating dendritic cell sarcoma (IDCS) (except C700-C729, C751-C753)\n* 9758: Follicular dendritic cell sarcoma (FDCS) (except C700-C729, C751-C753)\n* 9759: Fibroblastic reticular cell tumor (except C700-C729, C751-C753)\n* 9762: Heavy chain diseases, NOS (HCD)\n* 9766: Lymphomatoid granulomatosis (LyG) grade 3 (2021+ only) (except C700-C729, C751-C753 for 1/1/2023+)\n* 9800 Leukemia, NOS\n* 9801: Acute undifferentiated leukemia\n* 9805: Acute leukemia of ambiguous lineage with other defined genetic alterations\n* 9806: Mixed-phenotype acute leukemia (MPAL) with *BCR::ABL1* fusion\n* 9807: Mixed-phenotype acute leukemia (MPAL) with *KMT2A-rearranged*\n* 9808: Mixed -phenotype acute leukemia, B/myeloid, NOS\n* 9809: Mixed-phenotype acute leukemia (MPAL), T/myeloid, NOS\n* 9811: B-lymphoblastic leukemia/lymphoma [B-ALL/LBL], NOS\n* 9812: B-lymphoblastic leukemia/lymphoma [B-ALL/LBL] with *BCR::ABL1 fusion*\n* 9813: B lymphoblastic leukemia/lymphoma [B-ALL/LBL] with *KMT2A rearrangement*\n* 9814: B-lymphoblastic leukemia/lymphoma [B-ALL/LBL] with *ETV6::RUNX1 fusion*\n* 9815: B-lymphoblastic leukemia/lymphoma with high hyperdiploidy (B-ALL/LBL with high hyperdiploidy)\n* 9816: B-lymphoblastic leukemia/lymphoma [B-ALL/LBL] with hypodiploidy (Hypodiploid B-ALL/LBL)\n* 9817: B-lymphoblastic leukemia/lymphoma [B-ALL/LBL] with *IGH::IL3 fusion*\n* 9818: B-lymphoblastic leukemia/lymphoma [B-ALL/LBL] with *TCF3::PBX1*\n* 9819: B-lymphoblastic leukemia/lymphoma [B-ALL/LBL] with *BCR::ABL1 like features* (BCR::ABL1-like B-ALL/LBL) (2021+ only)\n* 9820: Lymphoid leukemia, NOS\n* 9831: T-large granular lymphocytic leukemia (T-LGLL)\n* 9832: Prolymphocytic leukemia (PPL), NOS\n* 9833: Prolymphocytic leukemia, B-cell type (BLL) \n* 9834: T-cell prolymphocytic leukemia (T-PLL)\n* 9837: T-lymphoblastic leukemia/lymphoma (T-ALL/LBL) \n* 9840: Acute erythroid leukemia (AEL)\n* 9860: Myeloid leukemia, NOS\n* 9861: Acute myeloid leukemia (AML), NOS\n* 9863: Chronic myeloid leukemia (CML), NOS\n* 9865: Acute myeloid leukemia with *DEK::NUP214 fusion*\n* 9866: Acute promyelocytic leukemia with *PML::RARA* fusion (APL with *PML::RARA*)\n* 9867: Acute myelomonocytic leukemia, NOS (AMML)\n* 9869: Acute myeloid leukemia with *MECOM rearrangement*\n* 9870: Acute basophilic leukemia\n* 9871: Acute myeloid leukemia with *CBFB::MYH11 fusion*\n* 9872: Acute myeloid leukemia, minimal differentiation\n* 9873: Acute myeloid leukemia without maturation\n* 9874: Acute myeloid leukemia with maturation\n* 9875: Chronic myeloid leukemia (CML), *BCR::ABL1 positive*\n* 9876: Myelodysplastic/myeloproliferative neoplasm with neutrophilia (MDS/MPN-N)\n* 9877: Acute myeloid leukemia with mutated *NPM1* (2021+ only)\n* 9878: Acute myeloid leukemia with *CEBPA mutation* (2021+ only)\n* 9879: Acute myeloid leukemia with mutated *RUNX1* (2021+ only)\n* 9891: Acute monocytic leukemia\n* 9895: Myelodysplasia-related acute myeloid leukemia (AML-MR)\n* 9896: Acute myeloid leukemia with *RUNX1::RUNX1T1*\n* 9897: Acute myeloid leukemia with *KMT2a rearrangement*\n* 9898: Myeloid leukemia associated with Down Syndrome (ML-DS)\n* 9910: Acute megakaryoblastic leukemia (AMKL)\n* 9911: Acute myeloid leukemia (megakaryoblastic) with *RBMI5::MRTFA*\n* 9912: Acute myeloid leukemia with *BCR::ABL1 fusion* (2021+ only)\n* 9920 Therapy-related myeloid neoplasms\n* 9930: Myeloid sarcoma (MS) (except C441, C690, C695-C696)\n* 9931: Acute panmyelosis with myelofibrosis (APMF)\n* 9940: Hairy cell leukemia (HCL)\n* 9945: Chronic myelomonocytic leukemia, NOS (CMML)\n* 9946: Juvenile myelomonocytic leukemia (JMML)\n* 9948: Aggressive NK-cell leukemia (ANKL)\n* 9950: Polycythemia vera (PV)\n* 9961: Primary myelofibrosis (PMF)\n* 9962: Essential thrombocythemia (ET)\n* 9963: Chronic neutrophilic leukemia (CNL)\n* 9964: Chronic eosinophilic leukemia (CEL)\n* 9965: Myeloid/lymphoid neoplasms with *PDGFRA* rearrangement\n* 9966: Myeloid/lymphoid neoplasm with *PDGFRB* rearrangement\n* 9967: Myeloid/lymphoid neoplasm with *FGFR1* rearrangement\n* 9968: Myeloid/lymphoid neoplasm with *JAK2* rearrangement (2021+ only)\n* 9971 Post-transplant lymphoproliferative disorder, NOS (PTLD, NOS) (2018-2020, 2025+)\n* *Note:* 9971 is /1 for 2021-2024, moved back to /3 for 1/1/2025+\n* 9975: Myelodysplastic/myeloproliferative neoplasm, NOS, unclassifiable (MPN/MDS-U)\n* 9980: Myelodysplastic neoplasm with low blasts and single-lineage dysplasia (MDS-LB-SLD)\n* 9982: Myelodysplastic syndrome with ring sideroblasts and single lineage dysplasia (MDS-RS-SLD) \n* 9983: Myelodysplastic neoplasm with increased blasts (MDS-IB)\n* 9985: Myelodysplastic neoplasm with low blasts, NOS (MDS-LB)\n* 9986: Myelodysplastic neoplasm with low blasts and 5q deletion (MDS-5q)\n* 9989: Myelodysplastic neoplasm, NOS\n* 9991: Refractory neutropenia (2018-2020 only, see code 9980/3 for 2021+)\n* 9992: Refractory thrombocytopenia (2018-2020 only, see code 9980/3 for 2021+)\n* 9993: Myelodysplastic syndrome with ring sideroblasts and multilineage dysplasia (2021+)", + "notes" : "9724, 9727, 9740-9742, 9749, 9762-9809, 9811-9820, 9831-9920, 9931-9993 \n* C700-C729, C751-C753 for 9749, 9766 (2018-2022 only) (See **Note 2**)\n\nC000-C440, C442-C689, C691-C694, C698-C809: 9591 and Schema Discriminator 1: 1, 2 \n\nC000-C699, C739-C750, C754-C809: 9751, 9755-9759 \n\nC000-C440, C442-C689, C691-C694, C698-C809: 9930 \n\n**Note 1:** **Sources used in the development of this schema**\n* SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998) (https://seer.cancer.gov/archive/manuals/EOD10Dig.3rd.pdf)\n* SEER Summary Staging Manual-2000: Codes and Coding Instructions (https://seer.cancer.gov/tools/ssm/ssm2000/)\n* Collaborative Stage Data Collection System, version 02.05: https://cancerstaging.org/cstage/Pages/default.aspx \n* Chapter 83 *Leukemia*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois.\n\n**Note 2:** **Histologies moved to Brain, CNS, Intracranial Gland** \n* For the histologies and primary sites listed below, these have moved to the Brain, CNS Other, and Intracranial Gland schemas starting with 2023 diagnoses.\n* If you have one of these cases for 2018-2022, then this is the appropriate schema. If you have one of these cases diagnosed on January 1, 2023, forward, see the appropriate schema\n * **9749, 9766** \n * **Brain**: C700, C710-C719\n * **CNS Other**: C701, C709, C720-C725, C728-C729\n * **Intracranial Gland**: C751-C753\n\n**Note 3:** **Other EOD Schemas with the listed histologies**\n* **Brain**: 9751, 9755-9759, (9749, 9766 for 2023+) (C700, C710-C719) \n* **CNS Other**: 9751, 9755-9759, (9749, 9766 for 2023+) (C701, C709, C720-C725, C728-C729) (9749, 9766 for 2023+)\n* **Intracranial Gland**: 9751, 9755-9759, (9749, 9766 for 2023+) (C751-C753)\n* **Lymphoma**: 9591 and Schema Discriminator 1: 3, 9 (C000-C440, C442-C689, C691-C694, C698-C809)\n* **Lymphoma Ocular Adnexa**: 9930 (C441, C690, C695-C696\n\n**Note 4:** **Summary Stage** \n* Summary Stage is the only applicable staging system for this site/histology/schema.\n\n**Note 5:** **Histologies and Primary Sites** \n* See list of specific histologies below, effective for cases diagnosed 2010 and forward. \n* All primary sites (C000-C809) are included unless otherwise specified. \n\n**Note 6:** **The preferred histology terms listed in this schema are from the 2024 WHO Classification of Tumours, Haematolymphoid tumours, 5th edition.**\n\n* 9591: Splenic B-cell lymphoma/leukemia, unclassifiable \n* 9724: Systemic EBV-positive T-cell lymphoma of childhood (SEBVTCL)\n* 9727: Blastic plasmacytoid dendritic cell neoplasm (BPDC)\n* 9740: Mast cell sarcoma (MSC)\n* 9741: Systemic mastocytosis with an associated hematological neoplasm (SM-AHN)\n* 9742: Mast cell leukemia (MCL)\n* 9749: Erdheim-Chester disease (ECD) *(2021+ only)* \n* 9750: ALK-positive histiocytosis\n* 9751: Langerhans cell histiocytosis, disseminated \n* 9755: Histiocytic sarcoma \n* 9756: Langerhans cell sarcoma (LCS)\n* 9757: Interdigitating dendritic cell sarcoma (IDCS) \n* 9758: Follicular dendritic cell sarcoma (FDCS) \n* 9759: Fibroblastic reticular cell tumor \n* 9762: Heavy chain diseases, NOS (HCD)\n* 9766: Lymphomatoid granulomatosis (LyG) grade 3 *(2021+ only)* \n* 9800: Leukemia, NOS\n* 9801: Acute undifferentiated leukemia\n* 9805: Acute leukemia of ambiguous lineage with other defined genetic alterations\n* 9806: Mixed-phenotype acute leukemia (MPAL) with *BCR::ABL1* fusion\n* 9807: Mixed-phenotype acute leukemia (MPAL) with *KMT2A-rearranged*\n* 9808: Mixed -phenotype acute leukemia, B/myeloid, NOS\n* 9809: Mixed-phenotype acute leukemia (MPAL), T/myeloid, NOS\n* 9811: B-lymphoblastic leukemia/lymphoma [B-ALL/LBL], NOS\n* 9812: B-lymphoblastic leukemia/lymphoma [B-ALL/LBL] with *BCR::ABL1 fusion*\n* 9813: B lymphoblastic leukemia/lymphoma [B-ALL/LBL] with *KMT2A rearrangement*\n* 9814: B-lymphoblastic leukemia/lymphoma [B-ALL/LBL] with *ETV6::RUNX1 fusion*\n* 9815: B-lymphoblastic leukemia/lymphoma with high hyperdiploidy (B-ALL/LBL with high hyperdiploidy)\n* 9816: B-lymphoblastic leukemia/lymphoma [B-ALL/LBL] with hypodiploidy (Hypodiploid B-ALL/LBL)\n* 9817: B-lymphoblastic leukemia/lymphoma [B-ALL/LBL] with *IGH::IL3 fusion*\n* 9818: B-lymphoblastic leukemia/lymphoma [B-ALL/LBL] with *TCF3::PBX1*\n* 9819: B-lymphoblastic leukemia/lymphoma [B-ALL/LBL] with *BCR::ABL1 like features* (BCR::ABL1-like B-ALL/LBL) *(2021+ only)*\n* 9820: Lymphoid leukemia, NOS\n* 9831: T-large granular lymphocytic leukemia (T-LGLL)\n* 9832: Prolymphocytic leukemia (PPL), NOS\n* 9833: Prolymphocytic leukemia, B-cell type (BLL) \n* 9834: T-cell prolymphocytic leukemia (T-PLL)\n* 9837: T-lymphoblastic leukemia/lymphoma (T-ALL/LBL) \n* 9840: Acute erythroid leukemia (AEL)\n* 9860: Myeloid leukemia, NOS\n* 9861: Acute myeloid leukemia (AML), NOS\n* 9863: Chronic myeloid leukemia (CML), NOS\n* 9865: Acute myeloid leukemia with *DEK::NUP214 fusion*\n* 9866: Acute promyelocytic leukemia with *PML::RARA* fusion (APL with *PML::RARA*)\n* 9867: Acute myelomonocytic leukemia, NOS (AMML)\n* 9869: Acute myeloid leukemia with *MECOM rearrangement*\n* 9870: Acute basophilic leukemia\n* 9871: Acute myeloid leukemia with *CBFB::MYH11 fusion*\n* 9872: Acute myeloid leukemia, minimal differentiation\n* 9873: Acute myeloid leukemia without maturation\n* 9874: Acute myeloid leukemia with maturation\n* 9875: Chronic myeloid leukemia (CML), *BCR::ABL1 positive*\n* 9876: Myelodysplastic/myeloproliferative neoplasm with neutrophilia (MDS/MPN-N)\n* 9877: Acute myeloid leukemia with mutated *NPM1* *(2021+ only)*\n* 9878: Acute myeloid leukemia with *CEBPA mutation* *(2021+ only)*\n* 9879: Acute myeloid leukemia with mutated *RUNX1* *(2021+ only)*\n* 9891: Acute monocytic leukemia\n* 9895: Myelodysplasia-related acute myeloid leukemia (AML-MR)\n* 9896: Acute myeloid leukemia with *RUNX1::RUNX1T1*\n* 9897: Acute myeloid leukemia with *KMT2a rearrangement*\n* 9898: Myeloid leukemia associated with Down Syndrome (ML-DS)\n* 9910: Acute megakaryoblastic leukemia (AMKL)\n* 9911: Acute myeloid leukemia (megakaryoblastic) with *RBMI5::MRTFA*\n* 9912: Acute myeloid leukemia with *BCR::ABL1 fusion* *(2021+ only)*\n* 9920 Therapy-related myeloid neoplasms\n* 9930: Myeloid sarcoma (MS) \n* 9931: Acute panmyelosis with myelofibrosis (APMF)\n* 9940: Hairy cell leukemia (HCL)\n* 9945: Chronic myelomonocytic leukemia, NOS (CMML)\n* 9946: Juvenile myelomonocytic leukemia (JMML)\n* 9948: Aggressive NK-cell leukemia (ANKL)\n* 9950: Polycythemia vera (PV)\n* 9961: Primary myelofibrosis (PMF)\n* 9962: Essential thrombocythemia (ET)\n* 9963: Chronic neutrophilic leukemia (CNL)\n* 9964: Chronic eosinophilic leukemia (CEL)\n* 9965: Myeloid/lymphoid neoplasms with *PDGFRA* rearrangement\n* 9966: Myeloid/lymphoid neoplasm with *PDGFRB* rearrangement\n* 9967: Myeloid/lymphoid neoplasm with *FGFR1* rearrangement\n* 9968: Myeloid/lymphoid neoplasm with *JAK2* rearrangement *(2021+ only)*\n* 9971 Post-transplant lymphoproliferative disorder, NOS (PTLD, NOS) *(2018-2020, 2025+)*\n * *Note:* 9971 is /1 for 2021-2024, moved back to /3 for 1/1/2025+\n* 9975: Myelodysplastic/myeloproliferative neoplasm, NOS, unclassifiable (MPN/MDS-U)\n* 9980: Myelodysplastic neoplasm with low blasts and single-lineage dysplasia (MDS-LB-SLD)\n* 9982 Myelodysplastic /myeloproliferative neoplasm with low blasts and SF3B1 mutation\n* 9983: Myelodysplastic neoplasm with increased blasts (MDS-IB)\n* 9985: Myelodysplastic neoplasm with low blasts, NOS (MDS-LB)\n* 9986: Myelodysplastic neoplasm with low blasts and 5q deletion (MDS-5q)\n* 9989: Myelodysplastic neoplasm, NOS\n* 9991: Refractory neutropenia *(2018-2020 only, see code 9980/3 for 2021+)*\n* 9992: Refractory thrombocytopenia *(2018-2020 only, see code 9980/3 for 2021+)*\n* 9993: Myelodysplastic syndrome with ring sideroblasts and multilineage dysplasia *(2021+)*", "schema_selection_table" : "schema_selection_heme_retic", "schema_discriminators" : [ "year_dx", "discriminator_1", "behavior" ], "inputs" : [ { @@ -312,6 +312,6 @@ } ] } ], "involved_tables" : [ "neoadjuvant_therapy_37302", "tumor_size_clinical_dna_64119", "nodes_pos_fpa", "tumor_size_summary_dna_13275", "neoadj_tx_clinical_response_31723", "grade_post_therapy_clin_74830", "histology", "nodes_exam_76029", "schema_discriminator_1_63995", "age_at_diagnosis_validation_65093", "mets_hna", "derived_ss2018_hemeretic_89184", "behavior", "nodes_dna", "jak2_80148", "derived_grade_21945", "tumor_size_pathological_dna_6742", "schema_selection_heme_retic", "ss2018_hemeretic_3793", "type_of_reporting_source_76696", "summary_stage_lymphoma_25139", "primary_site", "neoadj_tx_treatment_effect_52725", "year_dx_validation", "derived_summary_grade_na_6690", "grade_post_therapy_path_65729", "extension_bci", "grade_clinical_18316", "grade_pathological_73388" ], - "last_modified" : "2025-09-19T18:54:43.400Z", + "last_modified" : "2025-11-14T20:06:01.184Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/hypopharynx.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/hypopharynx.json index bfac7857f..dea262c7a 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/hypopharynx.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/hypopharynx.json @@ -250,10 +250,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] }, { "key" : "ln_size_of_mets", @@ -272,10 +272,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] }, { "key" : "seer_ssf1", @@ -339,6 +339,6 @@ } ] } ], "involved_tables" : [ "extranodal_extension_head_and_neck_pathological_87046", "neoadjuvant_therapy_37302", "tumor_size_pathological_43328", "derived_grade_46639", "grade_post_therapy_path_41285", "grade_pathological_31963", "grade_post_therapy_clin_41222", "nodes_pos_fpa", "schema_selection_hypopharynx", "neoadj_tx_clinical_response_31723", "histology", "nodes_exam_76029", "eod_mets_95518", "combined_grade_56638", "behavior", "extension_bar", "tumor_size_clinical_48894", "type_of_reporting_source_76696", "derived_ss2018_hypopharynx_33792", "neoadj_tx_treatment_effect_18122", "ss2018_hypopharynx_excluding_melanoma_8720_8790_copy_30010", "p16_hpv_human_papilloma_virus_status_head_and_neck_509", "primary_site", "extranodal_extension_head_and_neck_clinical_79321", "eod_regional_nodes_21853", "year_dx_validation", "grade_clinical_73056", "summary_stage_rpa", "tumor_size_summary_47973", "ln_size_70140" ], - "last_modified" : "2025-09-19T18:55:02.757Z", + "last_modified" : "2025-11-14T20:06:07.141Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/ill_defined_other.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/ill_defined_other.json index bbc0f1946..8b2086148 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/ill_defined_other.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/ill_defined_other.json @@ -275,6 +275,6 @@ } ] } ], "involved_tables" : [ "neoadjuvant_therapy_37302", "derived_ss2018_ill_defined_other_41227", "occult_head_and_neck_lymph_nodes_10277", "nodes_exam_dna_95635", "grade_post_therapy_clin_69737", "schema_selection_ill_defined_other", "neoadj_tx_clinical_response_31723", "histology", "mets_hna", "tumor_size_summary_63115", "combined_grade_56638", "nodes_dna", "grade_clinical_standard_non_ajcc_32473", "extension_bna", "grade_pathological_standard_non_ajcc_5627", "derived_grade_standard_non_ajcc_63932", "tumor_size_pathological_25597", "summary_stage_lymphoma_25139", "tumor_size_clinical_60979", "primary_site", "grade_post_therapy_path_75348", "neoadj_tx_treatment_effect_52725", "year_dx_validation", "ss2018_ill_defined_18664", "nodes_pos_dna_91511" ], - "last_modified" : "2025-09-19T18:54:42.095Z", + "last_modified" : "2025-11-14T20:05:16.583Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/intracranial_gland.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/intracranial_gland.json index 0c79633e7..fae6d10de 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/intracranial_gland.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/intracranial_gland.json @@ -270,6 +270,6 @@ } ] } ], "involved_tables" : [ "neoadjuvant_therapy_37302", "extension_bfy", "ss2018_intracranial_gland_98794", "eod_mets_25000", "grade_post_therapy_path_86055", "nodes_exam_dna_95635", "schema_selection_intracranial_gland", "neoadj_tx_clinical_response_31723", "histology", "tumor_size_summary_63115", "combined_grade_56638", "behavior", "grade_clinical_19997", "nodes_dna", "summary_stage_benign_3306", "type_of_reporting_source_76696", "tumor_size_pathological_25597", "tumor_size_clinical_60979", "grade_pathological_11803", "derived_grade_12594", "neoadj_tx_treatment_effect_18122", "primary_site", "grade_post_therapy_clin_26948", "year_dx_validation", "derived_ss2018_intracranial_gland_8078", "nodes_pos_dna_91511" ], - "last_modified" : "2025-09-19T18:54:51.086Z", + "last_modified" : "2025-11-14T20:05:15.595Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/intracranial_gland_v9_2023.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/intracranial_gland_v9_2023.json index 546c02af5..396066e14 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/intracranial_gland_v9_2023.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/intracranial_gland_v9_2023.json @@ -270,6 +270,6 @@ } ] } ], "involved_tables" : [ "neoadjuvant_therapy_37302", "ss2018_intracranial_gland_98794", "eod_mets_25000", "schema_selection_intracranial_gland_v9_2023", "nodes_exam_dna_95635", "grade_post_therapy_path_yp_3519", "grade_pathological_53280", "neoadj_tx_clinical_response_31723", "histology", "grade_clinical_78613", "grade_post_therapy_clin_yc_55565", "tumor_size_summary_63115", "combined_grade_56638", "behavior", "nodes_dna", "summary_stage_benign_3306", "eod_primary_tumor_12346", "type_of_reporting_source_76696", "tumor_size_pathological_25597", "tumor_size_clinical_60979", "neoadj_tx_treatment_effect_18122", "derived_grade_96207", "primary_site", "year_dx_validation", "derived_ss2018_intracranial_gland_8078", "nodes_pos_dna_91511" ], - "last_modified" : "2025-09-19T18:54:48.934Z", + "last_modified" : "2025-11-14T20:05:55.151Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/kaposi_sarcoma.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/kaposi_sarcoma.json index 1917178e5..6e4f40b99 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/kaposi_sarcoma.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/kaposi_sarcoma.json @@ -264,6 +264,6 @@ } ] } ], "involved_tables" : [ "neoadjuvant_therapy_37302", "tumor_size_clinical_dna_64119", "grade_post_therapy_path_36935", "nodes_pos_fpa", "tumor_size_summary_dna_13275", "neoadj_tx_clinical_response_31723", "grade_post_therapy_clin_1647", "histology", "nodes_exam_76029", "mets_hna", "combined_grade_56638", "grade_pathological_40399", "tumor_size_pathological_dna_6742", "derived_ss2018_kaposi_sarcoma_84609", "type_of_reporting_source_76696", "derived_grade_71227", "neoadj_tx_treatment_effect_18122", "grade_clinical_41135", "primary_site", "ss2018_kaposi_sarcoma_17563", "year_dx_validation", "nodes_dby", "summary_stage_rpa", "schema_selection_kaposi_sarcoma", "extension_bcj" ], - "last_modified" : "2025-09-19T18:54:34.459Z", + "last_modified" : "2025-11-14T20:05:43.353Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/kidney_parenchyma.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/kidney_parenchyma.json index e1ba2c142..35c2c4543 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/kidney_parenchyma.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/kidney_parenchyma.json @@ -233,10 +233,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] }, { "key" : "ipsilateral_adrenal_gland_involv", @@ -253,10 +253,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] }, { "key" : "major_vein_involv", @@ -273,10 +273,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] }, { "key" : "sarcomatoid_features", @@ -344,6 +344,6 @@ } ] } ], "involved_tables" : [ "ss2018_kidney_renal_parenchyma_30980", "neoadjuvant_therapy_37302", "extension_bbp", "tumor_size_pathological_43328", "derived_grade_83462", "nodes_pos_fpa", "derived_ss2018_kidney_parenchyma_35397", "mets_hcg", "nodes_dbg", "neoadj_tx_clinical_response_31723", "histology", "nodes_exam_76029", "grade_pathological_20722", "combined_grade_56638", "behavior", "tumor_size_clinical_48894", "type_of_reporting_source_76696", "neoadj_tx_treatment_effect_18122", "invasion_beyond_capsule_4149", "major_vein_involvement_87947", "primary_site", "grade_post_therapy_path_80308", "ipsilateral_adrenal_gland_involvement_61538", "sarcomatoid_features_99558", "year_dx_validation", "summary_stage_rpa", "tumor_size_summary_47973", "grade_clinical_18831", "grade_post_therapy_clin_97989", "schema_selection_kidney_parenchyma" ], - "last_modified" : "2025-09-19T18:54:40.749Z", + "last_modified" : "2025-11-14T20:05:40.252Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/kidney_renal_pelvis.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/kidney_renal_pelvis.json index 7811c9387..021dce546 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/kidney_renal_pelvis.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/kidney_renal_pelvis.json @@ -269,6 +269,6 @@ } ] } ], "involved_tables" : [ "neoadjuvant_therapy_37302", "eod_mets_25281", "nodes_pos_fpa", "nodes_dbe", "neoadj_tx_clinical_response_31723", "grade_post_therapy_path_55848", "histology", "nodes_exam_76029", "tumor_size_summary_63115", "combined_grade_56638", "behavior", "extension_bbn", "derived_grade_84046", "schema_selection_kidney_renal_pelvis", "derived_ss2018_kidney_renal_pelvis_4595", "type_of_reporting_source_76696", "tumor_size_pathological_25597", "tumor_size_clinical_60979", "neoadj_tx_treatment_effect_18122", "primary_site", "grade_pathological_59975", "grade_post_therapy_clin_68213", "year_dx_validation", "summary_stage_rpa", "grade_clinical_91989", "ss2018_kidney_renal_pelvis_29650" ], - "last_modified" : "2025-09-19T18:55:08.615Z", + "last_modified" : "2025-11-14T20:05:49.319Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/lacrimal_gland.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/lacrimal_gland.json index c0eb43e2f..a86924475 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/lacrimal_gland.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/lacrimal_gland.json @@ -268,10 +268,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] } ], "outputs" : [ { @@ -324,6 +324,6 @@ } ] } ], "involved_tables" : [ "neoadjuvant_therapy_37302", "tumor_size_pathological_43328", "grade_post_therapy_path_45323", "nodes_pos_fpa", "eod_mets_96081", "adenoid_cystic_basaloid_pattern_86314", "neoadj_tx_clinical_response_31723", "histology", "nodes_exam_76029", "grade_clinical_2756", "combined_grade_56638", "behavior", "eod_regional_nodes_86049", "perineural_invasion_24604", "schema_selection_lacrimal_gland", "extension_bct", "tumor_size_clinical_48894", "derived_ss2018_lacrimal_gland_sac_94643", "grade_pathological_85185", "type_of_reporting_source_76696", "derived_grade_30763", "neoadj_tx_treatment_effect_18122", "primary_site", "grade_post_therapy_clin_23317", "lacrimal_gland_lacrimal_sac_63106", "year_dx_validation", "summary_stage_rpa", "tumor_size_summary_47973", "ss2018_lacrimal_gland_82062" ], - "last_modified" : "2025-09-19T18:54:46.630Z", + "last_modified" : "2025-11-14T20:06:12.643Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/lacrimal_sac.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/lacrimal_sac.json index 79c668d2d..339f11ea6 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/lacrimal_sac.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/lacrimal_sac.json @@ -289,6 +289,6 @@ } ] } ], "involved_tables" : [ "seer_mets_48348", "neoadjuvant_therapy_37302", "nodes_pos_fpa", "grade_post_therapy_clin_69737", "neoadj_tx_clinical_response_31723", "histology", "nodes_exam_76029", "seer_regional_nodes_lacrimal_sac_33881", "tumor_size_summary_63115", "combined_grade_56638", "behavior", "schema_selection_lacrimal_sac", "extension_btb", "grade_clinical_standard_non_ajcc_32473", "derived_ss2018_lacrimal_gland_sac_94643", "grade_pathological_standard_non_ajcc_5627", "derived_grade_standard_non_ajcc_63932", "type_of_reporting_source_76696", "tumor_size_pathological_25597", "tumor_size_clinical_60979", "neoadj_tx_treatment_effect_18122", "primary_site", "grade_post_therapy_path_75348", "lacrimal_gland_lacrimal_sac_63106", "year_dx_validation", "summary_stage_rpa", "ss2018_lacrimal_gland_82062" ], - "last_modified" : "2025-09-19T18:55:06.598Z", + "last_modified" : "2025-11-14T20:05:46.357Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/larynx_glottic.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/larynx_glottic.json index 7faf6b7d6..3433b1393 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/larynx_glottic.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/larynx_glottic.json @@ -250,10 +250,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] }, { "key" : "ln_size_of_mets", @@ -272,10 +272,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] } ], "outputs" : [ { @@ -328,6 +328,6 @@ } ] } ], "involved_tables" : [ "extranodal_extension_head_and_neck_pathological_87046", "grade_post_therapy_clin_61658", "neoadjuvant_therapy_37302", "eod_regional_nodes_12613", "grade_clinical_6485", "nodes_pos_fpa", "neoadj_tx_clinical_response_31723", "histology", "nodes_exam_76029", "eod_mets_89421", "tumor_size_summary_63115", "combined_grade_56638", "behavior", "ss2018_larynx_glottic_excluding_melanoma_8720_8790_2238", "extension_bat", "grade_post_therapy_path_40048", "schema_selection_larynx_glottic", "type_of_reporting_source_76696", "tumor_size_pathological_25597", "tumor_size_clinical_60979", "neoadj_tx_treatment_effect_18122", "primary_site", "extranodal_extension_head_and_neck_clinical_79321", "grade_pathological_84704", "year_dx_validation", "derived_grade_69945", "summary_stage_rpa", "ln_size_70140", "derived_ss2018_larynx_glottic_7548" ], - "last_modified" : "2025-09-19T18:55:01.613Z", + "last_modified" : "2025-11-14T20:05:34.531Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/larynx_other.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/larynx_other.json index b270ecf78..a40b9fa57 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/larynx_other.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/larynx_other.json @@ -250,10 +250,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] }, { "key" : "ln_size_of_mets", @@ -272,10 +272,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] } ], "outputs" : [ { @@ -328,6 +328,6 @@ } ] } ], "involved_tables" : [ "extranodal_extension_head_and_neck_pathological_87046", "grade_post_therapy_clin_61658", "neoadjuvant_therapy_37302", "eod_regional_nodes_12613", "grade_clinical_6485", "nodes_pos_fpa", "neoadj_tx_clinical_response_31723", "histology", "nodes_exam_76029", "eod_mets_89421", "tumor_size_summary_63115", "combined_grade_56638", "behavior", "derived_ss2018_larynx_other_66228", "schema_selection_larynx_other", "grade_post_therapy_path_40048", "extension_baw", "type_of_reporting_source_76696", "tumor_size_pathological_25597", "tumor_size_clinical_60979", "neoadj_tx_treatment_effect_18122", "primary_site", "extranodal_extension_head_and_neck_clinical_79321", "grade_pathological_84704", "year_dx_validation", "derived_grade_69945", "summary_stage_rpa", "ln_size_70140", "ss2018_larynx_other_excluding_melanoma_8720_8790_40558" ], - "last_modified" : "2025-09-19T18:54:58.217Z", + "last_modified" : "2025-11-14T20:05:18.559Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/larynx_subglottic.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/larynx_subglottic.json index b8cc4d134..e54602a94 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/larynx_subglottic.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/larynx_subglottic.json @@ -250,10 +250,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] }, { "key" : "ln_size_of_mets", @@ -272,10 +272,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] } ], "outputs" : [ { @@ -328,6 +328,6 @@ } ] } ], "involved_tables" : [ "extranodal_extension_head_and_neck_pathological_87046", "grade_post_therapy_clin_61658", "neoadjuvant_therapy_37302", "eod_regional_nodes_12613", "schema_selection_larynx_subglottic", "derived_ss2018_larynx_subglottic_66548", "grade_clinical_6485", "nodes_pos_fpa", "neoadj_tx_clinical_response_31723", "histology", "nodes_exam_76029", "eod_mets_89421", "tumor_size_summary_63115", "combined_grade_56638", "behavior", "ss2018_larynx_subglottic_excluding_melanoma_8720_8790_93242", "extension_bav", "grade_post_therapy_path_40048", "type_of_reporting_source_76696", "tumor_size_pathological_25597", "tumor_size_clinical_60979", "neoadj_tx_treatment_effect_18122", "primary_site", "extranodal_extension_head_and_neck_clinical_79321", "grade_pathological_84704", "year_dx_validation", "derived_grade_69945", "summary_stage_rpa", "ln_size_70140" ], - "last_modified" : "2025-09-19T18:54:54.110Z", + "last_modified" : "2025-11-14T20:05:06.008Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/larynx_supraglottic.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/larynx_supraglottic.json index 3b215d206..7686c934d 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/larynx_supraglottic.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/larynx_supraglottic.json @@ -4,15 +4,16 @@ "version" : "3.3", "name" : "Larynx Supraglottic", "title" : "Larynx Supraglottic", - "notes" : "8000-8700\n\nC101 Epiglottis anterior\nC321 Supraglottis\n\n**Note 1:** **Sources used in the development of this schema**\n* SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998) (https://seer.cancer.gov/archive/manuals/EOD10Dig.3rd.pdf)\n* SEER Summary Staging Manual-2000: Codes and Coding Instructions (https://seer.cancer.gov/tools/ssm/ssm2000/)\n* Collaborative Stage Data Collection System, version 02.05: https://cancerstaging.org/cstage/Pages/default.aspx \n* Chapter 13 *Larynx*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois.\n\n**Note 2:** **Other EOD Schemas with Supraglottic Larynx sites**\n* **GIST**: 8935-8936\n* **Kaposi Sarcoma**: 9140\n* **Mycosis Fungoides**: 9700-9701\n* **Soft Tissue Head and Neck**: 8710-8714, 8800-8803, 8810-8905, 8912, 8921, 8932-8934, 8940-8990, 9000-9016, 9030-9043, 9045-9110, 9121-9138, 9141-9230, 9240-9580, 9582\n* **Melanoma Head and Neck**: 8720-8790\n* **Soft Tissue Other**: 8992\n* **Soft Tissue Rare**: 8804-8806, 8910, 8920, 8930-8931, 8991, 9020, 9044, 9120, 9231, 9581", + "notes" : "8000-8700\n\nC101 Anterior surface of epiglottis (2018-2025)\nC321 Supraglottis\n\n**Note 1:** **Sources used in the development of this schema**\n* SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998) (https://seer.cancer.gov/archive/manuals/EOD10Dig.3rd.pdf)\n* SEER Summary Staging Manual-2000: Codes and Coding Instructions (https://seer.cancer.gov/tools/ssm/ssm2000/)\n* Collaborative Stage Data Collection System, version 02.05: https://cancerstaging.org/cstage/Pages/default.aspx \n* Chapter 13 *Larynx*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois.\n\n**Note 2:** **Other EOD Schemas with Supraglottic Larynx sites**\n* **GIST**: 8935-8936\n* **Kaposi Sarcoma**: 9140\n* **Mycosis Fungoides**: 9700-9701\n* **Soft Tissue Head and Neck**: 8710-8714, 8800-8803, 8810-8905, 8912, 8921, 8932-8934, 8940-8990, 9000-9016, 9030-9043, 9045-9110, 9121-9138, 9141-9230, 9240-9580, 9582\n* **Melanoma Head and Neck**: 8720-8790\n* **Soft Tissue Other**: 8992\n* **Soft Tissue Rare**: 8804-8806, 8910, 8920, 8930-8931, 8991, 9020, 9044, 9120, 9231, 9581", "schema_selection_table" : "schema_selection_larynx_supraglottic", + "schema_discriminators" : [ "year_dx" ], "inputs" : [ { "key" : "year_dx", "name" : "Year of Diagnosis", "naaccr_item" : 390, "naaccr_xml_id" : "dateOfDiagnosis", "table" : "year_dx_validation", - "used_for_staging" : false + "used_for_staging" : true }, { "key" : "site", "name" : "Primary Site", @@ -250,10 +251,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] }, { "key" : "ln_size_of_mets", @@ -272,10 +273,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] } ], "outputs" : [ { @@ -328,6 +329,6 @@ } ] } ], "involved_tables" : [ "extranodal_extension_head_and_neck_pathological_87046", "grade_post_therapy_clin_61658", "neoadjuvant_therapy_37302", "eod_regional_nodes_12613", "grade_clinical_6485", "nodes_pos_fpa", "neoadj_tx_clinical_response_31723", "histology", "nodes_exam_76029", "eod_mets_89421", "ss2018_larynx_supraglottic_excluding_melanoma_8720_8790_91429", "schema_selection_larynx_supraglottic", "tumor_size_summary_63115", "combined_grade_56638", "behavior", "derived_ss2018_larynx_supraglottic_62635", "extension_bau", "grade_post_therapy_path_40048", "type_of_reporting_source_76696", "tumor_size_pathological_25597", "tumor_size_clinical_60979", "neoadj_tx_treatment_effect_18122", "primary_site", "extranodal_extension_head_and_neck_clinical_79321", "grade_pathological_84704", "year_dx_validation", "derived_grade_69945", "summary_stage_rpa", "ln_size_70140" ], - "last_modified" : "2025-09-19T18:54:50.705Z", + "last_modified" : "2025-11-14T20:05:28.205Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/lip.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/lip.json index 9d5805230..059408c3b 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/lip.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/lip.json @@ -251,10 +251,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] }, { "key" : "ln_size_of_mets", @@ -273,10 +273,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] }, { "key" : "seer_ssf1", @@ -340,6 +340,6 @@ } ] } ], "involved_tables" : [ "extranodal_extension_head_and_neck_pathological_87046", "grade_post_therapy_clin_61658", "neoadjuvant_therapy_37302", "tumor_size_pathological_43328", "eod_primary_tumor_3897", "grade_clinical_6485", "nodes_pos_fpa", "neoadj_tx_clinical_response_31723", "histology", "nodes_exam_76029", "derived_ss2018_lip_8421", "schema_selection_lip_lower", "combined_grade_56638", "behavior", "nodes_daa", "tumor_size_clinical_48894", "seer_mets_lip_lower_28596", "grade_post_therapy_path_40048", "type_of_reporting_source_76696", "neoadj_tx_treatment_effect_18122", "p16_hpv_human_papilloma_virus_status_head_and_neck_509", "primary_site", "extranodal_extension_head_and_neck_clinical_79321", "grade_pathological_84704", "year_dx_validation", "derived_grade_69945", "ss2018_lip_92534", "summary_stage_rpa", "tumor_size_summary_47973", "ln_size_70140" ], - "last_modified" : "2025-09-19T18:55:09.144Z", + "last_modified" : "2025-11-14T20:06:03.194Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/liver.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/liver.json index d5a9697ed..b04a69010 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/liver.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/liver.json @@ -342,7 +342,7 @@ }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", "start" : 2018, - "end" : 2025 + "end" : 2023 } ] } ], "outputs" : [ { @@ -395,6 +395,6 @@ } ] } ], "involved_tables" : [ "neoadjuvant_therapy_37302", "tumor_size_pathological_43328", "ss2018_liver_84469", "derived_grade_46639", "grade_post_therapy_path_41285", "grade_pathological_31963", "grade_post_therapy_clin_41222", "nodes_pos_fpa", "mets_haf", "extension_bbc", "derived_ss2018_liver_13967", "neoadj_tx_clinical_response_31723", "afp_pretx_lab_value_25871", "fibrosis_score_38658", "histology", "nodes_exam_76029", "bilirubin_pretx_unit_98627", "inr_prothrombin_time_6158", "combined_grade_56638", "behavior", "nodes_dau", "bilirubin_pretx_lab_value_68660", "schema_selection_liver", "tumor_size_clinical_48894", "type_of_reporting_source_76696", "creatinine_pretx_lab_value_56869", "afp_pretx_interpretation_66147", "neoadj_tx_treatment_effect_18122", "primary_site", "year_dx_validation", "grade_clinical_73056", "summary_stage_rpa", "tumor_size_summary_47973", "creatinine_pretx_unit_26973" ], - "last_modified" : "2025-09-19T18:54:48.098Z", + "last_modified" : "2025-11-14T20:05:18.214Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/lung.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/lung.json index 15ab428f6..45d6816a6 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/lung.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/lung.json @@ -234,6 +234,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, + "end" : 2023 + }, { + "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", + "start" : 2024, "end" : 2024 } ] }, { @@ -251,6 +255,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, + "end" : 2023 + }, { + "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", + "start" : 2024, "end" : 2024 } ] }, { @@ -340,6 +348,6 @@ } ] } ], "involved_tables" : [ "neoadjuvant_therapy_37302", "derived_grade_46639", "grade_post_therapy_path_41285", "mets_hab", "grade_pathological_31963", "grade_post_therapy_clin_41222", "tumor_size_pathological_full_62176", "nodes_pos_fpa", "alk_rearrangement_610", "neoadj_tx_clinical_response_31723", "histology", "nodes_exam_76029", "neoadj_tx_treatment_effect_4391", "combined_grade_56638", "behavior", "schema_selection_lung", "derived_ss2018_lung_59907", "tumor_size_clinical_full_74867", "nodes_dai", "egfr_mutational_analysis_51122", "type_of_reporting_source_76696", "visceral_pleural_invasion_25940", "tumor_size_summary_full_31213", "primary_site", "separate_tumor_nodules_69006", "year_dx_validation", "extension_baj", "grade_clinical_73056", "summary_stage_rpa", "ss2018_lung_41334" ], - "last_modified" : "2025-09-19T18:54:45.126Z", + "last_modified" : "2025-11-14T20:06:09.118Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/lung_v9_2025.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/lung_v9_2025.json index 1f4f8bb97..c166529dc 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/lung_v9_2025.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/lung_v9_2025.json @@ -231,13 +231,9 @@ "name" : "COC_REQUIRED" }, { "name" : "SSDI" - }, { - "name" : "SEER_REQUIRED", - "start" : 2025, - "end" : 2025 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2025 } ] }, { "key" : "visceral_pleural_invasion", @@ -251,13 +247,9 @@ "name" : "COC_REQUIRED" }, { "name" : "SSDI" - }, { - "name" : "SEER_REQUIRED", - "start" : 2025, - "end" : 2025 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2025 } ] }, { "key" : "alk_rearrangement", @@ -320,7 +312,7 @@ "key" : "stas", "name" : "Lung STAS", "naaccr_item" : 1176, - "naaccr_xml_id" : "lungSTAS", + "naaccr_xml_id" : "spreadThroughAirSpacesStas", "default" : "8", "table" : "spread_through_air_spaces_stas_67834", "used_for_staging" : false, @@ -385,6 +377,6 @@ } ] } ], "involved_tables" : [ "neoadjuvant_therapy_37302", "pd_l1_61573", "derived_grade_46639", "grade_post_therapy_path_41285", "grade_pathological_31963", "eod_primary_tumor_v9_75679", "grade_post_therapy_clin_41222", "tumor_size_pathological_full_62176", "nodes_pos_fpa", "schema_selection_lung_v9_2025", "alk_rearrangement_610", "neoadj_tx_clinical_response_31723", "histology", "nodes_exam_76029", "neoadj_tx_treatment_effect_4391", "combined_grade_56638", "behavior", "eod_mets_v9_76161", "derived_ss2018_lung_59907", "tumor_size_clinical_full_74867", "egfr_mutational_analysis_51122", "type_of_reporting_source_76696", "visceral_pleural_invasion_25940", "tumor_size_summary_full_31213", "primary_site", "separate_tumor_nodules_69006", "eod_regional_nodes_v9_56625", "year_dx_validation", "grade_clinical_73056", "summary_stage_rpa", "spread_through_air_spaces_stas_67834", "ss2018_lung_41334" ], - "last_modified" : "2025-09-19T18:55:09.463Z", + "last_modified" : "2025-11-14T20:06:08.669Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/lymphoma.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/lymphoma.json index c8e38d2fb..a20a5cd34 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/lymphoma.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/lymphoma.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Lymphoma", "title" : "Lymphoma", - "notes" : "9590, 9596-9663, 9673-9699, 9702-9719, 9725-9726, 9735, 9737-9738, 9826-9827 (varying primary sites and histologies)\n* C700-C729, C751-C753: 9690, 9719 (2018-2022 only) (See **Note 2**)\n\nC000-C440, C442-C689, C691-C694, C698-C809: 9591 and Schema Discriminator 1: 3, 9 \n\n*See SSDI Manual, Appendix A: Schema ID 00790: Lymphoma for detailed listing of primary site/histology combinations for this schema*\n\n**Note 1:** **Sources used in the development of this schema**\n* SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998) (https://seer.cancer.gov/archive/manuals/EOD10Dig.3rd.pdf)\n* SEER Summary Staging Manual-2000: Codes and Coding Instructions (https://seer.cancer.gov/tools/ssm/ssm2000/)\n* Collaborative Stage Data Collection System, version 02.05: https://cancerstaging.org/cstage/Pages/default.aspx \n* Chapter 79 *Hodgkin and Non-Hodgkin Lymphomas*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois.\n* Chapter 80 *Pediatric Hodgkin and Non-Hodgkin Lymphomas*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois.\n\n**Note 2:** **Histologies moved to Brain, CNS, Intracranial Gland** \n* For the histologies listed below, these have moved to the Brain, CNS Other and Intracranial Gland schemas starting with 2023 diagnoses. \n* If you have one of these cases for 2018-2022, then this is the appropriate schema. If you have one of these cases diagnosed on January 1, 2023, forward, see the appropriate schema\n* 9690, 9719 \n * **Brain**: C700, C710-C719\n * **CNS Other**: C701, C709, C720-C725, C728-C729\n * **Intracranial Gland**: C751-C753\n\n**Note 3:** **Other EOD Schemas with the listed histologies**\n* **Brain**: C700, C710-C719 (9680, 9699, 9702-9715)\n* **CNS Other**: C701, C709, C720-C725, C728-C729 (9680, 9699, 9702-9715)\n* **Heme Retic**: 9591 and Schema Discriminator 1: 1, 2 (C000-C440, C442-C689, C691-C694, C698-C809)\n* **Intracranial Gland**: C751-C753 (9680, 9699, 9702-9715)\n* **Lymphoma CLL/SLL**: C000-C440, C442-C689, C691-C694, C698-C809 (9823)\n* **Lymphoma Ocular Adnexa**: C441, C690, C695-C696 (9590-9699, 9673-9699, 9702-9719, 9725-9726, 9734-9738, 9823, 9826-9827, 9930)\n* **Primary Cutaneous Lymphoma**: C440, C442-C449, C510, C609, C632 (9597, 9680, 9708-9709, 9712, 9718-9719, 9726): *Primary Cutaneous Lymphomas*\n\n**Note 4:** **Lugano Staging** \n* The Cotswold modification of the Ann Arbor staging system (used in AJCC 6th and 7th editions) has been updated to the *Lugano classification*. \n* The *Lugano classification* includes an E suffix for lymphoma with either localized extralymphatic presentations (Stage IE) or by contiguous spread from nodal disease (Stage IIE). \n* A change from the Cotswold modification of the Ann Arbor Staging System, E lesions do not apply to patients with Stage III nodal disease; or any patient with nodal disease above and below the diaphragm with concurrent contiguous extralymphatic involvement (Stage IV), which was previously Stage IIIE.\n\n**Note 5:** **Schema includes the preferred terms based on the 2024 WHO Classification of Tumours, Haematolymphoid tumors, 5th edition**\n\n* 9590: Malignant lymphoma, NOS\n* 9591: Malignant lymphoma, non-Hodgkin, NOS\n* 9596: Mediastinal grey zone lymphoma (MGZL)\n* 9597: Primary cutaneous follicle centre lymphoma (PCFCL)\n* 9650: Classic Hodgkin lymphoma (cHL), NOS\n* 9651: Classic Hodgkin lymphoma, lymphocyte-rich (LR-cHL)\n* 9652: Classic Hodgkin lymphoma, mixed cellularity (MC-cHL)\n* 9653: Classic Hodgkin lymphoma, lymphocyte-depleted, NOS (LD-cHL)\n* 9659: Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL)\n* 9663: Classic Hodgkin lymphoma, nodular sclerosis, NOS (NSCHL) \n* 9673: Mantle cell lymphoma (MCL)\n* 9678: Primary effusion lymphoma (PEL)\n* 9679: Primary mediastinal large B-cell lymphoma (PBML/PMBCL)\n* 9680: Diffuse large B-cell lymphoma (DLBCL)\n* 9687: Burkitt lymphoma (BL), NOS\n* 9688: T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL)\n* 9689: Splenic marginal zone lymphoma (SMZL)\n* 9690 Follicular lymphoma (FL), NOS (except C700-C729, C751-C753 for 1/1/2023+)\n* 9691: Follicular lymphoma, grade 2\n* 9695: Follicular lymphoma, grade 1\n* 9698: Follicular lymphoma, grade 3\n* 9699: Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)\n* 9702: Peripheral T-cell lymphoma, NOS\n* 9705: Nodal T follicular helper cell lymphoma, angioimmunoblastic type\n* 9708: Subcutaneous panniculitis-like T-cell lymphoma (SPTCL)\n* 9709: Primary cutaneous peripheral T-cell lymphomas (pcCTCL)\n* 9712: Intravascular large B-cell lymphoma (IVLBCL)\n* 9714: Anaplastic large cell lymphoma, ALK-positive (ALCL)\n* 9715: Anaplastic large cell lymphoma, ALK-negative (ALK-ALCL) (2021+ only)\n* 9716: Hepatosplenic T-cell lymphoma (HSTCL)\n* 9717: Intestinal T-cell lymphoma, NOS (ITCL-NOS)\n* 9718: Primary cutaneous anaplastic large cell lymphoma (C-ALCL)\n* 9719: Extranodal NK/T-cell lymphoma (ENKTL) (except C700-C729, C751-C753 for 1/1/2023+)\n* 9725: Hydroa vacciniforme-like lymphoma (2018-2020 only, nonreportable as of 2021)\n* 9726 Primary cutaneous gamma-delta T-cell lymphoma (PCGD-TCL) (2018-2020 only, see code 9687/3 for 2021+)\n* 9735: Plasmablastic lymphoma (PBL)\n* 9737: ALK-positive large B-cell lymphoma (ALK+LBCL)\n* 9738: KSHV/HHV8-positive diffuse large B-cell lymphoma \n* 9826: Burkitt cell leukemia (2018-2020 only, see code 9687/3 for 2021+)\n* 9827: Adult T-cell leukemia/lymphoma (ATLL)", + "notes" : "9590, 9596-9663, 9673-9699, 9702-9719, 9725-9726, 9735, 9737-9738, 9826-9827 (varying primary sites and histologies)\n* C700-C729, C751-C753: 9690, 9719 (2018-2022 only) (See **Note 2**)\n\nC000-C440, C442-C689, C691-C694, C698-C809: 9591 and Schema Discriminator 1: 3, 9 \n\n*See SSDI Manual, Appendix A: Schema ID 00790: Lymphoma for detailed listing of primary site/histology combinations for this schema*\n\n**Note 1:** **Sources used in the development of this schema**\n* SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998) (https://seer.cancer.gov/archive/manuals/EOD10Dig.3rd.pdf)\n* SEER Summary Staging Manual-2000: Codes and Coding Instructions (https://seer.cancer.gov/tools/ssm/ssm2000/)\n* Collaborative Stage Data Collection System, version 02.05: https://cancerstaging.org/cstage/Pages/default.aspx \n* Chapter 79 *Hodgkin and Non-Hodgkin Lymphomas*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois.\n* Chapter 80 *Pediatric Hodgkin and Non-Hodgkin Lymphomas*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois.\n\n**Note 2:** **Histologies moved to Brain, CNS, Intracranial Gland** \n* For the histologies listed below, these have moved to the Brain, CNS Other and Intracranial Gland schemas starting with 2023 diagnoses. \n* If you have one of these cases for 2018-2022, then this is the appropriate schema. If you have one of these cases diagnosed on January 1, 2023, forward, see the appropriate schema\n* 9690, 9719 \n * **Brain**: C700, C710-C719\n * **CNS Other**: C701, C709, C720-C725, C728-C729\n * **Intracranial Gland**: C751-C753\n\n**Note 3:** **Other EOD Schemas with the listed histologies**\n* **Brain**: C700, C710-C719 (9680, 9699, 9702-9715) (9690, 9719, 2023+)\n* **CNS Other**: C701, C709, C720-C725, C728-C729 (9680, 9699, 9702-9715) (9690, 9719, 2023+)\n* **Heme Retic**: 9591 and Schema Discriminator 1: 1, 2 (C000-C440, C442-C689, C691-C694, C698-C809)\n* **Intracranial Gland**: C751-C753 (9680, 9699, 9702-9715) (9690, 9719, 2023+)\n* **Lymphoma CLL/SLL**: C000-C440, C442-C689, C691-C694, C698-C809 (9823)\n* **Lymphoma Ocular Adnexa**: C441, C690, C695-C696 (9590-9699, 9673-9699, 9702-9719, 9725-9726, 9734-9738, 9823, 9826-9827, 9930)\n* **Primary Cutaneous Lymphoma**: C440, C442-C449, C510, C609, C632 (9597, 9680, 9708-9709, 9712, 9718-9719, 9726): *Primary Cutaneous Lymphomas*\n\n**Note 4:** **Lugano Staging** \n* The Cotswold modification of the Ann Arbor staging system (used in AJCC 6th and 7th editions) has been updated to the *Lugano classification*. \n* The *Lugano classification* includes an E suffix for lymphoma with either localized extralymphatic presentations (Stage IE) or by contiguous spread from nodal disease (Stage IIE). \n* A change from the Cotswold modification of the Ann Arbor Staging System, E lesions do not apply to patients with Stage III nodal disease; or any patient with nodal disease above and below the diaphragm with concurrent contiguous extralymphatic involvement (Stage IV), which was previously Stage IIIE.\n\n**Note 5:** **The preferred histology terms in this schema are from the 2024 WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition.**\n\n* 9590: Malignant lymphoma, NOS\n* 9591: Malignant lymphoma, non-Hodgkin, NOS\n* 9596: Mediastinal grey zone lymphoma (MGZL)\n* 9597: Primary cutaneous follicle centre lymphoma (PCFCL)\n* 9650: Classic Hodgkin lymphoma (CHL), NOS\n* 9651: Classic Hodgkin lymphoma, lymphocyte-rich (LR-cHL)\n* 9652: Classic Hodgkin lymphoma, mixed cellularity (MC-cHL)\n* 9653: Classic Hodgkin lymphoma, lymphocyte-depleted, NOS (LD-cHL)\n* 9659: Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL)\n* 9663: Classic Hodgkin lymphoma, nodular sclerosis, NOS (NSCHL) \n* 9673: Mantle cell lymphoma (MCL)\n* 9678: Primary effusion lymphoma (PEL)\n* 9679: Primary mediastinal large B-cell lymphoma (PBML/PMBCL)\n* 9680: Diffuse large B-cell lymphoma (DLBCL)\n* 9687: Burkitt lymphoma (BL), NOS\n* 9688: T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL)\n* 9689: Splenic marginal zone lymphoma (SMZL)\n* 9690 Follicular lymphoma (FL), NOS \n* 9691: Follicular lymphoma, grade 2\n* 9695: Follicular lymphoma, grade 1\n* 9698: Follicular lymphoma, grade 3\n* 9699: Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)\n* 9702: Peripheral T-cell lymphoma, NOS\n* 9705: Nodal T follicular helper cell lymphoma, angioimmunoblastic type\n* 9708: Subcutaneous panniculitis-like T-cell lymphoma (SPTCL)\n* 9709: Primary cutaneous peripheral T-cell lymphomas (pcCTCL)\n* 9712: Intravascular large B-cell lymphoma (IVLBCL)\n* 9714: Anaplastic large cell lymphoma, ALK-positive (ALCL)\n* 9715: Anaplastic large cell lymphoma, ALK-negative (ALK-ALCL) *(2021+ only)*\n* 9716: Hepatosplenic T-cell lymphoma (HSTCL)\n* 9717: Intestinal T-cell lymphoma, NOS (ITCL-NOS)\n* 9718: Primary cutaneous anaplastic large cell lymphoma (C-ALCL)\n* 9719: Extranodal NK/T-cell lymphoma (ENKTL) \n* 9725: Hydroa vacciniforme-like lymphoma *(2018-2020 only, nonreportable as of 2021)*\n* 9726 Primary cutaneous gamma-delta T-cell lymphoma (PCGD-TCL) \n* 9735: Plasmablastic lymphoma (PBL)\n* 9737: ALK-positive large B-cell lymphoma (ALK+LBCL)\n* 9738: KSHV/HHV8-positive diffuse large B-cell lymphoma \n* 9826: Burkitt cell leukemia *(2018-2020 only, see code 9687/3 for 2021+)*\n* 9827: Adult T-cell leukemia/lymphoma (ATLL)", "schema_selection_table" : "schema_selection_lymphoma", "schema_discriminators" : [ "year_dx", "discriminator_1", "behavior" ], "inputs" : [ { @@ -254,12 +254,7 @@ }, { "name" : "CCCR_REQUIRED" }, { - "name" : "SEER_REQUIRED", - "start" : 2018, - "end" : 2025 - }, { - "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "name" : "SEER_REQUIRED" } ] }, { "key" : "hiv", @@ -272,7 +267,9 @@ "metadata" : [ { "name" : "SSDI" }, { - "name" : "SEER_REQUIRED" + "name" : "SEER_REQUIRED", + "start" : 2018, + "end" : 2023 }, { "name" : "COC_REQUIRED", "start" : 2018, @@ -293,10 +290,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] }, { "key" : "ptld", @@ -370,6 +367,6 @@ } ] } ], "involved_tables" : [ "neoadjuvant_therapy_37302", "tumor_size_clinical_dna_64119", "ss2018_lymphoma_27031", "hiv_status_12569", "nodes_exam_dna_95635", "tumor_size_summary_dna_13275", "ptld_17694", "neoadj_tx_clinical_response_31723", "grade_post_therapy_clin_74830", "histology", "derived_ss2018_lymphoma_35135", "schema_discriminator_1_63995", "intern_prognostic_index_90310", "mets_hna", "behavior", "nodes_dna", "derived_grade_21945", "schema_selection_lymphoma", "tumor_size_pathological_dna_6742", "type_of_reporting_source_76696", "summary_stage_lymphoma_25139", "primary_site", "neoadj_tx_treatment_effect_52725", "year_dx_validation", "systemic_symptoms_at_dx_60639", "derived_summary_grade_na_6690", "grade_post_therapy_path_65729", "eod_primary_tumor_72245", "grade_clinical_18316", "grade_pathological_73388", "nodes_pos_dna_91511" ], - "last_modified" : "2025-09-19T18:54:58.887Z", + "last_modified" : "2025-11-14T20:06:00.820Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/lymphoma_cll_sll.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/lymphoma_cll_sll.json index 165d807c3..a45e2da0d 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/lymphoma_cll_sll.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/lymphoma_cll_sll.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Lymphoma-CLL/SLL", "title" : "Lymphoma-CLL/SLL", - "notes" : "9823 (EXCEPT C441, C690, C695-C696)\n\n**Note 1:** **Sources used in the development of this schema**\n* SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998) (https://seer.cancer.gov/archive/manuals/EOD10Dig.3rd.pdf)\n* SEER Summary Staging Manual-2000: Codes and Coding Instructions (https://seer.cancer.gov/tools/ssm/ssm2000/)\n* Collaborative Stage Data Collection System, version 02.05: https://cancerstaging.org/cstage/Pages/default.aspx \n* Chapter 79 *Hodgkin and Non-Hodgkin Lymphomas*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois.\n* Chapter 80 *Pediatric Hodgkin and Non-Hodgkin Lymphomas*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois.\n\n**Note 2:** **See the following schema for the listed primary sites**\n* C441, C690, C695-C696 (9823): *Lymphoma Ocular Adnexa*\n\n**Note 3:** **CLL/SLL staging**\n* Chronic lymphocytic leukemia/Small lymphocytic lymphoma (CLL/SLL) is always staged as a lymphoma.\n\n**Note 4:** **Lugano Staging** \n* The Cotswold modification of the Ann Arbor staging system (used in AJCC 6th and 7th editions) has been updated to the *Lugano classification*. \n* The *Lugano classification* includes an E suffix for lymphoma with either localized extralymphatic presentations (Stage IE) or by contiguous spread from nodal disease (Stage IIE). \n* A change from the Cotswold modification of the Ann Arbor Staging System, E lesions do not apply to patients with Stage III nodal disease; or any patient with nodal disease above and below the diaphragm with concurrent contiguous extralymphatic involvement (Stage IV), which was previously Stage IIIE.\n\n**Note 5:** **Additional data items for CLL/SLL** \n* In addition to coding EOD Primary Tumor, the following data items are also needed to assign a stage group for CLL/SLL.\n * Lymphocytosis\n * Adenopathy\n * Organomegaly\n * Anemia\n * Thrombocytopenia", + "notes" : "**9823: Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)** *(EXCEPT C441, C690, C695-C696)*\n\n**Note 1:** **Sources used in the development of this schema**\n* SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998) (https://seer.cancer.gov/archive/manuals/EOD10Dig.3rd.pdf)\n* SEER Summary Staging Manual-2000: Codes and Coding Instructions (https://seer.cancer.gov/tools/ssm/ssm2000/)\n* Collaborative Stage Data Collection System, version 02.05: https://cancerstaging.org/cstage/Pages/default.aspx \n* Chapter 79 *Hodgkin and Non-Hodgkin Lymphomas*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois.\n* Chapter 80 *Pediatric Hodgkin and Non-Hodgkin Lymphomas*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois.\n\n**Note 2:** **See the following schema for the listed primary sites**\n* C441, C690, C695-C696 (9823): *Lymphoma Ocular Adnexa*\n\n**Note 3:** **CLL/SLL staging**\n* Chronic lymphocytic leukemia/Small lymphocytic lymphoma (CLL/SLL) is always staged as a lymphoma.\n\n**Note 4:** **Lugano Staging** \n* The Cotswold modification of the Ann Arbor staging system (used in AJCC 6th and 7th editions) has been updated to the *Lugano classification*. \n* The *Lugano classification* includes an E suffix for lymphoma with either localized extralymphatic presentations (Stage IE) or by contiguous spread from nodal disease (Stage IIE). \n* A change from the Cotswold modification of the Ann Arbor Staging System, E lesions do not apply to patients with Stage III nodal disease; or any patient with nodal disease above and below the diaphragm with concurrent contiguous extralymphatic involvement (Stage IV), which was previously Stage IIIE.\n\n**Note 5:** **Additional data items for CLL/SLL** \n* In addition to coding EOD Primary Tumor, the following data items are also needed to assign a stage group for CLL/SLL.\n * Lymphocytosis\n * Adenopathy\n * Organomegaly\n * Anemia\n * Thrombocytopenia", "schema_selection_table" : "schema_selection_chronic_lymphocytic_leukemia_small_lymphocytic_lymphoma_cll_sll", "schema_discriminators" : [ "behavior" ], "inputs" : [ { @@ -236,12 +236,7 @@ }, { "name" : "CCCR_REQUIRED" }, { - "name" : "SEER_REQUIRED", - "start" : 2018, - "end" : 2025 - }, { - "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "name" : "SEER_REQUIRED" } ] }, { "key" : "hiv", @@ -254,7 +249,9 @@ "metadata" : [ { "name" : "SSDI" }, { - "name" : "SEER_REQUIRED" + "name" : "SEER_REQUIRED", + "start" : 2018, + "end" : 2023 }, { "name" : "COC_REQUIRED", "start" : 2018, @@ -275,10 +272,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] }, { "key" : "lymphocytosis", @@ -445,6 +442,6 @@ } ] } ], "involved_tables" : [ "neoadjuvant_therapy_37302", "tumor_size_clinical_dna_64119", "thrombocytopenia_8479", "ss2018_lymphoma_27031", "lymphocytosis_79150", "hiv_status_12569", "derived_rai_stage_73218", "nodes_exam_dna_95635", "tumor_size_summary_dna_13275", "ptld_17694", "neoadj_tx_clinical_response_31723", "grade_post_therapy_clin_74830", "histology", "derived_ss2018_lymphoma_35135", "derive_rai_stage_42032", "intern_prognostic_index_90310", "mets_hna", "behavior", "adenopathy_40816", "nodes_dna", "eod_primary_tumor_copy_25294", "derived_grade_21945", "tumor_size_pathological_dna_6742", "type_of_reporting_source_76696", "summary_stage_lymphoma_25139", "anemia_15893", "organomegaly_16131", "primary_site", "neoadj_tx_treatment_effect_52725", "schema_selection_chronic_lymphocytic_leukemia_small_lymphocytic_lymphoma_cll_sll", "year_dx_validation", "systemic_symptoms_at_dx_60639", "derived_summary_grade_na_6690", "grade_post_therapy_path_65729", "grade_clinical_18316", "grade_pathological_73388", "nodes_pos_dna_91511" ], - "last_modified" : "2025-09-19T18:55:11.913Z", + "last_modified" : "2025-11-14T20:06:16.063Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/lymphoma_ocular_adnexa.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/lymphoma_ocular_adnexa.json index c74dade14..231c1bb89 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/lymphoma_ocular_adnexa.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/lymphoma_ocular_adnexa.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Lymphoma Ocular Adnexa", "title" : "Lymphoma Ocular Adnexa", - "notes" : "9590-9699, 9702-9719, 9725-9726, 9734-9738, 9823, 9826-9827, 9930 (C441, C690, C695-C696)\n\n**Note 1:** **Sources used in the development of this schema**\n* SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998) (https://seer.cancer.gov/archive/manuals/EOD10Dig.3rd.pdf)\n* SEER Summary Staging Manual-2000: Codes and Coding Instructions (https://seer.cancer.gov/tools/ssm/ssm2000/)\n* Collaborative Stage Data Collection System, version 02.05: https://cancerstaging.org/cstage/Pages/default.aspx \n* Chapter 71 *Ocular Adnexal Lymphoma*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois.\n\n**Note 2:** **Origination of Ocular Adnexal Lymphomas** \n* Ocular adnexal lymphomas (OAL) originate in conjunctiva, eyelids, lacrimal gland, lacrimal drainage apparatus, and other orbital tissues surrounding the eye. This schema should not be used for secondary lymphomatous involvement of ocular adnexa or for intraocular lymphomas.\n\n**Note 3:** **Schema includes the preferred terms based on the 2024 WHO Classification of Tumours, Haematolymphoid tumors, 5th edition**", + "notes" : "9590-9699, 9702-9719, 9725-9726, 9734-9738, 9823, 9826-9827, 9930 (C441, C690, C695-C696)\n\n**Note 1:** **Sources used in the development of this schema**\n* SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998) (https://seer.cancer.gov/archive/manuals/EOD10Dig.3rd.pdf)\n* SEER Summary Staging Manual-2000: Codes and Coding Instructions (https://seer.cancer.gov/tools/ssm/ssm2000/)\n* Collaborative Stage Data Collection System, version 02.05: https://cancerstaging.org/cstage/Pages/default.aspx \n* Chapter 71 *Ocular Adnexal Lymphoma*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois.\n\n**Note 2:** **Origination of Ocular Adnexal Lymphomas** \n* Ocular adnexal lymphomas (OAL) originate in conjunctiva, eyelids, lacrimal gland, lacrimal drainage apparatus, and other orbital tissues surrounding the eye. This schema should not be used for secondary lymphomatous involvement of ocular adnexa or for intraocular lymphomas.\n\n**Note 3:** **The preferred histology terms in this schema are based on the 2024 WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition.**\n\n* 9590: Malignant lymphoma, NOS\n* 9591: Malignant lymphoma, non-Hodgkin, NOS\n* 9596: Mediastinal grey zone lymphoma (MGZL)\n* 9597: Primary cutaneous follicle centre lymphoma (PCFCL)\n* 9650: Classic Hodgkin lymphoma (CHL), NOS\n* 9651: Classic Hodgkin lymphoma, lymphocyte-rich (LR-cHL)\n* 9652: Classic Hodgkin lymphoma, mixed cellularity (MC-cHL)\n* 9653: Classic Hodgkin lymphoma, lymphocyte-depleted, NOS (LD-cHL)\n* 9659: Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL)\n* 9663: Classic Hodgkin lymphoma, nodular sclerosis, NOS (NSCHL) \n* 9673: Mantle cell lymphoma (MCL)\n* 9678: Primary effusion lymphoma (PEL)\n* 9679: Primary mediastinal large B-cell lymphoma (PBML/PMBCL)\n* 9680: Diffuse large B-cell lymphoma (DLBCL)\n* 9687: Burkitt lymphoma (BL), NOS\n* 9688: T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL)\n* 9689: Splenic marginal zone lymphoma (SMZL)\n* 9690 Follicular lymphoma (FL), NOS (except C700-C729, C751-C753 for 1/1/2023+)\n* 9691: Follicular lymphoma, grade 2\n* 9695: Follicular lymphoma, grade 1\n* 9698: Follicular lymphoma, grade 3\n* 9699: Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)\n* 9702: Peripheral T-cell lymphoma, NOS\n* 9705: Nodal T follicular helper cell lymphoma, angioimmunoblastic type\n* 9708: Subcutaneous panniculitis-like T-cell lymphoma (SPTCL)\n* 9709: Primary cutaneous peripheral T-cell lymphomas (pcCTCL)\n* 9712: Intravascular large B-cell lymphoma (IVLBCL)\n* 9714: Anaplastic large cell lymphoma, ALK-positive (ALCL)\n* 9715: Anaplastic large cell lymphoma, ALK-negative (ALK-ALCL) (2021+ only)\n* 9716: Hepatosplenic T-cell lymphoma (HSTCL)\n* 9717: Intestinal T-cell lymphoma, NOS (ITCL-NOS)\n* 9718: Primary cutaneous anaplastic large cell lymphoma (C-ALCL)\n* 9719: Extranodal NK/T-cell lymphoma (ENKTL) (except C700-C729, C751-C753 for 1/1/2023+)\n* 9725: Hydroa vacciniforme-like lymphoma (2018-2020 only, nonreportable as of 2021)\n* 9726 Primary cutaneous gamma-delta T-cell lymphoma (PCGD-TCL) (2018-2020 only, see code 9687/3 for 2021+)\n* 9734: Extramedullary plasmacytoma (EMP)\n* 9735: Plasmablastic lymphoma (PBL)\n* 9737: ALK-positive large B-cell lymphoma (ALK+LBCL)\n* 9738: KSHV/HHV8-positive diffuse large B-cell lymphoma \n* 9823: Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)\n* 9826: Burkitt cell leukemia (2018-2020 only, see code 9687/3 for 2021+)\n* 9827: Adult T-cell leukemia/lymphoma (ATLL)\n* 9930: Myeloid Sarcoma", "schema_selection_table" : "schema_selection_lymphoma_ocular_adnexa", "inputs" : [ { "key" : "year_dx", @@ -262,6 +262,6 @@ } ] } ], "involved_tables" : [ "neoadjuvant_therapy_37302", "schema_selection_lymphoma_ocular_adnexa", "summary_stage_raa", "nodes_pos_fpa", "seer_regional_nodes_27397", "neoadj_tx_clinical_response_31723", "histology", "nodes_exam_76029", "seer_mets_90003", "ss2018_lymphoma_ocular_adnexa_3583", "tumor_size_summary_63115", "combined_grade_56638", "grade_pathological_49403", "derived_ss2018_lymphoma_ocular_adnexa_92324", "extension_bez", "grade_post_therapy_clin_43459", "type_of_reporting_source_76696", "tumor_size_pathological_25597", "tumor_size_clinical_60979", "grade_post_therapy_path_67342", "neoadj_tx_treatment_effect_18122", "primary_site", "grade_clinical_19087", "derived_grade_71063", "year_dx_validation" ], - "last_modified" : "2025-09-19T18:54:55.279Z", + "last_modified" : "2025-11-14T20:06:00.063Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/major_salivary_glands.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/major_salivary_glands.json index 3ec72d4e2..10d06578f 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/major_salivary_glands.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/major_salivary_glands.json @@ -251,6 +251,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, + "end" : 2023 + }, { + "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", + "start" : 2024, "end" : 2025 } ] }, { @@ -270,6 +274,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, + "end" : 2023 + }, { + "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", + "start" : 2024, "end" : 2025 } ] } ], @@ -323,6 +331,6 @@ } ] } ], "involved_tables" : [ "extranodal_extension_head_and_neck_pathological_87046", "neoadjuvant_therapy_37302", "tumor_size_pathological_43328", "nodes_pos_fpa", "neoadj_tx_clinical_response_31723", "histology", "nodes_exam_76029", "combined_grade_56638", "grade_post_therapy_clin_95734", "behavior", "grade_clinical_standard_94331", "ss2018_major_salivary_glands_43893", "tumor_size_clinical_48894", "derived_grade_standard_1196", "extension_bcv", "schema_selection_parotid_gland", "type_of_reporting_source_76696", "derived_ss2018_major_salivary_glands_88669", "neoadj_tx_treatment_effect_18122", "primary_site", "extranodal_extension_head_and_neck_clinical_79321", "eod_regional_nodes_94494", "year_dx_validation", "grade_pathological_standard_94268", "summary_stage_rpa", "ln_size_70140", "grade_post_therapy_path_32110", "tumor_size_summary_47973", "eod_mets_71734" ], - "last_modified" : "2025-09-19T18:55:03.701Z", + "last_modified" : "2025-11-14T20:05:06.506Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/major_salivary_glands_v9_2026.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/major_salivary_glands_v9_2026.json index 8898c8250..fb8586afe 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/major_salivary_glands_v9_2026.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/major_salivary_glands_v9_2026.json @@ -321,6 +321,6 @@ } ] } ], "involved_tables" : [ "extranodal_extension_head_and_neck_pathological_87046", "neoadjuvant_therapy_37302", "grade_pathological_91031", "tumor_size_pathological_43328", "grade_clinical_73461", "nodes_pos_fpa", "neoadj_tx_clinical_response_31723", "histology", "nodes_exam_76029", "grade_post_therapy_path_yp_8036", "grade_post_therapy_clin_yc_31990", "combined_grade_56638", "behavior", "ss2018_major_salivary_glands_43893", "tumor_size_clinical_48894", "derived_grade_standard_1196", "type_of_reporting_source_76696", "eod_regional_nodes_36470", "derived_ss2018_major_salivary_glands_88669", "neoadj_tx_treatment_effect_18122", "primary_site", "extranodal_extension_head_and_neck_clinical_79321", "year_dx_validation", "summary_stage_rpa", "eod_primary_tumor_38280", "schema_selection_major_salivary_glands_v9_2026", "ln_size_70140", "tumor_size_summary_47973", "eod_mets_71734" ], - "last_modified" : "2025-09-19T18:54:56.201Z", + "last_modified" : "2025-11-14T20:06:03.929Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/maxillary_sinus.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/maxillary_sinus.json index 331583cd1..16ba14a33 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/maxillary_sinus.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/maxillary_sinus.json @@ -250,10 +250,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] }, { "key" : "ln_size_of_mets", @@ -272,10 +272,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] } ], "outputs" : [ { @@ -328,6 +328,6 @@ } ] } ], "involved_tables" : [ "extranodal_extension_head_and_neck_pathological_87046", "grade_post_therapy_clin_61658", "neoadjuvant_therapy_37302", "derived_ss2018_nasal_cavity_and_paranasal_sinuses_97890", "schema_selection_sinus_maxillary", "grade_clinical_6485", "nodes_pos_fpa", "eod_mets_94984", "neoadj_tx_clinical_response_31723", "histology", "nodes_exam_76029", "tumor_size_summary_63115", "combined_grade_56638", "behavior", "grade_post_therapy_path_40048", "extension_bax", "type_of_reporting_source_76696", "tumor_size_pathological_25597", "tumor_size_clinical_60979", "ss2018_nasal_cavity_and_ethmoid_sinus_excluding_melanoma_8720_8790_21699", "neoadj_tx_treatment_effect_18122", "eod_regional_nodes_99855", "primary_site", "extranodal_extension_head_and_neck_clinical_79321", "grade_pathological_84704", "year_dx_validation", "derived_grade_69945", "summary_stage_rpa", "ln_size_70140" ], - "last_modified" : "2025-09-19T18:54:42.665Z", + "last_modified" : "2025-11-14T20:06:15.187Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/medulloblastoma_v9_2023.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/medulloblastoma_v9_2023.json index 0efadaa16..013d799dd 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/medulloblastoma_v9_2023.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/medulloblastoma_v9_2023.json @@ -285,6 +285,6 @@ } ] } ], "involved_tables" : [ "neoadjuvant_therapy_37302", "nodes_exam_dna_95635", "grade_post_therapy_path_yp_3519", "eod_mets_22894", "grade_pathological_53280", "neoadj_tx_clinical_response_31723", "histology", "ss2018_medulloblastoma_22906", "grade_clinical_78613", "grade_post_therapy_clin_yc_55565", "tumor_size_summary_63115", "combined_grade_56638", "behavior", "nodes_dna", "derived_ss2018_medulloblastoma_71501", "summary_stage_benign_3306", "schema_selection_medulloblastoma_v9_2023", "type_of_reporting_source_76696", "tumor_size_pathological_25597", "tumor_size_clinical_60979", "brain_molecular_markers_v9_48556", "neoadj_tx_treatment_effect_18122", "derived_grade_96207", "primary_site", "year_dx_validation", "eod_primary_tumor_60922", "nodes_pos_dna_91511" ], - "last_modified" : "2025-09-19T18:54:43.927Z", + "last_modified" : "2025-11-14T20:05:55.521Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/melanoma_choroid_ciliary_body.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/melanoma_choroid_ciliary_body.json index fd9b4e6cb..cf63eff54 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/melanoma_choroid_ciliary_body.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/melanoma_choroid_ciliary_body.json @@ -284,7 +284,7 @@ }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", "start" : 2018, - "end" : 2025 + "end" : 2023 } ] }, { "key" : "mvd", @@ -301,7 +301,7 @@ }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", "start" : 2018, - "end" : 2025 + "end" : 2023 } ] }, { "key" : "mitotic_count_uveal_mel", @@ -333,7 +333,7 @@ }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", "start" : 2018, - "end" : 2025 + "end" : 2023 } ] }, { "key" : "chrom_8q_status", @@ -350,7 +350,7 @@ }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", "start" : 2018, - "end" : 2025 + "end" : 2023 } ] } ], "outputs" : [ { @@ -403,6 +403,6 @@ } ] } ], "involved_tables" : [ "neoadjuvant_therapy_37302", "tumor_size_clinical_dna_64119", "grade_post_therapy_clin_2503", "nodes_pos_fpa", "tumor_size_summary_dna_13275", "neoadj_tx_clinical_response_31723", "derived_grade_93981", "histology", "schema_selection_melanoma_ciliary_body", "nodes_exam_76029", "grade_pathological_46618", "combined_grade_56638", "behavior", "extension_bfq", "grade_post_therapy_path_58350", "extravascular_matrix_patterns_1397", "chromosome_8q_status_83582", "measured_basal_diameter_70699", "melanoma_ciliary_body_melanoma_iris_79773", "tumor_size_pathological_dna_6742", "type_of_reporting_source_76696", "derived_ss2018_melanoma_uvea_22506", "microvascular_density_70589", "eod_regional_nodes_76612", "neoadj_tx_treatment_effect_18122", "primary_site", "mitotic_count_uveal_melanoma_26990", "ss2018_melanoma_choroid_ciliary_body_iris_21929", "measured_thickness_84907", "year_dx_validation", "chromosome_3_status_93464", "summary_stage_rpa", "grade_clinical_54911", "seer_mets_melanomachoroid_55264" ], - "last_modified" : "2025-09-19T18:55:05.700Z", + "last_modified" : "2025-11-14T20:05:50.514Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/melanoma_conjunctiva.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/melanoma_conjunctiva.json index 2f6bb6301..254c46439 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/melanoma_conjunctiva.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/melanoma_conjunctiva.json @@ -284,6 +284,6 @@ } ] } ], "involved_tables" : [ "neoadjuvant_therapy_37302", "nodes_pos_fpa", "neoadj_tx_clinical_response_31723", "histology", "nodes_exam_76029", "tumor_size_summary_63115", "combined_grade_56638", "grade_post_therapy_clin_95734", "behavior", "derived_ss2018_melanoma_conjunctiva_64436", "grade_clinical_standard_94331", "extension_bcs", "derived_grade_standard_1196", "ss2018_melanoma_conjunctiva_86342", "schema_selection_melanoma_conjunctiva", "type_of_reporting_source_76696", "tumor_size_pathological_25597", "eod_regional_nodes_8284", "tumor_size_clinical_60979", "neoadj_tx_treatment_effect_18122", "primary_site", "measured_thickness_84907", "year_dx_validation", "grade_pathological_standard_94268", "summary_stage_rpa", "grade_post_therapy_path_32110", "eod_mets_74247" ], - "last_modified" : "2025-09-19T18:55:14.057Z", + "last_modified" : "2025-11-14T20:05:13.066Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/melanoma_head_neck.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/melanoma_head_neck.json index 7432b8db5..350019d97 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/melanoma_head_neck.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/melanoma_head_neck.json @@ -250,10 +250,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] }, { "key" : "ln_size_of_mets", @@ -272,10 +272,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] }, { "key" : "ln_hn_1_2_3", @@ -292,10 +292,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] }, { "key" : "ln_hn_4_5", @@ -312,10 +312,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] }, { "key" : "ln_hn_6_7", @@ -332,10 +332,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] }, { "key" : "ln_hn_other", @@ -352,10 +352,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] } ], "outputs" : [ { @@ -408,6 +408,6 @@ } ] } ], "involved_tables" : [ "extranodal_extension_head_and_neck_pathological_87046", "neoadjuvant_therapy_37302", "eod_mets_mucosal_head_and_neck_45697", "lymph_nodes_head_and_neck_levels_i_iii_19222", "ss2018_melanoma_head_and_neck_8720_8790_46168", "nodes_pos_fpa", "neoadj_tx_clinical_response_31723", "histology", "nodes_exam_76029", "seer_regional_nodes_91716", "tumor_size_summary_63115", "combined_grade_56638", "schema_selection_melanoma_buccal_mucosa", "behavior", "grade_post_therapy_clin_95734", "grade_clinical_standard_94331", "lymph_nodes_head_and_neck_other_31141", "derived_grade_standard_1196", "lymph_nodes_head_and_neck_levels_vi_vii_32325", "type_of_reporting_source_76696", "tumor_size_pathological_25597", "tumor_size_clinical_60979", "neoadj_tx_treatment_effect_18122", "derived_ss2018_melanoma_head_and_neck_82003", "seer_primary_tumor_head_neck_melanoma_38698", "primary_site", "extranodal_extension_head_and_neck_clinical_79321", "grade_pathological_standard_94268", "year_dx_validation", "lymph_nodes_head_and_neck_levels_iv_v_55093", "summary_stage_rpa", "grade_post_therapy_path_32110", "ln_size_70140" ], - "last_modified" : "2025-09-19T18:54:57.025Z", + "last_modified" : "2025-11-14T20:06:06.338Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/melanoma_iris.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/melanoma_iris.json index 73505f03b..d2223fdc0 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/melanoma_iris.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/melanoma_iris.json @@ -403,6 +403,6 @@ } ] } ], "involved_tables" : [ "neoadjuvant_therapy_37302", "tumor_size_clinical_dna_64119", "grade_post_therapy_clin_2503", "nodes_pos_fpa", "tumor_size_summary_dna_13275", "neoadj_tx_clinical_response_31723", "derived_grade_93981", "histology", "nodes_exam_76029", "grade_pathological_46618", "combined_grade_56638", "schema_selection_melanoma_iris", "behavior", "extension_bfr", "grade_post_therapy_path_58350", "eod_regional_nodes_79068", "extravascular_matrix_patterns_1397", "chromosome_8q_status_83582", "measured_basal_diameter_70699", "melanoma_ciliary_body_melanoma_iris_79773", "tumor_size_pathological_dna_6742", "type_of_reporting_source_76696", "derived_ss2018_melanoma_uvea_22506", "microvascular_density_70589", "neoadj_tx_treatment_effect_18122", "primary_site", "mitotic_count_uveal_melanoma_26990", "ss2018_melanoma_choroid_ciliary_body_iris_21929", "measured_thickness_84907", "year_dx_validation", "chromosome_3_status_93464", "summary_stage_rpa", "grade_clinical_54911", "seer_mets_melanomachoroid_55264" ], - "last_modified" : "2025-09-19T18:54:49.233Z", + "last_modified" : "2025-11-14T20:06:02.493Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/melanoma_skin.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/melanoma_skin.json index 0e770b9c0..2ed3a9240 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/melanoma_skin.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/melanoma_skin.json @@ -304,10 +304,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] }, { "key" : "ldh_upper_limit", @@ -355,13 +355,13 @@ }, { "name" : "SEER_REQUIRED", "start" : 2023, - "end" : 2025 + "end" : 2023 }, { "name" : "COC_REQUIRED", "start" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] } ], "outputs" : [ { @@ -414,6 +414,6 @@ } ] } ], "involved_tables" : [ "tumor_size_summary_full_15510", "nodes_pos_fah", "schema_selection_melanoma_skin", "neoadjuvant_therapy_37302", "summary_stage_rac", "mets_had", "neoadj_tx_clinical_response_31723", "ulceration_5718", "mitotic_rate_melanoma_88184", "histology", "sentinel_nodes_pos_95909", "nodes_exam_76029", "nodes_dam", "ldh_level_12428", "clinical_margin_width_1179", "combined_grade_56638", "behavior", "grade_post_therapy_clin_95734", "tumor_size_pathological_full_93442", "tumor_size_clinical_full_19656", "grade_clinical_standard_94331", "derived_grade_standard_1196", "breslow_thickness_79262", "type_of_reporting_source_76696", "neoadj_tx_treatment_effect_18122", "derived_ss2018_melanoma_skin_34689", "ldh_lab_value_85652", "primary_site", "ss2018_melanoma_skin_64985", "grade_pathological_standard_94268", "sentinel_nodes_exam_7235", "year_dx_validation", "grade_post_therapy_path_32110", "ldh_upper_limits_of_normal_34244", "extension_ban" ], - "last_modified" : "2025-09-19T18:54:42.963Z", + "last_modified" : "2025-11-14T20:06:16.614Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/merkel_cell_skin.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/merkel_cell_skin.json index 298ec611a..572a49984 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/merkel_cell_skin.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/merkel_cell_skin.json @@ -234,10 +234,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] }, { "key" : "profound_immune_suppression", @@ -254,10 +254,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] }, { "key" : "extranodal_ext_clin", @@ -340,6 +340,6 @@ } ] } ], "involved_tables" : [ "nodes_pos_fah", "extranodal_extension_pathological_30739", "extension_bds", "neoadjuvant_therapy_37302", "tumor_size_pathological_43328", "extranodal_extension_clinical_5022", "schema_selection_merkel_cell_skin", "mets_hph", "neoadj_tx_clinical_response_31723", "histology", "nodes_exam_76029", "combined_grade_56638", "behavior", "grade_post_therapy_clin_95734", "derived_ss2018_merkel_cell_skin_71353", "lymph_nodes_isolated_tumor_cells_67876", "grade_clinical_standard_94331", "tumor_size_clinical_48894", "ss2018_merkel_cell_carcinoma_89481", "derived_grade_standard_1196", "type_of_reporting_source_76696", "neoadj_tx_treatment_effect_18122", "primary_site", "nodes_ddn", "profound_immune_suppression_68178", "grade_pathological_standard_94268", "year_dx_validation", "summary_stage_rpa", "grade_post_therapy_path_32110", "tumor_size_summary_47973" ], - "last_modified" : "2025-09-19T18:54:59.148Z", + "last_modified" : "2025-11-14T20:05:30.225Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/middle_ear.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/middle_ear.json index 66f21cff0..344d7c3c4 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/middle_ear.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/middle_ear.json @@ -269,6 +269,6 @@ } ] } ], "involved_tables" : [ "neoadjuvant_therapy_37302", "ss2018_middle_ear_16857", "nodes_pos_fpa", "grade_post_therapy_clin_69737", "seer_mets_sinus_othervs2_15755", "schema_selection_middle_ear", "neoadj_tx_clinical_response_31723", "nodes_daq", "derived_ss2018_middle_ear_38870", "histology", "nodes_exam_76029", "tumor_size_summary_63115", "combined_grade_56638", "behavior", "extension_bcr", "grade_clinical_standard_non_ajcc_32473", "grade_pathological_standard_non_ajcc_5627", "derived_grade_standard_non_ajcc_63932", "type_of_reporting_source_76696", "tumor_size_pathological_25597", "tumor_size_clinical_60979", "neoadj_tx_treatment_effect_18122", "primary_site", "grade_post_therapy_path_75348", "year_dx_validation", "summary_stage_rpa" ], - "last_modified" : "2025-09-19T18:54:51.644Z", + "last_modified" : "2025-11-14T20:05:16.920Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/mouth_other.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/mouth_other.json index 284f80b9f..e222aacbe 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/mouth_other.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/mouth_other.json @@ -250,10 +250,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] }, { "key" : "ln_size_of_mets", @@ -272,10 +272,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] }, { "key" : "seer_ssf1", @@ -339,6 +339,6 @@ } ] } ], "involved_tables" : [ "extranodal_extension_head_and_neck_pathological_87046", "grade_post_therapy_clin_61658", "neoadjuvant_therapy_37302", "tumor_size_pathological_43328", "grade_clinical_6485", "nodes_pos_fpa", "ss2018_mouth_other_31159", "schema_selection_mouth_other", "neoadj_tx_clinical_response_31723", "histology", "nodes_exam_76029", "combined_grade_56638", "behavior", "derived_ss2018_mouth_other_30776", "nodes_daa", "tumor_size_clinical_48894", "seer_mets_lip_lower_28596", "grade_post_therapy_path_40048", "type_of_reporting_source_76696", "neoadj_tx_treatment_effect_18122", "p16_hpv_human_papilloma_virus_status_head_and_neck_509", "primary_site", "extranodal_extension_head_and_neck_clinical_79321", "grade_pathological_84704", "year_dx_validation", "derived_grade_69945", "summary_stage_rpa", "tumor_size_summary_47973", "ln_size_70140", "eod_primary_tumor_43548" ], - "last_modified" : "2025-09-19T18:55:10.080Z", + "last_modified" : "2025-11-14T20:06:05.300Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/mycosis_fungoides.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/mycosis_fungoides.json index d5f1f212d..b6be19986 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/mycosis_fungoides.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/mycosis_fungoides.json @@ -287,6 +287,6 @@ } ] } ], "involved_tables" : [ "derived_ss2018_mycosis_fungoides_14217", "neoadjuvant_therapy_37302", "peripheral_blood_involv_92357", "nodes_pos_fpa", "mets_haz", "neoadj_tx_clinical_response_31723", "grade_post_therapy_clin_74830", "histology", "nodes_exam_76029", "tumor_size_summary_63115", "behavior", "ss2018_mycosis_fungoides_94448", "derived_grade_21945", "type_of_reporting_source_76696", "tumor_size_pathological_25597", "nodes_dce", "tumor_size_clinical_60979", "primary_site", "neoadj_tx_treatment_effect_52725", "year_dx_validation", "derived_summary_grade_na_6690", "grade_post_therapy_path_65729", "summary_stage_rpa", "grade_clinical_18316", "extension_bcp", "grade_pathological_73388", "schema_selection_mycosis_fungoides" ], - "last_modified" : "2025-09-19T18:54:52.925Z", + "last_modified" : "2025-11-14T20:05:46.823Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/nasal_cavity_ethmoid_sinus.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/nasal_cavity_ethmoid_sinus.json index e12e4141f..707a48883 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/nasal_cavity_ethmoid_sinus.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/nasal_cavity_ethmoid_sinus.json @@ -250,10 +250,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] }, { "key" : "ln_size_of_mets", @@ -272,10 +272,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] } ], "outputs" : [ { @@ -328,6 +328,6 @@ } ] } ], "involved_tables" : [ "extranodal_extension_head_and_neck_pathological_87046", "grade_post_therapy_clin_61658", "neoadjuvant_therapy_37302", "derived_ss2018_nasal_cavity_and_paranasal_sinuses_97890", "schema_selection_nasal_cavity", "grade_clinical_6485", "nodes_pos_fpa", "eod_mets_94984", "neoadj_tx_clinical_response_31723", "histology", "nodes_exam_76029", "tumor_size_summary_63115", "combined_grade_56638", "behavior", "extension_bcq", "grade_post_therapy_path_40048", "type_of_reporting_source_76696", "tumor_size_pathological_25597", "tumor_size_clinical_60979", "ss2018_nasal_cavity_and_ethmoid_sinus_excluding_melanoma_8720_8790_21699", "neoadj_tx_treatment_effect_18122", "eod_regional_nodes_99855", "primary_site", "extranodal_extension_head_and_neck_clinical_79321", "grade_pathological_84704", "year_dx_validation", "derived_grade_69945", "summary_stage_rpa", "ln_size_70140" ], - "last_modified" : "2025-09-19T18:54:49.794Z", + "last_modified" : "2025-11-14T20:06:07.488Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/nasopharynx.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/nasopharynx.json index 1143ee83a..39a1577e3 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/nasopharynx.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/nasopharynx.json @@ -269,6 +269,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, + "end" : 2023 + }, { + "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", + "start" : 2024, "end" : 2024 } ] }, { @@ -288,6 +292,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, + "end" : 2023 + }, { + "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", + "start" : 2024, "end" : 2024 } ] } ], @@ -341,6 +349,6 @@ } ] } ], "involved_tables" : [ "extranodal_extension_head_and_neck_pathological_87046", "neoadjuvant_therapy_37302", "nasopharynx_pharyngealtonsil_84756", "nodes_pos_fpa", "neoadj_tx_clinical_response_31723", "seer_mets_nasopharynx_46629", "histology", "nodes_exam_76029", "nodes_dcn", "derived_ss2018_nasopharynx_69453", "tumor_size_summary_63115", "combined_grade_56638", "behavior", "grade_post_therapy_clin_95734", "grade_clinical_standard_94331", "derived_grade_standard_1196", "extension_bas", "type_of_reporting_source_76696", "tumor_size_pathological_25597", "tumor_size_clinical_60979", "neoadj_tx_treatment_effect_18122", "ss2018_nasopharynx_excluding_melanoma_8720_8790_copy_99106", "primary_site", "extranodal_extension_head_and_neck_clinical_79321", "schema_selection_nasopharynx", "grade_pathological_standard_94268", "year_dx_validation", "summary_stage_rpa", "grade_post_therapy_path_32110", "ln_size_70140" ], - "last_modified" : "2025-09-19T18:54:52.623Z", + "last_modified" : "2025-11-14T20:06:04.289Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/nasopharynx_v9_2025.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/nasopharynx_v9_2025.json index 3022f2d7c..0a87549a9 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/nasopharynx_v9_2025.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/nasopharynx_v9_2025.json @@ -248,13 +248,9 @@ "name" : "SSDI" }, { "name" : "CCCR_REQUIRED" - }, { - "name" : "SEER_REQUIRED", - "start" : 2025, - "end" : 2025 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2025 } ] }, { "key" : "ln_size_of_mets", @@ -270,13 +266,9 @@ "name" : "SSDI" }, { "name" : "CCCR_REQUIRED" - }, { - "name" : "SEER_REQUIRED", - "start" : 2025, - "end" : 2025 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2025 } ] } ], "outputs" : [ { @@ -329,6 +321,6 @@ } ] } ], "involved_tables" : [ "extranodal_extension_head_and_neck_pathological_87046", "eod_mets_v9_58862", "neoadjuvant_therapy_37302", "schema_selection_nasopharynx_v9_2025", "nodes_pos_fpa", "neoadj_tx_clinical_response_31723", "histology", "nodes_exam_76029", "derived_ss2018_nasopharynx_69453", "eod_regional_nodes_v9_73197", "eod_primary_tumor_v9_192", "tumor_size_summary_63115", "combined_grade_56638", "grade_post_therapy_clin_95734", "behavior", "grade_clinical_standard_94331", "derived_grade_standard_1196", "type_of_reporting_source_76696", "tumor_size_pathological_25597", "tumor_size_clinical_60979", "neoadj_tx_treatment_effect_18122", "ss2018_nasopharynx_excluding_melanoma_8720_8790_copy_99106", "primary_site", "extranodal_extension_head_and_neck_clinical_79321", "year_dx_validation", "grade_pathological_standard_94268", "summary_stage_rpa", "ln_size_70140", "grade_post_therapy_path_32110" ], - "last_modified" : "2025-09-19T18:55:00.426Z", + "last_modified" : "2025-11-14T20:05:59.634Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/net_adrenal_gland.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/net_adrenal_gland.json index 68458c36b..1f0d43944 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/net_adrenal_gland.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/net_adrenal_gland.json @@ -269,6 +269,6 @@ } ] } ], "involved_tables" : [ "schema_selection_net_adrenal_gland", "neoadjuvant_therapy_37302", "tumor_size_pathological_43328", "nodes_pos_fpa", "neoadj_tx_clinical_response_31723", "eod_regional_nodes_97333", "histology", "nodes_exam_76029", "combined_grade_56638", "grade_post_therapy_clin_95734", "behavior", "seer_mets_21628", "grade_clinical_standard_94331", "derived_ss2018_adrenal_gland_258", "tumor_size_clinical_48894", "derived_grade_standard_1196", "type_of_reporting_source_76696", "ss2018_adrenal_gland_including_net_adrenal_70096", "neoadj_tx_treatment_effect_18122", "seer_primary_tumor_52444", "primary_site", "year_dx_validation", "grade_pathological_standard_94268", "summary_stage_rpa", "grade_post_therapy_path_32110", "tumor_size_summary_47973" ], - "last_modified" : "2025-09-19T18:55:09.768Z", + "last_modified" : "2025-11-14T20:05:21.084Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/net_ampulla.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/net_ampulla.json index 4b81f6a1e..b3892515c 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/net_ampulla.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/net_ampulla.json @@ -285,6 +285,6 @@ } ] } ], "involved_tables" : [ "neoadjuvant_therapy_37302", "seer_primary_tumor_42751", "grade_post_therapy_clin_2541", "nodes_pos_fpa", "neoadj_tx_clinical_response_31723", "seer_mets_61487", "ki_67_67661", "seer_regional_nodes_69051", "histology", "nodes_exam_76029", "tumor_size_summary_63115", "derived_ss2018_ampulla_of_vater_2679", "combined_grade_56638", "schema_selection_net_ampulla", "behavior", "ss2018_ampulla_of_vater_including_net_96311", "type_of_reporting_source_76696", "tumor_size_pathological_25597", "tumor_size_clinical_60979", "grade_pathological_26086", "neoadj_tx_treatment_effect_18122", "grade_post_therapy_path_76876", "primary_site", "grade_clinical_26768", "year_dx_validation", "summary_stage_rpa", "derived_grade_27440" ], - "last_modified" : "2025-09-19T18:55:12.216Z", + "last_modified" : "2025-11-14T20:05:49.772Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/net_ampulla_of_vater_v9_2024.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/net_ampulla_of_vater_v9_2024.json index 26d8d4c16..2da502a56 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/net_ampulla_of_vater_v9_2024.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/net_ampulla_of_vater_v9_2024.json @@ -285,6 +285,6 @@ } ] } ], "involved_tables" : [ "neoadjuvant_therapy_37302", "grade_post_therapy_clin_2541", "eod_primary_tumor_55521", "nodes_pos_fpa", "neoadj_tx_clinical_response_31723", "ki_67_67661", "histology", "nodes_exam_76029", "tumor_size_summary_63115", "derived_ss2018_ampulla_of_vater_2679", "combined_grade_56638", "behavior", "ss2018_ampulla_of_vater_including_net_96311", "type_of_reporting_source_76696", "tumor_size_pathological_25597", "tumor_size_clinical_60979", "eod_mets_88527", "grade_pathological_26086", "neoadj_tx_treatment_effect_18122", "grade_post_therapy_path_76876", "primary_site", "grade_clinical_26768", "schema_selection_net_ampulla_of_vater_v9_2024", "year_dx_validation", "summary_stage_rpa", "eod_regional_nodes_48374", "derived_grade_27440" ], - "last_modified" : "2025-09-19T18:54:44.831Z", + "last_modified" : "2025-11-14T20:05:09.154Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/net_appendix.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/net_appendix.json index b4cbf26e8..83eeb1160 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/net_appendix.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/net_appendix.json @@ -285,6 +285,6 @@ } ] } ], "involved_tables" : [ "extension_bdu", "neoadjuvant_therapy_37302", "grade_post_therapy_clin_2541", "tumor_size_pathological_43328", "nodes_pos_fpa", "neoadj_tx_clinical_response_31723", "ki_67_67661", "histology", "nodes_exam_76029", "derived_ss2018_appendix_76889", "schema_selection_carcinoid_appendix", "combined_grade_56638", "behavior", "ss2018_appendix_including_netl_54459", "tumor_size_clinical_48894", "type_of_reporting_source_76696", "grade_pathological_26086", "neoadj_tx_treatment_effect_18122", "grade_post_therapy_path_76876", "primary_site", "grade_clinical_26768", "nodes_ddp", "year_dx_validation", "summary_stage_rpa", "derived_grade_27440", "tumor_size_summary_47973", "mets_hbx" ], - "last_modified" : "2025-09-19T18:54:41.065Z", + "last_modified" : "2025-11-14T20:05:47.353Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/net_appendix_v9_2024.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/net_appendix_v9_2024.json index 5fdc92638..3d65e51c5 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/net_appendix_v9_2024.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/net_appendix_v9_2024.json @@ -285,6 +285,6 @@ } ] } ], "involved_tables" : [ "extension_bdu", "neoadjuvant_therapy_37302", "grade_post_therapy_clin_2541", "tumor_size_pathological_43328", "nodes_pos_fpa", "neoadj_tx_clinical_response_31723", "ki_67_67661", "histology", "nodes_exam_76029", "derived_ss2018_appendix_76889", "combined_grade_56638", "behavior", "schema_selection_net_appendix_v9_2024", "ss2018_appendix_including_netl_54459", "tumor_size_clinical_48894", "type_of_reporting_source_76696", "grade_pathological_26086", "neoadj_tx_treatment_effect_18122", "grade_post_therapy_path_76876", "primary_site", "grade_clinical_26768", "nodes_ddp", "year_dx_validation", "summary_stage_rpa", "derived_grade_27440", "tumor_size_summary_47973", "mets_hbx" ], - "last_modified" : "2025-09-19T18:55:10.957Z", + "last_modified" : "2025-11-14T20:05:55.824Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/net_colon_and_rectum_v9_2024.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/net_colon_and_rectum_v9_2024.json index 7d9446f73..30073ed4c 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/net_colon_and_rectum_v9_2024.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/net_colon_and_rectum_v9_2024.json @@ -285,6 +285,6 @@ } ] } ], "involved_tables" : [ "nodes_dfe", "neoadjuvant_therapy_37302", "grade_post_therapy_clin_2541", "ss2018_colon_and_rectum_including_net_40538", "tumor_size_pathological_full_62176", "nodes_pos_fpa", "mets_hci", "neoadj_tx_clinical_response_31723", "ki_67_67661", "histology", "nodes_exam_76029", "extension_bfi", "derived_ss2018_colon_and_rectum_35271", "combined_grade_56638", "behavior", "tumor_size_clinical_full_74867", "type_of_reporting_source_76696", "grade_pathological_26086", "tumor_size_summary_full_31213", "neoadj_tx_treatment_effect_18122", "grade_post_therapy_path_76876", "primary_site", "grade_clinical_26768", "year_dx_validation", "summary_stage_rpa", "derived_grade_27440", "schema_selection_net_colon_and_rectum_v9_2024" ], - "last_modified" : "2025-09-19T18:54:51.913Z", + "last_modified" : "2025-11-14T20:05:57.514Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/net_colon_rectum.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/net_colon_rectum.json index c0d3c7da3..8a410b95e 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/net_colon_rectum.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/net_colon_rectum.json @@ -285,6 +285,6 @@ } ] } ], "involved_tables" : [ "nodes_dfe", "neoadjuvant_therapy_37302", "grade_post_therapy_clin_2541", "ss2018_colon_and_rectum_including_net_40538", "tumor_size_pathological_full_62176", "nodes_pos_fpa", "mets_hci", "schema_selection_net_colon", "neoadj_tx_clinical_response_31723", "ki_67_67661", "histology", "nodes_exam_76029", "extension_bfi", "derived_ss2018_colon_and_rectum_35271", "combined_grade_56638", "behavior", "tumor_size_clinical_full_74867", "type_of_reporting_source_76696", "grade_pathological_26086", "tumor_size_summary_full_31213", "neoadj_tx_treatment_effect_18122", "grade_post_therapy_path_76876", "primary_site", "grade_clinical_26768", "year_dx_validation", "summary_stage_rpa", "derived_grade_27440" ], - "last_modified" : "2025-09-19T18:54:39.651Z", + "last_modified" : "2025-11-14T20:05:27.397Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/net_duodenum.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/net_duodenum.json index ad22bdbda..7e1a1c65e 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/net_duodenum.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/net_duodenum.json @@ -285,6 +285,6 @@ } ] } ], "involved_tables" : [ "neoadjuvant_therapy_37302", "grade_post_therapy_clin_2541", "nodes_pos_fpa", "seer_regional_nodes_83435", "neoadj_tx_clinical_response_31723", "derived_ss2018_small_intestine_48854", "ki_67_67661", "histology", "nodes_exam_76029", "schema_selection_net_duodenum", "tumor_size_summary_63115", "combined_grade_56638", "behavior", "ss2018_small_intestine_including_net_85335", "type_of_reporting_source_76696", "tumor_size_pathological_25597", "tumor_size_clinical_60979", "grade_pathological_26086", "neoadj_tx_treatment_effect_18122", "grade_post_therapy_path_76876", "primary_site", "seer_primary_tumor_96082", "grade_clinical_26768", "seer_mets_84419", "year_dx_validation", "summary_stage_rpa", "derived_grade_27440" ], - "last_modified" : "2025-09-19T18:55:07.505Z", + "last_modified" : "2025-11-14T20:05:22.389Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/net_duodenum_v9_2024.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/net_duodenum_v9_2024.json index d1e7ad86d..a8f7778de 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/net_duodenum_v9_2024.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/net_duodenum_v9_2024.json @@ -285,6 +285,6 @@ } ] } ], "involved_tables" : [ "neoadjuvant_therapy_37302", "grade_post_therapy_clin_2541", "nodes_pos_fpa", "seer_regional_nodes_83435", "neoadj_tx_clinical_response_31723", "derived_ss2018_small_intestine_48854", "ki_67_67661", "histology", "nodes_exam_76029", "tumor_size_summary_63115", "combined_grade_56638", "behavior", "ss2018_small_intestine_including_net_85335", "schema_selection_net_duodenum_v9_2024", "type_of_reporting_source_76696", "tumor_size_pathological_25597", "tumor_size_clinical_60979", "grade_pathological_26086", "neoadj_tx_treatment_effect_18122", "grade_post_therapy_path_76876", "primary_site", "seer_primary_tumor_96082", "grade_clinical_26768", "seer_mets_84419", "year_dx_validation", "summary_stage_rpa", "derived_grade_27440" ], - "last_modified" : "2025-09-19T18:54:44.231Z", + "last_modified" : "2025-11-14T20:05:57.781Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/net_jejunum_and_ileum_v9_2024.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/net_jejunum_and_ileum_v9_2024.json index 06a56ff05..ef7c5ffe0 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/net_jejunum_and_ileum_v9_2024.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/net_jejunum_and_ileum_v9_2024.json @@ -285,6 +285,6 @@ } ] } ], "involved_tables" : [ "neoadjuvant_therapy_37302", "grade_post_therapy_clin_2541", "mets_hcp", "nodes_dfl", "nodes_pos_fpa", "neoadj_tx_clinical_response_31723", "derived_ss2018_small_intestine_48854", "ki_67_67661", "histology", "nodes_exam_76029", "tumor_size_summary_63115", "combined_grade_56638", "behavior", "ss2018_small_intestine_including_net_85335", "extension_bfp", "type_of_reporting_source_76696", "tumor_size_pathological_25597", "tumor_size_clinical_60979", "grade_pathological_26086", "neoadj_tx_treatment_effect_18122", "grade_post_therapy_path_76876", "primary_site", "grade_clinical_26768", "year_dx_validation", "summary_stage_rpa", "derived_grade_27440", "schema_selection_net_jejunum_and_ileum_v9_2024" ], - "last_modified" : "2025-09-19T18:55:12.828Z", + "last_modified" : "2025-11-14T20:05:58.105Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/net_jejunum_ileum.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/net_jejunum_ileum.json index cb3dbd52e..017c82feb 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/net_jejunum_ileum.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/net_jejunum_ileum.json @@ -285,6 +285,6 @@ } ] } ], "involved_tables" : [ "neoadjuvant_therapy_37302", "grade_post_therapy_clin_2541", "mets_hcp", "nodes_dfl", "schema_selection_net_small_intestine", "nodes_pos_fpa", "neoadj_tx_clinical_response_31723", "derived_ss2018_small_intestine_48854", "ki_67_67661", "histology", "nodes_exam_76029", "tumor_size_summary_63115", "combined_grade_56638", "behavior", "ss2018_small_intestine_including_net_85335", "extension_bfp", "type_of_reporting_source_76696", "tumor_size_pathological_25597", "tumor_size_clinical_60979", "grade_pathological_26086", "neoadj_tx_treatment_effect_18122", "grade_post_therapy_path_76876", "primary_site", "grade_clinical_26768", "year_dx_validation", "summary_stage_rpa", "derived_grade_27440" ], - "last_modified" : "2025-09-19T18:54:45.690Z", + "last_modified" : "2025-11-14T20:05:47.864Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/net_pancreas.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/net_pancreas.json index 73034f4c6..64ca74691 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/net_pancreas.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/net_pancreas.json @@ -285,6 +285,6 @@ } ] } ], "involved_tables" : [ "neoadjuvant_therapy_37302", "ss2018_pancreas_95507", "grade_post_therapy_clin_2541", "seer_primary_tumor_43302", "tumor_size_pathological_43328", "nodes_pos_fpa", "neoadj_tx_clinical_response_31723", "seer_mets_57075", "ki_67_67661", "histology", "nodes_exam_76029", "combined_grade_56638", "behavior", "schema_selection_net_pancreas", "tumor_size_clinical_48894", "type_of_reporting_source_76696", "grade_pathological_26086", "neoadj_tx_treatment_effect_18122", "grade_post_therapy_path_76876", "primary_site", "eod_regional_nodes_3383", "grade_clinical_26768", "year_dx_validation", "summary_stage_rpa", "derived_grade_27440", "tumor_size_summary_47973", "derived_ss2018_pancreas_85813" ], - "last_modified" : "2025-09-19T18:54:39.494Z", + "last_modified" : "2025-11-14T20:05:22.909Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/net_pancreas_v9_2024.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/net_pancreas_v9_2024.json index 0393ecb5d..1521b5ab2 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/net_pancreas_v9_2024.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/net_pancreas_v9_2024.json @@ -285,6 +285,6 @@ } ] } ], "involved_tables" : [ "neoadjuvant_therapy_37302", "ss2018_pancreas_95507", "grade_post_therapy_clin_2541", "seer_primary_tumor_43302", "tumor_size_pathological_43328", "nodes_pos_fpa", "neoadj_tx_clinical_response_31723", "seer_mets_57075", "ki_67_67661", "histology", "nodes_exam_76029", "combined_grade_56638", "schema_selection_net_pancreas_v9_2024", "behavior", "tumor_size_clinical_48894", "type_of_reporting_source_76696", "grade_pathological_26086", "neoadj_tx_treatment_effect_18122", "grade_post_therapy_path_76876", "primary_site", "eod_regional_nodes_3383", "grade_clinical_26768", "year_dx_validation", "summary_stage_rpa", "derived_grade_27440", "tumor_size_summary_47973", "derived_ss2018_pancreas_85813" ], - "last_modified" : "2025-09-19T18:54:45.947Z", + "last_modified" : "2025-11-14T20:05:58.418Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/net_stomach.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/net_stomach.json index 4ef8dedbb..4dc379dfd 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/net_stomach.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/net_stomach.json @@ -285,6 +285,6 @@ } ] } ], "involved_tables" : [ "mets_hck", "neoadjuvant_therapy_37302", "nodes_dfg", "grade_post_therapy_clin_2541", "ss2018_stomach_including_net_stomach_35647", "tumor_size_pathological_full_62176", "nodes_pos_fpa", "neoadj_tx_clinical_response_31723", "ki_67_67661", "extension_bfk", "histology", "nodes_exam_76029", "derived_ss2018_stomach_19183", "combined_grade_56638", "behavior", "schema_selection_net_stomach", "tumor_size_clinical_full_74867", "type_of_reporting_source_76696", "grade_pathological_26086", "tumor_size_summary_full_31213", "neoadj_tx_treatment_effect_18122", "grade_post_therapy_path_76876", "primary_site", "grade_clinical_26768", "year_dx_validation", "summary_stage_rpa", "derived_grade_27440" ], - "last_modified" : "2025-09-19T18:54:48.634Z", + "last_modified" : "2025-11-14T20:05:48.407Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/net_stomach_v9_2024.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/net_stomach_v9_2024.json index 3dc04eed9..6e2a2aaf3 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/net_stomach_v9_2024.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/net_stomach_v9_2024.json @@ -285,6 +285,6 @@ } ] } ], "involved_tables" : [ "mets_hck", "neoadjuvant_therapy_37302", "nodes_dfg", "grade_post_therapy_clin_2541", "ss2018_stomach_including_net_stomach_35647", "tumor_size_pathological_full_62176", "nodes_pos_fpa", "neoadj_tx_clinical_response_31723", "ki_67_67661", "extension_bfk", "histology", "nodes_exam_76029", "derived_ss2018_stomach_19183", "combined_grade_56638", "behavior", "tumor_size_clinical_full_74867", "type_of_reporting_source_76696", "schema_selection_net_stomach_v9_2024", "grade_pathological_26086", "tumor_size_summary_full_31213", "neoadj_tx_treatment_effect_18122", "grade_post_therapy_path_76876", "primary_site", "grade_clinical_26768", "year_dx_validation", "summary_stage_rpa", "derived_grade_27440" ], - "last_modified" : "2025-09-19T18:55:07.202Z", + "last_modified" : "2025-11-14T20:05:58.727Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/orbital_sarcoma.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/orbital_sarcoma.json index 6337fce05..c3c057cfd 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/orbital_sarcoma.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/orbital_sarcoma.json @@ -270,6 +270,6 @@ } ] } ], "involved_tables" : [ "neoadjuvant_therapy_37302", "tumor_size_pathological_43328", "grade_post_therapy_path_36935", "nodes_pos_fpa", "eod_mets_47277", "derived_ss2018_orbital_sarcoma_90415", "neoadj_tx_clinical_response_31723", "grade_post_therapy_clin_1647", "histology", "nodes_exam_76029", "ss2018_orbit_27202", "combined_grade_56638", "behavior", "tumor_size_clinical_48894", "eod_regional_nodes_65616", "grade_pathological_40399", "type_of_reporting_source_76696", "derived_grade_71227", "neoadj_tx_treatment_effect_18122", "grade_clinical_41135", "primary_site", "year_dx_validation", "summary_stage_rpa", "schema_selection_orbit", "extension_bag", "tumor_size_summary_47973" ], - "last_modified" : "2025-09-19T18:54:39.923Z", + "last_modified" : "2025-11-14T20:05:36.300Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/oropharynx_hpv_associated_v9_2026.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/oropharynx_hpv_associated_v9_2026.json index 7d2a24663..0f4d7b56e 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/oropharynx_hpv_associated_v9_2026.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/oropharynx_hpv_associated_v9_2026.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Oropharynx HPV-Associated [V9: 2026+]", "title" : "Oropharynx HPV-Associated [V9: 2026+]", - "notes" : "C019, C024, C051-C052, C090-C091, C098-C099, C100, C102-C104, C108-C109 and Schema Discriminator 2: Oropharyngeal p16: 2 (8000-8700)\n\nC019 Base of tongue, NOS\nC024 Lingual tonsil\nC051 Soft palate, NOS\nC052 Uvula\nC090 Tonsillar fossa \nC091 Tonsillar pillar \nC098 Overlapping lesion of tonsil \nC099 Tonsil, NOS \nC100 Vallecula\nC102 Lateral wall of oropharynx\nC103 Posterior wall of oropharynx\nC104 Branchial cleft (site of neoplasm)\nC108 Overlapping lesion of oropharynx\nC109 Oropharynx, NOS\n\n**Note 1:** **Sources used in the development of this schema**\n* SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998) (https://seer.cancer.gov/archive/manuals/EOD10Dig.3rd.pdf)\n* SEER Summary Staging Manual-2000: Codes and Coding Instructions (https://seer.cancer.gov/tools/ssm/ssm2000/)\n* Collaborative Stage Data Collection System, version 02.05: https://cancerstaging.org/cstage/Pages/default.aspx \n* Oropharynx (HPV-Associated), from the AJCC Cancer Staging System Version 9 (2026). Used with permission of the American College of Surgeons, Chicago, Illinois.\n\n**Note 2:** **Other EOD Schemas with Oropharynx sites**\n* **GIST:** 8935-8936\n* **Kaposi Sarcoma:** 9140\n* **Melanoma Head and Neck:** 8720-8790\n* **Mycosis Fungoides:** 9700-9701\n* **Oropharynx HPV-Independent (p16-):** C019, C024, C051-C052, C090-C091, C098-C099, C100, C102-C104, C108-C109 and Schema Discriminator 2: Oropharyngeal p16: 1, 9 (8000-8700)\n* **Soft Tissue Head and Neck:** 8710-8714, 8800-8803, 8810-8905, 8912, 8921, 8932-8934, 8940-8990, 9000-9016, 9030-9043, 9045-9110, 9121-9138, 9141-9230, 9240-9580, 9582\n* **Soft Tissue Other:** 8992\n* **Soft Tissue Rare:** 8804-8806, 8910, 8920, 8930-8931, 8991, 9020, 9044, 9120, 9231, 9581\n\n**Note 3:** **p16 immunotesting** \n* p16 immunotesting is mandatory to use this staging system for HPV-associated cancer. HPV by in situ hybridization (ISH) may be done as an alternative. \n* If a case of oropharyngeal cancer has p16+, then this schema is used. \n* If a case if p16- or does not have p16, then the Oropharynx HPV-Independent schema is used.", + "notes" : "C019, C024, C051-C052, C090-C091, C098-C099, C100-C104, C108-C109 and Schema Discriminator 2: Oropharyngeal p16: 2 (8000-8700)\n\nC019 Base of tongue, NOS\nC024 Lingual tonsil\nC051 Soft palate, NOS\nC052 Uvula\nC090 Tonsillar fossa \nC091 Tonsillar pillar \nC098 Overlapping lesion of tonsil \nC099 Tonsil, NOS \nC100 Vallecula\nC101 Anterior surface of epiglottis\nC102 Lateral wall of oropharynx\nC103 Posterior wall of oropharynx\nC104 Branchial cleft (site of neoplasm)\nC108 Overlapping lesion of oropharynx\nC109 Oropharynx, NOS\n\n\n**Note 1:** **Sources used in the development of this schema**\n* SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998) (https://seer.cancer.gov/archive/manuals/EOD10Dig.3rd.pdf)\n* SEER Summary Staging Manual-2000: Codes and Coding Instructions (https://seer.cancer.gov/tools/ssm/ssm2000/)\n* Collaborative Stage Data Collection System, version 02.05: https://cancerstaging.org/cstage/Pages/default.aspx \n* Oropharynx (HPV-Associated), from the AJCC Cancer Staging System Version 9 (2026). Used with permission of the American College of Surgeons, Chicago, Illinois.\n\n**Note 2:** **Other EOD Schemas with Oropharynx sites**\n* **GIST:** 8935-8936\n* **Kaposi Sarcoma:** 9140\n* **Melanoma Head and Neck:** 8720-8790\n* **Mycosis Fungoides:** 9700-9701\n* **Oropharynx HPV-Independent (p16-):** C019, C024, C051-C052, C090-C091, C098-C099, C100, C102-C104, C108-C109 and Schema Discriminator 2: Oropharyngeal p16: 1, 9 (8000-8700)\n* **Soft Tissue Head and Neck:** 8710-8714, 8800-8803, 8810-8905, 8912, 8921, 8932-8934, 8940-8990, 9000-9016, 9030-9043, 9045-9110, 9121-9138, 9141-9230, 9240-9580, 9582\n* **Soft Tissue Other:** 8992\n* **Soft Tissue Rare:** 8804-8806, 8910, 8920, 8930-8931, 8991, 9020, 9044, 9120, 9231, 9581\n\n**Note 3:** **p16 immunotesting** \n* p16 immunotesting is mandatory to use this staging system for HPV-associated cancer. HPV by in situ hybridization (ISH) may be done as an alternative. \n* If a case of oropharyngeal cancer has p16+, then this schema is used. \n* If a case if p16- or does not have p16, then the Oropharynx HPV-Independent schema is used.", "schema_selection_table" : "schema_selection_oropharynx_hpv_associated_v9_2026", "schema_discriminators" : [ "year_dx", "discriminator_2" ], "inputs" : [ { @@ -351,6 +351,6 @@ } ] } ], "involved_tables" : [ "extranodal_extension_head_and_neck_pathological_87046", "neoadjuvant_therapy_37302", "tumor_size_pathological_43328", "nodes_pos_fpa", "oropharyngeal_p16_44685", "eod_mets_80017", "neoadj_tx_clinical_response_31723", "histology", "nodes_exam_76029", "derived_ss2018_oropharynx_79318", "eod_regional_nodes_6464", "combined_grade_56638", "behavior", "grade_post_therapy_clin_95734", "grade_clinical_standard_94331", "eod_primary_tumor_81646", "ss2018_oropharynx_excluding_melanoma_8720_8790_9999", "tumor_size_clinical_48894", "derived_grade_standard_1196", "type_of_reporting_source_76696", "neoadj_tx_treatment_effect_18122", "p16_hpv_human_papilloma_virus_status_head_and_neck_509", "primary_site", "extranodal_extension_head_and_neck_clinical_79321", "grade_pathological_standard_94268", "year_dx_validation", "summary_stage_rpa", "grade_post_therapy_path_32110", "tumor_size_summary_47973", "ln_size_70140", "schema_selection_oropharynx_hpv_associated_v9_2026" ], - "last_modified" : "2025-09-19T18:54:54.980Z", + "last_modified" : "2025-11-14T20:06:06.696Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/oropharynx_hpv_mediated_p16_pos.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/oropharynx_hpv_mediated_p16_pos.json index 4f10d7a42..81075144d 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/oropharynx_hpv_mediated_p16_pos.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/oropharynx_hpv_mediated_p16_pos.json @@ -288,6 +288,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, + "end" : 2023 + }, { + "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", + "start" : 2024, "end" : 2025 } ] }, { @@ -369,6 +373,6 @@ } ] } ], "involved_tables" : [ "extranodal_extension_head_and_neck_pathological_87046", "neoadjuvant_therapy_37302", "schema_selection_oropharynx", "nasopharynx_pharyngealtonsil_84756", "tumor_size_pathological_43328", "nodes_pos_fpa", "oropharyngeal_p16_44685", "eod_mets_80017", "neoadj_tx_clinical_response_31723", "histology", "nodes_exam_76029", "derived_ss2018_oropharynx_79318", "combined_grade_56638", "behavior", "nodes_dcu", "grade_post_therapy_clin_95734", "grade_clinical_standard_94331", "extension_bap", "ss2018_oropharynx_excluding_melanoma_8720_8790_9999", "tumor_size_clinical_48894", "derived_grade_standard_1196", "type_of_reporting_source_76696", "neoadj_tx_treatment_effect_18122", "p16_hpv_human_papilloma_virus_status_head_and_neck_509", "primary_site", "extranodal_extension_head_and_neck_clinical_79321", "grade_pathological_standard_94268", "year_dx_validation", "summary_stage_rpa", "grade_post_therapy_path_32110", "tumor_size_summary_47973", "ln_size_70140" ], - "last_modified" : "2025-09-19T18:54:53.527Z", + "last_modified" : "2025-11-14T20:06:05.897Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/oropharynx_p16_neg.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/oropharynx_p16_neg.json index 4b0033b1a..858ea1e07 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/oropharynx_p16_neg.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/oropharynx_p16_neg.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Oropharynx HPV-Independent", "title" : "Oropharynx HPV-Independent", - "notes" : "**2018-2024**\nC111 and Schema Discriminator 1: Nasopharynx/PharyngealTonsil: 2 AND Schema Discriminator 2: Oropharyngeal p16: 1, 9 (8000-8700) \n\n**2025+**\nC019, C024, C051-C052, C090-C091, C098-C099, C100, C102-C104, C108-C109 and Schema Discriminator 2: Oropharyngeal p16: 1, 9 (8000-8700)\n\nC019 Base of tongue, NOS\nC024 Lingual tonsil\nC051 Soft palate, NOS\nC052 Uvula\nC090 Tonsillar fossa \nC091 Tonsillar pillar \nC098 Overlapping lesion of tonsil \nC099 Tonsil, NOS \nC100 Vallecula\nC102 Lateral wall of oropharynx\nC103 Posterior wall of oropharynx\nC104 Branchial cleft (site of neoplasm)\nC108 Overlapping lesion of oropharynx\nC109 Oropharynx, NOS\nC111 Pharyngeal tonsil\n\n**Note 1:** **Sources used in the development of this schema**\n* SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998) (https://seer.cancer.gov/archive/manuals/EOD10Dig.3rd.pdf)\n* SEER Summary Staging Manual-2000: Codes and Coding Instructions (https://seer.cancer.gov/tools/ssm/ssm2000/)\n* Collaborative Stage Data Collection System, version 02.05: https://cancerstaging.org/cstage/Pages/default.aspx \n* Chapter 11 *Oropharynx (p16-) and Hypopharynx*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois.\n\n**Note 2:** **Other EOD Schemas with Oropharynx sites**\n* **GIST**: 8935-8936\n* **Kaposi Sarcoma**: 9140\n* **Melanoma Head and Neck**: 8720-8790\n* **Mycosis Fungoides**: 9700-9701\n* **Oropharynx HPV-Mediated (2018-2025)**: C019, C024, C051-C052, C090-C091, C098-C099, C100, C102-C104, C108-C109 and Schema Discriminator 2: Oropharyngeal p16: 2 (8000-8700)\n* **Oropharynx HPV-Associated (p16+) (2026+)**: C019, C024, C051-C052, C090-C091, C098-C099, C100, C102-C104, C108-C109 and Schema Discriminator 2: Oropharyngeal p16: 2 (8000-8700)\n* **Nasopharynx (2018-2024)** C111 AND Schema Discriminator 1: Nasopharynx/PharyngealTonsil:1 (8000-8700) or Year of Diagnosis is 2025 or later\n* **Soft Tissue Head and Neck**: 8710-8714, 8800-8803, 8810-8905, 8912, 8921, 8932-8934, 8940-8990, 9000-9016, 9030-9043, 9045-9110, 9121-9138, 9141-9230, 9240-9580, 9582\n* **Soft Tissue Other**: 8992\n* **Soft Tissue Rare**: 8804-8806, 8910, 8920, 8930-8931, 8991, 9020, 9044, 9120, 9231, 9581\n\n**Note 3:** **p16 immunotesting** \n* p16 immunotesting is mandatory to use this staging system for HPV-associated cancer. HPV by in situ hybridization (ISH) may be done as an alternative. \n* If a case of oropharyngeal cancer has p16+, then the Oropharynx HPV-Associated schema is used. \n* If case is p16- or does not have p16, then this schema is used.", + "notes" : "**2018-2024**\nC111 and Schema Discriminator 1: Nasopharynx/PharyngealTonsil: 2 AND Schema Discriminator 2: Oropharyngeal p16: 1, 9 (8000-8700) \n\n**2018+**\nC019, C024, C051-C052, C090-C091, C098-C099, C100, C102-C104, C108-C109 and Schema Discriminator 2: Oropharyngeal p16: 1, 9 (8000-8700)\n\n**2026+**\nC101 and Schema Discriminator 2: Oropharyngeal p16: 1, 9 (8000-8700)\n\nC019 Base of tongue, NOS\nC024 Lingual tonsil\nC051 Soft palate, NOS\nC052 Uvula\nC090 Tonsillar fossa \nC091 Tonsillar pillar \nC098 Overlapping lesion of tonsil \nC099 Tonsil, NOS \nC100 Vallecula\nC101 Anterior surface of epiglottis\nC102 Lateral wall of oropharynx\nC103 Posterior wall of oropharynx\nC104 Branchial cleft (site of neoplasm)\nC108 Overlapping lesion of oropharynx\nC109 Oropharynx, NOS\nC111 Pharyngeal tonsil\n\n**Note 1:** **Sources used in the development of this schema**\n* SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998) (https://seer.cancer.gov/archive/manuals/EOD10Dig.3rd.pdf)\n* SEER Summary Staging Manual-2000: Codes and Coding Instructions (https://seer.cancer.gov/tools/ssm/ssm2000/)\n* Collaborative Stage Data Collection System, version 02.05: https://cancerstaging.org/cstage/Pages/default.aspx \n* Chapter 11 *Oropharynx (p16-) and Hypopharynx*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois.\n\n**Note 2:** **Other EOD Schemas with Oropharynx sites**\n* **GIST**: 8935-8936\n* **Kaposi Sarcoma**: 9140\n* **Melanoma Head and Neck**: 8720-8790\n* **Mycosis Fungoides**: 9700-9701\n* **Oropharynx HPV-Mediated (2018-2025)**: C019, C024, C051-C052, C090-C091, C098-C099, C100, C102-C104, C108-C109 and Schema Discriminator 2: Oropharyngeal p16: 2 (8000-8700)\n* **Oropharynx HPV-Associated (p16+) (2026+)**: C019, C024, C051-C052, C090-C091, C098-C099, C100, C102-C104, C108-C109 and Schema Discriminator 2: Oropharyngeal p16: 2 (8000-8700)\n* **Nasopharynx (2018-2024)** C111 AND Schema Discriminator 1: Nasopharynx/PharyngealTonsil:1 (8000-8700) or Year of Diagnosis is 2025 or later\n* **Soft Tissue Head and Neck**: 8710-8714, 8800-8803, 8810-8905, 8912, 8921, 8932-8934, 8940-8990, 9000-9016, 9030-9043, 9045-9110, 9121-9138, 9141-9230, 9240-9580, 9582\n* **Soft Tissue Other**: 8992\n* **Soft Tissue Rare**: 8804-8806, 8910, 8920, 8930-8931, 8991, 9020, 9044, 9120, 9231, 9581\n\n**Note 3:** **p16 immunotesting** \n* p16 immunotesting is mandatory to use this staging system for HPV-associated cancer. HPV by in situ hybridization (ISH) may be done as an alternative. \n* If a case of oropharyngeal cancer has p16+, then the Oropharynx HPV-Associated schema is used. \n* If case is p16- or does not have p16, then this schema is used.", "schema_selection_table" : "schema_selection_tongue_base", "schema_discriminators" : [ "year_dx", "discriminator_1", "discriminator_2" ], "inputs" : [ { @@ -288,10 +288,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] }, { "key" : "ln_size_of_mets", @@ -310,10 +310,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] }, { "key" : "seer_ssf1", @@ -377,6 +377,6 @@ } ] } ], "involved_tables" : [ "extranodal_extension_head_and_neck_pathological_87046", "neoadjuvant_therapy_37302", "nasopharynx_pharyngealtonsil_84756", "tumor_size_pathological_43328", "derived_grade_46639", "grade_post_therapy_path_41285", "grade_pathological_31963", "grade_post_therapy_clin_41222", "nodes_pos_fpa", "oropharyngeal_p16_44685", "neoadj_tx_clinical_response_31723", "histology", "nodes_exam_76029", "derived_ss2018_oropharynx_79318", "schema_selection_tongue_base", "combined_grade_56638", "behavior", "eod_mets_29252", "ss2018_oropharynx_excluding_melanoma_8720_8790_9999", "tumor_size_clinical_48894", "eod_regional_nodes_55756", "type_of_reporting_source_76696", "neoadj_tx_treatment_effect_18122", "p16_hpv_human_papilloma_virus_status_head_and_neck_509", "primary_site", "extranodal_extension_head_and_neck_clinical_79321", "year_dx_validation", "grade_clinical_73056", "summary_stage_rpa", "tumor_size_summary_47973", "ln_size_70140", "extension_bam" ], - "last_modified" : "2025-09-19T18:54:47.792Z", + "last_modified" : "2025-11-14T20:05:05.480Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/ovary.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/ovary.json index a5f7b44f8..454d8d06f 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/ovary.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/ovary.json @@ -233,10 +233,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] }, { "key" : "ca125_pretx_interpretation", @@ -270,10 +270,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] } ], "outputs" : [ { @@ -326,6 +326,6 @@ } ] } ], "involved_tables" : [ "residual_tumor_volume_post_cytoreduction_90653", "grade_post_therapy_path_91649", "neoadjuvant_therapy_37302", "eod_regional_nodes_53169", "nodes_pos_fpa", "mets_hah", "neoadj_tx_clinical_response_31723", "histology", "schema_selection_ovary", "nodes_exam_76029", "grade_clinical_69174", "tumor_size_summary_63115", "combined_grade_56638", "behavior", "derived_grade_40528", "derived_ss2018_ovary_and_primary_peritoneal_carcinoma_26044", "type_of_reporting_source_76696", "ss2018_ovary_fallopian_tube_and_peritoneal_carcinoma_21678", "tumor_size_pathological_25597", "tumor_size_clinical_60979", "primary_site", "figo_stage_30513", "grade_pathological_42127", "grade_post_therapy_clin_54917", "year_dx_validation", "ca_125_pretx_interpretation_51295", "summary_stage_rpa", "eod_primary_tumor_72244", "neoadj_tx_treatment_effect_61650" ], - "last_modified" : "2025-09-19T18:54:35.006Z", + "last_modified" : "2025-11-14T20:05:19.738Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/palate_hard.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/palate_hard.json index e006fd3fc..633939928 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/palate_hard.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/palate_hard.json @@ -250,10 +250,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] }, { "key" : "ln_size_of_mets", @@ -272,10 +272,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] }, { "key" : "seer_ssf1", @@ -339,6 +339,6 @@ } ] } ], "involved_tables" : [ "eod_primary_tumor_3433", "extranodal_extension_head_and_neck_pathological_87046", "schema_selection_palate_hard", "grade_post_therapy_clin_61658", "neoadjuvant_therapy_37302", "derived_ss2018_palate_hard_38646", "tumor_size_pathological_43328", "grade_clinical_6485", "nodes_pos_fpa", "neoadj_tx_clinical_response_31723", "histology", "nodes_exam_76029", "combined_grade_56638", "behavior", "nodes_daa", "tumor_size_clinical_48894", "seer_mets_lip_lower_28596", "grade_post_therapy_path_40048", "type_of_reporting_source_76696", "neoadj_tx_treatment_effect_18122", "p16_hpv_human_papilloma_virus_status_head_and_neck_509", "primary_site", "extranodal_extension_head_and_neck_clinical_79321", "grade_pathological_84704", "year_dx_validation", "derived_grade_69945", "summary_stage_rpa", "tumor_size_summary_47973", "ln_size_70140", "ss2018_palate_hard_86267" ], - "last_modified" : "2025-09-19T18:54:54.683Z", + "last_modified" : "2025-11-14T20:06:04.954Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/pancreas.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/pancreas.json index 74d901e8c..7a014026d 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/pancreas.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/pancreas.json @@ -288,6 +288,6 @@ } ] } ], "involved_tables" : [ "grade_post_therapy_clin_61658", "neoadjuvant_therapy_37302", "ss2018_pancreas_95507", "tumor_size_pathological_43328", "grade_clinical_6485", "nodes_pos_fpa", "neoadj_tx_treatment_effect_90678", "neoadj_tx_clinical_response_31723", "histology", "nodes_exam_76029", "seer_mets_66514", "combined_grade_56638", "schema_selection_pancreas_body_tail", "behavior", "tumor_size_clinical_48894", "grade_post_therapy_path_40048", "type_of_reporting_source_76696", "seer_primary_tumor_95193", "primary_site", "ca_19_9_pretx_lab_value_17332", "grade_pathological_84704", "year_dx_validation", "eod_regional_nodes_11936", "derived_grade_69945", "summary_stage_rpa", "tumor_size_summary_47973", "derived_ss2018_pancreas_85813" ], - "last_modified" : "2025-09-19T18:55:13.131Z", + "last_modified" : "2025-11-14T20:05:34.982Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/parathyroid.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/parathyroid.json index e51850666..f90622da5 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/parathyroid.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/parathyroid.json @@ -269,6 +269,6 @@ } ] } ], "involved_tables" : [ "neoadjuvant_therapy_37302", "schema_selection_parathyroid", "ss2018_parathyroid_99309", "nodes_pos_fpa", "neoadj_tx_clinical_response_31723", "histology", "nodes_exam_76029", "grade_clinical_25704", "tumor_size_summary_63115", "combined_grade_56638", "grade_post_therapy_clin_35900", "behavior", "seer_regional_nodes_17757", "type_of_reporting_source_76696", "grade_pathological_27152", "tumor_size_pathological_25597", "tumor_size_clinical_60979", "neoadj_tx_treatment_effect_18122", "primary_site", "year_dx_validation", "grade_post_therapy_path_30693", "summary_stage_rpa", "seer_primary_tumor_25824", "mets_hbv", "derived_ss2018_parathyroid_93552", "derived_grade_2099" ], - "last_modified" : "2025-09-19T18:54:44.531Z", + "last_modified" : "2025-11-14T20:05:21.425Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/penis.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/penis.json index 73324e81b..cebe6c2f3 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/penis.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/penis.json @@ -299,6 +299,6 @@ } ] } ], "involved_tables" : [ "extension_bbs", "extranodal_extension_pathological_30739", "neoadjuvant_therapy_37302", "grade_post_therapy_clin_76032", "ss2018_penis_97065", "grade_pathological_29069", "nodes_dbj", "nodes_pos_fpa", "extranodal_extension_clinical_5022", "grade_clinical_22454", "neoadj_tx_clinical_response_31723", "histology", "nodes_exam_76029", "tumor_size_summary_63115", "combined_grade_56638", "behavior", "eod_mets_34827", "derived_grade_58317", "type_of_reporting_source_76696", "tumor_size_pathological_25597", "tumor_size_clinical_60979", "neoadj_tx_treatment_effect_18122", "primary_site", "grade_post_therapy_path_48765", "year_dx_validation", "summary_stage_rpa", "schema_selection_penis", "derived_ss2018_penis_70064" ], - "last_modified" : "2025-09-19T18:54:57.335Z", + "last_modified" : "2025-11-14T20:05:48.863Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/pharynx_other.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/pharynx_other.json index 8085fd07e..872e33e46 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/pharynx_other.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/pharynx_other.json @@ -269,6 +269,6 @@ } ] } ], "involved_tables" : [ "neoadjuvant_therapy_37302", "schema_selection_pharynx_other", "derived_ss2018_pharynx_other_63252", "nodes_pos_fpa", "grade_post_therapy_clin_69737", "seer_mets_sinus_othervs2_15755", "extension_bdd", "neoadj_tx_clinical_response_31723", "nodes_daq", "histology", "nodes_exam_76029", "tumor_size_summary_63115", "combined_grade_56638", "behavior", "grade_clinical_standard_non_ajcc_32473", "grade_pathological_standard_non_ajcc_5627", "derived_grade_standard_non_ajcc_63932", "type_of_reporting_source_76696", "tumor_size_pathological_25597", "tumor_size_clinical_60979", "neoadj_tx_treatment_effect_18122", "primary_site", "ss2018_pharynx_nos_excluding_melanoma_8720_8790_3303", "grade_post_therapy_path_75348", "year_dx_validation", "summary_stage_rpa" ], - "last_modified" : "2025-09-19T18:54:33.921Z", + "last_modified" : "2025-11-14T20:05:14.258Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/placenta.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/placenta.json index 2ea0f2071..0ec86d947 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/placenta.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/placenta.json @@ -233,10 +233,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] }, { "key" : "gestational_prog_index", @@ -306,6 +306,6 @@ } ] } ], "involved_tables" : [ "mets_hak", "neoadjuvant_therapy_37302", "derived_ss2018_placenta_6507", "nodes_dfm", "nodes_exam_dna_95635", "schema_selection_placenta", "neoadj_tx_clinical_response_31723", "histology", "figo_stage_placenta_73452", "tumor_size_summary_63115", "combined_grade_56638", "grade_post_therapy_clin_95734", "behavior", "extension_bbm", "grade_clinical_standard_94331", "derived_grade_standard_1196", "ss2018_placenta_66365", "type_of_reporting_source_76696", "tumor_size_pathological_25597", "tumor_size_clinical_60979", "neoadj_tx_treatment_effect_18122", "primary_site", "gestational_prog_index_28647", "year_dx_validation", "grade_pathological_standard_94268", "summary_stage_rpa", "grade_post_therapy_path_32110", "nodes_pos_dna_91511" ], - "last_modified" : "2025-09-19T18:55:12.525Z", + "last_modified" : "2025-11-14T20:06:14.492Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/plasma_cell_disorders.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/plasma_cell_disorders.json index 798a00a0a..edde1c5ce 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/plasma_cell_disorders.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/plasma_cell_disorders.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Plasma Cell Disorders", "title" : "Plasma Cell Disorders", - "notes" : "9671 Lymphoplasmacytic lymphoma (except C441, C690, C695-C696)\n * C700-C729, C751-C753 (2018-2022 only) (See Note 2)\n\n9731 Plasmacytoma, NOS \n9734 Plasmacytoma, extramedullary (except C441, C690, C695-C696)\n9761 Waldenstrom macroglobulinemia \n\n**Note 1:** **Sources used in the development of this schema**\n* SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998) (https://seer.cancer.gov/archive/manuals/EOD10Dig.3rd.pdf)\n* SEER Summary Staging Manual-2000: Codes and Coding Instructions (https://seer.cancer.gov/tools/ssm/ssm2000/)\n* Collaborative Stage Data Collection System, version 02.05: https://cancerstaging.org/cstage/Pages/default.aspx \n* Chapter 82 *Plasma Cell Myeloma and Plasma Cell Disorder*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois.\n\n**Note 2:** **Histologies moved to Brain, CNS, Intracranial Gland** For the histology listed below, this has moved to the Brain, CNS Other, and Intracranial Gland schemas starting with 2023 diagnoses. If you have one of these cases for 2018-2022, then this is the appropriate schema. If you have one of these cases diagnosed on January 1, 2023, forward, see the appropriate schema\n* 9671 \n * **Brain**: C700, C710-C719\n * **CNS Other**: C701, C709, C720-C725, C728-C729\n * **Intracranial Gland**: C751-C753\n\n**Note 3:** **Summary Stage** \n* Summary Stage is the only applicable staging system for this site/histology/schema.", + "notes" : "**The preferred histology terms listed in this schema are from the 2024 WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition.**\n\n* 9671: Lymphoplasmacytic lymphoma (LPL) *(EXCEPT C441, C690, C695-C696)*\n * C700-C729, C751-C753 (2018-2022 only) (See Note 2)\n\n* 9731: Solitary plasmacytoma of bone (SPB)\n* 9734: Extramedullary plasmacytoma (EMP) *(EXCEPT C441, C690, C695-C696)*\n* 9761: Waldenstrom macroglobulinemia (WM)\n\n**Note 1:** **Sources used in the development of this schema**\n* SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998) (https://seer.cancer.gov/archive/manuals/EOD10Dig.3rd.pdf)\n* SEER Summary Staging Manual-2000: Codes and Coding Instructions (https://seer.cancer.gov/tools/ssm/ssm2000/)\n* Collaborative Stage Data Collection System, version 02.05: https://cancerstaging.org/cstage/Pages/default.aspx \n* Chapter 82 *Plasma Cell Myeloma and Plasma Cell Disorder*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois.\n\n**Note 2:** **Histologies moved to Brain, CNS, Intracranial Gland** \nFor the histology listed below, this has moved to the Brain, CNS Other, and Intracranial Gland schemas starting with 2023 diagnoses. If you have one of these cases for 2018-2022, then this is the appropriate schema. If you have one of these cases diagnosed on January 1, 2023, forward, see the appropriate schema\n* 9671 \n * **Brain**: C700, C710-C719\n * **CNS Other**: C701, C709, C720-C725, C728-C729\n * **Intracranial Gland**: C751-C753\n\n**Note 3:** **Summary Stage** \n* Summary Stage is the only applicable staging system for this site/histology/schema.", "schema_selection_table" : "schema_selection_plasmacytomas", "schema_discriminators" : [ "year_dx", "behavior" ], "inputs" : [ { @@ -293,6 +293,6 @@ } ] } ], "involved_tables" : [ "neoadjuvant_therapy_37302", "tumor_size_clinical_dna_64119", "nodes_pos_2999", "derived_ss2018_myeloma_and_plasma_cell_disorders_3894", "tumor_size_summary_dna_13275", "schema_selection_plasmacytomas", "ptld_17694", "neoadj_tx_clinical_response_31723", "grade_post_therapy_clin_74830", "histology", "mets_hna", "behavior", "nodes_exam_17543", "ss2018_44993", "derived_grade_21945", "tumor_size_pathological_dna_6742", "type_of_reporting_source_76696", "primary_site", "neoadj_tx_treatment_effect_52725", "year_dx_validation", "derived_summary_grade_na_6690", "grade_post_therapy_path_65729", "summary_stage_rpa", "grade_clinical_18316", "eod_primary_tumor_3385", "grade_pathological_73388", "eod_regional_nodes_80411" ], - "last_modified" : "2025-09-19T18:55:13.437Z", + "last_modified" : "2025-11-14T20:06:14.827Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/plasma_cell_myeloma.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/plasma_cell_myeloma.json index 8fe51ab62..9d8605e1e 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/plasma_cell_myeloma.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/plasma_cell_myeloma.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Plasma Cell Myeloma", "title" : "Plasma Cell Myeloma", - "notes" : "9732 Multiple myeloma \n\n**Note 1:** **Sources used in the development of this schema**\n* SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998) (https://seer.cancer.gov/archive/manuals/EOD10Dig.3rd.pdf)\n* SEER Summary Staging Manual-2000: Codes and Coding Instructions (https://seer.cancer.gov/tools/ssm/ssm2000/)\n* Collaborative Stage Data Collection System, version 02.05: https://cancerstaging.org/cstage/Pages/default.aspx \n* Chapter 82 *Plasma Cell Myeloma and Plasma Cell Disorder*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois.\n\n**Note 2:** **Stage Definitions** \n* TNM data elements are not defined for this schema. TNM Stage Group is defined for multiple myeloma only (see Note 3) \n\n**Note 3:** **Additional data items for Staging** \n* The *Revised International Staging System (R-ISS)* is being used to stage plasma cell myeloma/multiple myeloma (9732). \n* The following variables must be collected at the time of diagnosis for staging:\n * High Risk Cytogenetics [NAACCR Data Item #3857]\n * LDH Pretreatment Level [NAACCR Data Item #3932]\n * Serum Albumin Pretreatment Level [NAACCR Data Item #3930]\n * Serum Beta-2 Microglobulin Pretreatment Level [NAACCR Data Item #3931]", + "notes" : "**9732: Plasma cell myeloma (PCM)**\n\n**Note 1:** **Sources used in the development of this schema**\n* SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998) (https://seer.cancer.gov/archive/manuals/EOD10Dig.3rd.pdf)\n* SEER Summary Staging Manual-2000: Codes and Coding Instructions (https://seer.cancer.gov/tools/ssm/ssm2000/)\n* Collaborative Stage Data Collection System, version 02.05: https://cancerstaging.org/cstage/Pages/default.aspx \n* Chapter 82 *Plasma Cell Myeloma and Plasma Cell Disorder*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois.\n\n**Note 2:** **Stage Definitions** \n* TNM data elements are not defined for this schema. TNM Stage Group is defined for multiple myeloma only (see Note 3) \n\n**Note 3:** **Additional data items for Staging** \n* The *Revised International Staging System (R-ISS)* is being used to stage plasma cell myeloma/multiple myeloma (9732). \n* The following variables must be collected at the time of diagnosis for staging:\n * High Risk Cytogenetics [NAACCR Data Item #3857]\n * LDH Pretreatment Level [NAACCR Data Item #3932]\n * Serum Albumin Pretreatment Level [NAACCR Data Item #3930]\n * Serum Beta-2 Microglobulin Pretreatment Level [NAACCR Data Item #3931]", "schema_selection_table" : "schema_selection_myeloma_plasma_cell_disorder", "schema_discriminators" : [ "behavior" ], "inputs" : [ { @@ -380,6 +380,6 @@ } ] } ], "involved_tables" : [ "multiple_myeloma_terminology_20875", "neoadjuvant_therapy_37302", "tumor_size_clinical_dna_64119", "derived_ss2018_myeloma_and_plasma_cell_disorders_3894", "b2_microglob_pretx_level_83264", "extension_bgc", "nodes_exam_dna_95635", "tumor_size_summary_dna_13275", "ptld_17694", "neoadj_tx_clinical_response_31723", "grade_post_therapy_clin_74830", "histology", "mets_hna", "behavior", "nodes_dna", "ss2018_44993", "derived_grade_21945", "tumor_size_pathological_dna_6742", "high_risk_cytogenetics_97806", "type_of_reporting_source_76696", "summary_stage_lymphoma_25139", "serum_alb_pretx_level_58159", "ldh_pretreatment_level_82697", "primary_site", "schema_selection_myeloma_plasma_cell_disorder", "neoadj_tx_treatment_effect_52725", "year_dx_validation", "derived_summary_grade_na_6690", "grade_post_therapy_path_65729", "grade_clinical_18316", "grade_pathological_73388", "nodes_pos_dna_91511" ], - "last_modified" : "2025-09-19T18:54:42.360Z", + "last_modified" : "2025-11-14T20:05:03.738Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/pleural_mesothelioma.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/pleural_mesothelioma.json index fed59481a..5e22b847c 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/pleural_mesothelioma.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/pleural_mesothelioma.json @@ -285,6 +285,6 @@ } ] } ], "involved_tables" : [ "tumor_size_summary_full_15510", "neoadjuvant_therapy_37302", "derived_grade_46639", "grade_post_therapy_path_41285", "grade_pathological_31963", "grade_post_therapy_clin_41222", "extension_bbx", "nodes_pos_fpa", "schema_selection_pleura", "neoadj_tx_clinical_response_31723", "histology", "nodes_exam_76029", "pleural_effusion_40041", "mets_hat", "combined_grade_56638", "behavior", "tumor_size_pathological_full_93442", "tumor_size_clinical_full_19656", "type_of_reporting_source_76696", "ss2018_pleura_60930", "neoadj_tx_treatment_effect_18122", "primary_site", "nodes_dbq", "year_dx_validation", "grade_clinical_73056", "summary_stage_rpa", "derived_ss2018_pleural_mesothelioma_74611" ], - "last_modified" : "2025-09-19T18:55:00.729Z", + "last_modified" : "2025-11-14T20:05:34.169Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/pleural_mesothelioma_v9_2025.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/pleural_mesothelioma_v9_2025.json index 60358ac04..c41e665dd 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/pleural_mesothelioma_v9_2025.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/pleural_mesothelioma_v9_2025.json @@ -35,6 +35,13 @@ "naaccr_xml_id" : "behaviorCodeIcdO3", "table" : "behavior", "used_for_staging" : false + }, { + "key" : "reporting_source", + "name" : "Type of Reporting Source", + "naaccr_item" : 500, + "naaccr_xml_id" : "typeOfReportingSource", + "table" : "type_of_reporting_source_76696", + "used_for_staging" : false }, { "key" : "size_clin", "name" : "Tumor Size Clinical", @@ -227,13 +234,6 @@ }, { "name" : "SEER_REQUIRED" } ] - }, { - "key" : "reporting_source", - "name" : "Type of Reporting Source", - "naaccr_item" : 500, - "naaccr_xml_id" : "typeOfReportingSource", - "table" : "type_of_reporting_source_76696", - "used_for_staging" : false } ], "outputs" : [ { "key" : "naaccr_schema_id", @@ -285,6 +285,6 @@ } ] } ], "involved_tables" : [ "tumor_size_summary_full_15510", "neoadjuvant_therapy_37302", "derived_grade_46639", "eod_mets_v9_3184", "nodes_pos_fpa", "neoadj_tx_clinical_response_31723", "histology", "nodes_exam_76029", "pleural_effusion_40041", "schema_selection_pleural_mesothelioma_v9_2025", "combined_grade_56638", "behavior", "grade_post_therapy_path_yp_v9_717", "tumor_size_pathological_full_93442", "tumor_size_clinical_full_19656", "grade_clinical_v9_88505", "grade_pathological_v9_76065", "eod_regional_nodes_v9_57286", "eod_primary_tumor_v9_52408", "type_of_reporting_source_76696", "ss2018_pleura_60930", "grade_post_therapy_clin_yc_v9_85438", "neoadj_tx_treatment_effect_18122", "primary_site", "year_dx_validation", "summary_stage_rpa", "derived_ss2018_pleural_mesothelioma_74611" ], - "last_modified" : "2025-09-19T18:54:38.885Z", + "last_modified" : "2025-11-14T20:05:09.594Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/primary_cutaneous_lymphoma_non_mf_ss.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/primary_cutaneous_lymphoma_non_mf_ss.json index 359581cbd..f9028790c 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/primary_cutaneous_lymphoma_non_mf_ss.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/primary_cutaneous_lymphoma_non_mf_ss.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Primary Cutaneous Lymphoma (excluding MF and SS)", "title" : "Primary Cutaneous Lymphoma (excluding MF and SS)", - "notes" : "9597, 9680, 9708-9709, 9712, 9718-9719, 9726 \n\nC440 Skin of lip, NOS\nC442 External ear\nC443 Skin of other and unspecified parts of face\nC444 Skin of scalp and neck\nC445 Skin of trunk\nC446 Skin of upper limb and shoulder\nC447 Skin of lower limb and hip\nC448 Overlapping lesion of skin\nC449 Skin, NOS\nC510 Labium majus\nC609 Penis\nC632 Scrotum, NOS\n\n**Note 1:** **Sources used in the development of this schema**\n* SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998) (https://seer.cancer.gov/archive/manuals/EOD10Dig.3rd.pdf)\n* SEER Summary Staging Manual-2000: Codes and Coding Instructions (https://seer.cancer.gov/tools/ssm/ssm2000/)\n* Collaborative Stage Data Collection System, version 02.05: https://cancerstaging.org/cstage/Pages/default.aspx \n* Chapter 81 *Primary Cutaneous Lymphomas*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois.\n\n**Note 2:** **Mycosis Fungoides schema** \n* See the *Mycosis Fungoides* schema for Mycosis Fungoides (9700) and Sezary syndrome (9701).\n\n**Note 3:** **Schema includes the preferred terms based on the 2024 WHO Classification of Tumours, Haematolymphoid tumors, 5th edition**\n\n* 9597: Primary cutaneous follicle center lymphoma (PCFCL)\n* 9680: Primary cutaneous diffuse large B-cell lymphoma, leg type (PCLBCL-LT) \n* 9708: Subcutaneous panniculitis-like T-cell lymphoma (SPTCL)\n* 9709: Primary cutaneous peripheral T-cell lymphoma (NOS) (pcPTCL)\n* 9712: Intravascular (large) B-cell lymphoma (IVLBCL)\n* 9718: Primary cutaneous anaplastic large cell lymphoma (C-ALCL)\n* 9719: Extranodal NK-/T-cell lymphoma (ENKTL)\n* 9726: Primary cutaneous gamma-delta T-cell lymphoma (PCGD-TCL)", + "notes" : "9597, 9680, 9708-9709, 9712, 9718-9719, 9726 \n\nC440 Skin of lip, NOS\nC442 External ear\nC443 Skin of other and unspecified parts of face\nC444 Skin of scalp and neck\nC445 Skin of trunk\nC446 Skin of upper limb and shoulder\nC447 Skin of lower limb and hip\nC448 Overlapping lesion of skin\nC449 Skin, NOS\nC510 Labium majus\nC609 Penis\nC632 Scrotum, NOS\n\n**Note 1:** **Sources used in the development of this schema**\n* SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998) (https://seer.cancer.gov/archive/manuals/EOD10Dig.3rd.pdf)\n* SEER Summary Staging Manual-2000: Codes and Coding Instructions (https://seer.cancer.gov/tools/ssm/ssm2000/)\n* Collaborative Stage Data Collection System, version 02.05: https://cancerstaging.org/cstage/Pages/default.aspx \n* Chapter 81 *Primary Cutaneous Lymphomas*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois.\n\n**Note 2:** **Mycosis Fungoides schema** \n* See the *Mycosis Fungoides* schema for Mycosis Fungoides (9700) and Sezary syndrome (9701).\n\n**Note 3:** **The preferred histology terms listed in this schema are from the 2024 WHO Classification of Tumours, Haematolymphoid tumours, 5th edition.**\n\n* 9597: Primary cutaneous follicle center lymphoma (PCFCL)\n* 9680: Primary cutaneous diffuse large B-cell lymphoma, leg type (PCLBCL-LT) \n* 9708: Subcutaneous panniculitis-like T-cell lymphoma (SPTCL)\n* 9709: Primary cutaneous peripheral T-cell lymphoma (NOS) (pcPTCL)\n* 9712: Intravascular (large) B-cell lymphoma (IVLBCL)\n* 9718: Primary cutaneous anaplastic large cell lymphoma (C-ALCL)\n* 9719: Extranodal NK-/T-cell lymphoma (ENKTL)\n* 9726: Primary cutaneous gamma-delta T-cell lymphoma (PCGD-TCL)", "schema_selection_table" : "schema_selection_primary_cutaneous_lymphoma_non_mf_ss", "inputs" : [ { "key" : "year_dx", @@ -283,6 +283,6 @@ } ] } ], "involved_tables" : [ "neoadjuvant_therapy_37302", "derived_ss2018_primary_cutaneous_lymphomas_45083", "tumor_size_pathological_43328", "nodes_pos_fpa", "ptld_17694", "neoadj_tx_clinical_response_31723", "grade_post_therapy_clin_74830", "histology", "nodes_exam_76029", "seer_regional_nodes_36710", "seer_mets_79245", "tumor_size_clinical_48894", "derived_grade_21945", "seer_primary_tumor_60433", "type_of_reporting_source_76696", "primary_site", "neoadj_tx_treatment_effect_52725", "year_dx_validation", "ss2018_primary_cutaneous_lymphomas_4605", "derived_summary_grade_na_6690", "grade_post_therapy_path_65729", "summary_stage_rpa", "tumor_size_summary_47973", "grade_clinical_18316", "grade_pathological_73388", "schema_selection_primary_cutaneous_lymphoma_non_mf_ss" ], - "last_modified" : "2025-09-19T18:54:55.896Z", + "last_modified" : "2025-11-14T20:06:00.507Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/primary_peritoneal_carcinoma.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/primary_peritoneal_carcinoma.json index e8e420547..f524d6707 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/primary_peritoneal_carcinoma.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/primary_peritoneal_carcinoma.json @@ -241,10 +241,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] }, { "key" : "ca125_pretx_interpretation", @@ -278,10 +278,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] } ], "outputs" : [ { @@ -334,6 +334,6 @@ } ] } ], "involved_tables" : [ "residual_tumor_volume_post_cytoreduction_90653", "grade_post_therapy_path_91649", "neoadjuvant_therapy_37302", "nodes_pos_fpa", "mets_hah", "neoadj_tx_clinical_response_31723", "histology", "nodes_exam_76029", "nodes_day", "grade_clinical_69174", "tumor_size_summary_63115", "combined_grade_56638", "behavior", "schema_selection_primary_peritoneal_carcinoma", "derived_grade_40528", "derived_ss2018_ovary_and_primary_peritoneal_carcinoma_26044", "type_of_reporting_source_76696", "ss2018_ovary_fallopian_tube_and_peritoneal_carcinoma_21678", "tumor_size_pathological_25597", "tumor_size_clinical_60979", "sex_assigned_at_birth_63290", "primary_site", "figo_stage_30513", "grade_pathological_42127", "grade_post_therapy_clin_54917", "year_dx_validation", "ca_125_pretx_interpretation_51295", "summary_stage_rpa", "eod_primary_tumor_96275", "neoadj_tx_treatment_effect_61650" ], - "last_modified" : "2025-09-19T18:54:34.682Z", + "last_modified" : "2025-11-14T20:06:10.466Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/prostate.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/prostate.json index a9fd51c20..c4b13fde9 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/prostate.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/prostate.json @@ -274,12 +274,7 @@ }, { "name" : "CCCR_REQUIRED" }, { - "name" : "SEER_REQUIRED", - "start" : 2018, - "end" : 2025 - }, { - "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "name" : "SEER_REQUIRED" } ] }, { "key" : "number_cores_exam", @@ -296,12 +291,7 @@ }, { "name" : "CCCR_REQUIRED" }, { - "name" : "SEER_REQUIRED", - "start" : 2018, - "end" : 2025 - }, { - "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "name" : "SEER_REQUIRED" } ] }, { "key" : "gleason_patterns_clin", @@ -398,7 +388,12 @@ }, { "name" : "CCCR_REQUIRED" }, { - "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC" + "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", + "start" : 2024 + }, { + "name" : "SEER_REQUIRED", + "start" : 2018, + "end" : 2023 } ] } ], "outputs" : [ { @@ -467,6 +462,6 @@ } ] } ], "involved_tables" : [ "neoadjuvant_therapy_37302", "mets_hal", "radiation_surg_seq", "gleason_patterns_pathological_833", "nodes_pos_fpa", "nodes_dbf", "grade_clinical_46962", "grade_post_therapy_clin_26978", "derived_ss2018_prostate_48792", "neoadj_tx_clinical_response_31723", "schema_selection_prostate", "histology", "combine_prostate_eod_extension_16771", "nodes_exam_76029", "gleason_score_pathological_82121", "grade_post_therapy_path_20786", "tumor_size_summary_63115", "ss2018_prostate_76172", "combined_grade_56638", "behavior", "extension_bbo", "number_of_cores_examined_64985", "number_of_cores_positive_87819", "grade_pathological_20069", "gleason_pattern_clinical_75179", "type_of_reporting_source_76696", "tumor_size_pathological_25597", "tumor_size_clinical_60979", "gleason_tertiary_pattern_6430", "systemic_surg_seq", "derived_grade_74326", "primary_site", "psa_46258", "neoadj_tx_treatment_effect_23019", "year_dx_validation", "summary_stage_rpa", "eod_prostate_pathologic_extension_2781", "gleason_score_clinical_67175" ], - "last_modified" : "2025-09-19T18:54:55.635Z", + "last_modified" : "2025-11-14T20:05:51.166Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/respiratory_other.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/respiratory_other.json index a8967f6bf..8792d7255 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/respiratory_other.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/respiratory_other.json @@ -269,6 +269,6 @@ } ] } ], "involved_tables" : [ "seer_mets_48348", "neoadjuvant_therapy_37302", "nodes_pos_fpa", "grade_post_therapy_clin_69737", "neoadj_tx_clinical_response_31723", "histology", "nodes_exam_76029", "derived_ss2018_respiratory_other_17734", "tumor_size_summary_63115", "combined_grade_56638", "behavior", "grade_clinical_standard_non_ajcc_32473", "grade_pathological_standard_non_ajcc_5627", "derived_grade_standard_non_ajcc_63932", "type_of_reporting_source_76696", "tumor_size_pathological_25597", "tumor_size_clinical_60979", "neoadj_tx_treatment_effect_18122", "primary_site", "ss2018_respiratory_other_36695", "grade_post_therapy_path_75348", "extension_bce", "year_dx_validation", "summary_stage_rpa", "nodes_dbv", "schema_selection_respiratory_other" ], - "last_modified" : "2025-09-19T18:54:43.283Z", + "last_modified" : "2025-11-14T20:05:09.977Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/retinoblastoma.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/retinoblastoma.json index 39677b8b4..c380fd82c 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/retinoblastoma.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/retinoblastoma.json @@ -279,6 +279,6 @@ } ] } ], "involved_tables" : [ "neoadjuvant_therapy_37302", "nodes_pos_fpa", "grade_post_therapy_path_98398", "neoadj_tx_clinical_response_31723", "histology", "nodes_exam_76029", "seer_primary_tumor_88917", "seer_mets_32413", "eod_regional_nodes_27426", "derived_grade_29698", "tumor_size_summary_63115", "combined_grade_56638", "derived_ss2018_retinoblastoma_10326", "ss2018_retinoblastoma_45411", "grade_pathological_12915", "type_of_reporting_source_76696", "tumor_size_pathological_25597", "tumor_size_clinical_60979", "neoadj_tx_treatment_effect_18122", "primary_site", "grade_clinical_62593", "year_dx_validation", "summary_stage_rpa", "schema_selection_retinoblastoma", "grade_post_therapy_clin_18631", "heritable_trait_49734" ], - "last_modified" : "2025-09-19T18:55:03.079Z", + "last_modified" : "2025-11-14T20:05:13.415Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/retroperitoneum.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/retroperitoneum.json index 4c432a91d..58794c3e0 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/retroperitoneum.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/retroperitoneum.json @@ -234,10 +234,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] } ], "outputs" : [ { @@ -290,6 +290,6 @@ } ] } ], "involved_tables" : [ "extension_bfv", "neoadjuvant_therapy_37302", "grade_post_therapy_clin_27082", "tumor_size_pathological_43328", "derived_ss2018_retroperitoneum_11521", "nodes_pos_fpa", "neoadj_tx_clinical_response_31723", "histology", "nodes_exam_76029", "bone_invasion_96628", "neoadj_tx_treatment_effect_4391", "combined_grade_56638", "grade_pathological_19141", "grade_post_therapy_path_35393", "ss2018_soft_tissue_retroperitoneum_5644", "tumor_size_clinical_48894", "type_of_reporting_source_76696", "schema_selection_retroperitoneum", "grade_clinical_64933", "sex_assigned_at_birth_63290", "eod_mets_23953", "primary_site", "nodes_dfq", "derived_grade_48704", "year_dx_validation", "summary_stage_rpa", "tumor_size_summary_47973" ], - "last_modified" : "2025-09-19T18:54:53.224Z", + "last_modified" : "2025-11-14T20:05:18.969Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/sinus_other.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/sinus_other.json index db103bece..cad3c35de 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/sinus_other.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/sinus_other.json @@ -269,6 +269,6 @@ } ] } ], "involved_tables" : [ "neoadjuvant_therapy_37302", "nodes_pos_fpa", "grade_post_therapy_clin_69737", "seer_mets_sinus_othervs2_15755", "neoadj_tx_clinical_response_31723", "nodes_daq", "histology", "nodes_exam_76029", "schema_selection_sinus_other", "extension_bdk", "tumor_size_summary_63115", "combined_grade_56638", "behavior", "grade_clinical_standard_non_ajcc_32473", "ss2018_sinus_other_excluding_melanoma_8720_8790_91859", "derived_ss2018_sinus_other_893", "grade_pathological_standard_non_ajcc_5627", "derived_grade_standard_non_ajcc_63932", "type_of_reporting_source_76696", "tumor_size_pathological_25597", "tumor_size_clinical_60979", "neoadj_tx_treatment_effect_18122", "primary_site", "grade_post_therapy_path_75348", "year_dx_validation", "summary_stage_rpa" ], - "last_modified" : "2025-09-19T18:54:52.324Z", + "last_modified" : "2025-11-14T20:05:14.613Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/skin_eyelid.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/skin_eyelid.json index d748ea2f4..04c7123fb 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/skin_eyelid.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/skin_eyelid.json @@ -284,6 +284,6 @@ } ] } ], "involved_tables" : [ "neoadjuvant_therapy_37302", "nodes_dde", "tumor_size_pathological_43328", "derived_grade_46639", "grade_post_therapy_path_41285", "grade_pathological_31963", "grade_post_therapy_clin_41222", "nodes_pos_fpa", "neoadj_tx_clinical_response_31723", "histology", "nodes_exam_76029", "extension_bdg", "mets_hcu", "combined_grade_56638", "behavior", "schema_selection_skin_eyelid", "derived_ss2018_skin_eyelid_74710", "perineural_invasion_24604", "tumor_size_clinical_48894", "type_of_reporting_source_76696", "neoadj_tx_treatment_effect_18122", "primary_site", "year_dx_validation", "ss2018_skin_of_eyelid_82925", "grade_clinical_73056", "summary_stage_rpa", "tumor_size_summary_47973" ], - "last_modified" : "2025-09-19T18:54:51.387Z", + "last_modified" : "2025-11-14T20:05:32.201Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/skin_other.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/skin_other.json index 605810ead..e8b5ac64a 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/skin_other.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/skin_other.json @@ -269,6 +269,6 @@ } ] } ], "involved_tables" : [ "neoadjuvant_therapy_37302", "nodes_ddj", "nodes_pos_fpa", "grade_post_therapy_clin_69737", "neoadj_tx_clinical_response_31723", "histology", "nodes_exam_76029", "seer_mets_90643", "tumor_size_summary_63115", "combined_grade_56638", "behavior", "extension_bdo", "grade_clinical_standard_non_ajcc_32473", "schema_selection_skin_other", "grade_pathological_standard_non_ajcc_5627", "derived_ss2018_skin_except_eyelid_95559", "derived_grade_standard_non_ajcc_63932", "type_of_reporting_source_76696", "tumor_size_pathological_25597", "tumor_size_clinical_60979", "neoadj_tx_treatment_effect_18122", "primary_site", "ss2018_skin_other_56341", "grade_post_therapy_path_75348", "year_dx_validation", "summary_stage_rpa" ], - "last_modified" : "2025-09-19T18:54:38.947Z", + "last_modified" : "2025-11-14T20:05:10.356Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/small_intestine.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/small_intestine.json index e39ca2d7d..445217ca7 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/small_intestine.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/small_intestine.json @@ -269,6 +269,6 @@ } ] } ], "involved_tables" : [ "neoadjuvant_therapy_37302", "derived_grade_46639", "grade_post_therapy_path_41285", "grade_pathological_31963", "grade_post_therapy_clin_41222", "nodes_pos_fpa", "neoadj_tx_clinical_response_31723", "derived_ss2018_small_intestine_48854", "histology", "schema_selection_small_intestine", "nodes_exam_76029", "extension_bbe", "nodes_daw", "tumor_size_summary_63115", "combined_grade_56638", "behavior", "ss2018_small_intestine_including_net_85335", "mets_hbo", "type_of_reporting_source_76696", "tumor_size_pathological_25597", "tumor_size_clinical_60979", "neoadj_tx_treatment_effect_18122", "primary_site", "year_dx_validation", "grade_clinical_73056", "summary_stage_rpa" ], - "last_modified" : "2025-09-19T18:54:41.789Z", + "last_modified" : "2025-11-14T20:05:41.143Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/soft_tissue_abdomen_thoracic.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/soft_tissue_abdomen_thoracic.json index 301d155bd..2837fe2bd 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/soft_tissue_abdomen_thoracic.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/soft_tissue_abdomen_thoracic.json @@ -238,10 +238,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] } ], "outputs" : [ { @@ -294,6 +294,6 @@ } ] } ], "involved_tables" : [ "tumor_size_summary_full_15510", "neoadjuvant_therapy_37302", "schema_discriminator_2_15990", "seer_primary_tumor_53926", "eod_mets_33408", "grade_post_therapy_path_36935", "nodes_pos_fpa", "neoadj_tx_clinical_response_31723", "grade_post_therapy_clin_1647", "histology", "nodes_exam_76029", "schema_selection_heart_mediastinum", "bone_invasion_96628", "neoadj_tx_treatment_effect_4391", "combined_grade_56638", "ss2018_soft_tissue_31311", "tumor_size_pathological_full_93442", "tumor_size_clinical_full_19656", "derived_ss2018_soft_tissue_and_sarcomas_99149", "grade_pathological_40399", "type_of_reporting_source_76696", "derived_grade_71227", "grade_clinical_41135", "primary_site", "year_dx_validation", "seer_regional_nodes_19661", "summary_stage_rpa" ], - "last_modified" : "2025-09-19T18:55:13.745Z", + "last_modified" : "2025-11-14T20:06:09.583Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/soft_tissue_head_neck.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/soft_tissue_head_neck.json index f34d57350..eab186f0c 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/soft_tissue_head_neck.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/soft_tissue_head_neck.json @@ -234,10 +234,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] } ], "outputs" : [ { @@ -290,6 +290,6 @@ } ] } ], "involved_tables" : [ "neoadjuvant_therapy_37302", "seer_primary_tumor_42176", "grade_post_therapy_path_36935", "tumor_size_pathological_full_62176", "nodes_pos_fpa", "schema_selection_soft_tissue_sarcoma_head_and_neck", "neoadj_tx_clinical_response_31723", "grade_post_therapy_clin_1647", "histology", "nodes_exam_76029", "seer_regional_nodes_93152", "bone_invasion_96628", "neoadj_tx_treatment_effect_4391", "eod_mets_23805", "combined_grade_56638", "behavior", "ss2018_soft_tissue_31311", "tumor_size_clinical_full_74867", "derived_ss2018_soft_tissue_and_sarcomas_99149", "grade_pathological_40399", "type_of_reporting_source_76696", "derived_grade_71227", "tumor_size_summary_full_31213", "grade_clinical_41135", "primary_site", "year_dx_validation", "summary_stage_rpa" ], - "last_modified" : "2025-09-19T18:54:52.200Z", + "last_modified" : "2025-11-14T20:05:40.699Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/soft_tissue_other.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/soft_tissue_other.json index 36ec0006c..0836c8773 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/soft_tissue_other.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/soft_tissue_other.json @@ -263,10 +263,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] } ], "outputs" : [ { @@ -319,6 +319,6 @@ } ] } ], "involved_tables" : [ "tumor_size_summary_full_15510", "neoadjuvant_therapy_37302", "schema_discriminator_2_15990", "occult_head_and_neck_lymph_nodes_10277", "schema_selection_peritoneum", "grade_post_therapy_path_36935", "nodes_pos_fpa", "neoadj_tx_clinical_response_31723", "grade_post_therapy_clin_1647", "histology", "nodes_exam_76029", "bone_invasion_96628", "neoadj_tx_treatment_effect_4391", "eod_regional_nodes_61282", "combined_grade_56638", "behavior", "ss2018_soft_tissue_31311", "tumor_size_pathological_full_93442", "tumor_size_clinical_full_19656", "derived_ss2018_soft_tissue_and_sarcomas_99149", "grade_pathological_40399", "type_of_reporting_source_76696", "derived_grade_71227", "eod_mets_2212", "grade_clinical_41135", "primary_site", "eod_primary_tumor_93027", "year_dx_validation", "summary_stage_rpa" ], - "last_modified" : "2025-09-19T18:54:49.488Z", + "last_modified" : "2025-11-14T20:06:10.045Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/soft_tissue_rare.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/soft_tissue_rare.json index a03c6b23c..292d53a01 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/soft_tissue_rare.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/soft_tissue_rare.json @@ -241,10 +241,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] } ], "outputs" : [ { @@ -297,6 +297,6 @@ } ] } ], "involved_tables" : [ "tumor_size_summary_full_15510", "extension_bbr", "neoadjuvant_therapy_37302", "nodes_dbi", "grade_post_therapy_path_36935", "nodes_pos_fpa", "neoadj_tx_clinical_response_31723", "grade_post_therapy_clin_1647", "histology", "nodes_exam_76029", "bone_invasion_96628", "neoadj_tx_treatment_effect_4391", "combined_grade_56638", "behavior", "ss2018_soft_tissue_31311", "tumor_size_pathological_full_93442", "tumor_size_clinical_full_19656", "derived_ss2018_soft_tissue_and_sarcomas_99149", "grade_pathological_40399", "type_of_reporting_source_76696", "derived_grade_71227", "schema_selection_soft_tissue_rare", "sex_assigned_at_birth_63290", "grade_clinical_41135", "primary_site", "eod_mets_20229", "year_dx_validation", "summary_stage_rpa" ], - "last_modified" : "2025-09-19T18:54:41.340Z", + "last_modified" : "2025-11-14T20:06:10.931Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/soft_tissue_trunk_extremities.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/soft_tissue_trunk_extremities.json index 864c388bd..af1a5098e 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/soft_tissue_trunk_extremities.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/soft_tissue_trunk_extremities.json @@ -238,10 +238,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] } ], "outputs" : [ { @@ -294,6 +294,6 @@ } ] } ], "involved_tables" : [ "neoadjuvant_therapy_37302", "grade_post_therapy_clin_27082", "schema_discriminator_2_15990", "tumor_size_pathological_full_62176", "nodes_pos_fpa", "seer_primary_tumor_31838", "neoadj_tx_clinical_response_31723", "histology", "nodes_exam_76029", "bone_invasion_96628", "schema_selection_soft_tissue_trunk_and_extremities", "neoadj_tx_treatment_effect_4391", "combined_grade_56638", "ss2018_soft_tissue_31311", "grade_pathological_19141", "grade_post_therapy_path_35393", "tumor_size_clinical_full_74867", "derived_ss2018_soft_tissue_and_sarcomas_99149", "type_of_reporting_source_76696", "grade_clinical_64933", "seer_regional_nodes_69974", "tumor_size_summary_full_31213", "primary_site", "eod_mets_22645", "derived_grade_48704", "year_dx_validation", "summary_stage_rpa" ], - "last_modified" : "2025-09-19T18:54:41.485Z", + "last_modified" : "2025-11-14T20:05:27.875Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/stomach.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/stomach.json index 22955d969..dc908f165 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/stomach.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/stomach.json @@ -303,6 +303,6 @@ } ] } ], "involved_tables" : [ "tumor_size_summary_full_15510", "neoadjuvant_therapy_37302", "esophagusgejunction_egj_stomach_57130", "ss2018_stomach_including_net_stomach_35647", "mets_hac", "nodes_pos_fpa", "neoadj_tx_treatment_effect_90678", "neoadj_tx_clinical_response_31723", "histology", "nodes_dak", "nodes_exam_76029", "derived_grade_21973", "derived_ss2018_stomach_19183", "grade_pathological_59340", "combined_grade_56638", "behavior", "schema_selection_stomach", "tumor_size_pathological_full_93442", "tumor_size_clinical_full_19656", "grade_post_therapy_clin_60334", "grade_post_therapy_path_90448", "type_of_reporting_source_76696", "primary_site", "grade_clinical_36085", "year_dx_validation", "summary_stage_rpa", "extension_bal", "her2_overall_summary_copy_71435" ], - "last_modified" : "2025-09-19T18:55:06.896Z", + "last_modified" : "2025-11-14T20:05:10.818Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/testis.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/testis.json index ff61fba33..3c3136d75 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/testis.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/testis.json @@ -282,10 +282,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] }, { "key" : "hcg_pre_orch_lab_value", @@ -317,10 +317,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] }, { "key" : "ldh_pre_orch_range", @@ -337,10 +337,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] }, { "key" : "afp_post_orch_lab_value", @@ -372,10 +372,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] }, { "key" : "hcg_post_orch_lab_value", @@ -407,10 +407,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] }, { "key" : "ldh_post_orch_range", @@ -427,10 +427,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] } ], "outputs" : [ { @@ -483,6 +483,6 @@ } ] } ], "involved_tables" : [ "neoadjuvant_therapy_37302", "nodes_pos_fpa", "nodes_ddf", "neoadj_tx_clinical_response_31723", "derived_ss2018_testis_36736", "histology", "ldh_pre_orchiectomy_range_42762", "nodes_exam_76029", "extension_bdh", "hcg_post_orchiectomy_range_92334", "schema_selection_testis", "tumor_size_summary_63115", "combined_grade_56638", "behavior", "grade_post_therapy_clin_95734", "s_category_pathologic_34448", "grade_clinical_standard_94331", "ldh_post_orchiectomy_range_38574", "derived_grade_standard_1196", "mets_hbb", "type_of_reporting_source_76696", "hcg_pre_orchiectomy_lab_value_55584", "afp_pre_orchiectomy_lab_value_94162", "tumor_size_pathological_25597", "tumor_size_clinical_60979", "afp_pre_orchiectomy_range_11386", "neoadj_tx_treatment_effect_18122", "s_category_clinical_19191", "primary_site", "hcg_post_orchiectomy_lab_value_13834", "hcg_pre_orchiectomy_range_67679", "afp_post_orchiectomy_range_84758", "grade_pathological_standard_94268", "afp_post_orchiectomy_lab_value_90733", "year_dx_validation", "summary_stage_rpa", "grade_post_therapy_path_32110", "ss2018_testis_82848" ], - "last_modified" : "2025-09-19T18:54:36.794Z", + "last_modified" : "2025-11-14T20:05:51.551Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/thymus.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/thymus.json index 47cc8f51a..9eda94f1c 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/thymus.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/thymus.json @@ -270,6 +270,6 @@ } ] } ], "involved_tables" : [ "neoadjuvant_therapy_37302", "seer_primary_tumor_68925", "nodes_pos_fpa", "neoadj_tx_clinical_response_31723", "histology", "nodes_exam_76029", "neoadj_tx_treatment_effect_4391", "tumor_size_summary_63115", "combined_grade_56638", "grade_post_therapy_clin_95734", "behavior", "seer_regional_nodes_copy_24179", "derived_ss2018_thymus_2194", "grade_clinical_standard_94331", "derived_grade_standard_1196", "ss2018_thymus_60066", "type_of_reporting_source_76696", "tumor_size_pathological_25597", "tumor_size_clinical_60979", "schema_selection_thymus", "primary_site", "seer_mets_4721", "year_dx_validation", "grade_pathological_standard_94268", "summary_stage_rpa", "grade_post_therapy_path_32110" ], - "last_modified" : "2025-09-19T18:55:00.053Z", + "last_modified" : "2025-11-14T20:05:21.868Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/thymus_v9_2025.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/thymus_v9_2025.json index 36e5a0bcf..66e44edbf 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/thymus_v9_2025.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/thymus_v9_2025.json @@ -270,6 +270,6 @@ } ] } ], "involved_tables" : [ "neoadjuvant_therapy_37302", "schema_selection_thymus_v9_2025", "nodes_pos_fpa", "eod_primary_tumor_v9_6892", "neoadj_tx_clinical_response_31723", "histology", "eod_regional_nodes_v9_3599", "nodes_exam_76029", "eod_mets_v9_1812", "neoadj_tx_treatment_effect_4391", "tumor_size_summary_63115", "combined_grade_56638", "grade_post_therapy_clin_95734", "behavior", "derived_ss2018_thymus_2194", "grade_clinical_standard_94331", "derived_grade_standard_1196", "ss2018_thymus_60066", "type_of_reporting_source_76696", "tumor_size_pathological_25597", "tumor_size_clinical_60979", "primary_site", "year_dx_validation", "grade_pathological_standard_94268", "summary_stage_rpa", "grade_post_therapy_path_32110" ], - "last_modified" : "2025-09-19T18:55:04.858Z", + "last_modified" : "2025-11-14T20:05:59.182Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/thyroid.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/thyroid.json index 9529e9dcb..01a200f73 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/thyroid.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/thyroid.json @@ -295,6 +295,6 @@ } ] } ], "involved_tables" : [ "neoadjuvant_therapy_37302", "tumor_size_pathological_43328", "ss2018_thyroid_33058", "schema_selection_thyroid", "nodes_pos_fpa", "neoadj_tx_clinical_response_31723", "histology", "nodes_exam_76029", "eod_mets_91154", "age_at_diagnosis_validation_65093", "combined_grade_56638", "grade_post_therapy_clin_95734", "thyroid_gland_thyroglossal_duct_21498", "behavior", "eod_regional_nodes_29442", "grade_clinical_standard_94331", "tumor_size_clinical_48894", "derived_grade_standard_1196", "type_of_reporting_source_76696", "neoadj_tx_treatment_effect_18122", "primary_site", "derived_ss2018_thyroid_44895", "year_dx_validation", "grade_pathological_standard_94268", "summary_stage_rpa", "seer_primary_tumor_6275", "grade_post_therapy_path_32110", "tumor_size_summary_47973" ], - "last_modified" : "2025-09-19T18:54:46.251Z", + "last_modified" : "2025-11-14T20:05:13.792Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/thyroid_medullary.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/thyroid_medullary.json index 200706c8d..93990b5b7 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/thyroid_medullary.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/thyroid_medullary.json @@ -288,6 +288,6 @@ } ] } ], "involved_tables" : [ "neoadjuvant_therapy_37302", "tumor_size_pathological_43328", "eod_regional_nodes_16316", "ss2018_thyroid_33058", "nodes_pos_fpa", "neoadj_tx_clinical_response_31723", "histology", "nodes_exam_76029", "combined_grade_56638", "grade_post_therapy_clin_95734", "thyroid_gland_thyroglossal_duct_21498", "behavior", "grade_clinical_standard_94331", "tumor_size_clinical_48894", "derived_grade_standard_1196", "type_of_reporting_source_76696", "neoadj_tx_treatment_effect_18122", "primary_site", "seer_primary_tumor_36538", "derived_ss2018_thyroid_44895", "schema_selection_thyroid_medullary", "year_dx_validation", "grade_pathological_standard_94268", "summary_stage_rpa", "grade_post_therapy_path_32110", "tumor_size_summary_47973", "eod_mets_53046" ], - "last_modified" : "2025-09-19T18:54:48.150Z", + "last_modified" : "2025-11-14T20:05:24.879Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/tongue_anterior.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/tongue_anterior.json index 4ec291df7..ff8828336 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/tongue_anterior.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/tongue_anterior.json @@ -250,10 +250,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] }, { "key" : "ln_size_of_mets", @@ -272,10 +272,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] }, { "key" : "seer_ssf1", @@ -339,6 +339,6 @@ } ] } ], "involved_tables" : [ "extranodal_extension_head_and_neck_pathological_87046", "grade_post_therapy_clin_61658", "neoadjuvant_therapy_37302", "tumor_size_pathological_43328", "grade_clinical_6485", "nodes_pos_fpa", "neoadj_tx_clinical_response_31723", "derived_ss2018_tongue_anterior_40968", "histology", "nodes_exam_76029", "combined_grade_56638", "behavior", "nodes_daa", "eod_primary_tumor_53330", "tumor_size_clinical_48894", "seer_mets_lip_lower_28596", "grade_post_therapy_path_40048", "type_of_reporting_source_76696", "schema_selection_tongue_anterior", "neoadj_tx_treatment_effect_18122", "p16_hpv_human_papilloma_virus_status_head_and_neck_509", "primary_site", "extranodal_extension_head_and_neck_clinical_79321", "grade_pathological_84704", "ss2018_tongue_anterior_66978", "year_dx_validation", "derived_grade_69945", "summary_stage_rpa", "tumor_size_summary_47973", "ln_size_70140" ], - "last_modified" : "2025-09-19T18:55:03.390Z", + "last_modified" : "2025-11-14T20:06:02.845Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/trachea.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/trachea.json index 340dadf5f..368cd66e4 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/trachea.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/trachea.json @@ -269,6 +269,6 @@ } ] } ], "involved_tables" : [ "seer_mets_48348", "neoadjuvant_therapy_37302", "nodes_pos_fpa", "grade_post_therapy_clin_69737", "neoadj_tx_clinical_response_31723", "histology", "nodes_exam_76029", "ss2018_trachea_70961", "tumor_size_summary_63115", "combined_grade_56638", "behavior", "grade_clinical_standard_non_ajcc_32473", "grade_pathological_standard_non_ajcc_5627", "derived_grade_standard_non_ajcc_63932", "type_of_reporting_source_76696", "tumor_size_pathological_25597", "tumor_size_clinical_60979", "neoadj_tx_treatment_effect_18122", "schema_selection_trachea", "primary_site", "grade_post_therapy_path_75348", "extension_bcf", "year_dx_validation", "summary_stage_rpa", "nodes_dbw", "derived_ss2018_trachea_96519" ], - "last_modified" : "2025-09-19T18:55:06.011Z", + "last_modified" : "2025-11-14T20:05:43.733Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/urethra.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/urethra.json index 93b93f5df..06a2cd133 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/urethra.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/urethra.json @@ -289,6 +289,6 @@ } ] } ], "involved_tables" : [ "eod_mets_83665", "neoadjuvant_therapy_37302", "nodes_pos_fpa", "urethra_prostatic_urethra_30106", "neoadj_tx_clinical_response_31723", "grade_post_therapy_path_55848", "histology", "nodes_exam_76029", "schema_selection_urethra", "tumor_size_summary_63115", "combined_grade_56638", "behavior", "seer_primary_tumor_94875", "derived_grade_84046", "type_of_reporting_source_76696", "tumor_size_pathological_25597", "tumor_size_clinical_60979", "neoadj_tx_treatment_effect_18122", "primary_site", "derived_ss2018_urethra_73432", "grade_pathological_59975", "grade_post_therapy_clin_68213", "year_dx_validation", "summary_stage_rpa", "grade_clinical_91989", "ss2018_urethra_14363", "nodes_dbu" ], - "last_modified" : "2025-09-19T18:55:07.740Z", + "last_modified" : "2025-11-14T20:05:12.652Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/urethra_prostatic.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/urethra_prostatic.json index 6d22b5650..0e561d215 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/urethra_prostatic.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/urethra_prostatic.json @@ -289,6 +289,6 @@ } ] } ], "involved_tables" : [ "eod_mets_83665", "neoadjuvant_therapy_37302", "nodes_pos_fpa", "urethra_prostatic_urethra_30106", "neoadj_tx_clinical_response_31723", "grade_post_therapy_path_55848", "histology", "nodes_exam_76029", "tumor_size_summary_63115", "combined_grade_56638", "behavior", "derived_grade_84046", "type_of_reporting_source_76696", "tumor_size_pathological_25597", "tumor_size_clinical_60979", "neoadj_tx_treatment_effect_18122", "primary_site", "derived_ss2018_urethra_73432", "grade_pathological_59975", "seer_primary_tumor_59317", "grade_post_therapy_clin_68213", "year_dx_validation", "summary_stage_rpa", "grade_clinical_91989", "schema_selection_urethra_prostatic", "ss2018_urethra_14363", "nodes_dbu" ], - "last_modified" : "2025-09-19T18:54:50.775Z", + "last_modified" : "2025-11-14T20:05:11.851Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/urinary_other.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/urinary_other.json index dcc8b4a53..184799ca8 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/urinary_other.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/urinary_other.json @@ -269,6 +269,6 @@ } ] } ], "involved_tables" : [ "seer_mets_48348", "neoadjuvant_therapy_37302", "nodes_pos_fpa", "derived_ss2018_urinary_other_89509", "grade_post_therapy_clin_69737", "neoadj_tx_clinical_response_31723", "histology", "nodes_exam_76029", "nodes_dcz", "schema_selection_urinary_other", "tumor_size_summary_63115", "combined_grade_56638", "behavior", "grade_clinical_standard_non_ajcc_32473", "grade_pathological_standard_non_ajcc_5627", "derived_grade_standard_non_ajcc_63932", "extension_bcy", "type_of_reporting_source_76696", "tumor_size_pathological_25597", "tumor_size_clinical_60979", "neoadj_tx_treatment_effect_18122", "primary_site", "grade_post_therapy_path_75348", "ss2018_urinary_other_87865", "year_dx_validation", "summary_stage_rpa" ], - "last_modified" : "2025-09-19T18:54:47.532Z", + "last_modified" : "2025-11-14T20:05:41.516Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/vagina.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/vagina.json index 552567eda..5ef57f6ce 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/vagina.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/vagina.json @@ -233,10 +233,10 @@ }, { "name" : "SEER_REQUIRED", "start" : 2018, - "end" : 2025 + "end" : 2023 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] }, { "key" : "ln_status_femoral_inguinal", @@ -409,6 +409,6 @@ } ] } ], "involved_tables" : [ "mets_haj", "nodes_dba", "lymph_nodes_distant_assessment_method_24499", "grade_post_therapy_clin_61658", "neoadjuvant_therapy_37302", "tumor_size_pathological_43328", "grade_clinical_6485", "nodes_pos_fpa", "ln_status_para_aortic_41020", "neoadj_tx_clinical_response_31723", "histology", "nodes_exam_76029", "schema_selection_vagina", "ln_status_femoral_inguinal_vagina_64638", "combined_grade_56638", "behavior", "tumor_size_clinical_48894", "grade_post_therapy_path_40048", "figo_stage_vagina_61098", "type_of_reporting_source_76696", "ss2018_vagina_94653", "neoadj_tx_treatment_effect_18122", "lymph_nodes_assessment_method_pelvic_33476", "primary_site", "lymph_nodes_distant_mediastinal_scalene_90567", "ln_status_pelvic_31753", "grade_pathological_84704", "extension_bad", "year_dx_validation", "lymph_nodes_assessment_method_para_aortic_56026", "derived_grade_69945", "derived_ss2018_vagina_63227", "summary_stage_rpa", "tumor_size_summary_47973", "ln_assessment_method_femoral_inguinal_48450" ], - "last_modified" : "2025-09-19T18:54:37.946Z", + "last_modified" : "2025-11-14T20:06:11.426Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/vulva.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/vulva.json index 71fe4e531..36af1920c 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/vulva.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/vulva.json @@ -364,6 +364,6 @@ } ] } ], "involved_tables" : [ "schema_selection_vulva", "ln_status_femoral_inguinal_13374", "nodes_dbb", "ln_status_pelvic_93438", "grade_post_therapy_clin_61658", "neoadjuvant_therapy_37302", "tumor_size_pathological_43328", "grade_clinical_6485", "nodes_pos_fpa", "derived_ss2018_vulva_47165", "neoadj_tx_clinical_response_31723", "histology", "nodes_exam_76029", "mets_hba", "lymph_nodes_assessment_method_femoral_46948", "extension_bbi", "combined_grade_56638", "behavior", "ss2018_vulva_49198", "tumor_size_clinical_48894", "grade_post_therapy_path_40048", "ln_assessment_method_pelvic_vulva_10928", "type_of_reporting_source_76696", "figo_stage_vulva_69787", "neoadj_tx_treatment_effect_18122", "lymph_node_laterality_65685", "primary_site", "grade_pathological_84704", "year_dx_validation", "derived_grade_69945", "summary_stage_rpa", "tumor_size_summary_47973" ], - "last_modified" : "2025-09-19T18:54:57.915Z", + "last_modified" : "2025-11-14T20:06:01.574Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/vulva_v9_2024.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/vulva_v9_2024.json index 240ae7302..1cecdf468 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/vulva_v9_2024.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/schemas/vulva_v9_2024.json @@ -231,13 +231,9 @@ "name" : "COC_REQUIRED" }, { "name" : "SSDI" - }, { - "name" : "SEER_REQUIRED", - "start" : 2024, - "end" : 2025 }, { "name" : "SEER_REQUIRED_WHEN_COC_ANALYTIC", - "start" : 2026 + "start" : 2024 } ] }, { "key" : "ln_status_femoral_inguinal", @@ -311,10 +307,6 @@ "name" : "COC_REQUIRED" }, { "name" : "SSDI" - }, { - "name" : "SEER_REQUIRED", - "start" : 2024, - "end" : 2025 } ] }, { "key" : "p16", @@ -388,6 +380,6 @@ } ] } ], "involved_tables" : [ "ln_status_femoral_inguinal_13374", "ln_status_pelvic_93438", "grade_post_therapy_clin_61658", "neoadjuvant_therapy_37302", "tumor_size_pathological_43328", "grade_clinical_6485", "nodes_pos_fpa", "eod_regional_nodes_38984", "derived_ss2018_vulva_47165", "p16_831", "neoadj_tx_clinical_response_31723", "histology", "nodes_exam_76029", "mets_hba", "lymph_nodes_assessment_method_femoral_46948", "combined_grade_56638", "behavior", "ss2018_vulva_49198", "tumor_size_clinical_48894", "grade_post_therapy_path_40048", "ln_assessment_method_pelvic_vulva_10928", "type_of_reporting_source_76696", "schema_selection_vulva_v9_2024", "figo_stage_vulva_69787", "neoadj_tx_treatment_effect_18122", "lymph_node_laterality_65685", "primary_site", "grade_pathological_84704", "year_dx_validation", "derived_grade_69945", "summary_stage_rpa", "tumor_size_summary_47973", "eod_primary_tumor_93022" ], - "last_modified" : "2025-09-19T18:55:01.292Z", + "last_modified" : "2025-11-14T20:06:02.082Z", "on_invalid_input" : "CONTINUE" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/adenoid_cystic_basaloid_pattern_86314.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/adenoid_cystic_basaloid_pattern_86314.json index 0a9014030..535dad955 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/adenoid_cystic_basaloid_pattern_86314.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/adenoid_cystic_basaloid_pattern_86314.json @@ -6,7 +6,7 @@ "title" : "Adenoid Cystic Basaloid Pattern", "description" : "Adenoid Cystic Basaloid Pattern, the presence of a basaloid pattern on pathological examination, is a prognostic factor for adenoid cystic carcinoma of the lacrimal gland.\n\nAdenoid cystic carcinoma (ICD-O-3 morphology code 8200/3) is the most common malignant epithelial tumor of the lacrimal gland. Adenoid cystic carcinoma is a tumor composed of modified myoepithelial and ductal differentiated cells. A genetic alteration (i.e., fusion oncogene MYB-NFIB) is found in the majority of adenoid cystic carcinomas There are three histologic patterns within the adenoid cystic carcinoma group: cribriform, solid, and tubular.", "notes" : "**Note 1:** **Physician Statement**\n* Physician statement of basaloid pattern can be used to code this data item when no other information is available.\n\n**Note 2:** **Applicable histologies**\n* This is most commonly found in Adenoid Cystic Carcinoma (8200/3) but can be present in other histologies.", - "last_modified" : "2025-02-24T14:30:12.285Z", + "last_modified" : "2025-11-06T21:28:24.907Z", "definition" : [ { "key" : "adenoid_cystic_basaloid_pattern", "name" : "Code", @@ -18,6 +18,6 @@ } ], "rows" : [ [ "0.0-100.0", "0.0 to 100.0 percent basaloid pattern" ], [ "XXX.5", "Basaloid pattern present, percentage not stated" ], [ "XXX.8", "Not applicable: Information not collected for this case\n(If this item is required by your standard setter, use of code XXX.8 will result in an edit error.)" ], [ "XXX.9", "Not documented in medical record\nAdenoid Cystic Basaloid Pattern not assessed or unknown if assessed" ] ], "additional_info" : "**Source documents:** pathology report\n\n**Other names include** ACC, basaloid type adenoid cystic carcinoma", - "coding_guidelines" : "**1)** **Code 0.0** when the pathology report states that basaloid or solid pattern is not present\n**2)** **Code 0.1-100.0** when the pathology report states the percent of basaloid or solid pattern that is present\n**3)** **Code XXX.5** when basaloid or solid pattern present but percentage not known\n**4)** **Code XXX.9** when\n* Histopathologic pattern not documented in the medical record\n* Histopathologic pattern not evaluated (assessed)\n* Unknown if histopathologic pattern evaluated (assessed)\n* When histologic type other than 8200 and there is no mention of basaloid pattern", + "coding_guidelines" : "**1)** **Code 0.0** when the pathology report states that basaloid or solid pattern is not present\n\n**2)** **Code 0.1-100.0** when the pathology report states the percent of basaloid or solid pattern that is present\n\n**3)** **Code XXX.5** when basaloid or solid pattern present but percentage not known\n\n**4)** **Code XXX.9** when\n* Histopathologic pattern not documented in the medical record\n* Histopathologic pattern not evaluated (assessed)\n* Unknown if histopathologic pattern evaluated (assessed)\n* When histologic type other than 8200 and there is no mention of basaloid pattern", "rationale" : "Adenoid Cystic Basaloid Pattern is a Registry Data Collection Variable in AJCC 8. This data item was previously collected as Lacrimal Gland, CS SSF #6." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/adenopathy_40816.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/adenopathy_40816.json index be9bb72aa..0ca9c86ad 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/adenopathy_40816.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/adenopathy_40816.json @@ -6,7 +6,7 @@ "title" : "Adenopathy", "description" : "Adenopathy is defined as the presence of lymph nodes > 1.5 cm on physical examination (PE) and is part of the staging criteria for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).\n\nFor cases diagnosed 1/1/2018 and later, all cases of CLL and SLL will require both the **Lugano classification, which is captured in the AJCC stage group data item, and the five components of the modified Rai staging system, which are captured in Site-Specific Data Items (adenopathy, anemia, lymphocytosis, organomegaly, and thrombocytopenia).**\n\nThe terms B-cell lymphocytic leukemia/chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are different clinical presentations of the same disease, with both terms coded 9823. \n\nTraditionally the lymphoma diagnosis was staged with the Ann Arbor staging system and it is now staged with the Lugano classification. In North America, CLL was staged with the Rai system. \n\nSee 3955: Derived Rai stage for additional information on the related data items.", "notes" : "**Note 1:** **Physician Statement**\n* Physician’s statement regarding the presence of adenopathy (present or absent) takes priority. If a physician’s statement and imaging are both available and in disagreement, go with the physician’s statement\n* If a physician’s statement is not available, use the definition of adenopathy in the ***Description*** to determine if adenopathy is present or not\n\n**Note 2:** **Record information from physical exam only**\n* This data item is determined from physical exam alone. If a physical exam cannot be used to detect adenopathy due to issues linked to the patient’s obesity, a physician statement of peripheral adenopathy based on a CT scan can be used. \n * A finding of retroperitoneal or mesenteric adenopathy on CT is not used in determining adenopathy and does not affect the assigned stage\n\n**Note 3:** **Rai Stage Criteria**\n* Rai stage is only applicable for CLL, in which the bone marrow and/or peripheral blood are involved (primary site C421 for bone marrow, see Hematopoietic Manual, Module 3: PH 5, 6). \n\n**Note 4:** **Pretreatment results only**\n* Record this data item based on physical exam, and physician's statement performed at diagnosis (pre-treatment)", - "last_modified" : "2025-02-24T16:01:34.838Z", + "last_modified" : "2025-11-06T21:55:56.594Z", "definition" : [ { "key" : "adenopathy", "name" : "Code", @@ -18,6 +18,6 @@ } ], "rows" : [ [ "0", "Adenopathy not identified/not present \nNo lymph nodes > 1.5 cm\n\nPhysician states Rai stage 0" ], [ "1", "Adenopathy present \nPresence of lymph nodes > 1.5 cm\n\nPhysician states Rai stage I" ], [ "5", "Not applicable: Primary site is not C421" ], [ "9", "Not documented in medical record\nAdenopathy not assessed or unknown if assessed\nNo Rai stage is documented in the record and there is no documentation of adenopathy\nPhysician states Rai stage II-IV and there is no documentation of adenopathy" ] ], "additional_info" : "**Source documents:** imaging, physical exam, clinician’s notes", - "coding_guidelines" : "**1)** **Code 0** when primary Site **is C421** AND there is no evidence of adenopathy \n* Physician documentation of Rai Stage 0\n\n**2)** **Code 1** when primary Site **is C421** AND there is evidence of adenopathy \n* Physician documentation of Rai Stage I\n\n**3)** **Code 5** when primary site **is NOT C421**\n \n**4) Code 9** when primary site **is C421**, AND there is no mention of adenopathy", + "coding_guidelines" : "**1)** **Code 0** when primary Site **is C421** AND there is no evidence of adenopathy \n* Physician documentation of Rai Stage 0\n\n**2)** **Code 1** when primary Site **is C421** AND there is evidence of adenopathy \n* Physician documentation of Rai Stage I\n\n**3)** **Code 5** when primary site **is NOT C421**\n\n**4)** **Code 9** when primary site **is C421**, AND there is no mention of adenopathy", "rationale" : "Adenopathy is a prognostic factor required for staging of CLL/SLL in AJCC 8th edition, Chapter 79 *Hodgkin, and Non-Hodgkin Lymphomas*. It is a new data item for cases diagnosed 1/1/2018+." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/afp_post_orchiectomy_lab_value_90733.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/afp_post_orchiectomy_lab_value_90733.json index d450040ee..1fd9d463e 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/afp_post_orchiectomy_lab_value_90733.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/afp_post_orchiectomy_lab_value_90733.json @@ -4,9 +4,9 @@ "version" : "3.3", "name" : "AFP Post-Orchiectomy Lab Value", "title" : "AFP (Alpha Fetoprotein) Post-Orchiectomy Lab Value", - "description" : "AFP (Alpha Fetoprotein) Post-Orchiectomy Lab Value refers to the lowest AFP value measured post-orchiectomy. AFP is a serum tumor marker that is often elevated in patients with nonseminomatous germ cell tumors of the testis. The Post-Orchiectomy lab value is used to monitor response to therapy.\n\nAlpha-fetoprotein (AFP) is a protein normally made by immature liver cells in the fetus. In adults, high AFP levels (> 500 ng/ml) in the blood occur only in hepatocellular carcinoma (>1000), liver metastases (from a primary elsewhere), and germ cell tumors of the testes and ovaries. Elevated AFP values are found in non-seminomatous malignancies and mixed tumors of the testis. AFP is used with HCG to identify the specific cell type of testicular cancer. AFP is not secreted by pure seminoma or teratoma. If AFP > 500 ng/ml, the underlying condition is unlikely to be benign. If AFP > 10,000 ng/ml at diagnosis, the patient is likely to have a poor prognosis.\nAFP is more useful in monitoring response to therapy than making a diagnosis. The half-life of AFP is 5 to 7 days. After orchiectomy, the AFP should fall to < 25 ng/ml in 25-35 days. If elevated AFP persists, this is an indication of residual tumor.\n\nFor Testis, there are 4 related data items that record information on AFP for Testis.\n* 3805: AFP Post-Orchiectomy Lab Value\n* 3806: AFP Post-Orchiectomy Range\n* 3807: AFP Pre-Orchiectomy Lab Value\n* 3808: AFP Pre-Orchiectomy Range", + "description" : "AFP (Alpha Fetoprotein) Post-Orchiectomy Lab Value refers to the lowest AFP value measured post-orchiectomy. AFP is a serum tumor marker that is often elevated in patients with nonseminomatous germ cell tumors of the testis. The Post-Orchiectomy lab value is used to monitor response to therapy.\n\nAlpha-fetoprotein (AFP) is a protein normally made by immature liver cells in the fetus. In adults, high AFP levels (> 500 ng/ml) in the blood occur only in hepatocellular carcinoma (>1000), liver metastases (from a primary elsewhere), and germ cell tumors of the testes and ovaries. Elevated AFP values are found in non-seminomatous malignancies and mixed tumors of the testis. AFP is used with HCG to identify the specific cell type of testicular cancer. AFP is not secreted by pure seminoma or teratoma. If AFP > 500 ng/ml, the underlying condition is unlikely to be benign. If AFP > 10,000 ng/ml at diagnosis, the patient is likely to have a poor prognosis.\n\nAFP is more useful in monitoring response to therapy than making a diagnosis. The half-life of AFP is 5 to 7 days. After orchiectomy, the AFP should fall to < 25 ng/ml in 25-35 days. If elevated AFP persists, this is an indication of residual tumor.\n\nFor Testis, there are 4 related data items that record information on AFP for Testis.\n* 3805: AFP Post-Orchiectomy Lab Value\n* 3806: AFP Post-Orchiectomy Range\n* 3807: AFP Pre-Orchiectomy Lab Value\n* 3808: AFP Pre-Orchiectomy Range", "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of the AFP (Alpha Fetoprotein) Post-Orchiectomy Lab Value can be used to code this data item when no other information is available. \n\n**Note 2:** **Timing** \n* Record the lab value of the AFP test results documented in the medical record **after orchiectomy** but prior to adjuvant therapy. The lab value may be documented in a lab report, history and physical, or clinical statement in the pathology report.\n\n**Note 3:** **Lab values elevated after orchiectomy** \n* If the initial post-orchiectomy AFP remains elevated, review subsequent tests and record the lowest AFP value (normalization or plateau) prior to adjuvant therapy or before the value rises again. \n\n**Note 4:** **Related data item** \n* The same laboratory test should be used to record the related data item 3806: AFP Post-Orchiectomy Range.", - "last_modified" : "2025-03-21T18:02:15.446Z", + "last_modified" : "2025-11-06T21:52:25.999Z", "definition" : [ { "key" : "afp_post_orch_lab_value", "name" : "Code", @@ -17,7 +17,7 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "0.0", "0.0 nanograms/milliliter (ng/mL)" ], [ "0.1-99999.9", "0.1 - 99,999.9 ng/mL" ], [ "XXXXX.1", "100,000 ng/mL or greater" ], [ "XXXXX.7", "Test ordered, results not in chart" ], [ "XXXXX.8", "Not applicable: Information not collected for this case\n(If this information is required by your standard setter, use of code XXXXX.8 may result in an edit error.)" ], [ "XXXXX.9", "Not documented in medical record\nNo orchiectomy performed\nAFP (Alpha Fetoprotein) Post-Orchiectomy Lab Value not assessed or unknown if assessed" ] ], - "additional_info" : "**Source documents:** clinical laboratory report (blood serum radioimmunoassay or enzyme assay (EIA)); sometimes in history and physical or clinical statement in pathology report\n\n**Other names include** AFP, aFP, Alpha Fetoprotein, Alpha-fetoprotein, alpha-fetoprotein, fetal alpha globulin\n\nFor further information, refer to the **Testis** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Testis*\n\n**Normal Reference Range**\n* Adult men 0-15 ng/ml (SI: 0-15 µg/L)\n \n**Measurements** \n* A lab value expressed in micrograms/liter (ug/L) is equivalent to the same value expressed in nanograms/milliliter (ng/mL).\n * ***Example***: 10 IU/mL: 10/0.83 = 12.04 ng/mL; 5 IU/mL: 5/0.83= 6.02 ng/mL\n\n* If the lab value is expressed in IU/ml, use the following conversion: 1 ng/mL = 0.83 IU/mL\n * To calculate ng from IU/mL, divide the value for IU by 0.83.\n * ***Example***: 10 IU/mL: 10/0.83 = 12.04 ng/mL; 5 IU/mL: 5/0.83= 6.02 ng/mL", - "coding_guidelines" : "**1)** **Code XXXXX.9** when\n* The only information available is a statement of elevated or normal\n* If the pre-orchiectomy AFP was normal; a post-orchiectomy AFP may not be performed. In this case, code XXXXX.9 should be recorded.\n\n***Examples***\n**1)** 1 ng/ml = Lab Value 1.0, Range 0\t\n**2)** 270 ug/l = Lab Value 270.0 (ng/ml = ug/L), Range 1\n**3)** 5500 ng/ml = Lab Value 5500.0, Range 2\n**4)** 12,500 ng/ml\t = Lab Value 12500.0, Range 3\n**5)** 110,000 ng/ml = Lab Value XXXXX.1, Range 3\n**6)** Physician states “AFP elevated,” but no value documented =\tLab value XXXXX.9, Range 4\n**7)** S value stated (no other information available) = Lab Value XXXXX.9, Range 9\n**8)** No AFP test done, or unknown if done = Lab Value XXXXX.9, Range 9", + "additional_info" : "**Source documents:** clinical laboratory report (blood serum radioimmunoassay or enzyme assay (EIA)); sometimes in history and physical or clinical statement in pathology report\n\n**Other names include** AFP, aFP, Alpha Fetoprotein, Alpha-fetoprotein, alpha-fetoprotein, fetal alpha globulin\n\nFor further information, refer to the **Testis** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Testis*.\n\n**Normal Reference Range**\n* Adult men 0-15 ng/ml (SI: 0-15 µg/L)\n \n**Measurements** \n* A lab value expressed in micrograms/liter (ug/L) is equivalent to the same value expressed in nanograms/milliliter (ng/mL).\n * ***Example***: 10 IU/mL: 10/0.83 = 12.04 ng/mL; 5 IU/mL: 5/0.83= 6.02 ng/mL\n\n* If the lab value is expressed in IU/ml, use the following conversion: 1 ng/mL = 0.83 IU/mL.\n * To calculate ng from IU/mL, divide the value for IU by 0.83.\n * ***Example***: 10 IU/mL: 10/0.83 = 12.04 ng/mL; 5 IU/mL: 5/0.83= 6.02 ng/mL", + "coding_guidelines" : "**1)** **Code XXXXX.9** when\n* The only information available is a statement of elevated or normal\n* If the pre-orchiectomy AFP was normal; a post-orchiectomy AFP may not be performed. In this case, code XXXXX.9 should be recorded.\n\n***Examples***\n\n**1)** 1 ng/ml = Lab Value 1.0, Range 0\t\n\n**2)** 270 ug/l = Lab Value 270.0 (ng/ml = ug/L), Range 1\n\n**3)** 5500 ng/ml = Lab Value 5500.0, Range 2\n\n**4)** 12,500 ng/ml\t = Lab Value 12500.0, Range 3\n\n**5)** 110,000 ng/ml = Lab Value XXXXX.1, Range 3\n\n**6)** Physician states “AFP elevated,” but no value documented =\tLab value XXXXX.9, Range 4\n\n**7)** S value stated (no other information available) = Lab Value XXXXX.9, Range 9\n\n**8)** No AFP test done, or unknown if done = Lab Value XXXXX.9, Range 9", "rationale" : "AFP (Alpha Fetoprotein) Post-Orchiectomy Lab Value is a Registry Data Collection Variable in AJCC. It was previously collected as Testis CS SSF #12." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/afp_post_orchiectomy_range_84758.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/afp_post_orchiectomy_range_84758.json index 1c0946059..73cd68683 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/afp_post_orchiectomy_range_84758.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/afp_post_orchiectomy_range_84758.json @@ -6,7 +6,7 @@ "title" : "AFP (Alpha Fetoprotein) Post-Orchiectomy Range", "description" : "AFP (Alpha Fetoprotein) Post-Orchiectomy Range identifies the range category of the lowest AFP value measured post-orchiectomy. AFP is a serum tumor marker that is often elevated in patients with nonseminomatous germ cell tumors of the testis. The Post-Orchiectomy lab value is used to monitor response to therapy.\n\nFor Testis, there are 4 related data items that record information on AFP for Testis.\n* 3805: AFP Post-Orchiectomy Lab Value\n* 3806: AFP Post-Orchiectomy Range\n* 3807: AFP Pre-Orchiectomy Lab Value\n* 3808: AFP Pre-Orchiectomy Range", "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of the AFP (Alpha Fetoprotein) Post-Orchiectomy Range can be used to code this data item when there is no other information available.\n\n**Note 2:** **Timing** \n* Record the range of the AFP test as documented in the medical record **after orchiectomy** but prior to adjuvant therapy. The lab value may be documented in a lab report, history and physical, or clinical statement in the pathology report.\n\n**Note 3:** **Lab values elevated after orchiectomy** \n* If the initial post-orchiectomy AFP remains elevated, review subsequent tests and record the lowest AFP value (normalization or plateau) prior to adjuvant therapy or before the value rises again.\n\n**Note 4:** **Pre-orchiectomy AFP normal** \n* If the pre-orchiectomy AFP was normal, a post-orchiectomy AFP may not be performed. In this case, code 5 should be recorded.\n\n**Note 5:** **Related data item** \n* The same laboratory test should be used to record the related data item 3805: AFP Post-Orchiectomy Lab Value.", - "last_modified" : "2025-03-21T18:02:37.107Z", + "last_modified" : "2025-11-06T16:28:14.963Z", "definition" : [ { "key" : "afp_post_orch_range", "name" : "Code", @@ -17,6 +17,6 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "0", "Within normal limits" ], [ "1", "Above normal and less than 1,000 nanograms/milliliter (ng/mL)" ], [ "2", "1,000 -10,000 ng/mL" ], [ "3", "Greater than 10,000 ng/mL" ], [ "4", "Post-Orchiectomy alpha fetoprotein (AFP) stated to be elevated" ], [ "5", "Post-Orchiectomy alpha fetoprotein (AFP) unknown or not done but pre-orchiectomy AFP was normal" ], [ "7", "Test ordered, results not in chart" ], [ "8", "Not applicable: Information not collected for this case\n(If this information is required by your standard setter, use of code 8 may result in an edit error.)" ], [ "9", "Not documented in medical record\nNo orchiectomy performed\nAFP (Alpha Fetoprotein) Post-Orchiectomy Range not assessed or unknown if assessed" ] ], - "additional_info" : "**Source documents:** clinical laboratory report (blood serum radioimmunoassay or enzyme assay (EIA)); sometimes in history and physical or clinical statement in pathology report\n\n**Other names include** AFP, aFP, Alpha Fetoprotein, Alpha-fetoprotein, alpha-fetoprotein, fetal alpha globulin\n\nFor further information, refer to the **Testis** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Testis*\n\n**Normal Reference Range**\n* Adult men 0-15 ng/ml (SI: 0-15 µg/L)\n \n**Measurements** \n* A lab value expressed in micrograms/liter (ug/L) is equivalent to the same value expressed in nanograms/milliliter (ng/mL).\n * ***Example***: 10 IU/mL: 10/0.83 = 12.04 ng/mL; 5 IU/mL: 5/0.83= 6.02 ng/mL\n\n* If the lab value is expressed in IU/ml, use the following conversion: 1 ng/mL = 0.83 IU/mL\n * To calculate ng from IU/mL, divide the value for IU by 0.83.\n * ***Example***: 10 IU/mL: 10/0.83 = 12.04 ng/mL; 5 IU/mL: 5/0.83= 6.02 ng/mL", + "additional_info" : "**Source documents:** clinical laboratory report (blood serum radioimmunoassay or enzyme assay (EIA)); sometimes in history and physical or clinical statement in pathology report\n\n**Other names include** AFP, aFP, Alpha Fetoprotein, Alpha-fetoprotein, alpha-fetoprotein, fetal alpha globulin\n\nFor further information, refer to the **Testis** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Testis*.\n\n**Normal Reference Range**\n* Adult men 0-15 ng/ml (SI: 0-15 µg/L)\n \n**Measurements** \n* A lab value expressed in micrograms/liter (ug/L) is equivalent to the same value expressed in nanograms/milliliter (ng/mL).\n * ***Example***: 10 IU/mL: 10/0.83 = 12.04 ng/mL; 5 IU/mL: 5/0.83= 6.02 ng/mL\n\n* If the lab value is expressed in IU/ml, use the following conversion: 1 ng/mL = 0.83 IU/mL\n * To calculate ng from IU/mL, divide the value for IU by 0.83.\n * ***Example***: 10 IU/mL: 10/0.83 = 12.04 ng/mL; 5 IU/mL: 5/0.83= 6.02 ng/mL", "rationale" : "AFP (Alpha Fetoprotein) Post-Orchiectomy Range is a Registry Data Collection Variable in AJCC. AFP (Alpha Fetoprotein) Post-Orchiectomy Range is used to assign the S Category Pathological and was previously collected as Testis CS SSF #13." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/afp_pre_orchiectomy_lab_value_94162.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/afp_pre_orchiectomy_lab_value_94162.json index 2579d42ef..532cb8a51 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/afp_pre_orchiectomy_lab_value_94162.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/afp_pre_orchiectomy_lab_value_94162.json @@ -4,9 +4,9 @@ "version" : "3.3", "name" : "AFP Pre-Orchiectomy Lab Value", "title" : "AFP (Alpha Fetoprotein) Pre-Orchiectomy Lab Value", - "description" : "AFP (Alpha Fetoprotein) Pre-Orchiectomy Lab Value refers to the AFP value measured prior to treatment. AFP is a tumor marker that is often elevated in patients with nonseminomatous germ cell tumors of the testis.\n\nAlpha-fetoprotein (AFP) is a protein normally made by immature liver cells in the fetus. In adults, high AFP levels (> 500 ng/ml) in the blood occur only in hepatocellular carcinoma (>1000), liver metastases (from a primary elsewhere), and germ cell tumors of the testes and ovaries. Elevated AFP values are found in non-seminomatous malignancies and mixed tumors of the testis. AFP is used with HCG to identify the specific cell type of testicular cancer. AFP is not secreted by pure seminoma or teratoma. If AFP > 500 ng/ml, the underlying condition is unlikely to be benign. If AFP > 10,000 ng/ml at diagnosis, the patient is likely to have a poor prognosis.\nAFP is more useful in monitoring response to therapy than making a diagnosis. The half-life of AFP is 5 to 7 days. After orchiectomy, the AFP should fall to < 25 ng/ml in 25-35 days. If elevated AFP persists, this is an indication of residual tumor.\n\nFor Testis, there are 4 related data items that record information on AFP for Testis.\n* 3805: AFP Post-Orchiectomy Lab Value\n* 3806: AFP Post-Orchiectomy Range\n* 3807: AFP Pre-Orchiectomy Lab Value\n* 3808: AFP Pre-Orchiectomy Range", + "description" : "AFP (Alpha Fetoprotein) Pre-Orchiectomy Lab Value refers to the AFP value measured prior to treatment. AFP is a tumor marker that is often elevated in patients with nonseminomatous germ cell tumors of the testis.\n\nAlpha-fetoprotein (AFP) is a protein normally made by immature liver cells in the fetus. In adults, high AFP levels (> 500 ng/ml) in the blood occur only in hepatocellular carcinoma (>1000), liver metastases (from a primary elsewhere), and germ cell tumors of the testes and ovaries. Elevated AFP values are found in non-seminomatous malignancies and mixed tumors of the testis. AFP is used with HCG to identify the specific cell type of testicular cancer. AFP is not secreted by pure seminoma or teratoma. If AFP > 500 ng/ml, the underlying condition is unlikely to be benign. If AFP > 10,000 ng/ml at diagnosis, the patient is likely to have a poor prognosis.\n\nAFP is more useful in monitoring response to therapy than making a diagnosis. The half-life of AFP is 5 to 7 days. After orchiectomy, the AFP should fall to < 25 ng/ml in 25-35 days. If elevated AFP persists, this is an indication of residual tumor.\n\nFor Testis, there are 4 related data items that record information on AFP for Testis.\n* 3805: AFP Post-Orchiectomy Lab Value\n* 3806: AFP Post-Orchiectomy Range\n* 3807: AFP Pre-Orchiectomy Lab Value\n* 3808: AFP Pre-Orchiectomy Range", "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of the AFP (Alpha Fetoprotein) Pre-Orchiectomy Lab Value can be used to code this data item when no other information is available. \n\n**Note 2:** **Timing** \n* Record the lab value of the highest AFP test result documented in the medical record **prior to orchiectomy** or prior to any systemic treatment. The lab value may be documented in a lab report, history and physical, or clinical statement in the pathology report.\n\n**Note 3:** **Related data item** \n* The same laboratory test should be used to record the related data item 3808: AFP Pre-Orchiectomy Range.", - "last_modified" : "2025-03-21T18:01:14.864Z", + "last_modified" : "2025-11-06T21:50:45.375Z", "definition" : [ { "key" : "afp_pre_orch_lab_value", "name" : "Code", @@ -17,7 +17,7 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "0.0", "0.0 nanograms/milliliter (ng/mL)" ], [ "0.1-99999.9", "0.1 - 99,999.9 ng/mL" ], [ "XXXXX.1", "100,000 ng/mL or greater" ], [ "XXXXX.7", "Test ordered, results not in chart" ], [ "XXXXX.8", "Not applicable: Information not collected for this case\n(If this information is required by your standard setter, use of code XXXXX.8 may result in an edit error.)" ], [ "XXXXX.9", "Not documented in medical record\nAFP (Alpha Fetoprotein) Pre-Orchiectomy Lab Value not assessed or unknown if assessed" ] ], - "additional_info" : "**Source documents:** clinical laboratory report (blood serum radioimmunoassay or enzyme assay (EIA)); sometimes in history and physical or clinical statement in pathology report\n\n**Other names include** AFP, aFP, Alpha Fetoprotein, Alpha-fetoprotein, alpha-fetoprotein, fetal alpha globulin\n\nFor further information, refer to the **Testis** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Testis*\n\n**Normal Reference Range**\n* Adult men 0-15 ng/ml (SI: 0-15 µg/L)\n \n**Measurements** \n* A lab value expressed in micrograms/liter (ug/L) is equivalent to the same value expressed in nanograms/milliliter (ng/mL).\n * ***Example***: 10 IU/mL: 10/0.83 = 12.04 ng/mL; 5 IU/mL: 5/0.83= 6.02 ng/mL\n\n* If the lab value is expressed in IU/ml, use the following conversion: 1 ng/mL = 0.83 IU/mL\n * To calculate ng from IU/mL, divide the value for IU by 0.83.\n * ***Example***: 10 IU/mL: 10/0.83 = 12.04 ng/mL; 5 IU/mL: 5/0.83= 6.02 ng/mL", - "coding_guidelines" : "***Examples***\n**1)** 1 ng/ml = Lab Value 1.0, Range 0\t\n**2)** 270 ug/l = Lab Value 270.0 (ng/ml = ug/L), Range 1\n**3)** 5500 ng/ml = Lab Value 5500.0, Range 2\n**4)** 12,500 ng/ml\t = Lab Value 12500.0, Range 3\n**5)** 110,000 ng/ml = Lab Value XXXXX.1, Range 3\n**6)** Physician states “AFP elevated,” but no value documented =\tLab value XXXXX.9, Range 4\n**7)** S value stated (no other information available) = Lab Value XXXXX.9, Range 9\n**8)** No AFP test done, or unknown if done = Lab Value XXXXX.9, Range 9", + "additional_info" : "**Source documents:** clinical laboratory report (blood serum radioimmunoassay or enzyme assay (EIA)); sometimes in history and physical or clinical statement in pathology report\n\n**Other names include** AFP, aFP, Alpha Fetoprotein, Alpha-fetoprotein, alpha-fetoprotein, fetal alpha globulin\n\nFor further information, refer to the **Testis** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Testis*.\n\n**Normal Reference Range**\n* Adult men 0-15 ng/ml (SI: 0-15 µg/L)\n \n**Measurements** \n* A lab value expressed in micrograms/liter (ug/L) is equivalent to the same value expressed in nanograms/milliliter (ng/mL).\n * ***Example***: 10 IU/mL: 10/0.83 = 12.04 ng/mL; 5 IU/mL: 5/0.83= 6.02 ng/mL\n\n* If the lab value is expressed in IU/ml, use the following conversion: 1 ng/mL = 0.83 IU/mL.\n * To calculate ng from IU/mL, divide the value for IU by 0.83.\n * ***Example***: 10 IU/mL: 10/0.83 = 12.04 ng/mL; 5 IU/mL: 5/0.83= 6.02 ng/mL", + "coding_guidelines" : "***Examples***\n\n**1)** 1 ng/ml = Lab Value 1.0, Range 0\t\n\n**2)** 270 ug/l = Lab Value 270.0 (ng/ml = ug/L), Range 1\n\n**3)** 5500 ng/ml = Lab Value 5500.0, Range 2\n\n**4)** 12,500 ng/ml\t = Lab Value 12500.0, Range 3\n\n**5)** 110,000 ng/ml = Lab Value XXXXX.1, Range 3\n\n**6)** Physician states “AFP elevated,” but no value documented =\tLab value XXXXX.9, Range 4\n\n**7)** S value stated (no other information available) = Lab Value XXXXX.9, Range 9\n\n**8)** No AFP test done, or unknown if done = Lab Value XXXXX.9, Range 9", "rationale" : "AFP (Alpha Fetoprotein) Pre-Orchiectomy Lab Value is a Registry Data Collection Variable in AJCC. It was previously collected as Testis CS SSF #6." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/afp_pre_orchiectomy_range_11386.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/afp_pre_orchiectomy_range_11386.json index 54c3e856d..b034308fc 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/afp_pre_orchiectomy_range_11386.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/afp_pre_orchiectomy_range_11386.json @@ -6,7 +6,7 @@ "title" : "AFP (Alpha Fetoprotein) Pre-Orchiectomy Range", "description" : "AFP (Alpha Fetoprotein) Pre-Orchiectomy Range identifies the range category of the highest AFP value measured prior to treatment. AFP is a serum tumor marker that is often elevated in patients with nonseminomatous germ cell tumors of the testis.\n\nFor Testis, there are 4 related data items that record information on AFP for Testis.\n* 3805: AFP Post-Orchiectomy Lab Value\n* 3806: AFP Post-Orchiectomy Range\n* 3807: AFP Pre-Orchiectomy Lab Value\n* 3808: AFP Pre-Orchiectomy Range", "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of the AFP (Alpha Fetoprotein) Pre-Orchiectomy Range can be used to code this data item when no other information is available. \n\n**Note 2:** **Timing** \n* Record the range of the highest AFP test result documented in the medical record **prior to orchiectomy** or prior to any systemic treatment. The lab value may be documented in a lab report, history and physical, or clinical statement in the pathology report.\n\n**Note 3:** **Related data item** \n* The same laboratory test should be used to record the related data item 3807: AFP Pre-Orchiectomy Lab Value.", - "last_modified" : "2025-03-21T18:01:53.048Z", + "last_modified" : "2025-11-06T16:30:39.117Z", "definition" : [ { "key" : "afp_pre_orch_range", "name" : "Code", @@ -17,6 +17,6 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "0", "Within normal limits" ], [ "1", "Above normal and less than 1,000 nanograms/milliliter (ng/mL)" ], [ "2", "1,000 -10,000 ng/mL" ], [ "3", "Greater than 10,000 ng/mL" ], [ "4", "Pre-Orchiectomy alpha fetoprotein (AFP) stated to be elevated" ], [ "7", "Test ordered, results not in chart" ], [ "8", "Not applicable: Information not collected for this case\n(If this information is required by your standard setter, use of code 8 may result in an edit error.)" ], [ "9", "Not documented in medical record\nAFP (Alpha Fetoprotein) Pre-Orchiectomy Range not assessed or unknown if assessed" ] ], - "additional_info" : "**Source documents:** clinical laboratory report (blood serum radioimmunoassay or enzyme assay (EIA)); sometimes in history and physical or clinical statement in pathology report\n\n**Other names include** AFP, aFP, Alpha Fetoprotein, Alpha-fetoprotein, alpha-fetoprotein, fetal alpha globulin\n\nFor further information, refer to the **Testis** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Testis*\n\n**Normal Reference Range**\n* Adult men 0-15 ng/ml (SI: 0-15 µg/L)\n \n**Measurements** \n* A lab value expressed in micrograms/liter (ug/L) is equivalent to the same value expressed in nanograms/milliliter (ng/mL).\n * ***Example***: 10 IU/mL: 10/0.83 = 12.04 ng/mL; 5 IU/mL: 5/0.83= 6.02 ng/mL\n\n* If the lab value is expressed in IU/ml, use the following conversion: 1 ng/mL = 0.83 IU/mL\n * To calculate ng from IU/mL, divide the value for IU by 0.83.\n * ***Example***: 10 IU/mL: 10/0.83 = 12.04 ng/mL; 5 IU/mL: 5/0.83= 6.02 ng/mL", + "additional_info" : "**Source documents:** clinical laboratory report (blood serum radioimmunoassay or enzyme assay (EIA)); sometimes in history and physical or clinical statement in pathology report\n\n**Other names include** AFP, aFP, Alpha Fetoprotein, Alpha-fetoprotein, alpha-fetoprotein, fetal alpha globulin\n\nFor further information, refer to the **Testis** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Testis*.\n\n**Normal Reference Range**\n* Adult men 0-15 ng/ml (SI: 0-15 µg/L)\n \n**Measurements** \n* A lab value expressed in micrograms/liter (ug/L) is equivalent to the same value expressed in nanograms/milliliter (ng/mL).\n * ***Example***: 10 IU/mL: 10/0.83 = 12.04 ng/mL; 5 IU/mL: 5/0.83= 6.02 ng/mL\n\n* If the lab value is expressed in IU/ml, use the following conversion: 1 ng/mL = 0.83 IU/mL\n * To calculate ng from IU/mL, divide the value for IU by 0.83.\n * ***Example***: 10 IU/mL: 10/0.83 = 12.04 ng/mL; 5 IU/mL: 5/0.83= 6.02 ng/mL", "rationale" : "AFP (Alpha Fetoprotein) is a Registry Data Collection Variable in AJCC. AFP (Alpha Fetoprotein) Pre-Orchiectomy Range is used to assign the S Category Clinical and was previously collected as Testis CS SSF #7." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/afp_pretx_lab_value_25871.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/afp_pretx_lab_value_25871.json index 21c456462..a78dde7e7 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/afp_pretx_lab_value_25871.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/afp_pretx_lab_value_25871.json @@ -6,7 +6,7 @@ "title" : "AFP (Alpha Fetoprotein) Pretreatment Lab Value", "description" : "AFP (Alpha Fetoprotein) Pretreatment Lab Value is a nonspecific serum protein that generally is elevated in the setting of hepatocellular carcinoma (HCC). This data item pertains to the pre-treatment lab value.\n\nA protein normally produced by a fetus. Alpha fetoprotein levels are usually undetectable in the blood of healthy adult men or women (who are not pregnant). An elevated level of alpha-fetoprotein suggests the presence of either a primary liver cancer or germ cell tumor.\n\nThere are 2 related data items that record information on CEA for Colon and Rectum.\n* 3810: AFP Pretreatment Lab Value\n* 3809: AFP Pretreatment Interpretation", "notes" : "**Note 1:** **Physician Statement**\n* Physician statement of AFP (Alpha Fetoprotein) Pretreatment Lab Value can be used to code this data item when no other information is available.\n\n**Note 2:** **Pretreatment results only**\n* Record the lab value of the highest AFP test result documented in the medical record prior to treatment. The lab value may be recorded in a lab report, history and physical, or clinical statement in the pathology report.\n\n**Note 3:** **Related data item**\n* The same laboratory test should be used to record information in the related data item 3810: AFP Pretreatment Lab Value", - "last_modified" : "2025-02-24T13:48:14.777Z", + "last_modified" : "2025-11-06T18:10:44.980Z", "definition" : [ { "key" : "afp_pretx_lab_value", "name" : "Code", @@ -19,5 +19,5 @@ "rows" : [ [ "0.0", "0.0 nanograms/milliliter (ng/ml); not detected" ], [ "0.1-9999.9", "0.1-9999.9 ng/ml\n(Exact value to nearest tenth of ng/ml)" ], [ "XXXX.1", "10,000.0 ng/ml or greater" ], [ "XXXX.7", "Test ordered, results not in chart" ], [ "XXXX.8", "Not applicable: Information not collected for this case\n(If this item is required by your standard setter, use of code XXXX.8 will result in an edit error.)" ], [ "XXXX.9", "Not documented in medical record\nAFP (Alpha Fetoprotein) Pretreatment Lab Value not assessed or unknown if assessed" ] ], "additional_info" : "**Source documents:** clinical laboratory report (blood serum radioimmunoassay or enzyme assay (EIA)); sometimes in history and physical or clinical statement in pathology report\n\n**Normal Reference Range:** \n* Adult men and non-pregnant women: 0-15 ng/ml (SI: 0-15 mg/L)", "coding_guidelines" : "**1)** Record the highest value prior to treatment in nanograms per milliliter (ng/ml) in the range 0.1 (1 ng/ml) to 9999.9 (9999 ng/ml) in the Lab Value data item.\n\n**2)** A lab value expressed in micrograms per liter (ug/L) is equivalent to the same value expressed in ng/ml.\n\n***Examples*** \n\n* AFP Lab Value 0 ng/ml - Code 0.0\n* AFP Lab Value 23.6 ng/ml - Code 23.6\n* AFP Lab Value 11,0000 - Code XXXX.,1\n* AFP Lab Value Test Ordered, results not in chart - Code XXXX.7\n* AFP Lab Value Not documented in medical record, AFP test not done, unknown if APF test done - Code XXXX.9", - "rationale" : "Data Collection Variable in AJCC. This data item was previously collected for Liver, CS SSF #3. AFP (Alpha Fetoprotein) Pretreatment Lab Value is a Registry" + "rationale" : "AFP (Alpha Fetoprotein) Pretreatment Lab Value is a Registry Data Collection Variable in AJCC. This data item was previously collected for Liver, CS SSF #3." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/alk_rearrangement_610.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/alk_rearrangement_610.json index 21353236a..1d08c7e17 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/alk_rearrangement_610.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/alk_rearrangement_610.json @@ -6,7 +6,7 @@ "title" : "ALK Rearrangement", "description" : "Testing for ALK rearrangement is performed for patients with advanced non-small cell lung cancer (NSCLC) to identify tumors which are sensitive to small-molecule ALK kinase inhibitors. \n\n“ALK positive cancer describes cancer cells that have a change in the structure of the anaplastic lymphoma kinase (ALK) gene or a higher-than-normal amount of ALK protein on their surface. In normal cells, ALK helps control cell growth. When cancer cells have the changed ALK gene or make too much ALK protein, the cancer cells may grow more quickly. Knowing whether a cancer is ALK positive may help plan treatment for advanced non-small cell cancers in the lung.” (NCI Dictionary of Cancer Terms Definition of EGFR - NCI Dictionary of Cancer Terms - NCI)\n\nThe absence or presence of ALK protein expression determines if the tumor will respond to treatment with a targeted inhibitor. ALK protein expression predicts the ALK rearrangement gene, which are more likely to respond to the targeted inhibitor treatment. The most common ALK rearrangements are. \n * EML4-ALK\n * KIF5B-ALK\n * TFG-ALK\n * KLC1-ALK", "notes" : "**Note 1:** **Effective years** \n* This SSDI is effective for diagnosis years 2021+\n* For cases diagnosed 2018-2020, this SSDI must be blank\n\n**Note 2:** **Physician Statement** \n* Physician statement of ALK rearrangement can be used to code this data item when no other information is available.\n* This data item only includes rearrangements. Ignore any amplification or point mutations\n\n**Note 3:** **Applicable histologies/stages**\n* ALK may be recorded for all histologies and stages; however, it is primarily performed for advanced non-small cell carcinomas. If information is not available, code 9. \n\n**Note 4:** **Neoadjuvant Therapy**\n* Record the assay from tumor specimens prior to neoadjuvant therapy.\n* If neoadjuvant therapy is given and there are no ALK results from pre-treatment specimens, report the findings from post-treatment specimens.", - "last_modified" : "2025-02-24T15:57:55.609Z", + "last_modified" : "2025-11-06T18:27:44.689Z", "definition" : [ { "key" : "alk_rearrangement", "name" : "Code", @@ -17,7 +17,7 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "0", "Normal\nALK negative\nNegative for rearrangement, no rearrangement identified, no mutations (somatic) identified, not present, not detected" ], [ "1", "Abnormal Rearrangement identified/detected: EML4-ALK, KIF5B-ALK, TFG-ALK, and/or KLC1-ALK " ], [ "2", "Rearrangement identified/detected: Other ALK Rearrangement not listed in code 1" ], [ "4", "Rearrangement, NOS" ], [ "7", "Test ordered, results not in chart" ], [ "8", "Not applicable: Information not collected for this case\n(If this information is required by your standard setter, use of code 8 may result in an edit error.)" ], [ "9", "Not documented in medical record\nALK Rearrangement not assessed or unknown if assessed" ], [ "", "Must be blank if diagnosis year is before 2021" ] ], - "additional_info" : "**Source documents:** pathology report or clinical laboratory report, molecular report, immunohistochemistry report\n\n**Other names include** ALK tyrosine kinase receptor, anaplastic lymphoma kinase, anaplastic lymphoma receptor tyrosine kinase, CD246, CD246 antigen, NBLST3\n\t\nFor further information, refer to the **Lung Biomarker Reporting** cancer protocol published by the College of American Pathologists", - "coding_guidelines" : "**1)** **Code 0** when ALK normal/negative/not identified\n**2)** **Code 1 or 2** when ALK identified/detected (EML4-ALK, KIF5B-ALK, TFG-ALK, KLC1-ALK)\n**3)** **Code 4** for when ALK identified/detected, and there is no mention of the specific rearrangement \n**4)** **Code 9** when \n* Insufficient amount of tissue available to perform test\n* Test done and documented to be equivocal\n* No microscopic confirmation of tumor\n* ALK Rearrangement not ordered or not done, or unknown if ordered or done", + "additional_info" : "**Source documents:** pathology report or clinical laboratory report, molecular report, immunohistochemistry report\n\n**Other names include** ALK tyrosine kinase receptor, anaplastic lymphoma kinase, anaplastic lymphoma receptor tyrosine kinase, CD246, CD246 antigen, NBLST3\n\t\nFor further information, refer to the **Lung Biomarker Reporting** cancer protocol published by the College of American Pathologists.", + "coding_guidelines" : "**1)** **Code 0** when ALK normal/negative/not identified\n\n**2)** **Code 1 or 2** when ALK identified/detected (EML4-ALK, KIF5B-ALK, TFG-ALK, KLC1-ALK)\n\n**3)** **Code 4** for when ALK identified/detected, and there is no mention of the specific rearrangement \n\n**4)** **Code 9** when \n* Insufficient amount of tissue available to perform test\n* Test done and documented to be equivocal\n* No microscopic confirmation of tumor\n* ALK Rearrangement not ordered or not done, or unknown if ordered or done", "rationale" : "ALK rearrangement is recommended by treatment guidelines for patients with advanced lung cancer to as a prognostic marker and factor in determining appropriate therapy. It is a new data item for cases diagnosed 1/1/2021+." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/b2_microglob_pretx_level_83264.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/b2_microglob_pretx_level_83264.json index 8be613d2a..6ce724c94 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/b2_microglob_pretx_level_83264.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/b2_microglob_pretx_level_83264.json @@ -6,7 +6,7 @@ "title" : "Serum Beta-2 Microglobulin Pretreatment Level", "description" : "Serum Beta-2 Microglobulin is a protein that is found on the surface of many cells and plentiful on the surface of white blood cells. Increased production or destruction of these cells causes Serum β2 (beta-2) Microglobulin level to increase. Elevated Serum β2 (beta-2) Microglobulin level is a prognostic factor for plasma cell myeloma.\n\nThe Revised International Staging System (R-ISS or RISS) is now used to stage plasma cell myeloma (9732/3), using several different criteria. The stages are based on the absence or presence of the following related criteria. \n* 3931: Serum Beta-2 Microglobulin Pretreatment Level\n* 3930: Serum Albumin Pretreatment Level\n* 3857: High Risk Cytogenetics\n* 3869: LDH Level\n\nRequired for Staging: The AJCC Staging System Plasma Cell Myeloma and Plasma Cell Disorders (9732/3 only) and EOD. \n* Note: R-ISS stage is not applicable for the descriptions of plasma multiple myeloma that are listed in the codes 1 and 9 in the SSDI Schema Discriminator 1: Plasma Cell Myeloma Terminology. If you have coded 1 or 9 for this Schema Discriminator, the four data items listed above are BLANK.\n\nThe R-ISS stages are\n* Stage I: Serum Beta-2-microglobulin <3.5 mg/L and serum albumin > 3.5 g/dL and no high-risk cytogenetics and Normal LDH\n* Stage II: Not R-ISS I or III\n* Stage III: Serum Beta-2-microglobulin > 5.5 mg/L and high-risk cytogenetics and/or high LDH", "notes" : "**Note 1:** **Physician statement**\n* Physician statement of Serum Beta-2-Microglobulin Pretreatment Level can be used to code this data item when no other information is available (See Note 3)\n\n**Note 2:** **Pretreatment results only**\n* Record this data item based on a **blood test** performed at diagnosis (pre-treatment). Use the highest value available.\n * Do not use results from a urine test\n\n**Note 3:** **Component of R-ISS Stage**\n* Serum Beta-2 Microglobulin is part of the Revised International Staging (R-ISS). \n* Elevated serum microglobulin is defined as ≥ 5.5 mg/L\n* Use the cut points listed in the table below regardless of the lab’s reference range.\n * **Code 0** if physician states **RISS Stage 1** and there is no other information\n * **Code 2** if physician states **RISS Stage 3** and there is no other information", - "last_modified" : "2025-06-04T20:23:11.306Z", + "last_modified" : "2025-11-06T16:07:15.721Z", "definition" : [ { "key" : "b2_microglob_pretx_level", "name" : "Code", @@ -17,7 +17,7 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "0", "β2-microglobulin < 3.5 mg/L" ], [ "1", "β2-microglobulin ≥ 3.5 mg/L < 5.5 mg/L" ], [ "2", "β2-microglobulin ≥ 5.5 mg/L" ], [ "5", "Schema Discriminator 1: Plasma Cell Myeloma Terminology coded to 1 or 9" ], [ "7", "Test ordered, results not in chart" ], [ "9", "Not documented in medical record\nSerum Beta-2 Microglobulin Pretreatment Level not assessed or unknown if assessed" ] ], - "additional_info" : "**Source documents:** laboratory tests (blood only), \n\n**Other names include** B2M, Total Beta-2 microglobulin, B2-microglobulin, and B2M", + "additional_info" : "**Source documents:** laboratory tests (blood only)\n\n**Other names include** B2M, Total Beta-2 microglobulin, B2-microglobulin, and B2M", "coding_guidelines" : "**1) Code 5** if Schema Discriminator 1: Plasma Cell Myeloma Terminology is coded to 1 or 9\n\n**2) Code 9** when there is no mention of the Serum beta-2-microglobulin", "rationale" : "Serum Beta-2 Microglobulin Pretreatment Level is a prognostic factor required in AJCC 8th edition, Chapter 82 *Plasma Cell Myeloma and Plasma Cell Disorders*, for staging of plasma cell myeloma. It is a new data item for cases diagnosed 1/1/2018+." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/bileductsdistal_bileductsperihilar_cysticduct_24541.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/bileductsdistal_bileductsperihilar_cysticduct_24541.json index 175d99139..96d7f4017 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/bileductsdistal_bileductsperihilar_cysticduct_24541.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/bileductsdistal_bileductsperihilar_cysticduct_24541.json @@ -5,8 +5,8 @@ "name" : "Schema Discriminator 1", "title" : "Schema Discriminator 1: BileDuctsDistal/BileDuctsPerihilar/CysticDuct", "description" : "Cystic duct, distal bile ducts, and perihilar bile ducts all have the same ICD-O topography code (C240). However, for purposes of stage grouping in the AJCC 8th edition, they each have different chapters for stage. A schema discriminator is necessary to distinguish between these primary sites so that the appropriate chapter/schema is used.", - "notes" : "**Note:** **Schema Discriminator for C240** \n* A schema discriminator is used to discriminate for primary site C240 (extrahepatic bile ducts) for the subsite in which the tumor arose.\n\n* **00242 : Cystic Duct (see code 3)**\nPer the AJCC Gallbladder Staging System, the gallbladder tapers into the cystic duct\n\n* **00250: Bile Ducts Perihilar (see codes 1, 5, 6, 9)**\nPer the AJCC Perihilar Bile Ducts Staging System, perihilar (or proximal) cholangiocarcinomas involve the main biliary confluence of the right and left hepatic ducts and comprise 50-70% of all cases of bile ducts carcinomas\n\n* **00260: Bile Ducts Distal ( see codes 4, 7)**\nPer the AJCC Distal Bile Duct Staging System, these tumors have their center located between the confluence of the cystic duct and common hepatic duct and the Ampulla of Vater (excluding ampullary carcinomas.)", - "last_modified" : "2025-02-07T17:17:07.225Z", + "notes" : "**Note:** **Schema Discriminator for C240** \n* A schema discriminator is used to discriminate for primary site C240 (extrahepatic bile ducts) for the subsite in which the tumor arose.\n\n* **00242 : Cystic Duct (see code 3)**\n\n Per the AJCC Gallbladder Staging System, the gallbladder tapers into the cystic duct\n\n* **00250: Bile Ducts Perihilar (see codes 1, 5, 6, 9)**\n\n Per the AJCC Perihilar Bile Ducts Staging System, perihilar (or proximal) cholangiocarcinomas involve the main biliary confluence of the right and left hepatic ducts and comprise 50-70% of all cases of bile ducts carcinomas\n\n* **00260: Bile Ducts Distal (see codes 4, 7)**\n\n Per the AJCC Distal Bile Duct Staging System, these tumors have their center located between the confluence of the cystic duct and common hepatic duct and the Ampulla of Vater (excluding ampullary carcinomas.)", + "last_modified" : "2025-11-06T18:19:00.127Z", "definition" : [ { "key" : "discriminator_1", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/bone_invasion_96628.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/bone_invasion_96628.json index 6365710f9..da46ad400 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/bone_invasion_96628.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/bone_invasion_96628.json @@ -6,7 +6,7 @@ "title" : "Bone Invasion", "description" : "Bone invasion, the presence or absence of bone invasion based on imaging, is a prognostic factor for soft tissue sarcoma.\n\nDirect tumor extension from the primary sarcoma into adjacent bone. This field does not include distant or discontinuous metastases to the skeletal system. Information in this field is based on radiology and other imaging techniques.", "notes" : "**Note 1:** **Physician Staging** \n* Physician statement of Bone Invasion can be used to code this data item when no other information is available.\n\n**Note 2:** **Criteria for Coding** \n* Record bone invasion as determined by **relevant imaging only for the primary tumor** \n* Imaging methodologies include computed tomography (CT) scans and magnetic resonance imaging (MRI).", - "last_modified" : "2025-02-24T14:00:36.360Z", + "last_modified" : "2025-11-06T18:32:52.675Z", "definition" : [ { "key" : "bone_invasion", "name" : "Code", @@ -18,6 +18,6 @@ } ], "rows" : [ [ "0", "Bone invasion not present/not identified on imaging" ], [ "1", "Bone invasion present/identified on imaging" ], [ "8", "Not applicable: Information not collected for this case\n(If this information is required by your standard setter, use of code 8 may result in an edit error.)" ], [ "9", "Not documented in medical record\nBone invasion not assessed or unknown if assessed" ] ], "additional_info" : "**Source documents:** imaging", - "coding_guidelines" : "**1)** **Code 0** when relevant imaging is performed and there is no mention of bone invasion\n**2)** **Code 1** when there is evidence of bone invasion on imaging\n**3)** **Code 9** when\n* No information in the medical record\n* Bone invasion not evaluated (assessed)\n* No relevant imaging of the primary site\n* Unknown if bone invasion evaluated (assessed)", + "coding_guidelines" : "**1)** **Code 0** when relevant imaging is performed and there is no mention of bone invasion\n\n**2)** **Code 1** when there is evidence of bone invasion on imaging\n\n**3)** **Code 9** when\n* No information in the medical record\n* Bone invasion not evaluated (assessed)\n* No relevant imaging of the primary site\n* Unknown if bone invasion evaluated (assessed)", "rationale" : "Bone Invasion is a Registry Data Collection Variable in AJCC. This data item was previously collected for Soft Tissue, SSF #3." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/braf_mutational_analysis_37823.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/braf_mutational_analysis_37823.json index 1c12dfa67..d83d2aa27 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/braf_mutational_analysis_37823.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/braf_mutational_analysis_37823.json @@ -6,7 +6,7 @@ "title" : "BRAF Mutational Analysis", "description" : "The BRAF oncoprotein is involved in transmitting cell growth and proliferation signals from KRAS and NRAS. The BRAF V600E mutation is associated with poorer prognosis and predicts lack of response to anti-EGFR therapies. \n\n“BRAF V600E is a specific mutation (change) in the BRAF gene, which makes a protein that is involved in sending signals in cells and in cell growth. This BRAF gene mutation is found in colorectal cancer. It may increase the growth and spread of cancer cells. Checking for this BRAF mutation in tumor tissue may help to plan cancer treatment. BRAF (V600E) kinase inhibitor RO5185426 blocks certain proteins made by the mutated BRAF gene, which may help keep cancer cells from growing.” (NCI Dictionary of Cancer Terms https://www.cancer.gov/publications/dictionaries/cancer-terms)\n\nNRAS is a gene which belongs to a class of genes known as oncogenes. When mutated, oncogenes have the potential to cause normal cells to become cancerous. Studies suggest that NRAS gene mutations are often present in colorectal cancer.\n\nThe most common BRAF mutations is BRAF V600E (c.1799T>A) mutation.", "notes" : "**Note 1:** **Effective years**\n* This SSDI is effective for diagnosis years 2021+\n* For cases diagnosed 2018-2020, this SSDI must be blank\n\n**Note 2:** **Physician Statement** \n* Physician statement of BRAF can be used to code this data item when no other information is available.\n\n**Note 3:** **Applicable stages**\n* BRAF may be recorded for all stages; however, it is primarily performed for patients with metastatic disease. If information is not available, code 9.\n\n**Note 4:** **Results from nodal or metastatic tissue**\n* Results from nodal or metastatic tissue may be used for BRAF.\n\n**Note 5:** **Neoadjuvant Therapy** \n* Record the assay from tumor specimens prior to neoadjuvant therapy.\n* If neoadjuvant therapy is given and there are no BRAF results from pre-treatment specimens, report the findings from post-treatment specimens.", - "last_modified" : "2025-02-24T13:45:11.796Z", + "last_modified" : "2025-11-06T18:04:38.446Z", "definition" : [ { "key" : "braf_mutational_analysis", "name" : "Code", @@ -17,7 +17,7 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "0", "Normal\nBRAF negative, BRAF wild type\nNegative for (somatic) mutations, no alterations, no (somatic) mutations identified, not present, not detected" ], [ "1", "Abnormal (mutated)/detected: BRAF V600E (c.1799T>A) mutation" ], [ "2", "Abnormal (mutated)/detected, but not BRAF V600E (c.1799T>A) mutation" ], [ "3", "Abnormal (mutated)/detected, *KIAA1549: BRAF* gene fusion" ], [ "4", "Abnormal (mutated), BRAF, NOS" ], [ "7", "Test ordered, results not in chart" ], [ "8", "Not applicable: Information not collected for this case\n(If this information is required by your standard setter, use of code 8 may result in an edit error.)" ], [ "9", "Not documented in medical record\nBRAF not assessed or unknown if assessed" ], [ "", "Must be blank if diagnosis year is before 2021" ] ], - "additional_info" : "**Source documents:** pathology report, clinical laboratory report\n\nFor further information, refer to the **Colon and Rectum Biomarker** Reporting cancer protocol published by the College of American Pathologists for the AJCC Staging System *Colon and Rectum*", - "coding_guidelines" : "**1)** **Code 0** when BRAF negative/wild type/not detected\n**2)** **Code 1, 2 or 3** when BRAF identified/detected\n**3)** **Code 4** for when BRAF identified, mutation not known \n**4)** **Code 9** when \n* Insufficient amount of tissue available to perform test\n* Test done and documented to be equivocal\n* No microscopic confirmation of tumor\n* BRAF mutational analysis not ordered or not done, or unknown if ordered or done", + "additional_info" : "**Source documents:** pathology report, clinical laboratory report\n\nFor further information, refer to the **Colon and Rectum Biomarker** Reporting cancer protocol published by the College of American Pathologists for the AJCC Staging System *Colon and Rectum*.", + "coding_guidelines" : "**1)** **Code 0** when BRAF negative/wild type/not detected\n\n**2)** **Code 1, 2 or 3** when BRAF identified/detected\n\n**3)** **Code 4** for when BRAF identified, mutation not known \n\n**4)** **Code 9** when \n* Insufficient amount of tissue available to perform test\n* Test done and documented to be equivocal\n* No microscopic confirmation of tumor\n* BRAF mutational analysis not ordered or not done, or unknown if ordered or done", "rationale" : "BRAF mutational analysis is recommended in clinical guidelines for patients with advanced colorectal cancer as a prognostic marker and factor in determining appropriate therapy. It is a new data item for cases diagnosed 1/1/2021+." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/brain_molecular_markers_75370.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/brain_molecular_markers_75370.json index 9226973b4..1f403802d 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/brain_molecular_markers_75370.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/brain_molecular_markers_75370.json @@ -6,7 +6,7 @@ "title" : "Brain Molecular Markers", "description" : "Multiple brain molecular markers have become standard pathology components necessary for diagnosis. This data item captures clinically important brain cancer subtypes identified by molecular markers that are not distinguishable by ICD-O-3 codes.\n\nOnly one code is applicable for each tumor. \n* *IDH mutation status* distinguishes between clinically important subtypes within ICD-O-3 **9400/3**, Diffuse astrocytoma and **9401/3**, Anaplastic astrocytoma.\n* *IDH mutant and 1p/19q co-deletion* distinguishes between clinically important subtypes within ICD-O-3 code **9450/3**, Oligodendroglioma and **9451/3**, Anaplastic Oligodendroglioma.\n* *IDH-wildtype* distinguishes clinically important subtypes within ICD-O-3 **9400/3**, Diffuse astrocytoma, **9401/3**, Anaplastic astrocytoma and **9440/3**, Glioblastoma, Epithelioid glioblastoma and Glioblastoma, NOS (note that the new ICD-O-3 code **9445/3** applies to Glioblastoma, IDH-mutant; information regarding this subtype is not collected using this data item).\n* *SHH-activation and TP53-wildtype* distinguishes between clinically important subtypes within ICD-O-3 histology code **9471/3**, Medulloblastoma. \n* *C19MC alteration status* distinguishes a clinically important highly aggressive subtype within ICD-O-3 **9478/3**, Embryonal tumor with multilayered rosettes.", "notes" : "**Note:** **Physician statement**\n* Physician statement of histologic subtype can be used to code this data item when no other information is available.", - "last_modified" : "2024-04-07T18:36:21.515Z", + "last_modified" : "2025-11-06T21:31:02.490Z", "definition" : [ { "key" : "brain_molecular_markers", "name" : "Code", @@ -17,7 +17,7 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "01", "Diffuse astrocytoma, IDH-mutant (9400/3)" ], [ "02", "Diffuse astrocytoma, IDH-wildtype (9400/3)" ], [ "03", "Anaplastic astrocytoma, IDH-mutant (9401/3)" ], [ "04", "Anaplastic astrocytoma, IDH-wildtype (9401/3)" ], [ "05", "Glioblastoma, IDH-wildtype (9440/3)" ], [ "06", "Oligodendroglioma, IDH-mutant and 1 p/19q co-deleted (9450/3)" ], [ "07", "Anaplastic oligodendroglioma, IDH-mutant and 1p/19q co-deleted (9451/3)" ], [ "08", "Medulloblastoma, SHH-activated and TP53-wildtype (9471/3)" ], [ "09", "Embryonal tumor with multilayered rosettes, C19MC-altered (9478/3)" ], [ "85", "Not applicable: Histology not 9400/3, 9401/3, 9440/3, 9450/3, 9451/3, 9471/3, 9478/3" ], [ "86", "Benign or borderline tumor" ], [ "87", "Test ordered, results not in chart" ], [ "88", "Not applicable: Information not collected for this case\n(If this item is required by your standard setter, use of code 88 will result in an edit error.)" ], [ "99", "Not documented in medical record\nNo microscopic confirmation\nBrain molecular markers not assessed or unknown if assessed" ] ], - "additional_info" : "**Source documents:** pathology report\n\nFor further information, refer to the **Central Nervous System** cancer protocol published by the College of American Pathologists", - "coding_guidelines" : "**1)** **Codes 01-09** are for specific ICD-O-3 codes\n\n**2)** **Code 85** when histology is **NOT** 9400/3, 9401/3, 9440/3, 9450/3, 9451/3, 9471/3 and 9478/3\n* **a.** This includes microscopically or non-microscopically confirmed cases\n\n**3)** **Code 86** when there is a **Benign (/0)** or **Borderline (/1)** tumor\n* **a.** This includes microscopically or non-microscopically confirmed cases\n\n **4)** **Code 99** when \n* **a.** Histology is 9400/3, 9401/3, 9440/3, 9450/3, 9451/3, 9471/3 and 9478/3\n* **b.** **AND** there is no microscopic confirmation\n\n***Examples:***\n1.\tBiopsy of brain tumor, microscopic confirmation diagnosis: Diffuse Astrocytoma (9400/3). Additional testing done, and IDH-mutant is identified. Code 01.\n2.\tBiopsy of brain tumor, microscopic confirmation diagnosis: Anaplastic astrocytoma (9401/3). No further testing or results unknown. Code 99.\n3.\tMRI of brain tumor, clinical diagnosis: glioblastoma. No further workup. Code 99.\n4.\tBiopsy of brain tumor, microscopic confirmation diagnosis: Mixed glioma (9382/3). Code 85.", + "additional_info" : "**Source documents:** pathology report\n\nFor further information, refer to the **Central Nervous System** cancer protocol published by the College of American Pathologists.", + "coding_guidelines" : "**1)** **Codes 01-09** are for specific ICD-O-3 codes\n\n**2)** **Code 85** when histology is **NOT** 9400/3, 9401/3, 9440/3, 9450/3, 9451/3, 9471/3 and 9478/3\n* This includes microscopically or non-microscopically confirmed cases\n\n**3)** **Code 86** when there is a **Benign (/0)** or **Borderline (/1)** tumor\n* This includes microscopically or non-microscopically confirmed cases\n\n **4)** **Code 99** when \n* Histology is 9400/3, 9401/3, 9440/3, 9450/3, 9451/3, 9471/3 and 9478/3\n* **AND** there is no microscopic confirmation\n\n***Examples:***\n\n**1.** Biopsy of brain tumor, microscopic confirmation diagnosis: Diffuse Astrocytoma (9400/3). Additional testing done, and IDH-mutant is identified. Code 01.\n**2.** Biopsy of brain tumor, microscopic confirmation diagnosis: Anaplastic astrocytoma (9401/3). No further testing or results unknown. Code 99.\n**3.** MRI of brain tumor, clinical diagnosis: glioblastoma. No further workup. Code 99.\n**4.** Biopsy of brain tumor, microscopic confirmation diagnosis: Mixed glioma (9382/3). Code 85.", "rationale" : "Collection of these clinically important brain cancer subtypes has been recommended by CBTRUS." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/brain_molecular_markers_v9_48556.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/brain_molecular_markers_v9_48556.json index cfef6e478..fae4312b8 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/brain_molecular_markers_v9_48556.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/brain_molecular_markers_v9_48556.json @@ -6,7 +6,7 @@ "title" : "Brain Molecular Markers", "description" : "Multiple brain molecular markers have become standard pathology components necessary for diagnosis. This data item captures clinically important brain cancer subtypes identified by molecular markers that are not distinguishable by ICD-O-3 codes.\nIf a mutation or alteration is in the name of the histopathology, it is required for diagnosis as it helps distinguish among clinically important subtypes within ICD-O-3 \n\n* *IDH mutation status* distinguishes between clinically important subtypes within ICD-O-3 **9400/3**, Diffuse astrocytoma and **9401/3**, Anaplastic astrocytoma.\n* *IDH mutant and 1p/19q co-deletion* distinguishes between clinically important subtypes within ICD-O-3 code **9450/3**, Oligodendroglioma and **9451/3**, Anaplastic Oligodendroglioma.\n* *IDH-wildtype* distinguishes clinically important subtypes within ICD-O-3 **9400/3**, Diffuse astrocytoma, **9401/3**, Anaplastic astrocytoma and **9440/3**, Glioblastoma, Epithelioid glioblastoma and Glioblastoma, NOS (note that the new ICD-O-3 code **9445/3** applies to Glioblastoma, IDH-mutant; information regarding this subtype is not collected using this data item).\n* *SHH-activation and TP53-wildtype* distinguishes between clinically important subtypes within ICD-O-3 histology code **9471/3**, Medulloblastoma.\n* *C19MC alteration* status distinguishes a clinically important highly aggressive subtype within ICD-O-3 **9478/3**, Embryonal tumor with multilayered rosettes\n* *Pediatric-type diffuse low-grade gliomas*: **9385/3** Diffuse hemispheric glioma, H3-G34-mutant, Diffuse midline glioma, H3 K27-altered, Diffuse pediatric-type high-grade glioma, H3-wildtype and IDH-wildtype, and Infant-type hemispheric glioma.\n* *Ependymal tumors* are distinguished by mutations required for diagnosis among clinically important subtypes: **9396/3** Posterior fossa group A (PFA) ependymoma, Posterior fossa group B (PFB) ependymoma, Spinal ependymoma, MYCN-amplified, Supratentorial ependymoma, YAPI fusion-positive, and Supratentorial ependymoma, ZFTA fusion-positive.\n* *Pediatric-type diffuse low-grade gliomas* are distinguished among subtypes by mutations required for diagnosis: **9421/1** Diffuse astrocytoma, MYB-or MYBL1-altered, Diffuse low-grade glioma, MAPK pathway-altered, and Pilocytic astrocytoma.\n* *Circumscribed astrocytic tumors* are distinguished among subtypes by mutations required for diagnosis: **9430/3** Astroblastoma, MN1-altered and Astroblastoma.\n* *Other CNS embryonal tumors* are distinguished among subtypes by mutations required for diagnosis: **9500/3** CNS neuroblastoma, FOXR2-activated, CNS tumor with BCOR internal tandem duplication, and Neuroblastoma, NOS.", "notes" : "**Note 1:** **Physician Statement**\n* Physician statement of histologic subtype can be used to code this data item when no other information is available. \n\n**Note 2:** **Data item history**\n* This data item was introduced in 2018 and applied to the following ICD-O-3 histology codes 9400/3, 9401/3, 9440/3, 9450/3, 9451/3, 9471/3, 9478/3\n * These are codes 01-09 and are applicable for cases diagnosed 2018+ and are in ICD-O-3 order\n* In 2022, the 5th edition of the CNS WHO Blue Book was released and the following histologies were added 9385/3, 9396/3, 9421/1, 9430/3, 9500/3\n * These are codes 10-23 and are applicable for cases diagnosed 2024+ and are in ICD-O-3 order", - "last_modified" : "2025-02-24T14:44:26.670Z", + "last_modified" : "2025-11-06T21:35:07.975Z", "definition" : [ { "key" : "brain_molecular_markers", "name" : "Code", @@ -21,7 +21,7 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "01", "9400/3", "Astrocytoma, IDH-mutant, grade 2 " ], [ "02", "9400/3", "Diffuse astrocytoma, IDH-wildtype " ], [ "03", "9401/3", "Astrocytoma, IDH-mutant, grade 3 " ], [ "04", "9401/3", "Anaplastic astrocytoma, IDH-wildtype " ], [ "05", "9440/3", "Glioblastoma, IDH-wildtype " ], [ "06", "9450/3", "Oligodendroglioma, IDH-mutant and 1 p/19q co-deleted " ], [ "07", "9451/3", "Oligodendroglioma, IDH-mutant and 1p/19q co-deleted, grade 3 " ], [ "08", "9471/3", "Medulloblastoma, SHH-activated and TP53-wildtype " ], [ "09", "9478/3", "Embryonal tumor with multilayered rosettes, C19MC-altered " ], [ "10", "9385/3", "Diffuse hemispheric glioma, H3-34 mutant " ], [ "11", "9385/3", "Diffuse midline glioma, H3 K27-altered " ], [ "12", "9385/3", "Diffuse pediatric-type high-grade glioma, H3-wildtype and IDH-wildtype" ], [ "13", "9385/3", "Infant-type hemispheric glioma " ], [ "14", "9396/3", "Posterior fossa group A (PFA) ependymoma " ], [ "15", "9396/3", "Posterior fossa group B (PFB) ependymoma " ], [ "16", "9396/3", "Spinal ependymoma, MYCN-amplified " ], [ "17", "9396/3", "Supratentorial ependymoma, YAP1 fusion-positive " ], [ "18", "9396/3", "Supratentorial ependymoma, ZFTA fusion-positive " ], [ "19", "9421/1", "Diffuse astrocytoma, MYB- or MYBL1-altered " ], [ "20", "9421/1", "Diffuse low-grade glioma, MAPK pathway-altered " ], [ "21", "9430/3", "Astroblastoma, MN1-altered " ], [ "22", "9500/3", "CNS neuroblastoma, FOXR2-activated" ], [ "23", "9500/3", "CNS tumor BCOR internal tandem duplication" ], [ "85", "NA", "Not applicable: Histology not 9385/3, 9396/3, 9400/3, 9401/3, 9421/1, 9430/3, 9440/3, 9450/3, 9451/3, 9471/3, 9478/3, 9421/1, 9430/3, 9500/3" ], [ "86", "NA", "Benign or borderline tumor \n*Excludes:* 9421/1 (codes 19-20)" ], [ "87", "NA", "Test ordered, results not in chart" ], [ "88", "NA", "Not applicable: Information not collected for this case\n(If this item is required by your standard setter, use of code 88 will result in an edit error.)" ], [ "99", "NA", "Not documented in medical record\nNo microscopic confirmation\nBrain molecular markers not assessed or unknown if assessed" ] ], - "additional_info" : "**Source documents:** pathology report\n\nFor further information, refer to the **Central Nervous System** cancer protocol published by the College of American Pathologists", - "coding_guidelines" : "**1)** **Codes 01-23** are for specific ICD-O-3 codes\n**2)** **Code 85** when histology is **NOT** 9385/3, 9396/3, 9400/3, 9401/3, 9430/3, 9440/3, 9450/3, 9451/3, 9471/3, 9478/3, 9421/1, 9430/3, 9500/3\n* This includes microscopically or non-microscopically confirmed cases\n\n**3)** **Code 86** when there is a **benign (/0)** or **borderline (/1)** tumor\n* This includes microscopically or non-microscopically confirmed cases\n* *Exception*: 9421/1 (see codes 19-20 when microscopically confirmed)\n * If codes 19 or 20 don't apply, or not microscopically confirmed, code 99\n\n**4)** **Code 99** when \n* Histology is 9385/3, 9396/3, 9400/3, 9401/3, 9430/3, 9440/3, 9450/3, 9451/3, 9471/3, 9478/3, 9421/1, 9430/3, 9500/3 \n* **AND** there is no microscopic confirmation\n\n\n***Examples:***\n1.\tBiopsy of brain tumor, microscopic confirmation diagnosis: Diffuse Astrocytoma (9400/3). Additional testing done, and IDH-mutant is identified. Code 01.\n2.\tBiopsy of brain tumor, microscopic confirmation diagnosis: Anaplastic astrocytoma (9401/3). No further testing or results unknown. Code 99.\n3.\tMRI of brain tumor, clinical diagnosis: glioblastoma. No further workup. Code 99.\n4.\tBiopsy of brain tumor, microscopic confirmation diagnosis: Mixed glioma (9382/3). Code 85.", + "additional_info" : "**Source documents:** pathology report\n\nFor further information, refer to the **Central Nervous System** cancer protocol published by the College of American Pathologists.", + "coding_guidelines" : "**1)** **Codes 01-23** are for specific ICD-O-3 codes\n\n**2)** **Code 85** when histology is **NOT** 9385/3, 9396/3, 9400/3, 9401/3, 9430/3, 9440/3, 9450/3, 9451/3, 9471/3, 9478/3, 9421/1, 9430/3, 9500/3\n* This includes microscopically or non-microscopically confirmed cases\n\n**3)** **Code 86** when there is a **benign (/0)** or **borderline (/1)** tumor\n* This includes microscopically or non-microscopically confirmed cases\n* *Exception*: 9421/1 (see codes 19-20 when microscopically confirmed)\n * If codes 19 or 20 don't apply, or not microscopically confirmed, code 99\n\n**4)** **Code 99** when \n* Histology is 9385/3, 9396/3, 9400/3, 9401/3, 9430/3, 9440/3, 9450/3, 9451/3, 9471/3, 9478/3, 9421/1, 9430/3, 9500/3 \n* **AND** there is no microscopic confirmation\n\n\n***Examples:***\n**1.** Biopsy of brain tumor, microscopic confirmation diagnosis: Diffuse Astrocytoma (9400/3). Additional testing done, and IDH-mutant is identified. Code 01.\n**2.** Biopsy of brain tumor, microscopic confirmation diagnosis: Anaplastic astrocytoma (9401/3). No further testing or results unknown. Code 99.\n**3.** MRI of brain tumor, clinical diagnosis: glioblastoma. No further workup. Code 99.\n**4.** Biopsy of brain tumor, microscopic confirmation diagnosis: Mixed glioma (9382/3). Code 85.", "rationale" : "Collection of these clinically important brain cancer subtypes has been recommended by CBTRUS." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/breslow_thickness_79262.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/breslow_thickness_79262.json index b8484f8e3..f394ab3d5 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/breslow_thickness_79262.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/breslow_thickness_79262.json @@ -6,7 +6,7 @@ "title" : "Breslow Tumor Thickness", "description" : "Breslow Tumor Thickness, the measurement of the thickness of a melanoma as defined by Dr. Alexander Breslow, is a prognostic factor for Melanoma of the Skin.\n\nA measure of how deeply a melanoma tumor has grown into the skin. The tumor thickness (depth) is usually measured from the top of the tumor to the deepest tumor cells. If the tumor is ulcerated (the skin is broken), it is measured from the base of the ulcer to the deepest tumor cells. Breslow thickness is used to help determine the stage of cancer. Thicker tumors are linked with lower survival rates.", "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of Breslow Tumor Thickness can be used to code this data item when no other information is available, or the available information is ambiguous. \n\n**Note 2:** **Breslow's depth** \n* Code a measurement specifically labeled as **thickness** or **depth** or **Breslow depth of invasion** from the pathology report. \n* In the absence of this label, a measurement described as taken from the cut surface of the specimen may be coded. And in the absence of either of these labels, the third dimension in a statement of tumor size can be used to code this field.", - "last_modified" : "2025-02-24T16:13:06.100Z", + "last_modified" : "2025-11-06T15:48:07.410Z", "definition" : [ { "key" : "breslow_thickness", "name" : "Code", @@ -17,7 +17,7 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "0.0", "No mass/tumor found" ], [ "0.1", "Greater than 0.0 and less than or equal to 0.1" ], [ "0.2-99.9", "0.2 - 99.9 millimeters" ], [ "XX.1", "100 millimeters or larger" ], [ "A0.1-A9.9", "Stated as \"at least\" some measured value of 0.1 to 9.9" ], [ "AX.0", "Stated as greater than 9.9 mm" ], [ "XX.8", "Not applicable: Information not collected for this schema\n(If this item is required by your standard setter, use of code XX.8 will result in an edit error)" ], [ "XX.9", "Not documented in medical record\nMicroinvasion; microscopic focus or foci only and no depth given\nCannot be determined by pathologist\nNon-invasive neoplasm (behavior /2)\nBreslow Tumor Thickness not assessed or unknown if assessed" ] ], - "additional_info" : "**Source documents:** pathology report\n\n**Other names include** maximum tumor thickness, Breslow depth of invasion, Breslow thickness, Breslow measurement, Breslow’s microstaging\n\nFor further information, refer to the **Melanoma of the Skin** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Melanoma of the Skin*", + "additional_info" : "**Source documents:** pathology report\n\n**Other names include** maximum tumor thickness, Breslow depth of invasion, Breslow thickness, Breslow measurement, Breslow’s microstaging\n\nFor further information, refer to the **Melanoma of the Skin** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Melanoma of the Skin*.", "coding_guidelines" : "**1)** **Code Breslow tumor thickness, not size**. Record actual measurement in tenths of millimeters from the pathology report. Measurement given in hundredths of millimeters should be rounded to the nearest tenth. \n\n**2)** Code the greatest measured thickness from any procedure performed on the lesion, whether it is described as a biopsy or an excision. \n* Do not add measurements together from different procedures. \n * ***Example:*** A punch biopsy with a thickness of 0.5 mm is followed by a re-excision with a thickness of residual tumor of 0.2 mm. Code 0.5 mm.\n * ***Exception:*** If there are multiple procedures, and the pathologist adds the measurement together to get a final Breslow’s depth, the registrar can use this.\n\n**3)** If the pathologist describes the thickness as \"at least,\" use the appropriate A code. An exact measurement takes precedence over A codes.\n* If the pathologist states \"greater than\" instead of \"at least\", code to XX.9, unless it is greater than 9.9 mm (Code AX.0)\n\n**4)** If the tumor is excised post-neoadjuvant treatment, tumor measurements **cannot be compared** before and after treatment to determine which would indicate the greater involvement. \n* The same code (XX.9) is used for cases with no surgical procedure of the primary site and cases with surgical procedure of the primary site after neoadjuvant treatment.\n\n**5)** Because the thickness table is similar to many other tables that collect a measurement, it is important to identify the correct unit of measurement. \n* In the range 0.1-99.9, code the actual tumor thickness, tumor depth, or Breslow measurement in tenths of millimeters as stated in the pathology report. If the measurement is given in hundredths of millimeters, use the general rules for rounding to determine the value in tenths of millimeters. This is a four-digit field with a decimal point in the third digit. \n\n***Examples:***\n* 0.4 mm - 0.4\n* 1.0 mm- 1.0\n* 2.5 mm - 2.5\n* 2.56 mm- 2.6\n* 11 mm - 11.0\n* 12.35 mm - 12.4\n* Pathologist states the thickness is \"at least 2.0 mm.\" Code A2.0\n* Pathologist states the thickness is \"greater than 4 mm.\" Code XX.9", "rationale" : "Breslow Tumor Thickness is a Registry Data Collection Variable in AJCC. It was previously collected as Melanoma Skin, CS SSF #1." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ca_125_pretx_interpretation_51295.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ca_125_pretx_interpretation_51295.json index 1a117a3a6..0ea80dab2 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ca_125_pretx_interpretation_51295.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ca_125_pretx_interpretation_51295.json @@ -6,7 +6,7 @@ "title" : "CA-125 (Carbohydrate Antigen 125) Pretreatment Interpretation", "description" : "Carbohydrate Antigen 125 (CA-125)/CA-125 II is a tumor marker that is useful for following the response to therapy in patients with ovarian cancer, who may have elevated levels of this marker.\n\nCA-125/CA-125 II is a tumor marker that is not specific to ovarian or primary peritoneal cancer but is useful to monitor for success of treatment and recurrence. Because it can be elevated in many diseases affecting the peritoneal lining of the abdominal and pelvic cavity, it is not a screening test for women who have no history of cancer. Any value over 35 is highly linked with cancer and about 80% of ovarian cancers show an elevated CA-125/CA-125 II. However, a result in the normal range does not rule out cancer. Values up to 65 U/ml may be considered borderline, and values over 200 are unlikely to be due to a benign condition. CA-125/CA-125 II monitors for success of treatment and recurrence. After obtaining a baseline value prior to treatment, a lower result on a subsequent test indicates a response to treatment, and an increasing value indicates possible recurrence.", "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of CA-125/CA-125 II pretreatment interpretation can be used to code this data item when no other information is available.\n\n**Note 2:** **Blood or Serum testing only** \n* Record only the blood or serum CA-125/CA-125 II interpretation for this data item. \n* Do not record CA-125 test results based on fluid from the chest or abdominal cavity. \n\n**Note 3:** **Pretreatment results only**\n* Record the CA-125/CA-125 II status prior to treatment.", - "last_modified" : "2025-02-24T16:19:05.960Z", + "last_modified" : "2025-11-06T20:37:30.956Z", "definition" : [ { "key" : "ca125_pretx_interpretation", "name" : "Code", @@ -17,7 +17,7 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "0", "Negative/normal; within normal limits" ], [ "1", "Positive/elevated" ], [ "2", "Stated as borderline; undetermined whether positive or negative" ], [ "7", "Test ordered, results not in chart" ], [ "8", "Not applicable: Information not collected for this case\n(If this item is required by your standard setter, use of code 8 will result in an edit error)" ], [ "9", "Not documented in medical record\nCA-125 not assessed or unknown if assessed" ] ], - "additional_info" : "**Source documents:** clinical laboratory report (blood or serum test); may be reported in history, clinician or consultant notes or pathology report\n\n**Other names include** Cancer Antigen 125, CA 125, CA125, Carbohydrate Antigen 125, mucin 16, MUC16, CA 125 II\n\n**Normal reference range**\n* < 35 units per milliliter (U/ml); SI: < 35 kiloUnits/Liter (KU/L).\n* May also be reported as micrograms/milliliter (g/mL or ug/mL).\n* Normal values may vary with patient age and from lab to lab \n* The typical human reference ranges are 0 to less than or equal 35 units per milliliter (U/mL). This is equivalent to kU/L.", - "coding_guidelines" : "**1)** Record the clinician’s interpretation of the highest value prior to treatment from a blood or serum test, based on the reference range used by the lab. \n**2)** Do **not** code the result from thoracentesis or paracentesis fluid. \n**3)** **Code 0** when the CA-125/CA-125 II is reported as negative or normal.\n**4)** **Code 1** when the CA-125/CA-125 II is reported as positive or elevated.\n**5)** **Code 2** when the CA-125/CA-125 II is reported as borderline; undetermined whether positive or negative.\n**6)** **Code 7** when the CA-125/CA-125 II test was ordered but the results are not in the medical record.\n**7)** **Code 9** when\n* No information in the medical record\n* CA-125/CA-125 II test not done (not assessed)\n* Unknown if CA-125/CA-125 II test was performed (unknown if assessed)\n* There is no statement that the CA-125/CA-125 II is positive/elevated, negative/normal, and the lab value with its normal range (from which you can determine interpretation) is not documented.", + "additional_info" : "**Source documents:** clinical laboratory report (blood or serum test); may be reported in history, clinician or consultant notes or pathology report\n\n**Other names include** Cancer Antigen 125, CA 125, CA125, Carbohydrate Antigen 125, mucin 16, MUC16, CA 125 II\n\n**Normal reference range**\n* < 35 units per milliliter (U/ml); SI: < 35 kiloUnits/Liter (KU/L)\n* May also be reported as micrograms/milliliter (μg/mL or ug/mL)\n* Normal values may vary with patient age and from lab to lab.\n* The typical human reference ranges are 0 to less than or equal 35 units per milliliter (U/mL). This is equivalent to kU/L.", + "coding_guidelines" : "**1)** Record the clinician’s interpretation of the highest value prior to treatment from a blood or serum test, based on the reference range used by the lab. \n\n**2)** Do **not** code the result from thoracentesis or paracentesis fluid. \n\n**3)** **Code 0** when the CA-125/CA-125 II is reported as negative or normal.\n\n**4)** **Code 1** when the CA-125/CA-125 II is reported as positive or elevated.\n\n**5)** **Code 2** when the CA-125/CA-125 II is reported as borderline; undetermined whether positive or negative.\n\n**6)** **Code 7** when the CA-125/CA-125 II test was ordered but the results are not in the medical record.\n\n**7)** **Code 9** when\n* No information in the medical record\n* CA-125/CA-125 II test not done (not assessed)\n* Unknown if CA-125/CA-125 II test was performed (unknown if assessed)\n* There is no statement that the CA-125/CA-125 II is positive/elevated, negative/normal, and the lab value with its normal range (from which you can determine interpretation) is not documented.", "rationale" : "Preoperative CA-125/CA-125 II is a Registry Data Collection Variable listed in AJCC. It was previously collected as Ovary, CS SSF #1." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ca_19_9_pretx_lab_value_17332.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ca_19_9_pretx_lab_value_17332.json index 6c7b46e58..d89cd7e8c 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ca_19_9_pretx_lab_value_17332.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ca_19_9_pretx_lab_value_17332.json @@ -6,7 +6,7 @@ "title" : "Carbohydrate Antigen 19-9 Pretreatment Lab Value", "description" : "Carbohydrate Antigen (CA) 19-9 Pretreatment Lab Value records the CA 19-9 value prior to treatment. CA 19-9 is a tumor marker that has prognostic significance for pancreatic cancer.\n\nCA 19-9 is a sialylated Lewis A blood group antigen that is commonly expressed and shed in pancreatic and hepatobiliary disease and in many malignancies, thus is not tumor specific. Preoperative CA 19-9 levels in pancreatic cancer patients correlate both with AJCC staging and resectability [NCCN Guidelines Version 3.2019 Pancreatic Adenocarcinoma].", "notes" : "**Note 1:** **Effective years**\n* This SSDI is effective for diagnosis years 2021+\n* For cases diagnosed 2018-2020, this SSDI must be blank\n\n**Note 2:** **Physician Statement**\n* Physician statement of CA 19-9 (Carbohydrate Antigen 19-9) Pretreatment Lab Value can be used to code this data item when no other information is available.", - "last_modified" : "2025-02-24T13:53:05.261Z", + "last_modified" : "2025-11-06T18:21:55.478Z", "definition" : [ { "key" : "ca19_9_pretx_lab_value", "name" : "Code", @@ -18,6 +18,6 @@ } ], "rows" : [ [ "0.0", "0.0 Units/milliliter (U/ml) exactly" ], [ "0.1-9999.9", "0.1-9999.9 U/ml\n(Exact value to nearest tenth in U/ml)" ], [ "XXXX.1", "10,000 U/ml or greater" ], [ "XXXX.2", "Lab value not available, physician states CA 19-9 is negative/normal" ], [ "XXXX.3", "Lab value not available, physician states CA 19-9 is positive/elevated/high" ], [ "XXXX.7", "Test ordered, results not in chart " ], [ "XXXX.8", "Not applicable: Information not collected for this case\n(If this information is required by your standard setter, use of code XXXX.8 may result in an edit error.)" ], [ "XXXX.9", "Not documented in medical record\nCA (Carbohydrate Antigen) 19-9 Pretreatment Lab Value not assessed or unknown if assessed" ], [ "", "Must be blank if diagnosis year is before 2021" ] ], "additional_info" : "**Source documents:** clinical laboratory report\n\n**Other names include** Carbohydrate Antigen 19-9, Cancer Antigen-GI, CA-GI, Cancer Antigen 19-9", - "coding_guidelines" : "**1:** Record to the nearest tenth in Units/milliliter (U/ml), the highest CA 19-9 lab value documented in the medical record prior to treatment. \n * ***Example 1***: Code a pretreatment CA 19-9 of 7 U/ml as 7.0\n * ***Example 2***: Code a pretreatment CA 19-9 of 1672.3 U/ml as 1672.3\n\n**2.** Record 0.1 when the lab results are stated as less than 0.1 U/ml with no exact value.\n\n**3:** A known lab value takes priority over codes XXXX.2 and XXXX.3\n* The lab value takes priority even if the physician documents the interpretation\n * ***Example:*** Patient noted to have a CA 19-9 of 3,219. Physician notes that the value is elevated\n * Code 3219.0 instead of XXXX.3 (elevated)", + "coding_guidelines" : "**1)** Record to the nearest tenth in Units/milliliter (U/ml), the highest CA 19-9 lab value documented in the medical record prior to treatment. \n * ***Example 1***: Code a pretreatment CA 19-9 of 7 U/ml as 7.0\n * ***Example 2***: Code a pretreatment CA 19-9 of 1672.3 U/ml as 1672.3\n\n**2)** Record 0.1 when the lab results are stated as less than 0.1 U/ml with no exact value.\n\n**3)** A known lab value takes priority over codes XXXX.2 and XXXX.3\n* The lab value takes priority even if the physician documents the interpretation\n * ***Example:*** Patient noted to have a CA 19-9 of 3,219. Physician notes that the value is elevated\n * Code 3219.0 instead of XXXX.3 (elevated)", "rationale" : "CA 19-9 Pretreatment Lab Value is a strong predictor of resectability in the absence of metastatic disease. It is a new data item for cases diagnosed 1/1/2021+." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/cea_pretx_interpretation_99474.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/cea_pretx_interpretation_99474.json index f47a621c8..efa372cdd 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/cea_pretx_interpretation_99474.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/cea_pretx_interpretation_99474.json @@ -4,9 +4,9 @@ "version" : "3.3", "name" : "CEA Pretreatment Interpretation", "title" : "CEA (Carcinoembryonic Antigen) Pretreatment Interpretation", - "description" : "CEA (Carcinoembryonic Antigen) Pretreatment Interpretation refers to the interpretation of the CEA value prior to treatment. CEA is a nonspecific tumor marker that has prognostic significance for colon and rectum cancer.\n\nCEA is\n**1)** A protein molecule found in many different cells of the body but associated with certain tumors and with the developing fetus. \n**2)** CEA is used as a tumor marker especially for gastrointestinal cancers, as colorectal cancer is the most frequent cause for an increased/elevated CEA. \n**3)** CEA is also elevated by biliary obstruction, alcoholic hepatitis, and heavy smoking. \n**4)** CEA level is most frequently tested on blood serum, but it may be tested in body fluids and/or biopsy tissue. \n**5)** An abnormally high CEA level prior to tumor resection is expected to fall following successful removal of the cancer. \n**6)** An increasing value indicates possible recurrence.\n\nThere are 2 related data items that record information on CEA for Colon and Rectum.\n* 3820: CEA Pretreatment Lab Value\n* 3819: CEA Pretreatment Interpretation", + "description" : "CEA (Carcinoembryonic Antigen) Pretreatment Interpretation refers to the interpretation of the CEA value prior to treatment. CEA is a nonspecific tumor marker that has prognostic significance for colon and rectum cancer.\n\nCEA is\n**1)** A protein molecule found in many different cells of the body but associated with certain tumors and with the developing fetus. \n\n**2)** CEA is used as a tumor marker especially for gastrointestinal cancers, as colorectal cancer is the most frequent cause for an increased/elevated CEA. \n\n**3)** CEA is also elevated by biliary obstruction, alcoholic hepatitis, and heavy smoking. \n\n**4)** CEA level is most frequently tested on blood serum, but it may be tested in body fluids and/or biopsy tissue. \n\n**5)** An abnormally high CEA level prior to tumor resection is expected to fall following successful removal of the cancer. \n\n**6)** An increasing value indicates possible recurrence.\n\nThere are 2 related data items that record information on CEA for Colon and Rectum.\n* 3820: CEA Pretreatment Lab Value\n* 3819: CEA Pretreatment Interpretation", "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of CEA (Carcinoembryonic Antigen) Interpretation can be used to code this data item when no other information is available. \n\n**Note 2:** **Pretreatment results only** \n* Record the interpretation of the highest CEA test result documented in the medical record **prior to treatment or a polypectomy**.\n\n**Note 3:** **Related data item**.\n* The same laboratory test should be used to record information in the related data item 3820: CEA Lab Value", - "last_modified" : "2025-02-24T13:33:39.831Z", + "last_modified" : "2025-11-06T17:28:49.408Z", "definition" : [ { "key" : "cea_pretx_interpretation", "name" : "Code", @@ -17,7 +17,7 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "0", "CEA negative/normal; within normal limits" ], [ "1", "CEA positive/elevated" ], [ "2", "Borderline" ], [ "3", "Undetermined if positive or negative (normal values not available)\nAND no MD interpretation" ], [ "7", "Test ordered, results not in chart" ], [ "8", "Not applicable: Information not collected for this case\n(If this data item is required by your standard setter, use of code 8 will result in an edit error.)" ], [ "9", "Not documented in medical record\nCEA (Carcinoembryonic Antigen) Pretreatment Interpretation not assessed or unknown if assessed" ] ], - "additional_info" : "**Source documents:** clinical laboratory report, sometimes pathology or cytology report; H&P, operative report; consultant report; discharge summary\n\n**Other names include** Carcinoembryonic antigen\n\n**Reference ranges**\n* Nonsmoker: < 2.5 ng/ml (SI: < 2.5 mg/L) SI Conversion: 1 mg/L = 1 ng/ml.\n* Smoker: < 5 ng/ml (SI: < 5 mg/L) SI Conversion: 1 mg/mL = 1 ng/L", + "additional_info" : "**Source documents:** clinical laboratory report, sometimes pathology or cytology report; H&P, operative report; consultant report; discharge summary\n\n**Other names include** Carcinoembryonic antigen\n\n**Reference ranges**\n* Nonsmoker: < 2.5 ng/ml (SI: < 2.5 mg/L) SI Conversion: 1 mg/L = 1 ng/ml\n* Smoker: < 5 ng/ml (SI: < 5 mg/L) SI Conversion: 1 mg/mL = 1 ng/L", "coding_guidelines" : "**1)** Record the clinician’s interpretation of the highest value **prior to treatment**, based on the reference range used by the lab in the Interpretation data item.\n* If the physician's statement is not available, use the **Reference Ranges** included in **Additional Information** for this data item to determine the interpretation\n\n**2)** **Code 3** when a CEA value was documented in the record, but there is no statement that the CEA is positive/elevated, negative/normal, and the normal range (from which you can determine interpretation), is not documented.", "rationale" : "CEA (Carcinoembryonic Antigen) is a Registry Data Collection Variable for AJCC 8. CEA (Carcinoembryonic Antigen) Pretreatment Interpretation was previously collected as Colon and Rectum, CS SSF #1." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/cea_pretx_lab_value_33864.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/cea_pretx_lab_value_33864.json index d7d3e286d..7e55cad8b 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/cea_pretx_lab_value_33864.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/cea_pretx_lab_value_33864.json @@ -4,9 +4,9 @@ "version" : "3.3", "name" : "CEA Pretreatment Lab Value", "title" : "CEA (Carcinoembryonic Antigen) Pretreatment Lab Value", - "description" : "CEA (Carcinoembryonic Antigen) Pretreatment Lab Value records the CEA value prior to treatment. CEA is a nonspecific tumor marker that has prognostic significance for colon and rectum cancer.\n\nCEA is\n**1)** A protein molecule found in many different cells of the body but associated with certain tumors and with the developing fetus. \n**2)** CEA is used as a tumor marker especially for gastrointestinal cancers, as colorectal cancer is the most frequent cause for an increased/elevated CEA. \n**3)** CEA is also elevated by biliary obstruction, alcoholic hepatitis, and heavy smoking. \n**4)** CEA level is most frequently tested on blood serum, but it may be tested in body fluids and/or biopsy tissue. \n**5)** An abnormally high CEA level prior to tumor resection is expected to fall following successful removal of the cancer. \n**6)** An increasing value indicates possible recurrence.\n\nThere are 2 related data items that record information on CEA for Colon and Rectum.\n* 3820: CEA Pretreatment Lab Value\n* 3819: CEA Pretreatment Interpretation", + "description" : "CEA (Carcinoembryonic Antigen) Pretreatment Lab Value records the CEA value prior to treatment. CEA is a nonspecific tumor marker that has prognostic significance for colon and rectum cancer.\n\nCEA is\n**1)** A protein molecule found in many different cells of the body but associated with certain tumors and with the developing fetus. \n\n**2)** CEA is used as a tumor marker especially for gastrointestinal cancers, as colorectal cancer is the most frequent cause for an increased/elevated CEA. \n\n**3)** CEA is also elevated by biliary obstruction, alcoholic hepatitis, and heavy smoking. \n\n**4)** CEA level is most frequently tested on blood serum, but it may be tested in body fluids and/or biopsy tissue. \n\n**5)** An abnormally high CEA level prior to tumor resection is expected to fall following successful removal of the cancer. \n\n**6)** An increasing value indicates possible recurrence.\n\nThere are 2 related data items that record information on CEA for Colon and Rectum.\n* 3820: CEA Pretreatment Lab Value\n* 3819: CEA Pretreatment Interpretation", "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of CEA (Carcinoembryonic Antigen) Pretreatment Lab Value can be used to code this data item when no other information is available. \n\n**Note 2:** **Pretreatment results only**\n* Record the interpretation of the highest CEA test result documented in the medical record **prior to treatment or a polypectomy**.\n\n**Note 3:** **Related data item**.\n* The same laboratory test should be used to record information in the related data item 3819: CEA Pretreatment Interpretation", - "last_modified" : "2025-02-24T13:32:52.438Z", + "last_modified" : "2025-11-06T17:28:18.394Z", "definition" : [ { "key" : "cea_pretx_lab_value", "name" : "Code", @@ -17,7 +17,7 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "0.0", "0.0 nanograms/milliliter (ng/ml) exactly" ], [ "0.1-9999.9", "0.1-9999.9 ng/ml\n(Exact value to nearest tenth in ng/ml)" ], [ "XXXX.1", "10,000 ng/ml or greater" ], [ "XXXX.7", "Test ordered, results not in chart" ], [ "XXXX.8", "Not applicable: Information not collected for this case\n(If this information is required by your standard setter, use of code XXXX.8 may result in an edit error.)" ], [ "XXXX.9", "Not documented in medical record\nCEA (Carcinoembryonic Antigen) Pretreatment Lab Value not assessed or unknown if assessed" ] ], - "additional_info" : "**Source documents:** clinical laboratory report, sometimes pathology or cytology report; H&P, operative report; consultant report; discharge summary\n\n**Other names include** Carcinoembryonic antigen\n\n**Reference ranges**\n* Nonsmoker: < 2.5 ng/ml (SI: < 2.5 mg/L) SI Conversion: 1 mg/L = 1 ng/ml.\n* Smoker: < 5 ng/ml (SI: < 5 mg/L) SI Conversion: 1 mg/mL = 1 ng/L", + "additional_info" : "**Source documents:** clinical laboratory report, sometimes pathology or cytology report; H&P, operative report; consultant report; discharge summary\n\n**Other names include** Carcinoembryonic antigen\n\n**Reference ranges**\n* Nonsmoker: < 2.5 ng/ml (SI: < 2.5 mg/L) SI Conversion: 1 mg/L = 1 ng/ml\n* Smoker: < 5 ng/ml (SI: < 5 mg/L) SI Conversion: 1 mg/mL = 1 ng/L", "coding_guidelines" : "**1)** Record the highest value prior to treatment in nanograms per milliliter (ng/ml) in the range 0.1 (1 ng/ml) to 9999.9 (9999 ng/ml) in the Lab Value data item and the\n\n**2)** Record to the nearest tenth in nanograms/milliliter (ng/ml) the highest CEA lab value documented in the medical record **prior to treatment or polypectomy**. (Code a pretreatment CEA of 7 ng/ml as 7.0).\n\n**3)** Record 0.1 when the lab results are stated as less than 0.1 ng/ml with no exact value.\n\n***Examples of CEA Lab Values***\n\n* CEA Lab Value 0 ng/ml - Code 0.0\n* CEA Lab Value 23.6 ng/ml- Code 23.6\n* CEA Lab Value 11,000-Code XXXX.1\n* CEA Lab Value = Test ordered, results not in chart- Code XXXX7 \n* CEA Lab Value = Not documented in medical record, CEA test not done, unknown if CEA test done - Code XXXX.9", "rationale" : "CEA (Carcinoembryonic Antigen) Pretreatment Lab Value is a Registry Data Collection Variable in AJCC. It was previously collected as Colon and Rectum, CS SSF #3." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/chromosome_19q_status_72683.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/chromosome_19q_status_72683.json index 46fab0a31..cbc442158 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/chromosome_19q_status_72683.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/chromosome_19q_status_72683.json @@ -6,7 +6,7 @@ "title" : "Chromosome 19q: Loss of Heterozygosity (LOH)", "description" : "Chromosome 19q: Loss of Heterozygosity (LOH) refers to the loss of genetic material normally found on the long arm of one of the patient's two copies of chromosome 19. Codeletion of Chromosome 1p and 19q is a diagnostic, prognostic and predictive marker for gliomas and is strongly associated with the oligodendroglioma phenotype.\n\nLoss of Heterozygosity Chromosome 1 p and Chromosome 19q are two genetic tests that are frequently done at the same time and reported together. Loss of heterozygosity (LOH) in a chromosome means that genetic material normally found in a specific area of a chromosome is missing. In other words, this is damage to the chromosome that results in failure of tumor suppression, which in turn may cause the development or progression of a malignancy. For 1p LOH, the specific chromosomal defect is on the short arm (p) of chromosome 1. For 19q LOH, the specific chromosomal defect is on the long arm (q) of chromosome 19.\n\nNormal cells have two complete copies of each chromosome, a state called heterozygosity. The loss of this section of the chromosome is associated with improved outcome. It can be used to aid diagnosis and to make treatment decisions because sensitivity to chemotherapy agents, such as lomustine, procarbazine, and vincristine, is increased with either 1p or 19q LOH. Special molecular diagnostic (polymerase chain reaction or gene amplification) tests look for missing genetic material. LOH for chromosome 1p and 19q is tested primarily for oligodendroglioma, anaplastic oligodendroglioma, oligoastrocytoma, and anaplastic oligoastrocytoma. It is infrequently tested for other gliomas, such as glioblastoma multiforme.", "notes" : "**Note 1:** **Physician Statement**\n* Physician statement of Chromosome 19qp deletion/LOH can be used to code this data item when no other information is available.\n\n**Note 2:** **Applicable histologies**\n* Below is a list of histologies/terms for which the Chromosome 1p test is commonly done. If the test was done, record the results, regardless of the histology. If the histology is not listed among those for which the Chromosome 1p test is commonly done, and the test result is not readily available, assume it was not done and code 9 for unknown.\n * 9382/3: Oligoastrocytoma (anaplastic, or NOS)\n * 9400/3: Diffuse astrocytoma (IDH mutant, IDH wild type, or NOS)\n * 9401/3: Anaplastic astrocytoma (IDH mutant, IDH wild type, or NOS)\n * 9411/3: Gemistocytic astrocytoma, IDH mutant\n * 9424/3: Anaplastic pleomorphic xanthoastrocytoma\n * 9430/3: Astroblastoma\n * 9440/3: Glioblastoma (epithelioid, IDH wild type, or NOS)\n * 9441/3: Giant cell glioblastoma\n * 9442/3: Gliosarcoma\n * 9445/3: Glioblastoma, IDH mutant\n * 9450/3: Oligodendroglioma (IDH mutant and 1p/19q codeleted, or NOS)\n * 9451/3: Anaplastic oligodendroglioma (IDH mutant and 1p/19q codeleted, or NOS)\n * 9505/3: Anaplastic ganglioglioma\n * 9530/3: Anaplastic (malignant) meningioma\n\n**Note 3:** **Related data item**\n* See also 3801: Chromosome 1p: Loss of Heterozygosity (LOH).", - "last_modified" : "2024-04-07T18:42:59.310Z", + "last_modified" : "2025-11-06T21:32:35.566Z", "definition" : [ { "key" : "chrom_19q_status", "name" : "Code", @@ -18,6 +18,6 @@ } ], "rows" : [ [ "0", "Chromosome 19q deletion/LOH not identified/not present" ], [ "1", "Chromosome 19q deletion/LOH present" ], [ "6", "Benign or borderline tumor" ], [ "7", "Test ordered, results not in chart" ], [ "8", "Not applicable: Information not collected for this case\n(If this item is required by your standard setter, use of code 8 will result in an edit error.)" ], [ "9", "Not documented in medical record\nCannot be determined by the pathologist\nChromosome 19q: LOH not assessed or unknown if assessed" ] ], "additional_info" : "**Source documents:** pathology report\n\n**Other names include** whole arm loss, allelic loss, gene deletion, 1p/19q fragment analysis", - "coding_guidelines" : "**1)** **Code 0** when the 1p/19q is not identified/not present \n**2)** **Code 1** when the 1p/19q is present\n**3)** **Code 6** for **Benign (/0)** or **Borderline (/1) tumors**\n**4)** **Code 9** when \n* **a.** No documentation in the medical record\n* **b.** 1p/19q test not done (not assessed)\n* **c.** Unknown if 1p/19q test was performed (unknown if assessed)", + "coding_guidelines" : "**1)** **Code 0** when the 1p/19q is not identified/not present \n\n**2)** **Code 1** when the 1p/19q is present\n\n**3)** **Code 6** for **Benign (/0)** or **Borderline (/1) tumors**\n\n**4)** **Code 9** when \n* No documentation in the medical record\n* 1p/19q test not done (not assessed)\n* Unknown if 1p/19q test was performed (unknown if assessed)", "rationale" : "Chromosome 19q: Loss of Heterozygosity (LOH) is a Registry Data Collection Variable in AJCC. It was previously collected as Brain, CS SSF #6." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/chromosome_1p_status_40269.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/chromosome_1p_status_40269.json index 52105719e..bb17e50da 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/chromosome_1p_status_40269.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/chromosome_1p_status_40269.json @@ -6,7 +6,7 @@ "title" : "Chromosome 1p: Loss of Heterozygosity (LOH)", "description" : "Chromosome 1p: Loss of Heterozygosity (LOH) refers to the loss of genetic material normally found on the short arm of one of the patient's two copies of chromosome 1. Codeletion of Chromosome 1p and 19q is a diagnostic, prognostic and predictive marker for gliomas and is strongly associated with the oligodendroglioma phenotype.\n\nLoss of Heterozygosity Chromosome 1 p and Chromosome 19q are two genetic tests that are frequently done at the same time and reported together. Loss of heterozygosity (LOH) in a chromosome means that genetic material normally found in a specific area of a chromosome is missing. In other words, this is damage to the chromosome that results in failure of tumor suppression, which in turn may cause the development or progression of a malignancy. For 1p LOH, the specific chromosomal defect is on the short arm (p) of chromosome 1. For 19q LOH, the specific chromosomal defect is on the long arm (q) of chromosome 19.\n\nNormal cells have two complete copies of each chromosome, a state called heterozygosity. The loss of this section of the chromosome is associated with improved outcome. It can be used to aid diagnosis and to make treatment decisions because sensitivity to chemotherapy agents, such as lomustine, procarbazine, and vincristine, is increased with either 1p or 19q LOH. Special molecular diagnostic (polymerase chain reaction or gene amplification) tests look for missing genetic material. LOH for chromosome 1p and 19q is tested primarily for oligodendroglioma, anaplastic oligodendroglioma, oligoastrocytoma, and anaplastic oligoastrocytoma. It is infrequently tested for other gliomas, such as glioblastoma multiforme.", "notes" : "**Note 1:** **Physician Statement**\n* Physician statement of Chromosome 1p deletion/LOH can be used to code this data item when no other information is available.\n\n**Note 2:** **Applicable histologies**\n* Below is a list of histologies/terms for which the Chromosome 1p test is commonly done. If the test was done, record the results, regardless of the histology. If the histology is not listed among those for which the Chromosome 1p test is commonly done, and the test result is not readily available, assume it was not done and code 9 for unknown.\n * 9382/3: Oligoastrocytoma (anaplastic, or NOS)\n * 9400/3: Diffuse astrocytoma (IDH mutant, IDH wild type, or NOS)\n * 9401/3: Anaplastic astrocytoma (IDH mutant, IDH wild type, or NOS)\n * 9411/3: Gemistocytic astrocytoma, IDH mutant\n * 9424/3: Anaplastic pleomorphic xanthoastrocytoma\n * 9430/3: Astroblastoma\n * 9440/3: Glioblastoma (epithelioid, IDH wild type, or NOS)\n * 9441/3: Giant cell glioblastoma\n * 9442/3: Gliosarcoma\n * 9445/3: Glioblastoma, IDH mutant\n * 9450/3: Oligodendroglioma (IDH mutant and 1p/19q codeleted, or NOS)\n * 9451/3: Anaplastic oligodendroglioma (IDH mutant and 1p/19q codeleted, or NOS)\n * 9505/3: Anaplastic ganglioglioma\n * 9530/3: Anaplastic (malignant) meningioma\n\n**Note 3:** **Related data item**\n* See also 3802: Chromosome 19q: Loss of Heterozygosity (LOH).", - "last_modified" : "2024-04-07T18:39:54.015Z", + "last_modified" : "2025-11-06T21:31:47.479Z", "definition" : [ { "key" : "chrom_1p_status", "name" : "Code", @@ -18,6 +18,6 @@ } ], "rows" : [ [ "0", "Chromosome 1p deletion/LOH not identified/not present" ], [ "1", "Chromosome 1p deletion/LOH identified/present" ], [ "6", "Benign or borderline tumor" ], [ "7", "Test ordered, results not in chart" ], [ "8", "Not applicable: Information not collected for this case\n(If this item is required by your standard setter, use of code 8 will result in an edit error.)" ], [ "9", "Not documented in medical record\nCannot be determined by the pathologist\nChromosome 1p deletion/LOH not assessed or unknown if assessed" ] ], "additional_info" : "**Source documents:** pathology report\n\n**Other names include** whole arm loss, allelic loss, gene deletion, 1p/19q fragment analysis", - "coding_guidelines" : "**1)** **Code 0** when the 1p/19q is not identified/not present \n**2)** **Code 1** when the 1p/19q is present\n**3)** **Code 6** for **Benign (/0)** or **Borderline (/1) tumors**\n**4)** **Code 9** when \n* **a.** No documentation in the medical record\n* **b.** 1p/19q test not done (not assessed)\n* **c.** Unknown if 1p/19q test was performed (unknown if assessed)", + "coding_guidelines" : "**1)** **Code 0** when the 1p/19q is not identified/not present \n\n**2)** **Code 1** when the 1p/19q is present\n\n**3)** **Code 6** for **Benign (/0)** or **Borderline (/1) tumors**\n\n**4)** **Code 9** when \n* No documentation in the medical record\n* 1p/19q test not done (not assessed)\n* Unknown if 1p/19q test was performed (unknown if assessed)", "rationale" : "Chromosome 1p: Loss of Heterozygosity (LOH) is a Registry Data Collection Variable in AJCC. It was previously collected as Brain, CS SSF #5." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/chromosome_3_status_93464.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/chromosome_3_status_93464.json index 162174736..b31eaa9de 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/chromosome_3_status_93464.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/chromosome_3_status_93464.json @@ -6,7 +6,7 @@ "title" : "Chromosome 3 Status", "description" : "Chromosome 3 Status refers to the partial or total loss of Chromosome 3, which is a prognostic factor for uveal melanoma.\n\nThe loss of an entire copy of chromosome 3, which occurs in about half of patients, is the most important indicator of poor prognosis for the uveal melanomas, particularly melanoma of the choroids and ciliary body. A variety of sophisticated tests can be used to determine chromosome 3 status. \n* Karyotyping\n* Fluorescence in situ hybridization\n* Comparative genomic hybridization\n* DNA polymorphism analysis (e.g., single nucleotide polymorphism, microsatellite)\n* Multiplex ligation probe amplification\n* Monosomy 3 means loss of chromosome 3. Determination of chromosome status may be affected by prior irradiation\n\nMonosomy 3, especially if combined with a frequently coexisting gain in chromosome 8q, is independently associated with metastatic risk. Chromosome 3 and 8 statuses may be determined with karyotyping or fluorescent in situ hybridization (FISH).", "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of chromosome 3 status can be used to code this data item when no other information is available.\n\n**Note 2:** **Related data item** \n* See related data item 3822: Chromosome 8q Status.", - "last_modified" : "2025-02-24T14:25:10.181Z", + "last_modified" : "2025-11-06T21:26:48.523Z", "definition" : [ { "key" : "chrom_3_status", "name" : "Code", @@ -17,7 +17,7 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "0", "No loss of chromosome 3" ], [ "1", "Partial loss of chromosome 3" ], [ "2", "Complete loss of chromosome 3" ], [ "3", "Loss of chromosome 3, NOS\nLoss of BAP1 expression" ], [ "7", "Test ordered, results not in chart" ], [ "8", "Not applicable: Information not collected for this case\n(If this information is required by your standard setter, use of code 8 may result in an edit error.)" ], [ "9", "Not documented in medical record\nChromosome 3 status not assessed or unknown if assessed" ] ], - "additional_info" : "**Source Documents:** pathology report, specialty/reference lab report, gene expression profile report, other statement in medical record\n\n**Other names include** Monosomy 3, loss of chromosome 3, chromosome 3 loss of heterozygosity (LOH), isodisomy 3 (rare)\n\nFor further information, refer to the **Uveal Melanoma** cancer protocol published by the College of American Pathologist for the AJCC Staging System *Uveal Melanoma*", - "coding_guidelines" : "**1)** **Code 0** when there is no loss of chromosome 3, or disomy 3\n**2)** **Code 1** when there is partial loss of chromosome 3\n**3)** **Code 2** when there is complete loss of chromosome 3, or monosomy 3\n**4)** **Code 3** when there is loss of chromosome 3, how much not known\n**5)** **Code 9** when\n* No documentation in the medical record\n* Chromosome 3 not evaluated (assessed)\n* Unknown if Chromosome 3 evaluated (assessed)\n* Patients received radiation therapy prior to testing", + "additional_info" : "**Source Documents:** pathology report, specialty/reference lab report, gene expression profile report, other statement in medical record\n\n**Other names include** Monosomy 3, loss of chromosome 3, chromosome 3 loss of heterozygosity (LOH), isodisomy 3 (rare)\n\nFor further information, refer to the **Uveal Melanoma** cancer protocol published by the College of American Pathologist for the AJCC Staging System *Uveal Melanoma*.", + "coding_guidelines" : "**1)** **Code 0** when there is no loss of chromosome 3, or disomy 3\n\n**2)** **Code 1** when there is partial loss of chromosome 3\n\n**3)** **Code 2** when there is complete loss of chromosome 3, or monosomy 3\n\n**4)** **Code 3** when there is loss of chromosome 3, how much not known\n\n**5)** **Code 9** when\n* No documentation in the medical record\n* Chromosome 3 not evaluated (assessed)\n* Unknown if Chromosome 3 evaluated (assessed)\n* Patients received radiation therapy prior to testing", "rationale" : "Chromosome 3 Status is a Registry Data Collection Variable in AJCC. This data item was previously collected as Uveal Melanoma, CS SSF #5." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/chromosome_8q_status_83582.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/chromosome_8q_status_83582.json index 108f4a93e..2d324c75a 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/chromosome_8q_status_83582.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/chromosome_8q_status_83582.json @@ -6,7 +6,7 @@ "title" : "Chromosome 8q Status", "description" : "Chromosome 8q Status refers to gain in Chromosome 8q, which is a prognostic factor for uveal melanoma.\n\nThe loss of an entire copy of chromosome 8, which occurs in about half of patients, is the most important indicator of poor prognosis for the uveal melanomas, particularly melanoma of the choroids and ciliary body. A variety of sophisticated tests can be used to determine chromosome 8 status \n* Karyotyping\n* Fluorescence in situ hybridization\n* Comparative genomic hybridization\n* DNA polymorphism analysis (e.g., single nucleotide polymorphism, microsatellite).\n* Multiplex ligation probe amplification\n\nMonosomy 3, especially if combined with a frequently coexisting gain in chromosome 8q, is independently associated with metastatic risk. Chromosome 3 and 8 statuses may be determined with karyotyping or fluorescent in situ hybridization (FISH).", "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of chromosome 8q status can be used to code this data item when no other information is available.\n\n**Note 2:** **Related data item** \n* See related data item 3821: Chromosome 3 Status.", - "last_modified" : "2025-02-24T14:25:37.637Z", + "last_modified" : "2025-11-06T21:27:05.578Z", "definition" : [ { "key" : "chrom_8q_status", "name" : "Code", @@ -18,6 +18,6 @@ } ], "rows" : [ [ "0", "No gain in chromosome 8q" ], [ "1", "Gain in chromosome 8q" ], [ "7", "Test ordered, results not in chart" ], [ "8", "Not applicable: Information not collected for this case\n(If this information is required by your standard setter, use of code 8 may result in an edit error.)" ], [ "9", "Not documented in medical record\nChromosome 8q status not assessed or unknown if assessed" ] ], "additional_info" : "**Source Documents:** pathology report, specialty/reference lab report, gene expression profile report, other statement in medical record\n\n**Other names include:** 8q duplication, 8q trisomy, duplication 8q, partial trisomy 8q, trisomy 8q\n\nFor further information, refer to the **Uveal Melanoma** cancer protocol published by the College of American Pathologist for the AJCC Staging System *Uveal Melanoma*.", - "coding_guidelines" : "**1)** **Code 0** when there is no gain in chromosome 8q\n**2)** **Code 1** when there is gain in chromosome 8q\n**3)** **Code 9** when\n* No documentation in the medical record\n* Chromosome 8q not evaluated (assessed)\n* Unknown if Chromosome 8q evaluated (assessed)\n* Patients received radiation therapy prior to testing", + "coding_guidelines" : "**1)** **Code 0** when there is no gain in chromosome 8q\n\n**2)** **Code 1** when there is gain in chromosome 8q\n\n**3)** **Code 9** when\n* No documentation in the medical record\n* Chromosome 8q not evaluated (assessed)\n* Unknown if Chromosome 8q evaluated (assessed)\n* Patients received radiation therapy prior to testing", "rationale" : "Chromosome 8q Status is a Registry Data Collection Variable in AJCC. This data item was previously collected as Uveal Melanoma, CS SSF #7." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/circumferential_resection_margin_77909.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/circumferential_resection_margin_77909.json index 848116851..b1ce78e59 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/circumferential_resection_margin_77909.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/circumferential_resection_margin_77909.json @@ -5,9 +5,9 @@ "name" : "Circumferential Resection Margin (CRM)", "title" : "Circumferential Resection Margin (CRM)", "subtitle" : "Circumferential or Radial Resection Margin (CRM)", - "description" : "Circumferential or Radial Resection Margin, the distance in millimeters between the leading edge of the tumor and the surgically dissected margin as recorded on the pathology report, is a prognostic indicator for colon and rectal cancer. This may also be referred to as the Radial Resection Margin or surgical clearance.\n\nThe CRM, also referred to as the radial margin or the mesenteric resection margin, is the measurement of the distance from the deepest invasion of the tumor to the margin of resection in the retroperitoneum or mesentery. In other words, the CRM is the width of the surgical margin at the deepest part of the tumor in an area of the large intestine or rectum without serosa (non-peritonealized rectum below the peritoneal reflection) or only partly covered by serosa (upper rectum, posterior aspects of ascending and descending colon).\n\nFor segments of the colon completely encased by peritoneum, the mesenteric resection margin is the only relevant circumferential margin.\n\nThe CRM is not the same as the distance to the proximal and distal margins of the colon specimen. For rectal cancers, the circumferential resection margin is the most important predictor of local-regional recurrence.\n\nPer the AJCC Staging System Colon and Rectum, \"the CRM is the distance in millimeters between the deepest point of tumor invasion in the primary cancer and the margin of resection in the retroperitoneum or mesentery.\"", - "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of Circumferential or Radial Resection Margin can be used to code this data item when no other information is available, provided the criteria for evaluation has been met *(see Note 2)*.\n\n**Note 2:** **Criteria for evaluating CRM**\n* A surgical resection must be done to evaluate circumferential resection margin.\n* See *Coding Guidelines #3 and #4* for further information\n\n**Note 3:** **Exact measurements versus XX codes**\n**An exact measurement takes precedence over codes 0.0 and those beginning with XX**. Exact measurement also takes priority even if the pathologist states the margin is positive.\n * ***Example:*** CRM stated as 0.3 mm in Final Diagnosis and Synoptic states: Circumferential (Radial) Margin Interpreted as involved by invasive carcinoma (tumor less than 1mm from margin).\n * Code the 0.3 mm instead of 0.0 (margin involved with tumor). \n * Code 0.0 is for positive margins, or margin is less than 0.1 mm.", - "last_modified" : "2025-03-28T20:30:37.251Z", + "description" : "Circumferential or Radial Resection Margin, the distance in millimeters between the leading edge of the tumor and the surgically dissected margin as recorded on the pathology report, is a prognostic indicator for colon and rectal cancer. This may also be referred to as the Radial Resection Margin or surgical clearance.\n\nThe CRM, also referred to as the radial margin or the mesenteric resection margin, is the measurement of the distance from the deepest invasion of the tumor to the margin of resection in the retroperitoneum or mesentery. In other words, the CRM is the width of the surgical margin at the deepest part of the tumor in an area of the large intestine or rectum without serosa (non-peritonealized rectum below the peritoneal reflection) or only partly covered by serosa (upper rectum, posterior aspects of ascending and descending colon).\n\nFor segments of the colon completely encased by peritoneum, the mesenteric resection margin is the only relevant circumferential margin.\n\nThe CRM is not the same as the distance to the proximal and distal margins of the colon specimen. For rectal cancers, the circumferential resection margin is the most important predictor of local-regional recurrence.\n\nPer the AJCC Staging System Colon and Rectum, \"the CRM is the distance in millimeters between the deepest point of tumor invasion in the primary cancer and the margin of resection in the retroperitoneum or mesentery\".", + "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of Circumferential or Radial Resection Margin can be used to code this data item when no other information is available, provided the criteria for evaluation has been met *(see Note 2)*.\n\n**Note 2:** **Criteria for evaluating CRM**\n* A surgical resection must be done to evaluate circumferential resection margin.\n* See *Coding Guidelines #3 and #4* for further information\n\n**Note 3:** **Exact measurements versus XX codes**\n\n**An exact measurement takes precedence over codes 0.0 and those beginning with XX**. Exact measurement also takes priority even if the pathologist states the margin is positive.\n * ***Example:*** CRM stated as 0.3 mm in Final Diagnosis and Synoptic states: Circumferential (Radial) Margin Interpreted as involved by invasive carcinoma (tumor less than 1mm from margin).\n * Code the 0.3 mm instead of 0.0 (margin involved with tumor). \n * Code 0.0 is for positive margins, or margin is less than 0.1 mm.", + "last_modified" : "2025-11-06T17:56:40.836Z", "definition" : [ { "key" : "crm", "name" : "Code", @@ -18,7 +18,7 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "0.0", "Circumferential resection margin (CRM) positive\nMargin IS involved with tumor\nDescribed as \"less than 0.1 millimeter (mm)\"" ], [ "0.1-99.9", "Distance of tumor from margin: 0.1- 99.9 millimeters (mm)\n(Exact size to nearest tenth of millimeter)" ], [ "XX.0", "100 mm or greater" ], [ "XX.1", "Margins clear, distance from tumor not stated\nCircumferential or radial resection margin negative, NOS\nNo residual tumor identified on specimen" ], [ "XX.2", "Margins cannot be assessed" ], [ "XX.3", "Described as \"at least\" 1 mm" ], [ "XX.4", "Described as \"at least\" 2 mm" ], [ "XX.5", "Described as \"at least\" 3 mm" ], [ "XX.6", "Described as \"greater than\" 3 mm" ], [ "XX.7", "No resection of primary site \nSurgical procedure did not remove enough tissue to measure the circumferential or radial resection margin\n(Examples include: polypectomy only, endoscopic mucosal resection (EMR), excisional biopsy only, transanal disk excision)" ], [ "XX.8", "Not applicable: Information not collected for this case\n(If this information is required by your standard setter, use of code XX.8 may result in an edit error.)" ], [ "XX.9", "Not documented in medical record\nNon-invasive neoplasm (behavior /2)\nCircumferential or radial resection margin not assessed or unknown if assessed" ] ], - "additional_info" : "**Source documents:** pathology report.\n\n**Other names include** circumferential radial margin, mesenteric (mesocolon) (mesorectal) margin, mesenteric excision plane, pericolonic resection margin, radial margin, soft tissue margin.\n\nFor further information refer to the **Colon and Rectum** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Colon and Rectum*", - "coding_guidelines" : "The following guidelines were developed for the coding of surgery codes in relation to CRM. These guidelines were confirmed by the CAP Cancer Committee.\n\n**1)** Record in Millimeters (mm) to the nearest tenth the distance between the leading edge of the tumor and the nearest edge of surgically dissected margin as recorded in the pathology report. \n * ***Examples:*** CRM is 2 mm, code 2.0; CRM is 2.78 mm, code 2.8\n\n**2)** **If the value is recorded in Centimeters**, multiply by 10 to get the value in Millimeters (mm). \n * ***Example:*** CRM recorded as 0.2 cm. Multiply 0.2 x 10 and record 2.0\n\n**3)** For **Colon** primaries, surgery of primary site must be a surgical resection\n * If surgery of primary site is not a surgical resection (i.e. polypectomy, excisional biopsy), then CRM must be coded as XX.7\n\n**4)** For **Rectal** primaries, surgery of primary site must be coded as excisional biopsy, transanal excision or surgical resection\n* For excisional biopsy, or transanal procedures, the tumor must be located in the peritonealized portion of the rectum. Only the peritonealized portion of the rectum is where you can get the CRM from these procedures \n * If the non-peritonealized portion of the rectum is involved or it’s unknown if the peritonealized portion of the rectum is involved, code XX.7\n * If surgery of primary site is not an excisional biopsy, transanal excision or surgical resection, code XX.7\n\n**5)** **Code 0.0** If the margin is involved (positive) \n**6)** **Code 0.0** if the margin is described as less than 0.1 mm with no more specific measurement\n**7)** **Code XX.0** for margins described as greater than 100 mm \n**8)** **Codes 0.1-99.9** are for coding the exact measurement in millimeters of the negative margin. \n**9)** **Code XX.1** when the margin is stated as clear, but the distance is not available.\n**10)** **Code XX.2** when the pathology reports/CAP checklist states that the margin cannot be assessed/evaluated. \n**11** **Codes XX.3-XX.6** is for when the pathology uses “at least” categories.\n**12)** **Code XX.7** when there is no surgical resection of the primary site.\n**13)** **Code XX.9** when\n * Not documented in the medical record\n * CRM is not evaluated (assessed)\n * Checked “Not applicable: Radial or Mesenteric Margin” on CAP Checklist\n * Pathology report describes only distal and proximal margins, or margins, NOS\n * Unknown if CRM is evaluated (assessed)", + "additional_info" : "**Source documents:** pathology report\n\n**Other names include** circumferential radial margin, mesenteric (mesocolon) (mesorectal) margin, mesenteric excision plane, pericolonic resection margin, radial margin, soft tissue margin\n\nFor further information refer to the **Colon and Rectum** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Colon and Rectum*.", + "coding_guidelines" : "The following guidelines were developed for the coding of surgery codes in relation to CRM. These guidelines were confirmed by the CAP Cancer Committee.\n\n**1)** Record in Millimeters (mm) to the nearest tenth the distance between the leading edge of the tumor and the nearest edge of surgically dissected margin as recorded in the pathology report. \n * ***Examples:*** CRM is 2 mm, code 2.0; CRM is 2.78 mm, code 2.8\n\n**2)** **If the value is recorded in Centimeters**, multiply by 10 to get the value in Millimeters (mm). \n * ***Example:*** CRM recorded as 0.2 cm. Multiply 0.2 x 10 and record 2.0\n\n**3)** For **Colon** primaries, surgery of primary site must be a surgical resection\n * If surgery of primary site is not a surgical resection (i.e. polypectomy, excisional biopsy), then CRM must be coded as XX.7\n\n**4)** For **Rectal** primaries, surgery of primary site must be coded as excisional biopsy, transanal excision or surgical resection\n* For excisional biopsy, or transanal procedures, the tumor must be located in the peritonealized portion of the rectum. Only the peritonealized portion of the rectum is where you can get the CRM from these procedures \n * If the non-peritonealized portion of the rectum is involved or it’s unknown if the peritonealized portion of the rectum is involved, code XX.7\n * If surgery of primary site is not an excisional biopsy, transanal excision or surgical resection, code XX.7\n\n**5)** **Code 0.0** If the margin is involved (positive) \n\n**6)** **Code 0.0** if the margin is described as less than 0.1 mm with no more specific measurement\n\n**7)** **Code XX.0** for margins described as greater than 100 mm \n\n**8)** **Codes 0.1-99.9** are for coding the exact measurement in millimeters of the negative margin. \n\n**9)** **Code XX.1** when the margin is stated as clear, but the distance is not available.\n\n**10)** **Code XX.2** when the pathology reports/CAP checklist states that the margin cannot be assessed/evaluated. \n\n**11** **Codes XX.3-XX.6** is for when the pathology uses “at least” categories.\n\n**12)** **Code XX.7** when there is no surgical resection of the primary site.\n\n**13)** **Code XX.9** when\n * Not documented in the medical record\n * CRM is not evaluated (assessed)\n * Checked “Not applicable: Radial or Mesenteric Margin” on CAP Checklist\n * Pathology report describes only distal and proximal margins, or margins, NOS\n * Unknown if CRM is evaluated (assessed)", "rationale" : "Circumferential or Radial Resection Margin is a Registry Data Collection Variable in AJCC. It was previously collected as Colon and Rectum CS SSF #6." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/creatinine_pretx_lab_value_56869.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/creatinine_pretx_lab_value_56869.json index 7a9c5caac..78647d391 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/creatinine_pretx_lab_value_56869.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/creatinine_pretx_lab_value_56869.json @@ -6,7 +6,7 @@ "title" : "Creatinine Pretreatment Lab Value", "description" : "Creatinine Pretreatment Lab Value, an indicator of kidney function, is required to calculate the Model for End-Stage Liver Disease (MELD) score, which is used to assign priority for liver transplant.\n\nCreatinine concentration in blood is a marker of renal function. Elevated levels are associated with severe liver disease. Creatinine can be measured in blood serum or urine, but these data items apply to blood levels only. Do not code urine creatinine or creatinine clearance in this field.\n\nThere are two methods of describing creatinine levels in the blood, weight in grams (milligrams per deciliter), usually used in the US, and molecular count in moles (micromoles per liter) in Canada. Conversion: 1 mg/dL = 17.1 umol/L. Code the unit of measure used by the facility laboratory. \n\nThe Model for End-Stage Liver Disease (MELD) is a numerical scale used to determine how urgently a patient with liver disease needs a liver transplant. Results from three routine lab tests are used to calculate the MELD score. Bilirubin, one of the tests, measures how effectively the liver excretes bile. The purpose of this scale was to help prioritize patients for liver transplant by estimating their risk of dying while waiting for transplant. \n\nThere are several related data items that are defined to record the MELD score. \n* 3813: Bilirubin Pretreatment Total Lab Value\n* 3814: Bilirubin Pretreatment Unit of Measure\n* 3824: Creatinine Pretreatment Lab Value\n* 3825: Creatinine Pretreatment Unit of Measure\n* 3860: International Normalized Ratio", "notes" : "**Note 1:** **Physician Statement**\n* Physician statement of Creatinine Pretreatment Lab Value can be used to code this data item when no other information is available. \n\n**Note 2:** **Pretreatment results only**\n* Record this data item based on a blood test performed at diagnosis (pre-treatment). Use the highest value available\n* Record the blood or serum creatinine value for this data item\n * Do not use urine results to code this data item.\n\n**Note 3:** **Related data item**\n* The same laboratory test should be used to record information in the related data item data item 3825: Creatinine Pretreatment Unit of Measure.", - "last_modified" : "2025-02-24T13:50:00.341Z", + "last_modified" : "2025-11-06T18:11:26.119Z", "definition" : [ { "key" : "creatinine_pretx_lab_value", "name" : "Code", @@ -17,7 +17,7 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "0.0", "0.0 milligram/deciliter (mg/dl)\n0.0 micromole/liter (umol/L)" ], [ "0.1-99.9", "0.1-99.9 milligram/deciliter (mg/dl)\n0.1-99.9 micromole/liter (umol/L)\n(Exact value to nearest tenth of mg/dl or umol/L)" ], [ "XX.1", "100 mg/dl or greater\n100 umol/L or greater" ], [ "XX.7", "Test ordered, results not in chart" ], [ "XX.8", "Not applicable: Information not collected for this case\n(If this item is required by your standard setter, use of code XX.8 will result in an edit error.)" ], [ "XX.9", "Not documented in medical record\nCreatinine Pretreatment Lab Value not assessed or unknown if assessed" ] ], - "additional_info" : "**Source documents:** clinical laboratory report (blood serum); value may be part of a metabolic or liver function panel\n\n**Other names include** Serum creatinine, plasma creatinine (PCr), blood creatinine, Creat, Cre. \n* Do not confuse with creatinine clearance or creatine; these are not the same tests. Do not code urine creatinine or creatinine clearance.\n\n**Normal Reference Range**\n* Women: 0.5-1.0 mg/dL (45-90 umol/L)\n* Men: 0.7-1.2 mg/dL (60-110 umol/L). Male values are usually higher due to greater muscle mass.\n* Normal value ranges may vary slightly among different laboratories", - "coding_guidelines" : "**1)** Record the highest value prior to treatment in the range 0.1 mg/ml to 999.9 mg/ml OR 0.1 umol/L to 999.9 umol/L. in the Lab Value data item and the unit of measure for measuring the lab value in the Unit of Measure data item.\n\n***Examples***\n* Creatinine Lab Value 0.0 mg/ml: Lab Value = 0.0, Unit Measure = 1\n* Creatinine Lab Value 0.7 umol/L: Lab Value = 0.7 Unit Measure = 2\n* Creatinine Lab Value 98.3: Lab Value = 98.3, Unit Measure = 9\n* Creatinine Lab Value Test Ordered, results not in chart: Lab Value = XXXX.7, Unit Measure = 7\n* Creatinine Lab Value Not documented in medical record, Bilirubin test not done, unknown if Bilirubin test done: Lab Value = XXXX.9, Unit Measure 9", + "additional_info" : "**Source documents:** clinical laboratory report (blood serum); value may be part of a metabolic or liver function panel\n\n**Other names include** Serum creatinine, plasma creatinine (PCr), blood creatinine, Creat, Cre \n* Do not confuse with creatinine clearance or creatine; these are not the same tests. Do not code urine creatinine or creatinine clearance.\n\n**Normal Reference Range**\n* Women: 0.5-1.0 mg/dL (45-90 umol/L)\n* Men: 0.7-1.2 mg/dL (60-110 umol/L). Male values are usually higher due to greater muscle mass.\n* Normal value ranges may vary slightly among different laboratories.", + "coding_guidelines" : "**1)** Record the highest value prior to treatment in the range 0.1 mg/ml to 999.9 mg/ml OR 0.1 umol/L to 999.9 umol/L in the Lab Value data item and the unit of measure for measuring the lab value in the Unit of Measure data item.\n\n***Examples***\n* Creatinine Lab Value 0.0 mg/ml: Lab Value = 0.0, Unit Measure = 1\n* Creatinine Lab Value 0.7 umol/L: Lab Value = 0.7 Unit Measure = 2\n* Creatinine Lab Value 98.3: Lab Value = 98.3, Unit Measure = 9\n* Creatinine Lab Value Test Ordered, results not in chart: Lab Value = XXXX.7, Unit Measure = 7\n* Creatinine Lab Value Not documented in medical record, Bilirubin test not done, unknown if Bilirubin test done: Lab Value = XXXX.9, Unit Measure 9", "rationale" : "Creatinine Pretreatment Lab Value is a Registry Data Collection Variable in AJCC. This data item was previously collected for Liver, CS SSF #4." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/creatinine_pretx_unit_26973.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/creatinine_pretx_unit_26973.json index 2ac2471e4..75bb421c4 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/creatinine_pretx_unit_26973.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/creatinine_pretx_unit_26973.json @@ -6,7 +6,7 @@ "title" : "Creatinine Pretreatment Unit of Measure", "description" : "Creatinine Pretreatment Unit of Measure identifies the unit of measure for the creatinine value measured in blood or serum prior to treatment. Creatinine is commonly measured in units of Milligrams/deciliter (mg/dL) in the United States and Micromoles/liter (umol/L) in Canada and Europe.\n\nThere are two methods of describing creatinine levels in the blood, weight in grams (milligrams per deciliter), usually used in the US, and molecular count in moles (micromoles per liter) in Canada. Conversion: 1 mg/dL = 17.1 mol/L. Code the unit of measure used by the facility laboratory. \n\nThere are two related data items that record information on Creatinine. \n* 3824: Creatinine Pretreatment Lab Value.\n* 3825: Creatinine Pretreatment Unit of Measure", "notes" : "**Note 1:** **Physician Statement**\n* Physician statement of Creatinine Pretreatment Unit of Measure can be used to code this data item when no other information is available.\n\n**Note 2:** **Pretreatment results only**\n* Record this data item based on a blood test performed at diagnosis (pre-treatment). Use the highest value available\n* Record the blood or serum creatinine value for this data item\n * Do not use urine results to code this data item. \n\n**Note 3:** **Measurement definitions** \n* There are two main methods of describing concentrations: by weight, and by molecular count.\n* Weights are recorded in grams, and molecular counts are recorded in moles.\n* Milligrams/deciliter (mg/dL) is the unit of measure commonly used in the United States.\n* Micromoles/liter (umol/L) is the designated Systeme International (SI) unit of measure commonly used in Canada and Europe.\n * 1 mg/dL of bilirubin is 17.1 umol/L.\n\n**Note 4:** **Related data item**\n* The same laboratory test should be used to record information in the related data item data item 3824: Creatinine Pretreatment Lab Value.", - "last_modified" : "2025-02-24T15:54:47.074Z", + "last_modified" : "2025-11-05T21:54:53.753Z", "definition" : [ { "key" : "creatinine_pretx_unit", "name" : "Code", @@ -17,6 +17,6 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "1", "Milligrams/deciliter (mg/dL)" ], [ "2", "Micromoles/liter (umol/L)" ], [ "7", "Test ordered, results not in chart " ], [ "8", "Not applicable: Information not collected for this case\n(If this item is required by your standard setter, use of code 8 will result in an edit error.)" ], [ "9", "Not documented in medical record\nCreatinine unit of measure not assessed or unknown if assessed" ] ], - "additional_info" : "**Source documents:** clinical laboratory report (blood serum); value may be part of a metabolic or liver function panel\n\n**Other names include** Serum creatinine, plasma creatinine (PCr), blood creatinine, Creat, Cre. \n* Do not confuse with creatinine clearance or creatine; these are not the same tests. Do not code urine creatinine or creatinine clearance.\n\n**Normal Reference Range**\n* Women: 0.5-1.0 mg/dL (45-90 umol/L)\n* Men: 0.7-1.2 mg/dL (60-110 umol/L). Male values are usually higher due to greater muscle mass.\n* Normal value ranges may vary slightly among different laboratories.", + "additional_info" : "**Source documents:** clinical laboratory report (blood serum); value may be part of a metabolic or liver function panel\n\n**Other names include** Serum creatinine, plasma creatinine (PCr), blood creatinine, Creat, Cre\n* Do not confuse with creatinine clearance or creatine; these are not the same tests. Do not code urine creatinine or creatinine clearance.\n\n**Normal Reference Range**\n* Women: 0.5-1.0 mg/dL (45-90 umol/L)\n* Men: 0.7-1.2 mg/dL (60-110 umol/L). Male values are usually higher due to greater muscle mass.\n* Normal value ranges may vary slightly among different laboratories.", "rationale" : "Creatinine Pretreatment Unit of Measure identifies the unit of measure for the creatinine value measured in blood or serum prior to treatment. Creatinine is commonly measured in units of Milligrams/deciliter (mg/dL) in the United States and Micromoles/liter (umol/L) in Canada and Europe." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/egfr_mutational_analysis_51122.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/egfr_mutational_analysis_51122.json index b9a96be8b..85e59b70b 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/egfr_mutational_analysis_51122.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/egfr_mutational_analysis_51122.json @@ -6,7 +6,7 @@ "title" : "EGFR Mutational Analysis", "description" : "Epidermal growth factor receptor (EGFR) mutational analysis is performed for patients with advanced non-small cell lung cancer (NSCLC) to identify patients with certain activating mutations in the EGFR gene which are sensitive to tyrosine kinase Inhibitors.\n\n“EGFR (epidermal growth factor receptor) is a protein found on certain types of cells that binds to a substance called epidermal growth factor. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations (changes) in the EGFR gene cause EGFR proteins to be made in higher-than-normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly.” (NCI Dictionary of Cancer Terms https://www.cancer.gov/publications/dictionaries/cancer-terms)\n\nThe presence of Exon 20 EGFR activating mutations are associated with a resistance to EGFR tyrosine kinase inhibits, such as erlotinib, afatinib, and gefitinib. There is limited data available on response for some of the other uncommon EGFR mutations (other than Exon 20). (CAP Cancer Protocol).\n\nThe most common EGFR mutations are \n * Exon 18 Gly719\n * Exon 19 deletion\n * Exon 20 insertion\n * Exon 20 Thr790Met\n * Exon 21 Leu858Arg", "notes" : "**Note 1:** **Effective years** \n* This SSDI is effective for diagnosis years 2021+\n* For cases diagnosed 2018-2020, this SSDI must be blank\n\n**Note 2:** **Physician Statement** \n* Physician statement of EGFR can be used to code this data item when no other information is available.\n\n**Note 3:** **Applicable histologies/stages**\n* EGFR may be recorded for all histologies and stages; however, it is primarily performed for advanced non-small cell carcinomas. If information is not available, code 9.\n\n**Note 4:** **Neoadjuvant Therapy**\n* Record the assay from tumor specimens prior to neoadjuvant therapy.\n* If neoadjuvant therapy is given and there are no EGFR results from pre-treatment specimens, report the findings from post-treatment specimens.", - "last_modified" : "2025-02-24T15:58:23.468Z", + "last_modified" : "2025-11-06T18:28:03.484Z", "definition" : [ { "key" : "egfr_mutational_analysis", "name" : "Code", @@ -17,7 +17,7 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "0", "Normal \nEGFR negative, EGFR wild type\nNegative for mutations, no alterations, no mutations (somatic) identified, not present, not detected" ], [ "1", "Abnormal (mutated)/detected in exon(s) 18, 19, 20, and/or 21 " ], [ "2", "Abnormal (mutated)/detected but not in exon(s) 18, 19, 20, and/or 21" ], [ "4", "Abnormal (mutated)/detected, NOS, exon(s) not specified" ], [ "7", "Test ordered, results not in chart" ], [ "8", "Not applicable: Information not collected for this case\n(If this information is required by your standard setter, use of code 8 may result in an edit error.)" ], [ "9", "Not documented in medical record\nEGFR not assessed or unknown if assessed" ], [ "", "Must be blank if diagnosis year is before 2021" ] ], - "additional_info" : "**Source documents:** pathology report or clinical laboratory report\n\n**Other names include** Epidermal growth factor receptor tyrosine kinase inhibitor, ERBB, ERBB1, ErbB1, HER1\n\nFor further information, refer to the **Lung Biomarker Reporting** cancer protocol published by the College of American Pathologists", - "coding_guidelines" : "**1)** **Code 0** when EGFR normal/negative/not identified\n**2)** **Code 1 or 2** when EGFR identified/detected\n**3)** **Code 4** when EGFR identified, and there is no mention of the specific mutation \n**4)** **Code 9** when \n* Insufficient amount of tissue available to perform test\n* Test done and documented to be equivocal\n* No microscopic confirmation of tumor\n* EGFR mutational analysis not ordered or not done, or unknown if ordered or done", + "additional_info" : "**Source documents:** pathology report or clinical laboratory report\n\n**Other names include** Epidermal growth factor receptor tyrosine kinase inhibitor, ERBB, ERBB1, ErbB1, HER1\n\nFor further information, refer to the **Lung Biomarker Reporting** cancer protocol published by the College of American Pathologists.", + "coding_guidelines" : "**1)** **Code 0** when EGFR normal/negative/not identified\n\n**2)** **Code 1 or 2** when EGFR identified/detected\n\n**3)** **Code 4** when EGFR identified, and there is no mention of the specific mutation \n\n**4)** **Code 9** when \n* Insufficient amount of tissue available to perform test\n* Test done and documented to be equivocal\n* No microscopic confirmation of tumor\n* EGFR mutational analysis not ordered or not done, or unknown if ordered or done", "rationale" : "EGFR mutational analysis is recommended by treatment guidelines for patients with advanced lung cancer as a prognostic marker and factor in determining appropriate therapy. It is a new data item for cases diagnosed 1/1/2021+" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_13303.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_13303.json index 3e980378a..ea586facc 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_13303.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_13303.json @@ -5,7 +5,7 @@ "name" : "EOD Mets", "title" : "EOD Mets", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Phan, A.T., Perrier, N.D., et al. **Adrenal Cortical Carcinoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:31.039Z", + "last_modified" : "2025-11-14T20:05:12.261Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_14084.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_14084.json index 668dbfc99..f5d46662b 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_14084.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_14084.json @@ -5,7 +5,7 @@ "name" : "EOD Mets", "title" : "EOD Mets", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) **Anus**, from the AJCC Cancer Staging System Version 9 (2022). Used with permission of the American College of Surgeons, Chicago, Illinois.", - "last_modified" : "2025-09-18T20:41:46.093Z", + "last_modified" : "2025-11-14T20:05:51.890Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_20229.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_20229.json index 4c230e0ba..6f1bea9a6 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_20229.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_20229.json @@ -5,7 +5,7 @@ "name" : "EOD Mets", "title" : "EOD Mets", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Pollock, R.E., Maki, R.G. **Introduction to Soft Tissue Sarcoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Maki, R.G., Pollock, R.E., et al. **Soft Tissue Sarcoma - Unusual Histologies and Sites**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:40.934Z", + "last_modified" : "2025-11-14T20:06:10.849Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_2212.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_2212.json index ae2257e5f..a92a4b406 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_2212.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_2212.json @@ -5,7 +5,7 @@ "name" : "EOD Mets", "title" : "EOD Mets", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)", - "last_modified" : "2025-09-18T20:42:08.302Z", + "last_modified" : "2025-11-14T20:06:09.962Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_22645.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_22645.json index 465004fe8..2b945ea5d 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_22645.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_22645.json @@ -5,7 +5,7 @@ "name" : "EOD Mets", "title" : "EOD Mets", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Pollock, R.E., Maki, R.G. **Introduction to Soft Tissue Sarcoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Yoon, S.S., Maki, R.G., Pollock, R.E., et al. **Soft Tissue Sarcoma of the Trunk and Extremities**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:42.086Z", + "last_modified" : "2025-11-14T20:05:27.780Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_22894.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_22894.json index 62cc16c1b..17abd8843 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_22894.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_22894.json @@ -6,7 +6,7 @@ "title" : "EOD Mets", "notes" : "**Note 1:** **Benign/borderline tumors** \n* Code 00 for benign (behavior /0) and borderline (behavior /1) tumors.\n\n**Note 2:** **Distant metastasis** \n* Use code 70 when the only information is “distant metastasis, NOS,” and there is no documentation regarding the specific metastases.\n* If there are specific metastasis documented that are not listed in codes 15, 25, or 35, or 45, assign code 45 for “other specified distant metastasis.”\n\n**Note 3:** **Types of extension coded in this data item** \n* The following adjacent structures/sites, by direct or contiguous extension, are coded to 25. \n * Adjacent connective/soft tissue\n * Adjacent muscle\n * Bone\n * Circulating cells in cerebral spinal fluid (CSF)\n * Major blood vessel(s)\n * Meninges (e.g.; dura)\n * Multiple/multifocal tumors\n * Nerves (cranial, NOS)\n * Ventricular system\n\n**Note 4:** **Leptomeningeal metastases** \n* Leptomeningeal metastases, also known as carcinomatous meningitis and meningeal carcinomatosis, refers to the spread of malignant cells through the CSF space. \n* These cells can originate from primary CNS tumors (e.g., in the form of drop metastases), as well as from distant tumors that have metastasized via hematogenous spread (code 35).", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) **Brain and Spinal Cord**, from the AJCC Cancer Staging System Version 9 (2022). Used with permission of the American College of Surgeons, Chicago, Illinois.", - "last_modified" : "2025-09-18T20:41:46.478Z", + "last_modified" : "2025-11-14T20:05:55.436Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_23805.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_23805.json index 76d22eeff..ee4660a53 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_23805.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_23805.json @@ -5,7 +5,7 @@ "name" : "EOD Mets", "title" : "EOD Mets", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Pollock, R.E., Maki, R.G. **Introduction to Soft Tissue Sarcoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) O'Sullivan, B., Maki, R.G., Pollock, R.E., et al. **Soft Tissue Sarcoma of the Head and Neck**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:42:19.489Z", + "last_modified" : "2025-11-14T20:05:40.616Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_23953.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_23953.json index 34d5d0d51..28955661d 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_23953.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_23953.json @@ -5,7 +5,7 @@ "name" : "EOD Mets", "title" : "EOD Mets", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Pollock, R.E., Maki, R.G. **Introduction to Soft Tissue Sarcoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Pollock, R.E., Maki, R.G., et al. **Soft Tissue Sarcoma of the Retroperitoneum**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:42:20.935Z", + "last_modified" : "2025-11-14T20:05:18.870Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_24042.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_24042.json index 4f4aa2acc..3036a1e82 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_24042.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_24042.json @@ -6,7 +6,7 @@ "title" : "EOD Mets", "notes" : "**Note 1:** **Benign/borderline tumors** \n* Code 00 for benign (behavior /0) and borderline (behavior /1) tumors.\n\n**Note 2:** **Leptomeningeal metastases**\n* Leptomeningeal metastases, also known as carcinomatous meningitis and meningeal carcinomatosis, refers to the spread of malignant cells through the CSF space.\n* These cells can originate from primary CNS tumors (e.g., in the form of drop metastases), as well as from distant tumors that have metastasized via hematogenous spread (code 70).", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) **Brain and Spinal Cord**, from the AJCC Cancer Staging System Version 9 (2022). Used with permission of the American College of Surgeons, Chicago, Illinois.", - "last_modified" : "2025-09-18T20:41:59.859Z", + "last_modified" : "2025-11-14T20:05:54.586Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_24606.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_24606.json index bb5574e3a..95ddf49e0 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_24606.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_24606.json @@ -6,7 +6,7 @@ "title" : "EOD Mets", "notes" : "**Note 1:** **FIGO and metastatic disease detail** \n* When both the Federation Internationale de Gynecologie et d'Obstetrique (FIGO) stage and metastatic detail are available, record the code with metastatic detail in preference to a statement of FIGO stage.\n\n**Note 2:** **Extension to Vagina** \n* EOD Mets excludes metastasis to the vagina (See EOD Primary Tumor) or to the pelvic or paraaortic nodes (See EOD Regional Nodes)", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) **Cervix Uteri**, from the AJCC Cancer Staging System Version 9 (2020). Used with permission of the American College of Surgeons, Chicago, Illinois.", - "last_modified" : "2025-09-18T20:42:09.975Z", + "last_modified" : "2025-11-14T20:06:11.879Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_25000.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_25000.json index 10868dc43..df351f2c2 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_25000.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_25000.json @@ -6,7 +6,7 @@ "title" : "EOD Mets", "notes" : "**Note 1:** **Benign/borderline tumors** \n* Code 00 for benign (behavior /0) and borderline (behavior /1) tumors.\n\n**Note 2:** **Leptomeningeal metastases** \n* Leptomeningeal metastases, also known as carcinomatous meningitis and meningeal carcinomatosis, refers to the spread of malignant cells through the CSF space. \n* These cells can originate from primary CNS tumors (e.g., in the form of drop metastases), as well as from distant tumors that have metastasized via hematogenous spread (code 70).", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Laws, E.R., Curran, W.J., et al. **Brain and Spinal Cord**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:42:06.873Z", + "last_modified" : "2025-11-14T20:05:15.492Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_25281.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_25281.json index bbe39d595..7f1fd4d03 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_25281.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_25281.json @@ -5,7 +5,7 @@ "name" : "EOD Mets", "title" : "EOD Mets", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) McKiernan, J.M., Hansel, D.E., Stadler, W.M., et al. **Renal Pelvis and Ureter**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:37.325Z", + "last_modified" : "2025-11-14T20:05:49.237Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_26533.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_26533.json index 984ac34dc..01090e5b1 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_26533.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_26533.json @@ -6,7 +6,7 @@ "title" : "EOD Mets", "notes" : "**Note:** **FIGO and metastatic disease detail** \n* When both the Federation Internationale de Gynecologie et d'Obstetrique (FIGO) stage and metastatic detail are available, record the code with metastatic detail in preference to a statement of FIGO stage.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05.** American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging.** In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) **Introduction to Female Reproductive Organs**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Dizon, D.S., Olawaiye, A.B., Mutch, D.G., et al. **Corpus Uteri - Sarcoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:42:12.182Z", + "last_modified" : "2025-11-14T20:05:26.774Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_28878.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_28878.json index 87f7d840c..12035a2ad 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_28878.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_28878.json @@ -6,7 +6,7 @@ "title" : "EOD Mets", "notes" : "**Note 1:** **Benign/borderline tumors** \n* Code 00 for benign (behavior /0) and borderline (behavior /1) tumors.\n\n**Note 2:** **Leptomeningeal metastases** \n* Leptomeningeal metastases, also known as carcinomatous meningitis and meningeal carcinomatosis, refers to the spread of malignant cells through the CSF space. \n* These cells can originate from primary CNS tumors (e.g., in the form of drop metastases), as well as from distant tumors that have metastasized via hematogenous spread (code 70).", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) **Brain and Spinal Cord**, from the AJCC Cancer Staging System Version 9 (2022). Used with permission of the American College of Surgeons, Chicago, Illinois.", - "last_modified" : "2025-09-18T20:41:37.884Z", + "last_modified" : "2025-11-14T20:05:54.231Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_29252.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_29252.json index ba65f5790..441d8fda0 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_29252.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_29252.json @@ -5,7 +5,7 @@ "name" : "EOD Mets", "title" : "EOD Mets", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Lydiatt, W.M., Patel, S.G., Shah, J.P., et al. **Staging Head and Neck Cancers**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Lydiatt, W.M., Ridge, J.A., Shah, J.P., et al. **Oropharynx (p16-) and Hypopharynx**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:59.734Z", + "last_modified" : "2025-11-14T20:05:05.383Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_30426.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_30426.json index f12f35b74..96e21120c 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_30426.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_30426.json @@ -6,7 +6,7 @@ "title" : "EOD Mets", "notes" : "**Note:** **FIGO and metastatic disease detail** \n* When both the Federation Internationale de Gynecologie et d'Obstetrique (FIGO) stage and metastatic detail are available, record the code with metastatic detail in preference to a statement of FIGO stage.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05.** American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging.** In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) **Introduction to Female Reproductive Organs**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Powell, M.A., Olawaiye, A.B., Mutch, D.G., et al. **Corpus Uteri - Carcinoma and Carcinosarcoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:42:00.209Z", + "last_modified" : "2025-11-14T20:05:04.126Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_33408.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_33408.json index bac5ac65d..3b68c7cfb 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_33408.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_33408.json @@ -5,7 +5,7 @@ "name" : "EOD Mets", "title" : "EOD Mets", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Pollock, R.E., Maki, R.G. **Introduction to Soft Tissue Sarcoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Raut, C.P., Maki, R.G., Pollock, R.E., et al. **Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:42:16.349Z", + "last_modified" : "2025-11-14T20:06:09.489Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_34827.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_34827.json index cb333e633..0d57f6332 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_34827.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_34827.json @@ -5,7 +5,7 @@ "name" : "EOD Mets", "title" : "EOD Mets", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Pettaway, C.A., Srigley, J.R., Amin, M.B., et al. **Penis**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:42:11.679Z", + "last_modified" : "2025-11-14T20:05:48.782Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_3742.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_3742.json index 29026b9a8..ea7c51505 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_3742.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_3742.json @@ -5,7 +5,7 @@ "name" : "EOD Mets", "title" : "EOD Mets", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Lydiatt, W.M., Patel, S.G., Shah, J.P., et al. **Staging Head and Neck Cancers**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Califano, J.A., Lydiatt, W.M., Shah, J.P., et al. **Cutaneous Carcinoma of the Head and Neck**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:42:13.887Z", + "last_modified" : "2025-11-14T20:06:07.815Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_41985.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_41985.json index dd8f91c36..0257493b4 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_41985.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_41985.json @@ -5,7 +5,7 @@ "name" : "EOD Mets", "title" : "EOD Mets", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Welton, M.L., Jessup, J.M., et al. **Anus**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:58.288Z", + "last_modified" : "2025-11-14T20:05:37.112Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_47277.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_47277.json index e767e28b2..f649ebc10 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_47277.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_47277.json @@ -5,7 +5,7 @@ "name" : "EOD Mets", "title" : "EOD Mets", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Dutton, J.J., Finger, P.T., et al. **Orbital Sarcoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:34.390Z", + "last_modified" : "2025-11-14T20:05:36.215Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_53046.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_53046.json index 516cdd49b..a795c067e 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_53046.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_53046.json @@ -5,7 +5,7 @@ "name" : "EOD Mets", "title" : "EOD Mets", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Rosen, J.E., Lloyd, R.V., Perrier, N.D., et al. **Thyroid - Medullary**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:42:00.948Z", + "last_modified" : "2025-11-14T20:05:23.278Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_56430.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_56430.json index 8252a7d4e..fd783e249 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_56430.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_56430.json @@ -5,7 +5,7 @@ "name" : "EOD Mets", "title" : "EOD Mets", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Conway, R.M., Finger, P.T., et al. **Conjunctival Carcinoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:41.732Z", + "last_modified" : "2025-11-14T20:05:06.757Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_71734.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_71734.json index 5ffaf6d26..625458f7f 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_71734.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_71734.json @@ -5,7 +5,7 @@ "name" : "EOD Mets", "title" : "EOD Mets", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Lydiatt, W.M., Patel, S.G., Shah, J.P., et al. **Staging Head and Neck Cancers**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Lydiatt, W.M., Shah, J.P., et al. **Major Salivary Glands**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(7) **Salivary Glands**, from the AJCC Cancer Staging System Version 9 (2026). Used with permission of the American College of Surgeons, Chicago, Illinois.", - "last_modified" : "2025-09-18T20:41:55.763Z", + "last_modified" : "2025-11-14T20:05:06.360Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_74247.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_74247.json index 39c2a0928..2d5c7d3ec 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_74247.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_74247.json @@ -5,7 +5,7 @@ "name" : "EOD Mets", "title" : "EOD Mets", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Coupland, S.E., Finger, P.T., et al. **Conjunctival Melanoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:26.596Z", + "last_modified" : "2025-11-14T20:05:12.977Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_76404.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_76404.json index 247355131..47e99bd91 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_76404.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_76404.json @@ -5,7 +5,7 @@ "name" : "EOD Mets", "title" : "EOD Mets", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Pollock, R.E., Maki, R.G. **Introduction to Soft Tissue Sarcoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Raut, C.P., Maki, R.G., Pollock, R.E., et al. **Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:32.373Z", + "last_modified" : "2025-11-14T20:05:20.545Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_79894.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_79894.json index 203d2d740..f53aa9b47 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_79894.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_79894.json @@ -6,7 +6,7 @@ "title" : "EOD Mets", "notes" : "**Note:** **FIGO and metastatic disease detail** \n* When both the Federation Internationale de Gynecologie et d'Obstetrique (FIGO) stage and metastatic detail are available, record the code with metastatic detail in preference to a statement of FIGO stage.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05.** American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging.** In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) **Introduction to Female Reproductive Organs**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Dizon, D.S., Olawaiye, A.B., Mutch, D.G., et al. **Corpus Uteri - Sarcoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:42:06.516Z", + "last_modified" : "2025-11-14T20:05:52.363Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_80017.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_80017.json index fead0168f..59376d599 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_80017.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_80017.json @@ -5,7 +5,7 @@ "name" : "EOD Mets", "title" : "EOD Mets", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Lydiatt, W.M., Patel, S.G., Shah, J.P., et al. **Staging Head and Neck Cancers**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) O'Sullivan, B., Lydiatt, W.M., Shah, J.P., et al. **Oropharynx HPV-mediated (HPV-Associated) Cancer**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(7) Lydiatt, W.M., Ridge, J.A., Shah, J.P., et al. **Oropharynx (p16-) and Hypopharynx**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(8) **Oropharynx HPV-Associated**, from the AJCC Cancer Staging System Version 9 (2025). Used with permission of the American College of Surgeons, Chicago, Illinois.", - "last_modified" : "2025-09-18T20:41:46.841Z", + "last_modified" : "2025-11-14T20:06:05.690Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_83665.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_83665.json index 0948791d3..1fc4837cb 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_83665.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_83665.json @@ -5,7 +5,7 @@ "name" : "EOD Mets", "title" : "EOD Mets", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Hansel, D.E., Reuter, V.E., McKiernan, J.M., et al. **Urethra**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:42:14.973Z", + "last_modified" : "2025-11-14T20:05:11.746Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_88527.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_88527.json index ee049dc26..5fdcb065c 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_88527.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_88527.json @@ -6,7 +6,7 @@ "title" : "EOD Mets", "notes" : "**Note 1:** **Liver mets WITH other metastatic involvement** \n* Use code 50 only when there are liver metastasis WITH other metastatic involvement. \n * If there are multiple distant mets but liver is not one of them, code 30.\n\n**Note 2:** **Distant metastasis, NOS** \n* Use code 70 when the only information is “distant metastasis, NOS,” and there is no documentation regarding the specific metastases. \n * If there are specific metastasis documented that are not listed in codes 10, 20, or 30, assign code 30 for “other specified distant metastasis.”", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Bergsland, E.K., Woltering, E.A., Klimstra, D.S., et al. **Neuroendocrine Tumors of the Duodenum and Ampulla of Vater.** In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) **Neuroendocrine Tumors of the Duodenum and Ampulla of Vater**, from the AJCC Cancer Staging System Version 9 (2023). Used with permission of the American College of Surgeons, Chicago, Illinois.", - "last_modified" : "2025-09-18T20:41:50.377Z", + "last_modified" : "2025-11-14T20:05:09.068Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_89421.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_89421.json index 80e981c01..1f0810e12 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_89421.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_89421.json @@ -5,7 +5,7 @@ "name" : "EOD Mets", "title" : "EOD Mets", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Lydiatt, W.M., Patel, S.G., Shah, J.P., et al. **Staging Head and Neck Cancers**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Patel, S.G., Lydiatt, W.M., Shah, J.P., et al. **Larynx**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:31.508Z", + "last_modified" : "2025-11-14T20:05:05.874Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_89986.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_89986.json index 5bf9415bc..3d434ddd0 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_89986.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_89986.json @@ -6,7 +6,7 @@ "title" : "EOD Mets", "notes" : "**Note 1:** **Peritoneal spread and Peritoneal implants** \n* Peritoneal spread is common in appendiceal tumors and is coded as 30 if limited to the peritoneum. \n* Peritoneal implants involving abdominopelvic organs, such as the serosa of the small or large bowel and the surface of the ovary, spleen, or liver, should be coded as 30, regardless of whether implants demonstrate infiltration of underlying tissue, manifested as invasion. \n* Nonperitoneal metastasis, such as pleuropulmonary involvement is rare and would be coded as 50.\n\n**Note 2:** **Distant metastasis, NOS** \n* Use code 70 when the only information is “distant metastasis, NOS,” and there is no documentation regarding the specific metastases. \n* If there are specific metastasis documented that are not listed in codes 10, 30, 40, or 50, assign code 50 for “other specified distant metastasis.”", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) **Appendix**, from the AJCC Cancer Staging System Version 9 (2022). Used with permission of the American College of Surgeons, Chicago, Illinois.", - "last_modified" : "2025-09-18T20:41:28.468Z", + "last_modified" : "2025-11-14T20:05:04.941Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_91004.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_91004.json index 87809de96..953f92266 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_91004.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_91004.json @@ -6,7 +6,7 @@ "title" : "EOD Mets", "notes" : "**Note:** **Distant metastasis** \n* Use code 70 when the only information is “distant metastasis, NOS,” and there is no documentation regarding the specific metastases. \n* If there are specific metastasis documented that are not listed in codes 10 or 50, assign code 50 for “other specified distant metastasis.”", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Bochner, B.H., Hansel, D.E., Stadler, W.M., et al. **Urinary Bladder**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:42:03.539Z", + "last_modified" : "2025-11-14T20:05:38.754Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_91154.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_91154.json index dc016d97a..9455411a7 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_91154.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_91154.json @@ -5,7 +5,7 @@ "name" : "EOD Mets", "title" : "EOD Mets", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Tuttle, R.M., Perrier, N.D., et al. **Thyroid - Differentiated and Anaplastic Carcinoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:56.910Z", + "last_modified" : "2025-11-14T20:05:13.751Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_94984.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_94984.json index d17411b6d..06eba0d4a 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_94984.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_94984.json @@ -5,7 +5,7 @@ "name" : "EOD Mets", "title" : "EOD Mets", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Lydiatt, W.M., Patel, S.G., Shah, J.P., et al. **Staging Head and Neck Cancers**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Kraus, D.H., Lydiatt, W.M., Shah, J.P., et al. **Nasal Cavity and Paranasal Sinuses**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:43.396Z", + "last_modified" : "2025-11-14T20:06:07.406Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_95518.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_95518.json index 0bd6ee50e..f707a1a5a 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_95518.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_95518.json @@ -5,7 +5,7 @@ "name" : "EOD Mets", "title" : "EOD Mets", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Lydiatt, W.M., Patel, S.G., Shah, J.P., et al. **Staging Head and Neck Cancers**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Lydiatt, W.M., Ridge, J.A., Shah, J.P., et al. **Oropharynx (p16-) and Hypopharynx**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:42:10.633Z", + "last_modified" : "2025-11-14T20:06:07.057Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_96081.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_96081.json index d503b3399..44898ac97 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_96081.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_96081.json @@ -5,7 +5,7 @@ "name" : "EOD Mets", "title" : "EOD Mets", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) White, V.A., Finger, P.T., et al. **Lacrimal Gland Carcinoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:57.314Z", + "last_modified" : "2025-11-14T20:06:12.515Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_98654.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_98654.json index d39ebfe6e..b95ade1a0 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_98654.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_98654.json @@ -5,7 +5,7 @@ "name" : "EOD Mets", "title" : "EOD Mets", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Lydiatt, W.M., Patel, S.G., Shah, J.P., et al. **Staging Head and Neck Cancers**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Patel, S.G., Lydiatt, W.M., Shah, J.P., et al. **Cervical Lymph Nodes and Unknown Primary Tumors of the Head and Neck**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:42:21.394Z", + "last_modified" : "2025-11-14T20:06:15.572Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_mucosal_head_and_neck_45697.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_mucosal_head_and_neck_45697.json index 2654fea91..6d2d8a2d8 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_mucosal_head_and_neck_45697.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_mucosal_head_and_neck_45697.json @@ -5,7 +5,7 @@ "name" : "EOD Mets Mucosal Head and Neck", "title" : "EOD Mets", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Lydiatt, W.M., Patel, S.G., Shah, J.P., et al. **Staging Head and Neck Cancers**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Lydiatt, W.M., Brandwein-Gensler, M., Shah, J.P., et al. **Mucosal Melanoma of the Head and Neck**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:40.015Z", + "last_modified" : "2025-11-14T20:06:06.248Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_v9_1812.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_v9_1812.json index fd826e245..740904794 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_v9_1812.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_v9_1812.json @@ -6,7 +6,7 @@ "title" : "EOD Mets", "notes" : "**Note:** **Distant metastasis** \n* Use code 70 when the only information is “distant metastasis, NOS,” and there is no documentation regarding the specific metastases. \n* If there are specific metastasis documented that are not listed in codes 10, 30, or 50, assign code 50 for “other specified distant metastasis.”", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) **Thymus**, from the AJCC Cancer Staging System Version 9 (2025). Used with permission of the American College of Surgeons, Chicago, Illinois.", - "last_modified" : "2025-09-18T20:42:07.317Z", + "last_modified" : "2025-11-14T20:05:59.097Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_v9_3184.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_v9_3184.json index 8a48a4bb5..2ae152bc2 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_v9_3184.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_v9_3184.json @@ -6,7 +6,7 @@ "title" : "EOD Mets", "notes" : "**Note 1:** **Pleural effusion** \n* A physician’s statement of positive (malignant) pleural effusion or a positive cytology confirming a malignant pleural effusion must be used to code 05. \n * If the physician feels the pleural effusion is due to tumor, despite negative cytology, the physician’s assessment can be used to code EOD Mets\n* If pleural fluid cytology is described as suspicious/suspicious for mesothelioma, code 05\n* A positive pleural effusion (code 05) should not be coded as present under the Mets at Dx-Other field. \n * Code 0 for Mets at Dx-Other when code 05 is coded in EOD Mets.\n\n**Note 2:** **Additional data item for staging** \n* In addition to EOD Mets, the following data item is also collected to determine the results of the Pleural Effusion, which include negative, atypical, or Pleural effusion, NOS\n* Pleural effusion [NAACCR Data Item #3913]\n\n**Note 3:** **Pleural effusion with other mets** \n* If there is a malignant pleural effusion WITH other mets, code 70.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) **Diffuse Pleural Mesothelioma**, from the AJCC Cancer Staging System Version 9 (2025). Used with permission of the American College of Surgeons, Chicago, Illinois.", - "last_modified" : "2025-09-18T20:41:29.872Z", + "last_modified" : "2025-11-14T20:05:09.510Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_v9_58862.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_v9_58862.json index 2344a651b..403e86ef0 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_v9_58862.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_v9_58862.json @@ -5,7 +5,7 @@ "name" : "EOD Mets V9", "title" : "EOD Mets", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Lydiatt, W.M., Patel, S.G., Shah, J.P., et al. **Staging Head and Neck Cancers**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) **Nasopharynx**, from the AJCC Cancer Staging System Version 9 (2025). Used with permission of the American College of Surgeons, Chicago, Illinois.", - "last_modified" : "2025-09-18T20:42:17.791Z", + "last_modified" : "2025-11-14T20:05:59.550Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_v9_76161.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_v9_76161.json index f07217f7b..4071bcd26 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_v9_76161.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_mets_v9_76161.json @@ -6,7 +6,7 @@ "title" : "EOD Mets", "notes" : "**Note 1:** **Pleural and pericardial effusions**\n* Most pleural and pericardial effusions with lung cancer are due to tumor\n* In a few patients, however, multiple cytopathological examinations of pleural and/or pericardial fluid are negative for tumor, and the fluid is non-bloody and is not an exudate. Where these elements and clinical judgment dictate that the effusion is not related to the tumor, the effusion should be excluded as a staging element. \n * Code 00 in the absence of any other metastasis.\n\n**Note 2:** **Extrathoracic metastasis**\n* Organs \n * Abdominal organs\n * Adjacent rib (noncontiguous involvement only) (see *EOD Primary Tumor* for contiguous involvement)\n * Skin of chest \n * Separate lesion in chest wall or diaphragm\n\n* Distant lymph node(s)\n - Cervical \n - Distant lymph node(s), NOS\n\n* Carcinomatosis \n* Distant metastasis WITH or WITHOUT distant lymph node(s)", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) **Lung**, from the AJCC Cancer Staging System Version 9 (2025). Used with permission of the American College of Surgeons, Chicago, Illinois.", - "last_modified" : "2025-09-18T20:41:40.533Z", + "last_modified" : "2025-11-14T20:06:08.579Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_12346.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_12346.json index c74fe8715..bb68da51b 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_12346.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_12346.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note:** **Benign/borderline tumors** \n* Benign (/0) or Borderline (/1) tumors are always coded to 050 regardless of size or extension to adjacent sites.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05.** American Joint Committee on Cancer (Chicago, IL)\n\n(4) **Brain and Spinal Cord**, from the AJCC Cancer Staging System Version 9 (2022). Used with permission of the American College of Surgeons, Chicago, Illinois.", - "last_modified" : "2025-09-18T20:52:13.065Z", + "last_modified" : "2025-11-14T20:05:54.978Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_19089.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_19089.json index 00197bac2..c0d1225ba 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_19089.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_19089.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **FIGO and extension information** \n* When both the Federation Internationale de Gynecologie et d'Obstetrique (FIGO) stage and extension information on the primary tumor are available, use the extension information to assign the code in preference to a statement of FIGO stage.\n\n**Note 2:** **STIC** \n* Codes 050, 070, and 80 are used for the following in situ histology (behavior /2) only\n* High-grade serous tubal intraepithelial carcinoma (STIC) (8441/2)\n\n**Note 3:** **Malignant ascites** \n* Tumors in codes 100-250 with malignant ascites are coded 300. \n * Ascites, NOS should be excluded as a staging element\n\n**Note 4:** **Ovary involvement** \n* If there is involvement of the ovary (including surgical spill and/or capsule rupture) with no further evidence of extension and the physician states that this is a fallopian tube primary, code 400.\n\n**Note 5:** **Pelvic organs** \n* Both extension to and/or discontinuous metastasis to any of the following pelvic organs are included in code 450\n - Adjacent (pelvic) peritoneum\n - Bladder\n - Bladder serosa\n - Cul de sac (rectouterine pouch)\n - Ligament(s) (broad, ovarian, round, suspensory)\n - Mesosalpinx (Meosvarium)\n - Parametrium\n - Pelvic wall\n - Rectosigmoid\n - Rectum\n - Sigmoid colon (including sigmoid mesentery)\n - Ureter (pelvic portion)\n\n**Note 6:** **Peritoneal implants** \n* Peritoneal implants or peritoneal carcinomatosis may also be called seeding, salting, talcum powder appearance, or studding.\n * Code 600, 650, or 700 based on microscopic or the macroscopic size\n* Extraperitoneal carcinomatosis are coded in EOD Mets\n\n**Note 7:** **Location of implants** \n* If implants are mentioned, determine whether they are in the pelvis or in the abdomen and code appropriately. If the location of the implants is not specified, code 750.\n\n**Note 8:** **Abdominal organs** \n* Both extension to and/or discontinuous metastasis to any of the following abdominal organs by way of peritoneal seeding or implants are included in codes 600-750\n - Abdominal mesentery\n - Diaphragm\n - Gallbladder\n - Intestine, large (except rectum, rectosigmoid and sigmoid colon)\n - Kidneys\n - Liver (peritoneal surface)\n - Omentum (infracolic, NOS)\n - Pancreas\n - Pericolic gutter\n - Peritoneum, NOS\n - Small intestine\n - Spleen (capsular involvement only)\n - Stomach\n - Ureters (outside pelvis)\n\n**Note 9:** **Peritoneal surface of the liver** \n* Tumor limited to the peritoneal surface of the liver or splenic capsule is coded 700, regardless of the size (microscopic or macroscopic)\n - Liver and splenic **parenchymal** involvement is coded in EOD Mets (code 50)", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) **Introduction to Female Reproductive Organs**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Prat, J., Olawaiye, A.B., Mutch, D.G., et al. **Ovary, Fallopian Tube, and Primary Peritoneal Carcinoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:52:25.494Z", + "last_modified" : "2025-11-14T20:05:15.759Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_3385.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_3385.json index 87b67b10e..7f49a4446 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_3385.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_3385.json @@ -4,9 +4,9 @@ "version" : "3.3", "name" : "EOD Primary Tumor", "title" : "EOD Primary Tumor", - "notes" : "**Note 1:** **Osseous plasmacytomas** \n* Osseous (medullary) plasmacytomas (9731) are localized tumors occurring in the bone. \n* There may be soft tissue extension.\n\n**Note 2:** **Extraosseous plasmacytomas** \n* Extraosseous (extramedullary) plasmacytomas (9734) are plasma cell neoplasms that arise in tissues other than bone. \n* The most common sites are the upper respiratory tract, the gastrointestinal tract, lymph nodes, bladder, central nervous system (CNS), breast, thyroid, testis and skin.\n\n**Note 3:** **Lymphoplasmacytic lymphoma** \n* Lymphoplasmacytic lymphoma (9671) and Waldenstrom Macroglobulinemia (9761) are now collected with the plasma cell disorders. These are systemic diseases and should always be coded 700.\n\n**Note 4:** **Multiple plasmacytomas** \n* Per the 2016 WHO Hematopoietic and Lymphoid Neoplasms blue book, a plasmacytoma is defined as a single lesion. \n* If there are multiple lesions/plasmacytomas, this is diagnostic of plasma cell myeloma (9732/3) and the Plasma Cell Myeloma Schema should be used to assign EOD.", + "notes" : "**Note 1:** **Osseous plasmacytomas** \n* Osseous (medullary) plasmacytoma (9731) is a **single**, localized tumor occurring in the bone. \n* There may be soft tissue extension.\n\n**Note 2:** **Extraosseous plasmacytomas** \n* Extraosseous (extramedullary) plasmacytoma (9734) is a **single**, localized tumor that arises in tissue other than bone. \n* The most common sites are the upper respiratory tract, the gastrointestinal tract, lymph nodes, bladder, central nervous system (CNS), breast, thyroid, testis and skin.\n\n**Note 3:** **Lymphoplasmacytic lymphoma** \n* Lymphoplasmacytic lymphoma (9671) and Waldenstrom Macroglobulinemia (9761) are now collected with the plasma cell disorders. These are systemic diseases and should always be coded 700.\n\n**Note 4:** **Multiple plasmacytomas** \n* Per the 2024 WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition, ***a plasmacytoma is defined as a single lesion.*** \n* If there are multiple lesions/plasmacytomas, this is diagnostic of plasma cell myeloma (9732/3) and the Plasma Cell Myeloma Schema should be used to assign EOD.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) **Introduction to Hematologic Malignancies**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Bergsagel, P.L., Jaffe, E.S., Leonard, J.P., et al. **Plasma Cell Myeloma and Plasma Cell Disorders**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:52:24.944Z", + "last_modified" : "2025-11-14T20:06:14.607Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_3433.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_3433.json index f86842bf7..6aba77d7b 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_3433.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_3433.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **Periosteum** \n* Periosteum is a fibrous membrane that wraps the outer surface of bones. \n * Cortical bone is the dense compact outer layer of the bone. \n * Trabecular, cancellous, or spongy bone (spongiosa) is a porous network of tissue filling the interior of bone, decreasing weight and allowing room for blood vessels and marrow.\n\n**Note 2:** **Criteria for EOD Primary Tumor** \n* For codes 100-500, the derived EOD T is based on depth of invasion (DOI) in conjunction with size. In addition, some of the anatomical structures listed are localized for Summary Stage 2018 while others are regional for Summary Stage 2018. The anatomical structures are divided into two groups: Group 1 is for localized tumors, while Group 2 is for regional tumor. \n\n**Group 1 extension WITH any size tumor: Use the following for codes 100, 150, 200**\n\n- Invasive tumor on one side confined to mucoperiosteum (stroma)\n- Tumor crosses midline\n- Confined to hard palate, NOS\n- Localized, NOS\n\n**Group 2 extension WITH any size tumor: Use the following for codes 300, 400, 500**\n- Bone, NOS\n + Cortical bone (maxilla, palatine, NOS)\n + Maxilla, NOS\n + Palatine bone, NOS\n- Buccal mucosa (inner cheek)\n- Gingiva, upper\n- Glossopalatine arch\n- Pharyngopalatine arch\n- Soft palate including uvula\n\n\n**Note 3:** **Depth of invasion** \n* Once the correct group is determined, the codes are then determined based on the depth of invasion.\n - Depth of invasion less than or equal to 5 mm or UNKNOWN depth of invasion (codes 100, 300)\n - Depth of invasion greater than 5 mm to less than or equal to 10 mm (codes 150, 400)\n - Depth of invasion greater than 10 mm (codes 200, 500)\n\n**Note 4:** **Cortical bone** \n* Invasion through cortical bone is required for assignment of code 600.\n - Code 300, 400, or 500 (depending on the depth of invasion) when the tumor is limited to the cortical bone/cortex of maxilla. Invasion of the bone, NOS (maxilla, NOS) is **not** equivalent to invasion through the cortical bone (code 600).", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Lydiatt, W.M., Patel, S.G., Shah, J.P., et al. **Staging Head and Neck Cancers**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Ridge, J.A., Lydiatt, W.M., Shah, J.P., et al. **Oral Cavity**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:52:37.914Z", + "last_modified" : "2025-11-14T20:06:04.773Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_38280.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_38280.json index 3714f8b04..26edead5a 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_38280.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_38280.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **Periosteum** \n* Periosteum is a fibrous membrane that wraps the outer surface of bones. \n* Mucoperiosteum is a compound structure of mucous membrane and periosteum. Cortical bone is the dense compact outer layer of bone.\n\n**Note 2:** **Macroscopic extraparenchymal extension** \n* Macroscopic extraparenchymal extension (code 300) is based on clinical evaluation or macroscopic evidence of extraparenchymal extension at the time of surgery.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Lydiatt, W.M., Patel, S.G., Shah, J.P., et al. **Staging Head and Neck Cancers**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Lydiatt, W.M., Shah, J.P., et al. **Major Salivary Glands**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(7) **Salivary Glands**, from the AJCC Cancer Staging System Version 9 (2026). Used with permission of the American College of Surgeons, Chicago, Illinois.", - "last_modified" : "2025-09-18T20:52:39.769Z", + "last_modified" : "2025-11-14T20:06:03.742Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_3897.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_3897.json index 0177de851..ad6ed8a77 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_3897.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_3897.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **Periosteum** \n* Periosteum is a fibrous membrane that wraps the outer surface of bones. \n * Cortical bone is the dense compact outer layer of the bone. \n * Trabecular, cancellous, or spongy bone (spongiosa) is a porous network of tissue filling the interior of bone, decreasing weight and allowing room for blood vessels and marrow.\n\n**Note 2:** **Criteria for EOD Primary Tumor** \n* For codes 100-500, the derived EOD T is based on depth of invasion (DOI) in conjunction with size. In addition, some of the anatomical structures listed are localized for Summary Stage 2018 while others are regional for Summary Stage 2018. The anatomical structures are divided into two groups: Group 1 is for localized tumors, while Group 2 is for regional tumor. \n\n**Group 1 extension WITH any size tumor: Use the following for codes 100, 150, 200**\n- Invasive tumor confined to\n + Labial mucosa (inner lip)\n + Lamina propria\n + Multiple foci\n + Musculature \n + Submucosa (superficial invasion)\n- Superficial extension to\n + Skin of lip\n + Subcutaneous soft tissue of lip\n- Confined to lip, NOS\n- Localized, NOS\n\n**Group 2 extension WITH any size tumor: Use the following for codes 300, 400, 500**\n- Bone, NOS \n + Cartilage (mandible, maxilla, NOS)\n + Cortical (mandible, maxilla, NOS)\n + Mandible, NOS (lower and other lip)\n + Maxilla, NOS (upper and other lip)\n- Buccal mucosa (inner cheek)\n- Commissure\n- Gingiva, NOS\n + Lower gingiva (lower lip)\n + Upper gingiva (upper lip) (from commissure only for lower lip)\n- Opposite lip (both lips)\n\n**Note 3:** **Depth of invasion** \n* Once the correct group is determined, the codes are then determined based on the depth of invasion.\n - Depth of invasion less than or equal to 5 mm or UNKNOWN depth of invasion (codes 100, 300)\n - Depth of invasion greater than 5 mm to less than or equal to 10 mm (codes 150, 400)\n - Depth of invasion greater than 10 mm (codes 200, 500)\n\n**Note 4:** **Cortical bone** \n* Invasion through cortical bone is required for assignment of code 650.\n - Code 300, 400, or 500 (depending on the depth of invasion) when the tumor is limited to the cortical bone/cortex of the mandible or maxilla. Invasion of the bone, NOS (mandible, NOS or maxilla, NOS) is **not** equivalent to invasion through the cortical bone (code 650).", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Lydiatt, W.M., Patel, S.G., Shah, J.P., et al. **Staging Head and Neck Cancers**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Ridge, J.A., Lydiatt, W.M., Shah, J.P., et al. **Oral Cavity**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:51:55.147Z", + "last_modified" : "2025-11-14T20:06:03.010Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_40607.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_40607.json index 9a4dbe9a5..725c94342 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_40607.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_40607.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **Benign/Borderline** \n* Benign (/0) or Borderline (/1) tumors **are always coded to 050** regardless of size, extension to adjacent sites, or multiple tumors. \n\n**Note 2:** **Midline shift** \n* A midline shift is not the same thing as crossing the midline (code 500).\n* Documentation must state \"crossing/crosses the midline\"\n\n**Note 3:** **Drop metastasis** \n* Discontiguous spread, or \"drop metastasis\" are coded in EOD Mets.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) **Brain and Spinal Cord**, from the AJCC Cancer Staging System Version 9 (2022). Used with permission of the American College of Surgeons, Chicago, Illinois.", - "last_modified" : "2025-09-18T20:52:09.330Z", + "last_modified" : "2025-11-14T20:05:54.444Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_42615.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_42615.json index 611c6ef22..cdd2f73ad 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_42615.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_42615.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **Cortex of the bone**\n* The cortex of a bone is the dense outer shell that provides strength to the bone; the spongy center of a bone is the cancellous portion. \n* The periosteum of the bone is the fibrous membrane covering of a bone that contains the blood vessels and nerves; the periosteum is similar to the capsule on a visceral organ.\n\n**Note 2:** **Number of pelvic segments** \n* The number of pelvic segments involved by the primary tumor determines the appropriate EOD Primary Tumor (codes 100 through 550). The four pelvic segments used in these codes are: \n * Acetabulum\n * Iliac wing\n * Pubic ramus/Symphysis/Ischium\n * Sacrum", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Kneisl, J.S., Rosenberg, A.E., et al. **Bone**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:52:00.911Z", + "last_modified" : "2025-11-14T20:06:13.429Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_43548.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_43548.json index bca8adb20..a12d385bf 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_43548.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_43548.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **Periosteum** \n* Periosteum is a fibrous membrane that wraps the outer surface of bones. \n * Cortical bone is the dense compact outer layer of the bone. \n * Trabecular, cancellous, or spongy bone (spongiosa) is a porous network of tissue filling the interior of bone, decreasing weight and allowing room for blood vessels and marrow.\n\n**Note 2:** **Criteria for EOD Primary Tumor** \n* For codes 100-500, the derived EOD T is based on depth of invasion (DOI) in conjunction with size. In addition, some of the anatomical structures listed are localized for Summary Stage 2018 while others are regional for Summary Stage 2018. The anatomical structures are divided into two groups: Group 1 is for localized tumors, while Group 2 is for regional tumor. \n\n**Group 1 extension WITH any size tumor: Use the following for codes 100, 150, 200**\n- Invasive tumor confined to\n + Lamina propria\n + Musculature (buccinator)\n + Submucosa\n- Confined to mouth, NOS\n- Localized, NOS\n\n**Group 2 extension WITH any size tumor: Use the following for codes 300, 400, 500**\n- Adjacent oral cavity \n- Oropharynx\n + Inferior surface of soft palate\n + Lateral pharyngeal wall\n + Lingual surface of epiglottis\n + Vallecula \n\n**Note 3:** **Depth of invasion** \n* Once the correct group is determined, the codes are then determined based on the depth of invasion.\n - Depth of invasion less than or equal to 5 mm or UNKNOWN depth of invasion (codes 100, 300)\n - Depth of invasion greater than 5 mm to less than or equal to 10 mm (codes 150, 400)\n - Depth of invasion greater than 10 mm (codes 200, 500)\n\n**Note 4:** **Cortical bone** \n* Invasion through cortical bone is required for assignment of code 600.\n - Code 300, 400, or 500 (depending on the depth of invasion) when the tumor is limited to the cortical bone/cortex of the mandible or maxilla. Invasion of the bone, NOS (mandible, NOS or maxilla, NOS) is **not** equivalent to invasion through the cortical bone (code 600).", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Lydiatt, W.M., Patel, S.G., Shah, J.P., et al. **Staging Head and Neck Cancers**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Ridge, J.A., Lydiatt, W.M., Shah, J.P., et al. **Oral Cavity**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:52:00.278Z", + "last_modified" : "2025-11-14T20:06:05.119Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_4717.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_4717.json index 20453a356..c0ba99a41 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_4717.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_4717.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **FIGO and extension detail** \n* When both the Federation Internationale de Gynecologie et d'Obstetrique (FIGO) stage and extension information on the primary tumor are available, use the extension information to code primary tumor in preference to a statement of FIGO stage.\n\n**Note 2:** **Extension to vagina** \n* EOD Primary Tumor includes direct extension or discontinuous metastasis to the vagina (see codes 400 and 550).\n\n**Note 3:** **Extension to adnexa or uterine serosa** \n* EOD Primary tumor excludes metastasis to adnexa or uterine serosa (See EOD Mets).", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging.** In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) **Introduction to Female Reproductive Organs**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Dizon, D.S., Olawaiye, A.B., Mutch, D.G., et al. **Corpus Uteri - Sarcoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:52:12.749Z", + "last_modified" : "2025-11-14T20:05:52.187Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_50451.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_50451.json index 6315f0a57..390d899e3 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_50451.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_50451.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **Periosteum** \n* Periosteum is a fibrous membrane that wraps the outer surface of bones. \n* Cortical bone is the dense compact outer layer of the bone. Trabecular, cancellous, or spongy bone (spongiosa) is a porous network of tissue filling the interior of bone, decreasing weight and allowing room for blood vessels and marrow.\n\n**Note 2:** **Criteria for EOD Primary Tumor** \n* For codes 100-500, the derived EOD T is based on depth of invasion (DOI) in conjunction with size. In addition, some of the anatomical structures listed are localized for Summary Stage 2018 while others are regional for Summary Stage 2018. The anatomical structures are divided into two groups: Group 1 is for localized tumors, while Group 2 is for regional tumors. \n\n**Group 1 extension WITH any size tumor: Use the following for codes 100, 150, 200**\n- Invasive tumor confined to\n + Lamina propria\n + Musculature (buccinator)\n + Submucosa\n- Confined to buccal mucosa (inner cheek), NOS\n- Localized, NOS\n\n**Group 2 extension WITH any size tumor: Use the following for codes 300, 400, 500**\n- Gingiva\n- Lateral pharyngeal wall\n- Lip(s) including commissure\n- Subcutaneous soft tissue of cheek\n- Tonsillar pillars and fossae\n- Tonsils\n\n**Note 3:** **Depth of invasion** \n* Once the correct group is determined, the codes are then determined based on the depth of invasion.\n - Depth of invasion less than or equal to 5 mm or UNKNOWN depth of invasion (codes 100, 300)\n - Depth of invasion greater than 5 mm to less than or equal to 10 mm (codes 150, 400)\n - Depth of invasion greater than 10 mm (codes 200, 500)\n\n**Note 4:** **Cortical bone** \n* Invasion through cortical bone is required for assignment of code 600.\n - Code 300, 400, or 500 (depending on the depth of invasion) when the tumor is limited to the cortical bone/cortex of the mandible or maxilla. Invasion of the bone, NOS (mandible, NOS or maxilla, NOS) is **not** equivalent to invasion through the cortical bone (code 600).", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Lydiatt, W.M., Patel, S.G., Shah, J.P., et al. **Staging Head and Neck Cancers**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Ridge, J.A., Lydiatt, W.M., Shah, J.P., et al. **Oral Cavity**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:52:37.561Z", + "last_modified" : "2025-11-14T20:06:03.384Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_53330.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_53330.json index 690551108..222ddc2fd 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_53330.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_53330.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **Periosteum**\n* Periosteum is a fibrous membrane that wraps the outer surface of bones. \n* Cortical bone is the dense compact outer layer of the bone. Trabecular, cancellous, or spongy bone (spongiosa) is a porous network of tissue filling the interior of bone, decreasing weight and allowing room for blood vessels and marrow.\n\n**Note 2:** **Criteria for EOD Primary Tumor** \n* For codes 100-500, the derived EOD T is based on depth of invasion (DOI) in conjunction with size. In addition, some of the anatomical structures listed are localized for Summary Stage 2018 while others are regional for Summary Stage 2018. The anatomical structures are divided into two groups: Group 1 is for localized tumors, while Group 2 is for regional tumor. \n\n**Group 1 extension WITH any size tumor: Use the following for codes 100, 150, 200**\n- Invasive tumor on one side confined to\n + Lamina propria\n + Musculature of tongue, intrinsic or NOS\n + Submucosa\n- Tumor cross midline/midline tumor\n- Confined to anterior tongue, NOS\n- Localized, NOS\n\n**Group 2 extension WITH any size tumor: Use the following for codes 300, 400, 500**\n- Base of tongue\n- Bone, NOS\n + Bone (mandible, maxilla, palatine)\n + Cartilage (mandible, maxilla, NOS)\n + Cortical bone, invasion of (mandible, maxilla, NOS)\n- Floor of mouth\n- Gingiva, lower\n- Retromolar trigone\n- Sublingual gland\n\n**Note 3:** **Depth of invasion** \n* Once the correct group is determined, the codes are then determined based on the depth of invasion.\n- Depth of invasion less than or equal to 5 mm or UNKNOWN depth of invasion (codes 100, 300)\n- Depth of invasion greater than 5 mm to less than or equal to 10 mm (codes 150, 400)\n- Depth of invasion greater than 10 mm (codes 200, 500)\n\n**Note 4:** **Cortical bone** \n* Invasion through cortical bone is required for assignment of code 650.\n - Code 300, 400, or 500 (depending on the depth of invasion) when the tumor is limited to the cortical bone/cortex of the mandible or maxilla. Invasion of the bone, NOS (mandible, NOS or maxilla, NOS) is **not** equivalent to invasion through the cortical bone (code 650).", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Lydiatt, W.M., Patel, S.G., Shah, J.P., et al. **Staging Head and Neck Cancers**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Ridge, J.A., Lydiatt, W.M., Shah, J.P., et al. **Oral Cavity**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:52:20.627Z", + "last_modified" : "2025-11-14T20:06:02.661Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_55521.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_55521.json index f9643364e..6f2c68bbf 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_55521.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_55521.json @@ -5,7 +5,7 @@ "name" : "EOD Primary Tumor V9", "title" : "EOD Primary Tumor V9", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Bergsland, E.K., Woltering, E.A., Klimstra, D.S., et al. **Neuroendocrine Tumors of the Duodenum and Ampulla of Vater.** In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) **Neuroendocrine Tumors of the Duodenum and Ampulla of Vater**, from the AJCC Cancer Staging System Version 9 (2023). Used with permission of the American College of Surgeons, Chicago, Illinois.", - "last_modified" : "2025-09-18T20:52:04.810Z", + "last_modified" : "2025-11-14T20:05:08.839Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_60922.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_60922.json index 109eedefa..a7db59348 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_60922.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_60922.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **Benign/borderline tumors** \n* Benign (/0) or Borderline (/1) tumors **are always coded to 050** regardless of size, extension to adjacent sites, or multiple tumors. \n * **Note:** Benign (/0) or Borderline (/1) Medulloblastoma's are very rare.\n\n**Note 2:** **Single tumors** \n* For invasive tumors, EOD Primary tumor is coded only for **single tumors confined to the primary site** (see code 150) or a **single** tumor crossing the midline without extension to adjacent structures (see code 250).\n * Code 999 if there are multiple tumors in the brain\n * The presence of multiple tumors is recorded in EOD Mets\n\n**Note 3:** **Midline shift** \n* A midline shift is not the same thing as crossing the midline\n * Code 150 if you have a single tumor confined to the primary site with a midline shift that is not extending into adjacent structures (see Note 4). \n\n**Note 4:** **Types of extension coded in EOD Mets** \n* Direct or contiguous extension to an adjacent site is collected in EOD Mets. \n * If the only information available is extension to an adjacent site, code EOD Primary Tumor 999 and assign the appropriate EOD Mets code\n* The following are collected in EOD Mets (see code 25 for all except circulating cells in CSF (code 15))\n * Adjacent connective/soft tissue\n * Adjacent muscle\n * Bone\n * Circulating cells in cerebral spinal fluid (CSF)\n * Major blood vessel(s)\n * Meninges (e.g.; dura)\n * Multiple/multifocal tumors\n * Nerves (cranial, NOS)\n * Ventricular system", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) **Brain and Spinal Cord**, from the AJCC Cancer Staging System Version 9 (2022). Used with permission of the American College of Surgeons, Chicago, Illinois.", - "last_modified" : "2025-09-18T20:52:03.016Z", + "last_modified" : "2025-11-14T20:05:55.310Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_72244.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_72244.json index 5dd47344b..98090de67 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_72244.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_72244.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **FIGO and extension information** \n* When both the Federation Internationale de Gynecologie et d'Obstetrique (FIGO) stage and extension information on the primary tumor are available, use the extension information to assign the code in preference to a statement of FIGO stage.\n\n**Note 2:** **STIC** \n* Code 050 is for the following in situ histology (behavior /2) only\n - High-grade serous tubal intraepithelial carcinoma (STIC) (8441/2)\n\n**Note 3:** **Malignant ascites** \n* Tumors in codes 100-250 with malignant ascites are coded 300. \n * Ascites, NOS should be excluded as a staging element\n\n**Note 4:** **Fallopian tube involvement** \n* If there is involvement of the fallopian tube with no further evidence of extension, and the physician verifies this is an ovary primary, code 400.\n\n**Note 5:** **Pelvic organs** \n* Both extension to and/or discontinuous metastasis to any of the following pelvic organs are included in code 450\n - Adjacent (pelvic) peritoneum\n - Bladder\n - Bladder serosa\n - Cul de sac (rectouterine pouch)\n - Ligament(s) (broad, ovarian, round, suspensory)\n - Mesosalpinx (Mesovarium) \n - Parametrium\n - Pelvic wall\n - Rectosigmoid\n - Rectum\n - Sigmoid colon (including sigmoid mesentery)\n - Ureter (pelvic portion)\n\n**Note 6:** **Peritoneal implants** \n* Peritoneal implants or peritoneal carcinomatosis may also be called seeding, salting, talcum powder appearance, or studding.\n * Code 600, 650, or 700 based on microscopic or the macroscopic size\n* Extraperitoneal carcinomatosis are coded in EOD Mets (code 50)\n\n**Note 7:** **Location of peritoneal implants** \n* If implants are mentioned, determine whether they are in the pelvis or in the abdomen and code appropriately. If the location of the implants is not specified, code 750.\n\n**Note 8:** **Abdominal organs** \n* Both extension to and/or discontinuous metastasis to any of the following abdominal organs by way of peritoneal seeding or implants are included in codes 600-750\n - Abdominal mesentery\n - Diaphragm\n - Gallbladder\n - Intestine, large (except rectum, rectosigmoid and sigmoid colon)\n - Kidneys\n - Omentum (infracolic, NOS)\n - Pancreas\n - Pericolic gutter\n - Peritoneum, NOS\n - Small intestine\n - Stomach\n - Ureters (outside pelvis)\n\n**Note 9:** **Peritoneal surface of the liver** \n* Tumor limited to the peritoneal surface of the liver or splenic capsule is coded 700, regardless of the size (microscopic or macroscopic).\n - Any **parenchymal** involvement of the liver or spleen is coded in EOD Mets (code 50)\n\n**Note 10:** **Benign/borderline tumors** \n* In some registries benign/borderline ovarian tumors are reportable by agreement. \n * If the tumor being reported is benign or borderline, code 999.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) **Introduction to Female Reproductive Organs**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Prat, J., Olawaiye, A.B., Mutch, D.G., et al. **Ovary, Fallopian Tube, and Primary Peritoneal Carcinoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:51:48.974Z", + "last_modified" : "2025-11-14T20:05:19.560Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_72245.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_72245.json index 11e89ebaa..598315fa6 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_72245.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_72245.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **Lymphatic sites (nodal regions)** \n* Lymph nodes (C770-C779)\n* Waldeyer's ring (tonsils) (C024, C090-C099, C111, C142)\n* Spleen (C422)\n* Thymus (C379)\n\n**Note 2:** **Defining multiple lymph node regions** \n* Use the AJCC definitions for lymph node regions (Chapter 79, Figure 79.1) to determine when single (code 100) or multiple (300-600) lymph node regions are involved. \n* See also the Hematopoietic Manual, Appendix C, for definition of lymph node regions.\n\n**Note 3:** **Extralymphatic sites** \n* Extralymphatic sites (extranodal regions) include all other sites (e.g., stomach, colon, lung, breast, nasopharynx). \n\n**Note 4:** **Lymph node involvement** \n* Any mention of the terms including fixed, matted, mass in the hilum, mediastinum, retroperitoneum, and/or mesentery, palpable, enlarged, shotty, lymphadenopathy are all regarded as involvement for lymphomas when determining appropriate code.\n\n**Note 5:** **Bulky disease** \n* Bulky disease\" (code 500) varies by the lymphoma histology. For Hodgkin lymphoma, it is defined as the ratio between the maximum diameter of the mediastinal mass and maximal intrathoracic diameter based on CT imaging in the Lugano classification. \n* Bulk of other disease is defined as a mass greater than 10 cm. For non-Hodgkin lymphomas, the main criteria is based on size with cutoffs ranging from 5-10 cm, although 10 cm is recommended.\n\n**Note 6:** **Limited versus Advanced Stage** \n* Lymphomas confined to a single lymphatic or extralymphatic site WITH or WITHOUT involvement of lymph node regions on the SAME side of the diaphragm are also referred to as \"limited stage.\" (Codes 100-500). \n* Lymphomas with involvement on BOTH sides of the diaphragm or other metastatic disease are also referred to as \"advanced stage\" (Codes 500-800).\n * Bulky disease may be either early or advanced stage based on the lymphoma histology or other factors\n\n**Note 7:** **Liver involvement** \n* Clinical enlargement of the liver is not enough to indicate involvement. Involvement is indicated by diffuse uptake or mass lesion or abnormal liver function tests. Liver biopsy may be used to confirm equivocal involvement.\n * Any involvement of liver (including primary liver lymphoma) is coded as 800\n\n**Note 8:** **Splenic involvement** \n* Splenic involvement is based on splenomegaly and FDG-PET or CT scans that state diffuse update, solitary mass, miliary lesions, or enlargement of greater than 13 cm\n * A physician’s statement of splenomegaly may be used \n * FDG uptake in the spleen that is not diffuse is not enough to code as splenic involvement \n\n**Note 9:** **Lung involvement** \n* Lung involvement is indicated by pulmonary nodules or parenchymal involvement on FDG-PET or CT in the absence of other likely causes. \n* Lung biopsy may be used to confirm equivocal involvement.\n* Multifocal lung involvement is coded as 700 or 800 based on lung mets, code also \"Mets at Dx-Lung as 1\n\n**Note 10:** **Bone involvement** \n* Bone involvement (excluding bone marrow involvement, see Note 11) is indicated by avid lesions on FDG-PET. \n* Bone biopsy may be used to confirm equivocal involvement. \n* Bone involvement (except for bone primary lymphomas) is coded as 800. Code also \"Mets at Dx-Bone\" as 1. (See Note 11 on how to code bone marrow involvement)\n\n**Note 11:** **CNS Involvement** \n* Central nervous system (CNS) involvement is often suspected due to symptoms and can be confirmed by plain radiology, CT scan, or MRI. Cerebrospinal fluid (CSF) examination by flow cytometry may be done. \n* CNS involvement may be the result of soft tissue disease representing extension from bone metastasis or parenchymal brain disease. \n * CNS involvement (except for CNS primary lymphomas) is coded as 800. Code also \"Mets at Dx-Brain\" as 1\n * CSF involvement is coded as 800. Code also \"Mets at Dx-Other\" as 1\n\n**Note 12:** **Peripheral Blood Involvement** \n* Peripheral blood involvement is assessed by an aspiration or peripheral blood smear.\n* Primary site is coded to bone marrow (C421): Do not code \"Met at Dx-Other\" as 1 \n - In cases where peripheral blood smear is not performed, but a physician's clinical assessment indicates peripheral blood involvement, the physician's clinical assessment can be used\n - If **ONLY** the peripheral blood is involved, code 750\n - If there is peripheral blood involvement **WITH** other involvement, code 800\n\n**Note 13:** **Bone Marrow involvement** \n* Bone marrow involvement is assessed by an aspiration and bone marrow biopsy. \n+ Bone marrow involvement is coded as 800. Code also \"Mets at Dx-Other\" as 1. Do not code to \"Mets at Dx-Bone\" as 1\n - If only involvement is bone marrow, code primary site to bone marrow (C421), EOD Primary Tumor 800. Do not code \"Mets at Dx-Other\" as 1\n - In cases where bone marrow biopsy/aspiration is not performed, but a physician's clinical assessment indicates bone marrow involvement, the physician's clinical assessment can be used\n\n**Note 14:** **Bilateral sites** \n* Code 800 for involvement of bilateral sites (i.e.; breast, eye, kidney, etc.).\n * *Example*: Patient with extranodal non-Hodgkin's Lymphoma, involving bilateral choroids, (single focus both sites), and no lymph node involvement. \n * Code 800 for bilateral involvement of choroids (eye)\n\n**Note 15:** **B Symptoms** \n* See the data item *B symptoms* [NAACCR Data Item Number: #3812] to code the presence or absence of B symptoms.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) **Introduction to Hematologic Malignancies**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Zelenetz, A.D., Jaffe, E.S., Leonard, J.P., et al. **Hodgkin and Non-Hodgkin Lymphomas**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(7) Link, M.P., Jaffe, E.S., Leonard, J.P. **Pediatric Hodgkin and Non-Hodgkin Lymphomas**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-19T18:54:58.689Z", + "last_modified" : "2025-11-14T20:06:00.640Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_72332.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_72332.json index 3d9d2e6ef..0e34de519 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_72332.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_72332.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **Cortex of the bone**\n* The cortex of a bone is the dense outer shell that provides strength to the bone; the spongy center of a bone is the cancellous portion. \n* The periosteum of the bone is the fibrous membrane covering of a bone that contains the blood vessels and nerves; the periosteum is similar to the capsule on a visceral organ.\n\n**Note 2:** **Vertebral segments**\n* The number of vertebral segments involved by the primary tumor determines the appropriate EOD Primary Tumor (codes 100 through 400). The five vertebral segments used in these codes are:\n * Body (left)\n * Body (right)\n * Pedicle (left)\n * Pedicle (right)\n * Posterior element", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Kneisl, J.S., Rosenberg, A.E., et al. **Bone**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:52:10.245Z", + "last_modified" : "2025-11-14T20:05:19.017Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_81646.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_81646.json index 76460c774..76ada4c9a 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_81646.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_81646.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **Intrinsic and extrinsic muscles** \n* The intrinsic muscles of tongue are four paired muscles within the tongue which control its shape. \n* The extrinsic muscles originate from structures outside the tongue and control its positioning.\n\n**Note 2:** **Laryngeal involvement**\n* Mucosal extension to the lingual surface of the epiglottis from primary tumors of the base of the tongue and vallecula is not recorded as extension to the larynx (code 600).\n\n**Note 3:** **Parapharyngeal involvement** \n* Parapharyngeal involvement (pharyngeal space invasion) (code 700) denotes postero-lateral infiltration of tumor beyond the pharyngobasilar fascia. \n* The pharyngobasilar fascia is the fibrous layer of the pharyngeal wall between the mucosa and the muscular layer, attached superiorly to the basilar part of the occipital bone and diminishing in thickness as it descends.\n\n**Note 4:** **Masticator space** \n* The masticator space (code 700) primarily consists of the muscles of mastication, the medial and lateral pterygoid, masseter, and temporalis muscles. \n* The space also includes the ramus of the mandible and the third division of cranial nerve V as it passes through the foramen ovale into the suprahyoid neck.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Lydiatt, W.M., Patel, S.G., Shah, J.P., et al. **Staging Head and Neck Cancers**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) O'Sullivan, B., Lydiatt, W.M., Shah, J.P., et al. **Oropharynx HPV-Mediated**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(7) **Oropharynx HPV-Associated**, from the AJCC Cancer Staging System Version 9 (2025). Used with permission of the American College of Surgeons, Chicago, Illinois.", - "last_modified" : "2025-09-18T20:52:38.272Z", + "last_modified" : "2025-11-14T20:06:06.467Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_84520.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_84520.json index f459172f9..cf2c1683f 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_84520.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_84520.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **Benign/Borderline tumors** \n* Benign (/0) or Borderline (/1) tumors **are always coded to 050** regardless of size, extension to adjacent sites, or multiple tumors. \n\n**Note 2:** **Infratentorial and Supratentorial** \n* The tentorium cerebelli is an extension of the dura mater that separates the cerebellum from the inferior portion of the occipital lobes. \n* The location of the tumor above or below the tentorium can help in determining the type of tumor; also, most adult brain tumors are supratentorial, and most pediatric brain tumors are infratentorial. \n* In the following list, note that ICD-O-3 codes C71.0 and C71.9 include both supratentorial and infratentorial subsites.\n\n- The following subsites are **Infratentorial**\n * All subsites for codes C716-C717 \n * Hypothalamus (C710)\n * Pallium (C710)\n * Posterior cranial fossa (C719)\n * Thalamus (C710)\n- The following subsites are **Supratentorial**\n * All subsites for codes C711-C715\n * Primary site C710 (excluding hypothalamus, pallium, thalamus)\n * Anterior cranial fossa (C719)\n * Corpus callosum (C718)\n * Middle cranial fossa (C719)\n * Tapetum (C718)\n * Suprasellar (C719)\n\n**Note 3:** **Midline shift** \n* A midline shift is not the same thing as crossing the midline (code 500).\n * Documentation must state \"crossing/crosses the midline\"\n\n**Note 4:** **Drop metastasis** \n* Discontiguous spread, or \"drop metastasis\" are coded in EOD mets.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) **Brain and Spinal Cord**, from the AJCC Cancer Staging System Version 9 (2022). Used with permission of the American College of Surgeons, Chicago, Illinois.", - "last_modified" : "2025-09-18T20:51:54.255Z", + "last_modified" : "2025-11-14T20:05:54.089Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_85962.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_85962.json index 899137f84..918381e75 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_85962.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_85962.json @@ -5,7 +5,7 @@ "name" : "EOD Primary Tumor", "title" : "EOD Primary Tumor", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Lydiatt, W.M., Patel, S.G., Shah, J.P., et al. **Staging Head and Neck Cancers**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Patel, S.G., Lydiatt, W.M., Shah, J.P., et al. **Cervical Lymph Nodes and Unknown Primary Tumors of the Head and Neck**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:52:40.817Z", + "last_modified" : "2025-11-14T20:06:15.359Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_93022.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_93022.json index 07173ab0e..223fea164 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_93022.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_93022.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note:** **FIGO and extension information** When both the Federation Internationale de Gynecologie et d'Obstetrique (FIGO) stage and extension information on the primary tumor are available, use the extension information to code primary tumor in preference to a statement of FIGO stage.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) **Introduction to Female Reproductive Organs**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Gibb, R.K., Olawaiye, A.B., Mutch, D.G., et al. **Vulva**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(7) **Vulva,** from the AJCC Cancer Staging System Version 9 (2023). Used with permission of the American College of Surgeons, Chicago, Illinois.", - "last_modified" : "2025-09-18T20:51:54.789Z", + "last_modified" : "2025-11-14T20:06:01.754Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_93027.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_93027.json index 60344f73f..c79d80307 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_93027.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_93027.json @@ -5,7 +5,7 @@ "name" : "EOD Primary Tumor", "title" : "EOD Primary Tumor", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)", - "last_modified" : "2025-09-18T20:52:15.511Z", + "last_modified" : "2025-11-14T20:06:09.748Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_93243.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_93243.json index 23ebac9cf..918bd50c8 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_93243.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_93243.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **In-situ and HAMN** \n* Code 000 (behavior code 2) includes cancer cells confined within the glandular basement membrane (intraepithelial) or described as in situ or high-grade appendiceal mucinous neoplasms (HAMN)\n\n**Note 2:** **LAMN** \n* Code 050 (behavior code 2) for low-grade appendiceal mucinous neoplasms (LAMN) that are confined by the muscularis propria. \n* See codes 300-750 for LAMN tumors that extend beyond the muscularis propria \n\n**Note 3:** **Code 070 (behavior code 3)** \n* Intramucosal, NOS\n* Lamina propria\n* Mucosa, NOS\n* Confined to, but not through the muscularis mucosa\n\n**Note 4:** **Intraluminal extension** \n* Ignore intraluminal extension to adjacent segment(s) of colon/rectum or to the ileum from the cecum; code depth of invasion or extracolonic spread as indicated.\n\n**Note 5:** **Mucinous Tumors** \n* Mucinous tumors are identified by morphology codes 8480, 8481, and 8490.\n\n**Note 6:** **Invasion of subserosa or mesoappendix** \n* Code 300 when the only statement is \"Tumor invades through the muscularis propria into subserosa or mesoappendix but does not extend to serosal surface\" and there isn't enough information to clarify subserosa versus mesoappendix. \n\n**Note 7:** **Macroscopic adhesions** \n* Use code 700 for macroscopic adhesions if no pathological confirmation, and for microscopically confirmed tumor in adhesions.\n* However, if no tumor is present in adhesion(s) upon microscopic examination, the classification is based upon extent of tumor invasion into or through the wall (see codes 100-600). \n\n**Note 8:** **Contiguous extension** \n* Codes 700 and 750 are used for contiguous extension from the site of origin. \n* Except for intraperitoneal metastases limited to the right lower quadrant (RLQ) of the abdomen for **mucinous tumors (see code 600), discontinuous involvement is coded in EOD Mets.**", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) **Appendix**, from the AJCC Cancer Staging System Version 9 (2022). Used with permission of the American College of Surgeons, Chicago, Illinois.", - "last_modified" : "2025-09-18T20:51:46.207Z", + "last_modified" : "2025-11-14T20:05:04.761Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_96275.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_96275.json index ae47a69cb..0af8e3fc6 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_96275.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_96275.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **FIGO and extension information** \n* When both the Federation Internationale de Gynecologie et d'Obstetrique (FIGO) stage and extension information on the primary tumor are available, use the extension information to assign the code in preference to a statement of FIGO stage.\n\n**Note 2:** **Peritoneal implants** \n* Peritoneal implants or peritoneal carcinomatosis may also be called seeding, salting, talcum powder appearance, or studding\n- Extraperitoneal carcinomatosis are coded in EOD Mets\n\n**Note 3:** **Tumor confined to peritoneum** \n* A tumor confined to the peritoneum (code 300) is when there is one pelvic peritoneal tumor, or multiple pelvic peritoneal tumors, without any mention of implants on the specific pelvic/abdominal structures listed in codes 400-750.\n\n**Note 4:** **Pelvic organs** \n* Both extension to and/or discontinuous metastasis to any of the following pelvic organs are included in code 450\n - Adjacent pelvic (peritoneum)\n - Bladder\n - Bladder serosa\n - Cul de sac (rectouterine pouch)\n - Ligament(s) (broad, ovarian, round, suspensory)\n - Mesosalpinx (Meosvarium)\n - Parametrium\n - Pelvic wall\n - Rectosigmoid\n - Rectum\n - Sigmoid colon (including sigmoid mesentery)\n - Ureter (pelvic portion)\n\n**Note 5:** **Implants, NOS** \n* If implants are mentioned, determine whether they are in the pelvis or in the abdomen and code appropriately. If the location of the implants is not specified, code 750.\n\n**Note 6:** **Abdominal organs** \n* Both extension to and/or discontinuous metastasis to any of the following abdominal organs by way of peritoneal seeding or implants are included in codes 600-750\n - Abdominal mesentery\n - Diaphragm\n - Gallbladder\n - Intestine, large (except rectum, rectosigmoid and sigmoid colon)\n - Kidneys\n - Omentum (infracolic, NOS)\n - Pancreas\n - Pericolic gutter\n - Peritoneum, NOS\n - Small intestine\n - Stomach\n - Ureters (outside pelvis)\n\n**Note 7:** **Peritoneal surface of the liver** \n* Tumor limited to the peritoneal surface of the liver or splenic capsule is coded 700, regardless of the size (microscopic or macroscopic)\n - Any **parenchymal** involvement of the liver or spleen is coded in EOD Mets (code 50)", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05.** American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) **Introduction to Female Reproductive Organs**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Prat, J., Olawaiye, A.B., Mutch, D.G., et al. **Ovary, Fallopian Tube, and Primary Peritoneal Carcinoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:51:45.922Z", + "last_modified" : "2025-11-14T20:06:10.214Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_97833.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_97833.json index ee9fe35c1..643be7381 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_97833.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_97833.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **FIGO and extension information** \n* When both the Federation Internationale de Gynecologie et d'Obstetrique (FIGO) stage and extension information on the primary tumor are available, use the extension information to code primary tumor in preference to a statement of FIGO stage.\n\n**Note 2:** **Extension to Vagina** \n* EOD Primary Tumor includes direct extension or discontinuous metastasis to the vagina (see codes 400 and 550).\n\n**Note 3:** **Extension to adnexa or uterine serosa** \n* EOD Primary tumor excludes metastasis to adnexa or uterine serosa (See EOD Mets).", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) **Cervix Uteri**, from the AJCC Cancer Staging System Version 9 (2020). Used with permission of the American College of Surgeons, Chicago, Illinois.", - "last_modified" : "2025-09-18T20:52:24.489Z", + "last_modified" : "2025-11-14T20:06:11.608Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_98910.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_98910.json index a1a3ac1fc..c2f83c399 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_98910.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_98910.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **Periosteum** \n* Periosteum is a fibrous membrane that wraps the outer surface of bones. \n * Cortical bone is the dense compact outer layer of the bone. \n * Trabecular, cancellous, or spongy bone (spongiosa) is a porous network of tissue filling the interior of bone, decreasing weight and allowing room for blood vessels and marrow.\n\n**Note 2:** **Criteria for EOD Primary Tumor** \n* For codes 100-500, the derived EOD T is based on depth of invasion (DOI) in conjunction with size. In addition, some of the anatomical structures listed are localized for Summary Stage 2018 while others are regional for Summary Stage 2018. \n* The anatomical structures are divided into two groups: Group 1 is for localized tumors, while Group 2 is for regional tumor. \n\n**Group 1 extension WITH any size tumor: Use the following for codes 100, 150, 200**\n\n- Invasive tumor on one side confined to\n + Lamina propria\n + Submucosa\n + Tumor crosses midline\n- Confined to floor of mouth, NOS\n- Localized, NOS\n\n**Group 2 extension WITH any size tumor: Use the following for codes 300, 400, 500**\n\n- Anterior 2/3 of tongue\n- Base of tongue\n- Bone, NOS\n + Cartilage, NOS\n + Cortical bone (mandible, NOS)\n + Mandible, NOS\n + Periosteum of mandible\n- Epiglottis\n- Gingiva (alveolar ridge), lower\n- Glossoepiglottic fold\n- Glossopharyngeal sulcus\n- Lateral pharyngeal wall\n- Pharyngeal (lingual) surface\n- Pharyngoepiglottic fold\n- Subcutaneous soft tissue of chin/neck\n- Sublingual gland, including ducts\n- Submandibular (submaxillary) glands, including ducts\n- Tonsillar pillars and fossae\n- Tonsils\n- Vallecula\n\n**Note 3:** **Depth of invasion** \n* Once the correct group is determined, the codes are then determined based on the depth of invasion.\n - Depth of invasion less than or equal to 5 mm or UNKNOWN depth of invasion (codes 100, 300)\n - Depth of invasion greater than 5 mm to less than or equal to 10 mm (codes 150, 400)\n - Depth of invasion greater than 10 mm (codes 200, 500)\n\n**Note 4:** **Cortical bone** Invasion through cortical bone is required for assignment of code 650.\n- Code 300, 400, or 500 (depending on the depth of invasion) when the tumor is limited to the cortical bone/cortex of the mandible. Invasion of the bone, NOS (mandible, NOS) is **not** equivalent to invasion through the cortical bone (code 600).", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Lydiatt, W.M., Patel, S.G., Shah, J.P., et al. **Staging Head and Neck Cancers**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Ridge, J.A., Lydiatt, W.M., Shah, J.P., et al. **Oral Cavity**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:52:08.574Z", + "last_modified" : "2025-11-14T20:06:04.457Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_copy_25294.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_copy_25294.json index e6a63719a..6da62d296 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_copy_25294.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_copy_25294.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **Lymphatic sites (nodal regions)**\n* Lymph nodes (C770-C779)\n* Waldeyer's ring (tonsils) (C024, C090-C099, C111, C142)\n* Spleen (C422)\n* Thymus (C379)\n\n**Note 2:** **Defining multiple lymph node regions** \n* Use the AJCC definitions for lymph node regions (Chapter 79, Figure 79.1) to determine when single (code 100) or multiple (300-600) lymph node regions are involved. \n* See also the Hematopoietic Manual, Appendix C, for definition of lymph node regions.\n\n**Note 3:** **Extralymphatic sites** \n* Extralymphatic sites (extranodal regions) include all other sites (e.g., stomach, colon, lung, breast, nasopharynx). \n\n**Note 4:** **Lymph node involvement** \n* Any mention of the terms including fixed, matted, mass in the hilum, mediastinum, retroperitoneum, and/or mesentery, palpable, enlarged, shotty, lymphadenopathy are all regarded as involvement for lymphomas when determining appropriate code.\n\n**Note 5:** **Bulky disease** \n* \"Bulky disease\" (code 500) varies by the lymphoma histology. For Hodgkin lymphoma, it is defined as the ratio between the maximum diameter of the mediastinal mass and maximal intrathoracic diameter based on CT imaging in the Lugano classification. \n* Bulk of other disease is defined as a mass greater than 10 cm. For non-Hodgkin lymphomas, the main criteria is based on size with cutoffs ranging from 5-10 cm, although 10 cm is recommended.\n\n**Note 6:** **Limited versus Advanced Stage** \n* Lymphomas confined to a single lymphatic or extralymphatic site WITH or WITHOUT involvement of lymph node regions on the SAME side of the diaphragm are also referred to as \"limited stage.\" (Codes 100-500). Lymphomas with involvement on BOTH sides of the diaphragm or other metastatic disease are also referred to as \"advanced stage\" (Codes 500-800).\n * Bulky disease may be either early or advanced stage based on the lymphoma histology or other factors\n\n**Note 7:** **Liver involvement** \n* Clinical enlargement of the liver is not enough to indicate involvement. Involvement is indicated by diffuse uptake or mass lesion or abnormal liver function tests. Liver biopsy may be used to confirm equivocal involvement.\n * Any involvement of liver (including primary liver lymphoma) is coded as 800\n\n**Note 8:** **Splenic involvement** \n* Splenic involvement is based on splenomegaly and FDG-PET or CT scans that state diffuse update, solitary mass, miliary lesions, or enlargement of greater than 13 cm\n * A physician’s statement of splenomegaly may be used \n * FDG uptake in the spleen that is not diffuse is not enough to code as splenic involvement \n\n**Note 9:** **Lung involvement** \n* Lung involvement is indicated by pulmonary nodules or parenchymal involvement on FDG-PET or CT in the absence of other likely causes. \n* Lung biopsy may be used to confirm equivocal involvement.\n* Multifocal lung involvement is coded as 700 or 800 based on lung mets, code also \"Mets at Dx-Lung as 1\n\n**Note 10:** **Bone involvement** \n* Bone involvement (excluding bone marrow involvement, see Note 11) is indicated by avid lesions on FDG-PET. Bone biopsy may be used to confirm equivocal involvement. \n * Bone involvement (except for bone primary lymphomas) is coded as 800. Code also \"Mets at Dx-Bone\" as 1. (See Note 11 on how to code bone marrow involvement)\n\n**Note 11:** **CNS involvement** \n* Central nervous system (CNS) involvement is often suspected due to symptoms and can be confirmed by plain radiology, CT scan, or MRI. Cerebrospinal fluid (CSF) examination by flow cytometry may be done. \n* CNS involvement may be the result of soft tissue disease representing extension from bone metastasis or parenchymal brain disease. \n* CNS involvement (except for CNS primary lymphomas) is coded as 800. Code also \"Mets at Dx-Brain\" as 1\n * CSF involvement is coded as 800. Code also \"Mets at Dx-Other\" as 1\n\n**Note 12:** **Peripheral blood involvement** \n* Peripheral blood involvement is assessed by an aspiration or peripheral blood smear.\n+ Primary site is coded to bone marrow (C421): Do not code \"Met at Dx-Other\" as 1\n - In cases where peripheral blood smear is not performed, but a physician's clinical assessment indicates peripheral blood involvement, the physician's clinical assessment can be used\n - If **ONLY** the peripheral blood is involved, code 750\n - If there is peripheral blood involvement **WITH** other involvement, code 800\n\n**Note 13:** **Bone marrow involvement** \n* Bone marrow involvement is assessed by an aspiration and bone marrow biopsy. \n+ Primary site is coded bone marrow (C421): Code 800. Do not code \"Mets at Dx-Other as 1\" \n - In cases where bone marrow biopsy/aspiration is not performed, but a physician's clinical assessment indicates bone marrow involvement, the physician's clinical assessment can be used\n\n**Note 14:** **Bilateral sites** \n* Code 800 for involvement of bilateral sites (i.e.; breast, eye, kidney, etc.).\n * *Example*: Patient with extranodal non-Hodgkin's Lymphoma, involving bilateral choroids, (single focus both sites), and no lymph node involvement. \n * Code 800 for bilateral involvement of choroids (eye)\n\n**Note 15:** **B Symptoms** \n* See the data item *B symptoms* [NAACCR Data Item Number: #3812] to code the presence or absence of B symptoms.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) **Introduction to Hematologic Malignancies**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Zelenetz, A.D., Jaffe, E.S., Leonard, J.P., et al. **Hodgkin and Non-Hodgkin Lymphomas**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(7) Link, M.P., Jaffe, E.S., Leonard, J.P. **Pediatric Hodgkin and Non-Hodgkin Lymphomas**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-19T18:55:11.705Z", + "last_modified" : "2025-11-14T20:06:15.842Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_v9_192.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_v9_192.json index 449ea32a6..6d995d0ec 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_v9_192.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_v9_192.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **Pharyngeal space** \n* Involvement of the pharyngeal space (code 300) is defined as posterolateral infiltration from the nasopharynx beyond the buccopharyngeal fascia into the triangular space lateral to the pharynx. \n\n**Note 2:** **Parapharyngeal involvement** \n* Parapharyngeal involvement denotes posterolateral infiltration of tumor beyond the pharyngobasilar fascia. \n* The pharyngobasilar fascia is the fibrous layer of the pharyngeal wall between the mucosa and the muscular layer, attached superiorly to the basilar part of the occipital bone and diminishing in thickness as it descends.\n\n**Note 3:** **Masticator space** \n* The masticator space primarily consists of the muscles of mastication, the medial and lateral pterygoid, masseter, and temporalis muscles. \n* The space also includes the ramus of the mandible and the third division of cranial nerve V as it passes through the foramen ovale into the suprahyoid neck.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Lydiatt, W.M., Patel, S.G., Shah, J.P., et al. **Staging Head and Neck Cancers**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) **Nasopharynx**, from the AJCC Cancer Staging System Version 9 (2025). Used with permission of the American College of Surgeons, Chicago, Illinois.", - "last_modified" : "2025-09-18T20:52:31.082Z", + "last_modified" : "2025-11-14T20:05:59.349Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_v9_52408.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_v9_52408.json index 3af8e5b61..239c97416 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_v9_52408.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_v9_52408.json @@ -5,7 +5,7 @@ "name" : "EOD Primary Tumor V9", "title" : "EOD Primary Tumor", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) **Diffuse Pleural Mesothelioma**, from the AJCC Cancer Staging System Version 9 (2025). Used with permission of the American College of Surgeons, Chicago, Illinois.", - "last_modified" : "2025-09-18T20:51:47.380Z", + "last_modified" : "2025-11-14T20:05:09.283Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_v9_58724.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_v9_58724.json index 80c97c8c0..2f5ae6a8d 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_v9_58724.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_v9_58724.json @@ -5,7 +5,7 @@ "name" : "EOD Primary Tumor V9", "title" : "EOD Primary Tumor", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) **Anus**, from the AJCC Cancer Staging System Version 9 (2022). Used with permission of the American College of Surgeons, Chicago, Illinois.", - "last_modified" : "2025-09-18T20:52:02.635Z", + "last_modified" : "2025-11-14T20:05:51.692Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_v9_6892.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_v9_6892.json index 0489a0607..be31d3788 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_v9_6892.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_v9_6892.json @@ -5,7 +5,7 @@ "name" : "EOD Primary Tumor V9", "title" : "EOD Primary Tumor", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) **Thymus**, from the AJCC Cancer Staging System Version 9 (2025). Used with permission of the American College of Surgeons, Chicago, Illinois.", - "last_modified" : "2025-09-18T20:52:13.357Z", + "last_modified" : "2025-11-14T20:05:58.894Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_v9_75679.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_v9_75679.json index 8609c7ab5..15374cc1d 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_v9_75679.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_primary_tumor_v9_75679.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor V9", "notes" : "**Note 1:** **Bronchopneumonia and Obstructive pneumonitis**\n* Bronchopneumonia is not the same thing as obstructive pneumonitis and should not be coded as such. \n * **Bronchopneumonia** is an acute inflammation of the walls of the bronchioles, usually a result of spread of infection from the upper to the lower respiratory tract\n * **Obstructive pneumonitis** is a combination of atelectasis, bronchiectasis with mucous plugging, and parenchymal inflammation that develops distal to an obstructing endobronchial lesion\n\n**Note 2:** **Ground glass opacities (GGO), ground glass nodules (GGN), and ground/glass lepidic (GG/L)**\n* Ground glass opacities (GGO), ground glass nodules (GGN), and ground/glass lepidic (GG/L) are frequently observed on CT and are increasingly detected with the advancements in imaging and are described as an area of hazy increased lung opacity. GGO, GGN, and GG/L can be observed in both benign and malignant lung conditions along with pre-invasive lesions (adenocarcinoma in situ, minimally invasive adenocarcinoma, and lepidic carcinoma). \n* They are often associated with early stage lung cancer but not necessarily malignancies themselves.\n* For staging purposes, these are **not to be counted as separate tumor nodules**\n\n**Note 3:** **Minimally invasive adenocarcinoma**\n* Code 100 is to be used only when the following criteria are met\n * Minimally invasive adenocarcinoma (less than or equal to 3 cm)\n * **WITH** predominantly **lepidic pattern** **AND**\n * less than or equal to 5 mm invasion in greatest dimension\n * If predominantly **lepidic pattern** is present and the size of the invasive component is unknown, see code 300\n\n**Note 4:** **Superficial spreading tumor**\n* Code 200 is to be used for **superficial spreading tumors** only. The pathology report must state that it is superficially spreading.\n* These types of tumors are uncommon, and this code should be used very sparingly. If in doubt, do not use this code\n\n**Note 5:** **Localized tumor**\n* Code 300 is to be used for a localized cancer where size defines the extent of the primary tumor \n * It is not a predominantly lepidic pattern (code 100), or a superficial spreading tumor (code 200), and there is no involvement of adjacent structures or invasion of the pleural (codes 400 and above).\n\n**Note 6:** **Atelectasis** \n* Atelectasis is the failure of the lung to expand (inflate) completely\n* This may be caused by a blocked airway, a tumor, general anesthesia, pneumonia or other lung infection, lung disease, or long-term bed rest with shallow breathing. Sometimes called a collapsed lung. \n * If the atelectasis is clearly related to the obstructing tumor, code to 450\n * If the atelectasis is clearly related to the lymph nodes, code the involvement in lymph nodes\n * If unable to determine if the atelectasis is due to direct extension or lymph node involvement, record as lymph node involvement\n\n**Note 7:** **Visceral pleural invasion**\n* Specific information about visceral pleura invasion is captured in codes 450 (PL1, PL2, or NOS) and 500 (PL3)\n* Elastic layer involvement has prognostic significance for lung cancer. \n\n**Note 8:** **Penetration of the visceral pleural**\n* Penetration of the visceral pleura indicates a progression of invasion, even in small (≤ 3cm) tumors, and indicates a less favorable prognosis\n* Visceral pleural invasion is determined to be present both in tumors that extend to the visceral pleural surface (type PL2 invasion), and in tumors that penetrate beyond the elastic layer of the visceral pleura (type PL1 invasion)\n* Further invasion, which extends to the parietal pleura, is also described as type PL3 invasion.\n\n**Note 9:** **\"Vocal cord paralysis\" or \"Superior vena cava syndrome\"** \n* \"Vocal cord paralysis,\" \"superior vena cava syndrome,\" and \"compression of the trachea or the esophagus\" are classified as either direct extension from the primary tumor or mediastinal lymph node involvement\n\n* **Caused by direct extension of the primary tumor**\n * Code as primary tumor involvement (EOD Primary Tumor, code 650)\n* **Primary tumor is peripheral and clearly unrelated to vocal cord paralysis, SVC obstruction, or compression of the trachea, or the esophagus**\n * These manifestations are secondary to lymph node involvement; code as mediastinal lymph node involvement (EOD Lymph Nodes, code 400)\n* **Unable to determine if manifestations due to direct extension or mediastinal lymph node involvement**\n * Record as mediastinal lymph node involvement (EOD Lymph Nodes, code 400)\n\n**Note 10:** **Separate tumor nodules**\n* Separate ipsilateral tumor nodules of the same histopathological type (intrapulmonary metastases)\n* Coded either 500 (same lobe) or 700 (different ipsilateral lobe). \n* Separate tumor nodules in the contralateral lung are assigned in EOD Mets.\n\n**Note 11:** **Occult carcinoma**\n* Occult carcinoma occurs when tumor is proven by the presence of malignant cells in sputum or bronchial washings, but there is no other evidence of the tumor. \n* In these cases, assign EOD Primary Tumor 980, EOD Regional Nodes 000, and EOD Mets 00.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) **Lung**, from the AJCC Cancer Staging System Version 9 (2025). Used with permission of the American College of Surgeons, Chicago, Illinois.", - "last_modified" : "2025-09-18T20:51:55.993Z", + "last_modified" : "2025-11-14T20:06:08.377Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_prostate_pathologic_extension_2781.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_prostate_pathologic_extension_2781.json index 4a3a6c229..ffc4e97ec 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_prostate_pathologic_extension_2781.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_prostate_pathologic_extension_2781.json @@ -6,7 +6,7 @@ "title" : "EOD Prostate Pathologic Extension", "notes" : "**Note 1:** **Radical prostatectomy or autopsy results only** \n* Only use histologic information from a radical prostatectomy and/or autopsy in this field. \n* Information from biopsy of extraprostatic sites is coded in EOD Primary Tumor.\n * Code results from a transurethral resection of prostate (TURP) or simple prostatectomy in EOD Primary Tumor\n\n**Note 2:** **No radical prostatectomy or autopsy** \n* Code 900 if there is no radical prostatectomy or autopsy performed within first course of treatment. (See also Note 9)\n * A radical prostatectomy is defined as Surgery of Primary Site codes 50-70 (A500-A700)\n * If Surgery of primary site is 00-30, 90, 99 (A000-A300, A900, A999) then code 900\n * *Note:* Surgery of primary site can be 00 if an autopsy is done\n\n**Note 3:** **Criteria for data item** \n* Limit information in this field to first course of treatment in the absence of disease progression. \n\n**Note 4:** **Incidental finding** \n* When prostate cancer is an incidental finding during a prostatectomy for other reasons (for example, a cystoprostatectomy for bladder cancer), or an autopsy, use the appropriate code for the extent of disease found. \n\n**Note 5:** **Radical prostatectomy, no residual disease** \n* Code 300 when there is a microscopically confirmed clinical diagnosis of prostate cancer and the radical prostatectomy shows no residual disease\n\n**Note 6:** **Prostatic urethra** \n* Involvement of the prostatic urethra does not alter the extension code. \n\n**Note 7:** **Frozen pelvis** \n* \"Frozen pelvis\" is a clinical term which means tumor extends to pelvic sidewall(s). \n* In the absence of a more detailed statement of involvement, assign this to code 700.\n\n**Note 8:** **No evidence of primary tumor** \n* Code 800 is only to be used when there is a clinical diagnosis of prostate cancer that has not been microscopically confirmed (i.e., diagnosed via imaging with bone mets) and a radical prostatectomy or autopsy is done and there is no evidence of primary tumor. \n\n**Note 9:** **Active surveillance, then Radical Prostatectomy** \n* Code 950 is used when first course of treatment is active surveillance, but a radical prostatectomy is done at a later date due to disease progression or the patient changed their mind. \n* When code 950 is used, code the following SSDIs as X9: Gleason Patterns Pathological, Gleason Score Pathological, and Gleason Tertiary\n\n**Note 10:** **Coding unknown** \n* Code 999 when\n * Radical prostatectomy is performed, but there is no information on the extension\n * Surgery of Primary Site is Prostatectomy, NOS (Surgery of Primary Site is 80)\n * Unknown if surgery is done (Surgery of Primary Site is 99)", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Buyyounouski, M.K., Lin, D.W., et al. **Prostate**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:52:39.070Z", + "last_modified" : "2025-11-14T20:05:50.847Z", "definition" : [ { "key" : "eod_prostate_path_extension", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_10020.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_10020.json index c725dacaf..878649c6a 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_10020.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_10020.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS**\n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n\n**Note 2:** **Para-aortic nodes** \n* Para-aortic nodes are now regional instead of distant. \n\n**Note 3:** **FIGO and lymph node detail** \n* When both the Federation Internationale de Gynecologie et d'Obstetrique (FIGO) stage and lymph node detail are available, record the code with lymph node detail in preference to a statement of FIGO stage.\n\n**Note 4:** **Isolated tumor cells** \n* Isolated tumor cells (ITCs) are defined as single tumor cells or small clusters not greater than 0.2 mm, usually detected by immunohistochemical (IHC) or molecular methods. ITCs do not usually show evidence of malignant activity (e.g., proliferation or stromal reaction). Lymph nodes with ITCs only are not counted as positive nodes. \n * For positive ITCs with NO regional lymph node involvement, code 050\n\n**Note 5:** **Lymph nodes, NOS**\n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05.** American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging.** In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) **Introduction to Female Reproductive Organs**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Dizon, D.S., Olawaiye, A.B., Mutch, D.G., et al. **Corpus Uteri - Sarcoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:42:06.416Z", + "last_modified" : "2025-11-14T20:05:52.279Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_11936.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_11936.json index e8d8d632a..bfe6cf4df 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_11936.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_11936.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS in this field. Distant nodes are coded in EOD Mets.\n\n**Note 2:** **Mesenteric nodes** \n* The specific location of the mesenteric nodes determines whether they are regional or distant. \n* If the specific location is not described, code in EOD Regional Nodes.\n\n**Note 3:** **Porta hepatic nodes** \n* Porta hepatic nodes are recorded as distant for Body and Tail and should be coded in EOD Mets. \n* If the specific location for hepatic nodes is not described, code in EOD Regional Nodes.\n\n**Note 4:** **CLINICAL AND PATHOLOGICAL codes** \n* This schema has lymph node codes that are defined as **CLINICAL** assessment only or **PATHOLOGICAL** assessment only. \n\n**No surgical resection**\n* Use **CLINICAL** assessment only codes (700, 725, 775) when there is a clinical work up only and there is **NO surgical resection of the primary tumor or site** WITH \n * Any microscopic examination of regional lymph nodes, which includes FNA, core biopsy, sentinel node biopsy, lymph node excision, or lymph node dissection done during the clinical work up. \n\n**Surgical resection without neoadjuvant therapy**\n* Use **PATHOLOGICAL** assessment only codes (300, 700) when there is a **surgical resection of the primary tumor or site** WITH \n * Any microscopic examination of regional lymph nodes, which includes FNA, core biopsy, sentinel node biopsy, lymph node excision done or lymph node dissection performed.\n\n**Surgical resection after neoadjuvant therapy**\n* If patient has neoadjuvant therapy, and the clinical assessment is equal to or greater than the pathological assessment, then the clinical assessment codes take priority. Otherwise, code the pathologic assessment. \n * See ***EOD 2018 General Instructions*** for further instructions on coding cases with neoadjuvant therapy, https://seer.cancer.gov/tools/staging/eod/.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Kakar, S., Pawlik, T.M., Vauthey, J.N., et al. **Exocrine Pancreas**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cacer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:42:05.736Z", + "last_modified" : "2025-11-14T20:05:34.814Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_12613.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_12613.json index d195a7da5..c99dbb950 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_12613.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_12613.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Definition of Head and Neck Lymph Nodes** \n* For head and neck schemas, this field includes all lymph nodes defined as Levels I-VII and Other by TNM. \n\n**Note 2:** **CLINICAL AND PATHOLOGICAL codes** \n* This schema has lymph node codes that are defined as **CLINICAL** assessment only or **PATHOLOGICAL** assessment only.\n\n**No surgical resection**\n* Use **CLINICAL** assessment only codes (450) when there is a clinical work up only and there is **NO surgical resection of the primary tumor or site** WITH \n * Any microscopic examination of regional lymph nodes, which includes FNA, core biopsy, sentinel node biopsy, lymph node excision, or lymph node dissection done during the clinical work up. \n\n**Surgical resection without neoadjuvant therapy**\n* Use **PATHOLOGICAL** assessment only codes (150, 500, 600, 700) when there is a **surgical resection of the primary tumor or site** WITH \n * Any microscopic examination of regional lymph nodes, which includes FNA, core biopsy, sentinel node biopsy, lymph node excision done or lymph node dissection performed.\n\n**Surgical resection after neoadjuvant therapy**\n* If patient has neoadjuvant therapy, and the clinical assessment is equal to or greater than the pathological assessment, then the clinical assessment codes take priority. Otherwise, code the pathologic assessment. \n * See ***EOD 2018 General Instructions*** for further instructions on coding cases with neoadjuvant therapy, https://seer.cancer.gov/tools/staging/eod/.\n\n**Note 3:** **Laterality** \n* If laterality of lymph nodes is not specified, assume nodes are ipsilateral. Midline nodes are ipsilateral.\n\n**Note 4:** **Supraclavicular lymph nodes** \n* Supraclavicular lymph nodes can be either Level IV or Level V\n * Level IV: deep to the sternocleidomastoid muscle, in the lower jugular chain\n * Level V: in the posterior triangle, inferior to the transverse cervical artery, supraclavicular lymph nodes, NOS\n\n**Note 5:** **Extranodal Extension** \n* Extranodal extension (ENE) is defined as the extension of a nodal metastasis through the lymph node capsule into adjacent tissue. The following codes record the status of the lymph nodes with positive ENE\n * Code 150: Pathological only: single ipsilateral node, less than or equal to 3 cm\n * Code 450: Clinical only: overt ENE\n * Code 500: Pathological only: single ipsilateral node, greater than 3 cm\n * Code 600: Pathological only: multiple ipsilateral, bilateral or contralateral nodes\n * Code 700: Pathological only: Single contralateral node\n\n**Note 6:** **Regional lymph nodes for Head and Neck tumors** \n* **Note:** For codes 100-700, use the list below for named regional lymph nodes. If the only information available is \"regional lymph nodes, NOS\" or \"lymph nodes,\" code 800.\n\n**Level I**\nLevel IA - Submental\nLevel IB - Submandibular (submaxillary), sublingual\n\n**Level II - Upper jugular** \nJugulodigastric (subdigastric)\nUpper deep cervical \nLevel IIA - Anterior\nLevel IIB - Posterior \n\n**Level III - Middle jugular**\nMiddle deep cervical\n\n**Level IV - Lower jugular**\nJugulo-omohyoid (supraomohyoid)\nLower deep cervical \nVirchow node\n\n**Level V - Posterior triangle group**\nPosterior cervical\nLevel VA - Spinal accessory \nLevel VB - Transverse cervical, supraclavicular \n\n**Level VI - Anterior compartment group**\nLaterotracheal\nParalaryngeal\nParatracheal - above suprasternal notch\nPerithyroidal\nPrecricoid (Delphian)\nPrelaryngeal\nPretracheal - above suprasternal notch\nRecurrent laryngeal\n\n**Level VII - Superior mediastinal group (for other mediastinal node(s) see EOD Mets)**\nEsophageal groove\nParatracheal - below suprasternal notch\nPretracheal - below suprasternal notch \n\n**Other groups**\nCervical, NOS\nDeep cervical, NOS\nFacial\n- Buccinator (buccal)\n- Mandibular\n- Nasolabial\n\nInternal jugular, NOS\nParapharyngeal \nParotid\n- Infraauricular\n- Intraparotid\n- Periparotid\n- Preauricular\n\nRetroauricular (mastoid)\nRetropharyngeal\nSuboccipital", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Lydiatt, W.M., Patel, S.G., Shah, J.P., et al. **Staging Head and Neck Cancers**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Patel, S.G., Lydiatt, W.M., Shah, J.P., et al. **Larynx**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:31.376Z", + "last_modified" : "2025-11-14T20:05:05.688Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_16316.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_16316.json index d6ed9607e..0d83f2f6f 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_16316.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_16316.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n\n**Note 2:** **Psammoma bodies only**\n* Psammoma bodies are counted as positive regional lymph nodes\n\n**Note 3:** **Lymph nodes, NOS** \n * Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Rosen, J.E., Lloyd, R.V., Perrier, N.D., et al. **Thyroid - Medullary**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:42:00.902Z", + "last_modified" : "2025-11-14T20:05:23.190Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_21853.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_21853.json index 5189ed24f..9817beba5 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_21853.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_21853.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n\n**Note 2:** **CLINICAL AND PATHOLOGICAL codes** \n* This schema has lymph node codes that are defined as **CLINICAL** assessment only or **PATHOLOGICAL** assessment only.\n\n**No surgical resection**\n* Use **CLINICAL** assessment only codes (450) when there is a clinical work up only and there is **NO surgical resection of the primary tumor or site** WITH \n * Any microscopic examination of regional lymph nodes, which includes FNA, core biopsy, sentinel node biopsy, lymph node excision, or lymph node dissection done during the clinical work up. \n\n**Surgical resection without neoadjuvant therapy**\n* Use **PATHOLOGICAL** assessment only codes (150, 500, 600, 700) when there is a **surgical resection of the primary tumor or site** WITH \n * Any microscopic examination of regional lymph nodes, which includes FNA, core biopsy, sentinel node biopsy, lymph node excision done or lymph node dissection performed.\n\n**Surgical resection after neoadjuvant therapy**\n* If patient has neoadjuvant therapy, and the clinical assessment is equal to or greater than the pathological assessment, then the clinical assessment codes take priority. Otherwise, code the pathologic assessment. \n * See ***EOD 2018 General Instructions*** for further instructions on coding cases with neoadjuvant therapy, https://seer.cancer.gov/tools/staging/eod/.\n \n+ Remaining codes (no designation of **CLINICAL** or **PATHOLOGICAL** only assessment) can be used based on clinical and/or pathological information\n\n**Note 3:** **Laterality**\n* If laterality of lymph nodes is not specified, assume nodes are ipsilateral. Midline nodes are ipsilateral.\n\n**Note 4:** **Supraclavicular lymph nodes** \n* Supraclavicular lymph nodes can be either Level IV or Level V\n * Level IV: deep to the sternocleidomastoid muscle, in the lower jugular chain\n * Level V: in the posterior triangle, inferior to the transverse cervical artery, supraclavicular lymph nodes, NOS\n\n**Note 5:** **Extranodal extension** \n* Extranodal extension (ENE) is defined as the extension of a nodal metastasis through the lymph node capsule into adjacent tissue. The following codes record the status of the lymph nodes with positive ENE\n * Code 150: Pathological only: single ipsilateral node, less than or equal to 3 cm\n * Code 450: Clinical only: overt ENE\n * Code 500: Pathological only: single ipsilateral node, greater than 3 cm\n * Code 600: Pathological only: multiple ipsilateral, bilateral or contralateral nodes\n * Code 700: Pathological only: Single contralateral node\n\n**Note 6:** **Regional lymph nodes for Head and Neck tumors**\n* **Note:** For codes 100-700, use the list below for named regional lymph nodes. If the only information available is \"regional lymph nodes, NOS\" or \"lymph nodes,\" code 800.\n\n**Level I**\nLevel IA - Submental\nLevel IB - Submandibular (submaxillary), sublingual\n\n**Level II - Upper jugular** \nJugulodigastric (subdigastric)\nUpper deep cervical \nLevel IIA - Anterior\nLevel IIB - Posterior \n\n**Level III - Middle jugular**\nMiddle deep cervical\n\n**Level IV - Lower jugular**\nJugulo-omohyoid (supraomohyoid)\nLower deep cervical \nVirchow node\n\n**Level V - Posterior triangle group**\nPosterior cervical\nLevel VA - Spinal accessory \nLevel VB - Transverse cervical, supraclavicular \n\n**Level VI - Anterior compartment group**\nLaterotracheal\nParalaryngeal\nParatracheal - above suprasternal notch\nPerithyroidal\nPrecricoid (Delphian)\nPrelaryngeal\nPretracheal - above suprasternal notch\nRecurrent laryngeal\n\n**Level VII - Superior mediastinal group (for other mediastinal node(s), see EOD Mets)**\nEsophageal groove\nParatracheal - below suprasternal notch\nPretracheal - below suprasternal notch \n\n**Other groups**\nCervical, NOS\nDeep cervical, NOS\nFacial\n- Buccinator (buccal)\n- Mandibular\n- Nasolabial\n\nInternal jugular, NOS\nParapharyngeal \nParotid\n- Infraauricular\n- Intraparotid\n- Periparotid\n- Preauricular\n\nRetroauricular (mastoid)\nRetropharyngeal\nSuboccipital\n\n**Note 7:** **Lymph nodes, NOS** \n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Lydiatt, W.M., Patel, S.G., Shah, J.P., et al. **Staging Head and Neck Cancers**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Lydiatt, W.M., Ridge, J.A., Shah, J.P., et al. **Oropharynx (p16-) and Hypopharynx**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:42:10.593Z", + "last_modified" : "2025-11-14T20:06:06.969Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_22383.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_22383.json index aaf65cc56..6acc5b1f4 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_22383.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_22383.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS**\n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n\n**Note 2:** **Lymph nodes, NOS** \n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Phan, A.T., Perrier, N.D., et al. **Adrenal Cortical Carcinoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:30.930Z", + "last_modified" : "2025-11-14T20:05:12.173Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_27426.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_27426.json index 710b6a966..e7121b853 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_27426.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_27426.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n\n**Note 2:** **Lymph nodes, NOS** \n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Mallipatna, A.C., Finger, P.T., et al. **Retinoblastoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:42:09.158Z", + "last_modified" : "2025-11-14T20:05:13.231Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_29442.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_29442.json index e9346db59..0f5b2f7e9 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_29442.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_29442.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n\n**Note 2:** **Psammoma bodies only**\n* Psammoma bodies are counted as positive regional lymph nodes\n\n**Note 3:** **Lymph nodes, NOS** \n * Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Tuttle, R.M., Perrier, N.D., et al. **Thyroid - Differentiated and Anaplastic Carcinoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:56.800Z", + "last_modified" : "2025-11-14T20:05:13.663Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_30921.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_30921.json index 6eba612ab..78162287b 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_30921.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_30921.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n\n**Note 2:** **Lymph nodes, NOS** \n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) **Anus**, from the AJCC Cancer Staging System Version 9 (2022). Used with permission of the American College of Surgeons, Chicago, Illinois.", - "last_modified" : "2025-09-18T20:41:45.993Z", + "last_modified" : "2025-11-14T20:05:51.805Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_3383.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_3383.json index 295afdd56..501124c02 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_3383.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_3383.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n\n**Note 2:** **Mesenteric nodes** \n* The specific location of the mesenteric nodes determines whether they are regional or distant. \n* If the specific location is not described, code in EOD Regional Nodes.\n\n**Note 3:** **Porta hepatic nodes** \n* Porta hepatic nodes are recorded as distant for Body and Tail and should be coded in EOD Mets. \n* If the specific location for hepatic nodes is not described, code in EOD Regional Nodes.\n\n**Note 4:** **Lymph nodes, NOS** \n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Bergsland, E.K., Woltering, E.A., Klimstra, D.S., et al. **Neuroendocrine Tumors of the Pancreas**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) **Neuroendocrine Tumors of the Pancreas**, from the AJCC Cancer Staging System Version 9 (2023). Used with permission of the American College of Surgeons, Chicago, Illinois.", - "last_modified" : "2025-09-18T20:41:33.022Z", + "last_modified" : "2025-11-14T20:05:22.700Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_36470.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_36470.json index 04cd3afab..ceb4bac53 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_36470.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_36470.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Definition of Head and Neck Lymph Nodes** \n* For head and neck schemas, this field includes all lymph nodes defined as Levels I-VII and Other by TNM. \n\n**Note 2:** **CLINICAL AND PATHOLOGICAL codes** \n* This schema has lymph node codes that are defined as **CLINICAL** assessment only or **PATHOLOGICAL** assessment only.\n\n**No surgical resection**\n* Use **CLINICAL** assessment only codes (325, 425, 525) when there is a clinical work up only and there is **NO surgical resection of the primary tumor or site** WITH \n * Any microscopic examination of regional lymph nodes, which includes FNA, core biopsy, sentinel node biopsy, lymph node excision, or lymph node dissection done during the clinical work up. \n\n**Surgical resection without neoadjuvant therapy**\n* Use **PATHOLOGICAL** assessment only codes (125, 225) when there is a **surgical resection of the primary tumor or site** WITH \n * Any microscopic examination of regional lymph nodes, which includes FNA, core biopsy, sentinel node biopsy, lymph node excision done or lymph node dissection performed.\n\n**Surgical resection after neoadjuvant therapy**\n* If patient has neoadjuvant therapy, and the clinical assessment is equal to or greater than the pathological assessment, then the clinical assessment codes take priority. Otherwise, code the pathologic assessment. \n * See ***EOD 2018 General Instructions*** for further instructions on coding cases with neoadjuvant therapy, https://seer.cancer.gov/tools/staging/eod/.\n\n\n**Note 3:** **Laterality** \n* If laterality of lymph nodes is not specified, assume nodes are ipsilateral. Midline nodes are ipsilateral.\n\n**Note 4:** **Supraclavicular lymph nodes** \n* Supraclavicular lymph nodes can be either Level IV or Level V\n * Level IV: deep to the sternocleidomastoid muscle, in the lower jugular chain\n * Level V: in the posterior triangle, inferior to the transverse cervical artery, supraclavicular lymph nodes, NOS\n\n**Note 5:** **Regional lymph nodes for Head and Neck tumors** \n\n**Level I**\nLevel IA - Submental\nLevel IB - Submandibular (submaxillary), sublingual\n\n**Level II - Upper jugular** \nJugulodigastric (subdigastric)\nUpper deep cervical \nLevel IIA - Anterior\nLevel IIB - Posterior \n\n**Level III - Middle jugular**\nMiddle deep cervical\n\n**Level IV - Lower jugular**\nJugulo-omohyoid (supraomohyoid)\nLower deep cervical \nVirchow node\n\n**Level V - Posterior triangle group**\nPosterior cervical\nLevel VA - Spinal accessory \nLevel VB - Transverse cervical, supraclavicular \n\n**Level VI - Anterior compartment group**\nLaterotracheal\nParalaryngeal\nParatracheal - above suprasternal notch\nPerithyroidal\nPrecricoid (Delphian)\nPrelaryngeal\nPretracheal - above suprasternal notch\nRecurrent laryngeal\n\n**Level VII - Superior mediastinal group (for other mediastinal node(s) see EOD Mets)**\nEsophageal groove\nParatracheal - below suprasternal notch\nPretracheal - below suprasternal notch \n\n**Other groups**\nCervical, NOS\nDeep cervical, NOS\nFacial\n- Buccinator (buccal)\n- Mandibular\n- Nasolabial\n\nInternal jugular, NOS\nParapharyngeal \nParotid\n- Infraauricular\n- Intraparotid\n- Periparotid\n- Preauricular\n\nRetroauricular (mastoid)\nRetropharyngeal\nSuboccipital", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Lydiatt, W.M., Patel, S.G., Shah, J.P., et al. **Staging Head and Neck Cancers**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Lydiatt, W.M., Shah, J.P., et al. **Major Salivary Glands**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(7) **Salivary Glands**, from the AJCC Cancer Staging System Version 9 (2026). Used with permission of the American College of Surgeons, Chicago, Illinois.", - "last_modified" : "2025-09-18T20:41:55.673Z", + "last_modified" : "2025-11-14T20:06:03.832Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_38984.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_38984.json index 134096f57..1f939ed09 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_38984.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_38984.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n\n**Note 2:** **FIGO and lymph node detail** \n* When both the Federation Internationale de Gynecologie et d'Obstetrique (FIGO) stage and lymph node detail are available, record the code with lymph node detail in preference to a statement of FIGO stage.\n\n**Note 3:** **Isolated tumor cells** \n* Isolated tumor cells (ITCs) are defined as single tumor cells or small clusters not greater than 0.2 mm, usually detected by immunohistochemical (IHC) or molecular methods. ITCs do not usually show evidence of malignant activity (e.g., proliferation or stromal reaction). Lymph nodes with ITCs only are not counted as positive nodes. \n* For positive ITCs with NO regional lymph node involvement, code 040\n\n**Note 4:** **Regional lymph nodes include**\n- Femoral\n- Inguinal, NOS\n + Inguinofemoral (groin)\n + Node of Cloquet or Rosenmuller (highest deep inguinal)\n + Superficial inguinal\n\n**Note 5:** **Lymph nodes, NOS** \n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) **Introduction to Female Reproductive Organs**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Gibb, R.K., Olawaiye, A.B., Mutch, D.G., et al. **Vulva**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(7) **Vulva,** from the AJCC Cancer Staging System Version 9 (2023). Used with permission of the American College of Surgeons, Chicago, Illinois.", - "last_modified" : "2025-09-18T20:41:38.940Z", + "last_modified" : "2025-11-14T20:06:01.901Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_48374.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_48374.json index 1b48b4e6d..d044fe0d9 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_48374.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_48374.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n\n**Note 2:** **Lymph nodes, NOS** \n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Bergsland, E.K., Woltering, E.A., Klimstra, D.S., et al. **Neuroendocrine Tumors of the Duodenum and Ampulla of Vater.** In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) **Neuroendocrine Tumors of the Duodenum and Ampulla of Vater**, from the AJCC Cancer Staging System Version 9 (2023). Used with permission of the American College of Surgeons, Chicago, Illinois.", - "last_modified" : "2025-09-18T20:41:48.779Z", + "last_modified" : "2025-11-14T20:05:08.980Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_53169.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_53169.json index 469c17254..34894b8df 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_53169.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_53169.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n\n**Note 2:** **Inguinal lymph nodes** \n* Inguinal lymph nodes are no longer coded as regional lymph nodes. See EOD Mets.\n\n**Note 3:** **Isolated tumor cells** \n* Isolated tumor cells (ITCs) are defined as single tumor cells or small clusters not greater than 0.2 mm, usually detected by immunohistochemical (IHC) or molecular methods. \n* ITCs do not usually show evidence of malignant activity (e.g., proliferation or stromal reaction). Lymph nodes with ITCs only are not counted as positive nodes \n * For positive ITCs with NO regional lymph node involvement, code 050\n\n**Note 4:** **Regional lymph nodes include (bilateral and contralateral)**\n- Intrabdominal \n- Para-aortic, NOS\n + Aortic\n + Lateral aortic/lateral lumbar\n + Periaortic\n- Pelvic, NOS\n + Iliac, NOS\n + Common\n + External\n + Internal (hypogastric) (obturator)\n + Paracervical\n + Parametrial\n + Sacral, NOS\n + Lateral (laterosacral)\n + Middle (promontorial) (Gerota's node)\n + Presacral\n + Uterosacral\n- Retroperitoneal, NOS\n\n**Note 5:** **Lymph nodes, NOS** \n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) **Introduction to Female Reproductive Organs**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Prat, J., Olawaiye, A.B., Mutch, D.G., et al. **Ovary, Fallopian Tube, and Primary Peritoneal Carcinoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:31.880Z", + "last_modified" : "2025-11-14T20:05:15.943Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_55756.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_55756.json index 2ed136f86..f9fcba8dc 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_55756.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_55756.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Definition of Head and Neck Lymph Nodes** \n* For head and neck schemas, this field includes all lymph nodes defined as Levels I-VII and Other by TNM. \n\n**Note 2:** **CLINICAL AND PATHOLOGICAL codes** \n* This schema has lymph node codes that are defined as **CLINICAL** assessment only or **PATHOLOGICAL** assessment only.\n\n**No surgical resection**\n* Use **CLINICAL** assessment only codes (450) when there is a clinical work up only and there is **NO surgical resection of the primary tumor or site** WITH \n * Any microscopic examination of regional lymph nodes, which includes FNA, core biopsy, sentinel node biopsy, lymph node excision, or lymph node dissection done during the clinical work up. \n\n**Surgical resection without neoadjuvant therapy**\n* Use **PATHOLOGICAL** assessment only codes (150, 500, 600, 700) when there is a **surgical resection of the primary tumor or site** WITH \n * Any microscopic examination of regional lymph nodes, which includes FNA, core biopsy, sentinel node biopsy, lymph node excision done or lymph node dissection performed.\n\n**Surgical resection after neoadjuvant therapy**\n* If patient has neoadjuvant therapy, and the clinical assessment is equal to or greater than the pathological assessment, then the clinical assessment codes take priority. Otherwise, code the pathologic assessment. \n * See ***EOD 2018 General Instructions*** for further instructions on coding cases with neoadjuvant therapy, https://seer.cancer.gov/tools/staging/eod/.\n\n\n**Note 3:** **Laterality** \n* If laterality of lymph nodes is not specified, assume nodes are ipsilateral. Midline nodes are ipsilateral.\n\n**Note 4:** **Supraclavicular lymph nodes** \n* Supraclavicular lymph nodes can be either Level IV or Level V\n * Level IV: deep to the sternocleidomastoid muscle, in the lower jugular chain\n * Level V: in the posterior triangle, inferior to the transverse cervical artery, supraclavicular lymph nodes, NOS\n\n**Note 5:** **Extranodal extension** \n* Extranodal extension (ENE) is defined as the extension of a nodal metastasis through the lymph node capsule into adjacent tissue. The following codes record the status of the lymph nodes with positive ENE\n * Code 150: Pathological only: single ipsilateral node, less than or equal to 3 cm\n * Code 450: Clinical only: overt ENE\n * Code 500: Pathological only: single ipsilateral node, greater than 3 cm\n * Code 600: Pathological only: multiple ipsilateral, bilateral or contralateral nodes\n * Code 700: Pathological only: Single contralateral node\n\n**Note 6:** **Regional lymph nodes for Head and Neck tumors** \n* **Note:** For codes 100-700, use the list below for named regional lymph nodes. If the only information available is \"regional lymph nodes, NOS\" or \"lymph nodes,\" code 800.\n\n**Level I**\nLevel IA - Submental\nLevel IB - Submandibular (submaxillary), sublingual\n\n**Level II - Upper jugular** \nJugulodigastric (subdigastric)\nUpper deep cervical \nLevel IIA - Anterior\nLevel IIB - Posterior \n\n**Level III - Middle jugular**\nMiddle deep cervical\n\n**Level IV - Lower jugular**\nJugulo-omohyoid (supraomohyoid)\nLower deep cervical \nVirchow node\n\n**Level V - Posterior triangle group**\nPosterior cervical\nLevel VA - Spinal accessory \nLevel VB - Transverse cervical, supraclavicular \n\n**Level VI - Anterior compartment group**\nLaterotracheal\nParalaryngeal\nParatracheal - above suprasternal notch\nPerithyroidal\nPrecricoid (Delphian)\nPrelaryngeal\nPretracheal - above suprasternal notch\nRecurrent laryngeal\n\n**Level VII - Superior mediastinal group (for other mediastinal nodes see EOD Mets)**\nEsophageal groove\nParatracheal - below suprasternal notch\nPretracheal - below suprasternal notch \n\n**Other groups**\nCervical, NOS\nDeep cervical, NOS\nFacial\n- Buccinator (buccal)\n- Mandibular\n- Nasolabial\n\nInternal jugular, NOS\nParapharyngeal \nParotid\n- Infraauricular\n- Intraparotid\n- Periparotid\n- Preauricular\n\nRetroauricular (mastoid)\nRetropharyngeal\nSuboccipital\n\n**Note 7:** **Lymph nodes, NOS** \n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Lydiatt, W.M., Patel, S.G., Shah, J.P., et al. **Staging Head and Neck Cancers**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Lydiatt, W.M., Ridge, J.A., Shah, J.P., et al. **Oropharynx (p16-) and Hypopharynx**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:59.628Z", + "last_modified" : "2025-11-14T20:05:05.333Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_58339.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_58339.json index 52e6401ca..638cf4414 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_58339.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_58339.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n\n**Note 2:** **Lymph nodes, NOS** \n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Conway, R.M., Finger, P.T., et al. **Conjunctival Carcinoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:41.640Z", + "last_modified" : "2025-11-14T20:05:06.673Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_61282.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_61282.json index e9821eb01..526ad8e22 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_61282.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_61282.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n\n**Note 2:** **Nodal metastasis rare** \n* Regional lymph node involvement is rare. For this schema, if there is no mention of lymph node involvement clinically, assume that lymph nodes are negative. \n* Code 999 (Unknown) only when there is no available information on the extent of the patient's disease, for example when a lab-only case is abstracted from a biopsy report and no clinical history is available.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)", - "last_modified" : "2025-09-18T20:42:08.210Z", + "last_modified" : "2025-11-14T20:06:09.836Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_62689.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_62689.json index 83f85d4b1..c75ebde91 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_62689.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_62689.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n\n**Note 2:** **LAMN tumors** \n* Nodal metastasis is very rare in low-grade appendiceal neoplasms (LAMN). If there is no mention of lymph nodes in the pathology report for a LAMN, code as none (000). \n\n**Note 3:** **CLINICAL and PATHOLOGICAL codes** \n* This schema has lymph node codes that are defined as **CLINICAL** assessment only or **PATHOLOGICAL** assessment only. \n\n**No surgical resection**\n* Use **CLINICAL** assessment only codes (450, 500, 550, 600, 650, 700) when there is a clinical work up only and there is **NO surgical resection of the primary tumor or site** WITH \n * Any microscopic examination of regional lymph nodes, which includes FNA, core biopsy, sentinel node biopsy, lymph node excision, or lymph node dissection done during the clinical work up. \n\n**Surgical resection without neoadjuvant therapy**\n* Use **PATHOLOGICAL** assessment only codes (300, 400) when there is a **surgical resection of the primary tumor or site** WITH \n * Any microscopic examination of regional lymph nodes, which includes FNA, core biopsy, sentinel node biopsy, lymph node excision done or lymph node dissection performed.\n\n**Surgical resection after neoadjuvant therapy**\n* If patient has neoadjuvant therapy, and the clinical assessment is equal to or greater than the pathological assessment, then the clinical assessment codes take priority. Otherwise, code the pathologic assessment. \n * See ***EOD 2018 General Instructions*** for further instructions on coding cases with neoadjuvant therapy, https://seer.cancer.gov/tools/staging/eod/.\n\n**Note 4:** **Tumor Deposits** \n* Code 400 is defined as **PATHOLOGICAL** assessment only. This is used when\n * Primary tumor or site surgically resected with\n * Any positive microscopic examination of tumor deposits WITHOUT positive lymph nodes\n * If there are also positive lymph nodes, code 300", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) **Appendix**, from the AJCC Cancer Staging System Version 9 (2022). Used with permission of the American College of Surgeons, Chicago, Illinois.", - "last_modified" : "2025-09-18T20:41:28.405Z", + "last_modified" : "2025-11-14T20:05:04.844Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_6464.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_6464.json index 046cf8a9b..bcf922ce6 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_6464.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_6464.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Definition of Head and Neck Lymph Nodes** \n* For head and neck schemas, this field includes all lymph nodes defined as Levels I-VII and Other by TNM. \n\n**Note 2:** **CLINICAL AND PATHOLOGICAL codes** \n* This schema has lymph node codes that are defined as **CLINICAL** assessment only or **PATHOLOGICAL** assessment only.\n\n**No surgical resection**\n* Use **CLINICAL** assessment only codes (250, 350, 450, 550, 650) when there is a clinical work up only and there is **NO surgical resection of the primary tumor or site** WITH \n * Any microscopic examination of regional lymph nodes, which includes FNA, core biopsy, sentinel node biopsy, lymph node excision, or lymph node dissection done during the clinical work up. \n\n**Surgical resection without neoadjuvant therapy**\n* Use **PATHOLOGICAL** assessment only codes (100, 200) when there is a **surgical resection of the primary tumor or site** WITH \n * Any microscopic examination of regional lymph nodes, which includes FNA, core biopsy, sentinel node biopsy, lymph node excision done or lymph node dissection performed.\n\n**Surgical resection after neoadjuvant therapy**\n* If patient has neoadjuvant therapy, and the clinical assessment is equal to or greater than the pathological assessment, then the clinical assessment codes take priority. Otherwise, code the pathologic assessment. \n * See ***EOD 2018 General Instructions*** for further instructions on coding cases with neoadjuvant therapy, https://seer.cancer.gov/tools/staging/eod/.\n\n \n**Note 3:** **Laterality** \n* If laterality of lymph nodes is not specified, assume nodes are ipsilateral. Midline nodes are ipsilateral.\n\n**Note 4:** **Supraclavicular lymph nodes** \n* Supraclavicular lymph nodes can be either Level IV or Level V\n * Level IV: deep to the sternocleidomastoid muscle, in the lower jugular chain\n * Level V: in the posterior triangle, inferior to the transverse cervical artery, supraclavicular lymph nodes, NOS\n\n**Note 5:** **Regional lymph nodes for Head and Neck tumors** \n* **Note:** For codes 300, 400, or 500, use the list below for named regional lymph nodes. If the only information available is \"regional lymph nodes, NOS\" or \"lymph nodes,\" code 800.\n\n**Level I**\n- Level IA - Submental\n- Level IB - Submandibular (submaxillary), sublingual\n\n**Level II - Upper jugular** \n- Jugulodigastric (subdigastric)\n- Upper deep cervical \n- Level IIA - Anterior\n- Level IIB - Posterior \n\n**Level III - Middle jugular**\n- Middle deep cervical\n\n**Level IV - Lower jugular**\n- Jugulo-omohyoid (supraomohyoid)\n- Lower deep cervical \n- Virchow node\n\n**Level V - Posterior triangle group**\n- Posterior cervical\n- Level VA - Spinal accessory \n- Level VB - Transverse cervical, supraclavicular \n\n**Level VI - Anterior compartment group**\n- Laterotracheal\n- Paralaryngeal\n- Paratracheal - above suprasternal notch\n- Perithyroidal\n- Precricoid (Delphian)\n- Prelaryngeal\n- Pretracheal - above suprasternal notch\n- Recurrent laryngeal\n\n**Level VII - Superior mediastinal group (for other mediastinal node(s), see EOD Mets)**\n- Esophageal groove\n- Paratracheal - below suprasternal notch\n- Pretracheal - below suprasternal notch \n\n**Other groups**\n- Cervical, NOS\n- Deep cervical, NOS\n- Facial\n + Buccinator (buccal)\n + Mandibular\n + Nasolabial\n- Internal jugular, NOS\n- Parapharyngeal \n- Parotid\n + Infraauricular\n + Intraparotid\n + Periparotid\n + Preauricular\n- Retroauricular (mastoid)\n- Retropharyngeal\n- Suboccipital\n- Regional lymph node(s), NOS\n- Lymph node(s), NOS\n\n**Note 6:** **Lymph nodes, NOS** \n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Lydiatt, W.M., Patel, S.G., Shah, J.P., et al. **Staging Head and Neck Cancers**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) O'Sullivan, B., Lydiatt, W.M., Shah, J.P., et al. **Oropharynx HPV-Mediated**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(7) **Oropharynx HPV-Associated**, from the AJCC Cancer Staging System Version 9 (2025). Used with permission of the American College of Surgeons, Chicago, Illinois.", - "last_modified" : "2025-09-19T18:45:25.572Z", + "last_modified" : "2025-11-14T20:06:06.559Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_65616.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_65616.json index 463f7ca36..d2327c296 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_65616.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_65616.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n\n**Note 2:** **Lymph nodes, NOS** \n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Dutton, J.J., Finger, P.T., et al. **Orbital Sarcoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:34.298Z", + "last_modified" : "2025-11-14T20:05:36.130Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_7080.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_7080.json index 11d75efd6..bab79427d 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_7080.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_7080.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n\n**Note 2:** **CLINICAL AND PATHOLOGICAL codes** \n* This schema has lymph node codes that are defined as **CLINICAL** assessment only or **PATHOLOGICAL** assessment only.\n\n**No surgical resection**\n* Use **CLINICAL** assessment only codes (450) when there is a clinical work up only and there is **NO surgical resection of the primary tumor or site** WITH \n * Any microscopic examination of regional lymph nodes, which includes FNA, core biopsy, sentinel node biopsy, lymph node excision, or lymph node dissection done during the clinical work up. \n\n**Surgical resection without neoadjuvant therapy**\n* Use **PATHOLOGICAL** assessment only codes (150, 500, 600, 700) when there is a **surgical resection of the primary tumor or site** WITH \n * Any microscopic examination of regional lymph nodes, which includes FNA, core biopsy, sentinel node biopsy, lymph node excision done or lymph node dissection performed.\n\n**Surgical resection after neoadjuvant therapy**\n* If patient has neoadjuvant therapy, and the clinical assessment is equal to or greater than the pathological assessment, then the clinical assessment codes take priority. Otherwise, code the pathologic assessment. \n * See ***EOD 2018 General Instructions*** for further instructions on coding cases with neoadjuvant therapy, https://seer.cancer.gov/tools/staging/eod/.\n\n**Note 3:** **Laterality** \n* If laterality of lymph nodes is not specified, assume nodes are ipsilateral. Midline nodes are ipsilateral.\n\n**Note 4:** **Supraclavicular lymph nodes** \n* Supraclavicular lymph nodes can be either Level IV or Level V\n * Level IV: deep to the sternocleidomastoid muscle, in the lower jugular chain\n * Level V: in the posterior triangle, inferior to the transverse cervical artery, supraclavicular lymph nodes, NOS\n\n**Note 5:** **Bilateral and contralateral nodes** \n* Bilateral or contralateral nodes are classified as regional nodes for head, neck, and truncal tumors with bidirectional drainage to primary nodal basins, as shown on lymphoscintigraphy. \n * Truncal tumors may also drain to both cephalad and caudal primary nodal basins as shown on lymphoscintigraphy.\n* Clinical assessment of bilateral/contralateral or cephalad/caudal regional nodal involvement is required for tumors where lymphoscintigraphy is not performed\n\n**Note 6:** **Nodal basins** \n* Contiguous or secondary nodal basins are the next nodal drainage basins beyond the primary nodal basins and are coded as regional nodes.\n\n**Note 7:** **Extranodal extension** \n* Extranodal extension (ENE) is defined as the extension of a nodal metastasis through the lymph node capsule into adjacent tissue. The following codes record the status of the lymph nodes with positive ENE\n * Code 150: Pathological only: single ipsilateral node, less than or equal to 3 cm\n * Code 450: Clinical only: overt ENE\n * Code 500: Pathological only: single ipsilateral node, greater than 3 cm\n * Code 600: Pathological only: multiple ipsilateral, bilateral or contralateral nodes\n * Code 700: Pathological only: Single contralateral node\n\n**Note 8:** **Regional lymph nodes for Head and Neck tumors**\n* **Note:** For codes 100-700, use the list below for named regional lymph nodes. If the only information available is \"regional lymph nodes, NOS\" or \"lymph nodes,\" code 800.\n\n**Level I**\nLevel IA - Submental\nLevel IB - Submandibular (submaxillary), sublingual\n\n**Level II - Upper jugular** \nJugulodigastric (subdigastric)\nUpper deep cervical \nLevel IIA - Anterior\nLevel IIB - Posterior \n\n**Level III - Middle jugular**\nMiddle deep cervical\n\n**Level IV - Lower jugular**\nJugulo-omohyoid (supraomohyoid)\nLower deep cervical \nVirchow node\n\n**Level V - Posterior triangle group**\nPosterior cervical\nLevel VA - Spinal accessory \nLevel VB - Transverse cervical, supraclavicular \n\n**Level VI - Anterior compartment group**\nLaterotracheal\nParalaryngeal\nParatracheal - above suprasternal notch\nPerithyroidal\nPrecricoid (Delphian)\nPrelaryngeal\nPretracheal - above suprasternal notch\nRecurrent laryngeal\n\n**Level VII - Superior mediastinal group (for other mediastinal node(s) see EOD Mets)**\nEsophageal groove\nParatracheal - below suprasternal notch\nPretracheal - below suprasternal notch \n\n**Other groups**\nCervical, NOS\nDeep cervical, NOS\nFacial\n- Buccinator (buccal)\n- Mandibular\n- Nasolabial\n\nInternal jugular, NOS\nParapharyngeal \nParotid\n- Infraauricular\n- Intraparotid\n- Periparotid\n- Preauricular\n\nRetroauricular (mastoid)\nRetropharyngeal\nSuboccipital", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Lydiatt, W.M., Patel, S.G., Shah, J.P., et al. **Staging Head and Neck Cancers**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Califano, J.A., Lydiatt, W.M., Shah, J.P., et al. **Cutaneous Carcinoma of the Head and Neck**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:42:13.835Z", + "last_modified" : "2025-11-14T20:06:07.733Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_76612.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_76612.json index ae89d86b2..69289188a 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_76612.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_76612.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n\n**Note 2:** **Lymph nodes, NOS** \n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Kivelä, T., Finger, P.T., et al. **Uveal Melanoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:42:21.781Z", + "last_modified" : "2025-11-14T20:05:50.384Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_77237.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_77237.json index 47fea8e96..d4c12732e 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_77237.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_77237.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Definition of Head and Neck Lymph Nodes** \n* For head and neck schemas, this field includes all lymph nodes defined as Levels I-VII and Other by TNM. \n\n**Note 2:** **Code 000** \n* For this schema, code 000 (no regional lymph node involvement) is not applicable. This code was removed effective Version 2.0 and later in an effort to stop this schema being used when it is not applicable. \n* To get into this schema, there **must** be lymph node involvement (clinically or pathologically)\n - If you are in this schema and there are negative nodes clinically, please review the response to Schema Discriminator 1: Occult Head and Neck Lymph Nodes and reassign appropriately (Code 1is for primary site C760 with negative lymph node involvement)\n - This schema may be used for nodes that are clinically positive (FNA, core biopsy, lymph node biopsy, lymph node excision or sentinel lymph node biopsy), but are confirmed to be pathologically negative on a lymph node dissection. In these cases, the clinical lymph node involvement has priority and should be coded in this field\n * ***Example 1:*** Excision of a single cervical node was positive, subsequent cervical lymph node dissection was negative\n * ***Example 2:*** Biopsy of a cervical was positive, the patient underwent neoadjuvant treatment, followed by a negative lymph node dissection\n - This schema may **not** be used when nodes are positive on imaging only (not microscopically confirmed clinically) and the same nodes are removed and negative. In this situation, the pathological lymph node involvement would take priority and the lymph nodes would be coded as not involved (see first bullet about reviewing the schema discriminator)\n\n**Note 3:** **CLINICAL AND PATHOLOGICAL codes** \n* This schema has lymph node codes that are defined as **CLINICAL** assessment only or **PATHOLOGICAL** assessment only.\n\n+ **PATHOLOGICAL** assessment only codes (150, 500, 600, 700) are used when\n * Any microscopic examination of regional lymph nodes. Includes\n - FNA, core biopsy, sentinel node biopsy or lymph node excision done during the clinical work up and/or\n - Lymph node dissection performed\n \n * Pathological codes 150, 500, 600, 700 take priority over clinical code 450\n * *Exception:* If patient has neoadjuvant therapy, and the clinical assessment is greater than the pathological assessment, then the clinical assessment code would take priority\n\n+ **CLINICAL** assessment only code (450) is used when there is a clinical work up only and there is no surgical resection of the primary tumor or site. This includes FNA, core biopsy, sentinel node biopsy, or lymph node excision\n \n+ Remaining codes (no designation of **CLINICAL** or **PATHOLOGICAL** only assessment) can be used based on clinical and/or pathological information\n\n\n**Note 4:** **Laterality** \n* If laterality of lymph nodes is not specified, assume nodes are ipsilateral. Midline nodes are ipsilateral.\n\n**Note 5:** **Supraclavicular lymph nodes** \n* Supraclavicular lymph nodes can be either Level IV or Level V\n * Level IV: deep to the sternocleidomastoid muscle, in the lower jugular chain\n * Level V: in the posterior triangle, inferior to the transverse cervical artery, supraclavicular lymph nodes, NOS\n\n**Note 6:** **Regional lymph nodes for Head and Neck tumors**\n\n* **Note:** For codes 100-700, use the list below for named regional lymph nodes. If the only information available is \"regional lymph nodes, NOS\" or \"lymph nodes,\" code 800.\n\n**Level I**\nLevel IA - Submental\nLevel IB - Submandibular (submaxillary), sublingual\n\n**Level II - Upper jugular** \nJugulodigastric (subdigastric)\nUpper deep cervical \nLevel IIA - Anterior\nLevel IIB - Posterior \n\n**Level III - Middle jugular**\nMiddle deep cervical\n\n**Level IV - Lower jugular**\nJugulo-omohyoid (supraomohyoid)\nLower deep cervical \nVirchow node\n\n**Level V - Posterior triangle group**\nPosterior cervical\nLevel VA - Spinal accessory \nLevel VB - Transverse cervical, supraclavicular. \n\n**Level VI - Anterior compartment group**\nLaterotracheal\nParalaryngeal\nParatracheal - above suprasternal notch\nPerithyroidal\nPrecricoid (Delphian)\nPrelaryngeal\nPretracheal - above suprasternal notch\nRecurrent laryngeal\n\n**Level VII - Superior mediastinal group (for other mediastinal node(s) see EOD Mets)**\nEsophageal groove\nParatracheal - below suprasternal notch\nPretracheal - below suprasternal notch \n\n**Other groups**\nCervical, NOS\nDeep cervical, NOS\nFacial\n- Buccinator (buccal)\n- Mandibular\n- Nasolabial\n\nInternal jugular, NOS\nParapharyngeal \nParotid\n- Infraauricular\n- Intraparotid\n- Periparotid\n- Preauricular\n\nRetroauricular (mastoid)\nRetropharyngeal\nSuboccipital\n\n**Note 7:** **Lymph nodes, NOS**\n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Lydiatt, W.M., Patel, S.G., Shah, J.P., et al. **Staging Head and Neck Cancers**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Patel, S.G., Lydiatt, W.M., Shah, J.P., et al. **Cervical Lymph Nodes and Unknown Primary Tumors of the Head and Neck**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:42:21.295Z", + "last_modified" : "2025-11-14T20:06:15.482Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_79068.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_79068.json index 9a7a01dee..05400fd85 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_79068.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_79068.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n\n**Note 2:** **Lymph nodes, NOS** \n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Kivelä, T., Finger, P.T., et al. **Uveal Melanoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:42:07.807Z", + "last_modified" : "2025-11-14T20:06:02.357Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_80411.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_80411.json index 1559c90a0..24be640b3 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_80411.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_80411.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Extraosseous plasmacytomas** Extraosseous plasmacytomas (9734), especially those in the respiratory tract, may metastasize to regional lymph nodes. \n\n**Note 2:** **Histologies not applicable** \n* Code 987, not applicable, for\n * Lymphoplasmacytic lymphoma (9671)\n * Plasmacytoma, NOS (9731) \n * Single plasmacytoma occurring in bone (osseous or medullary) (9731)\n * Waldenstrom Macroglobulinemia (9761)", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) **Introduction to Hematologic Malignancies**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Bergsagel, P.L., Jaffe, E.S., Leonard, J.P., et al. **Plasma Cell Myeloma and Plasma Cell Disorders**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:42:10.288Z", + "last_modified" : "2025-11-14T20:06:14.694Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_8284.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_8284.json index d6c4692fc..869594c7c 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_8284.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_8284.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n\n**Note 2:** **Lymph nodes, NOS** \n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Coupland, S.E., Finger, P.T., et al. **Conjunctival Melanoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:26.421Z", + "last_modified" : "2025-11-14T20:05:12.892Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_86049.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_86049.json index 9821e74e3..2c25e46a8 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_86049.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_86049.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n\n**Note 2:** **Lymph nodes, NOS** \n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) White, V.A., Finger, P.T., et al. **Lacrimal Gland Carcinoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:57.226Z", + "last_modified" : "2025-11-14T20:06:12.412Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_92760.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_92760.json index a69e898b0..9213382c2 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_92760.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_92760.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS**\n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n\n**Note 2:** **Para-aortic nodes** \n* Para-aortic nodes are now regional instead of distant.\n\n**Note 3:** **FIGO and lymph node detail** \n* When both the Federation Internationale de Gynecologie et d'Obstetrique (FIGO) stage and lymph node detail are available, record the code with lymph node detail in preference to a statement of FIGO stage.\n\n**Note 4:** **Isolated tumor cells** \n* Isolated tumor cells (ITCs) are defined as single tumor cells or small clusters not greater than 0.2 mm, usually detected by immunohistochemical (IHC) or molecular methods. ITCs do not usually show evidence of malignant activity (e.g., proliferation or stromal reaction). Lymph nodes with ITCs only are not counted as positive nodes \n* For positive ITCs with NO regional lymph node involvement, code 050\n\n**Note 5:** **Regional lymph nodes include**:\n* Pelvic, NOS (codes 100-300)\n - Iliac, NOS \n + Common\n + External\n + Internal (hypogastric) (obturator)\n - Paracervical\n - Parametrial\n - Pelvic, NOS\n - Sacral, NOS \n + Lateral (laterosacral)\n + Middle (promontorial) (Gerota's node)\n + Presacral\n + Uterosacral\n \n* Para-aortic, NOS (WITH or WITHOUT pelvic lymph nodes) (codes 400-600)\n - Aortic\n - Lateral aortic/lateral lumbar\n - Periaortic\n\n**Note 6:** **Lymph nodes, NOS**\n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) **Cervix Uteri**, from the AJCC Cancer Staging System Version 9 (2020). Used with permission of the American College of Surgeons, Chicago, Illinois.", - "last_modified" : "2025-09-18T20:42:09.917Z", + "last_modified" : "2025-11-14T20:06:11.757Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_94494.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_94494.json index 9b86ac413..88ab132c6 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_94494.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_94494.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Definition of Head and Neck Lymph Nodes** \n* For head and neck schemas, this field includes all lymph nodes defined as Levels I-VII and Other by TNM. \n\n**Note 2:** **CLINICAL AND PATHOLOGICAL codes** \n* This schema has lymph node codes that are defined as **CLINICAL** assessment only or **PATHOLOGICAL** assessment only.\n\n**No surgical resection**\n* Use **CLINICAL** assessment only codes (450) when there is a clinical work up only and there is **NO surgical resection of the primary tumor or site** WITH \n * Any microscopic examination of regional lymph nodes, which includes FNA, core biopsy, sentinel node biopsy, lymph node excision, or lymph node dissection done during the clinical work up. \n\n**Surgical resection without neoadjuvant therapy**\n* Use **PATHOLOGICAL** assessment only codes (150, 500, 600, 700) when there is a **surgical resection of the primary tumor or site** WITH \n * Any microscopic examination of regional lymph nodes, which includes FNA, core biopsy, sentinel node biopsy, lymph node excision done or lymph node dissection performed.\n\n**Surgical resection after neoadjuvant therapy**\n* If patient has neoadjuvant therapy, and the clinical assessment is equal to or greater than the pathological assessment, then the clinical assessment codes take priority. Otherwise, code the pathologic assessment. \n * See ***EOD 2018 General Instructions*** for further instructions on coding cases with neoadjuvant therapy, https://seer.cancer.gov/tools/staging/eod/.\n\n \n**Note 3:** **Laterality** \n* If laterality of lymph nodes is not specified, assume nodes are ipsilateral. Midline nodes are ipsilateral.\n\n**Note 4:** **Supraclavicular lymph nodes** \n* Supraclavicular lymph nodes can be either Level IV or Level V\n * Level IV: deep to the sternocleidomastoid muscle, in the lower jugular chain\n * Level V: in the posterior triangle, inferior to the transverse cervical artery, supraclavicular lymph nodes, NOS\n\n**Note 5:** **Extranodal Extension** \n* Extranodal extension (ENE) is defined as the extension of a nodal metastasis through the lymph node capsule into adjacent tissue. The following codes record the status of the lymph nodes with positive ENE\n * Code 150: Pathological only: single ipsilateral node, less than or equal to 3 cm\n * Code 450: Clinical only: overt ENE\n * Code 500: Pathological only: single ipsilateral node, greater than 3 cm\n * Code 600: Pathological only: multiple ipsilateral, bilateral or contralateral nodes\n * Code 700: Pathological only: Single contralateral node\n\n**Note 6:** **Regional lymph nodes for Head and Neck tumors** \n* **Note:** For codes 100-700, use the list below for named regional lymph nodes. If the only information available is \"regional lymph nodes, NOS\" or \"lymph nodes,\" code 800.\n\n**Level I**\nLevel IA - Submental\nLevel IB - Submandibular (submaxillary), sublingual\n\n**Level II - Upper jugular** \nJugulodigastric (subdigastric)\nUpper deep cervical \nLevel IIA - Anterior\nLevel IIB - Posterior \n\n**Level III - Middle jugular**\nMiddle deep cervical\n\n**Level IV - Lower jugular**\nJugulo-omohyoid (supraomohyoid)\nLower deep cervical \nVirchow node\n\n**Level V - Posterior triangle group**\nPosterior cervical\nLevel VA - Spinal accessory \nLevel VB - Transverse cervical, supraclavicular \n\n**Level VI - Anterior compartment group**\nLaterotracheal\nParalaryngeal\nParatracheal - above suprasternal notch\nPerithyroidal\nPrecricoid (Delphian)\nPrelaryngeal\nPretracheal - above suprasternal notch\nRecurrent laryngeal\n\n**Level VII - Superior mediastinal group (for other mediastinal node(s) see EOD Mets)**\nEsophageal groove\nParatracheal - below suprasternal notch\nPretracheal - below suprasternal notch \n\n**Other groups**\nCervical, NOS\nDeep cervical, NOS\nFacial\n- Buccinator (buccal)\n- Mandibular\n- Nasolabial\n\nInternal jugular, NOS\nParapharyngeal \nParotid\n- Infraauricular\n- Intraparotid\n- Periparotid\n- Preauricular\n\nRetroauricular (mastoid)\nRetropharyngeal\nSuboccipital", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Lydiatt, W.M., Patel, S.G., Shah, J.P., et al. **Staging Head and Neck Cancers**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Lydiatt, W.M., Shah, J.P., et al. **Major Salivary Glands**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:42:14.507Z", + "last_modified" : "2025-11-14T20:05:06.268Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_97333.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_97333.json index 0a9f63ab9..9bc9fec7c 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_97333.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_97333.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n\n**Note 2:** **Lymph nodes, NOS** \n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions,** National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05.** American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Jimenez, C., Perrier, N.D., et al. **Adrenal - Neuroendocrine Tumors**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:32.699Z", + "last_modified" : "2025-11-14T20:05:20.907Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_99855.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_99855.json index aa6e8e945..5ba675d32 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_99855.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_99855.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Definition of Head and Neck Lymph Nodes** \n* For head and neck schemas, this field includes all lymph nodes defined as Levels I-VII and Other by TNM. \n\n**Note 2:** **CLINICAL AND PATHOLOGICAL codes** \n* This schema has lymph node codes that are defined as **CLINICAL** assessment only or **PATHOLOGICAL** assessment only.\n\n**No surgical resection**\n* Use **CLINICAL** assessment only codes (450) when there is a clinical work up only and there is **NO surgical resection of the primary tumor or site** WITH \n * Any microscopic examination of regional lymph nodes, which includes FNA, core biopsy, sentinel node biopsy, lymph node excision, or lymph node dissection done during the clinical work up. \n\n**Surgical resection without neoadjuvant therapy**\n* Use **PATHOLOGICAL** assessment only codes (150, 500, 600, 700) when there is a **surgical resection of the primary tumor or site** WITH \n * Any microscopic examination of regional lymph nodes, which includes FNA, core biopsy, sentinel node biopsy, lymph node excision done or lymph node dissection performed.\n\n**Surgical resection after neoadjuvant therapy**\n* If patient has neoadjuvant therapy, and the clinical assessment is equal to or greater than the pathological assessment, then the clinical assessment codes take priority. Otherwise, code the pathologic assessment. \n * See ***EOD 2018 General Instructions*** for further instructions on coding cases with neoadjuvant therapy, https://seer.cancer.gov/tools/staging/eod/.\n\n**Note 3:** **Laterality** \n* If laterality of lymph nodes is not specified, assume nodes are ipsilateral. Midline nodes are ipsilateral.\n\n**Note 4:** **Supraclavicular lymph nodes** \n* Supraclavicular lymph nodes can be either Level IV or Level V\n * Level IV: deep to the sternocleidomastoid muscle, in the lower jugular chain\n * Level V: in the posterior triangle, inferior to the transverse cervical artery, supraclavicular lymph nodes, NOS\n\n**Note 5:** **Extranodal extension** \n* Extranodal extension (ENE) is defined as the extension of a nodal metastasis through the lymph node capsule into adjacent tissue. The following codes record the status of the lymph nodes with positive ENE\n * Code 150: Pathological only: single ipsilateral node, less than or equal to 3 cm\n * Code 450: Clinical only: overt ENE\n * Code 500: Pathological only: single ipsilateral node, greater than 3 cm\n * Code 600: Pathological only: multiple ipsilateral, bilateral or contralateral nodes\n * Code 700: Pathological only: Single contralateral node\n\n**Note 6:** **Regional lymph nodes for Head and Neck tumors** \n* **Note:** For codes 100-700, use the list below for named regional lymph nodes. If the only information available is \"regional lymph nodes, NOS\" or \"lymph nodes,\" code 800.\n\n**Level I**\nLevel IA - Submental\nLevel IB - Submandibular (submaxillary), sublingual\n\n**Level II - Upper jugular** \nJugulodigastric (subdigastric)\nUpper deep cervical \nLevel IIA - Anterior\nLevel IIB - Posterior \n\n**Level III - Middle jugular**\nMiddle deep cervical\n\n**Level IV - Lower jugular**\nJugulo-omohyoid (supraomohyoid)\nLower deep cervical \nVirchow node\n\n**Level V - Posterior triangle group**\nPosterior cervical\nLevel VA - Spinal accessory \nLevel VB - Transverse cervical, supraclavicular \n\n**Level VI - Anterior compartment group**\nLaterotracheal\nParalaryngeal\nParatracheal - above suprasternal notch\nPerithyroidal\nPrecricoid (Delphian)\nPrelaryngeal\nPretracheal - above suprasternal notch\nRecurrent laryngeal\n\n**Level VII - Superior mediastinal group (for other mediastinal node(s) see EOD Mets)**\nEsophageal groove\nParatracheal - below suprasternal notch\nPretracheal - below suprasternal notch \n\n**Other groups**\nCervical, NOS\nDeep cervical, NOS\nFacial\n- Buccinator (buccal)\n- Mandibular\n- Nasolabial\n\nInternal jugular, NOS\nParapharyngeal \nParotid\n- Infraauricular\n- Intraparotid\n- Periparotid\n- Preauricular\n\nRetroauricular (mastoid)\nRetropharyngeal\nSuboccipital", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Lydiatt, W.M., Patel, S.G., Shah, J.P., et al. **Staging Head and Neck Cancers**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Kraus, D.H., Lydiatt, W.M., Shah, J.P., et al. **Nasal Cavity and Paranasal Sinuses**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:43.279Z", + "last_modified" : "2025-11-14T20:06:07.290Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_v9_3599.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_v9_3599.json index 3ab8e4a0b..31f59311e 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_v9_3599.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_v9_3599.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n\n**Note 2:** **Lymph nodes, NOS** \n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) **Thymus**, from the AJCC Cancer Staging System Version 9 (2025). Used with permission of the American College of Surgeons, Chicago, Illinois.", - "last_modified" : "2025-09-18T20:42:07.223Z", + "last_modified" : "2025-11-14T20:05:59.007Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_v9_56625.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_v9_56625.json index a226c039c..951a95165 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_v9_56625.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_v9_56625.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes V9", "notes" : "**Note 1:** **Regional nodes and nodes, NOS**\n* Code only regional nodes and nodes, NOS, in this field. \n* Distant nodes are coded in EOD Mets.\n\n**Note 2:** **Mediastinal and Subcarinal Lymph Nodes**\n* For codes **400-500**, EOD Regional Nodes is based on the number of mediastinal/subcarinal nodal stations (2-9) are involved. \n* **There are 14 Nodal Stations based on the [IASLC mapping]\n(https://www.frontiersin.org/files/Articles/580203/fsurg-07-580203-HTML/image_m/fsurg-07-580203-g001.jpg)**. \n* Of those 14 Nodal Stations, **8 of them are for mediastinal, including 1 for subcarinal**. \n \n**Upper Zone** \n**Superior mediastinal nodes (Stations 2-4)**\n * 2R, 2L: Upper paratracheal nodes (Carinal (tracheobronchial) (tracheal bifurcation), Precarinal)\n * 2R: Right upper paratracheal nodes\n * 2L: Left upper paratracheal nodes\n * Includes pericardial lymph nodes\n * 3a: Prevascular \n * Anterior mediastinal lymph nodes\n * Pretracheal, NOS\n * 3p: Retrotracheal \n * Posterior lymph nodes (tracheoesophageal)\n * 4R, 4L: Lower paratracheal nodes (includes Azygos)\n * 4R: Right lower paratracheal nodes\n * 4L: Left lower paratracheal nodes\n\n **AP Zone** \n**Aortic nodes (Stations 5-6)**\n * 5: Subaortic \n * Aortic-pulmonary window\n * 6: Para-aortic\n * Ascending aorta (phrenic)\n * Aortic (above diaphragm), NOS\n * Peri/para-aortic, NOS\n\n **Inferior mediastinal nodes (Nodal stations 7-9)**\n**Subcarinal Zone (Station 7)**\n**Lower Zone (Stations 8-9)**\n* 8: Paraesophageal, periesophageal \n* 9: Pulmonary ligament \n\n**Note 3:** **\"Vocal cord paralysis\" or \"Superior vena cava syndrome\"**\n* \"Vocal cord paralysis,\" \"superior vena cava syndrome,\" and \"compression of the trachea or the esophagus\" are classified as either direct extension from the primary tumor or mediastinal lymph node involvement\n\n* **Caused by direct extension of the primary tumor**\n * Code as primary tumor involvement (EOD Primary Tumor, code 650)\n* **Primary tumor is peripheral and clearly unrelated to vocal cord paralysis, SVC obstruction, or compression of the trachea, or the esophagus**\n * These manifestations are secondary to lymph node involvement; code as mediastinal lymph node involvement (EOD Lymph Nodes, code 400, 450 or 500, depending on the number of involved mediastinal lymph nodes)\n* **Unable to determine if manifestations due to direct extension or mediastinal lymph node involvement** \n * Record as mediastinal lymph node involvement (EOD Lymph Nodes, code 400, 450 or 500, depending on the number of involved mediastinal lymph nodes)\n\n**Note 4:** **Lymph nodes, NOS**\n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) **Lung**, from the AJCC Cancer Staging System Version 9 (2025). Used with permission of the American College of Surgeons, Chicago, Illinois.", - "last_modified" : "2025-09-18T20:41:40.431Z", + "last_modified" : "2025-11-14T20:06:08.488Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_v9_57286.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_v9_57286.json index 5b6f7c7f1..d89aceee2 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_v9_57286.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_v9_57286.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n\n**Note 2:** **Lymph nodes, NOS** \n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) **Diffuse Pleural Mesothelioma**, from the AJCC Cancer Staging System Version 9 (2025). Used with permission of the American College of Surgeons, Chicago, Illinois.", - "last_modified" : "2025-09-18T20:41:29.780Z", + "last_modified" : "2025-11-14T20:05:09.420Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_v9_73197.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_v9_73197.json index 3ad03da7e..d94d1a675 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_v9_73197.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/eod_regional_nodes_v9_73197.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Definition of Head and Neck Lymph Nodes** \n* For head and neck schemas, this field includes all lymph nodes defined as Levels I-VII and Other by TNM.\n\n**Note 2:** **Laterality** \n* If laterality of lymph nodes is not specified, assume nodes are ipsilateral. Midline nodes are ipsilateral.\n\n**Note 3:** **Supraclavicular lymph nodes** \n* Supraclavicular lymph nodes can be either Level IV or Level V\n * Level IV: deep to the sternocleidomastoid muscle, in the lower jugular chain\n * Level V: in the posterior triangle, inferior to the transverse cervical artery, supraclavicular lymph nodes, NOS\n\n**Note 4:** **Regional lymph nodes for Head and Neck tumors** \n* For nasopharynx, Levels I, II, III, V, VI, are assigned code 300 or 400 based on size and/or unilateral vs bilateral. \n* For Levels IV, VB, and VII, see code 600. If the only information available is \"regional lymph nodes, NOS\" or \"lymph nodes,\" code 800.\n\n **Level I**\n Level IA - Submental\n Level IB - Submandibular (submaxillary), sublingual\n\n**Level II - Upper jugular** \n Jugulodigastric (subdigastric)\n Upper deep cervical \n Level IIA - Anterior\n Level IIB - Posterior \n\n**Level III - Middle jugular**\nMiddle deep cervical\n\n**Level IV - Lower jugular**\nJugulo-omohyoid (supraomohyoid)\nLower deep cervical \nVirchow node\n\n**Level V - Posterior triangle group**\nPosterior cervical\nLevel VA - Spinal accessory \nLevel VB - Transverse cervical, supraclavicular \n\n**Level VI - Anterior compartment group**\nLaterotracheal\nParalaryngeal\nParatracheal - above suprasternal notch\nPerithyroidal\nPrecricoid (Delphian)\nPrelaryngeal\nPretracheal - above suprasternal notch\nRecurrent laryngeal\n\n**Level VII - Superior mediastinal group (for other mediastinal node(s) see EOD Mets)**\nEsophageal groove\nParatracheal - below suprasternal notch\nPretracheal - below suprasternal notch \n\n**Other groups**\nCervical, NOS\nDeep cervical, NOS\nFacial\n- Buccinator (buccal)\n- Mandibular\n- Nasolabial\n\nInternal jugular, NOS\nParapharyngeal \nParotid\n- Infraauricular\n- Intraparotid\n- Periparotid\n- Preauricular\n\nRetroauricular (mastoid)\nRetropharyngeal\nSuboccipital\n\n**Note 5:** **Lymph nodes, NOS** \n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Lydiatt, W.M., Patel, S.G., Shah, J.P., et al. **Staging Head and Neck Cancers**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) **Nasopharynx**, from the AJCC Cancer Staging System Version 9 (2025). Used with permission of the American College of Surgeons, Chicago, Illinois.", - "last_modified" : "2025-09-18T20:42:17.716Z", + "last_modified" : "2025-11-14T20:05:59.466Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/er_allred_score_36612.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/er_allred_score_36612.json index 6a432c63d..d013a43f4 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/er_allred_score_36612.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/er_allred_score_36612.json @@ -6,7 +6,7 @@ "title" : "ER (Estrogen Receptor) Total Allred Score", "description" : "Estrogen Receptor Total Allred Score is based on the percentage of cells that stain positive by IHC for estrogen receptor (ER) and the intensity of that staining.\n\nThe Allred Score is a method of quantifying ER and PR using both intensity and percentage of positive cells. The Allred Score is calculated by adding the Proportion Score and the Intensity Score, as defined in the tables below.\n\nThe Allred score combines the percentage of positive cells (proportion score) and the intensity score of the reaction product in most of the carcinoma. The 2 scores are added together for a final score with 8 possible values (00-08). \n\nPositive cells = 0; Proportion score = 0\nPositive cells = <1; Proportion score = 1\nPositive cells = 1 to 10; Proportion score = 2\nPositive cells = 11 to 33; Proportion score = 3\nPositive cells = 34 to 66; Proportion score = 4\nPositive cells = 67 or greater; Proportion score = 5\n\nIntensity = None; Intensity Score = 0\nIntensity = Weak; Intensity Score = 1\nIntensity = Intermediate/Moderate; Intensity Score = 2\nIntensity = Strong; Intensity Score = 3", "notes" : "**Note 1:** **No longer required by any standard setter** \n* This SSDI is no longer required by any of the standard setters starting with 2023 diagnoses\n* For cases diagnosed 2023+, this SSDI may be left blank\n\n**Note 2:** **Physician Statement** \n* Physician statement of ER (Estrogen Receptor) Total Allred Score can be used to code this data item.\n\n**Note 3:** **Related data item** \n* Code this data item using the same report used to record the related data item 3827: Estrogen Receptor Summary.", - "last_modified" : "2024-04-08T19:54:41.600Z", + "last_modified" : "2025-11-05T21:00:55.155Z", "definition" : [ { "key" : "er_allred_score", "name" : "Code", @@ -17,7 +17,7 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "00", "Total ER Allred score of 0 " ], [ "01", "Total ER Allred score of 1" ], [ "02", "Total ER Allred score of 2" ], [ "03", "Total ER Allred score of 3" ], [ "04", "Total ER Allred score of 4" ], [ "05", "Total ER Allred score of 5" ], [ "06", "Total ER Allred score of 6" ], [ "07", "Total ER Allred score of 7" ], [ "08", "Total ER Allred score of 8" ], [ "X8", "Not applicable: Information not collected for this case\n(If this item is required by your standard setter, use of code X8 will result in an edit error.)" ], [ "X9", "Not documented in medical record\nER (Estrogen Receptor) Total Allred Score not assessed, or unknown if assessed" ], [ "", "May be blank if diagnosis year is after 2022" ] ], - "additional_info" : "**Source documents:** pathology report\n\nFor further information, refer to the **Breast Biomarker Reporting** cancer protocols published by the College of American Pathologists for the AJCC Staging System *Breast*", + "additional_info" : "**Source documents:** pathology report\n\nFor further information, refer to the **Breast Biomarker Reporting** cancer protocols published by the College of American Pathologists for the AJCC Staging System *Breast*.", "coding_guidelines" : "**1)** Registrar should not calculate the Allred Score unless both components are available (proportion score and intensity)\n\n**2)** **Code X9** if ER test is performed, but Allred score is not documented, or cannot be calculated", "rationale" : "Estrogen Receptor Total Allred Score is a Registry Data Collection Variable in AJCC. It is a new data item for cases diagnosed 1/1/2018+." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/er_percent_positive_61867.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/er_percent_positive_61867.json index 5501838ba..6b7ded804 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/er_percent_positive_61867.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/er_percent_positive_61867.json @@ -6,7 +6,7 @@ "title" : "ER (Estrogen Receptor) Percent Positive or Range", "description" : "Estrogen Receptor Percent Positive or Range is the percent of cells staining estrogen receptor positive by IHC.\n\nThe two most common ways to report ER and PR results are the percentage of cells with nuclear positivity and the average intensity of staining. Both the PS and IS are based on immunohistochemical staining of tumor cells. \n\nER and PR status, the percentage of tumor cells with positive nuclear staining, may be reported as a specific number or a range if more than 10%. Intensity refers to degree of nuclear positivity (i.e., pale to dark); average intensity of staining is recorded as weak, moderate, or strong.", "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of ER (Estrogen Receptor) Percent Positive or Range can be used to code this data item when no other information is available.\n\n**Note 2:** **Related data item** \n* Code this data item using the same report used to record the related data item 3827: Estrogen Receptor Summary.", - "last_modified" : "2025-02-24T14:46:19.420Z", + "last_modified" : "2025-11-06T18:50:50.182Z", "definition" : [ { "key" : "er_percent_positive", "name" : "Code", @@ -17,7 +17,7 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "000", "ER negative, or stated as less than 1%" ], [ "001-100", "1-100 percent" ], [ "R10", "Stated as 1-10%" ], [ "R20", "Stated as 11-20%" ], [ "R30", "Stated as 21-30%" ], [ "R40", "Stated as 31-40%" ], [ "R50", "Stated as 41-50%" ], [ "R60", "Stated as 51-60%" ], [ "R70", "Stated as 61-70%" ], [ "R80", "Stated as 71-80%" ], [ "R90", "Stated as 81-90%" ], [ "R99", "Stated as 91-100%" ], [ "XX7", "Test done, results not in chart " ], [ "XX8", "Not applicable: Information not collected for this case\n(If this item is required by your standard setter, use of code XX8 will result in an edit error.)" ], [ "XX9", "Not documented in medical record\nER (Estrogen Receptor) Percent Positive or Range not assessed or unknown if assessed" ] ], - "additional_info" : "**Source documents:** pathology report\n\nFor further information, refer to the **Breast Biomarker Reporting** cancer protocols published by the College of American Pathologists for the AJCC Staging System *Breast*", - "coding_guidelines" : "**1)** **Code 000** when ER is negative, or percentage is less than 1%\n**2)** **Code 01-100** for the actual percentage\n* The actual ER (1-100%) percent takes priority over the range codes\n\n**3)** **Code XX7** if ER is positive, but percentage is unknown\n**4)** **R10-R99** Ranges for the codes in this data item are defined in steps of 10 which correspond to the CAP protocol. If a range in a report is given in steps other than those provided in the R codes, code per the following.\n* If the range is less than or equal to 10, then code the appropriate R code based on the lower number\n * ***Example 1***: Report documents 1-5%. Code R10 (1-10%)\n * ***Example 2***: Report documents 25-34%. Code R30 (21-30%)\n* If the range is greater than 10, then code to unknown\n * ***Example 1***: Report documents 10-25%. Code XX9\n * ***Example 2:*** Report documents 67-100%. Code XX9", + "additional_info" : "**Source documents:** pathology report\n\nFor further information, refer to the **Breast Biomarker Reporting** cancer protocols published by the College of American Pathologists for the AJCC Staging System *Breast*.", + "coding_guidelines" : "**1)** **Code 000** when ER is negative, or percentage is less than 1%\n\n**2)** **Code 01-100** for the actual percentage\n* The actual ER (1-100%) percent takes priority over the range codes\n\n**3)** **Code XX7** if ER is positive, but percentage is unknown\n\n**4)** **R10-R99** Ranges for the codes in this data item are defined in steps of 10 which correspond to the CAP protocol. If a range in a report is given in steps other than those provided in the R codes, code per the following.\n* If the range is less than or equal to 10, then code the appropriate R code based on the lower number\n * ***Example 1***: Report documents 1-5%. Code R10 (1-10%)\n * ***Example 2***: Report documents 25-34%. Code R30 (21-30%)\n* If the range is greater than 10, then code to unknown\n * ***Example 1***: Report documents 10-25%. Code XX9\n * ***Example 2:*** Report documents 67-100%. Code XX9", "rationale" : "Estrogen Receptor Percent Positive or Range is a Registry Data Collection Variable in AJCC. It is a new data item for cases diagnosed 1/1/2018+." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/er_summary_44166.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/er_summary_44166.json index d43e34b24..1421daa13 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/er_summary_44166.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/er_summary_44166.json @@ -4,9 +4,9 @@ "version" : "3.3", "name" : "Estrogen Receptor Summary", "title" : "ER (Estrogen Receptor) Summary", - "description" : "Estrogen Receptor Summary is a summary of results of the estrogen receptor (ER) assay.\n\nEstrogen receptor (ER) positivity and progesterone receptor (PR) positivity are favorable prognostic factors in breast cancer, as well as endometrial carcinoma and meningioma. Positive results predict a favorable response to endocrine (hormonal) therapy. Combined ER and PR positivity is associated with increased response to antiestrogen therapies. \nThere are a variety of ways to report information on ER and PR results, but there is almost always a summary statement that the result is positive or negative.", - "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of ER (Estrogen Receptor) Summary status can be used to code this data item when no other information is available.\n\n**Note 2:** **In-situ and Invasive components present**\n* If ER is positive on an in-situ component and ER is negative on all tested invasive components in the primary tumor, code ER as negative (code 0)\n* If in situ and invasive components present and ER only done on the in-situ component in the primary tumor, code unknown (code 9)\n\n**Note 3:** **Single tumor, multiple biopsies or surgical resection, different results**\n* Use the highest (positive versus negative)\n\n**Note 4:** **Multiple tumors, different results**\n* Code the results from the largest tumor size (determined either clinically or pathologically) when multiple tumors are present.\n * Do not use specimen size to determine the largest tumor size\n\n**Note 5:** **Results from nodal or metastatic tissue**\n* May be used ONLY when there is no evidence of primary tumor\n * **Note:** In-situ is evidence of primary tumor\n\n**Note 6:** **Neoadjuvant Therapy**\n* Record the assay from tumor specimens prior to neoadjuvant therapy.\n* If neoadjuvant therapy is given and there are no ER results from pre-treatment specimens, report the findings from post-treatment specimens\n\n**Note 7:** **ER Positive and Oncotype**\n* If the patient is ER positive and node negative, a multigene test such as Oncotype Dx may be performed, in which case another ER test will be performed. Do not record the results of that test in this field.\n* Record only the results of the test which made the patient eligible to be given the multigene test\n\n**Note 8:** **Others tests for ER**\n* Do not use results from the following tests to record ER or PR results\n * MammaPrint\n * EndoPredict\n * PAM 50 (Prosigna)\n * Any other test that records ER", - "last_modified" : "2025-02-24T14:48:45.452Z", + "description" : "Estrogen Receptor Summary is a summary of results of the estrogen receptor (ER) assay.\n\nEstrogen receptor (ER) positivity and progesterone receptor (PR) positivity are favorable prognostic factors in breast cancer, as well as endometrial carcinoma and meningioma. Positive results predict a favorable response to endocrine (hormonal) therapy. Combined ER and PR positivity is associated with increased response to antiestrogen therapies.\n\nThere are a variety of ways to report information on ER and PR results, but there is almost always a summary statement that the result is positive or negative.", + "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of ER (Estrogen Receptor) Summary status can be used to code this data item when no other information is available.\n\n**Note 2:** **In-situ and Invasive components present**\n* If ER is positive on an in-situ component and ER is negative on all tested invasive components in the primary tumor, code ER as negative (code 0)\n* If in situ and invasive components present and ER only done on the in-situ component in the primary tumor, code unknown (code 9)\n\n**Note 3:** **Single tumor, multiple biopsies or surgical resection, different results**\n* Use the highest (positive versus negative)\n\n**Note 4:** **Multiple tumors, different results**\n* Code the results from the largest tumor size (determined either clinically or pathologically) when multiple tumors are present.\n * Do not use specimen size to determine the largest tumor size\n\n**Note 5:** **Results from nodal or metastatic tissue**\n* May be used ONLY when there is no evidence of primary tumor\n * **Note:** In-situ is evidence of primary tumor\n\n**Note 6:** **Neoadjuvant Therapy**\n* Record the assay from tumor specimens prior to neoadjuvant therapy.\n* If neoadjuvant therapy is given and there are no ER results from pre-treatment specimens, report the findings from post-treatment specimens\n\n**Note 7:** **ER Positive and Oncotype**\n* If the patient is ER positive and node negative, a multigene test such as Oncotype Dx may be performed, in which case another ER test will be performed. Do not record the results of that test in this field.\n* Record only the results of the test which made the patient eligible to be given the multigene test\n\n**Note 8:** **Other tests for ER**\n* Do not use results from the following tests to record ER or PR results\n * MammaPrint\n * EndoPredict\n * PAM 50 (Prosigna)\n * Any other test that records ER", + "last_modified" : "2025-11-06T18:48:56.301Z", "definition" : [ { "key" : "er", "name" : "Code", @@ -17,7 +17,7 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "0", "ER negative (0.0% or less than 1%)" ], [ "1", "ER positive" ], [ "7", "Test ordered, results not in chart" ], [ "9", "Not documented in medical record\nCannot be determined (indeterminate)\nER (Estrogen Receptor) Summary status not assessed or unknown if assessed" ] ], - "additional_info" : "**Source documents:** pathology report\n\nFor further information, refer to the **Breast Biomarker Reporting** cancer protocols published by the College of American Pathologists for the AJCC Staging System Breast", - "coding_guidelines" : "**1)** **Code 0** when the ER is reported as negative or normal\n**2)** **Code 1** when the ER is reported as positive or elevated\n**3)** **Code 7** when the ER test was ordered but the results are not available\n**4)** **Code 9** when the ER is \n * Reported as borderline; undetermined whether positive or negative \n * Cannot be determined by the pathologist (e.g., inadequate specimen)\n * It is unknown whether the ER test was performed\n * The patient has only a clinical diagnosis of breast cancer (no tissue diagnosis)", + "additional_info" : "**Source documents:** pathology report\n\nFor further information, refer to the **Breast Biomarker Reporting** cancer protocols published by the College of American Pathologists for the AJCC Staging System Breast.", + "coding_guidelines" : "**1)** **Code 0** when the ER is reported as negative or normal\n\n**2)** **Code 1** when the ER is reported as positive or elevated\n\n**3)** **Code 7** when the ER test was ordered but the results are not available\n\n**4)** **Code 9** when the ER is \n * Reported as borderline; undetermined whether positive or negative \n * Cannot be determined by the pathologist (e.g., inadequate specimen)\n * It is unknown whether the ER test was performed\n * The patient has only a clinical diagnosis of breast cancer (no tissue diagnosis)", "rationale" : "This data item is required for prognostic stage grouping in AJCC 8th edition, Chapter 48, Breast. It was previously collected as Breast CS SSF # 1." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/esoph_tumor_epicenter_18976.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/esoph_tumor_epicenter_18976.json index b2b45ea49..9b9687212 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/esoph_tumor_epicenter_18976.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/esoph_tumor_epicenter_18976.json @@ -6,7 +6,7 @@ "title" : "Esophagus and EGJ, Squamous Cell (including adenosquamous), Tumor Location", "description" : "Esophagus and Esophagogastric Junction (EGJ), Squamous Cell (including adenosquamous), Tumor Location refers to the position of the epicenter of the tumor in the esophagus.\n\n**Required for Staging:** The AJCC Esophagus Staging System and EOD, for **Squamous Cell Carcinomas only**.", "notes" : "**Note 1:** **Pathological Staging** \n* This data item is used for pathological staging for squamous cell carcinoma of the esophagus and esophagogastric junction. If information is available for clinical staging, record it.\n\n**Note 2:** **Defining the epicenter**\n* Location is defined by the position of the **epicenter** of the tumor in the esophagus.\n * ***Example***: If the lesion was from 15-21 cm, this is a 6-cm lesion with epicenter at 18 cm. It is the midpoint \n\n**Note 3:** **Priority statements of epicenter**\n* Clinician or pathologist statement of epicenter being the upper, middle, or lower takes priority over any individual results or measurements \n* If no statement of epicenter is provided indicating upper, middle, or lower is provided, the following measurements may be used.\n * 15-24 cm from incisors = upper\n * 25-29 cm from incisors = middle\n * 30-40/45 cm from incisors = lower\n\n**Note 4:** **Epicenter and Primary Site**\n* The ascertainment of the epicenter of the tumor is for staging purposes and is separate from the assignment of the ICD-O-3 topography code\n* If you have an overlapping tumor (C158), do not recode the topography based on the epicenter.\n\n**Note 5:** **Primary Site C159** \n* If primary site is C159 (Esophagus, NOS), code 9.", - "last_modified" : "2024-04-08T15:37:14.274Z", + "last_modified" : "2025-11-05T21:42:31.117Z", "definition" : [ { "key" : "esoph_tumor_epicenter", "name" : "Code", @@ -17,6 +17,6 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "0", "U: Upper (Cervical/Proximal esophagus to lower border of azygos vein)" ], [ "1", "M: Middle (Lower border of azygos vein to lower border of inferior pulmonary vein)" ], [ "2", "L: Lower (Lower border of inferior pulmonary vein to stomach, including gastroesophageal junction)" ], [ "9", "X: Esophagus, NOS\nSpecific location of epicenter not documented in medical record\nSpecific location of epicenter not assessed or unknown if assessed" ] ], - "additional_info" : "**Source documents:** pathology report, operative report, imaging, clinician's statement\n\nFor further information, refer to the **Esophagus** cancer protocol published by the College of American Pathologist for the AJCC Staging System *Esophagus (including GE Junction) Squamous*", + "additional_info" : "**Source documents:** pathology report, operative report, imaging, clinician's statement\n\nFor further information, refer to the **Esophagus** cancer protocol published by the College of American Pathologist for the AJCC Staging System *Esophagus (including GE Junction) Squamous*.", "rationale" : "This data item is required for prognostic stage grouping for squamous and adenosquamous carcinoma in AJCC 8th edition, Chapter 16 Esophagus and Esophagogastric Junction. It is a new data item for cases diagnosed 1/1/2018 and forward." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/esophagusgejunction_egj_stomach_57130.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/esophagusgejunction_egj_stomach_57130.json index 9159151ce..65e63ce93 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/esophagusgejunction_egj_stomach_57130.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/esophagusgejunction_egj_stomach_57130.json @@ -5,8 +5,8 @@ "name" : "Schema Discriminator 1", "title" : "Schema Discriminator 1: EsophagusGEJunction (EGJ)/Stomach", "description" : "The esophagus chapter of the AJCC Cancer Staging Manual 8th edition includes the esophagogastric junction (also called the cardia or gastroesophageal junction) and the proximal 2 cm of the stomach. The cardia is defined as the opening or junction between the esophagus and the stomach, and it is between 0.1 and 0.4 cm in length. This 2-cm boundary measurement is based on the Siewert classification of gastroesophageal cancers, which defines an area 2 cm above and 2 cm below the cardia or esophagogastric junction. Both of these areas are coded to primary site C160, so a discriminator is needed to get to the correct chapter.\n\nTo determine whether a cancer of the cardia should be coded according to the esophagus schema or the stomach system, it is necessary to identify the midpoint or epicenter of the tumor. If the midpoint is at or above the cardia, the tumor is esophageal. If the midpoint of the tumor is within 2 cm distal to the gastroesophageal junction (GEJ) and the lesion extends to or across the GEJ, the case should be coded with the esophagus system. If the midpoint of the tumor is within 2 cm distal to the GEJ and the lesion does not extend to the GEJ, the case should be coded with the stomach schema. Any tumor with a midpoint more distal than 2 cm from the GEJ is coded with the stomach schema.", - "notes" : "**Note 1:** **Schema Discriminator for C160** \n* Under primary site code C160, there are two different structures that are staged differently.\n * Esophagogastric junction (Esophagus schema)\n * Cardia of the Stomach (Stomach schema)\n\n**Note 2:** **The gastroesophageal junction** \n* The gastroesophageal junction (GEJ) (primary site C160) is a poorly defined anatomic area that represents the junction between the distal esophagus and the proximal stomach (cardia). \n* The true anatomic GEJ corresponds to the most proximal aspect of the gastric folds, which represents an endoscopically apparent transition point in most individuals. \n\n**Note 3:** **The cardia** \n* The cardia (also assigned primary site C160) is the **first part of the stomach.** It is the region where the stomach meets the end of the esophageal tube. \n* This region is also referred to as the Z-line or the esophagogastric junction.\n\n**Note 4:** **Physician's statement** \n* Physician's statement can be used to code this data item when no other information is available. \n * ***Example:*** Patient diagnosed with tumor involving the cardia. No other information available. Physician stages the patient using the Esophagus Staging System/CAP protocol\n * ***Answer:*** Code 2 based on physician using the Esophagus Staging System \n\n**Note 5:** **Midpoint (epicenter)** \n* Tumors with their midpoint (epicenter) in the GE Junction are staged as Esophagus, while tumors with their midpoint (epicenter) in the cardia/stomach are staged using the Stomach Staging System.\n * **Note:** The CAP protocol uses \"midpoint\" instead of \"epicenter.\" This is the pathologist's assessment of the point of tumor origin, regardless of tumor extension into other tissues.", - "last_modified" : "2025-03-21T18:08:05.111Z", + "notes" : "**Note 1:** **Schema Discriminator for C160** \n* Under primary site code C160, there are two different structures that are staged differently.\n * Esophagogastric junction (Esophagus schema)\n * Cardia of the Stomach (Stomach schema)\n\n**Note 2:** **The gastroesophageal junction** \n* The gastroesophageal junction (GEJ) (primary site C160) is a poorly defined anatomic area that represents the junction between the distal esophagus and the proximal stomach (cardia). \n* The true anatomic GEJ corresponds to the most proximal aspect of the gastric folds, which represents an endoscopically apparent transition point in most individuals. \n\n**Note 3:** **The cardia** \n* The cardia (also assigned primary site C160) is the **first part of the stomach.** It is the region where the stomach meets the end of the esophageal tube. \n* This region is also referred to as the Z-line or the esophagogastric junction.\n\n**Note 4:** **Physician's statement** \n* Physician's statement can be used to code this data item when no other information is available. \n * ***Example:*** Patient diagnosed with tumor involving the cardia. No other information available. Physician stages the patient using the Esophagus Staging System/CAP protocol\n * ***Answer:*** Code 2 based on physician using the Esophagus Staging System \n\n**Note 5:** **Midpoint (epicenter)** \n* Tumors with their midpoint (epicenter) in the GE Junction are staged as Esophagus, while tumors with their midpoint (epicenter) in the cardia/stomach are staged using the Stomach Staging System.\n * **Note:** The CAP protocol uses \"midpoint\" instead of \"epicenter\". This is the pathologist's assessment of the point of tumor origin, regardless of tumor extension into other tissues.", + "last_modified" : "2025-11-06T17:26:35.609Z", "definition" : [ { "key" : "discriminator_1", "name" : "Code", @@ -21,7 +21,7 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "0", "NO involvement of esophagus or gastroesophageal junction\n\nAND epicenter at ANY DISTANCE into the proximal stomach (including into the proximal stomach distance unknown)", "00170: Stomach" ], [ "2", "INVOLVEMENT of esophagus or esophagogastric junction (EGJ)\n\nAND epicenter LESS THAN OR EQUAL TO 2 cm into the proximal stomach\n\nOR no stated involvement of or into the stomach", "00161, 00169: Esophagus Schemas \nAND go to Schema Discriminator 2: Histology discriminator for 8020/3" ], [ "3", "INVOLVEMENT of esophagus or esophagogastric junction (EGJ) \n\nAND epicenter GREATER THAN 2 cm into the proximal stomach", "00170: Stomach" ], [ "9", "UNKNOWN involvement of esophagus or gastroesophageal junction \n\nAND epicenter at ANY DISTANCE into the proximal stomach (including into the proximal stomach distance unknown)", "00170: Stomach" ], [ "", "Primary Site is NOT C160, Discriminator is not necessary", "" ] ], - "additional_info" : "**Source documents:** pathology report, imaging, operative report, clinician's statement\n\nFor further information, refer to the **Esophagus** cancer protocol published by the College of American Pathologist for the AJCC Staging System *Esophagus (including GE Junction)*", - "coding_guidelines" : "Select the code that best describes the location and extent of the tumor, and the computer algorithm will bring the correct schema to the screen\n\n**Chapter 16: Esophagus and Esophagogastric Junction (see code 2)**\n\n**1)** **Code 2** when\n* EGJ is documented as involved and the midpoint (epicenter) is within the proximal (above) 2 cm of the cardia \n* EGJ is documented as involved and there is no mention of extension into the stomach or stomach involvement\n * ***Example 1:*** MRI: Findings most consistent with metastatic GE junction cancer. Upper EUS: Medium-sized, fungating, polypoid and ulcerated mass with no active bleeding was found in the gastric cardia extending from GEJ to 42 cm from incisors. One malignant-appearing lymph node was visualized in the peripancreatic region. \n * ***Answer:*** Code 2 for involvement of the GE Junction/Cardia and no mention of involvement of the stomach\n* EGJ is documented as involved and there is no information on stomach involvement and \n * Esophagus CAP Protocol is used OR\n * Esophagus Staging System is used\n * If the CAP Protocol and AJCC Staging System are different, default to the AJCC Staging System\n\n**Chapter 17: Stomach (see codes 0, 3, and 9)**\n\n**2)** **Code 0** when only the cardia is documented as involved (no mention of EGJ)\n\n**3)** **Code 3** when\n* EGJ is documented as involved and the midpoint (epicenter) is more than 2 cm distal (below) from the EGJ\n* EGJ is documented as involved and there is no information on stomach involvement AND\n * Stomach CAP Protocol is used OR\n * Stomach AJCC Staging System is used\n * If the CAP Protocol and AJCC Staging System are different, default to the AJCC Staging System\n\n**4)** **Code 9** when there is no documentation regarding EGJ involvement.", + "additional_info" : "**Source documents:** pathology report, imaging, operative report, clinician's statement\n\nFor further information, refer to the **Esophagus** cancer protocol published by the College of American Pathologist for the AJCC Staging System *Esophagus (including GE Junction)*.", + "coding_guidelines" : "Select the code that best describes the location and extent of the tumor, and the computer algorithm will bring the correct schema to the screen.\n\n**Chapter 16: Esophagus and Esophagogastric Junction (see code 2)**\n\n**1)** **Code 2** when\n* EGJ is documented as involved and the midpoint (epicenter) is within the proximal (above) 2 cm of the cardia \n* EGJ is documented as involved and there is no mention of extension into the stomach or stomach involvement\n * ***Example 1:*** MRI: Findings most consistent with metastatic GE junction cancer. Upper EUS: Medium-sized, fungating, polypoid and ulcerated mass with no active bleeding was found in the gastric cardia extending from GEJ to 42 cm from incisors. One malignant-appearing lymph node was visualized in the peripancreatic region. \n * ***Answer:*** Code 2 for involvement of the GE Junction/Cardia and no mention of involvement of the stomach\n* EGJ is documented as involved and there is no information on stomach involvement and \n * Esophagus CAP Protocol is used OR\n * Esophagus Staging System is used\n * If the CAP Protocol and AJCC Staging System are different, default to the AJCC Staging System\n\n**Chapter 17: Stomach (see codes 0, 3, and 9)**\n\n**2)** **Code 0** when only the cardia is documented as involved (no mention of EGJ)\n\n**3)** **Code 3** when\n* EGJ is documented as involved and the midpoint (epicenter) is more than 2 cm distal (below) from the EGJ\n* EGJ is documented as involved and there is no information on stomach involvement AND\n * Stomach CAP Protocol is used OR\n * Stomach AJCC Staging System is used\n * If the CAP Protocol and AJCC Staging System are different, default to the AJCC Staging System\n\n**4)** **Code 9** when there is no documentation regarding EGJ involvement.", "rationale" : "A schema discriminator is used to assign AJCC ID when site and histology alone are insufficient to identify the applicable AJCC staging method and to assign Schema ID, which links each case to the appropriate SSDIs, Grade, Summary Stage and EOD data collection system." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_baa.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_baa.json index 7b0450ad4..6df5e9dad 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_baa.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_baa.json @@ -5,7 +5,7 @@ "name" : "EOD Primary Tumor", "title" : "EOD Primary Tumor", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Welton, M.L., Jessup, J.M., et al. **Anus**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:52:08.002Z", + "last_modified" : "2025-11-14T20:05:36.941Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bad.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bad.json index 669a76748..f5c95a710 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bad.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bad.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note:** **FIGO and extension information** \n* When both the Federation Internationale de Gynecologie et d'Obstetrique (FIGO) stage and extension information on the primary tumor are available, use the extension information to code primary tumor in preference to a statement of FIGO stage.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05.** American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging.** In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) **Introduction to Female Reproductive Organs**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Gibb, R.K., Olawaiye, A.B., Mutch, D.G., et al. **Vagina**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:52:03.784Z", + "last_modified" : "2025-11-14T20:06:11.106Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bag.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bag.json index 30f79f824..4a33e551c 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bag.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bag.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **Orbital tissues** \n* The orbital tissues are the support systems of the globe, confined to the space within the surrounding bony structure. The tissues include fat, striated and smooth muscle, fibroconnective, vascular, lymphoid, peripheral nerve, and optic nerve tissue.\n\n**Note 2:** **In situ cases** \n* In situ (code 000) may be used only for non-sarcoma histologies coded to this site. Sarcomas do not present as in situ or noninvasive tumors.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Dutton, J.J., Finger, P.T., et al. **Orbital Sarcoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:51:50.497Z", + "last_modified" : "2025-11-14T20:05:35.989Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_baj.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_baj.json index 3e3681bc3..20ed0f6a7 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_baj.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_baj.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **Bronchopneumonia and Obstructive pneumonitis**\n* Bronchopneumonia is not the same thing as obstructive pneumonitis and should not be coded as such. \n * **Bronchopneumonia** is an acute inflammation of the walls of the bronchioles, usually a result of spread of infection from the upper to the lower respiratory tract\n * **Obstructive pneumonitis** is a combination of atelectasis, bronchiectasis with mucous plugging, and parenchymal inflammation that develops distal to an obstructing endobronchial lesion\n\n**Note 2:** **Ground glass opacities (GGO), ground glass nodules (GGN), and ground/glass lepidic (GG/L)**\n* Ground glass opacities (GGO), ground glass nodules (GGN), and ground/glass lepidic (GG/L) are frequently observed on CT and are increasingly detected with the advancements in imaging and are described as an area of hazy increased lung opacity. GGO, GGN, and GG/L can be observed in both benign and malignant lung conditions along with pre-invasive lesions (adenocarcinoma in situ, minimally invasive adenocarcinoma, and lepidic carcinoma). \n* They are often associated with early stage lung cancer but not necessarily malignancies themselves.\n* For staging purposes, these are **not to be counted as separate tumor nodules**\n\n**Note 3:** **Minimally invasive adenocarcinoma**\n* Code 100 is to be used only when the following criteria are met\n * Minimally invasive adenocarcinoma (less than or equal to 3 cm)\n * **WITH** predominantly **lepidic pattern** **AND**\n * less than or equal to 5 mm invasion in greatest dimension\n * If predominantly **lepidic pattern** is present and the size of the invasive component is unknown, see code 300\n\n**Note 4:** **Superficial spreading tumor**\n* Code 200 is to be used for **superficial spreading tumors** only. The pathology report must state that it is superficially spreading.\n* These types of tumors are uncommon, and this code should be used very sparingly. If in doubt, do not use this code\n\n**Note 5:** **Localized tumor**\n* Code 300 is to be used for a localized cancer where size defines the extent of the primary tumor \n * It is not a predominantly lepidic pattern (code 100), or a superficial spreading tumor (code 200), and there is no involvement of adjacent structures or invasion of the pleural (codes 400 and above).\n\n**Note 6:** **Atelectasis** \n* Atelectasis is the failure of the lung to expand (inflate) completely\n* This may be caused by a blocked airway, a tumor, general anesthesia, pneumonia or other lung infection, lung disease, or long-term bed rest with shallow breathing. Sometimes called a collapsed lung. \n * If the atelectasis is clearly related to the obstructing tumor, code to 450\n * If the atelectasis is clearly related to the lymph nodes, code the involvement in lymph nodes\n * If unable to determine if the atelectasis is due to direct extension or lymph node involvement, record as lymph node involvement\n\n**Note 7:** **Visceral pleural invasion**\n* Specific information about visceral pleura invasion is captured in codes 450 (PL1, PL2, or NOS) and 500 (PL3)\n* Elastic layer involvement has prognostic significance for lung cancer. \n\n**Note 8:** **Penetration of the visceral pleural**\n* Penetration of the visceral pleura indicates a progression of invasion, even in small (≤ 3cm) tumors, and indicates a less favorable prognosis\n* Visceral pleural invasion is determined to be present both in tumors that extend to the visceral pleural surface (type PL2 invasion), and in tumors that penetrate beyond the elastic layer of the visceral pleura (type PL1 invasion)\n* Further invasion, which extends to the parietal pleura, is also described as type PL3 invasion.\n\n**Note 9:** **\"Vocal cord paralysis\" or \"Superior vena cava syndrome\"** \n* \"Vocal cord paralysis,\" \"superior vena cava syndrome,\" and \"compression of the trachea or the esophagus\" are classified as either direct extension from the primary tumor or mediastinal lymph node involvement\n\n* **Caused by direct extension of the primary tumor**\n * Code as primary tumor involvement (EOD Primary Tumor, code 650)\n* **Primary tumor is peripheral and clearly unrelated to vocal cord paralysis, SVC obstruction, or compression of the trachea, or the esophagus**\n * These manifestations are secondary to lymph node involvement; code as mediastinal lymph node involvement (EOD Lymph Nodes, code 400)\n* **Unable to determine if manifestations due to direct extension or mediastinal lymph node involvement**\n * Record as mediastinal lymph node involvement (EOD Lymph Nodes, code 400)\n\n**Note 10:** **Separate tumor nodules**\n* Separate ipsilateral tumor nodules of the same histopathological type (intrapulmonary metastases)\n* Coded either 500 (same lobe) or 700 (different ipsilateral lobe). \n* Separate tumor nodules in the contralateral lung are assigned in EOD Mets.\n\n**Note 11:** **Occult carcinoma**\n* Occult carcinoma occurs when tumor is proven by the presence of malignant cells in sputum or bronchial washings, but there is no other evidence of the tumor. \n* In these cases, assign EOD Primary Tumor 980, EOD Regional Nodes 000, and EOD Mets 00.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Rami-Porta, R., Asamura, H., Travis, W.D., Rusch, V.W. **Lung**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:52:05.176Z", + "last_modified" : "2025-11-14T20:06:08.835Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bak.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bak.json index ee7500b1d..23baf3d7c 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bak.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bak.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **Dimpling, tethering** \n* Changes such as dimpling of the skin, tethering, and nipple retraction are caused by tension on Cooper's ligament(s), not by actual skin involvement. \n* They do not alter the classification.\n\n**Note 2:** **Clinical evidence ONLY descriptions** \n* Adherence, attachment, fixation, induration, and thickening are clinical evidence of extension to skin or subcutaneous tissue; assign code 200 if that is the only information available.\n * Do not use these descriptions for pathological assessment of the breast.\n\n**Note 3:** **Fixation, NOS**\n* **\"Fixation\", NOS** is involvement of pectoralis muscle; assign code 200.\n\n**Note 4:** **Inflammatory carcinoma**\n* Inflammatory carcinoma is a clinical diagnosis. It is defined as greater than 33% of a breast involved WITH erythema, edema, peau d'orange, or other terms describing skin changes. \n * See codes **400 and 500** for descriptions of inflammation **WITHOUT** a diagnosis of inflammatory carcinoma.\n * See code **600** for a diagnosis of inflammatory carcinoma", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Hortobagyi, G.N., Giuliano, A., et al. **Breast**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:51:56.602Z", + "last_modified" : "2025-11-14T20:06:12.831Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bal.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bal.json index 2e474c118..e42044a49 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bal.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bal.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **Wall of the stomach** \n* The wall of the stomach has five layers\n * Mucosal (code 100)\n * Submucosal (code 200)\n * Muscular (code 400)\n * Subserosal (code 500) and serosal (code 600). \n\n**Note 2:** **Linitis plastica** \n* Code 400 if the diagnosis states linitis plastica and no other information regarding extension is available. \n* Linitis plastica is defined as diffuse involvement of the entire thickness of the stomach wall.\n\n**Note 3:** **Intraluminal or intramural extension**\n* Intraluminal or intramural extension to esophagus and duodenum is classified by the depth of greatest invasion in any of these sites, including stomach. \n * (For extension to esophagus or duodenum via serosa, see code 700).\n\n**Note 4:** **Contiguous versus discontiguous extension** \n* For structures listed in codes 700 and 750, contiguous extension is coded in this field. \n* If there is discontiguous extension of any of these structures, code involvement in EOD Mets.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Ajani, J.A., In, H., Sano, T., Hofstetter, W.L., et al. **Stomach**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:52:04.107Z", + "last_modified" : "2025-11-14T20:05:10.488Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bam.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bam.json index a6f83c7bc..75e59ae7c 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bam.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bam.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **Intrinsic and extrinsic muscles of tongue** \n* The intrinsic muscles of tongue are four paired muscles within the tongue which control its shape. \n* The extrinsic muscles originate from structures outside the tongue and control its positioning.\n\n**Note 2:** **Parapharyngeal involvement** \n* Parapharyngeal involvement (pharyngeal space invasion) (code 700) denotes postero-lateral infiltration of tumor beyond the pharyngobasilar fascia. \n* The pharyngobasilar fascia is the fibrous layer of the pharyngeal wall between the mucosa and the muscular layer, attached superiorly to the basilar part of the occipital bone and diminishing in thickness as it descends.\n\n**Note 3:** **Masticator space** \n* The masticator space (code 700) primarily consists of the muscles of mastication, the medial and lateral pterygoid, masseter, and temporalis muscles. \n* The space also includes the ramus of the mandible and the third division of cranial nerve V as it passes through the foramen ovale into the suprahyoid neck.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Lydiatt, W.M., Patel, S.G., Shah, J.P., et al. **Staging Head and Neck Cancers**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Lydiatt, W.M., Ridge, J.A., Shah, J.P., et al. **Oropharynx (p16-) and Hypopharynx**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:52:08.976Z", + "last_modified" : "2025-11-14T20:05:05.138Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_ban.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_ban.json index 42797121b..e8c7aec7d 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_ban.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_ban.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **Clark Level versus pathological description** \n* If there is a discrepancy between the Clark level and the pathological description of extent (invasion into the layers of the dermis), use the higher (more extensive) code.\n\n**Note 2:** **Code greatest extent** \n* Code the greatest extent of invasion from any procedure performed on the lesion, whether it is described as a biopsy or an excision. \n* For example, if a punch biopsy with involvement of Clark level IV is followed by a re-excision with residual tumor involving Clark level II, code 300 (Clark level IV).\n\n**Note 3:** **Satellite lesions/nodules** \n* Satellite lesions/nodules or in-transit metastases are coded in EOD Regional Nodes.\n\n**Note 4:** **Breslow's depth only available** \n* If a Breslow’s depth is given in the pathology report and there is **no other indication of involvement**, the following guidelines may be used (***Note:** If a physician documents a different Clark's Level then provided by these guidelines, go with the physician's Clark Level*)\n * Code 000: Level I (In situ)\n * Code 100: Level II (< 0.75 mm Breslow’s Depth)\n * Code 200: Level III (0.76 mm to 1.50 mm Breslow’s Depth)\n * Code 300: Level IV (> 1.50 mm Breslow’s Depth)\n\n**Note 5:** **Additional data items for staging** \n* In addition to EOD Primary Tumor, the following data items are also collected to determine the extent of the primary tumor:\n - *Breslow's Thickness* [NAACCR Data Item #3817] and \n - *Ulceration* [NAACCR Data Item #3936]", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Gershenwald, J.E., Scolyer, R.A., et al. **Melanoma of the Skin**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:52:00.592Z", + "last_modified" : "2025-11-14T20:06:16.296Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bao.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bao.json index 62a6ec1db..70597389c 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bao.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bao.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **In situ tumors** \n* Code 000 (behavior code 2) includes cancer cells confined within the glandular basement membrane (intraepithelial), or described as in situ. \n\n**Note 2:** **Code 050 (behavior /3)** \n* Code 050 (behavior code 3) includes the following:\n* Intramucosal, NOS\n* Lamina propria\n* Mucosa, NOS\n* Confined to, but not through the muscularis mucosa\n\n**Note 3:** **Intraluminal extension** \n* Ignore intraluminal extension to adjacent segment(s) of colon/rectum or to the ileum from the cecum; code depth of invasion or extracolonic spread as indicated.\n\n**Note 4:** **Adherent tumors** \n* Tumor that is adherent to other organs or structures, macroscopically, is coded as 600 or 700. However, if no tumor is present in the adhesion, microscopically, the classification should be coded to 100-500.\n\n**Note 5:** **Peritonealized parts of the Colon and Rectum** \n* The colon and rectum may be entirely peritonealized, partially peritonealized, or non-peritonealized. Use this list to help distinguish between EOD Primary Tumor codes 300 and 400 (See Note 6).\n * Entirely peritonealized segments: Cecum, Transverse colon, Sigmoid colon, Rectosigmoid colon\n * Segmental surfaces that are peritonealized: Anterior and lateral surfaces of: Ascending colon, Descending colon, Hepatic flexure, Splenic flexure, Upper third of rectum. Anterior surface: Middle third of rectum.\n * Entirely non-peritonealized segment: Lower third of rectum\n * Segmental surfaces that are non-peritonealized: Posterior surface of: Ascending colon, Descending colon, Hepatic flexure, Splenic flexure, Upper two-thirds of rectum\n\n**Note 6:** **Invasion into “pericolonic/pericolorectal tissue** \n* Invasion into “pericolonic/pericolorectal tissue” can be either code 300 or 400, depending on the primary site and whether it is peritonealized (fully or partially) or not. When extension is described as “pericolonic/pericolorectal tissue”\n * Code 300 may NOT be used for entirely peritonealized sites (cecum, transverse colon, sigmoid colon, rectosigmoid colon), as this would be equivalent to peritonealized pericolic/perirectal tissue invasion (code 400)\n * Code 300 may ONLY be used for peritonealized sites (See Note 5) when the extension is described using other terms listed under code 300 (ex. subserosal fat). If there are no other terms used to describe the extension, other than invasion of “pericolorectal tissue”, then assign code 400\n * For partially peritonealized sites (See Note 5), “pericolonic/pericolorectal tissue” may indicate invasion of either non-peritonealized (code 300) or peritonealized tissue (code 400)\n * Check for mention of serosa/peritoneum in the operative report and/or pathology report final diagnosis or gross description to determine the correct code. Again, if other descriptions besides “pericolonic/pericolorectal tissue” are used, assign code 300 or 400 based on the terminology used\n * If the pathologist does not further describe the “pericolic/perirectal tissues” as either “non-peritonealized pericolic/perirectal tissues” vs “peritonealized pericolic/perirectal tissues” and the operative report and/or gross description does not describe the tumor relation to the serosa/peritoneal surface, and it cannot be determined whether the tumor arises in a peritonealized portion of the colon, code 300.\n\n**Note 7:** **Involvement of serosal surface** \n* Tumors characterized by involvement of the serosal surface (visceral peritoneum) by direct extension or perforation in which the tumor cells are continuous with the serosal surface through inflammation are coded to 500.\n\n**Note 8:** **Transmural extension**\n* In the case of colon cancer, transmural extension means that the tumor has extended through the wall of the colon and may invade a regional organ or tissue\n * These would be coded as invasion or adherence to adjacent organs or tissues (see codes 600 or 700)", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Jessup, J.M., Goldberg, R.M., et al. **Colon and Rectum**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:51:55.769Z", + "last_modified" : "2025-11-14T20:06:08.069Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bap.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bap.json index 5a6dec8af..90590090e 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bap.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bap.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **Intrinsic and extrinsic muscles** \n* The intrinsic muscles of tongue are four paired muscles within the tongue which control its shape. \n* The extrinsic muscles originate from structures outside the tongue and control its positioning.\n\n**Note 2:** **Parapharyngeal involvement** \n* Parapharyngeal involvement (pharyngeal space invasion) (code 700) denotes postero-lateral infiltration of tumor beyond the pharyngobasilar fascia. \n* The pharyngobasilar fascia is the fibrous layer of the pharyngeal wall between the mucosa and the muscular layer, attached superiorly to the basilar part of the occipital bone and diminishing in thickness as it descends.\n\n**Note 3:** **Masticator space** \n* The masticator space (code 700) primarily consists of the muscles of mastication, the medial and lateral pterygoid, masseter, and temporalis muscles. \n* The space also includes the ramus of the mandible and the third division of cranial nerve V as it passes through the foramen ovale into the suprahyoid neck.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Lydiatt, W.M., Patel, S.G., Shah, J.P., et al. **Staging Head and Neck Cancers**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) O'Sullivan, B., Lydiatt, W.M., Shah, J.P., et al. **HPV-Mediated (p16+) Oropharyngeal Cancer**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:52:35.861Z", + "last_modified" : "2025-11-14T20:06:05.465Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bar.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bar.json index c093990d7..cf2ccb3e9 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bar.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bar.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note:** **Fixation** \n* Code 300 If there is fixation of hemilarynx or larynx.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Lydiatt, W.M., Patel, S.G., Shah, J.P., et al. **Staging Head and Neck Cancers**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Lydiatt, W.M., Ridge, J.A., Shah, J.P., et al. **Oropharynx (p16-) and Hypopharynx**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:52:25.216Z", + "last_modified" : "2025-11-14T20:06:06.863Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bas.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bas.json index a46b826bd..ddc73bdbd 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bas.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bas.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **Pharyngeal Space** \n* Involvement of the pharyngeal space (code 300) is defined as posterolateral infiltration from the nasopharynx beyond the buccopharyngeal fascia into the triangular space lateral to the pharynx. \n\n**Note 2:** **Parapharyngeal involvement** \n* Parapharyngeal involvement denotes posterolateral infiltration of tumor beyond the pharyngobasilar fascia. \n* The pharyngobasilar fascia is the fibrous layer of the pharyngeal wall between the mucosa and the muscular layer, attached superiorly to the basilar part of the occipital bone and diminishing in thickness as it descends.\n\n**Note 3:** **Masticator space** \n* The masticator space primarily consists of the muscles of mastication, the medial and lateral pterygoid, masseter, and temporalis muscles. \n* The space also includes the ramus of the mandible and the third division of cranial nerve V as it passes through the foramen ovale into the suprahyoid neck.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Lydiatt, W.M., Patel, S.G., Shah, J.P., et al. **Staging Head and Neck Cancers**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Lee, A.W.M., Lydiatt, W.M., Shah, J.P., et al. **Nasopharynx**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:52:34.889Z", + "last_modified" : "2025-11-14T20:06:03.989Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bat.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bat.json index 7c6b7fd33..2d03eb28e 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bat.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bat.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **Impaired vocal cord mobility** \n* Impaired vocal cord mobility, also described as vocal cord paresis, may suggest invasion of intrinsic laryngeal muscle. Fixation of the vocal cord may be described as immobility of the arytenoids noted on endoscopy, vocal cord paralysis, or deviation of larynx to fixed side.\n\n**Note 2:** **Localized tumor** \n* Code 100 for localized tumor only if no information is available to identify further extension.\n\n**Note 3:** **Limited to the larynx** \n* Tumor limited to the larynx (code 200) includes tumor involving, but limited to, the supraglottis, glottis and subglottis.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Lydiatt, W.M., Patel, S.G., Shah, J.P., et al. **Staging Head and Neck Cancers**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Patel, S.G., Lydiatt, W.M., Shah, J.P., et al. **Larynx**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:52:07.701Z", + "last_modified" : "2025-11-14T20:05:34.339Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bau.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bau.json index 24d147323..573aa071f 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bau.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bau.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **Impaired vocal cord mobility** \n* Impaired vocal cord mobility, also described as vocal cord paresis, may suggest invasion of intrinsic laryngeal muscle. \n* Fixation of the vocal cord may be described as immobility of the arytenoids noted on endoscopy, vocal cord paralysis, or deviation of larynx to fixed side.\n\n**Note 2:** **Localized tumor** \n* Code 100 for localized tumor only if no information is available to identify further extension.\n\n**Note 3:** **Limited to the larynx** \n* Tumor limited to the larynx (code 200) includes tumor involving, but limited to, the supraglottis, glottis and subglottis.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Lydiatt, W.M., Patel, S.G., Shah, J.P., et al. **Staging Head and Neck Cancers**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Patel, S.G., Lydiatt, W.M., Shah, J.P., et al. **Larynx**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:52:27.440Z", + "last_modified" : "2025-11-14T20:05:28.053Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bav.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bav.json index 42ab0d2a4..4b0e474f5 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bav.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bav.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **Impaired vocal cord mobility** \n* Impaired vocal cord mobility, also described as vocal cord paresis, may suggest invasion of intrinsic laryngeal muscle. \n* Fixation of the vocal cord may be described as immobility of the arytenoids noted on endoscopy, vocal cord paralysis, or deviation of larynx to fixed side.\n\n**Note 2:** **Localized tumor** \n* Code 100 for localized tumor only if no information is available to identify further extension.\n\n**Note 3:** **Limited to the larynx** \n* Tumor limited to the larynx (code 200) includes tumor involving, but limited to, the supraglottis, glottis and subglottis.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Lydiatt, W.M., Patel, S.G., Shah, J.P., et al. **Staging Head and Neck Cancers**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Patel, S.G., Lydiatt, W.M., Shah, J.P., et al. **Larynx**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:52:36.572Z", + "last_modified" : "2025-11-14T20:05:05.574Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_baw.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_baw.json index e50645df8..a959c2215 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_baw.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_baw.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **Impaired vocal cord mobility** \n* Impaired vocal cord mobility may be described as vocal cord paresis and may suggest invasion of intrinsic laryngeal muscle. Fixation of the vocal cord maybe described as immobility of the arytenoids noted on endoscopy, paralysis of the vocal cords, or deviation of larynx to the fixed side.\n\n**Note 2:** **Localized tumor** \n* Code 100 for localized tumor only if no information is available to identify further extension.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Lydiatt, W.M., Patel, S.G., Shah, J.P., et al. **Staging Head and Neck Cancers**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Patel, S.G., Lydiatt, W.M., Shah, J.P., et al. **Larynx**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:51:48.560Z", + "last_modified" : "2025-11-14T20:05:18.380Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bax.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bax.json index 1a1facd4f..8cf089696 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bax.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bax.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **Extension to bone** \n* Involvement of or extension to bone includes any type of tumor extension to the bone, such as erosion, invasion, extension, penetration, or destruction.\n\n**Note 2:** **Base of skull involvement** \n* Code 400 for base of skull, NOS when there is no information available for more specific bony structures in the skull.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Lydiatt, W.M., Patel, S.G., Shah, J.P., et al. **Staging Head and Neck Cancers**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Kraus, D.H., Lydiatt, W.M., Shah, J.P., et al. **Nasal Cavity and Paranasal Sinuses**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:51:59.967Z", + "last_modified" : "2025-11-14T20:06:14.999Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bbb.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bbb.json index 725780b6b..3c05b8650 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bbb.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bbb.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **Wall of the Esophagus** \n* The wall of the esophagus has five layers: mucosal (code 100), submucosal (code 150), muscular (code 250), subserosal (code 300) and serosal (code 400). \n * The three layers of the mucosa (epithelium, lamina propria, and muscularis mucosae) may be called the m1, m2, and m3 layers. The submucosa may be described as having inner, middle, and outer thirds called sm1, sm2, and sm3.\n\n**Note 2:** **High grade dysplasia** \n* Non-invasive carcinomas in the esophagus formerly called in situ are now called high grade dysplasia. \n* High grade dysplasia and severe dysplasia are generally not reportable in cancer registries. \n * Code 000 if your registry collects these tumors\n\n**Note 3:** **Intraluminal extension** \n* Ignore intraluminal extension to adjacent segment(s) of esophagus or to cardia of stomach and code depth of invasion or extra-esophageal spread as indicated.\n\n**Note 4:** **Through the muscularis propria** \n* If the tumor's extension is only described by a phrase like \"through the muscularis propria\", this could mean that the cancer has penetrated the outermost muscle cells but not beyond (code 250); but usually \"through the muscularis\" or \"through the esophageal wall\" is used to indicate that the cancer extends beyond the muscle and into adjacent tissue (code 300).", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Rice, T.W., Kelsen, D., Hofstetter, W.L., et al. **Esophagus and Esophagogastric Junction**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:52:10.864Z", + "last_modified" : "2025-11-14T20:05:35.414Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bbc.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bbc.json index 882ef1827..cbf40752c 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bbc.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bbc.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **Intrahepatic vascular invasion** \n* Intrahepatic vascular invasion is used synonymously with vascular invasion for tumors in codes 100-500 and includes gross and microscopic involvement (microvascular invasion) of vessels. \n\n**Note 2:** **Multiple tumors** \n* Multiple tumors include satellitosis, multifocal tumors, and intrahepatic metastasis.\n\n**Note 3:** **Segments of the Liver** \n* The liver is divided into several lobes as defined below. If multiple lobes (such as the Caudate lobe and the Left Lobe) are involved, see codes 300-500. \n* If multiple segments (such as 5 and 6 in the right lobe) in the same lobe are involved, this would be multiple tumors within one lobe (code 200)\n * Caudate lobe: Segment 1\n * Quadrate lobe: Segment 4b\n * Left lobe: Segments 2, 3, 4a\n * Right lobe: Segments 5, 6, 7, 8", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Abou-Alfa, G.K., Pawlik, T.M., Vauthey, J.N., et al. **Liver**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:52:09.930Z", + "last_modified" : "2025-11-14T20:05:17.907Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bbd.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bbd.json index ffa8615c1..0814ff9cf 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bbd.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bbd.json @@ -5,7 +5,7 @@ "name" : "EOD Primary Tumor", "title" : "EOD Primary Tumor", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Zhu, A.X., Pawlik, T.M., Vauthey, J.N., et al. **Gallbladder**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:52:26.828Z", + "last_modified" : "2025-11-14T20:05:39.460Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bbe.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bbe.json index ed9f8a1e3..1228aaee0 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bbe.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bbe.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **High grade dysplasia** \n* High grade dysplasia and severe dysplasia of the small intestine are generally not reportable in cancer registries.\n * Code 000 if your registry collects these tumors\n\n**Note 2:** **Depth of invasion** \n* Code depth of invasion in preference to intraluminal spread or lateral extension to adjacent segment(s) of small intestine or cecum.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Coit, D.G., Kelsen, D., Hofstetter, W.L., et al. **Small Intestine**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:51:58.963Z", + "last_modified" : "2025-11-14T20:05:40.869Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bbi.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bbi.json index ca2a1b8ca..4e6524644 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bbi.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bbi.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note:** **FIGO and extension information** \n* When both the Federation Internationale de Gynecologie et d'Obstetrique (FIGO) stage and extension information on the primary tumor are available, use the extension information to code primary tumor in preference to a statement of FIGO stage.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) **Introduction to Female Reproductive Organs**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Gibb, R.K., Olawaiye, A.B., Mutch, D.G., et al. **Vulva**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:51:54.474Z", + "last_modified" : "2025-11-14T20:06:01.232Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bbj.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bbj.json index f5fd33aa8..8b368b6d6 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bbj.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bbj.json @@ -5,7 +5,7 @@ "name" : "EOD Primary Tumor", "title" : "EOD Primary Tumor", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Conway, R.M., Finger, P.T., et al. **Conjunctival Carcinoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:51:56.923Z", + "last_modified" : "2025-11-14T20:05:06.594Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bbk.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bbk.json index 14d692610..df92deee6 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bbk.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bbk.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note:** **FIGO and extension information** \n* When both the Federation Internationale de Gynecologie et d'Obstetrique (FIGO) stage and extension information on the primary tumor are available, use the extension information to code primary tumor in preference to a statement of FIGO stage.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) **Introduction to Female Reproductive Organs**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Erickson, B.A., Olawaiye, A.B., Mutch, D.G., et al. **Cervix Uteri**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:52:28.919Z", + "last_modified" : "2025-11-14T20:05:19.908Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bbl.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bbl.json index 3be9cf505..aa5c4ecb9 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bbl.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bbl.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **FIGO and extension information** \n* When both the Federation Internationale de Gynecologie et d'Obstetrique (FIGO) stage and extension information on the primary tumor are available, use the extension information to code primary tumor in preference to a statement of FIGO stage.\n\n**Note 2:** **EID and SEIC** \n* Code 050 is for the following in situ histologies (behavior /2) only\n - Endometrial intraepithelial carcinoma (EID) (8380/2)\n - Serous endometrial intraepithelial carcinoma (SEIC) (8441/2)", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05.** American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging.** In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) **Introduction to Female Reproductive Organs**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Powell, M.A., Olawaiye, A.B., Mutch, D.G., et al. **Corpus Uteri - Carcinoma and Carcinosarcoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:52:09.614Z", + "last_modified" : "2025-11-14T20:05:03.873Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bbm.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bbm.json index fb728622b..313aa8611 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bbm.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bbm.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **FIGO and extension information** \n* When both the Federation Internationale de Gynecologie et d'Obstetrique (FIGO) stage and extension information on the primary tumor are available, use the extension information to code primary tumor in preference to a statement of FIGO stage.\n\n**Note 2:** **Genital metastasis** \n* Genital metastasis (vagina, ovary, broad ligament, fallopian tube) is coded to 700. \n* Any involvement of non-genital structures, whether by direct invasion or metastasis is coded in EOD Mets.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) **Introduction to Female Reproductive Organs**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Chen, L., Olawaiye, A.B., Mutch, D.G., et al. **Gestational Trophoblastic Neoplasms**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:51:47.001Z", + "last_modified" : "2025-11-14T20:06:14.173Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bbn.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bbn.json index 509935f20..068679c8c 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bbn.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bbn.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **Multifocal tumors** \n* In case of multifocal papillary noninvasive tumors (code 000) and nonpapillary in situ tumors (code 050), code 050.\n\n**Note 2:** **Involvement of both renal pelvis and ureter** \n* Tumor involving both renal pelvis and ureter (unifocal or multifocal) is classified by the depth of greatest invasion in either organ. \n\n**Note 3:** **Ureter tumor with bladder invasion** \n* Direct invasion of the bladder by a ureteral tumor is classified by the depth of greatest invasion of the bladder or ureter.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) McKiernan, J.M., Hansel, D.E., Stadler, W.M., et al. **Renal Pelvis and Ureter**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:52:37.261Z", + "last_modified" : "2025-11-14T20:05:49.031Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bbo.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bbo.json index 4bd314778..bad58ce6c 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bbo.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bbo.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **Clinical extension only** \n* For this schema, the EOD Primary Tumor field captures a clinical extent of disease only. \n* The guidelines for assigning Clinical Extension for AJCC and EOD are different. \n * Per AJCC, a digital rectal exam (DRE) is required to assign a clinical T (cT). \n * For EOD, a code can be assigned if there is no DRE information. (See Note 7). \n\n**Note 2:** **Information from radical prostatectomy and autopsy** \nRecord information from radical prostatectomy and autopsy in EOD Prostate Pathologic Extension\n * ***Note:*** A simple prostatectomy (Surgery code 30) does not qualify for a radical prostatectomy. Results from a simple prostatectomy are recorded in EOD Primary Tumor \n\n**Note 3:** **Do not use Imaging** \n* Imaging is **not** used to determine the clinical extension. \n* If a physician incorporates imaging findings into their evaluation (including the clinical T category), **do not** use this information. \n* If it cannot be determined if the physician is using imaging, assume they are not and code the clinical extension based on the physician’s statement\n\n**Note 4:** **TURP only cases** \n* Codes 100, 110, or 150 are used when there is a TURP only during the clinical workup and there was no clinically apparent tumor (DRE negative or unknown) (See Note 6 if positive DRE). \n* Code 150 if only a TURP is done, and the percentage of cells is not noted in the pathology report\n\n**Note 5:** **Clinically inapparent (DRE negative)** \n* Code 120 when the tumor is clinically inapparent (DRE negative). \n * Do not use this code when there is no information about the DRE results (see Note 7 for code 300).\n* **Clinically inapparent tumors** are not palpable. \n * Physician documentation of a DRE that does not mention a palpable “tumor”, “mass”, or “nodule” can be inferred as inapparent. This would include DRE findings of only benign prostate enlargement/hypertrophy\n * Do not use ICD-10-CM code R97.20 (Elevated prostate specific antigen [PSA]) alone to code 120\n\n**Note 6:** **Clinically apparent tumors (DRE positive(** \n* Codes 200-250 are for clinically apparent tumors (DRE positive).\n * **Clinically apparent tumors** are palpable. If a clinician documents a “tumor”, “mass”, or “nodule” by physical examination, this can be inferred as apparent\n* Do not infer inapparent or apparent tumor based on the registrar’s interpretation of other terms \n\n**Note 7:** **Localized cancers** \n* Code 300 for localized cancers when the DRE result is not documented, or DRE not done and there is no clinical evidence of extraprostatic extension, or the physician incorporates imaging findings into their evaluation\n * ***Example 1:*** Patient with elevated PSA and positive needle core biopsy, but no documentation regarding tumor apparency (inapparent versus apparent), and there is no evidence of extraprostatic extension \n * ***Example 2:*** Pathology report from a needle core biopsy done confirming cancer. No information on PSA, DRE or physician statement regarding clinical extension\n * Applies to \"path only\" cases \n * This instruction is only for prostate. Do not apply this instruction to any other primary site\n * ***Example 3:*** Pathology report from a needle core biopsy done confirming cancer. No information on PSA, DRE or physician statement regarding clinical extension. Physician states imaging shows extraprostatic extension and assigns cT3a\n\n**Note 8:** **Extraprostatic extension** \n* Codes 350-700 are for when there is positive extraprostatic extension, which can be determined by DRE, clinical exam, or needle core biopsy\n * If a needle core biopsy confirms extraprostatic extension, that information can be used for EOD\n\n**Note 9:** **No DRE information** \n* If there is no information from the DRE, or the terminology used is not documented in Note 5, but the physician assigns a clinical extent of disease, the registrar can use that. \n * ***Example:*** DRE reveals prostate is “firm.” Physician states the patient as a cT2a.\nThe T2a can be used in the physician has documented this. Code 200\n * ***Exception:*** If the physician is clearly using imaging findings to determine clinical stage or extension of disease, do not use this information and code as 300 (Localized, NOS) (See Note 7)\n\n**Note 10:** **Involvement of prostatic urethra** \n* Involvement of the prostatic urethra does not alter the EOD code. * Extraprostatic urethra involved is captured in code 600.\n\n**Note 11:** **Frozen pelvis** \n* “Frozen pelvis” is a clinical term which means tumor extends to pelvic sidewall(s). In the absence of a more detailed statement of involvement, assign a description of frozen pelvis to code 700.\n\n**Note 12:** **Incidental finding of prostate cancer** \n* Code 800 when an incidental finding of prostate cancer is found during a prostatectomy performed for other reasons (i.e., prostate cancer not suspected). \n * ***Example 1:*** Cystoprostatectomy done for bladder cancer and prostate cancer found incidentally\n * ***Example 2:*** Patient found to have prostate cancer during autopsy\n \n**Note 13:** **Unknown clinical extension** \n* Code 999 when there is no documentation regarding a prostate evaluation (PSA, physical exam or physician’s statement) prior to prostatectomy/autopsy.\n * ***Example:*** Patient presents for prostatectomy for known prostate cancer. No information on clinical evaluation", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Buyyounouski, M.K., Lin, D.W., et al. **Prostate**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:52:38.975Z", + "last_modified" : "2025-11-14T20:05:50.679Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bbp.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bbp.json index ac9e7e8b7..0ffae8544 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bbp.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bbp.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **Gerota's fascia** \n* Gerota's fascia is a fibrous tissue sheath surrounding the kidney and suprarenal or adrenal gland. The perirenal fat, renal capsule, and renal parenchyma lie below the fascia.\n\n**Note 2:** **Proximal convoluted tubule** \n* The most common site for renal parenchymal cancer to develop is in the proximal convoluted tubule. \n* Tumor extension from one of these structures into another is coded 100 and is dependent on size in the absence of further involvement.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Rini, B.I., McKiernan, J.M., Stadler, W.M., et al. **Kidney**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:51:53.395Z", + "last_modified" : "2025-11-14T20:05:39.926Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bbr.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bbr.json index 49d20a37c..22a94f372 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bbr.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bbr.json @@ -5,7 +5,7 @@ "name" : "EOD Primary Tumor", "title" : "EOD Primary Tumor", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Pollock, R.E., Maki, R.G. **Introduction to Soft Tissue Sarcoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Maki, R.G., Pollock, R.E., et al. **Soft Tissue Sarcoma - Unusual Histologies and Sites**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:51:56.262Z", + "last_modified" : "2025-11-14T20:06:10.633Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bbs.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bbs.json index 0c73e5870..93f748d1c 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bbs.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bbs.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **Common histology** \n* Over 90% of penile cancers are squamous cell carcinomas arising in the skin. \n* Other cancers arising in the skin include adenocarcinomas (5%) arising in sweat glands, melanomas (2%, included in the Melanoma schema), and basal cell carcinoma (2%). About 1% of penile cancers are sarcomas, arising in subcutaneous connective tissues.\n\n**Note 2:** **Verrucous carcinoma** \n* If verrucous carcinoma (8051/3) is described as noninvasive or as having a broad pushing border or penetration, assign code 050. \n* If verrucous carcinoma is not so characterized, assign code 070, Verrucous carcinoma, NOS. \n* If there is destructive invasion of verrucous carcinoma into structures in code 100 or greater, assign the appropriate higher code.\n\n**Note 3:** **Limited to the penis** \n* Tumors limited to the penis (see codes 100, 200, 300) include\n * Dartos fascia (foreskin)\n * Dermis (foreskin)\n * Lamina propria (glans and foreskin)\n * Subepithelial connective tissue (shaft)", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Pettaway, C.A., Srigley, J.R., Amin, M.B., et al. **Penis**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:52:26.196Z", + "last_modified" : "2025-11-14T20:05:48.573Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bbx.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bbx.json index ee5cdebf4..21d2faa12 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bbx.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bbx.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **Locally advanced, resectable tumor** \n* Code 500 describes locally advanced, but potentially resectable tumor.\n\n**Note 2:** **Locally advanced, unresectable tumor** \n* Codes 600 and 700 describes locally advanced, technically unresectable tumor.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Rusch, V.W., et al. **Malignant Plural Mesothelioma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:52:36.916Z", + "last_modified" : "2025-11-14T20:05:32.379Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bcb.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bcb.json index 711cff937..04d7ee90f 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bcb.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bcb.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **Flat and papillary bladder cancer**\n* The two main types of bladder cancer are the flat (sessile) variety and the papillary type. \n * The flat (sessile) variety is called in situ when tumor has not penetrated the basement membrane. \n * Papillary tumor that has not penetrated the basement membrane is called noninvasive.\n\n**Note 2:** **Noninvasive papillary transitional carcinoma** \n* Noninvasive papillary transitional carcinoma: Pathologists use many different descriptive terms for noninvasive papillary transitional cell carcinoma. \n* Frequently, the pathology report does not contain a definite statement of non-invasion; however, non-invasion can be inferred from the microscopic description. \n\n**Definite statements of non-invasion for papillary transitional cell carcinomas (Ta) include**\n- Noninfiltrating\n- Noninvasive\n- No evidence of invasion\n- No extension into lamina propria\n- No stromal invasion\n- No extension into underlying supporting tissue\n- Negative lamina propria and superficial muscle\n- Negative muscle and (subepithelial) connective tissue\n- No infiltrative behavior/component\n\n**Inferred descriptions of non-invasion for papillary transitional cell carcinomas include**\n- No involvement of muscularis propria and no mention of subepithelium/submucosa\n- No statement of invasion (microscopic description present)\n- (Underlying) Tissue insufficient to judge depth of invasion\n- No invasion of bladder wall\n- No involvement of muscularis propria\n- Benign deeper tissue\n- Microscopic description problematic (non-invasion versus superficial invasion)\n- Frond surfaced by transitional cell\n- No mural infiltration\n- No evidence of invasion (no sampled stroma)\n- Confined to mucosa \n\n**Note 3:** **Noninvasive (in situ) flat transitional cell carcinoma**\n* Noninvasive (in situ) flat transitional cell carcinoma: Careful attention must be given to the use of the term \"confined to mucosa\" for flat bladder carcinomas. \n* Historically, carcinomas described as \"confined to mucosa\" were coded as localized. However, pathologists use this designation for non-invasion as well. Pathologists also vary in their use of the terms \"invasion of mucosa, grade 1\" and \"invasion of mucosa, grade 2\" to distinguish between noninvasive and invasive carcinomas. In order to accurately code tumors described as \"confined to mucosa\", abstractors should determine \n - If the tumor is confined to the epithelium and is a non-invasive papillary carcinoma, code 000 \n - If the tumor is confined to the epithelium and is a non-invasive, non-papillary (i.e. transitional) tumor, code 050 \n - If the tumor has penetrated the basement membrane to invade the lamina propria: then it is invasive and coded to 100 for localized. The lamina propria and submucosa tend to merge when there is no muscularis mucosa, so these terms may be used interchangeably, along with stroma and subepithelial connective tissue. \n - If the distinction between involvement of the epithelium and lamina propria cannot be made, then the tumor should be coded as \"confined to mucosa, NOS\" (100).\n - Statements meaning confined to mucosa, NOS for flat transitional cell carcinomas include\n + Confined to mucosal surface\n + Limited to mucosa, no invasion of submucosa and muscularis\n + No infiltration/invasion of fibromuscular and muscular stroma\n + Superficial, NOS\n\n**Note 4:** **Multifocal noninvasive tumors** \n* In case of multifocal papillary noninvasive tumors (code 000) and nonpapillary in situ tumors (code 050), code 050\n\n**Note 5:** **Invasion of the muscularis propria**\n* Coding of the involvement of the muscularis propria is divided into superficial muscle (inner half) and deep muscle (outer half). This distinction can only be made when a cystectomy is done\n * If only a TURB is done and states “invasion of the muscularis propria,” code to 370\n * If there is “invasion of the muscularis propria” and the distal ureter is involved, code to 400\n * If there is a TURB only and the pathologist/physician documents superficial muscle or deep muscle, code to 370 or 400 as appropriate. \n* Codes 200, 250, 300, 350 should only be used when a cystectomy has been done\n\n**Note 6:** **Extension through full thickness of bladder wall**\n* Code 300 if the only description of extension is through full thickness of bladder wall, and there is no clear statement as to whether or not the cancer has extended into fat. \n\n**Note 7:** **In situ tumor with extension to prostate, ureter**\n* An associated in situ component of tumor extending into the prostatic ducts, prostatic glands, or ureter without invasion is disregarded in staging classification. \n * Assign the code that best describes depth of bladder wall invasion. \n\n**Note 8:** **Direct invasion of the ureter** \n* Direct invasion of the distal ureter is classified by the depth of greatest invasion in the bladder or ureter. \n * Code 100 if the distal ureter is defined as below the iliac vessel, within the pelvic brim is involved. \n\n**Note 9:** **Prostatic urethra** \n* Code 130 when there is extension from the bladder into the subepithelial tissue of prostatic urethra.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Bochner, B.H., Hansel, D.E., Stadler, W.M., et al. **Urinary Bladder**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:52:11.492Z", + "last_modified" : "2025-11-14T20:05:38.544Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bcc.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bcc.json index 675c96e2f..8b275b386 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bcc.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bcc.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **Benign/Borderline tumors**\n* Benign (/0) or Borderline (/1) tumors **are always coded to 050** regardless of size, extension to adjacent sites, or multiple tumors. \n\n**Note 2:** **Infratentorial and Supratentorial** \n* The tentorium cerebelli is an extension of the dura mater that separates the cerebellum from the inferior portion of the occipital lobes. \n* The location of the tumor above or below the tentorium can help in determining the type of tumor; also, most adult brain tumors are supratentorial, and most pediatric brain tumors are infratentorial. \n* In the following list, note that ICD-O-3 codes C71.0 and C71.9 include both supratentorial and infratentorial subsites.\n\n- The following subsites are **Infratentorial**\n * All subsites for codes C716-C717 \n * Hypothalamus (C710)\n * Pallium (C710)\n * Posterior cranial fossa (C719)\n * Thalamus (C710)\n- The following subsites are **Supratentorial**\n * All subsites for codes C711-C715\n * Primary site C710 (excluding hypothalamus, pallium, thalamus)\n * Anterior cranial fossa (C719)\n * Corpus callosum (C718)\n * Middle cranial fossa (C719)\n * Tapetum (C718)\n * Suprasellar (C719)\n\n**Note 3:** **Midline shift** \n* A midline shift is not the same thing as crossing the midline (code 500).\n * Documentation must state \"crossing/crosses the midline\"\n\n**Note 4:** **Drop metastasis**\n* Discontiguous spread, or \"drop metastasis\" are coded in EOD mets.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Laws, E.R., Curran, W.J., et al. **Brain and Spinal Cord**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:51:44.682Z", + "last_modified" : "2025-11-14T20:05:14.735Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bcd.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bcd.json index b9cdbe471..183bdd6ee 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bcd.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bcd.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **Benign/Borderline tumors** \n* Benign (/0) or Borderline (/1) tumors **are always coded to 050** regardless of size, extension to adjacent sites, or multiple tumors. \n\n**Note 2:** **Midline shift** \n* A midline shift is not the same thing as crossing the midline (code 500).\n* Documentation must state \"crossing/crosses the midline\"\n\n**Note 3:** **Drop metastasis** \n* Discontiguous spread, or \"drop metastasis\" are coded in EOD Mets.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Laws, E.R., Curran, W.J., et al. **Brain and Spinal Cord**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:52:36.345Z", + "last_modified" : "2025-11-14T20:05:15.141Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bce.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bce.json index b45f6ba2d..dc0e93750 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bce.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bce.json @@ -5,7 +5,7 @@ "name" : "EOD Primary Tumor", "title" : "EOD Primary Tumor", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)", - "last_modified" : "2025-09-18T20:52:01.258Z", + "last_modified" : "2025-11-14T20:05:09.766Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bcf.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bcf.json index 604d0ac00..625e00f9a 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bcf.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bcf.json @@ -5,7 +5,7 @@ "name" : "EOD Primary Tumor", "title" : "EOD Primary Tumor", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)", - "last_modified" : "2025-09-18T20:51:45.294Z", + "last_modified" : "2025-11-14T20:05:43.517Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bcg.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bcg.json index 1f997b19a..e34edf445 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bcg.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bcg.json @@ -5,7 +5,7 @@ "name" : "EOD Primary Tumor", "title" : "EOD Primary Tumor", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)", - "last_modified" : "2025-09-18T20:52:36.084Z", + "last_modified" : "2025-11-14T20:05:43.893Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bci.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bci.json index f95522f3a..83233a1f9 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bci.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bci.json @@ -4,9 +4,9 @@ "version" : "3.3", "name" : "EOD Primary Tumor", "title" : "EOD Primary Tumor", - "notes" : "**Note 1:** **The following histologies can be localized (code 100), systemic (700) or unknown (999)** \n\n* 9740: Mast cell sarcoma (MCS)\n* 9749: Erdheim-Chester disease (ECD) (2021+ only)\n* 9755: Histiocytic sarcoma\n* 9756: Langerhans cell sarcoma (LCS) \n* 9757: Interdigitating dendritic cell sarcoma (IDCS) \n* 9758: Follicular dendritic cell sarcoma (FDCS) \n* 9759: Fibroblastic reticular cell tumor \n* 9766: Lymphomatoid granulomatosis, grade 3 (2021+ only)\n* 9930: Myeloid sarcoma \n* 9971: Polymorphic PTLD (2018-2020, 2025+) \n* *Note:* 9971 is /1 and non-reportable (except for C700-C729, C751-C753) for 2021-2024, moved back to /3 for 1/1/2025+\n\n**Note 2:** **Lymph node involvement** \n* For histologies listed in **Note 1**, it is possible to have lymph node involvement; however, at this time, lymph node involvement for these histologies is not collected.\n\n**Note 3:** **The following histologies are systemic (code 700):**\n\n* 9591 Splenic B-cell lymphoma/leukemia, unclassifiable (except C441, C690, C695-C696)\n* 9724: Systemic EBV-positive T-cell lymphoma of childhood (SEBVTCL)\n* 9727: Blastic plasmacytoid dendritic cell neoplasm (BPDC)\n* 9741: Systemic mastocytosis with an associated hematological neoplasm (SM-AHN)\n* 9742: Mast cell leukemia (MCL)\n* 9750: ALK-positive histiocytosis\n* 9751: Langerhans cell histiocytosis (LCH), disseminated\n* 9762: Heavy chain diseases, NOS (HCD)\n* 9800 Leukemia, NOS\n* 9801: Acute undifferentiated leukemia\n* 9805: Acute leukemia of ambiguous lineage with other defined genetic alterations\n* 9806: Mixed-phenotype acute leukemia (MPAL) with *BCR::ABL1* fusion\n* 9807: Mixed-phenotype acute leukemia (MPAL) with *KMT2A-rearranged*\n* 9808: Mixed -phenotype acute leukemia, B/myeloid, NOS\n* 9809: Mixed-phenotype acute leukemia (MPAL), T/myeloid, NOS\n* 9811: B-lymphoblastic leukemia/lymphoma [B-ALL/LBL], NOS\n* 9812: B-lymphoblastic leukemia/lymphoma [B-ALL/LBL] with *BCR::ABL1 fusion*\n* 9813: B lymphoblastic leukemia/lymphoma [B-ALL/LBL] with *KMT2A rearrangement*\n* 9814: B-lymphoblastic leukemia/lymphoma [B-ALL/LBL] with *ETV6::RUNX1 fusion*\n* 9815: B-lymphoblastic leukemia/lymphoma with high hyperdiploidy (B-ALL/LBL with high hyperdiploidy)\n* 9816: B-lymphoblastic leukemia/lymphoma [B-ALL/LBL] with hypodiploidy (Hypodiploid B-ALL/LBL)\n* 9817: B-lymphoblastic leukemia/lymphoma [B-ALL/LBL] with *IGH::IL3 fusion*\n* 9818: B-lymphoblastic leukemia/lymphoma [B-ALL/LBL] with *TCF3::PBX1*\n* 9819: B-lymphoblastic leukemia/lymphoma [B-ALL/LBL] with *BCR::ABL1 like features* (BCR::ABL1-like B-ALL/LBL) (2021+ only)\n* 9820: Lymphoid leukemia, NOS\n* 9831: T-large granular lymphocytic leukemia (T-LGLL)\n* 9832: Prolymphocytic leukemia (PPL), NOS\n* 9833: Prolymphocytic leukemia, B-cell type (BLL) \n* 9834: T-cell prolymphocytic leukemia (T-PLL)\n* 9837: T-lymphoblastic leukemia/lymphoma (T-ALL/LBL) \n* 9840: Acute erythroid leukemia (AEL)\n* 9860: Myeloid leukemia, NOS\n* 9861: Acute myeloid leukemia (AML), NOS\n* 9863: Chronic myeloid leukemia (CML), NOS\n* 9865: Acute myeloid leukemia with *DEK::NUP214 fusion*\n* 9866: Acute promyelocytic leukemia with *PML::RARA* fusion (APL with *PML::RARA*)\n* 9867: Acute myelomonocytic leukemia, NOS (AMML)\n* 9869: Acute myeloid leukemia with *MECOM rearrangement*\n* 9870: Acute basophilic leukemia\n* 9871: Acute myeloid leukemia with *CBFB::MYH11 fusion*\n* 9872: Acute myeloid leukemia, minimal differentiation\n* 9873: Acute myeloid leukemia without maturation\n* 9874: Acute myeloid leukemia with maturation\n* 9875: Chronic myeloid leukemia (CML), *BCR::ABL1 positive*\n* 9876: Myelodysplastic/myeloproliferative neoplasm with neutrophilia (MDS/MPN-N)\n* 9877: Acute myeloid leukemia with mutated *NPM1* (2021+ only)\n* 9878: Acute myeloid leukemia with *CEBPA mutation* (2021+ only)\n* 9879: Acute myeloid leukemia with mutated *RUNX1* (2021+ only)\n* 9891: Acute monocytic leukemia\n* 9895: Myelodysplasia-related acute myeloid leukemia (AML-MR)\n* 9896: Acute myeloid leukemia with *RUNX1::RUNX1T1*\n* 9897: Acute myeloid leukemia with *KMT2a rearrangement*\n* 9898: Myeloid leukemia associated with Down Syndrome (ML-DS)\n* 9910: Acute megakaryoblastic leukemia (AMKL)\n* 9911: Acute myeloid leukemia (megakaryoblastic) with *RBMI5::MRTFA*\n* 9912: Acute myeloid leukemia with *BCR::ABL1 fusion* (2021+ only)\n* 9920 Therapy-related myeloid neoplasms\n* 9931: Acute panmyelosis with myelofibrosis (APMF)\n* 9940: Hairy cell leukemia (HCL)\n* 9945: Chronic myelomonocytic leukemia, NOS (CMML)\n* 9946: Juvenile myelomonocytic leukemia (JMML)\n* 9948: Aggressive NK-cell leukemia (ANKL)\n* 9950: Polycythemia vera (PV)\n* 9961: Primary myelofibrosis (PMF)\n* 9962: Essential thrombocythemia (ET)\n* 9963: Chronic neutrophilic leukemia (CNL)\n* 9964: Chronic eosinophilic leukemia (CEL)\n* 9965: Myeloid/lymphoid neoplasms with *PDGFRA* rearrangement\n* 9966: Myeloid/lymphoid neoplasm with *PDGFRB* rearrangement\n* 9967: Myeloid/lymphoid neoplasm with *FGFR1* rearrangement\n* 9968: Myeloid/lymphoid neoplasm with *JAK2* rearrangement (2021+ only)\n* 9975: Myelodysplastic/myeloproliferative neoplasm, NOS, unclassifiable (MPN/MDS-U)\n* 9980: Myelodysplastic neoplasm with low blasts and single-lineage dysplasia (MDS-LB-SLD)\n* 9982: Myelodysplastic syndrome with ring sideroblasts and single lineage dysplasia (MDS-RS-SLD) \n* 9983: Myelodysplastic neoplasm with increased blasts (MDS-IB)\n* 9985: Myelodysplastic neoplasm with low blasts, NOS (MDS-LB)\n* 9986: Myelodysplastic neoplasm with low blasts and 5q deletion (MDS-5q)\n* 9989: Myelodysplastic neoplasm, NOS\n* 9991: Refractory neutropenia (2018-2020 only, see code 9980/3 for 2021+)\n* 9992: Refractory thrombocytopenia (2018-2020 only, see code 9980/3 for 2021+)\n* 9993: Myelodysplastic syndrome with ring sideroblasts and multilineage dysplasia (2021+)", + "notes" : "**Note 1:** **The preferred histology terms listed below are from the 2024 WHO Classification of Tumours, Haematolymphoid tumours, 5th edition.**\n\n**Note 2:** **The following histologies can be localized (code 100), systemic (700) or unknown (999)** \n\n* 9740: Mast cell sarcoma (MCS)\n* 9749: Erdheim-Chester disease (ECD) (2021+ only)\n* 9755: Histiocytic sarcoma\n* 9756: Langerhans cell sarcoma (LCS) \n* 9757: Interdigitating dendritic cell sarcoma (IDCS) \n* 9758: Follicular dendritic cell sarcoma (FDCS) \n* 9759: Fibroblastic reticular cell tumor \n* 9766: Lymphomatoid granulomatosis, grade 3 (2021+ only)\n* 9930: Myeloid sarcoma \n* 9971: Polymorphic PTLD (2018-2020, 2025+) \n * *Note:* 9971 is /1 and non-reportable (except for C700-C729, C751-C753) for 2021-2024, moved back to /3 for 1/1/2025+\n\n**Note 3:** **Lymph node involvement** \n* For histologies listed in **Note 1**, it is possible to have lymph node involvement; however, at this time, lymph node involvement for these histologies is not collected.\n\n**Note 4:** **The following histologies are systemic (code 700):**\n\n* 9591: Splenic B-cell lymphoma/leukemia, unclassifiable (except C441, C690, C695-C696)\n* 9724: Systemic EBV-positive T-cell lymphoma of childhood (SEBVTCL)\n* 9727: Blastic plasmacytoid dendritic cell neoplasm (BPDC)\n* 9741: Systemic mastocytosis with an associated hematological neoplasm (SM-AHN)\n* 9742: Mast cell leukemia (MCL)\n* 9750: ALK-positive histiocytosis\n* 9751: Langerhans cell histiocytosis (LCH), disseminated\n* 9762: Heavy chain diseases, NOS (HCD)\n* 9800: Leukemia, NOS\n* 9801: Acute undifferentiated leukemia\n* 9805: Acute leukemia of ambiguous lineage with other defined genetic alterations\n* 9806: Mixed-phenotype acute leukemia (MPAL) with *BCR::ABL1* fusion\n* 9807: Mixed-phenotype acute leukemia (MPAL) with *KMT2A-rearranged*\n* 9808: Mixed -phenotype acute leukemia, B/myeloid, NOS\n* 9809: Mixed-phenotype acute leukemia (MPAL), T/myeloid, NOS\n* 9811: B-lymphoblastic leukemia/lymphoma [B-ALL/LBL], NOS\n* 9812: B-lymphoblastic leukemia/lymphoma [B-ALL/LBL] with *BCR::ABL1 fusion*\n* 9813: B lymphoblastic leukemia/lymphoma [B-ALL/LBL] with *KMT2A rearrangement*\n* 9814: B-lymphoblastic leukemia/lymphoma [B-ALL/LBL] with *ETV6::RUNX1 fusion*\n* 9815: B-lymphoblastic leukemia/lymphoma with high hyperdiploidy (B-ALL/LBL with high hyperdiploidy)\n* 9816: B-lymphoblastic leukemia/lymphoma [B-ALL/LBL] with hypodiploidy (Hypodiploid B-ALL/LBL)\n* 9817: B-lymphoblastic leukemia/lymphoma [B-ALL/LBL] with *IGH::IL3 fusion*\n* 9818: B-lymphoblastic leukemia/lymphoma [B-ALL/LBL] with *TCF3::PBX1*\n* 9819: B-lymphoblastic leukemia/lymphoma [B-ALL/LBL] with *BCR::ABL1 like features* (BCR::ABL1-like B-ALL/LBL) (2021+ only)\n* 9820: Lymphoid leukemia, NOS\n* 9831: T-large granular lymphocytic leukemia (T-LGLL)\n* 9832: Prolymphocytic leukemia (PPL), NOS\n* 9833: Prolymphocytic leukemia, B-cell type (BLL) \n* 9834: T-cell prolymphocytic leukemia (T-PLL)\n* 9837: T-lymphoblastic leukemia/lymphoma (T-ALL/LBL) \n* 9840: Acute erythroid leukemia (AEL)\n* 9860: Myeloid leukemia, NOS\n* 9861: Acute myeloid leukemia (AML), NOS\n* 9863: Chronic myeloid leukemia (CML), NOS\n* 9865: Acute myeloid leukemia with *DEK::NUP214 fusion*\n* 9866: Acute promyelocytic leukemia with *PML::RARA* fusion (APL with *PML::RARA*)\n* 9867: Acute myelomonocytic leukemia, NOS (AMML)\n* 9869: Acute myeloid leukemia with *MECOM rearrangement*\n* 9870: Acute basophilic leukemia\n* 9871: Acute myeloid leukemia with *CBFB::MYH11 fusion*\n* 9872: Acute myeloid leukemia, minimal differentiation\n* 9873: Acute myeloid leukemia without maturation\n* 9874: Acute myeloid leukemia with maturation\n* 9875: Chronic myeloid leukemia (CML), *BCR::ABL1 positive*\n* 9876: Myelodysplastic/myeloproliferative neoplasm with neutrophilia (MDS/MPN-N)\n* 9877: Acute myeloid leukemia with mutated *NPM1* (2021+ only)\n* 9878: Acute myeloid leukemia with *CEBPA mutation* (2021+ only)\n* 9879: Acute myeloid leukemia with mutated *RUNX1* (2021+ only)\n* 9891: Acute monocytic leukemia\n* 9895: Myelodysplasia-related acute myeloid leukemia (AML-MR)\n* 9896: Acute myeloid leukemia with *RUNX1::RUNX1T1*\n* 9897: Acute myeloid leukemia with *KMT2a rearrangement*\n* 9898: Myeloid leukemia associated with Down Syndrome (ML-DS)\n* 9910: Acute megakaryoblastic leukemia (AMKL)\n* 9911: Acute myeloid leukemia (megakaryoblastic) with *RBMI5::MRTFA*\n* 9912: Acute myeloid leukemia with *BCR::ABL1 fusion* (2021+ only)\n* 9920 Therapy-related myeloid neoplasms\n* 9931: Acute panmyelosis with myelofibrosis (APMF)\n* 9940: Hairy cell leukemia (HCL)\n* 9945: Chronic myelomonocytic leukemia, NOS (CMML)\n* 9946: Juvenile myelomonocytic leukemia (JMML)\n* 9948: Aggressive NK-cell leukemia (ANKL)\n* 9950: Polycythemia vera (PV)\n* 9961: Primary myelofibrosis (PMF)\n* 9962: Essential thrombocythemia (ET)\n* 9963: Chronic neutrophilic leukemia (CNL)\n* 9964: Chronic eosinophilic leukemia (CEL)\n* 9965: Myeloid/lymphoid neoplasms with *PDGFRA* rearrangement\n* 9966: Myeloid/lymphoid neoplasm with *PDGFRB* rearrangement\n* 9967: Myeloid/lymphoid neoplasm with *FGFR1* rearrangement\n* 9968: Myeloid/lymphoid neoplasm with *JAK2* rearrangement (2021+ only)\n* 9975: Myelodysplastic/myeloproliferative neoplasm, NOS, unclassifiable (MPN/MDS-U)\n* 9980: Myelodysplastic neoplasm with low blasts and single-lineage dysplasia (MDS-LB-SLD)\n* 9982 Myelodysplastic /myeloproliferative neoplasm with low blasts and SF3B1 mutation\n* 9983: Myelodysplastic neoplasm with increased blasts (MDS-IB)\n* 9985: Myelodysplastic neoplasm with low blasts, NOS (MDS-LB)\n* 9986: Myelodysplastic neoplasm with low blasts and 5q deletion (MDS-5q)\n* 9989: Myelodysplastic neoplasm, NOS\n* 9991: Refractory neutropenia (2018-2020 only, see code 9980/3 for 2021+)\n* 9992: Refractory thrombocytopenia (2018-2020 only, see code 9980/3 for 2021+)\n* 9993: Myelodysplastic syndrome with ring sideroblasts and multilineage dysplasia (2021+)", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) **Introduction to Hematologic Malignancies**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Radich, J.P., Jaffe, E.S., Leonard, J.P., et al. **Leukemia**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:52:02.275Z", + "last_modified" : "2025-11-14T20:06:00.989Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bcj.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bcj.json index 9b5863247..a07550d06 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bcj.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bcj.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **Kaposi Sarcoma defined** \n* In the United States and Canada, Kaposi sarcoma is usually an illness related to acquired immunodeficiency syndrome (AIDS) which affects primarily the skin; however, lesions may also form in the connective tissue, mucosa (e.g. oral cavity) or visceral organs (e.g. lungs). \n* For connective tissue tumors (C49._), use extension codes for skin.\n\n**Note 2:** **Choice of EOD Primary Tumor for Kaposi Sarcoma** \n* Depends on the number and location of lesions\n * Code 100 (Localized) is for a single lesion involving one of the following: skin, mucosa or viscera\n * Code 200 (Localized) is for multiple lesions involving one of the following: skin, mucosa or viscera\n * Code 300 (Regional) is for multiple lesions involving a combination of skin, mucosa or viscera", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions,** National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05.** American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Pollock, R.E., Maki, R.G. **Introduction to Soft Tissue Sarcoma** In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Maki, R.G., Pollock, R.E., et al. **Soft Tissue Sarcoma - Unusual Histologies and Sites**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:51:44.985Z", + "last_modified" : "2025-11-14T20:05:43.143Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bcl.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bcl.json index 422e57e3b..7df3eeb7b 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bcl.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bcl.json @@ -5,7 +5,7 @@ "name" : "EOD Primary Tumor", "title" : "EOD Primary Tumor", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)", - "last_modified" : "2025-09-18T20:51:46.745Z", + "last_modified" : "2025-11-14T20:05:08.503Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bcm.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bcm.json index becaef2ce..e67b67269 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bcm.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bcm.json @@ -5,7 +5,7 @@ "name" : "EOD Primary Tumor", "title" : "EOD Primary Tumor", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)", - "last_modified" : "2025-09-18T20:52:30.162Z", + "last_modified" : "2025-11-14T20:05:08.128Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bcn.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bcn.json index f769277de..7d81458ff 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bcn.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bcn.json @@ -5,7 +5,7 @@ "name" : "EOD Primary Tumor", "title" : "EOD Primary Tumor", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)", - "last_modified" : "2025-09-18T20:52:17.321Z", + "last_modified" : "2025-11-14T20:05:06.964Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bco.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bco.json index a912002b1..0407dae5e 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bco.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bco.json @@ -5,7 +5,7 @@ "name" : "EOD Primary Tumor", "title" : "EOD Primary Tumor", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)", - "last_modified" : "2025-09-18T20:52:40.123Z", + "last_modified" : "2025-11-14T20:05:07.872Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bcp.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bcp.json index dedc450c9..5fefd792e 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bcp.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bcp.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **Patches** \n* For skin, patch indicates any size skin lesion without significant elevation or induration.\n\n**Note 2:** **Plaque** \n* For skin, plaque indicates any size skin lesion that is elevated or indurated.\n\n**Note 3:** **Tumor** \n* For skin, tumor indicates at least one 1 cm diameter solid or nodular lesion with evidence of depth and/or vertical growth.\n\n**Note 4:** **Sezary syndrome** \n* Sezary syndrome is the leukemic form of Mycosis Fungoides. EOD Primary Tumor for Sezary syndrome is still coded based on the amount/type of skin involvement. \n* Peripheral blood involvement, which is indicative of the leukemic variant, is coded in Peripheral Blood Involvement [NAACCR Data Item #3910]", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) **Introduction to Hematologic Malignancies**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Rosen, S.T., Jaffe, E.S., Leonard, J.P., et al. **Primary Cutaneous Lymphomas**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:52:35.191Z", + "last_modified" : "2025-11-14T20:05:46.521Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bcq.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bcq.json index e6cb4972d..a25087f02 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bcq.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bcq.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **Bones of the lateral wall** \n* The bones of the lateral wall of the nasal cavity include the maxilla, the perpendicular plate of the palatine bone, the medial pterygoid plate, the labyrinth and inferior concha of the ethmoid. \n* The roof of the nasal cavity is formed by the nasal bone. \n* The floor of the nasal cavity, which forms the roof of the mouth, is composed of the bones of the hard palate\n* The horizontal plate of the palatine bone posteriorly and the palatine process of the maxilla anteriorly.\n\n**Note 2:** **Extension to bone** \n* Involvement of or extension to bone includes any type of tumor extension to the bone, such as erosion, invasion, extension, penetration, or destruction.\n\n**Note 3:** **Bony invasion** \n* **Does not** include extension to palate, cribriform plate, or pterygoid plates. \n * Extension to these structures is coded separately.\n* **Does** include involvement of perpendicular plate of ethmoid bone or ethmoid air cells.\n\n**Note 4:** **Base of skull involvement** \n* Code 300 for base of skull, NOS when there is no information available for more specific bony structures in the skull.\n\n**Note 5:** **Extension to anterior cranial fossa** \n* Minimal extension to anterior cranial fossa implies tumor pushing through the cribriform plate, but without invasion of the dura or brain.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Lydiatt, W.M., Patel, S.G., Shah, J.P., et al. **Staging Head and Neck Cancers**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Kraus, D.H., Lydiatt, W.M., Shah, J.P., et al. **Nasal Cavity and Paranasal Sinuses**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:52:22.715Z", + "last_modified" : "2025-11-14T20:06:07.184Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bcr.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bcr.json index 848801b62..1e4edfffc 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bcr.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bcr.json @@ -5,7 +5,7 @@ "name" : "EOD Primary Tumor", "title" : "EOD Primary Tumor", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)", - "last_modified" : "2025-09-18T20:52:31.389Z", + "last_modified" : "2025-11-14T20:05:16.746Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bcs.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bcs.json index 02745e567..4137c34a2 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bcs.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bcs.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **Primary acquired melanosis** \n* Melanoma in situ is also called primary acquired melanosis.\n\n**Note 2:** **Nodular or well-defined conjunctival melanomas** \n* Nodular or well-defined conjunctival melanomas are clinically categorized according to the regional location of their posterior and anterior margins (i.e., cornea, limbus, bulbar conjunctiva, fornix, palpebral conjunctiva, plica, caruncle, or eyelid skin) and by their circumferential extent, in clock minutes, in each of these regions. \n* A \"quadrant\" comprises 15 clock minutes regardless of the meridian locations of the lateral margins.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Coupland, S.E., Finger, P.T., et al. **Conjunctival Melanoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:51:44.106Z", + "last_modified" : "2025-11-14T20:05:12.782Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bct.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bct.json index 510fa83c2..ada59d40c 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bct.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bct.json @@ -5,7 +5,7 @@ "name" : "EOD Primary Tumor", "title" : "EOD Primary Tumor", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) White, V.A., Finger, P.T., et al. **Lacrimal Gland Carcinoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:52:07.049Z", + "last_modified" : "2025-11-14T20:06:12.262Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bcv.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bcv.json index 2fbb9855e..9b44a9978 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bcv.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bcv.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **Periosteum** \n* Periosteum is a fibrous membrane that wraps the outer surface of bones. \n* Mucoperiosteum is a compound structure of mucous membrane and periosteum. Cortical bone is the dense compact outer layer of bone.\n\n**Note 2:** **Macroscopic extraparenchymal extension** \n* Macroscopic extraparenchymal extension (code 300) is based on clinical evaluation or macroscopic evidence of extraparenchymal extension at the time of surgery.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Lydiatt, W.M., Patel, S.G., Shah, J.P., et al. **Staging Head and Neck Cancers**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Lydiatt, W.M., Shah, J.P., et al. **Major Salivary Glands**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:52:28.279Z", + "last_modified" : "2025-11-14T20:05:06.135Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bcx.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bcx.json index 7d3dc7d17..50d684d9b 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bcx.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bcx.json @@ -5,7 +5,7 @@ "name" : "EOD Primary Tumor", "title" : "EOD Primary Tumor", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)", - "last_modified" : "2025-09-18T20:51:46.518Z", + "last_modified" : "2025-11-14T20:05:07.540Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bcy.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bcy.json index 0ad6af772..079cb00c8 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bcy.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bcy.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note:** **Code 000** \n* If EOD Primary Tumor is 000, Behavior ICD-O-3 must be coded as 2. If EOD Primary Tumor is 100 or greater, Behavior ICD-O-3 must be coded as 3.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)", - "last_modified" : "2025-09-18T20:52:08.760Z", + "last_modified" : "2025-11-14T20:05:41.307Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bdd.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bdd.json index bfda2f792..a91332e71 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bdd.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bdd.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note:** **Connective tissue** \n* Connective tissues large enough to be given a specific name are adjacent structures. For example, prevertebral fascia and jugular vein have names. Continuous tumor growth from one organ into an adjacent named structure is coded to regional.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User\nDocumentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)", - "last_modified" : "2025-09-18T20:51:44.372Z", + "last_modified" : "2025-11-14T20:05:13.955Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bde.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bde.json index 4140a2083..a7c7ea596 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bde.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bde.json @@ -5,7 +5,7 @@ "name" : "EOD Primary Tumor", "title" : "EOD Primary Tumor", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Herman, J.M., Pawlik, T.M., Vauthey, J.N., et al. **Ampulla of Vater**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:52:01.626Z", + "last_modified" : "2025-11-14T20:05:36.477Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bdg.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bdg.json index f351cc8e2..35fae1edc 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bdg.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bdg.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **Multiple simultaneous tumors** \n* Code the tumor with the greatest extension when there are multiple simultaneous tumors.\n\n**Note 2:** **Full eyelid thickness definition** \n* Full eyelid thickness (code 300) is defined as including skin, orbicularis muscle, tarsus and conjunctiva (palpebral).", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Esmaeli, B., Finger, P.T., et al. **Eyelid Carcinoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:52:30.852Z", + "last_modified" : "2025-11-14T20:05:30.398Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bdh.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bdh.json index 3c05ee805..1367fbe9b 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bdh.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bdh.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **CLINICAL AND PATHOLOGICAL codes** \n* This schema has extension codes that are defined as “PATHOLOGICAL assessment only” \n* PATHOLOGICAL assessment only codes (100, 150, 200, 300, 400, 500) are used when there is an orchiectomy\n\n**Note 2:** **Pure seminomas** \n* Pure seminomas are defined as 9061/3. (See codes 100 and 150)\n\n**Note 3:** **Lymphovascular invasion** \n* For codes 000, 100, 150, and 200, LVI [NAACCR # 1182] must be coded as none (code 0), not applicable (8), or unknown (9).\n * See the STORE or SEER manual for instructions on how to code LVI", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Brimo, F., Srigley, J.R., Lin, D.W., et al. **Testis**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:51:54.023Z", + "last_modified" : "2025-11-14T20:05:51.213Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bdk.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bdk.json index 2bd0e93b3..fa8a84a1a 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bdk.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bdk.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note:** **Extension to bone** \n* Involvement of or extension to bone includes any type of tumor extension to the bone, such as erosion, invasion, extension, penetration, or destruction.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)", - "last_modified" : "2025-09-18T20:52:34.541Z", + "last_modified" : "2025-11-14T20:05:14.440Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bdl.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bdl.json index dadb726ab..b16540977 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bdl.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bdl.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **Peritoneum** \n* Periosteum is a fibrous membrane that wraps the outer surface of bones. Cortical bone is the dense compact outer layer of the bone. Trabecular, cancellous, or spongy bone (spongiosa) is a porous network of tissue filling the interior of bone, decreasing weight and allowing room for blood vessels and marrow.\n\n**Note 2:** **Criteria for Derived T** \n* For codes 100-500, the derived EOD T is based on depth of invasion (DOI) in conjunction with size. In addition, some of the anatomical structures listed are localized for Summary Stage 2018 while others are regional for Summary Stage 2018. The anatomical structures are divided into two groups: Group 1 is for localized tumors, while Group 2 is for regional tumor. \n\n**Group 1 extension WITH any size tumor: Use the following for codes 100, 150, 200**\n- Invasive tumor confined to lamina propria (mucoperiosteum) (stroma)\n- Confined to gum, NOS\n- Localized, NOS\n\n**Group 2 extension WITH any size tumor: Use the following for codes 300, 400, 500**\n- Bone, NOS\n + Bone (mandible, maxilla, palatine)\n + Cartilage (mandible, maxilla, NOS)\n + Cortical bone, invasion of (mandible, maxilla, NOS)\n- Buccal mucosa (inner cheek)\n- Facial muscle, NOS\n- Floor of mouth\n- Hard palate (includes cortical palatine bone)\n- Labial mucosa (inner lip)\n- Lateral pharyngeal wall\n- Lip, NOS\n- Soft palate including uvula\n- Subcutaneous soft tissue of face\n- Tongue mucosa\n- Tonsillar pillars and fossae\n- Tonsils\n\n**Note 3:** **Depth of invasion** \n* Once the correct group is determined, the codes are then determined based on the depth of invasion.\n - Depth of invasion less than or equal to 5 mm or UNKNOWN depth of invasion (codes 100, 300)\n - Depth of invasion greater than 5 mm to less than or equal to 10 mm (codes 150, 400)\n - Depth of invasion greater than 10 mm (codes 200, 500)\n\n**Note 4:** **Cortical bone** Invasion through cortical bone is required for assignment of code 600.\n- Code 300, 400, or 500 (depending on the depth of invasion) when the tumor is limited to the cortical bone/cortex of the mandible or maxilla. Invasion of the bone, NOS (mandible, NOS or maxilla, NOS) is **not** equivalent to invasion through the cortical bone (code 600).", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Lydiatt, W.M., Patel, S.G., Shah, J.P., et al. **Staging Head and Neck Cancers**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Ridge, J.A., Lydiatt, W.M., Shah, J.P., et al. **Oral Cavity**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:52:27.137Z", + "last_modified" : "2025-11-14T20:05:17.092Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bdo.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bdo.json index 119e4a3bf..fa02c25e0 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bdo.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bdo.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **Multiple simultaneous tumors** \n* In the case of multiple simultaneous tumors, code the tumor with the greatest extension.\n\n**Note 2:** **Skin ulceration** \n* Skin ulceration does not alter the classification.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)", - "last_modified" : "2025-09-18T20:51:47.681Z", + "last_modified" : "2025-11-14T20:05:10.141Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bds.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bds.json index f73c6b9c3..4cfbb75c6 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bds.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bds.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **Multiple simultaneous tumors** \n* In the case of multiple simultaneous tumors, code the tumor with the greatest extension.\n\n**Note 2:** **In transit metastases** \n* In transit metastasis is defined as a tumor distinct from the primary lesion and located either between the primary lesion and the draining regional lymph node(s) or distal to the primary lesion. \n* In transit metastasis with positive lymph node(s) are coded under EOD Regional Nodes.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Bichakjian, C.K., Nghiem, P., Sober, A.J., et al. **Merkel Cell Carcinoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:52:30.506Z", + "last_modified" : "2025-11-14T20:05:28.373Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bdu.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bdu.json index 22e92fe00..54cdf8f2a 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bdu.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bdu.json @@ -5,7 +5,7 @@ "name" : "EOD Primary Tumor", "title" : "EOD Primary Tumor", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Woltering, E.A., Bergsland, E.K., et al. **Neuroendocrine Tumors of the Appendix**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) **Neuroendocrine Tumors of the Appendix**, from the AJCC Cancer Staging System Version 9 (2023). Used with permission of the American College of Surgeons, Chicago, Illinois.", - "last_modified" : "2025-09-18T20:51:53.702Z", + "last_modified" : "2025-11-14T20:05:46.989Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bez.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bez.json index 4e24df5d6..597d4e130 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bez.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bez.json @@ -5,7 +5,7 @@ "name" : "EOD Primary Tumor", "title" : "EOD Primary Tumor", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Heegaard, S., Finger, P.T., et al. **Ocular Adnexal Lymphoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:52:38.630Z", + "last_modified" : "2025-11-14T20:05:59.760Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bfa.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bfa.json index 50401e5e3..feb88f79a 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bfa.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bfa.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **Multiple tumors** \n* Multiple tumors include satellitosis, multifocal tumors, and intrahepatic metastasis.\n\n**Note 2:** **Vascular invasion**\n* Intrahepatic vascular invasion (codes 200 and 300) include the following\n * Major hepatic vessel invasion \n * First and second-order branches of the portal veins or hepatic arteries\n * Hepatic veins (right, middle, or left)\n * Microscopic invasion of smaller intraparenchymal vascular structures (identified on histopathological examination)", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Aloia, T., Pawlik, T.M., Vauthey, J.N., et al. **Intrahepatic Bile Ducts**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:51:52.588Z", + "last_modified" : "2025-11-14T20:05:37.840Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bfg.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bfg.json index 6be9a8079..1bf2facf8 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bfg.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bfg.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **In-situ and HAMN** \n* Code 000 (behavior code 2) includes cancer cells confined within the glandular basement membrane (intraepithelial) or described as in situ or high-grade appendiceal mucinous neoplasms (HAMN)\n\n**Note 2:** **LAMN** \n* Code 050 (behavior code 2) for low-grade appendiceal mucinous neoplasms (LAMN) that are confined by the muscularis propria.\n* See codes 350-750 for LAMN tumors that extend beyond the muscularis propria \n\n**Note 3:** **Code 070 (behavior code 3)**\n* Intramucosal, NOS\n* Lamina propria\n* Mucosa, NOS\n* Confined to, but not through the muscularis mucosa\n\n**Note 4:** **Intraluminal extension** \n* Ignore intraluminal extension to adjacent segment(s) of colon/rectum or to the ileum from the cecum; code depth of invasion or extracolonic spread as indicated.\n\n**Note 5:** **Mucinous Tumors** \n* Mucinous tumors are identified by morphology codes 8480, 8481, and 8490.\n\n**Note 6:** **Invasion of subserosa or mesoappendix** \n* Code 300 when the only statement is \"Tumor invades through the muscularis propria into subserosa or mesoappendix but does not extend to serosal surface\" and there isn't enough information to clarify subserosa versus mesoappendix. \n\n**Note 7:** **Macroscopic adhesions** \n* Use code 700 for macroscopic adhesions if no pathological confirmation, and for microscopically confirmed tumor in adhesions. \n* However, if no tumor is present in adhesion(s) upon microscopic examination, the classification is based upon extent of tumor invasion into or through the wall (see codes 100-600). \n\n**Note 8:** **Contiguous extension** \n* Codes 700 and 750 are used for contiguous extension from the site of origin\n* Except for intraperitoneal metastases limited to the right lower quadrant (RLQ) of the abdomen for **mucinous tumors (see code 600)**, **discontinuous involvement is coded in EOD Mets**.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Overman, M.J., Jessup, J.M., et al. **Appendix - Carcinoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:52:27.970Z", + "last_modified" : "2025-11-14T20:05:04.319Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bfh.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bfh.json index d59eed9a7..8321dee99 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bfh.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bfh.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **GIST tumors in the Digestive System** \n* For GIST tumors arising in the tubular organs of the digestive system (Esophagus, Stomach, Small Intestine, Appendix, Colon and Rectum), any extension beyond the muscular wall (e.g. invasion beyond the muscularis propria/muscularis, NOS) into adjacent tissues, sites or organs is no longer confined to the site of origin (EOD Primary Tumor code 100). \n * Extension through the wall, NOS, or through the muscularis propria/muscularis, NOS without further extension would be EOD Primary Tumor code 100 (confined to the site of origin).\n * Extension through the wall, NOS or through the muscularis propria/muscularis, NOS with any further extension into underlying tissues/fat, organs or structures would be included in EOD Primary Tumor codes 400 or 700 (Adjacent (connective) tissue, NOS or Extension to organs/structures, NOS).\n\n**Note:** **EOD references** \n See the schema corresponding to the primary site for information about the site's anatomy. \n* The corresponding schema can be used to help determine what the adjacent (connective) tissues, structures or organs are, but the site-specific schema codes are not to be used to determine whether a GIST tumor is localized, regional or distant.\n* See the chapter (schema) corresponding to the primary site for information about extension. \n* *For example*: For primary colon GIST, see the colon chapter (schema) for extension information.\n * **Esophagus**: C150-C155, C158-C159\n * **Small Intestine**: C170-C172, C178-C17\n * **Stomach**: C160-C166, C168-C169 \n * **Appendix**: C181 \n * **Colon and Rectum**: C180, C182-C189, C199, C209\n * **Retroperitoneum**: C480-C482, C488\n\n**Note 3:** **Retroperitoneum GIST** \n* For GIST tumors arising in the Retroperitoneum (C480-C482, C488), refer to the EOD General Instructions for the definition of adjacent (connective) tissue. \n* Refer to the General Instructions to determine whether the GIST tumor involves adjacent tissues or is confined to the primary site.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Pollock, R.E., Maki, R.G. **Introduction to Soft Tissue Sarcoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) DeMatteo, R.P., Maki, R.G., Pollock, R.E., et al. **Gastrointestinal Stromal Tumor**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:51:47.907Z", + "last_modified" : "2025-11-14T20:05:10.987Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bfi.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bfi.json index b27ba2f37..2a6d40759 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bfi.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bfi.json @@ -5,7 +5,7 @@ "name" : "EOD Primary Tumor", "title" : "EOD Primary Tumor", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Shi, C., Woltering, E.A., Washington, M.K., et al. **Neuroendocrine Tumors of the Colon and Rectum**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) **Neuroendocrine Tumors of the Colon and Rectum**, from the AJCC Cancer Staging System Version 9 (2023). Used with permission of the American College of Surgeons, Chicago, Illinois.", - "last_modified" : "2025-09-18T20:51:50.264Z", + "last_modified" : "2025-11-14T20:05:27.006Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bfk.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bfk.json index 032bacf0a..65fdafd59 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bfk.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bfk.json @@ -5,7 +5,7 @@ "name" : "EOD Primary Tumor", "title" : "EOD Primary Tumor", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Woltering, E.A., Bergsland, E.K., et al. **Neuroendocrine Tumors of the Stomach**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) **Neuroendocrine Tumors of the Stomach,** from the AJCC Cancer Staging System Version 9 (2023). Used with permission of the American College of Surgeons, Chicago, Illinois.", - "last_modified" : "2025-09-18T20:52:06.549Z", + "last_modified" : "2025-11-14T20:05:48.041Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bfl.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bfl.json index b026ef09b..596f1e88f 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bfl.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bfl.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note:** **FIGO and extension information** \n* When both the Federation Internationale de Gynecologie et d'Obstetrique (FIGO) stage and extension information on the primary tumor are available, use the extension information to code primary tumor in preference to a statement of FIGO stage.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05.** American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging.** In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) **Introduction to Female Reproductive Organs**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Dizon, D.S., Olawaiye, A.B., Mutch, D.G., et al. **Corpus Uteri - Sarcoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:52:29.197Z", + "last_modified" : "2025-11-14T20:05:26.516Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bfm.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bfm.json index eb8e23f22..4b5cc8d62 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bfm.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bfm.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note:** **FIGO and extension information** \n* When both the Federation Internationale de Gynecologie et d'Obstetrique (FIGO) stage and extension information on the primary tumor are available, use the extension information to code primary tumor in preference to a statement of FIGO stage.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging.** In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) **Introduction to Female Reproductive Organs**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Dizon, D.S., Olawaiye, A.B., Mutch, D.G., et al. **Corpus Uteri - Sarcoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:52:26.491Z", + "last_modified" : "2025-11-14T20:05:35.066Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bfp.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bfp.json index 34f44fc82..4e3842d75 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bfp.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bfp.json @@ -5,7 +5,7 @@ "name" : "EOD Primary Tumor", "title" : "EOD Primary Tumor", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Woltering, E.A., Bergsland, E.K., et al. **Neuroendocrine Tumors of the Jejunum and Ileum**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) **Neuroendocrine Tumors of the Jejunum and Ileum**, from the AJCC Cancer Staging System Version 9 (2023). Used with permission of the American College of Surgeons, Chicago, Illinois.", - "last_modified" : "2025-09-18T20:51:45.599Z", + "last_modified" : "2025-11-14T20:05:47.495Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bfq.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bfq.json index 7d8e131e7..084d50c65 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bfq.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bfq.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **Uveal melanomas** \n* Uveal melanomas arise most commonly in the choroid, less frequently in the ciliary body, and least often in the iris. \n* Melanomas of the iris tend to be small, and those arising from or extending to the ciliary body typically are large.\n\n**Note 2:** **Ciliary body and choroid melanomas** \n* Primary ciliary body and choroidal melanomas are classified according to four tumor size categories. The tumor size categories are based on the largest basal and thickness.\n * Basal diameter is collected in data item *Measured Basal Diameter* [NAACCR Date Item #3887] \n * Thickness is collected in the data item *Measured Thickness* [NAACCR Data Item #3888]\n\n**Note 3:** **Discrete tumor deposit(s)** \n* Discrete tumor deposit(s) in the orbit that are not contiguous to the eye are recorded in lymph nodes (See EOD Regional Nodes).", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Kivelä, T., Finger, P.T., et al. **Uveal Melanoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:52:40.515Z", + "last_modified" : "2025-11-14T20:05:50.243Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bfr.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bfr.json index decb465a6..ed2e18136 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bfr.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bfr.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **Uveal Melanomas** \n* Uveal melanomas arise most commonly in the choroid, less frequently in the ciliary body, and least often in the iris. \n* Melanomas of the iris tend to be small, and those arising from or extending to the ciliary body typically are large.\n\n**Note 2:** **Discrete tumor nodules** \n* Discrete tumor deposit(s) in the orbit that are not contiguous to the eye are recorded in lymph nodes (See EOD Regional Nodes).", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Kivelä, T., Finger, P.T., et al. **Uveal Melanoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:52:13.702Z", + "last_modified" : "2025-11-14T20:06:02.252Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bfs.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bfs.json index df9cb3207..54e1246d4 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bfs.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bfs.json @@ -5,7 +5,7 @@ "name" : "EOD Primary Tumor", "title" : "EOD Primary Tumor", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Krasinskas, A., Pawlik, T.M., Vauthey, J.N., et al. **Distal Bile Duct**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:51:50.839Z", + "last_modified" : "2025-11-14T20:05:37.365Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bft.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bft.json index d24983f9c..eef3327f6 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bft.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bft.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **Biliary radicals** \n* The biliary radicals are the ducts or tubes that drain bile into the intestine as part of the digestive process. \n* The second-order biliary radicals are the next largest branches or ducts of the biliary system which join to form or empty into the main hepatic bile duct.\n\n**Note 2:** **Vessel invasion** \n* Codes 400 and 500 are defined strictly in terms of invasion into specific large blood vessels and the biliary radicals within the liver. \n* Code 500 when the specified vessels and/or the biliary radical within the liver plus other named organs are involved. \n\n**Note 3:** **Porta hepatis involvement** \n* Involvement within the porta hepatis is coded according to the structures involved: portal vein, common hepatic artery, and common hepatic duct.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Nagorney, D.M., Pawlik, T.M., Vauthey, J.N., et al. **Perihilar Bile Ducts**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:51:52.816Z", + "last_modified" : "2025-11-14T20:05:38.165Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bfv.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bfv.json index e047c5bbc..de512184a 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bfv.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bfv.json @@ -5,7 +5,7 @@ "name" : "EOD Primary Tumor", "title" : "EOD Primary Tumor", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Pollock, R.E., Maki, R.G. **Introduction to Soft Tissue Sarcoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Pollock, R.E., Maki, R.G., et al. **Soft Tissue Sarcoma of the Retroperitoneum**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:52:35.502Z", + "last_modified" : "2025-11-14T20:05:18.642Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bfw.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bfw.json index 97b1273d1..5f40d3ecd 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bfw.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bfw.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **Cystic duct location** \n* The cystic duct extends from the neck of the gallbladder to its junction with the common hepatic duct, to form the common bile duct.\n\n**Note 2:** **Portal hepatis involvement** \n* Involvement within the porta hepatis is coded according to the structures involved: portal vein, common hepatic artery, and common hepatic duct.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05.** American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging.** In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Zhu, A.X., Pawlik, T.M., Vauthey, J.N., et al. **Gallbladder**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:51:53.165Z", + "last_modified" : "2025-11-14T20:05:39.004Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bfy.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bfy.json index 15064bef0..1da493699 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bfy.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bfy.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note:** **Benign/Borderline** \n* Benign (/0) or Borderline (/1) tumors are always coded to 050 regardless of size or extension to adjacent sites.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05.** American Joint Committee on Cancer (Chicago, IL)\n\n(4) Laws, E.R., Curran, W.J., et al. **Brain and Spinal Cord**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:52:29.468Z", + "last_modified" : "2025-11-14T20:05:15.359Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bgc.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bgc.json index 67a0b5402..63ced8551 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bgc.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bgc.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note:** **Definition of Plasma Cell Myeloma** \n* Plasma cell myeloma/multiple myeloma (9732) is a widely disseminated plasma cell neoplasm, characterized by a single clone of plasma cells derived from B cells that grows in the bone marrow. It is always coded to 700 for systemic involvement.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) **Introduction to Hematologic Malignancies**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Bergsagel, P.L., Jaffe, E.S., Leonard, J.P., et al. **Plasma Cell Myeloma and Plasma Cell Disorders**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:51:59.660Z", + "last_modified" : "2025-11-14T20:05:02.389Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bna.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bna.json index 0913eeac9..c8675bd2c 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bna.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_bna.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "EOD Primary Tumor", "title" : "EOD Primary Tumor", - "last_modified" : "2025-09-18T20:51:59.355Z", + "last_modified" : "2025-11-14T20:05:16.406Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_btb.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_btb.json index eeb30fdbf..d17d1430f 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_btb.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extension_btb.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **Lacrimal Sac** \n* The lacrimal sac is the upper dilated end of the nasolacrimal duct, lodged in a deep groove formed by the lacrimal bone and frontal process of the maxilla. \n* The sac connects the lacrimal canaliculi, which drain tears from the eye's surface, and the nasolacrimal duct, which conveys this fluid into the nasal cavity. \n* The most common epithelial tumors of the lacrimal sac are squamous cell and transitional cell carcinomas.\n\n**Note 2:** **Periosteum** \n* Periosteum is a fibrous membrane that wraps the outer surface of bones.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)", - "last_modified" : "2025-09-18T20:52:06.199Z", + "last_modified" : "2025-11-14T20:05:46.153Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extranodal_extension_clinical_5022.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extranodal_extension_clinical_5022.json index 907b5b40c..ad18434a4 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extranodal_extension_clinical_5022.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extranodal_extension_clinical_5022.json @@ -6,7 +6,7 @@ "title" : "Extranodal Extension Clinical", "description" : "Extranodal Extension (ENE) Clinical is defined as “the extension of a nodal metastasis through the lymph node capsule into adjacent tissue” during the diagnostic workup. This data item defines clinical ENE for sites other than Head and Neck.\n\nThe presence of extranodal extension (ENE) from regional lymph nodes is an important prognostic factor in some cancers because these patients are rarely cured without some type of systemic chemotherapy or radiation. \n\nExtranodal extension is defined as metastatic tumor growing from within the lymph node outward through the lymph node capsule and into surrounding connective tissues. \n* \"A regional node extending into a distant structure or organ is categorized as ENE and is not recorded as distant metastatic disease.\"\n\n**Clinical ENE is described as** \"Unambiguous evidence of gross ENE on clinical examination (e.g., invasion of skin, infiltration of musculature, tethering to adjacent structures, or cranial nerve, brachial plexus, sympathetic trunk, or phrenic nerve invasion with dysfunction)\"\n* The terms 'fixed' or 'matted' are used to describe lymph nodes\n\nThis data item is for ENE that is detected clinically.", "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of Extranodal Extension (ENE) Clinical or physician clinical staging can be used to code this data item when there is no other information available.\n\n**Note 2:** **Criteria for coding** \n* Code the status of extranodal extension assessed during the diagnostic working for the assignment of the clinical stage for the most involved regional lymph node(s)\n* This is mainly determined by physical examination and included statements such as fixed or matted nodes\n* The assessment for ENE **in addition to physical examination** may include imaging, biopsy of the regional lymph node, and/or biopsy of tissues surrounding the regional lymph node\n* Do not code ENE for any distant nodes\n* Be aware that the rules for coding ENE for head and neck sites compared to non-head and neck sites are different.", - "last_modified" : "2025-02-24T14:02:53.683Z", + "last_modified" : "2025-11-06T18:43:18.440Z", "definition" : [ { "key" : "extranodal_ext_clin", "name" : "Code", @@ -17,7 +17,7 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "0", "Regional lymph node(s) involved, ENE not present/not identified during diagnostic workup" ], [ "1", "Regional lymph node(s) involved, ENE present/identified during diagnostic workup, \nbased on physical exam WITH or WITHOUT imaging" ], [ "2", "Regional lymph node(s) involved, ENE present/identified during diagnostic workup, \nbased on microscopic confirmation" ], [ "4", "Regional lymph nodes involved, ENE present/identified, unknown how identified" ], [ "7", "No lymph node involvement identified during diagnostic workup (cN0)\nNon-invasive neoplasm (behavior /2)" ], [ "8", "Not applicable: Information not collected for this case\n(If this information is required by your standard setter, use of code 8 may result in an edit error)" ], [ "9", "Not documented in medical record \nClinical ENE not assessed or unknown if assessed during diagnostic workup\nClinical assessment of lymph node(s) not done, or unknown if done" ] ], - "additional_info" : "**Source documents:** pathology report from surgical resection x\n\n**Other names include** ENE, extracapsular extension, ECE, extracapsular extension, ECE, extranodal spread, extracapsular extension, or extracapsular spread\n * *Note*: ENE is the preferred terminology\n\nFor further information, refer to the **Merkel Cell Carcinoma** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Merkel Cell Carcinoma*", - "coding_guidelines" : "**1)** **Code 0** when lymph nodes are determined to be **clinically positive** and physical examination does not indicate any signs of extranodal extension.\n**2)** **Code 1** when **ENE** is unquestionable as determined by physical examination \n**3)** **Code 2** when there are positive nodes clinically, ENE is identified by biopsy (microscopically confirmed)\n**4)** **Code 4** when there are positive nodes clinically, ENE is identified, but not known how identified\n**5)** **Code 7** when nodes are clinically negative (cN0)\n**6)** **Code 9** when \n* No information in the medical record\n* Positive nodes clinically, not evaluated (assessed) for ENE\n* Positive nodes clinically, unknown if evaluated (assessed) for ENE\n* Lymph nodes not evaluated (assessed) clinically\n* Unknown if lymph nodes evaluated (assessed) clinically\n* Lymph node biopsy (e.g., FNA, core, incisional, excisional, sentinel node) performed and is negative for ENE or not stated", + "additional_info" : "**Source documents:** pathology report from surgical resection \n\n**Other names include** ENE, extracapsular extension, ECE, extracapsular extension, ECE, extranodal spread, extracapsular extension, or extracapsular spread\n * **Note**: ENE is the preferred terminology\n\nFor further information, refer to the **Merkel Cell Carcinoma** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Merkel Cell Carcinoma*.", + "coding_guidelines" : "**1)** **Code 0** when lymph nodes are determined to be **clinically positive** and physical examination does not indicate any signs of extranodal extension\n\n**2)** **Code 1** when **ENE** is unquestionable as determined by physical examination \n\n**3)** **Code 2** when there are positive nodes clinically, ENE is identified by biopsy (microscopically confirmed)\n\n**4)** **Code 4** when there are positive nodes clinically, ENE is identified, but not known how identified\n\n**5)** **Code 7** when nodes are clinically negative (cN0)\n\n**6)** **Code 9** when \n* No information in the medical record\n* Positive nodes clinically, not evaluated (assessed) for ENE\n* Positive nodes clinically, unknown if evaluated (assessed) for ENE\n* Lymph nodes not evaluated (assessed) clinically\n* Unknown if lymph nodes evaluated (assessed) clinically\n* Lymph node biopsy (e.g., FNA, core, incisional, excisional, sentinel node) performed and is negative for ENE or not stated", "rationale" : "Extranodal Extension Clinical (non-Head and Neck) is a Registry Data Collection Variable for AJCC. This data item was previously collected for Penis, SSF #17." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extranodal_extension_head_and_neck_clinical_79321.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extranodal_extension_head_and_neck_clinical_79321.json index 6bc2f0fe6..fdb6b37b4 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extranodal_extension_head_and_neck_clinical_79321.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extranodal_extension_head_and_neck_clinical_79321.json @@ -6,8 +6,8 @@ "title" : "Extranodal Extension Head and Neck Clinical", "subtitle" : "ENE, Extracapsular extension (ECE)", "description" : "Extranodal extension is defined as “the extension of a nodal metastasis through the lymph node capsule into adjacent tissue” and is a prognostic factor for most head and neck tumors. This data item pertains to extranodal extension detected radiologically or by physical examination and may not correlate with pathological extranodal extension.\n\nENE on physical examination (clinical ENE, cENE) is described in the AJCC Head and Neck Staging System as \"unambiguous evidence of gross ENE on clinical examination (e.g., invasion of skin, infiltration of musculature, tethering to adjacent structures, or cranial nerve, brachial plexus, sympathetic trunk, or phrenic nerve invasion with dysfunction)\"\n\nImaging-detected extranodal extension (iENE) refers to unequivocal radiological signs of tumor invasion through the through the capsule of a lymph node into either perinodal fat or adjacent tissues (e.g. skin, muscle, or neurovascular structures) or a coalescent nodal mass (a coalescent nodal mass comprises ≥ 2 adjacent lymph nodes that have lost their intervening tissue planes and capsules to merge into a single indivisible structure).", - "notes" : "**Note 1:** ** Physican Statement** \n* Physician statement indicating the presence or absence of extranodal extension (ENE) can be used to code this data item when no other information is available\n* Physical exam alone is sufficient to determine Clinical ENE\n\n**Note 2:** **Clinical assessment criteria** \n* The assessment of ENE must be based on evidence acquired prior to definitive surgery of the primary site, chemotherapy, radiation, or other type of treatment, i.e., the clinical timeframe for staging. \n* The assessment for ENE in may **include imaging and/or physical examination.** \n * Biopsy of the regional lymph node or surrounding tissue can be used to confirm the presence of metastatic carcinoma and thus verify the clinical assessment, but cannot be used in isolation to determine ENE during clinical staging\n* Fixed nodes are clinical indications of cENE\n* Matted nodes are indications of iENE\n* iENE is identified exclusively on imaging\n* ENE during clinical staging is considered present when cENE and/or iENE are present\n * Note that the rules for coding ENE for head and neck sites compared to non-head and neck sites are different", - "last_modified" : "2025-06-01T17:08:15.943Z", + "notes" : "**Note 1:** **•\tPhysician Statement** \n* Physician statement indicating the presence or absence of extranodal extension (ENE) can be used to code this data item when no other information is available\n* Physical exam alone is sufficient to determine Clinical ENE\n\n**Note 2:** **Clinical assessment criteria** \n* The assessment of ENE must be based on evidence acquired prior to definitive surgery of the primary site, chemotherapy, radiation, or other type of treatment, i.e., the clinical timeframe for staging. \n* The assessment for ENE may **include imaging and/or physical examination.** \n * Biopsy of the regional lymph node or surrounding tissue can be used to confirm the presence of metastatic carcinoma and thus verify the clinical assessment, but cannot be used in isolation to determine ENE during clinical staging\n* Fixed nodes are clinical indications of cENE\n* Matted nodes are indications of iENE\n* iENE is identified exclusively on imaging\n* ENE during clinical staging is considered present when cENE and/or iENE are present\n * Note that the rules for coding ENE for head and neck sites compared to non-head and neck sites are different", + "last_modified" : "2025-11-06T16:57:31.396Z", "definition" : [ { "key" : "extranodal_ext_hn_clin", "name" : "Code", @@ -18,7 +18,7 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "0", "Regional lymph node(s) involved, ENE not present/not identified during diagnostic workup" ], [ "1", "Regional lymph node(s) involved, ENE present/identified during diagnostic workup, \nbased on physical exam and/or imaging" ], [ "2", "Regional lymph node(s) involved, ENE present/identified during diagnostic workup, \nbased on microscopic confirmation" ], [ "4", "Regional lymph nodes involved, ENE present/identified, unknown how identified" ], [ "7", "No lymph node involvement during diagnostic workup (cN0)" ], [ "8", "Not applicable: Information not collected for this case\n(If this information is required by your standard setter, use of code 8 may result in an edit" ], [ "9", "Not documented in medical record\nENE not assessed during diagnostic workup, or unknown if assessed\nClinical assessment of lymph node(s) not done, or unknown if done" ] ], - "additional_info" : "**Source documents:** imaging reports, physical exam\n\n**Other names include** Extracapsular extension (ECE), extranodal spread (ENS), or extracapsular spread (ECS)\n* *Note*: ENE is the preferred terminology, and includes\n * **cENE** for clinical ENE\n * **iENE** for imaging-detected ENE\n * **pENE** for pathological ENE\n\nFor further information, refer to the **Head and Neck** cancer protocols published by the College of American Pathologist for the AJCC Staging Systems for *Head and Neck.*", - "coding_guidelines" : "**1) Code 0** when lymph nodes are determined to be **clinically positive** and there is **no clinical evidence of ENE** based on physical examination.\n**2) Code 1** when there is **definitive (unquestionable) evidence of ENE** as determined by physical examination \n**3) Code 2** when there is **definitive (unquestionable) evidence of ENE** as determined by physical examination and/or imaging **and** nodal involvement is microscopically confirmed by biopsy \n**4) Code 4** when there is **definitive (unquestionable) evidence of ENE**, but the means of identification is not known\n**5) Code 7** when nodes are clinically negative (cN0)\n**6) Code 9** when \n* No information in the medical record\n* Positive nodes clinically, not evaluated (assessed) for ENE\n* Positive nodes clinically, unknown if evaluated (assessed) for ENE\n* Lymph nodes not evaluated (assessed) clinically\n* Unknown if lymph nodes evaluated (assessed) clinically", + "additional_info" : "**Source documents:** imaging reports, physical exam\n\n**Other names include** Extracapsular extension (ECE), extranodal spread (ENS), or extracapsular spread (ECS)\n* **Note**: ENE is the preferred terminology, and includes\n * **cENE** for clinical ENE\n * **iENE** for imaging-detected ENE\n * **pENE** for pathological ENE\n\nFor further information, refer to the **Head and Neck** cancer protocols published by the College of American Pathologist for the AJCC Staging Systems for *Head and Neck*.", + "coding_guidelines" : "**1) Code 0** when lymph nodes are determined to be **clinically positive** and there is **no clinical evidence of ENE** based on physical examination.\n\n**2) Code 1** when there is **definitive (unquestionable) evidence of ENE** as determined by physical examination \n\n**3) Code 2** when there is **definitive (unquestionable) evidence of ENE** as determined by physical examination and/or imaging **and** nodal involvement is microscopically confirmed by biopsy \n\n**4) Code 4** when there is **definitive (unquestionable) evidence of ENE**, but the means of identification is not known\n\n**5) Code 7** when nodes are clinically negative (cN0)\n\n**6) Code 9** when \n* No information in the medical record\n* Positive nodes clinically, not evaluated (assessed) for ENE\n* Positive nodes clinically, unknown if evaluated (assessed) for ENE\n* Lymph nodes not evaluated (assessed) clinically\n* Unknown if lymph nodes evaluated (assessed) clinically", "rationale" : "Extranodal Extension Head and Neck Clinical is a Registry Data Collection Variable in AJCC. It was previously collected as Head and Neck SSF #8 (Common SSF). Since the introduction of iENE in AJCC Version 9, both clinical ENE and imaging-detected ENE should be considered in this data item." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extranodal_extension_head_and_neck_pathological_87046.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extranodal_extension_head_and_neck_pathological_87046.json index 1d9819208..2064517ad 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extranodal_extension_head_and_neck_pathological_87046.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extranodal_extension_head_and_neck_pathological_87046.json @@ -5,9 +5,9 @@ "name" : "Extranodal Extension Head and Neck Pathological", "title" : "Extranodal Extension Head and Neck Pathological", "subtitle" : "ENE, Extracapsular extension (ECE)", - "description" : "Extranodal extension (ENE) is defined as “the extension of a nodal metastasis through the lymph node capsule into adjacent tissue” and is a prognostic factor for most head and neck tumors. This data item pertains to pathological staging extension.\n\nThe presence of extranodal extension (ENE) from regional lymph nodes is an important prognostic factor in some cancers because these patients are rarely cured without some type of systemic chemotherapy or radiation. Extranodal extension is defined as metastatic tumor growing from within the lymph node outward through the lymph node capsule and into surrounding connective tissues. \n\n* A regional node extending into a distant structure or organ is categorized as ENE and is not recorded as distant metastatic disease.”\n\nThis data item for ENE that is detected pathologically for head and neck primaries.", + "description" : "Extranodal extension (ENE) is defined as “the extension of a nodal metastasis through the lymph node capsule into adjacent tissue” and is a prognostic factor for most head and neck tumors. This data item pertains to pathological staging extension.\n\nThe presence of extranodal extension (ENE) from regional lymph nodes is an important prognostic factor in some cancers because these patients are rarely cured without some type of systemic chemotherapy or radiation. Extranodal extension is defined as metastatic tumor growing from within the lymph node outward through the lymph node capsule and into surrounding connective tissues. \n\n* \"A regional node extending into a distant structure or organ is categorized as ENE and is not recorded as distant metastatic disease.”\n\nThis data item is for ENE that is detected pathologically for head and neck primaries.", "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of extranodal extension (ENE) pathologically during a lymph node dissection or physician pathological stage indicating the absence or presence of ENE can be used to code this data item when no other information is available.\n\n**Note 2:** **Pathological assessment criteria** \n* Code the status of ENE assessed on histopathologic examination of **surgically resected** involved regional lymph node(s) \n * Includes presence of ENE in a sentinel lymph node.\n \n* Do not code ENE from a lymph node biopsy (FNA, core, incisional), or the absence of ENE from a sentinel\n\n**Note 3:** **Regional vs. distant lymph nodes**\n* Do not code ENE for any distant lymph nodes\n\n**Note 4:** **Minor and Major ENE**\n * Minor ENE is defined as less than or equal to 2 mm\n * Major ENE is defined as greater than 2 mm\n * Matted lymph nodes and soft tissue metastasis are considered major ENE", - "last_modified" : "2025-06-01T17:08:39.283Z", + "last_modified" : "2025-11-06T17:01:11.898Z", "definition" : [ { "key" : "extranodal_ext_hn_path", "name" : "Code", @@ -18,7 +18,7 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "0.0", "Lymph nodes positive for cancer but ENE not identified or negative" ], [ "0.1-9.9", "ENE 0.1 to 9.9 mm" ], [ "X.1", "ENE 10 mm or greater" ], [ "X.2", "ENE minor, size unknown\nStated as ENE (mi)" ], [ "X.3", "ENE major, size unknown\nStated as ENE (ma)" ], [ "X.4", "ENE present, minor or major unknown, size unknown" ], [ "X.7", "Surgically resected regional lymph node(s) negative for cancer (pN0)" ], [ "X.8", "Not applicable: Information not collected for this case\n(If this information is required by your standard setter, use of code X.8 may result in an edit error)" ], [ "X.9", "Not documented in medical record\nNo surgical resection of regional lymph node(s)\nENE not assessed pathologically, or unknown if assessed\nPathological assessment of lymph node(s) not done, or unknown if done" ] ], - "additional_info" : "**Source documents:** imaging reports, physical exam\n\n**Other names include** Extracapsular extension (ECE), extranodal spread (ENS), or extracapsular spread (ECS)\n* *Note*: ENE is the preferred terminology, and includes\n * **cENE** for clinical ENE\n * **iENE** for imaging-detected ENE\n * **pENE** for pathological ENE\n\nFor further information, refer to the **Head and Neck** cancer protocols published by the College of American Pathologist for the AJCC Staging Systems for *Head and Neck.*", - "coding_guidelines" : "**1) Code 0.0** when there are positive nodes pathologically, but ENE not identified/not present.\n* **Absence of ENE**, positive lymph nodes assessed by lymph node dissection (1292: Scope of Regional Lymph Node Surgery must be 3-7)\n\n**2) Code the actual size of the ENE in the range 0.1-9.9 mm**\n\n**3) Code X.1** when actual size of the ENE is 10 mm or greater\n**4) Code X.2** when stated to be microscopic [ENE (mi)]\n**5) Code X.3** when stated to be major [ENE (ma)]\n**6) Code X.4** when size not documented, unknown whether microscopic (mi) or major (ma)\n\n**7) Codes 0.1-9.9, X.1, X.2, X.3, X.4** as appropriate for\n* Presence of ENE assessed by Sentinel Lymph Node biopsy\n* Presence of ENE assessed by lymph node biopsy\n* If codes 0.1-0.9, X.1-X.7 are used, this indicates that the lymph nodes were surgically resected, or a Sentinel Lymph Node biopsy was done and Scope of Regional Lymph Node Surgery [NAACCR Data Item: 1292] must be 2-7\n\n**8) Code X.7** when nodes are surgically resected, and they are negative (pN0)\n* Lymph nodes negative for cancer assessed by Sentinel lymph node biopsy or lymph node dissection\n* 1292: Scope of Regional Lymph Node Surgery must be 2-7\n \n**9) Code X.9** when \n* Absence of ENE, positive lymph nodes assessed by Sentinel Lymph Nodes Biopsy\n * Positive nodes pathologically, not evaluated (assessed) for ENE\n* Positive nodes pathologically, unknown if evaluated (assessed) for ENE\n* Lymph nodes not evaluated (assessed) pathologically (no surgical resection of lymph nodes)\n* Unknown if lymph nodes evaluated pathologically (assessed)", + "additional_info" : "**Source documents:** imaging reports, physical exam\n\n**Other names include** Extracapsular extension (ECE), extranodal spread (ENS), or extracapsular spread (ECS)\n* *Note*: ENE is the preferred terminology, and includes\n * **cENE** for clinical ENE\n * **iENE** for imaging-detected ENE\n * **pENE** for pathological ENE\n\nFor further information, refer to the **Head and Neck** cancer protocols published by the College of American Pathologist for the AJCC Staging Systems for *Head and Neck*.", + "coding_guidelines" : "**1) Code 0.0** when there are positive nodes pathologically, but ENE not identified/not present.\n* **Absence of ENE**, positive lymph nodes assessed by lymph node dissection (1292: Scope of Regional Lymph Node Surgery must be 3-7)\n\n**2) Code the actual size of the ENE in the range 0.1-9.9 mm**\n\n**3) Code X.1** when actual size of the ENE is 10 mm or greater\n\n**4) Code X.2** when stated to be microscopic [ENE (mi)]\n\n**5) Code X.3** when stated to be major [ENE (ma)]\n\n**6) Code X.4** when size not documented, unknown whether microscopic (mi) or major (ma)\n\n**7) Codes 0.1-9.9, X.1, X.2, X.3, X.4** as appropriate for\n* Presence of ENE assessed by Sentinel Lymph Node biopsy\n* Presence of ENE assessed by lymph node biopsy\n* If codes 0.1-0.9, X.1-X.7 are used, this indicates that the lymph nodes were surgically resected, or a Sentinel Lymph Node biopsy was done and Scope of Regional Lymph Node Surgery [NAACCR Data Item: 1292] must be 2-7\n\n**8) Code X.7** when nodes are surgically resected, and they are negative (pN0)\n* Lymph nodes negative for cancer assessed by Sentinel lymph node biopsy or lymph node dissection\n* 1292: Scope of Regional Lymph Node Surgery must be 2-7\n\n**9) Code X.9** when \n* Absence of ENE, positive lymph nodes assessed by Sentinel Lymph Nodes Biopsy\n * Positive nodes pathologically, not evaluated (assessed) for ENE\n* Positive nodes pathologically, unknown if evaluated (assessed) for ENE\n* Lymph nodes not evaluated (assessed) pathologically (no surgical resection of lymph nodes)\n* Unknown if lymph nodes evaluated pathologically (assessed)", "rationale" : "Extranodal Extension Head and Neck Pathological is a Registry Data Collection Variable in AJCC. It was previously collected as Head and Neck SSF #9 (Common SSF)." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extranodal_extension_pathological_30739.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extranodal_extension_pathological_30739.json index e932ac995..a262cb4d8 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extranodal_extension_pathological_30739.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extranodal_extension_pathological_30739.json @@ -6,7 +6,7 @@ "title" : "Extranodal Extension Pathological", "description" : "Extranodal Extension (ENE) Pathological is defined as “the extension of a nodal metastasis through the lymph node capsule into adjacent tissue.\" This data item defines pathological ENE for sites other than Head and Neck.\n\nExtranodal extension is defined as metastatic tumor growing from within the lymph node outward through the lymph node capsule and into surrounding connective tissues. \n* \"A regional node extending into a distant structure or organ is categorized as ENE and is not recorded as distant metastatic disease.\"\n\nThis data item is for ENE that is detected pathologically.", "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of Extranodal Extension (ENE) Pathological or physician pathological staging can be used to code this data item when there is no other information available.\n * Note that the rules for coding ENE for head and neck sites compared to non-head and neck sites are different.\n\n**Note 2:** **Criteria for Coding**\n* Code the status of extranodal extension assessed on the **surgical resection** specimen for the most involved regional lymph node(s)\n* Do not code ENE for any distant lymph nodes.\n* Be aware that the rules for coding ENE for head and neck sites compared to non-head and neck sites are different.", - "last_modified" : "2025-02-24T14:05:17.180Z", + "last_modified" : "2025-11-06T18:44:30.164Z", "definition" : [ { "key" : "extranodal_ext_path", "name" : "Code", @@ -17,7 +17,7 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "0", "Regional lymph node(s) involved, ENE not present/not identified from surgical resection" ], [ "1", "Regional lymph node(s) involved, ENE present/identified from surgical resection" ], [ "7", "No lymph node involvement identified from surgical resection (pN0)" ], [ "8", "Not applicable: Information not collected for this case\n(If this information is required by your standard setter, use of code 8 may result in an edit error)" ], [ "9", "Not documented in medical record\nNo surgical resection of regional lymph node(s)\nNon-invasive neoplasm (behavior /2)\nCannot be determined\nPathological assessment of lymph node(s) not done, or unknown if done\nExtranodal Extension Pathological not assessed or unknown if assessed" ] ], - "additional_info" : "**Source documents:** pathology report from surgical resection x\n\n**Other names include** ENE, extracapsular extension, ECE, extracapsular extension, ECE, extranodal spread, extracapsular extension, or extracapsular spread\n * *Note*: ENE is the preferred terminology\n\nFor further information, refer to the **Merkel Cell Carcinoma** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Merkel Cell Carcinoma*", + "additional_info" : "**Source documents:** pathology report from surgical resection \n\n**Other names include** ENE, extracapsular extension, ECE, extracapsular extension, ECE, extranodal spread, extracapsular extension, or extracapsular spread\n * **Note**: ENE is the preferred terminology\n\nFor further information, refer to the **Merkel Cell Carcinoma** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Merkel Cell Carcinoma*.", "coding_guidelines" : "**1)** **Code 0** when\n* Absence of ENE, positive lymph nodes assessed by lymph node dissection\n* 1292: Scope of Regional Lymph Node Surgery must be 3-7\n\n**2)** **Code 1** when\n* Presence of ENE assessed by Sentinel Lymph Node biopsy\n* Presence of ENE assessed by lymph node dissection\n* 1292: Scope of Regional Lymph Node Surgery must be 2-7\n\n**3)** **Code 7** when\n* Lymph nodes negative for cancer assessed by Sentinel lymph node biopsy or lymph node dissection\n* 1292: Scope of Regional Lymph Node Surgery must be 2-7\n\n**4)** **Code 9** when\n* Absence of ENE, positive lymph nodes assessed by Sentinel Lymph Node biopsy\n * A positive Sentinel Lymph Node biopsy cannot assess the absence of ENE, only the presence of it. This is because there is not enough surrounding tissue in a Sentinel Lymph node biopsy to accurately assess ENE\n * Scope of Regional Lymph Node Surgery [NAACCR Data Item: 1292] must be 2-7\n* No information in the medical record\n* Positive nodes pathologically, not evaluated (assessed) for ENE\n* Positive nodes pathologically, unknown if evaluated (assessed) for ENE\n* Lymph nodes not evaluated (assessed) pathologically (no surgical resection of lymph nodes)\n* Unknown if lymph nodes evaluated pathologically (assessed)", "rationale" : "Extranodal Extension Pathological (non-Head and Neck) is a Registry Data Collection Variable for AJCC. This data item was previously collected for Penis, SSF #17." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extravascular_matrix_patterns_1397.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extravascular_matrix_patterns_1397.json index 62db7beeb..3fb496356 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extravascular_matrix_patterns_1397.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/extravascular_matrix_patterns_1397.json @@ -6,7 +6,7 @@ "title" : "Extravascular Matrix Patterns", "description" : "Extravascular Matrix Patterns, the presence of loops and networks in extracellular matrix patterns, is a prognostic factor for uveal melanoma.\n\nThe presence of extravascular matrix patterns is an indicator for shorter survival. There are two different types of patterns: loops only, or loops forming networks. The identification of the complex monocirculatory patterns (i.e., loops, networks, arcs with branching, parallel with cross-linking or a combination of these patterns) are done using confocal indocyanine green angiography. The patterns are assessed with light microscopy under a dark green filter after staining with periodic-acid Schiff without counterstain. This determines the presence or absence of each matrix pattern, which appear deep purple against a pink background.", "notes" : "**Note:** **Physician Statement** \n* Physician statement of extravascular matrix patterns can be used to code this data item when no other information is available.", - "last_modified" : "2025-02-24T14:24:24.549Z", + "last_modified" : "2025-11-06T21:25:48.838Z", "definition" : [ { "key" : "extravascular_matrix_patterns", "name" : "Code", @@ -17,7 +17,7 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "0", "Extravascular matrix patterns not present/not identified" ], [ "1", "Extravascular matrix patterns present/identified" ], [ "8", "Not applicable: Information not collected for this case\n(If this information is required by your standard setter, use of code 8 may result in an edit error.)" ], [ "9", "Not documented in medical record\nExtravascular Matrix Patterns not assessed or unknown if assessed" ] ], - "additional_info" : "**Source documents:** pathology report, confocal indocyanine green angiography report, clinician comment.\n\nFor further information, refer to the **Uveal Melanoma** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Uveal Melanoma*", - "coding_guidelines" : "**1)** **Code 0** when pathology report states that loops and networks are not found\n**2)** **Code 1** when pathology reports states networks and/or loops present\n**3)** **Code 9** when\n* Pathology report available and there is no mention of extravascular matrix patterns (loops or networks)\n* Extravascular matrix patterns not assessed or unknown if assessed", + "additional_info" : "**Source documents:** pathology report, confocal indocyanine green angiography report, clinician comment.\n\nFor further information, refer to the **Uveal Melanoma** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Uveal Melanoma*.", + "coding_guidelines" : "**1)** **Code 0** when pathology report states that loops and networks are not found\n\n**2)** **Code 1** when pathology reports states networks and/or loops present\n\n**3)** **Code 9** when\n* Pathology report available and there is no mention of extravascular matrix patterns (loops or networks)\n* Extravascular matrix patterns not assessed or unknown if assessed", "rationale" : "Extravascular Matrix Patterns is a Registry Data Collection Variable in AJCC 8. This data item was previously collected as Uveal Melanoma, CS SSF #11, and CS SSF #12. These two data items were combined into one data for cases diagnosed 1/1/2018+." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/figo_stage_30513.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/figo_stage_30513.json index 2b437e9ca..798fe168f 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/figo_stage_30513.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/figo_stage_30513.json @@ -4,9 +4,9 @@ "version" : "3.3", "name" : "FIGO Stage", "title" : "FIGO Stage Ovary, Fallopian Tube, and Primary Peritoneal Carcinoma", - "description" : "Federation Internationale de Gynecologie et d'Obstetrique (FIGO) is a staging system for female reproductive cancers.\n\nFIGO is a worldwide organization of obstetricians and gynecologists who maintain the international staging systems for female genital organs. The FIGO staging system has been adapted into the AJCC staging manual. FIGO uses Roman numerals and subscripts to define a stage. There is no T, N, or M descriptor with FIGO stage, only a stage group. For example, FIGO Stage IA is equivalent to T1a, FIGO Stage III can be either T3_ or N1, and FIGO Stage IV is M1. \n\nFIGO stages vary by primary site, but the structure is similar throughout. FIGO no longer includes an in-situ stage (Tis, Stage 0). For in situ tumors, code the following \n* Code 97: Not applicable: Carcinoma in situ (intraepithelial, noninvasive, preinvasive)\n\nNote: Do not confuse FIGO stage with FIGO grade.", + "description" : "Federation Internationale de Gynecologie et d'Obstetrique (FIGO) is a staging system for female reproductive cancers.\n\nFIGO is a worldwide organization of obstetricians and gynecologists who maintain the international staging systems for female genital organs. The FIGO staging system has been adapted into the AJCC staging manual. FIGO uses Roman numerals and subscripts to define a stage. There is no T, N, or M descriptor with FIGO stage, only a stage group. For example, FIGO Stage IA is equivalent to T1a, FIGO Stage III can be either T3_ or N1, and FIGO Stage IV is M1. \n\nFIGO stages vary by primary site, but the structure is similar throughout. FIGO no longer includes an in-situ stage (Tis, Stage 0). For in situ tumors, code the following \n* Code 97: Not applicable: Carcinoma in situ (intraepithelial, noninvasive, preinvasive)\n\n**Note:** Do not confuse FIGO stage with FIGO grade.", "notes" : "**Note 1:** **Physician Statement**\n* There must be a statement about FIGO stage from the managing physician in order to code this data item.\n * Do not code FIGO stage based on the pathology report\n * Do not code FIGO stage based only on T, N, M\n * If \"FIGO\" is not included with a stated stage, then do not assume it is a FIGO stage\n\n**Note 2:** **FIGO Stage vs FIGO Grade** \n* FIGO stage is not the same thing as FIGO grade. Only code FIGO stage in this field, do not code FIGO grade.\n* Code FIGO grade in the grade fields\n\n**Note 3:** **Multiple FIGO stages**\n* If there is more than one FIGO stage provided from the clinical and pathological work up, code the most extensive FIGO stage.\n\n**Note 4:** **HGSC, STIC, LGSC, and SIC (8441/2)** \n* For High-grade serous carcinoma **(HGSC)** (8441/2) or serous tubal intraepithelial carcinoma **(STIC)** (8441/2), assign the FIGO stage based on the managing physician's documentation of FIGO. (See Note 1). \n* If FIGO stage for HGSC or STIC is not documented by the managing physician, code unknown (code 99)\n * Do not code 97 (in situ) for HGSC or STIC since FIGO does not have a Stage 0\n* If diagnosis is low grade serous intraepithelial carcinoma **(LGSC)** (8441/2) or serous intraepithelial carcinoma **(SIC)** (no grade stated) (8441/2), code 97\n\n**Note 5:** **Remaining in situ histologies**\n* Code 97 for any remaining in situ histologies (/2) since the FIGO stage definitions do not include Stage 0.", - "last_modified" : "2024-08-22T16:24:44.869Z", + "last_modified" : "2025-11-06T20:37:00.721Z", "definition" : [ { "key" : "figo", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/figo_stage_cervix_46535.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/figo_stage_cervix_46535.json index 130cf97a2..1c8ae13af 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/figo_stage_cervix_46535.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/figo_stage_cervix_46535.json @@ -4,9 +4,9 @@ "version" : "3.3", "name" : "FIGO Stage", "title" : "FIGO Stage Cervix", - "description" : "Federation Internationale de Gynecologie et d'Obstetrique (FIGO) is a staging system for female reproductive cancers.\n\nFIGO is a worldwide organization of obstetricians and gynecologists who maintain the international staging systems for female genital organs. The FIGO staging system has been adapted into the AJCC staging manual. FIGO uses Roman numerals and subscripts to define a stage. There is no T, N, or M descriptor with FIGO stage, only a stage group. For example, FIGO Stage IA is equivalent to T1a, FIGO Stage III can be either T3_ or N1, and FIGO Stage IV is M1. \n\nFIGO stages vary by primary site, but the structure is similar throughout. FIGO no longer includes an in-situ stage (Tis, Stage 0). For in situ tumors, code the following \n* Code 97: Not applicable: Carcinoma in situ (intraepithelial, noninvasive, preinvasive)\n\nNote: Do not confuse FIGO stage with FIGO grade.", + "description" : "Federation Internationale de Gynecologie et d'Obstetrique (FIGO) is a staging system for female reproductive cancers.\n\nFIGO is a worldwide organization of obstetricians and gynecologists who maintain the international staging systems for female genital organs. The FIGO staging system has been adapted into the AJCC staging manual. FIGO uses Roman numerals and subscripts to define a stage. There is no T, N, or M descriptor with FIGO stage, only a stage group. For example, FIGO Stage IA is equivalent to T1a, FIGO Stage III can be either T3_ or N1, and FIGO Stage IV is M1. \n\nFIGO stages vary by primary site, but the structure is similar throughout. FIGO no longer includes an in-situ stage (Tis, Stage 0). For in situ tumors, code the following \n* Code 97: Not applicable: Carcinoma in situ (intraepithelial, noninvasive, preinvasive)\n\n**Note:** Do not confuse FIGO stage with FIGO grade.", "notes" : "**Note 1:** **Physician Statement**\n* There must be a statement about FIGO stage from the managing physician in order to code this data item.\n * Do not code FIGO stage based on the pathology report\n * Do not code FIGO stage based only on T, N, M\n * If \"FIGO\" is not included with a stated stage, then do not assume it is a FIGO stage\n\n**Note 2:** **FIGO Stage vs FIGO Grade** \n* FIGO stage is not the same thing as FIGO grade. Only code FIGO stage in this field, do not code FIGO grade.\n* Code FIGO grade in the grade fields\n\n**Note 3:** **Multiple FIGO stages**\n* If there is more than one FIGO stage provided from the clinical and pathological work up, code the most extensive FIGO stage.\n\n**Note 4:** **FIGO Stage 0 (in-situ)**\n* The FIGO stage definitions do not include Stage 0 (Tis).\n* Code 97 for any non-invasive neoplasm (behavior /2)", - "last_modified" : "2024-04-08T20:25:49.010Z", + "last_modified" : "2025-11-06T20:22:39.091Z", "definition" : [ { "key" : "figo", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/figo_stage_corpus_adenosarcoma_24886.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/figo_stage_corpus_adenosarcoma_24886.json index 1620556fb..636432105 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/figo_stage_corpus_adenosarcoma_24886.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/figo_stage_corpus_adenosarcoma_24886.json @@ -4,9 +4,9 @@ "version" : "3.3", "name" : "FIGO Stage", "title" : "FIGO Stage Corpus Adenosarcoma", - "description" : "Federation Internationale de Gynecologie et d'Obstetrique (FIGO) is a staging system for female reproductive cancers.\n\nFIGO is a worldwide organization of obstetricians and gynecologists who maintain the international staging systems for female genital organs. The FIGO staging system has been adapted into the AJCC staging manual. FIGO uses Roman numerals and subscripts to define a stage. There is no T, N, or M descriptor with FIGO stage, only a stage group. For example, FIGO Stage IA is equivalent to T1a, FIGO Stage III can be either T3_ or N1, and FIGO Stage IV is M1. \n\nFIGO stages vary by primary site, but the structure is similar throughout. FIGO no longer includes an in-situ stage (Tis, Stage 0). For in situ tumors, code the following \n* Code 97: Not applicable: Carcinoma in situ (intraepithelial, noninvasive, preinvasive)\n\nNote: Do not confuse FIGO stage with FIGO grade.", + "description" : "Federation Internationale de Gynecologie et d'Obstetrique (FIGO) is a staging system for female reproductive cancers.\n\nFIGO is a worldwide organization of obstetricians and gynecologists who maintain the international staging systems for female genital organs. The FIGO staging system has been adapted into the AJCC staging manual. FIGO uses Roman numerals and subscripts to define a stage. There is no T, N, or M descriptor with FIGO stage, only a stage group. For example, FIGO Stage IA is equivalent to T1a, FIGO Stage III can be either T3_ or N1, and FIGO Stage IV is M1. \n\nFIGO stages vary by primary site, but the structure is similar throughout. FIGO no longer includes an in-situ stage (Tis, Stage 0). For in situ tumors, code the following \n* Code 97: Not applicable: Carcinoma in situ (intraepithelial, noninvasive, preinvasive)\n\n**Note:** Do not confuse FIGO stage with FIGO grade.", "notes" : "**Note 1:** **Physician Statement**\n* There must be a statement about FIGO stage from the managing physician in order to code this data item.\n * Do not code FIGO stage based on the pathology report\n * Do not code FIGO stage based only on T, N, M\n * If \"FIGO\" is not included with a stated stage, then do not assume it is a FIGO stage\n\n**Note 2:** **FIGO Stage vs FIGO Grade** \n* FIGO stage is not the same thing as FIGO grade. Only code FIGO stage in this field, do not code FIGO grade.\n* Code FIGO grade in the grade fields\n\n**Note 3:** **Multiple FIGO stages**\n* If there is more than one FIGO stage provided from the clinical and pathological work up, code the most extensive FIGO stage.\n\n**Note 4:** **FIGO Stage 0 (in-situ)**\n* The FIGO stage definitions do not include Stage 0 (Tis).\n* Code 97 for any non-invasive neoplasm (behavior /2)", - "last_modified" : "2024-04-08T20:31:43.937Z", + "last_modified" : "2025-11-06T20:36:08.399Z", "definition" : [ { "key" : "figo", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/figo_stage_corpus_carcinoma_and_carcinosarcoma_69186.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/figo_stage_corpus_carcinoma_and_carcinosarcoma_69186.json index 58666d612..9e92b5917 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/figo_stage_corpus_carcinoma_and_carcinosarcoma_69186.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/figo_stage_corpus_carcinoma_and_carcinosarcoma_69186.json @@ -4,9 +4,9 @@ "version" : "3.3", "name" : "FIGO Stage", "title" : "FIGO Stage Corpus Carcinoma and Carcinosarcoma", - "description" : "Federation Internationale de Gynecologie et d'Obstetrique (FIGO) is a staging system for female reproductive cancers.\n\nFIGO is a worldwide organization of obstetricians and gynecologists who maintain the international staging systems for female genital organs. The FIGO staging system has been adapted into the AJCC staging manual. FIGO uses Roman numerals and subscripts to define a stage. There is no T, N, or M descriptor with FIGO stage, only a stage group. For example, FIGO Stage IA is equivalent to T1a, FIGO Stage III can be either T3_ or N1, and FIGO Stage IV is M1. \n\nFIGO stages vary by primary site, but the structure is similar throughout. FIGO no longer includes an in-situ stage (Tis, Stage 0). For in situ tumors, code the following \n* Code 97: Not applicable: Carcinoma in situ (intraepithelial, noninvasive, preinvasive)\n\nNote: Do not confuse FIGO stage with FIGO grade", + "description" : "Federation Internationale de Gynecologie et d'Obstetrique (FIGO) is a staging system for female reproductive cancers.\n\nFIGO is a worldwide organization of obstetricians and gynecologists who maintain the international staging systems for female genital organs. The FIGO staging system has been adapted into the AJCC staging manual. FIGO uses Roman numerals and subscripts to define a stage. There is no T, N, or M descriptor with FIGO stage, only a stage group. For example, FIGO Stage IA is equivalent to T1a, FIGO Stage III can be either T3_ or N1, and FIGO Stage IV is M1. \n\nFIGO stages vary by primary site, but the structure is similar throughout. FIGO no longer includes an in-situ stage (Tis, Stage 0). For in situ tumors, code the following \n* Code 97: Not applicable: Carcinoma in situ (intraepithelial, noninvasive, preinvasive)\n\n**Note:** Do not confuse FIGO stage with FIGO grade", "notes" : "**Note 1:** **Physician Statement**\n* There must be a statement about FIGO stage from the managing physician in order to code this data item.\n * Do not code FIGO stage based on the pathology report\n * Do not code FIGO stage based only on T, N, M\n * If \"FIGO\" is not included with a stated stage, then do not assume it is a FIGO stage\n\n**Note 2:** **FIGO Stage vs FIGO Grade** \n* FIGO stage is not the same thing as FIGO grade. Only code FIGO stage in this field, do not code FIGO grade.\n* Code FIGO grade in the grade fields\n\n**Note 3:** **Multiple FIGO stages**\n* If there is more than one FIGO stage provided from the clinical and pathological work up, code the most extensive FIGO stage.\n\n**Note 4:** **EIC, SEIC, EIN** \n* For Endometrial intraepithelial carcinoma **(EIC)** (8380/2) and Serous endometrial intraepithelial carcinoma **(SEIC)** (8441/2), assign the FIGO staged based on the managing physician's documentation of FIGO. (See Note 1). \n* If FIGO stage for EIC or SEIC is not documented by the managing physician, code unknown (code 99)\n* Do not code 97 (in situ) for EIC or SEIC since FIGO does not have a Stage 0\n* If diagnosis is Endometrial intraepithelial neoplasia **(EIN)** (8380/2), code 97.\n\n**Note 5:** **Remaining in situ histologies**\n* Code 97 for any remaining in situ histologies (/2) since the FIGO stage definitions do not include Stage 0.", - "last_modified" : "2024-04-08T20:32:21.119Z", + "last_modified" : "2025-11-06T20:27:07.365Z", "definition" : [ { "key" : "figo", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/figo_stage_corpus_sarcoma_78807.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/figo_stage_corpus_sarcoma_78807.json index 46e798c0a..f35ec86b5 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/figo_stage_corpus_sarcoma_78807.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/figo_stage_corpus_sarcoma_78807.json @@ -4,9 +4,9 @@ "version" : "3.3", "name" : "FIGO Stage", "title" : "FIGO Stage Corpus Sarcoma", - "description" : "Federation Internationale de Gynecologie et d'Obstetrique (FIGO) is a staging system for female reproductive cancers.\n\nFIGO is a worldwide organization of obstetricians and gynecologists who maintain the international staging systems for female genital organs. The FIGO staging system has been adapted into the AJCC staging manual. FIGO uses Roman numerals and subscripts to define a stage. There is no T, N, or M descriptor with FIGO stage, only a stage group. For example, FIGO Stage IA is equivalent to T1a, FIGO Stage III can be either T3_ or N1, and FIGO Stage IV is M1. \n\nFIGO stages vary by primary site, but the structure is similar throughout. FIGO no longer includes an in-situ stage (Tis, Stage 0). For in situ tumors, code the following \n* Code 97: Not applicable: Carcinoma in situ (intraepithelial, noninvasive, preinvasive)\n\nNote: Do not confuse FIGO stage with FIGO grade.", + "description" : "Federation Internationale de Gynecologie et d'Obstetrique (FIGO) is a staging system for female reproductive cancers.\n\nFIGO is a worldwide organization of obstetricians and gynecologists who maintain the international staging systems for female genital organs. The FIGO staging system has been adapted into the AJCC staging manual. FIGO uses Roman numerals and subscripts to define a stage. There is no T, N, or M descriptor with FIGO stage, only a stage group. For example, FIGO Stage IA is equivalent to T1a, FIGO Stage III can be either T3_ or N1, and FIGO Stage IV is M1. \n\nFIGO stages vary by primary site, but the structure is similar throughout. FIGO no longer includes an in-situ stage (Tis, Stage 0). For in situ tumors, code the following \n* Code 97: Not applicable: Carcinoma in situ (intraepithelial, noninvasive, preinvasive)\n\n**Note:** Do not confuse FIGO stage with FIGO grade.", "notes" : "**Note 1:** **Physician Statement**\n* There must be a statement about FIGO stage from the managing physician in order to code this data item.\n * Do not code FIGO stage based on the pathology report\n * Do not code FIGO stage based only on T, N, M\n * If \"FIGO\" is not included with a stated stage, then do not assume it is a FIGO stage\n\n**Note 2:** **FIGO Stage vs FIGO Grade** \n* FIGO stage is not the same thing as FIGO grade. Only code FIGO stage in this field, do not code FIGO grade.\n* Code FIGO grade in the grade fields\n\n**Note 3:** **Multiple FIGO stages**\n* If there is more than one FIGO stage provided from the clinical and pathological work up, code the most extensive FIGO stage.\n\n**Note 4:** **FIGO Stage 0 (in-situ)**\n* The FIGO stage definitions do not include Stage 0 (Tis).\n* Code 97 for any non-invasive neoplasm (behavior /2)", - "last_modified" : "2024-04-08T20:32:58.811Z", + "last_modified" : "2025-11-06T20:23:27.668Z", "definition" : [ { "key" : "figo", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/figo_stage_placenta_73452.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/figo_stage_placenta_73452.json index b24963b4e..f38c4b766 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/figo_stage_placenta_73452.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/figo_stage_placenta_73452.json @@ -4,9 +4,9 @@ "version" : "3.3", "name" : "FIGO Stage", "title" : "FIGO Stage Placenta", - "description" : "Federation Internationale de Gynecologie et d'Obstetrique (FIGO) is a staging system for female reproductive cancers.\n\nFIGO is a worldwide organization of obstetricians and gynecologists who maintain the international staging systems for female genital organs. The FIGO staging system has been adapted into the AJCC staging manual. FIGO uses Roman numerals and subscripts to define a stage. There is no T, N, or M descriptor with FIGO stage, only a stage group. For example, FIGO Stage IA is equivalent to T1a, FIGO Stage III can be either T3_ or N1, and FIGO Stage IV is M1. \n\nFIGO stages vary by primary site, but the structure is similar throughout. FIGO no longer includes an in-situ stage (Tis, Stage 0). For in situ tumors, code the following \n* Code 97: Not applicable: Carcinoma in situ (intraepithelial, noninvasive, preinvasive)\n\nNote: Do not confuse FIGO stage with FIGO grade.", + "description" : "Federation Internationale de Gynecologie et d'Obstetrique (FIGO) is a staging system for female reproductive cancers.\n\nFIGO is a worldwide organization of obstetricians and gynecologists who maintain the international staging systems for female genital organs. The FIGO staging system has been adapted into the AJCC staging manual. FIGO uses Roman numerals and subscripts to define a stage. There is no T, N, or M descriptor with FIGO stage, only a stage group. For example, FIGO Stage IA is equivalent to T1a, FIGO Stage III can be either T3_ or N1, and FIGO Stage IV is M1. \n\nFIGO stages vary by primary site, but the structure is similar throughout. FIGO no longer includes an in-situ stage (Tis, Stage 0). For in situ tumors, code the following \n* Code 97: Not applicable: Carcinoma in situ (intraepithelial, noninvasive, preinvasive)\n\n**Note:** Do not confuse FIGO stage with FIGO grade.", "notes" : "**Note 1:** **Physician Statement**\n* There must be a statement about FIGO stage from the managing physician in order to code this data item.\n * Do not code FIGO stage based on the pathology report\n * Do not code FIGO stage based only on T, N, M\n * If \"FIGO\" is not included with a stated stage, then do not assume it is a FIGO stage\n\n**Note 2:** **FIGO Stage vs FIGO Grade** \n* FIGO stage is not the same thing as FIGO grade. Only code FIGO stage in this field, do not code FIGO grade.\n* Code FIGO grade in the grade fields\n\n**Note 3:** **Multiple FIGO stages**\n* If there is more than one FIGO stage provided from the clinical and pathological work up, code the most extensive FIGO stage.\n\n**Note 4:** **FIGO Stage 0 (in-situ)**\n* The FIGO stage definitions do not include Stage 0 (Tis).\n* Code 97 for any non-invasive neoplasm (behavior /2)", - "last_modified" : "2024-04-08T20:48:39.131Z", + "last_modified" : "2025-11-06T20:39:09.799Z", "definition" : [ { "key" : "figo", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/figo_stage_vagina_61098.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/figo_stage_vagina_61098.json index 86a838c1a..640aae30e 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/figo_stage_vagina_61098.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/figo_stage_vagina_61098.json @@ -4,9 +4,9 @@ "version" : "3.3", "name" : "FIGO Stage", "title" : "FIGO Stage Vagina", - "description" : "Federation Internationale de Gynecologie et d'Obstetrique (FIGO) is a staging system for female reproductive cancers.\n\nFIGO is a worldwide organization of obstetricians and gynecologists who maintain the international staging systems for female genital organs. The FIGO staging system has been adapted into the AJCC staging manual. FIGO uses Roman numerals and subscripts to define a stage. There is no T, N, or M descriptor with FIGO stage, only a stage group. For example, FIGO Stage IA is equivalent to T1a, FIGO Stage III can be either T3_ or N1, and FIGO Stage IV is M1. \n\nFIGO stages vary by primary site, but the structure is similar throughout. FIGO no longer includes an in-situ stage (Tis, Stage 0). For in situ tumors, code the following \n* Code 97: Not applicable: Carcinoma in situ (intraepithelial, noninvasive, preinvasive)\n\nNote: Do not confuse FIGO stage with FIGO grade.", + "description" : "Federation Internationale de Gynecologie et d'Obstetrique (FIGO) is a staging system for female reproductive cancers.\n\nFIGO is a worldwide organization of obstetricians and gynecologists who maintain the international staging systems for female genital organs. The FIGO staging system has been adapted into the AJCC staging manual. FIGO uses Roman numerals and subscripts to define a stage. There is no T, N, or M descriptor with FIGO stage, only a stage group. For example, FIGO Stage IA is equivalent to T1a, FIGO Stage III can be either T3_ or N1, and FIGO Stage IV is M1. \n\nFIGO stages vary by primary site, but the structure is similar throughout. FIGO no longer includes an in-situ stage (Tis, Stage 0). For in situ tumors, code the following \n* Code 97: Not applicable: Carcinoma in situ (intraepithelial, noninvasive, preinvasive)\n\n**Note:** Do not confuse FIGO stage with FIGO grade.", "notes" : "**Note 1:** **Physician Statement**\n* There must be a statement about FIGO stage from the managing physician in order to code this data item.\n * Do not code FIGO stage based on the pathology report\n * Do not code FIGO stage based only on T, N, M\n * If \"FIGO\" is not included with a stated stage, then do not assume it is a FIGO stage\n\n**Note 2:** **FIGO Stage vs FIGO Grade** \n* FIGO stage is not the same thing as FIGO grade. Only code FIGO stage in this field, do not code FIGO grade.\n* Code FIGO grade in the grade fields\n\n**Note 3:** **Multiple FIGO stages**\n* If there is more than one FIGO stage provided from the clinical and pathological work up, code the most extensive FIGO stage.\n\n**Note 4:** **FIGO Stage 0 (in-situ)**\n* The FIGO stage definitions do not include Stage 0 (Tis).\n* Code 97 for any non-invasive neoplasm (behavior /2)", - "last_modified" : "2024-04-08T20:12:54.366Z", + "last_modified" : "2025-11-06T20:14:26.454Z", "definition" : [ { "key" : "figo", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/figo_stage_vulva_69787.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/figo_stage_vulva_69787.json index 2e243245e..96fb22acd 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/figo_stage_vulva_69787.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/figo_stage_vulva_69787.json @@ -4,9 +4,9 @@ "version" : "3.3", "name" : "FIGO Stage", "title" : "FIGO Stage Vulva", - "description" : "Federation Internationale de Gynecologie et d'Obstetrique (FIGO) is a staging system for female reproductive cancers.\n\nFIGO is a worldwide organization of obstetricians and gynecologists who maintain the international staging systems for female genital organs. The FIGO staging system has been adapted into the AJCC staging manual. FIGO uses Roman numerals and subscripts to define a stage. There is no T, N, or M descriptor with FIGO stage, only a stage group. For example, FIGO Stage IA is equivalent to T1a, FIGO Stage III can be either T3_ or N1, and FIGO Stage IV is M1. \n\nFIGO stages vary by primary site, but the structure is similar throughout. FIGO no longer includes an in-situ stage (Tis, Stage 0). For in situ tumors, code the following \n* Code 97: Not applicable: Carcinoma in situ (intraepithelial, noninvasive, preinvasive)\n\nNote: Do not confuse FIGO stage with FIGO grade.", + "description" : "Federation Internationale de Gynecologie et d'Obstetrique (FIGO) is a staging system for female reproductive cancers.\n\nFIGO is a worldwide organization of obstetricians and gynecologists who maintain the international staging systems for female genital organs. The FIGO staging system has been adapted into the AJCC staging manual. FIGO uses Roman numerals and subscripts to define a stage. There is no T, N, or M descriptor with FIGO stage, only a stage group. For example, FIGO Stage IA is equivalent to T1a, FIGO Stage III can be either T3_ or N1, and FIGO Stage IV is M1. \n\nFIGO stages vary by primary site, but the structure is similar throughout. FIGO no longer includes an in-situ stage (Tis, Stage 0). For in situ tumors, code the following \n* Code 97: Not applicable: Carcinoma in situ (intraepithelial, noninvasive, preinvasive)\n\n**Note:** Do not confuse FIGO stage with FIGO grade.", "notes" : "**Note 1:** **Physician Statement**\n* There must be a statement about FIGO stage from the managing physician in order to code this data item.\n * Do not code FIGO stage based on the pathology report\n * Do not code FIGO stage based only on T, N, M\n * If \"FIGO\" is not included with a stated stage, then do not assume it is a FIGO stage\n\n**Note 2:** **FIGO Stage vs FIGO Grade** \n* FIGO stage is not the same thing as FIGO grade. Only code FIGO stage in this field, do not code FIGO grade.\n* Code FIGO grade in the grade fields\n\n**Note 3:** **Multiple FIGO stages**\n* If there is more than one FIGO stage provided from the clinical and pathological work up, code the most extensive FIGO stage.\n\n**Note 4:** **FIGO Stage 0 (in-situ)**\n* The FIGO stage definitions do not include Stage 0 (Tis).\n* Code 97 for any non-invasive neoplasm (behavior /2)", - "last_modified" : "2024-04-30T18:36:02.289Z", + "last_modified" : "2025-11-06T20:10:44.482Z", "definition" : [ { "key" : "figo", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/gleason_pattern_clinical_75179.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/gleason_pattern_clinical_75179.json index e5c93c2c1..5e2fae600 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/gleason_pattern_clinical_75179.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/gleason_pattern_clinical_75179.json @@ -6,7 +6,7 @@ "title" : "Gleason Patterns Clinical", "description" : "Prostate cancers are graded using Gleason score or pattern. This data item represents the Gleason primary and secondary patterns from needle core biopsy or TURP.\n\nThe pathologist determines the Gleason patterns by looking at the prostate tissue under the microscope. The pathologist assigns a grade to the most predominant pattern (largest surface area of involvement, more than 50% of tissue) and a grade for the secondary pattern (second most predominant) based on published Gleason criteria. When a patient undergoes radical prostatectomy, the pathologist may look for a third or tertiary pattern in the specimen. When Gleason pattern 5 is present as a tertiary pattern, its presence should be indicated in the pathology report, as a high Gleason pattern appears to be an indicator for worse outcome (shortened time to recurrence). Studies indicate that a Gleason score 7, with tertiary pattern 5, is associated with a worse prognosis than without tertiary pattern 5 and is similar to the prognosis for Gleason score 8 – 10. \n* For example, in a specimen where the primary Gleason pattern is 3, the secondary is 4 and there is less than 5% Gleason 5, the report should indicate a Gleason score of 7 (3+4) with tertiary Gleason pattern 5. Gleason grades (patterns) range from 1 (small, uniform gland) to 5 (lack of glands, sheets of cells.)\n\nFor the Gleason Patterns data items, there is a long list of codes and definitions in the table, but it may be easier to assign a value if you understand the structure of the code. This is a two-digit field. \n* First digit is the Gleason primary pattern value\n* Second digit is the Gleason secondary pattern value\n\nThe Gleason system for grading prostate cancer is the one recommended by the AJCC and College of American Pathologists. The following related data items are used to collect information on Gleason.", "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of Gleason Patterns Clinical can be used to code this data item when there is no other information available. \n\n**Note 2:** **Procedures** \n* Code the Gleason Patterns Clinical from a needle core biopsy, trans rectal ultrasound (TRUS) guided biopsy, transurethral resection of prostate (TURP), and/or simple prostatectomy in this field.\n* Gleason primary and secondary patterns provided for any prostate tissue identified from a transurethral resection of a bladder tumor (TURBT) specimen can also be used in this field\n\n**Note 3:** **Neoadjuvant Treatment** \n* Code the Gleason primary and secondary patterns prior to neoadjuvant treatment.\n\n**Note 4:** **Gleason Grading** \n* Usually, prostate cancers are graded using Gleason score or pattern. Gleason grading for prostate primaries is based on a 5-component system (5 histologic patterns). Prostatic cancer generally shows two main histologic patterns. The primary pattern, the pattern occupying greater than 50% of the cancer, is usually indicated by the first number of the Gleason grade, and the secondary pattern is usually indicated by the second number. These two numbers are added together to create a pattern score. \n* If there are two numbers, assume that they refer to two patterns (the first number being the primary pattern and the second number the secondary pattern), and sum them to obtain the score.\n* If only one number is given, and it is less than or equal to 5, assume that it describes a pattern (since scores of 5 or less would reflect Primary or Secondary Pattern Scores of 1 or 2). Code the number as the primary pattern and code the secondary pattern as Unknown. \n * For ***example,*** if only one number is given and it is a 3, code \"39\" for Gleason Patterns and \"X9\" for Gleason Score.\n* If only one number is given, and it is greater than 5, assume that it is a score. \n * For ***example,*** if only one number is given, and it is a 7, code \"X6\" for Gleason Patterns and \"07\" for Gleason Score. \n* If the pathology report specifies a specific number out of a total of 10, the first number given is the score. \n * For ***example,*** if the pathology report says Gleason 7/10, code \"07' for Gleason Score and \"X6\" for Gleason Patterns. \n\n**Note 5:** **Different patterns** \n* If different patterns are documented on multiple needle core biopsies, code the pattern that reflects the highest or most aggressive score regardless of if the pathologist provides an overall pattern in a final summary. If different patterns equal the same high score, give priority to the highest primary pattern and then the highest secondary pattern. \n * For ***example,*** both Gleason 3, 4 and Gleason 4, 3 equal Gleason score 7; code 43. Do not mix patterns from multiple specimens.\n\n**Note 6:** **Multiple procedures** \n* If multiple procedures are performed (e.g., needle core biopsy, trans rectal ultrasound (TRUS) guided biopsy, transurethral resection of prostate (TURP), and/or simple prostatectomy), code the pattern that reflects the highest score.\n\n**Note 7:** **Related data item** \n* The clinical score is recorded in the related data item 3840: Gleason Score Clinical.", - "last_modified" : "2025-02-24T14:20:55.113Z", + "last_modified" : "2025-11-06T21:46:42.563Z", "definition" : [ { "key" : "gleason_patterns_clin", "name" : "Code", @@ -17,7 +17,7 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "11", "Primary pattern 1, secondary pattern 1 " ], [ "12", "Primary pattern 1, secondary pattern 2" ], [ "13", "Primary pattern 1, secondary pattern 3" ], [ "14", "Primary pattern 1, secondary pattern 4" ], [ "15", "Primary pattern 1, secondary pattern 5" ], [ "19", "Primary pattern 1, secondary pattern unknown" ], [ "21", "Primary pattern 2, secondary pattern 1" ], [ "22", "Primary pattern 2, secondary pattern 2" ], [ "23", "Primary pattern 2, secondary pattern 3" ], [ "24", "Primary pattern 2, secondary pattern 4" ], [ "25", "Primary pattern 2, secondary pattern 5" ], [ "29", "Primary pattern 2, secondary pattern unknown" ], [ "31", "Primary pattern 3, secondary pattern 1" ], [ "32", "Primary pattern 3, secondary pattern 2" ], [ "33", "Primary pattern 3, secondary pattern 3" ], [ "34", "Primary pattern 3, secondary pattern 4" ], [ "35", "Primary pattern 3, secondary pattern 5" ], [ "39", "Primary pattern 3, secondary pattern unknown" ], [ "41", "Primary pattern 4, secondary pattern 1" ], [ "42", "Primary pattern 4, secondary pattern 2" ], [ "43", "Primary pattern 4, secondary pattern 3" ], [ "44", "Primary pattern 4, secondary pattern 4" ], [ "45", "Primary pattern 4, secondary pattern 5" ], [ "49", "Primary pattern 4, secondary pattern unknown" ], [ "51", "Primary pattern 5, secondary pattern 1" ], [ "52", "Primary pattern 5, secondary pattern 2" ], [ "53", "Primary pattern 5, secondary pattern 3" ], [ "54", "Primary pattern 5, secondary pattern 4" ], [ "55", "Primary pattern 5, secondary pattern 5" ], [ "59", "Primary pattern 5, secondary pattern unknown" ], [ "X6", "TURP and/or Biopsy done, primary pattern unknown, secondary pattern unknown" ], [ "X7", "No needle core biopsy/TURP performed" ], [ "X8", "Not applicable: Information not collected for this case\n(If this information is required by your standard setter, use of code X8 may result in an edit error.)" ], [ "X9", "Not documented in medical record\nGleason Patterns Clinical not assessed or unknown if assessed\nUnknown whether TURP and/or Biopsy done" ] ], - "additional_info" : "**Source documents:** pathology reports from needle biopsies, transurethral resection of prostate/bladder, or simple prostatectomy that contains prostate tissue\n\nFor further information, refer to the **Prostate** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Prostate*", - "coding_guidelines" : "**1)** **Code X6** If the only information available is the Gleason Score\n**2)** **Code X7** if no needle core biopsy/TURP is done\n**3)** **Code X9** when only Grade Group is available, do not infer Gleason Primary and Secondary Pattern from Grade group\n\n***Examples***\n**1)** Gleason 3+3 = Patterns 33, Score 06\n**2)** Gleason 4+3 = Patterns 43, Score 07\n**3)** Gleason 4 (Assume a number in the range 2-5 is a primary pattern and code unknown (9) in the second digit) = Patterns 49, Score X9\n**4)** Gleason 7 (Assume a number in the range 6-10 is a score) = Pattern X6, Score 07\n**5)** Gleason 10 (only combination of values that equals 10 is 5+5) = Pattern 55, Score 10\n**6)** Needle core biopsy or TURP not done = Patterns X7, Score X7\n**7)** Gleason not done, or unknown if done = Patterns X9, Score X9", + "additional_info" : "**Source documents:** pathology reports from needle biopsies, transurethral resection of prostate/bladder, or simple prostatectomy that contains prostate tissue\n\nFor further information, refer to the **Prostate** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Prostate*.", + "coding_guidelines" : "**1)** **Code X6** If the only information available is the Gleason Score\n\n**2)** **Code X7** if no needle core biopsy/TURP is done\n\n**3)** **Code X9** when only Grade Group is available, do not infer Gleason Primary and Secondary Pattern from Grade group\n\n***Examples***\n\n**1)** Gleason 3+3 = Patterns 33, Score 06\n\n**2)** Gleason 4+3 = Patterns 43, Score 07\n\n**3)** Gleason 4 (Assume a number in the range 2-5 is a primary pattern and code unknown (9) in the second digit) = Patterns 49, Score X9\n\n**4)** Gleason 7 (Assume a number in the range 6-10 is a score) = Pattern X6, Score 07\n\n**5)** Gleason 10 (only combination of values that equals 10 is 5+5) = Pattern 55, Score 10\n\n**6)** Needle core biopsy or TURP not done = Patterns X7, Score X7\n\n**7)** Gleason not done, or unknown if done = Patterns X9, Score X9", "rationale" : "Gleason Patterns Pathological is a Registry Data Collection Variable for AJCC. This data item was previously collected as Prostate, CS SSF #9." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/gleason_patterns_pathological_833.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/gleason_patterns_pathological_833.json index e3a7b5599..34b20e27b 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/gleason_patterns_pathological_833.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/gleason_patterns_pathological_833.json @@ -6,7 +6,7 @@ "title" : "Gleason Patterns Pathological", "description" : "Prostate cancers are graded using Gleason score or pattern. This data item represents the Gleason primary and secondary patterns from a radical prostatectomy or autopsy. \n\nThe pathologist determines the Gleason patterns by looking at the prostate tissue under the microscope. The pathologist assigns a grade to the most predominant pattern (largest surface area of involvement, more than 50% of tissue) and a grade for the secondary pattern (second most predominant) based on published Gleason criteria. When a patient undergoes radical prostatectomy, the pathologist may look for a third or tertiary pattern in the specimen. When Gleason pattern 5 is present as a tertiary pattern, its presence should be indicated in the pathology report, as a high Gleason pattern appears to be an indicator for worse outcome (shortened time to recurrence). Studies indicate that a Gleason score 7, with tertiary pattern 5, is associated with a worse prognosis than without tertiary pattern 5 and is similar to the prognosis for Gleason score 8 – 10. \n* For example, in a specimen where the primary Gleason pattern is 3, the secondary is 4 and there is less than 5% Gleason 5, the report should indicate a Gleason score of 7 (3+4) with tertiary Gleason pattern 5. Gleason grades (patterns) range from 1 (small, uniform gland) to 5 (lack of glands, sheets of cells.)\n\nFor the Gleason Patterns data items, there is a long list of codes and definitions in the table, but it may be easier to assign a value if you understand the structure of the code. This is a two-digit field. \n* First digit is the Gleason primary pattern value\n* Second digit is the Gleason secondary pattern value\n\nThe Gleason system for grading prostate cancer is the one recommended by the AJCC and College of American Pathologists. The following related data items are used to collect information on Gleason.", "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of Gleason Patterns Pathological can be used to code this data item when there is no other information available.\n\n**Note 2:** **Procedures** \n* Code the Gleason primary and secondary patterns from a radical prostatectomy or autopsy only in this field. Unlike Grade Group Pathological, do not include patterns from tissues taken prior to prostatectomy.\n * Code results from a transurethral resection of prostate (TURP) or simple prostatectomy in Gleason Patterns Clinical\n\n**Note 3:** **Gleason Grading** \n* Usually, prostate cancers are graded using Gleason score or pattern. Gleason grading for prostate primaries is based on a 5-component system (5 histologic patterns). Prostatic cancer generally shows two main histologic patterns. The primary pattern, the pattern occupying greater than 50% of the cancer, is usually indicated by the first number of the Gleason grade, and the secondary pattern is usually indicated by the second number. These two numbers are added together to create a pattern score. \n* If there are two numbers, assume that they refer to two patterns (the first number being the primary pattern and the second number the secondary pattern), and sum them to obtain the score.\n* If only one number is given, and it is less than or equal to 5, assume that it describes a pattern (since scores of 5 or less would reflect Primary or Secondary Pattern Scores of 1 or 2). Code the number as the primary pattern and code the secondary pattern as Unknown. \n * For ***example***, if only one number is given, and it is a 3, code \"39\" for Gleason Patterns and \"X9\" for Gleason Score.\n* If only one number is given, and it is greater than 5, assume that it is a score. \n * For ***example***, if only one number is given, and it is a 7, code \"X6\" for Gleason Patterns and \"07\" for Gleason Score. \n* If the pathology report specifies a specific number out of a total of 10, the first number given is the score. \n * For ***example,*** if the pathology report says Gleason 7/10, code \"07' for Gleason Score and \"X6\" for Gleason Patterns. \n\n**Note 4:** **Different patterns** \n* If different patterns are documented on multiple specimens, code the pattern that reflects the highest or most aggressive score regardless of if the pathologist provides an overall pattern in a final summary. If different patterns equal the same high score, give priority to the highest primary pattern and then the highest secondary pattern.\n\n**Note 5:** **Tertiary pattern** \n* If a tertiary pattern is documented on prostatectomy or autopsy, code in the related data item 3842: Gleason Tertiary Pattern.\n\n**Note 6:** **Neoadjuvant therapy** \n* Code X9 when neoadjuvant therapy was given\n\n**Note 7:** **Active surveillance, then Radical Prostatectomy**\n* Code X9 when first course of treatment is active surveillance, but a radical prostatectomy is done at a later date due to disease progression or the patient changed their mind\n\n**Note 8:** **Related data item** \n* The pathological score is recorded in the related data item 3841: Gleason Score Pathological.", - "last_modified" : "2025-02-24T14:20:06.085Z", + "last_modified" : "2025-11-06T21:49:46.694Z", "definition" : [ { "key" : "gleason_patterns_path", "name" : "Code", @@ -17,7 +17,7 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "11", "Primary pattern 1, secondary pattern 1 " ], [ "12", "Primary pattern 1, secondary pattern 2" ], [ "13", "Primary pattern 1, secondary pattern 3" ], [ "14", "Primary pattern 1, secondary pattern 4" ], [ "15", "Primary pattern 1, secondary pattern 5" ], [ "19", "Primary pattern 1, secondary pattern unknown" ], [ "21", "Primary pattern 2, secondary pattern 1" ], [ "22", "Primary pattern 2, secondary pattern 2" ], [ "23", "Primary pattern 2, secondary pattern 3" ], [ "24", "Primary pattern 2, secondary pattern 4" ], [ "25", "Primary pattern 2, secondary pattern 5" ], [ "29", "Primary pattern 2, secondary pattern unknown" ], [ "31", "Primary pattern 3, secondary pattern 1" ], [ "32", "Primary pattern 3, secondary pattern 2" ], [ "33", "Primary pattern 3, secondary pattern 3" ], [ "34", "Primary pattern 3, secondary pattern 4" ], [ "35", "Primary pattern 3, secondary pattern 5" ], [ "39", "Primary pattern 3, secondary pattern unknown" ], [ "41", "Primary pattern 4, secondary pattern 1" ], [ "42", "Primary pattern 4, secondary pattern 2" ], [ "43", "Primary pattern 4, secondary pattern 3" ], [ "44", "Primary pattern 4, secondary pattern 4" ], [ "45", "Primary pattern 4, secondary pattern 5" ], [ "49", "Primary pattern 4, secondary pattern unknown" ], [ "51", "Primary pattern 5, secondary pattern 1" ], [ "52", "Primary pattern 5, secondary pattern 2" ], [ "53", "Primary pattern 5, secondary pattern 3" ], [ "54", "Primary pattern 5, secondary pattern 4" ], [ "55", "Primary pattern 5, secondary pattern 5" ], [ "59", "Primary pattern 5, secondary pattern unknown" ], [ "X6", "Radical prostatectomy done, primary pattern unknown, secondary pattern unknown" ], [ "X7", "No radical prostatectomy/autopsy performed" ], [ "X8", "Not applicable: Information not collected for this case\n(If this information is required by your standard setter, use of code X8 may result in an edit error.)" ], [ "X9", "Not documented in medical record\nGleason Patterns Pathological not assessed or unknown if assessed\nUnknown if radical prostatectomy done" ] ], - "additional_info" : "**Source documents:** pathology report from a radical prostatectomy or autopsy report\n\nFor further information, refer to the **Prostate** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Prostate*", - "coding_guidelines" : "**1)** **Code X6** If the only information available is the Gleason Score\n**2)** **Code X7** if no radical prostatectomy or autopsy is done\n**3)** **Code X9** when only Grade Group is available\n\n***Examples***\n**1)** Gleason 3+3 = Patterns 33, Score 06\n**2)** Gleason 4+3 = Patterns 43, Score 07\n**3)** Gleason 4 (Assume a number in the range 2-5 is a primary pattern and code unknown (9) in the second digit) = Patterns 49, Score X9\n**4)** Gleason 7 (Assume a number in the range 6-10 is a score) = Pattern X6, Score 07\n**5)** Gleason 10 (only combination of values that equals 10 is 5+5) = Pattern 55, Score 10\n**6)** Needle core biopsy or TURP not done = Patterns X7, Score X7\n**7)** Gleason not done, or unknown if done = Patterns X9, Score X9", + "additional_info" : "**Source documents:** pathology report from a radical prostatectomy or autopsy report\n\nFor further information, refer to the **Prostate** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Prostate*.", + "coding_guidelines" : "**1)** **Code X6** If the only information available is the Gleason Score\n\n**2)** **Code X7** if no radical prostatectomy or autopsy is done\n\n**3)** **Code X9** when only Grade Group is available\n\n***Examples***\n\n**1)** Gleason 3+3 = Patterns 33, Score 06\n\n**2)** Gleason 4+3 = Patterns 43, Score 07\n\n**3)** Gleason 4 (Assume a number in the range 2-5 is a primary pattern and code unknown (9) in the second digit) = Patterns 49, Score X9\n\n**4)** Gleason 7 (Assume a number in the range 6-10 is a score) = Pattern X6, Score 07\n\n**5)** Gleason 10 (only combination of values that equals 10 is 5+5) = Pattern 55, Score 10\n\n**6)** Needle core biopsy or TURP not done = Patterns X7, Score X7\n\n**7)** Gleason not done, or unknown if done = Patterns X9, Score X9", "rationale" : "Gleason Patterns Pathological is a Registry Data Collection Variable for AJCC. This data item was previously collected as Prostate, CS SSF #9." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/gleason_score_clinical_67175.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/gleason_score_clinical_67175.json index 24da32dad..8eb2bbf3f 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/gleason_score_clinical_67175.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/gleason_score_clinical_67175.json @@ -5,8 +5,8 @@ "name" : "Gleason Score Clinical", "title" : "Gleason Score Clinical", "description" : "This data item records the Gleason score based on adding the values for primary and secondary patterns in Needle Core Biopsy or TURP.\n\nThe Gleason system for grading prostate cancer is the one recommended by the AJCC and College of American Pathologists. The following related data items are used to collect information on Gleason.\n* 3838: Gleason Patterns Clinical\n* 3839: Gleason Patterns Pathological\n* 3840: Gleason Score Clinical\n* 3841: Gleason Score Pathological\n* 3842: Gleason Tertiary Pattern\n\nThe Gleason score is the sum of the values of the Gleason primary and secondary patterns. A low Gleason score means the cancer tissue is similar to normal prostate tissue and the tumor is less likely to spread; a high Gleason score means the cancer tissue is very different from normal and the tumor is more likely to spread.", - "notes" : "**Note 1:** **Physician Statement** \nPhysician statement of Gleason Score Clinical can be used to code this data item when there is no other information available.\n\n**Note 2:** **Procedures** \n* Code the Gleason Score Clinical from a needle core biopsy, trans rectal ultrasound (TRUS) guided biopsy, transurethral resection of prostate (TURP), and/or simple prostatectomy in this field.\n* Gleason primary and secondary patterns provided for any prostate tissue identified from a transurethral resection of a bladder tumor (TURBT) specimen can also be used in this field\n\n**Note 3:** **Neoadjuvant Treatment** \n* Code the Gleason primary and secondary patterns prior to neoadjuvant treatment.\n\n**Note 4:** **Gleason Grading** \n* Usually, prostate cancers are graded using Gleason score or pattern. Gleason grading for prostate primaries is based on a 5-component system (5 histologic patterns). Prostatic cancer generally shows two main histologic patterns. The primary pattern, the pattern occupying greater than 50% of the cancer, is usually indicated by the first number of the Gleason grade, and the secondary pattern is usually indicated by the second number. These two numbers are added together to create a pattern score. \n* If there are two numbers, assume that they refer to two patterns (the first number being the primary pattern and the second number the secondary pattern), and sum them to obtain the score.\n* If only one number is given, and it is less than or equal to 5, assume that it describes a pattern (since scores of 5 or less would reflect Primary or Secondary Pattern Scores of 1 or 2). Code the number as the primary pattern and code the secondary pattern as Unknown. \n * For ***example,*** if only one number is given and it is a 3, code \"39\" for Gleason Patterns and \"X9\" for Gleason Score.\n* If only one number is given, and it is greater than 5, assume that it is a score. \n * For ***example,*** if only one number is given, and it is a 7, code \"X6\" for Gleason Patterns and \"07\" for Gleason Score. \n* If the pathology report specifies a specific number out of a total of 10, the first number given is the score. \n * For ***example***, if the pathology report says Gleason 7/10, code \"07' for Gleason Score and \"X6\" for Gleason Patterns. \n\n**Note 5:** **Multiple procedures** \n* If multiple procedures are performed (e.g., needle core biopsy, trans rectal ultrasound (TRUS) guided biopsy, transurethral resection of prostate (TURP), and/or simple prostatectomy), code the pattern that reflects the highest score.\n\n**Note 6:** **Related data item** \n* Record the Gleason score based on the addition of the primary and secondary patterns coded in the related data item 3838: Gleason Patterns Clinical.", - "last_modified" : "2024-04-08T20:52:55.079Z", + "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of Gleason Score Clinical can be used to code this data item when there is no other information available.\n\n**Note 2:** **Procedures** \n* Code the Gleason Score Clinical from a needle core biopsy, trans rectal ultrasound (TRUS) guided biopsy, transurethral resection of prostate (TURP), and/or simple prostatectomy in this field.\n* Gleason primary and secondary patterns provided for any prostate tissue identified from a transurethral resection of a bladder tumor (TURBT) specimen can also be used in this field\n\n**Note 3:** **Neoadjuvant Treatment** \n* Code the Gleason primary and secondary patterns prior to neoadjuvant treatment.\n\n**Note 4:** **Gleason Grading** \n* Usually, prostate cancers are graded using Gleason score or pattern. Gleason grading for prostate primaries is based on a 5-component system (5 histologic patterns). Prostatic cancer generally shows two main histologic patterns. The primary pattern, the pattern occupying greater than 50% of the cancer, is usually indicated by the first number of the Gleason grade, and the secondary pattern is usually indicated by the second number. These two numbers are added together to create a pattern score. \n* If there are two numbers, assume that they refer to two patterns (the first number being the primary pattern and the second number the secondary pattern), and sum them to obtain the score.\n* If only one number is given, and it is less than or equal to 5, assume that it describes a pattern (since scores of 5 or less would reflect Primary or Secondary Pattern Scores of 1 or 2). Code the number as the primary pattern and code the secondary pattern as Unknown. \n * For ***example,*** if only one number is given and it is a 3, code \"39\" for Gleason Patterns and \"X9\" for Gleason Score.\n* If only one number is given, and it is greater than 5, assume that it is a score. \n * For ***example,*** if only one number is given, and it is a 7, code \"X6\" for Gleason Patterns and \"07\" for Gleason Score. \n* If the pathology report specifies a specific number out of a total of 10, the first number given is the score. \n * For ***example***, if the pathology report says Gleason 7/10, code \"07' for Gleason Score and \"X6\" for Gleason Patterns. \n\n**Note 5:** **Multiple procedures** \n* If multiple procedures are performed (e.g., needle core biopsy, trans rectal ultrasound (TRUS) guided biopsy, transurethral resection of prostate (TURP), and/or simple prostatectomy), code the pattern that reflects the highest score.\n\n**Note 6:** **Related data item** \n* Record the Gleason score based on the addition of the primary and secondary patterns coded in the related data item 3838: Gleason Patterns Clinical.", + "last_modified" : "2025-11-06T21:47:20.773Z", "definition" : [ { "key" : "gleason_score_clin", "name" : "Code", @@ -18,6 +18,6 @@ } ], "rows" : [ [ "02", "Gleason score 2" ], [ "03", "Gleason score 3" ], [ "04", "Gleason score 4" ], [ "05", "Gleason score 5" ], [ "06", "Gleason score 6" ], [ "07", "Gleason score 7" ], [ "08", "Gleason score 8" ], [ "09", "Gleason score 9" ], [ "10", "Gleason score 10" ], [ "X7", "No needle core biopsy/TURP performed" ], [ "X8", "Not applicable: Information not collected for this case\n(If this information is required by your standard setter, use of code X8 may result in an edit error.)" ], [ "X9", "Not documented in medical record\nGleason Score Clinical not assessed or unknown if assessed" ] ], "additional_info" : "**Source documents:** pathology reports from needle biopsies, transurethral resection of prostate/bladder, or simple prostatectomy that contains prostate tissue\n\nFor further information, refer to the **Prostate** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Prostate*", - "coding_guidelines" : "**1)** **Code X7** if no needle core biopsy/TURP is done\n**2)** **Code X9** when only Grade Group is available\n\n***Examples***\n**1)** Gleason 3+3 = Patterns 33, Score 06\n**2)** Gleason 4+3 = Patterns 43, Score 07\n**3)** Gleason 4 (Assume a number in the range 2-5 is a primary pattern and code unknown (9) in the second digit) = Patterns 49, Score X9\n**4)** Gleason 7 (Assume a number in the range 6-10 is a score) = Pattern X6, Score 07\n**5)** Gleason 10 (only combination of values that equals 10 is 5+5) = Pattern 55, Score 10\n**6)** Needle core biopsy or TURP not done = Patterns X7, Score X7\n**7)** Gleason not done, or unknown if done = Patterns X9, Score X9", + "coding_guidelines" : "**1)** **Code X7** if no needle core biopsy/TURP is done\n\n**2)** **Code X9** when only Grade Group is available\n\n***Examples***\n\n**1)** Gleason 3+3 = Patterns 33, Score 06\n\n**2)** Gleason 4+3 = Patterns 43, Score 07\n\n**3)** Gleason 4 (Assume a number in the range 2-5 is a primary pattern and code unknown (9) in the second digit) = Patterns 49, Score X9\n\n**4)** Gleason 7 (Assume a number in the range 6-10 is a score) = Pattern X6, Score 07\n\n**5)** Gleason 10 (only combination of values that equals 10 is 5+5) = Pattern 55, Score 10\n\n**6)** Needle core biopsy or TURP not done = Patterns X7, Score X7\n\n**7)** Gleason not done, or unknown if done = Patterns X9, Score X9", "rationale" : "Gleason Score Clinical is a Registry Data Collection Variable for AJCC. This data item was previously collected as Prostate, CS SSF #8." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/gleason_score_pathological_82121.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/gleason_score_pathological_82121.json index ce51ee8b1..c15b95b42 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/gleason_score_pathological_82121.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/gleason_score_pathological_82121.json @@ -5,8 +5,8 @@ "name" : "Gleason Score Pathological", "title" : "Gleason Score Pathological", "description" : "This data item records the Gleason score based on adding the values for primary and secondary patterns from a radical prostatectomy or autopsy. \n\nThe Gleason system for grading prostate cancer is the one recommended by the AJCC and College of American Pathologists. The following related data items are used to collect information on Gleason.\n* 3838: Gleason Patterns Clinical\n* 3839: Gleason Patterns Pathological\n* 3840: Gleason Score Clinical\n* 3841: Gleason Score Pathological\n* 3842: Gleason Tertiary Pattern\n\nThe Gleason score is the sum of the values of the Gleason primary and secondary patterns. A low Gleason score means the cancer tissue is similar to normal prostate tissue and the tumor is less likely to spread; a high Gleason score means the cancer tissue is very different from normal and the tumor is more likely to spread.", - "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of Gleason Score Pathological can be used to code this data item when there is no other information available.\n\n**Note 2:** **Procedures** \n* Code the Gleason Score Pathological from a radical prostatectomy or autopsy only in this field. Unlike Grade Group Pathological, do not include patterns from tissues taken prior to a radical prostatectomy.\n * Code results from a transurethral resection of prostate (TURP) or simple prostatectomy in Gleason Score Clinical\n \n**Note 3:** **Gleason Grading** \n* Usually, prostate cancers are graded using Gleason's score or pattern. Gleason's grading for prostate primaries is based on a 5-component system (5 histologic patterns). Prostatic cancer generally shows two main histologic patterns. The primary pattern, the pattern occupying greater than 50% of the cancer, is usually indicated by the first number of the Gleason's grade, and the secondary pattern is usually indicated by the second number. These two numbers are added together to create a pattern score, ranging from 2 to 10. \n* If there are two numbers, assume that they refer to two patterns (the first number being the primary pattern and the second number the secondary pattern), and sum them to obtain the score.\n* If only one number is given, and it is less than or equal to 5, code the total score to X9, unknown or no information. \n* If only one number is given, and it is greater than 5, assume that it is a score and code as stated. \n* If the pathology report specifies a specific number out of a total of 10, the first number given is the score. \n\n* ***Example:*** The pathology report says Gleason's 3/10. The Gleason's score would be 3 and coded as 03.\n\n**Note 4:** **Neoadjuvant therapy** \n* Code X9 when neoadjuvant therapy was given\n\n**Note 5:** **Active surveillance, then Radical Prostatectomy**\n* Code X9 when first course of treatment is active surveillance, but a radical prostatectomy is done at a later date due to disease progression or the patient changed their mind\n\n**Note 6:** **Related data item** \n* Record the Gleason score based on the addition of the primary and secondary patterns coded in the related data item 3839: Gleason Patterns Pathological.", - "last_modified" : "2024-06-12T15:27:36.197Z", + "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of Gleason Score Pathological can be used to code this data item when there is no other information available.\n\n**Note 2:** **Procedures** \n* Code the Gleason Score Pathological from a radical prostatectomy or autopsy only in this field. Unlike Grade Group Pathological, do not include patterns from tissues taken prior to a radical prostatectomy.\n * Code results from a transurethral resection of prostate (TURP) or simple prostatectomy in Gleason Score Clinical\n \n**Note 3:** **Gleason Grading** \n* Usually, prostate cancers are graded using Gleason score or pattern. Gleason grading for prostate primaries is based on a 5-component system (5 histologic patterns). Prostatic cancer generally shows two main histologic patterns. The primary pattern, the pattern occupying greater than 50% of the cancer, is usually indicated by the first number of the Gleason grade, and the secondary pattern is usually indicated by the second number. These two numbers are added together to create a pattern score, ranging from 2 to 10. \n* If there are two numbers, assume that they refer to two patterns (the first number being the primary pattern and the second number the secondary pattern), and sum them to obtain the score.\n* If only one number is given, and it is less than or equal to 5, code the total score to X9, unknown or no information. \n* If only one number is given, and it is greater than 5, assume that it is a score and code as stated. \n* If the pathology report specifies a specific number out of a total of 10, the first number given is the score. \n\n* ***Example:*** The pathology report says Gleason 3/10. The Gleason score would be 3 and coded as 03.\n\n**Note 4:** **Neoadjuvant therapy** \n* Code X9 when neoadjuvant therapy was given\n\n**Note 5:** **Active surveillance, then Radical Prostatectomy**\n* Code X9 when first course of treatment is active surveillance, but a radical prostatectomy is done at a later date due to disease progression or the patient changed their mind\n\n**Note 6:** **Related data item** \n* Record the Gleason score based on the addition of the primary and secondary patterns coded in the related data item 3839: Gleason Patterns Pathological.", + "last_modified" : "2025-11-06T21:49:10.419Z", "definition" : [ { "key" : "gleason_score_path", "name" : "Code", @@ -17,7 +17,7 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "02", "Gleason score 2" ], [ "03", "Gleason score 3" ], [ "04", "Gleason score 4" ], [ "05", "Gleason score 5" ], [ "06", "Gleason score 6" ], [ "07", "Gleason score 7" ], [ "08", "Gleason score 8" ], [ "09", "Gleason score 9" ], [ "10", "Gleason score 10" ], [ "X7", "No radical prostatectomy/autopsy performed" ], [ "X8", "Not applicable: Information not collected for this case\n(If this information is required by your standard setter, use of code X8 may result in an edit error.)" ], [ "X9", "Not documented in medical record\nGleason Score Pathological not assessed or unknown if assessed\nUnknown if radical prostatectomy done" ] ], - "additional_info" : "**Source documents:** pathology report from a radical prostatectomy or autopsy report\n\nFor further information, refer to the **Prostate** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Prostate*", - "coding_guidelines" : "**1)** **Code X6** If the only information available is the Gleason Score\n**2)** **Code X7** if no radical prostatectomy or autopsy is done\n**3)** **Code X9** when only Grade Group is available\n\n***Examples***\n**1)** Gleason 3+3 = Patterns 33, Score 06\n**2)** Gleason 4+3 = Patterns 43, Score 07\n**3)** Gleason 4 (Assume a number in the range 2-5 is a primary pattern and code unknown (9) in the second digit) = Patterns 49, Score X9\n**4)** Gleason 7 (Assume a number in the range 6-10 is a score) = Pattern X6, Score 07\n**5)** Gleason 10 (only combination of values that equals 10 is 5+5) = Pattern 55, Score 10\n**6)** Needle core biopsy or TURP not done = Patterns X7, Score X7\n**7)** Gleason not done, or unknown if done = Patterns X9, Score X9", + "additional_info" : "**Source documents:** pathology report from a radical prostatectomy or autopsy report\n\nFor further information, refer to the **Prostate** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Prostate*.", + "coding_guidelines" : "**1)** **Code X6** If the only information available is the Gleason Score\n\n**2)** **Code X7** if no radical prostatectomy or autopsy is done\n\n**3)** **Code X9** when only Grade Group is available\n\n***Examples***\n\n**1)** Gleason 3+3 = Patterns 33, Score 06\n\n**2)** Gleason 4+3 = Patterns 43, Score 07\n\n**3)** Gleason 4 (Assume a number in the range 2-5 is a primary pattern and code unknown (9) in the second digit) = Patterns 49, Score X9\n\n**4)** Gleason 7 (Assume a number in the range 6-10 is a score) = Pattern X6, Score 07\n\n**5)** Gleason 10 (only combination of values that equals 10 is 5+5) = Pattern 55, Score 10\n\n**6)** Needle core biopsy or TURP not done = Patterns X7, Score X7\n\n**7)** Gleason not done, or unknown if done = Patterns X9, Score X9", "rationale" : "Gleason Score Pathological is a Registry Data Collection Variable for AJCC. This data item was previously collected as Prostate, CS SSF #10." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/gleason_tertiary_pattern_6430.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/gleason_tertiary_pattern_6430.json index 25d5f02f5..d89c22c84 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/gleason_tertiary_pattern_6430.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/gleason_tertiary_pattern_6430.json @@ -6,7 +6,7 @@ "title" : "Gleason Tertiary Pattern", "description" : "Prostate cancers are graded using Gleason score or pattern. This data item represents the tertiary pattern value from a radical prostatectomy or autopsy.\n\nA high Gleason Tertiary Pattern appears to be an indication for a worse outcome.\n\nThe Gleason system for grading prostate cancer is the one recommended by the AJCC and College of American Pathologists. The following related data items are used to collect information on Gleason.\n* 3838: Gleason Patterns Clinical\n* 3839: Gleason Patterns Pathological\n* 3840: Gleason Score Clinical\n* 3841: Gleason Score Pathological\n* 3842: Gleason Tertiary Pattern", "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of Gleason tertiary pattern can be used to code this data item when there is no other information available.\n\n**Note 2:** **Procedures** \n* Record the tertiary pattern documented on radical prostatectomy or autopsy only. Record the tertiary pattern prior to neoadjuvant treatment. \n* If a tertiary pattern is documented on needle core biopsy or transurethral resection of prostate (TURP), it should be disregarded. \n* Do not code the tertiary pattern on radical prostatectomy or autopsy in Gleason Patterns Pathological.\n\n**Note 3:** **Tertiary Patterns 1 and 2** \n* The CAP Prostate Protocol does not include Patterns 1 and 2 for Tertiary Pattern.\n\n**Note 4:** **Neoadjuvant therapy** \n* Code X9 when neoadjuvant therapy was given\n\n**Note 5:** **Active surveillance, then Radical Prostatectomy**\n* Code X9 when first course of treatment is active surveillance, but a radical prostatectomy is done at a later date due to disease progression or the patient changed their mind", - "last_modified" : "2024-06-12T15:27:30.735Z", + "last_modified" : "2025-11-06T16:12:56.125Z", "definition" : [ { "key" : "gleason_tertiary_pattern", "name" : "Code", @@ -17,6 +17,6 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "10", "Tertiary pattern 1" ], [ "20", "Tertiary pattern 2" ], [ "30", "Tertiary pattern 3" ], [ "40", "Tertiary pattern 4" ], [ "50", "Tertiary pattern 5" ], [ "X7", "No radical prostatectomy/autopsy performed" ], [ "X8", "Not applicable: Information not collected for this case\n(If this information is required by your standard setter, use of code X8 may result in an edit error.)" ], [ "X9", "Not documented in medical record\nGleason Tertiary Pattern not assessed or unknown if assessed" ] ], - "additional_info" : "**Source documents:** pathology report from a radical prostatectomy or autopsy report\n\nFor further information, refer to the **Prostate** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Prostate*", + "additional_info" : "**Source documents:** pathology report from a radical prostatectomy or autopsy report\n\nFor further information, refer to the **Prostate** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Prostate*.", "rationale" : "Tertiary Gleason pattern on prostatectomy is a Registry Data Collection Variable for AJCC. This data item was previously collected as Prostate, CS SSF #11." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/hcg_post_orchiectomy_lab_value_13834.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/hcg_post_orchiectomy_lab_value_13834.json index 5a633232d..4008a550f 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/hcg_post_orchiectomy_lab_value_13834.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/hcg_post_orchiectomy_lab_value_13834.json @@ -6,7 +6,7 @@ "title" : "hCG (Human Chorionic Gonadotropin) Post-Orchiectomy Lab Value", "description" : "hCG (Human Chorionic Gonadotropin) Post-Orchiectomy Lab Value refers to the lowest hCG value measured post-orchiectomy. hCG is a serum tumor marker that is often elevated in patients with nonseminomatous germ cell tumors of the testis. The Post-Orchiectomy lab value is used to monitor response to therapy.\n\nHuman chorionic gonadotropin (hCG) is a hormone produced by the placenta and some germ cell tumors. Two subunits, alpha and beta, can be measured in blood or serum. The alpha subunit is a non-specific marker for pancreatic and pituitary tumors. Beta-hCG levels are never found in normal healthy men. When the presence of beta-hCG is detected in serum, it always indicates a malignancy. Beta-hCG is secreted by some non- seminomatous germ cell tumors and mixed tumors and is used with AFP to identify the specific cell type of testicular cancer. Beta-hCG is also useful in monitoring response to therapy. After orchiectomy, the hCG should be undetectable within 5 to 8 days. If elevated hCG persists, this is an indication of residual tumor.\n\nFor Testis, there are 4 related data items that record information on hCG.\n* 3846: hCG Post-Orchiectomy Lab Value\n* 3847: hCG Post-Orchiectomy Range\n* 3848: hCG Pre-Orchiectomy Lab Value\n* 3849: hCG Pre-Orchiectomy Range", "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of the hCG (Human Chorionic Gonadotropin) Post-Orchiectomy Lab Value can be used to code this data item when no other information is available. \n\n**Note 2:** **Timing** \n* Record the value of the hCG test as documented in the medical record **after orchiectomy** but prior to adjuvant therapy. The lab value may be documented in a lab report, history and physical, or clinical statement in the pathology report.\n\n**Note 3:** **Lab values elevated after orchiectomy** \n* If the initial post-orchiectomy hCG remains elevated, review subsequent tests and record the lowest hCG value (normalization or plateau) prior to adjuvant therapy or before the value rises again.\n\n**Note 4:** **Related Data Item** \n* The same laboratory test should be used to record the related data item 3847: hCG Post-Orchiectomy Range.", - "last_modified" : "2025-02-24T16:38:47.995Z", + "last_modified" : "2025-11-06T21:53:11.758Z", "definition" : [ { "key" : "hcg_post_orch_lab_value", "name" : "Code", @@ -17,7 +17,7 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "0.0", "0.0 milli-International Units/milliliter (mIU/mL)" ], [ "0.1-99999.9", "0.1 - 99,999.9 mIU/mL" ], [ "XXXXX.1", "100,000 mIU/mL or greater" ], [ "XXXXX.7", "Test ordered, results not in chart" ], [ "XXXXX.8", "Not applicable: Information not collected for this case\n(If this information is required by your standard setter, use of code XXXXX.8 may result in an edit error.)" ], [ "XXXXX.9", "Not documented in medical record\nNo orchiectomy performed\nhCG (Human Chorionic Gonadotropin) Post-Orchiectomy Lab Value not assessed or unknown if assessed" ] ], - "additional_info" : "**Source documents:** clinical laboratory report (blood or serum test), sometimes in history and physical or clinical statement in pathology report\n\n**Other names include** Human chorionic gonadotropin, b-hCG, beta subunit HCG, beta hCG, -hCG•\t\n\nFor further information, refer to the **Testis** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Testis*\n\n**Normal Reference Range**\n * < 2 ng/ml (SI: < 2 µg/L or < 2 ug/L) 1 ng/ml of HCG is approximately 5 mIU/ml.\n * < 5 mIU/mL (< 5 IU/L) To record mIU/mL in ng/ml, divide the test result by 5.\n \n**Measurements** \n * A lab value expressed in International Units/liter (IU/L) is equivalent to the same value expressed in milli-International Units/milliliter (mIU/mL).", - "coding_guidelines" : "**1)** **Code XXXXX.9** when\n* The only information available is a statement of elevated or normal\n* If the pre-orchiectomy hCG was normal; a post-orchiectomy hCG may not be performed. In this case, code XXXXX.9 should be recorded.\n\n***Examples***\n**1)** 2.0 mIU/mL = Lab Value 2.0, Range 0\n**2)** 412 mIU/mL = Lab Value 412.0, Range1\n**3)** 6213 mIU/mL = Lab Value 6213.0, Range 2\n**4)** 14,724 mIU/mL = Lab Value 14724.0, Range 3\n**5)** 108,325 mIU/mL = Lab Value XXXXX.1, Range 3\n**6)** Physician states “hCG elevated,” but no value documented = Lab Value XXXXX.9, Range 4\n**7)** S value stated (no other information available) = Lab Value XXXXX.9, Range 9\n**8)** No hCG test done, or unknown if done = Lab Value XXXXX.9, Range 9", + "additional_info" : "**Source documents:** clinical laboratory report (blood or serum test), sometimes in history and physical or clinical statement in pathology report\n\n**Other names include** Human chorionic gonadotropin, b-hCG, beta subunit HCG, beta hCG, β-hCG\n\nFor further information, refer to the **Testis** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Testis*.\n\n**Normal Reference Range**\n * < 2 ng/ml (SI: < 2 µg/L or < 2 ug/L) 1 ng/ml of HCG is approximately 5 mIU/ml.\n * < 5 mIU/mL (< 5 IU/L) To record mIU/mL in ng/ml, divide the test result by 5\n \n**Measurements** \n * A lab value expressed in International Units/liter (IU/L) is equivalent to the same value expressed in milli-International Units/milliliter (mIU/mL).", + "coding_guidelines" : "**1)** **Code XXXXX.9** when\n* The only information available is a statement of elevated or normal\n* If the pre-orchiectomy hCG was normal; a post-orchiectomy hCG may not be performed. In this case, code XXXXX.9 should be recorded.\n\n***Examples***\n\n**1)** 2.0 mIU/mL = Lab Value 2.0, Range 0\n\n**2)** 412 mIU/mL = Lab Value 412.0, Range1\n\n**3)** 6213 mIU/mL = Lab Value 6213.0, Range 2\n\n**4)** 14,724 mIU/mL = Lab Value 14724.0, Range 3\n\n**5)** 108,325 mIU/mL = Lab Value XXXXX.1, Range 3\n\n**6)** Physician states “hCG elevated,” but no value documented = Lab Value XXXXX.9, Range 4\n\n**7)** S value stated (no other information available) = Lab Value XXXXX.9, Range 9\n\n**8)** No hCG test done, or unknown if done = Lab Value XXXXX.9, Range 9", "rationale" : "hCG (Human Chorionic Gonadotropin) Post-Orchiectomy Lab Value is a Registry Data Collection Variable in AJCC. It was previously collected as Testis CS SSF #14." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/hcg_post_orchiectomy_range_92334.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/hcg_post_orchiectomy_range_92334.json index d88790a75..d76aa6dce 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/hcg_post_orchiectomy_range_92334.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/hcg_post_orchiectomy_range_92334.json @@ -6,7 +6,7 @@ "title" : "hCG (Human Chorionic Gonadotropin) Post-Orchiectomy Range", "description" : "Human Chorionic Gonadotropin (hCG) Post-Orchiectomy Range identifies the range category of the lowest hCG value measured post-orchiectomy. hCG is a serum tumor marker that is often elevated in patients with nonseminomatous germ cell tumors of the testis. The post-orchiectomy lab value is used to monitor response to therapy.\n\nFor Testis, there are 4 related data items that record information on hCG.\n* 3846: hCG Post-Orchiectomy Lab Value\n* 3847: hCG Post-Orchiectomy Range\n* 3848: hCG Pre-Orchiectomy Lab Value\n* 3849: hCG Pre-Orchiectomy Range", "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of the hCG (Human Chorionic Gonadotropin) Post-Orchiectomy Range can be used to code this data item when there is no other information available.\n\n**Note 2:** **Timing** \n* Record the range of the hCG test as documented in the medical record **after orchiectomy** but prior to adjuvant therapy. The lab value may be documented in a lab report, history and physical, or clinical statement in the pathology report.\n\n**Note 3:** **Lab values elevated after orchiectomy** \n* If the initial post-orchiectomy hCG remains elevated, review subsequent tests and record the lowest hCG value (normalization or plateau) prior to adjuvant therapy or before the value rises again.\n\n**Note 4:** **Pre-orchiectomy hCG normal** \n* If the pre-orchiectomy hCG was normal, a post-orchiectomy hCG may not be performed. In this case, code 5 should be recorded.\n\n**Note 5:** **Related Data Item** \n* The same laboratory test should be used to record the related data item 3846: hCG Post-Orchiectomy Lab Value.", - "last_modified" : "2024-04-07T16:21:52.513Z", + "last_modified" : "2025-11-06T16:27:06.289Z", "definition" : [ { "key" : "hcg_post_orch_range", "name" : "Code", @@ -17,6 +17,6 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "0", "Within normal limits" ], [ "1", "Above normal and less than 5,000 milli-International Units/milliliter (mIU/mL)" ], [ "2", "5,000 - 50,000 mIU/mL" ], [ "3", "Greater than 50,000 mIU/mL" ], [ "4", "Post-orchiectomy human chorionic gonadotropin (hCG) stated to be elevated" ], [ "5", "Post-Orchiectomy human chorionic gonadotropin (hCG) unknown or not done but pre-orchiectomy hCG was normal" ], [ "7", "Test ordered, results not in chart" ], [ "8", "Not applicable: Information not collected for this case\n(If this information is required by your standard setter, use of code 8 may result in an edit error.)" ], [ "9", "Not documented in medical record\nNo orchiectomy performed\nhCG (Human Chorionic Gonadotropin) Post-Orchiectomy Range not assessed or unknown if assessed" ] ], - "additional_info" : "**Source documents:** clinical laboratory report (blood or serum test), sometimes in history and physical or clinical statement in pathology report\n\n**Other names include** Human chorionic gonadotropin, b-hCG, beta subunit HCG, beta hCG, -hCG•\t\n\nFor further information, refer to the **Testis** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Testis*\n\n**Normal Reference Range**\n * < 2 ng/ml (SI: < 2 µg/L or < 2 ug/L) 1 ng/ml of HCG is approximately 5 mIU/ml.\n * < 5 mIU/mL (< 5 IU/L) To record mIU/mL in ng/ml, divide the test result by 5.\n \n**Measurements** \n * A lab value expressed in International Units/liter (IU/L) is equivalent to the same value expressed in milli-International Units/milliliter (mIU/mL).", + "additional_info" : "**Source documents:** clinical laboratory report (blood or serum test), sometimes in history and physical or clinical statement in pathology report\n\n**Other names include** Human chorionic gonadotropin, b-hCG, beta subunit HCG, beta hCG, β-hCG\n\nFor further information, refer to the **Testis** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Testis*.\n\n**Normal Reference Range**\n * < 2 ng/ml (SI: < 2 µg/L or < 2 ug/L) 1 ng/ml of HCG is approximately 5 mIU/ml\n * < 5 mIU/mL (< 5 IU/L) To record mIU/mL in ng/ml, divide the test result by 5\n \n**Measurements** \n * A lab value expressed in International Units/liter (IU/L) is equivalent to the same value expressed in milli-International Units/milliliter (mIU/mL).", "rationale" : "hCG (Human Chorionic Gonadotropin) is a Registry Data Collection Variable in AJCC. hCG (Human Chorionic Gonadotropin) Post-orchiectomy Range is used to assign the S Category Pathological and was previously collected as Testis CS SSF #15." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/hcg_pre_orchiectomy_lab_value_55584.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/hcg_pre_orchiectomy_lab_value_55584.json index ba9301a5c..c262e967a 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/hcg_pre_orchiectomy_lab_value_55584.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/hcg_pre_orchiectomy_lab_value_55584.json @@ -6,7 +6,7 @@ "title" : "hCG (Human Chorionic Gonadotropin) Pre-Orchiectomy Lab Value", "description" : "hCG (Human Chorionic Gonadotropin) Pre-Orchiectomy Lab Value refers to the hCG value measured prior to treatment. hCG is a serum tumor marker that is often elevated in patients with nonseminomatous germ cell tumors of the testis.\n\nHuman chorionic gonadotropin (hCG) is a hormone produced by the placenta and some germ cell tumors. Two subunits, alpha and beta, can be measured in blood or serum. The alpha subunit is a non-specific marker for pancreatic and pituitary tumors. Beta-hCG levels are never found in normal healthy men. When the presence of beta-hCG is detected in serum, it always indicates a malignancy. Beta-hCG is secreted by some non- seminomatous germ cell tumors and mixed tumors and is used with AFP to identify the specific cell type of testicular cancer. Beta-hCG is also useful in monitoring response to therapy. After orchiectomy, the hCG should be undetectable within 5 to 8 days. If elevated hCG persists, this is an indication of residual tumor.\n\nFor Testis, there are 4 related data items that record information on hCG.\n* 3846: hCG Post-Orchiectomy Lab Value\n* 3847: hCG Post-Orchiectomy Range\n* 3848: hCG Pre-Orchiectomy Lab Value\n* 3849: hCG Pre-Orchiectomy Range", "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of the hCG (Human Chorionic Gonadotropin) Pre-Orchiectomy Lab Value can be used to code this data item when no other information is available. \n\n**Note 2:** **Timing** \n* Record the lab value of the highest hCG test result documented in the medical record prior to orchiectomy or prior to any systemic treatment. The lab value may be documented in a lab report, history and physical, or clinical statement in the pathology report.\n\n**Note 3:** **Related data item** \n* The same laboratory test should be used to record the related data item 3849: hCG Pre-Orchiectomy Range.", - "last_modified" : "2024-04-07T16:22:53.774Z", + "last_modified" : "2025-11-06T21:51:34.996Z", "definition" : [ { "key" : "hcg_pre_orch_lab_value", "name" : "Code", @@ -17,7 +17,7 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "0.0", "0.0 milli-International Units/milliliter (mIU/mL)" ], [ "0.1-99999.9", "0.1 - 99,999.9 mIU/mL" ], [ "XXXXX.1", "100,000 mIU/mL or greater" ], [ "XXXXX.7", "Test ordered, results not in chart" ], [ "XXXXX.8", "Not applicable: Information not collected for this case\n(If this information is required by your standard setter, use of code XXXXX.8 may result in an edit error.)" ], [ "XXXXX.9", "Not documented in medical record\nhCG (Human Chorionic Gonadotropin) Pre-Orchiectomy Lab Value not assessed or unknown if assessed" ] ], - "additional_info" : "**Source documents:** clinical laboratory report (blood or serum test), sometimes in history and physical or clinical statement in pathology report\n\n**Other names include** Human chorionic gonadotropin, b-hCG, beta subunit HCG, beta hCG, -hCG•\t\n\nFor further information, refer to the **Testis** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Testis*\n\n**Normal Reference Range**\n * < 2 ng/ml (SI: < 2 µg/L or < 2 ug/L) 1 ng/ml of HCG is approximately 5 mIU/ml.\n * < 5 mIU/mL (< 5 IU/L) To record mIU/mL in ng/ml, divide the test result by 5.\n \n**Measurements** \n * A lab value expressed in International Units/liter (IU/L) is equivalent to the same value expressed in milli-International Units/milliliter (mIU/mL).", - "coding_guidelines" : "***Examples***\n**1)** 2.0 mIU/mL = Lab Value 2.0, Range 0\n**2)** 412 mIU/mL = Lab Value 412.0, Range1\n**3)** 6213 mIU/mL = Lab Value 6213.0, Range 2\n**4)** 14,724 mIU/mL = Lab Value 14724.0, Range 3\n**5)** 108,325 mIU/mL = Lab Value XXXXX.1, Range 3\n**6)** Physician states “hCG elevated,” but no value documented = Lab Value XXXXX.9, Range 4\n**7)** S value stated (no other information available) = Lab Value XXXXX.9, Range 9\n**8)** No hCG test done, or unknown if done = Lab Value XXXXX.9, Range 9", + "additional_info" : "**Source documents:** clinical laboratory report (blood or serum test), sometimes in history and physical or clinical statement in pathology report\n\n**Other names include:** Human chorionic gonadotropin, b-hCG, beta subunit HCG, beta hCG, β-hCG\n\nFor further information, refer to the **Testis** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Testis*.\n\n**Normal Reference Range**\n * < 2 ng/ml (SI: < 2 µg/L or < 2 ug/L) 1 ng/ml of HCG is approximately 5 mIU/ml.\n * < 5 mIU/mL (< 5 IU/L) To record mIU/mL in ng/ml, divide the test result by 5.\n \n**Measurements** \n * A lab value expressed in International Units/liter (IU/L) is equivalent to the same value expressed in milli-International Units/milliliter (mIU/mL).", + "coding_guidelines" : "***Examples***\n\n**1)** 2.0 mIU/mL = Lab Value 2.0, Range 0\n\n**2)** 412 mIU/mL = Lab Value 412.0, Range1\n\n**3)** 6213 mIU/mL = Lab Value 6213.0, Range 2\n\n**4)** 14,724 mIU/mL = Lab Value 14724.0, Range 3\n\n**5)** 108,325 mIU/mL = Lab Value XXXXX.1, Range 3\n\n**6)** Physician states “hCG elevated,” but no value documented = Lab Value XXXXX.9, Range 4\n\n**7)** S value stated (no other information available) = Lab Value XXXXX.9, Range 9\n\n**8)** No hCG test done, or unknown if done = Lab Value XXXXX.9, Range 9", "rationale" : "hCG (Human Chorionic Gonadotropin) Pre-Orchiectomy Lab Value is a Registry Data Collection Variable in AJCC. It was previously collected as Testis CS SSF #8." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/hcg_pre_orchiectomy_range_67679.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/hcg_pre_orchiectomy_range_67679.json index 86d5fc778..f3aa99168 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/hcg_pre_orchiectomy_range_67679.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/hcg_pre_orchiectomy_range_67679.json @@ -6,7 +6,7 @@ "title" : "hCG (Human Chorionic Gonadotropin) Pre-Orchiectomy Range", "description" : "Human Chorionic Gonadotropin (hCG) Pre-Orchiectomy Range identifies the range category of the highest hCG value measured prior to treatment. hCG is a serum tumor marker that is often elevated in patients with nonseminomatous germ cell tumors of the testis.\n\nFor Testis, there are 4 related data items that record information on hCG.\n* 3846: hCG Post-Orchiectomy Lab Value\n* 3847: hCG Post-Orchiectomy Range\n* 3848: hCG Pre-Orchiectomy Lab Value\n* 3849: hCG Pre-Orchiectomy Range", "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of the hCG (Human Chorionic Gonadotropin) Pre-Orchiectomy Range can be used to code this data item when no other information is available. \n\n**Note 2:** **Timing** \n* Record the range of the highest hCG test result documented in the medical record **prior to orchiectomy** or prior to any systemic treatment. The lab value may be documented in a lab report, history and physical, or clinical statement in the pathology report.\n\n**Note 3:** **Related data item** \n* The same laboratory test should be used to record the related data item 3848: hCG Pre-orchiectomy Lab Value.", - "last_modified" : "2024-04-07T16:22:31.201Z", + "last_modified" : "2025-11-06T16:29:30.927Z", "definition" : [ { "key" : "hcg_pre_orch_range", "name" : "Code", @@ -17,6 +17,6 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "0", "Within normal limits" ], [ "1", "Above normal and less than 5,000 milli-International Units/milliliter (mIU/mL)" ], [ "2", "5,000 - 50,000 mIU/mL" ], [ "3", "Greater than 50,000 mIU/mL" ], [ "4", "Pre-orchiectomy human chorionic gonadotropin (hCG) stated to be elevated" ], [ "7", "Test ordered, results not in chart" ], [ "8", "Not applicable: Information not collected for this case\n(If this information is required by your standard setter, use of code 8 may result in an edit error.)" ], [ "9", "Not documented in medical record\nhCG Pre-Orchiectomy range not assessed or unknown if assessed" ] ], - "additional_info" : "**Source documents:** clinical laboratory report (blood or serum test), sometimes in history and physical or clinical statement in pathology report\n\n**Other names include** Human chorionic gonadotropin, b-hCG, beta subunit HCG, beta hCG, -hCG•\t\n\nFor further information, refer to the **Testis** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Testis*\n\n**Normal Reference Range**\n * < 2 ng/ml (SI: < 2 µg/L or < 2 ug/L) 1 ng/ml of HCG is approximately 5 mIU/ml.\n * < 5 mIU/mL (< 5 IU/L) To record mIU/mL in ng/ml, divide the test result by 5.\n \n**Measurements** \n * A lab value expressed in International Units/liter (IU/L) is equivalent to the same value expressed in milli-International Units/milliliter (mIU/mL).", + "additional_info" : "**Source documents:** clinical laboratory report (blood or serum test), sometimes in history and physical or clinical statement in pathology report\n\n**Other names include** Human chorionic gonadotropin, b-hCG, beta subunit HCG, beta hCG, β-hCG\n\nFor further information, refer to the **Testis** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Testis*.\n\n**Normal Reference Range**\n * < 2 ng/ml (SI: < 2 µg/L or < 2 ug/L) 1 ng/ml of HCG is approximately 5 mIU/ml.\n * < 5 mIU/mL (< 5 IU/L) To record mIU/mL in ng/ml, divide the test result by 5.\n \n**Measurements** \n * A lab value expressed in International Units/liter (IU/L) is equivalent to the same value expressed in milli-International Units/milliliter (mIU/mL).", "rationale" : "hCG (Human Chorionic Gonadotropin) is a Registry Data Collection Variable in AJCC. hCG (Human Chorionic Gonadotropin) Pre-Orchiectomy Range is used to assign the S Category Clinical and was previously collected as Testis CS SSF #9." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/her2_ihc_summary_57693.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/her2_ihc_summary_57693.json index 345a8c16b..3a37f89f3 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/her2_ihc_summary_57693.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/her2_ihc_summary_57693.json @@ -6,7 +6,7 @@ "title" : "HER2 IHC Summary", "description" : "HER2 IHC Summary is the summary score for HER2 testing by IHC.\n\nThe simplest test used is the IHC (immunohistochemistry). An immunohistochemistry (IHC) test identifies the protein expressed by the gene (ERBB2), and an in-situ hybridization (ISH) test identifies the number of copies of the gene (ERBB2) itself. If the IHC test is borderline or indeterminate, an ISH (in situ hybridization) test may be performed. \n\nReporting Results of HER2 Testing by Immunohistochemistry (IHC)\n* Negative (Score 0): No staining observed or incomplete, faint/barely perceptible membrane staining in ≤10% of invasive tumor cells\n* Negative (Score 1+): Incomplete, faint/barely perceptible membrane staining in >10% of invasive tumor cells\n* Equivocal (Score 2+): Incomplete and/or weak to moderate circumferential membrane staining in >10% of invasive tumor cells or complete, intense, circumferential membrane staining in ≤10% of invasive tumor cells\n* Positive (Score 3+): Complete, intense, circumferential membrane staining in >10% of invasive tumor cells", "notes" : "**Note 1:** This SSDI is no longer required by any of the standard setters starting with 2021 diagnoses. \n* For cases diagnosed 2021+, this SSDI may be left blank\n\n**Note 2:** Physician statement of HER2 IHC Summary can be used to code this data item when no other information is available.\n\n**Note 3:** The HER2 IHC test performed on the primary breast tissue is to be recorded in this data item. \n\n**Note 4:** A 2+ (equivocal) finding by IHC should result in additional testing with ISH to determine gene copy number.\n\n**Note 5:** Do not use results from the following tests to record HER2 \n * MammaPrint\n * EndoPredict\n * PAM 50 (Prosigna)\n * Any other test that records HER2", - "last_modified" : "2024-03-28T19:51:11.442Z", + "last_modified" : "2025-11-05T21:00:44.030Z", "definition" : [ { "key" : "her2_ihc_summary", "name" : "Code", @@ -17,6 +17,6 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "0", "Negative (Score 0)" ], [ "1", "Negative (Score 1+)" ], [ "2", "Equivocal (Score 2+)\nStated as equivocal\nBorderline" ], [ "3", "Positive (Score 3+)\nStated as positive" ], [ "4", "Stated as negative, but score not stated " ], [ "7", "Test ordered, results not in chart" ], [ "8", "Not applicable: Information not collected for this case\n(If this item is required by your standard setter, use of code 8 will result in an edit error.)" ], [ "9", "Not documented in medical record\nCannot be determined (indeterminate)\nHER2 IHC Summary not assessed or unknown if assessed" ], [ "", "May be blank if diagnosis year is after 2020" ] ], - "additional_info" : "* **Source documents:** pathology report\n* **For further information,** refer to the **Breast Biomarker Reporting** cancer protocols published by the College of American Pathologists for the AJCC Staging System *Breast*", + "additional_info" : "* **Source documents:** pathology report\n* **For further information,** refer to the **Breast Biomarker Reporting** cancer protocols published by the College of American Pathologists for the AJCC Staging System *Breast*.", "rationale" : "HER2 IHC Summary is a Registry Data Collection Variable in AJCC. It is a new data item for cases diagnosed 1/1/2018+." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/her2_ish_dp_copy_no_89821.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/her2_ish_dp_copy_no_89821.json index bedbbd01b..7c398ad9b 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/her2_ish_dp_copy_no_89821.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/her2_ish_dp_copy_no_89821.json @@ -6,7 +6,7 @@ "title" : "HER2 ISH Dual Probe Copy Number", "description" : "HER2 in situ hybridization (ISH) Dual Probe Copy Number is the HER2 copy number based on a dual probe test.\n\nReporting Results of HER2 Testing by In Situ Hybridization (dual-probe assay)\n* Negative (not amplified): HER2/CEP17 ratio <2.0 AND average HER2 copy number <4.0 signals/cell\n* Equivocal: HER2/CEP17 ratio <2.0 AND average HER2 copy number ≥4.0 but <6.0 signals/cell\n* Positive (amplified): HER2/CEP17 ratio ≥2.0 (regardless of average HER2 copy number) or Average HER2 copy number ≥6.0 signals/cell (regardless of ratio)\n\nNote: TP52, SMSCR and RARA are gene that are also on chromosome 17. However, they are not close to the centromere, and thus can be used to assess borderline/equivocal fish results (ratios) when the centromeric probe for chromosome 17 (CEP17) performance may be problematic. Although these may be helpful in some cases, they are not the same as the CEP17 result or the ratio determined from CEP17. There should always be a prior CEP17 result when these other results are found in the chart. If one of these tests (TP52, SMSCR, RARA, or others) are used and a dual probe copy number/ratio are documented, record that result in the appropriate data item.\n* D17Z1 is the CEP17 probe used in the Vysis (Abbot) FISH kit. So, for the HER2 data items, D17Z1 and CEP17 are to be treated as the same thing.", "notes" : "**Note 1:** This SSDI is no longer required by any of the standard setters starting with 2021 diagnoses. \n* For cases diagnosed 2021+, this SSDI may be left blank\n\n**Note 2:** Physician statement of HER2 in situ hybridization (ISH) Dual Probe Copy Number can be used to code this data item.\n\n**Note 3:** A dual probe test will report average number or mean signals per cell for both HER2 and CEP17, the latter used as a control. Record the HER2 average number or mean signals per cells in this data item. The average number or mean signals per cells is also called the copy number.\n\n* ***Example:*** \n\n SISH RESULTS: FINAL HER2 IN SITU HYBRIDIZATION INTERPRETATION: EQUIVOCAL, INDETERMINATE. HER2 gene copy between 4 & 6 with HER2/CEP17 ratio <2. \n \n HER2/CEP17 RATIO: 4.26 / 3.13 = 1.36\n \n HER-2/neu SILVER IN SITU HYBRIDIZATION (SISH) \n HER-2neu gene (Inform HER2 DNA probe) \n Number of tumor cell nuclei counted: 120 \n Number of Her-2/neu gene copies: 511 \n Mean HER-2/neu gene copy number: 4.26\n \n CEP-17 SILVER IN SITU HYBRIDIZATION (SISH) \n CEP-17 (Inform Chromosome 17 probe) \n Number of cell nuclei counted: 60 \n Number of CEP-17 gene copies: 188 \n Mean CEP-17 gene copies/nucl: 3.13\n\n Code Dual Probe HER2 Copy Number: 4.2\n [Note: This is calculated by dividing 511 by 120]\n\n**Note 4:** **Registrars are not to calculate the copy number.**\n\n**Note 5:** Following ASCO-CAP guidelines, a 2+ (equivocal) finding by **immunohistochemistry (IHC)** should result in additional testing with ISH to determine gene copy number. \n\n**Note 6:** Any type of ISH test (e.g., FISH, CISH, SISH) can be used to code this data item. Code this data item using the same report used to record information in the related data item 3854: HER2 ISH Summary.\n\n**Note 7:** A HER2 ISH test may be called \"ERBB2.\" ERBB2 is the standard symbol for the gene 'erb-b2 receptor tyrosine kinase 2.' An IHC test identifies the protein expressed by the gene, and an ISH test identifies the gene itself.\n\n**Note 8:** If a HER2 ISH single probe copy number test is done, and the results are between 4 and 6 (equivocal), dual probe tests are recommended.\n\n**Note 9:** If the test results are presented to the hundredth decimal, ignore the hundredth decimal. Do NOT round.\n\n* ***Example:***\n Reported as 4.99, code as 4.9", - "last_modified" : "2024-03-08T16:22:06.540Z", + "last_modified" : "2025-11-05T21:00:27.763Z", "definition" : [ { "key" : "her2_ish_dp_copy_no", "name" : "Code", @@ -17,6 +17,6 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "0.0-99.9", "Reported HER2 copy number of 0.0-99.9" ], [ "XX.1", "Reported HER2 copy number of 100 or greater" ], [ "XX.7", "Test ordered, results not in chart" ], [ "XX.8", "Not applicable: Information not collected for this case\n(If this item is required by your standard setter, use of code XX.8 will result in an edit error.)" ], [ "XX.9", "Not documented in medical record\nCannot be determined (indeterminate)\nDual probe test not done; only single probe test performed\nHER2 ISH Dual Probe Copy Number not assessed or unknown if assessed" ], [ "", "May be blank if diagnosis year is after 2020" ] ], - "additional_info" : "* **Source documents:** pathology report\n* **For further information,** refer to the **Breast Biomarker Reporting** cancer protocols published by the College of American Pathologists for the AJCC Staging System *Breast*", + "additional_info" : "* **Source documents:** pathology report\n* **For further information,** refer to the **Breast Biomarker Reporting** cancer protocols published by the College of American Pathologists for the AJCC Staging System *Breast*.", "rationale" : "HER2 ISH Dual Probe Copy Number is a Registry Data Collection Variable in AJCC. It is a new data item for cases diagnosed 1/1/2018+." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/her2_ish_dual_probe_ration_4635.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/her2_ish_dual_probe_ration_4635.json index 04214821c..a15db9e8c 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/her2_ish_dual_probe_ration_4635.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/her2_ish_dual_probe_ration_4635.json @@ -5,8 +5,8 @@ "name" : "HER2 ISH DP Ratio", "title" : "HER2 ISH Dual Probe Ratio", "description" : "HER2 ISH Dual Probe Ratio is the summary score for HER2 testing using a dual probe. The test will report results for both HER2 and CEP17, the latter used as a control. The HER2/CEP17 ratio is reported.", - "notes" : "**Note 1:** This SSDI is no longer required by any of the standard setters starting with 2021 diagnoses. \n* For cases diagnosed 2021+, this SSDI may be left blank\n\n**Note 2:** Physician statement of HER2 in situ hybridization (ISH) Dual Probe Ratio can be used to code this data item.\n\n**Note 3:** A dual probe test will report results for both HER2 and CEP17, the latter used as a control. The HER2/CEP17 ratio will be reported. Record the ratio in this data item. \n\n* ***Example:*** \n\n SISH RESULTS: FINAL HER 2 IN SITU HYBRIDIZATION INTERPRETATION: EQUIVOCAL, INDETERMINATE. HER2 gene copy between 4 & 6 with HER2/CEP17 ratio <2. \n \n HER2/CEP17 RATIO: 4.26 / 3.13 = 1.36\n \n HER-2/neu SILVER IN SITU HYBRIDIZATION (SISH) \n HER-2neu gene (Inform HER2 DNA probe) \n Number of tumor cell nuclei counted: 120 \n Number of Her-2/neu gene copies: 511\n Mean HER-2/neu gene copy number: 4.26\n \n CEP-17 SILVER IN SITU HYBRIDIZATION (SISH) \n CEP-17 (Inform Chromosome 17 probe) \n Number of cell nuclei counted: 60\n Number of CEP-17 gene copies: 188\n Mean CEP-17 gene copies/nucl: 3.13\n Code Dual Probe HER2 Copy Number: 4.2\n\n Code Dual Probe Ratio: 1.3\n\n**Note 4:** **Registrars are not to calculate the ratio.**\n\n**Note 5:** Following ASCO-CAP guidelines, a 2+ (equivocal) finding by immunohistochemistry (IHC) should result in additional testing with ISH to determine gene copy number. \n\n**Note 6:** Any type of ISH test (e.g., FISH, CISH, SISH) can be used to code this data item. Code this data item using the same report used to record information in the related data item 3854: HER2 ISH Summary.\n\n**Note 7:** A HER2 ISH test may be called \"ERBB2.\" ERBB2 is the standard symbol for the gene 'erb-b2 receptor tyrosine kinase 2.' An IHC test identifies the protein expressed by the gene, and an ISH test identifies the gene itself.\n\n**Note 8:** If the test results are presented to the hundredth decimal, ignore the hundredth decimal. Do NOT round.\n\n* ***Example:*** \n Reported as 1.99, code as 1.9", - "last_modified" : "2024-03-08T16:23:06.437Z", + "notes" : "**Note 1:** This SSDI is no longer required by any of the standard setters starting with 2021 diagnoses. \n* For cases diagnosed 2021+, this SSDI may be left blank\n\n**Note 2:** Physician statement of HER2 in situ hybridization (ISH) Dual Probe Ratio can be used to code this data item.\n\n**Note 3:** A dual probe test will report results for both HER2 and CEP17, the latter used as a control. The HER2/CEP17 ratio will be reported. Record the ratio in this data item. \n\n* ***Example:*** \n\n SISH RESULTS: FINAL HER 2 IN SITU HYBRIDIZATION INTERPRETATION: EQUIVOCAL, INDETERMINATE. HER2 gene copy between 4 & 6 with HER2/CEP17 ratio <2. \n \n HER2/CEP17 RATIO: 4.26 / 3.13 = 1.36\n \n HER-2/neu SILVER IN SITU HYBRIDIZATION (SISH) \n HER-2neu gene (Inform HER2 DNA probe) \n Number of tumor cell nuclei counted: 120 \n Number of Her-2/neu gene copies: 511\n Mean HER-2/neu gene copy number: 4.26\n \n CEP-17 SILVER IN SITU HYBRIDIZATION (SISH) \n CEP-17 (Inform Chromosome 17 probe) \n Number of cell nuclei counted: 60\n Number of CEP-17 gene copies: 188\n Mean CEP-17 gene copies/nucl: 3.13\n Code Dual Probe HER2 Copy Number: 4.2\n\n Code Dual Probe Ratio: 1.3\n\n**Note 4:** **Registrars are not to calculate the ratio.**\n\n**Note 5:** Following ASCO-CAP guidelines, a 2+ (equivocal) finding by immunohistochemistry (IHC) should result in additional testing with ISH to determine gene copy number. \n\n**Note 6:** Any type of ISH test (e.g., FISH, CISH, SISH) can be used to code this data item. Code this data item using the same report used to record information in the related data item 3854: HER2 ISH Summary.\n\n**Note 7:** A HER2 ISH test may be called \"ERBB2.\" ERBB2 is the standard symbol for the gene 'erb-b2 receptor tyrosine kinase 2.' An IHC test identifies the protein expressed by the gene, and an ISH test identifies the gene itself.\n\n**Note 8:** If the test results are presented to the hundredth decimal, ignore the hundredth decimal. Do NOT round.\n\n* ***Example:*** \n\n * Reported as 1.99, code as 1.9", + "last_modified" : "2025-11-06T22:03:04.189Z", "definition" : [ { "key" : "her2_ish_dp_ratio", "name" : "Code", @@ -17,6 +17,6 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "0.0-99.9", "Ratio of 0.0 to 99.9 " ], [ "XX.2", "Less than 2.0" ], [ "XX.3", "Greater than or equal to 2.0" ], [ "XX.7", "Test ordered, results not in chart" ], [ "XX.8", "Not applicable: Information not collected for this case\n(If this item is required by your standard setter, use of code XX.8 will result in an edit error.)" ], [ "XX.9", "Not documented in medical record\nResults cannot be determined (indeterminate)\nDual probe test not done; only single probe test performed\nHER2 ISH dual probe ratio not assessed or unknown if assessed" ], [ "", "May be blank if diagnosis year is after 2020" ] ], - "additional_info" : "* **Source documents:** pathology report\n* **For further information,** refer to the **Breast Biomarker Reporting** cancer protocols published by the College of American Pathologists for the AJCC Staging System *Breast*", + "additional_info" : "* **Source documents:** pathology report\n* **For further information,** refer to the **Breast Biomarker Reporting** cancer protocols published by the College of American Pathologists for the AJCC Staging System *Breast*.", "rationale" : "HER2 ISH Dual Probe Ratio is a Registry Data Collection Variable in AJCC. It is a new data item for cases diagnosed 1/1/2018+." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/her2_ish_sp_copy_no_95955.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/her2_ish_sp_copy_no_95955.json index 175e4583f..13ae1f61c 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/her2_ish_sp_copy_no_95955.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/her2_ish_sp_copy_no_95955.json @@ -5,8 +5,8 @@ "name" : "HER2 ISH SP Copy No", "title" : "HER2 ISH Single Probe Copy Number", "description" : "HER2 in situ hybridization (ISH) Single Probe Copy Number is the HER2 copy number based on a single probe test.\n\nReporting Results of HER2 Testing by In Situ Hybridization (single-probe assay)\n* Negative (not amplified): Average HER2 copy number <4.0 signals/cell\n* Equivocal: Average HER2 copy number ≥4.0 and <6.0 signals/cell\n* Positive (amplified): Average HER2 copy number ≥6.0 signals/cell", - "notes" : "**Note 1:** This SSDI is no longer required by any of the standard setters starting with 2021 diagnoses. \n* For cases diagnosed 2021+, this SSDI may be left blank\n\n**Note 2:** Physician statement of HER2 in situ hybridization (ISH) Single Probe Copy Number can be used to code this data item.\n\n**Note 3:** A single probe test will report average number or mean signals per cell for HER2. Record the HER2 average number or mean signals per cells in this data item. The average number or mean signals per cell is also called the copy number.\n\n* ***Example:*** \n\n SISH RESULTS: FINAL HER 2 IN SITU HYBRIDIZATION INTERPRETATION: POSITIVE (>6 gene copies) HER-2/neu gene amplification. \n \n HER-2/neu SILVER IN SITU HYBRIDIZATION (SISH) \n HER-2neu gene (Inform HER2 DNA probe) \n Number of tumor cell nuclei counted: 60\n Number of Her-2/neu gene copies: 418\n Mean HER-2/neu gene copy number: 6.9\n\n Code Single Probe HER2 Copy Number: 6.9\n [Note: This is calculated by dividing 418 by 60]\n\n**Note 4:** **Registrars are not to calculate the copy number.** \n\n**Note 5:** Following ASCO-CAP guidelines, a 2+ (equivocal) finding by immunohistochemistry (IHC) should result in additional testing with ISH to determine gene copy number. \n\n**Note 6:** Any type of ISH test (e.g., FISH, CISH, SISH) can be used to code this data item. Code this data item using the same report used to record information in the related data item 3854: HER2 ISH Summary.\n\n**Note 7:** A HER2 ISH test may be called \"ERBB2.\" ERBB2 is the standard symbol for the gene 'erb-b2 receptor tyrosine kinase 2.' An IHC test identifies the protein expressed by the gene, and an ISH test identifies the gene itself.\n\n**Note 8:** If a HER2 ISH single probe copy number test is done, and the results are between 4 and 6 (equivocal), dual probe tests are recommended.\n\n**Note 9:** If the test results are presented to the hundredth decimal, ignore the hundredth decimal. Do NOT round.\n\n* ***Example:***\n Reported as 6.97, code 6.9", - "last_modified" : "2025-03-21T18:18:51.836Z", + "notes" : "**Note 1:** This SSDI is no longer required by any of the standard setters starting with 2021 diagnoses. \n* For cases diagnosed 2021+, this SSDI may be left blank\n\n**Note 2:** Physician statement of HER2 in situ hybridization (ISH) Single Probe Copy Number can be used to code this data item.\n\n**Note 3:** A single probe test will report average number or mean signals per cell for HER2. Record the HER2 average number or mean signals per cells in this data item. The average number or mean signals per cell is also called the copy number.\n\n* ***Example:*** \n\n SISH RESULTS: FINAL HER 2 IN SITU HYBRIDIZATION INTERPRETATION: POSITIVE (>6 gene copies) HER-2/neu gene amplification. \n \n HER-2/neu SILVER IN SITU HYBRIDIZATION (SISH) \n HER-2neu gene (Inform HER2 DNA probe) \n Number of tumor cell nuclei counted: 60\n Number of Her-2/neu gene copies: 418\n Mean HER-2/neu gene copy number: 6.9\n\n Code Single Probe HER2 Copy Number: 6.9\n [Note: This is calculated by dividing 418 by 60]\n\n**Note 4:** **Registrars are not to calculate the copy number.** \n\n**Note 5:** Following ASCO-CAP guidelines, a 2+ (equivocal) finding by immunohistochemistry (IHC) should result in additional testing with ISH to determine gene copy number. \n\n**Note 6:** Any type of ISH test (e.g., FISH, CISH, SISH) can be used to code this data item. Code this data item using the same report used to record information in the related data item 3854: HER2 ISH Summary.\n\n**Note 7:** A HER2 ISH test may be called \"ERBB2.\" ERBB2 is the standard symbol for the gene 'erb-b2 receptor tyrosine kinase 2.' An IHC test identifies the protein expressed by the gene, and an ISH test identifies the gene itself.\n\n**Note 8:** If a HER2 ISH single probe copy number test is done, and the results are between 4 and 6 (equivocal), dual probe tests are recommended.\n\n**Note 9:** If the test results are presented to the hundredth decimal, ignore the hundredth decimal. Do NOT round.\n\n* ***Example:***\n\n * Reported as 6.97, code 6.9", + "last_modified" : "2025-11-06T22:03:28.201Z", "definition" : [ { "key" : "her2_ish_sp_copy_no", "name" : "Code", @@ -17,6 +17,6 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "0.0-99.9", "Reported HER2 copy number of 0.0-99.9" ], [ "XX.1", "Reported HER2 copy number of 100 or greater" ], [ "XX.7", "Test ordered, results not in chart" ], [ "XX.8", "Not applicable: Information not collected for this case\n(If this item is required by your standard setter, use of code XX.8 will result in an edit error.)" ], [ "XX.9", "Not documented in medical record\nCannot be determined (indeterminate)\nSingle probe test not done; only dual probe test performed\nHER2 ISH Single Probe Copy Number not assessed or unknown if assessed" ], [ "", "May be blank if diagnosis year is after 2022" ] ], - "additional_info" : "* **Source documents:** pathology report\n* **For further information,** refer to the **Breast Biomarker Reporting** cancer protocols published by the College of American Pathologists for the AJCC Staging System *Breast*", + "additional_info" : "* **Source documents:** pathology report\n* **For further information,** refer to the **Breast Biomarker Reporting** cancer protocols published by the College of American Pathologists for the AJCC Staging System *Breast*.", "rationale" : "HER2 ISH Single Probe Copy Number is a Registry Data Collection Variable in AJCC. It is a new data item for cases diagnosed 1/1/2018+." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/her2_ish_summary_40783.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/her2_ish_summary_40783.json index eaf5df7b9..d7ed05626 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/her2_ish_summary_40783.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/her2_ish_summary_40783.json @@ -6,7 +6,7 @@ "title" : "HER2 ISH Summary", "description" : "HER2 in situ hybridization (ISH) Summary is the summary score for results of testing for ERBB2 gene copy number by any ISH method. An immunohistochemistry (IHC) test identifies the protein expressed by the gene (ERBB2), and an ISH test identifies the number of copies of the gene (ERBB2) itself.\n\nIf an Immunochemistry (IHC) test is borderline or indeterminate, an ISH test may be performed. The ISH test is a method of testing for overexpression of the HER2 gene that uses fluorescent pieces of DNA that attach only to the HER2 gene copies in cells, which can then be counted under a special microscope. ISH studies determine the presence or absence of gene amplification and methods include fluorescence in situ hybridization (FISH), chromogenic in situ hybridization (CISH), and silver-enhanced in situ hybridization (SISH). Some assays use a single probe to determine the number of HER2 gene copies present (single-probe assays) and others include a chromosome enumeration probe (CEP17) to determine the ratio of HER2 signals to copies of chromosome 17 (dual-probe assays). \n\nResults from single probe and dual probe ISH tests are reported differently and are collected in different data items. For dual probe tests, both HER2/CEP17 ratio and HER2 copy number results are collected in separate data items.", "notes" : "**Note 1:** This SSDI is no longer required by any of the standard setters starting with 2021 diagnoses. \n* For cases diagnosed 2021+, this SSDI may be left blank\n\n**Note 2:** Physician statement of HER2 in situ hybridization (ISH) Summary can be used to code this data item when no other information is available.\n\n**Note 3:** The HER2 ISH test performed on the primary breast tissue is to be recorded in this data item. \n\n**Note 4:** Any type of ISH test (e.g., FISH, CISH, SISH) can be used to code this data item. The same test should be used to code all the HER2 ISH data items.", - "last_modified" : "2024-03-28T19:51:34.873Z", + "last_modified" : "2025-11-05T21:00:38.926Z", "definition" : [ { "key" : "her2_ish_summary", "name" : "Code", @@ -17,6 +17,6 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "0", "Negative [not amplified]" ], [ "2", "Equivocal " ], [ "3", "Positive [amplified]" ], [ "7", "Test ordered, results not in chart" ], [ "8", "Not applicable: Information not collected for this case\n(If this item is required by your standard setter, use of code 8 will result in an edit error.)" ], [ "9", "Not documented in medical record\nResults cannot be determined (indeterminate)\nBorderline\nHER2 ISH Summary not assessed or unknown if assessed" ], [ "", "May be blank if diagnosis year is after 2020" ] ], - "additional_info" : "* **Source documents:** pathology report\n* **For further information,** refer to the **Breast Biomarker Reporting** cancer protocols published by the College of American Pathologists for the AJCC Staging System *Breast*", + "additional_info" : "* **Source documents:** pathology report\n* **For further information,** refer to the **Breast Biomarker Reporting** cancer protocols published by the College of American Pathologists for the AJCC Staging System *Breast*.", "rationale" : "HER2 ISH Summary is a Registry Data Collection Variable in AJCC. It is a new data item for cases diagnosed 1/1/2018+." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/her2_summary_30512.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/her2_summary_30512.json index 71adcb6e7..649a3dedb 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/her2_summary_30512.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/her2_summary_30512.json @@ -4,9 +4,9 @@ "version" : "3.3", "name" : "HER2 Summary", "title" : "HER2 Overall Summary", - "description" : "HER2 Overall Summary is a summary of results from HER2 testing.\n\nA subset of breast carcinomas (approximately 15% to 20%) overexpress human epidermal growth factor receptor 2 (HER2). The presence of HER2 overexpression in untreated patients is associated with worse prognosis in both node-negative and node-positive patients. Protein overexpression is usually due to HER2 gene amplification. The HER2 protein may also be referred to as ERBB2 and the HER2 gene may also be referred to as the ERBB2 gene.\nThe development of HER-2 targeting agents for the treatment of HER2 positive breast cancer has dramatically improved outcomes for patients with HER2 positive breast cancers. HER2 status is primarily evaluated to determine patient eligibility for anti-HER2 therapy.", - "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of HER2 Overall Summary status can be used to code this data item when no other information is available.\n\n**Note 2:** **In-situ and Invasive components present**\n* If HER2 is positive on an in-situ component and HER2 is negative on all tested invasive components in the primary tumor, code HER2 as negative (code 0)\n* If in situ and invasive components present and HER2 only done on the in-situ component in the primary tumor, code unknown (code 9)\n\n**Note 3:** **Single tumor, multiple biopsies or surgical resection, different results**\n* Use the highest (positive versus negative)\n\n**Note 4:** **Multiple tumors, different results**\n* Code the results from the largest tumor size (determined either clinically or pathologically) when multiple tumors are present.\n * Do not use specimen size to determine the largest tumor size\n\n**Note 5:** **Results from nodal or metastatic tissue**\n* May be used, ONLY when there is no evidence of primary tumor\n * **Note:** In-situ is evidence of primary tumor\n\n**Note 6:** **Neoadjuvant Therapy**\n* Record the assay from tumor specimens prior to neoadjuvant therapy.\n* If neoadjuvant therapy is given and there are no ER results from pre-treatment specimens, report the findings from post-treatment specimens\n\n**Note 7:** **HER2 Positive and Oncotype**\n* In some cases, the Oncotype DX report may include a quantitative HER2 result. However, this value from the OncotypeDx report should not be recorded in the registry.\n* The HER2 result recorded should be from the physician report based on the IHC and/or ISH as described for this element.\n\n\n\n**Note 8:** **HER2 and in situ tumors**\n * HER2 is not routinely done on pure in situ tumors (behavior /2); however, if you have an in-situ tumor and there are HER2 results, go ahead and record it. Otherwise, code 9", - "last_modified" : "2025-07-07T15:56:13.853Z", + "description" : "HER2 Overall Summary is a summary of results from HER2 testing.\n\nA subset of breast carcinomas (approximately 15% to 20%) overexpress human epidermal growth factor receptor 2 (HER2). The presence of HER2 overexpression in untreated patients is associated with worse prognosis in both node-negative and node-positive patients. Protein overexpression is usually due to HER2 gene amplification. The HER2 protein may also be referred to as ERBB2 and the HER2 gene may also be referred to as the ERBB2 gene.\n\nThe development of HER-2 targeting agents for the treatment of HER2 positive breast cancer has dramatically improved outcomes for patients with HER2 positive breast cancers. HER2 status is primarily evaluated to determine patient eligibility for anti-HER2 therapy.", + "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of HER2 Overall Summary status can be used to code this data item when no other information is available.\n\n**Note 2:** **In-situ and Invasive components present**\n* If HER2 is positive on an in-situ component and HER2 is negative on all tested invasive components in the primary tumor, code HER2 as negative (code 0)\n* If in situ and invasive components present and HER2 only done on the in-situ component in the primary tumor, code unknown (code 9)\n\n**Note 3:** **Single tumor, multiple biopsies or surgical resection, different results**\n* Use the highest (positive versus negative)\n\n**Note 4:** **Multiple tumors, different results**\n* Code the results from the largest tumor size (determined either clinically or pathologically) when multiple tumors are present.\n * Do not use specimen size to determine the largest tumor size\n\n**Note 5:** **Results from nodal or metastatic tissue**\n* May be used, ONLY when there is no evidence of primary tumor\n * **Note:** In-situ is evidence of primary tumor\n\n**Note 6:** **Neoadjuvant Therapy**\n* Record the assay from tumor specimens prior to neoadjuvant therapy.\n* If neoadjuvant therapy is given and there are no ER results from pre-treatment specimens, report the findings from post-treatment specimens\n\n**Note 7:** **HER2 Positive and Oncotype**\n* In some cases, the Oncotype DX report may include a quantitative HER2 result. However, this value from the OncotypeDx report should not be recorded in the registry.\n* The HER2 result recorded should be from the physician report based on the IHC and/or ISH as described for this element.\n\n**Note 8:** **HER2 and in situ tumors**\n * HER2 is not routinely done on pure in situ tumors (behavior /2); however, if you have an in-situ tumor and there are HER2 results, go ahead and record it. Otherwise, code 9", + "last_modified" : "2025-11-06T18:51:37.350Z", "definition" : [ { "key" : "her2_summary", "name" : "Code", @@ -17,7 +17,7 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "0", "HER2 negative; equivocal" ], [ "1", "HER2 positive" ], [ "7", "Test ordered, results not in chart" ], [ "9", "Not documented in medical record\nCannot be determined (indeterminate)\nBorderline\nHER2 Overall Summary status not assessed or unknown if assessed" ] ], - "additional_info" : "**Source documents:** pathology report\n\nFor further information, refer to the **Breast Biomarker Reporting** cancer protocols published by the College of American Pathologists for the AJCC Staging System *Breast*", - "coding_guidelines" : "Record the pathologist’s interpretation of the HER2 test from the primary tumor specimen. \n\n**1)** **Code 0** when the HER2 is reported as negative or normal\n**2)** **Code 1** when the HER2 is reported as positive or elevated\n**3)** **Code 7** when the HER2 test was ordered but the results are not available\n**4)** **Code 9** when the HER2 is\n* Reported as borderline; undetermined whether positive or negative \n* Cannot be determined by the pathologist (e.g., inadequate specimen)\n* It is unknown whether the HER2 test was performed\n* The patient has only a clinical diagnosis of breast cancer (no tissue diagnosis)", + "additional_info" : "**Source documents:** pathology report\n\nFor further information, refer to the **Breast Biomarker Reporting** cancer protocols published by the College of American Pathologists for the AJCC Staging System *Breast*.", + "coding_guidelines" : "Record the pathologist’s interpretation of the HER2 test from the primary tumor specimen. \n\n**1)** **Code 0** when the HER2 is reported as negative or normal\n\n**2)** **Code 1** when the HER2 is reported as positive or elevated\n\n**3)** **Code 7** when the HER2 test was ordered but the results are not available\n\n**4)** **Code 9** when the HER2 is\n* Reported as borderline; undetermined whether positive or negative \n* Cannot be determined by the pathologist (e.g., inadequate specimen)\n* It is unknown whether the HER2 test was performed\n* The patient has only a clinical diagnosis of breast cancer (no tissue diagnosis)", "rationale" : "This data item is required for prognostic stage grouping in AJCC 8th edition, Chapter 48 Breast. It was previously collected as Breast, CS SSF # 15. Experts recommend that every invasive breast cancer be tested for the presence of HER2 because anti-HER2 treatments are highly effective for these tumors." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/heritable_trait_49734.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/heritable_trait_49734.json index 9e49856d2..685af72e4 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/heritable_trait_49734.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/heritable_trait_49734.json @@ -6,7 +6,7 @@ "title" : "Heritable Trait", "description" : "Heritable trait pertains to evidence that a tumor is associated with a heritable mutation. In retinoblastoma, the heritable trait is a germline mutation in the RB1 gene, which is associated with bilateral disease, family history of retinoblastoma, presence of concomitant CNS midline embryonic tumor (commonly in pineal region), or retinoblastoma with an intracranial primitive neuroectodermal tumor (i.e., trilateral retinoblastoma). Children with any of these features may be assigned the H1 status without molecular testing. High quality molecular testing for RB1 mutation is required to determine the presence or absence of RB1 mutation for children without clinical features of a heritable mutation.\n\nHeritable disease (trait) is defined by the presence of a germline mutation of the RB1 gene. This germline mutation may have been inherited from an affected progenitor (25% of cases) or may have occurred in a germ cell before conception or in utero during early embryogenesis in patients with sporadic disease (75% of cases). The presence of positive family history or bilateral or multifocal disease is suggestive of heritable disease. \n\nHeritable retinoblastoma may manifest as unilateral or bilateral disease. The penetrance of the RB1 mutation (laterality, age at diagnosis, and number of tumors) is probably dependent on concurrent genetic modifiers such as MDM2 and MDM4 polymorphisms. All children with bilateral disease and approximately 15% of patients with unilateral disease are presumed to have the heritable form, even though only 25% have an affected parent.\n\nIn heritable retinoblastoma, tumors tend to be diagnosed at a younger age than in the nonheritable form of the disease. Unilateral retinoblastoma in children younger than 1 year raises concern for heritable disease, whereas older children with a unilateral tumor are more likely to have the nonheritable form of the disease.\n\nChildren with a germline RB1 mutation may continue to develop new tumors for a few years after diagnosis and treatment; for this reason, they need to be examined frequently. It is common practice for examinations to occur every 2 to 4 months for at least 28 months. The interval between exams is based on the stability of the disease and age of the child (i.e., less frequent visits as the child ages).\n\nPatients with heritable retinoblastoma are also at a greater risk for subsequent neoplasms.\n\nHeritable trait is required for prognostic stage grouping in the AJCC Staging System Retinoblastoma. It is a new data item for cases diagnosed 1/1/2018+.", "notes" : "**Note:** **Physician Statement** \n* Physician statement of retinoblastoma heritable trait can be used to code this data item when no other information is available.", - "last_modified" : "2025-02-24T14:29:04.659Z", + "last_modified" : "2025-11-06T16:10:33.293Z", "definition" : [ { "key" : "heritable_trait", "name" : "Code", @@ -17,7 +17,7 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "0", "H0: Normal RB1 alleles\nNo clinical evidence of mutation" ], [ "1", "H1: RB1 gene mutation OR \nClinical evidence of mutation" ], [ "7", "Test ordered, results not in chart" ], [ "9", "HX: Not documented in medical record\nTest not done, or unknown if done\nInsufficient evidence of a constitutional RB1 gene mutation" ] ], - "additional_info" : "**Source documents:** pathology report (tissue), lab reports (blood)\n\n**Definition of Heritable trait (H)** is listed in the AJCC 8th edition Chapter 68: *Retinoblastoma*\n\nFor further information, refer to the **Retinoblastoma** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Retinoblastoma*", + "additional_info" : "**Source documents:** pathology report (tissue), lab reports (blood)\n\n**Definition of Heritable trait (H)** is listed in the AJCC 8th edition Chapter 68: *Retinoblastoma*.\n\nFor further information, refer to the **Retinoblastoma** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Retinoblastoma*.", "coding_guidelines" : "**1)** **Code 0** (H0) when\n* If clinical features do not exist OR \n* Laboratory germline RB1 test is negative OR \n* There is no clinical evidence of mutation\n* Residual (false negative) risk for a mutation is less than 1% or at population risk (0.007%) in a laboratory with demonstrated sensitivity greater than 97%.\n\n**2)** **Code 1** (H1) when\n* Positive molecular testing for germline RB1 gene\n* May be assigned based on clinical evidence of any of the following features even without molecular testing (in particular for children). When discrete clinical evidence of heritable trait is not present, high-quality molecular evidence is mandatory before designating a child as H1 positive\n * Bilateral disease \n * Family history of retinoblastoma\n * Presence of concomitant CNS midline embryonic tumor (commonly in pineal region)\n * Retinoblastoma with an intracranial primitive neuroectodermal tumor (i.e., trilateral retinoblastoma)\n\n**3)** **Code 9** (HX) when\n* Results are stated as variants of unknown significance \n* Insufficient evidence of a constitutional RB1 gene mutation\n* Not documented in medical record", "rationale" : "Heritable trait is required for prognostic stage grouping in AJCC 8th edition, Chapter 68 Retinoblastoma. It is a new data item for cases diagnosed 1/1/2018+." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/high_risk_cytogenetics_97806.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/high_risk_cytogenetics_97806.json index 4e4188dad..0b897df18 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/high_risk_cytogenetics_97806.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/high_risk_cytogenetics_97806.json @@ -4,9 +4,9 @@ "version" : "3.3", "name" : "High Risk Cytogenetics", "title" : "High Risk Cytogenetics", - "description" : "High Risk Cytogenetics is defined as one or more of t(4;14), t(14;16), or del 17p identified from FISH test results and is part of the staging criteria for plasma cell myeloma.\n\nThe Revised International Staging System (R-ISS or RISS) is now used to stage plasma cell myeloma (9732/3), using several different criteria. The stages are based on the absence or presence of the following related criteria. \n* 3931: Serum Beta-2 Microglobulin Pretreatment Level\n* 3930: Serum Albumin Pretreatment Level\n* 3857: High Risk Cytogenetics\n* 3869: LDH Level\n\nRequired for Staging: The AJCC Staging System Plasma Cell Myeloma and Plasma Cell Disorders (9732/3 only) and EOD. \n* Note: R-ISS stage is not applicable for the descriptions of plasma multiple myeloma that are listed in the codes 1 and 9 in the SSDI Schema Discriminator 1: Plasma Cell Myeloma Terminology. If you have coded 1 or 9 for this Schema Discriminator, the four data items listed above are BLANK.\n\nThe R-ISS stages are\n* Stage I: Serum Beta-2-microglobulin <3.5 mg/L and serum albumin > 3.5 g/dL and no high-risk cytogenetics and Normal LDH\n* Stage II: Not R-ISS I or III\n* Stage III: Serum Beta-2-microglobulin > 5.5 mg/L and high-risk cytogenetics and/or high LDH", + "description" : "High Risk Cytogenetics is defined as one or more of t(4;14), t(14;16), or del 17p identified from FISH test results and is part of the staging criteria for plasma cell myeloma.\n\nThe Revised International Staging System (R-ISS or RISS) is now used to stage plasma cell myeloma (9732/3), using several different criteria. The stages are based on the absence or presence of the following related criteria. \n* 3931: Serum Beta-2 Microglobulin Pretreatment Level\n* 3930: Serum Albumin Pretreatment Level\n* 3857: High Risk Cytogenetics\n* 3869: LDH Level\n\nRequired for Staging: The AJCC Staging System Plasma Cell Myeloma and Plasma Cell Disorders (9732/3 only) and EOD. \n* **Note:** R-ISS stage is not applicable for the descriptions of plasma multiple myeloma that are listed in the codes 1 and 9 in the SSDI Schema Discriminator 1: Plasma Cell Myeloma Terminology. If you have coded 1 or 9 for this Schema Discriminator, the four data items listed above are BLANK.\n\nThe R-ISS stages are\n* Stage I: Serum Beta-2-microglobulin <3.5 mg/L and serum albumin > 3.5 g/dL and no high-risk cytogenetics and Normal LDH\n* Stage II: Not R-ISS I or III\n* Stage III: Serum Beta-2-microglobulin > 5.5 mg/L and high-risk cytogenetics and/or high LDH", "notes" : "**Note 1:** **Physician statement**\n* Physician statement of presence or absence of high-risk cytogenetics can be used to code this data item when no other information is available\n* Record this data item based on physician statement or FISH test interpretation performed at diagnosis (pre-treatment).\n* If the presence/absence of high-risk cytogenetics determined by available test results differs from the physician statement of presence/absence, the physician's statement takes precedence.\n\n**Note 2:** **Component of RISS Stage**\n * High-risk cytogenetics is part of the Revised International Staging (R-ISS). \n * **Code 0** if physician states **RISS Stage 1 or 2** and there is no other information", - "last_modified" : "2025-06-05T12:57:27.982Z", + "last_modified" : "2025-11-06T21:58:45.300Z", "definition" : [ { "key" : "high_risk_cytogenetics", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/high_risk_features_73750.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/high_risk_features_73750.json index 8d2330619..d6318a025 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/high_risk_features_73750.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/high_risk_features_73750.json @@ -4,9 +4,9 @@ "version" : "3.3", "name" : "High Risk Features", "title" : "High Risk Histologic Features", - "description" : "High Risk Histologic Features are defined in AJCC 8 Chapter 15 to include the terms “poor differentiation, desmoplasia, sarcomatoid differentiation, undifferentiated.” High risk histologic features are a prognostic factor for cutaneous cell carcinomas of the head and neck.\n\nIn addition to the tumor size (diameter, not depth), the presence of certain specific high-risk features is of prognostic significance for skin cancers of the head and neck.", - "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of high-risk histologic features can be used to code this data item when no other information is available.\n\n**Note 2:** **High risk histologic features include** \n* Desmoplasia\n* Poor differentiation (grade 3)\n* Sarcomatoid differentiation (features)\n* Undifferentiated (grade 4)", - "last_modified" : "2025-02-24T13:26:58.694Z", + "description" : "High Risk Histologic Features are defined in AJCC 8 Chapter 15 to include the terms “poor differentiation, desmoplasia, sarcomatoid differentiation, undifferentiated.” High risk histologic features are a prognostic factor for cutaneous cell carcinomas of the head and neck.\n\nIn addition to the tumor size (diameter, not depth), the presence of certain specific high risk features is of prognostic significance for skin cancers of the head and neck.", + "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of high risk histologic features can be used to code this data item when no other information is available.\n\n**Note 2:** **High risk histologic features include** \n* Desmoplasia\n* Poor differentiation (grade 3)\n* Sarcomatoid differentiation (features)\n* Undifferentiated (grade 4)", + "last_modified" : "2025-11-06T17:22:37.270Z", "definition" : [ { "key" : "high_risk_features", "name" : "Code", @@ -17,7 +17,7 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "0", "No high risk histologic features\nNon-invasive neoplasm (behavior /2)" ], [ "1", "Desmoplasia" ], [ "2", "Poor differentiation (grade 3)" ], [ "3", "Sarcomatoid differentiation" ], [ "4", "Undifferentiated (grade 4)" ], [ "5", "Multiple high risk histologic features" ], [ "6", "Histologic features, NOS (type of high risk histologic feature not specified)" ], [ "8", "Not applicable: Information not collected for this case\n(If this information is required by your standard setter, use of code 8 may result in an edit error)" ], [ "9", "Not documented in medical record\nHigh risk histologic features not assessed or unknown if assessed" ] ], - "additional_info" : "**Source documents** pathology report, consultation report, other statements in the medical record\n\n**Other names include** high risk histologic features, high risk tumor features\n\nFor further information, refer to the **Cutaneous Carcinoma of Head and Neck** cancer protocols published by the College of American Pathologist for the AJCC Staging Systems for *Cutaneous Carcinoma of Head and Neck*", - "coding_guidelines" : "**1)** Code the presence or absence of high-risk histologic features as documented in the pathology report.\n**2)** **Code 1** for desmoplasia\n**3)** **Code 2** for poor differentiation (grade 3)\n**4)** **Code 3** for sarcomatoid differentiation (features)\n**5)** **Code 4** for undifferentiated (grade 4)\n**6)** **Code 5** when more than one high-risk feature is present\n**7)** **Code 6** when high risk features are present, but it is not specified which one\n**8)** **Code 9** when\n * Not documented in medical record\n * High risk features not evaluated (assessed)\n * Unknown if high-risk features evaluated (assessed)", + "additional_info" : "**Source documents** pathology report, consultation report, other statements in the medical record\n\n**Other names include** high risk histologic features, high risk tumor features\n\nFor further information, refer to the **Cutaneous Carcinoma of Head and Neck** cancer protocols published by the College of American Pathologist for the AJCC Staging Systems for *Cutaneous Carcinoma of Head and Neck*.", + "coding_guidelines" : "**1)** Code the presence or absence of high risk histologic features as documented in the pathology report.\n\n**2)** **Code 1** for desmoplasia\n\n**3)** **Code 2** for poor differentiation (grade 3)\n\n**4)** **Code 3** for sarcomatoid differentiation (features)\n\n**5)** **Code 4** for undifferentiated (grade 4)\n\n**6)** **Code 5** when more than one high risk feature is present\n\n**7)** **Code 6** when high risk features are present, but it is not specified which one\n\n**8)** **Code 9** when\n * Not documented in medical record\n * High risk features not evaluated (assessed)\n * Unknown if high risk features evaluated (assessed)", "rationale" : "High Risk Histologic Features is a Registry Data Collection Variable in AJCC. It was previously collected as Skin, CS SSF # 12." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/histologic_subtype_8603.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/histologic_subtype_8603.json index c716cfa81..c49782499 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/histologic_subtype_8603.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/histologic_subtype_8603.json @@ -4,9 +4,9 @@ "version" : "3.3", "name" : "Histologic Subtype", "title" : "Histologic Subtype", - "description" : "Histology code for appendiceal tumors (8480) is defined as “Mucinous Adenocarcinoma (in situ or invasive).” In addition, there are also low-grade appendiceal mucinous neoplasm (LAMN) and high-grade appendiceal mucinous neoplasm (HAMN) diagnoses that are assigned the same histology.", + "description" : "Histology code for appendiceal tumors (8480) is defined as “Mucinous Adenocarcinoma (in situ or invasive)”. In addition, there are also low-grade appendiceal mucinous neoplasm (LAMN) and high-grade appendiceal mucinous neoplasm (HAMN) diagnoses that are assigned the same histology.", "notes" : "**Note 1:** **Effective years**\n* This SSDI is effective for diagnosis years 2023+\n* For cases diagnosed 2018-2022, this SSDI must be blank\n\n**Note 2:** **Determining histology** \n* Use the **Solid Tumor Rules** to determine histology prior to coding this SSDI.\n* Histology 8480/2 or 8480/3 have multiple definitions that are collected in this histology. \n* This data item is used to further identify specific subtypes for histology code 8480/2 or 8480/3.", - "last_modified" : "2024-04-08T15:38:56.654Z", + "last_modified" : "2025-11-06T17:49:57.987Z", "definition" : [ { "key" : "histologic_subtype", "name" : "Code", @@ -17,7 +17,7 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "0", "Histology is NOT 8480" ], [ "1", "Low-grade appendiceal mucinous neoplasm\nLAMN" ], [ "2", "High-grade appendiceal mucinous neoplasm\nHAMN" ], [ "3", "Mucinous Adenocarcinoma/carcinoma\nMucus Adenocarcinoma/carcinoma\nMucoid adenocarcinoma/carcinoma\nColloid adenocarcinoma/carcinoma" ], [ "4", "Other terminology coded to 8480" ], [ "", "NA-Diagnosis year is prior to 2023" ] ], - "additional_info" : "**Source documents:** pathology report, Solid Tumor Rules\n\nFor further information, refer to the **Appendix** cancer protocol published by the College of American Pathologist for the AJCC Staging System *Appendix, Version 9*", - "coding_guidelines" : "***Examples:***\n**1.** Appendix: Disseminated peritoneal adenomucinous/low grade mucinous carcinoma peritonei. Final diagnosis: Low grade appendiceal mucinous neoplasm\n * **Code 1**: This is a low grade mucinous (appendiceal) carcinoma (8480/3), which is LAMN. The peritoneal adenomucinous/low grade mucinous carcinoma peritonei is describing metastatic disease and not the histology\n\n**2.** Appendix: Low grade (well diff) appendiceal adenocarcinoma\n * **Code 0**: This is an adenocarcinoma (8140/3), the low grade (well diff) is describing the grade and not the histology\n\n**3.** Appendix, appendectomy: Low grade appendiceal mucinous neoplasm (LAMN) with focal high grade mucinous neoplasm.\n * **Code 1**: Based on the Solid Tumor Rules, the “focal” would be ignored and this would be a LAMN.\n\n**4.** Appendectomy: Mucinous adenocarcinoma of the appendix\n * **Code 3**: Mucinous adenocarcinoma is the preferred terminology for histology code 8480/3. Since there is no mention of “low grade” or “high grade”, this would not be LAMN or HAMN\n\n**5.** Appendix: Mucinous (colloid) adenocarcinoma\n * **Code 3**: Colloid adenocarcinoma is an alternate name for 8480/3", + "additional_info" : "**Source documents:** pathology report, Solid Tumor Rules\n\nFor further information, refer to the **Appendix** cancer protocol published by the College of American Pathologist for the AJCC Staging System *Appendix, Version 9*.", + "coding_guidelines" : "***Examples:***\n\n**1.** Appendix: Disseminated peritoneal adenomucinous/low grade mucinous carcinoma peritonei. Final diagnosis: Low grade appendiceal mucinous neoplasm\n * **Code 1**: This is a low grade mucinous (appendiceal) carcinoma (8480/3), which is LAMN. The peritoneal adenomucinous/low grade mucinous carcinoma peritonei is describing metastatic disease and not the histology\n\n**2.** Appendix: Low grade (well diff) appendiceal adenocarcinoma\n * **Code 0**: This is an adenocarcinoma (8140/3), the low grade (well diff) is describing the grade and not the histology\n\n**3.** Appendix, appendectomy: Low grade appendiceal mucinous neoplasm (LAMN) with focal high grade mucinous neoplasm.\n * **Code 1**: Based on the Solid Tumor Rules, the “focal” would be ignored and this would be a LAMN.\n\n**4.** Appendectomy: Mucinous adenocarcinoma of the appendix\n * **Code 3**: Mucinous adenocarcinoma is the preferred terminology for histology code 8480/3. Since there is no mention of “low grade” or “high grade”, this would not be LAMN or HAMN\n\n**5.** Appendix: Mucinous (colloid) adenocarcinoma\n * **Code 3**: Colloid adenocarcinoma is an alternate name for 8480/3", "rationale" : "Due to the different natures of these histologies, there is interest in tracking these different types of tumors. With the current histology codes, a distinction cannot be made. A histology subtype data item is needed." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/histology_discriminator_for_8020_3_93311.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/histology_discriminator_for_8020_3_93311.json index 99a715882..feb7c9b54 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/histology_discriminator_for_8020_3_93311.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/histology_discriminator_for_8020_3_93311.json @@ -4,9 +4,9 @@ "version" : "3.3", "name" : "Schema Discriminator 2", "title" : "Schema Discriminator 2: Histology Discriminator for 8020/3", - "description" : "Histology code 8020/3 is defined as “undifferentiated carcinoma.” In the AJCC 8th chapter for Esophagus, this histology code is further subdivided into squamous or glandular component, which are staged differently. A schema discriminator is necessary to distinguish between these histologies so that the appropriate stage group table is used.", - "notes" : "**Note:** **Schema discriminator for 8020/3** \n* A schema discriminator is used to discriminate for histology 8020/3: Undifferentiated carcinoma to determine which AJCC Stage Group table to use.\n* **8020/3: Undifferentiated carcinoma with squamous component (see code 1)**\nUse the Squamous Cell Carcinoma AJCC Stage Group Table\n* **8020/3: Undifferentiated carcinoma with glandular component (see code 2)**\nUse the Adenocarcinoma AJCC Stage Group Table\n* **8020/3: Undifferentiated carcinoma, NOS (no mention of squamous or glandular component) (see code 3)**\nUse the Squamous Cell Carcinoma AJCC Stage Group Table", - "last_modified" : "2025-03-21T19:56:33.572Z", + "description" : "Histology code 8020/3 is defined as “undifferentiated carcinoma”. In the AJCC 8th chapter for Esophagus, this histology code is further subdivided into squamous or glandular component, which are staged differently. A schema discriminator is necessary to distinguish between these histologies so that the appropriate stage group table is used.", + "notes" : "**Note:** **Schema discriminator for 8020/3** \n* A schema discriminator is used to discriminate for histology 8020/3: Undifferentiated carcinoma to determine which AJCC Stage Group table to use.\n* **8020/3: Undifferentiated carcinoma with squamous component (see code 1)**\n * Use the Squamous Cell Carcinoma AJCC Stage Group Table\n* **8020/3: Undifferentiated carcinoma with glandular component (see code 2)**\n * Use the Adenocarcinoma AJCC Stage Group Table\n* **8020/3: Undifferentiated carcinoma, NOS (no mention of squamous or glandular component) (see code 3)**\n * Use the Squamous Cell Carcinoma AJCC Stage Group Table", + "last_modified" : "2025-11-06T17:27:12.146Z", "definition" : [ { "key" : "discriminator_2", "name" : "Code", @@ -21,6 +21,6 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "1", "Undifferentiated carcinoma with squamous component", "00161: Esophagus (including GE junction) Squamous" ], [ "2", "Undifferentiated carcinoma with glandular component", "00169: Esophagus (including GE junction) (excluding Squamous)" ], [ "9", "Undifferentiated carcinoma, NOS ", "00161: Esophagus (including GE junction) Squamous" ], [ "", "Histology is NOT 8020, Discriminator is not necessary", "" ] ], - "additional_info" : "**Source documents:** pathology report \n\nFor further information, refer to the **Esophagus** cancer protocol published by the College of American Pathologist for the AJCC Staging Systems *Esophagus (including GE Junction)*", + "additional_info" : "**Source documents:** pathology report \n\nFor further information, refer to the **Esophagus** cancer protocol published by the College of American Pathologist for the AJCC Staging Systems *Esophagus (including GE Junction)*.", "rationale" : "A schema discriminator is used to assign AJCC ID when site and histology alone are insufficient to identify the applicable AJCC staging method and to assign Schema ID, which links each case to the appropriate SSDIs, Grade, Summary Stage and EOD data collection system." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/inr_prothrombin_time_6158.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/inr_prothrombin_time_6158.json index 458be755b..40eb60bac 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/inr_prothrombin_time_6158.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/inr_prothrombin_time_6158.json @@ -6,7 +6,7 @@ "title" : "INR (International Normalized Ratio for Prothrombin Time)", "description" : "International Normalized Ratio for Prothrombin Time (INR), an indicator of the liver’s ability to make clotting factors, is required to calculate the Model for End-Stage Liver Disease (MELD) score, is used to assign priority for liver transplant.\n\nThe prothrombin time is a measure of how quickly the blood clots, which may also indicate liver disease. The international normalized ratio (INR) is a calculation of the patient’s prothrombin time divided by the normal mean prothrombin time for the particular thromboplastin reagent used and is expressed as a decimal number. An elevated level indicates the blood is too “thin” and does not clot properly, increasing the risk of bleeding. A value under 1.0 increases the risk of blood clots.\n\nThe Model for End-Stage Liver Disease (MELD) is a numerical scale used to determine how urgently a patient with liver disease needs a liver transplant. Results from three routine lab tests are used to calculate the MELD score. International normalized ratio for prothrombin time (INR), one of the tests, measures the liver's ability to make blood clotting factors.\n\nThere are several related data items that are defined to record the MELD score. \n* 3813: Bilirubin Pretreatment Total Lab Value\n* 3814: Bilirubin Pretreatment Unit of Measure\n* 3824: Creatinine Pretreatment Lab Value\n* 3825: Creatinine Pretreatment Unit of Measure\n* 3860: International Normalized Ratio", "notes" : "**Note 1:** **Physician Statement**\n* Physician statement of the International Normalized Ratio for Prothrombin Time (INR) can be used to code this data item when no other information is available.\n\n**Note 2:** **Pretreatment results only**\n* Record the value of the highest INR test results documented in the medical record prior to treatment. The value may be recorded in a lab report, history and physical, or clinical statement in the pathology report.", - "last_modified" : "2025-02-24T15:55:24.014Z", + "last_modified" : "2025-11-06T18:11:58.970Z", "definition" : [ { "key" : "inr_prothrombin_time", "name" : "Code", @@ -17,7 +17,7 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "0.0", "0.0" ], [ "0.1", "0.1 or less" ], [ "0.2-9.9", "0.2 - 9.9\n(Exact ratio to nearest tenth)" ], [ "X.1", "10 or greater" ], [ "X.7", "Test ordered, results not in chart" ], [ "X.8", "Not applicable: Information not collected for this case\n(If this information is required by your standard setter, use of code X.8 may result in an edit error.)" ], [ "X.9", "Not documented in medical record\nINR (International Normalized Ratio for Prothrombin Time) not assessed or unknown if assessed" ] ], - "additional_info" : "**Source documents:** clinical laboratory report (blood serum); value may be part of a metabolic or liver function panel; outpatient or ambulatory blood test (finger stick) reported in patient history\n\n**Other names include** INR\n\n**Normal ranges:**\n* For a healthy person is 0.9-1.3\n* A high INR level such as INR=5 indicates that there is a high chance of bleeding\n* A low level such as INR = 0.5 indicates a high chance of abnormal clotting. Normal values may vary from lab to lab.", - "coding_guidelines" : "**1)** **Codes 0.1-9.9** are for coding the highest INR exact value in the blood prior to treatment\n**2)** **Code X.1** for an INR of 10.0 or greater.\n**3)** **Code X.7** if the test was ordered and the results are not in the medical record.\n**4)** **Code X.9** when \n* There is no information in the medical record about the INR or prothrombin time\n* The test is not done or it’s unknown if the test was done", + "additional_info" : "**Source documents:** clinical laboratory report (blood serum); value may be part of a metabolic or liver function panel; outpatient or ambulatory blood test (finger stick) reported in patient history\n\n**Other names include** INR\n\n**Normal ranges:**\n* For a healthy person is 0.9-1.3\n* A high INR level such as INR=5 indicates that there is a high chance of bleeding.\n* A low level such as INR = 0.5 indicates a high chance of abnormal clotting. Normal values may vary from lab to lab.", + "coding_guidelines" : "**1)** **Codes 0.1-9.9** are for coding the highest INR exact value in the blood prior to treatment\n\n**2)** **Code X.1** for an INR of 10.0 or greater.\n\n**3)** **Code X.7** if the test was ordered and the results are not in the medical record.\n\n**4)** **Code X.9** when \n* There is no information in the medical record about the INR or prothrombin time\n* The test is not done or it’s unknown if the test was done", "rationale" : "International Normalized Ratio for Prothrombin Time (INR) is a Registry Data Collection Variable in AJCC. This data item was previously collected for Liver, CS SSF #8." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/intern_prognostic_index_90310.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/intern_prognostic_index_90310.json index 3ca393b3e..f5bc7bea1 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/intern_prognostic_index_90310.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/intern_prognostic_index_90310.json @@ -6,7 +6,7 @@ "title" : "NCCN International Prognostic Index (IPI)", "description" : "The NCCN International Prognostic Index (IPI) (previously only “IPI”) is used to define risk groups for specific lymphomas using a 0-8 score range, based on age, stage, number of extranodal sites of involvement, patient’s performance status and LDH level.\n\nThe NCCN International Prognostic Index (IPI) has been developed for lymphomas and predicts outcome based on the following adverse factors:\n* Age greater than or equal to 60 years \n* Serum LDH greater than normal\n* Performance status 2-4 \n* Stage III or IV\n* Extranodal involvement greater than 1 site\n* Kidney and Adrenal Involvement (CNS Lymphomas only)", "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of NCCN IPI **must** be used to code this data item. \n * Do not calculate points or assign risk. Only record points or risk if a physician has documented them\n * Use points over risk if both are available\n\n**Note 2:** **NCCN is applicable for non-Hodgkin lymphomas only.**\n* If you have a score for Hodgkin lymphomas (IPS), do not record that information here. Code X9.\n\n**Note 3:** **NCCN and Rai Stage** \n* A low, intermediate or high risk associated with a Rai Stage is not recorded in this data item.", - "last_modified" : "2025-05-15T12:02:52.395Z", + "last_modified" : "2025-11-05T22:00:50.661Z", "definition" : [ { "key" : "intern_prog_index", "name" : "Code", @@ -17,6 +17,6 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "00-08", "0-8 points" ], [ "X1", "Stated as low risk (0-1 point)" ], [ "X2", "Stated as low intermediate risk (2-3 points)" ], [ "X3", "Stated as intermediate risk (4-5 points)" ], [ "X4", "Stated as high risk (6-8 points)" ], [ "X8", "Not applicable: Information not collected for this case\n(If this item is required by your standard setter, use of code X8 will result in an edit error.)" ], [ "X9", "Not documented in medical record\nNCCN International Prognostic Index (IPI) not assessed or unknown if assessed" ] ], - "additional_info" : "**Source documents:** patient history, progress notes, consultant notes, other statements in medical record.\n\n**Other names include:** NCCN CNS IPI (for CNS primaries)", + "additional_info" : "**Source documents:** patient history, progress notes, consultant notes, other statements in medical record\n\n**Other names include:** NCCN CNS IPI (for CNS primaries)", "rationale" : "NCCN International Prognostic Index (IPI) is a Registry Data Collection Variable in AJCC. It was previously collected for Lymphomas, SSF #3." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/invasion_beyond_capsule_4149.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/invasion_beyond_capsule_4149.json index e1b796421..8d45e5b78 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/invasion_beyond_capsule_4149.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/invasion_beyond_capsule_4149.json @@ -6,7 +6,7 @@ "title" : "Invasion Beyond Capsule", "description" : "Kidney Tumor Extension pertains to the pathologically confirmed invasion of the tumor beyond the fibrous capsule in which the kidney is enclosed.\n\nThis data item collects additional information on the description of tumor spread (invasion beyond capsule) as documented in the pathology report. Do not include clinical findings in this field.", "notes" : "**Note 1:** **Physician Statement**\n* Physician statement of pathologically confirmed invasion of the tumor beyond the fibrous capsule (invasion beyond capsule) can be used to code this data item when no other information is available.\n\n**Note 2:** **Relevance to Staging**\n* Information about invasion beyond the capsule is collected in primary tumor as an element in anatomic staging. It is also collected in this field as it may have an independent effect on prognosis. \n\n**Note 3:** **Perinephric/sinus fat invasion**\n* Should be confirmed microscopically and is invasion into fat by tumor cells, with or without desmoplastic reaction, and vascular invasion into perinephric/sinus soft tissue.\n * Synonyms include renal sinus fat, medial invasion\n\n* **Do not code invasion of renal hilum in this data item.** \n * Invasion of the renal hilum is invasion of vessels, nerves, lymphatics, and/or ureter before they enter the kidney parenchyma. If the only information you have is that the renal hilum is involved, code to 9 (unknown)", - "last_modified" : "2025-02-24T15:46:43.860Z", + "last_modified" : "2025-11-06T21:17:45.824Z", "definition" : [ { "key" : "invasion_beyond_capsule", "name" : "Code", @@ -17,7 +17,7 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "0", "Invasion beyond capsule not identified" ], [ "1", "Perinephric (beyond renal capsule) fat or tissue" ], [ "2", "Renal sinus" ], [ "3", "Gerota's fascia" ], [ "4", "Any combination of codes 1-3" ], [ "5", "Invasion beyond capsule, NOS" ], [ "8", "Not applicable: Information not collected for this case\n(If this information is required by your standard setter, use of code 8 may result in an edit error.)" ], [ "9", "Not documented in medical record\nInvasion beyond capsule not assessed or unknown if assessed\nNo surgical resection of primary site is performed" ] ], - "additional_info" : "**Source documents:** surgical pathology report\n\nFor further information, refer to the **Kidney** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Kidney*", - "coding_guidelines" : "**1)** Record invasion beyond capsule as documented in the surgical \n pathology report\n* Surgical resection of primary site must be done \n* Do not use imaging findings to code this data item.\n\n**2)** **Code 0**: There is no invasion beyond capsule\n* If surgical resection is done and tumor is “confined to kidney” and staging is based on size, then there has been no invasion through the capsule (no invasion into perinephric fat)\n\n**3)** **Code 1**: Perinephric fat, which is the layer of fat (adipose tissue) outside the renal capsule but inside Gerota’s fascia\n**4)** **Code 2**: Renal sinus, which is the elongated oval indentation in the renal parenchyma occupied by the renal pelvis, renal calyces, blood vessels, nerves, and perisinus fat \n* Synonyms include renal sinus fat, medial invasion\n\n**5)** **Code 3**: Gerota’s fascia (Gerota’s capsule), which is a fibrous envelope of tissue that surrounds the kidney\n**6)** **Code 4**: Any combination of codes 1-3\n**7)** **Code 5**: Invasion beyond the capsule, NOS\n**8)** **Code 9** when\n* There is no documentation in the medical record\n* Clinical diagnosis only\n* Evaluation of capsule invasion not done or unknown if done\n* Surgical resection of the primary site is performed, tumor is **not** confined to the kidney and there is no mention of invasion beyond capsule", + "additional_info" : "**Source documents:** surgical pathology report\n\nFor further information, refer to the **Kidney** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Kidney*.", + "coding_guidelines" : "**1)** Record invasion beyond capsule as documented in the surgical pathology report\n* Surgical resection of primary site must be done \n* Do not use imaging findings to code this data item.\n\n**2)** **Code 0**: There is no invasion beyond capsule\n* If surgical resection is done and tumor is “confined to kidney” and staging is based on size, then there has been no invasion through the capsule (no invasion into perinephric fat)\n\n**3)** **Code 1**: Perinephric fat, which is the layer of fat (adipose tissue) outside the renal capsule but inside Gerota’s fascia\n\n**4)** **Code 2**: Renal sinus, which is the elongated oval indentation in the renal parenchyma occupied by the renal pelvis, renal calyces, blood vessels, nerves, and perisinus fat \n\n* Synonyms include renal sinus fat, medial invasion\n\n**5)** **Code 3**: Gerota’s fascia (Gerota’s capsule), which is a fibrous envelope of tissue that surrounds the kidney\n\n**6)** **Code 4**: Any combination of codes 1-3\n\n**7)** **Code 5**: Invasion beyond the capsule, NOS\n\n**8)** **Code 9** when\n* There is no documentation in the medical record\n* Clinical diagnosis only\n* Evaluation of capsule invasion not done or unknown if done\n* Surgical resection of the primary site is performed, tumor is **not** confined to the kidney and there is no mention of invasion beyond capsule", "rationale" : "Kidney Tumor Extension into specific tissues for Kidney is a Registry Data Collection Variable in AJCC. It was previously collected as Kidney, CS SSF #1." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ipsilateral_adrenal_gland_involvement_61538.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ipsilateral_adrenal_gland_involvement_61538.json index 28fc30ac6..8ad0836d6 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ipsilateral_adrenal_gland_involvement_61538.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ipsilateral_adrenal_gland_involvement_61538.json @@ -6,7 +6,7 @@ "title" : "Ipsilateral Adrenal Gland Involvement", "description" : "Ipsilateral adrenal gland involvement pertains to direct extension of the tumor into the ipsilateral adrenal gland (continuous) or ipsilateral adrenal gland involvement by a separate nodule (discontiguous).\n\nThe adrenal gland is contained within Gerota’s fascia and is contiguous with the kidney, but it has its own lymphatic and vascular drainage systems. Involvement of the ipsilateral (same side) adrenal gland by kidney tumor—an adverse prognostic indicator—may be by direct extension (contiguous) or hematogenous (through the bloodstream; discontiguous). Do not include clinical findings in this field.", "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of Ipsilateral Adrenal Gland (suprarenal gland, same side [ipsilateral]) Involvement can be used to code this data item when no other information is available.\n\n**Note 2:** **Relevance to Staging** \n* Information about contiguous ipsilateral adrenal gland involvement is collected in primary tumor, and discontiguous ipsilateral adrenal gland involvement is collected in distant metastasis, as elements in anatomic staging. This information is also collected in this field as it may have an independent effect on prognosis.", - "last_modified" : "2025-02-24T15:47:20.670Z", + "last_modified" : "2025-11-06T21:18:06.817Z", "definition" : [ { "key" : "ipsilateral_adrenal_gland_involv", "name" : "Code", @@ -17,7 +17,7 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "0", "Ipsilateral adrenal gland involvement not present/not identified" ], [ "1", "Adrenal gland involvement by direct involvement (contiguous involvement)" ], [ "2", "Adrenal gland involvement by separate nodule (noncontiguous involvement)" ], [ "3", "Combination of code 1-2" ], [ "4", "Ipsilateral adrenal gland involvement, unknown if direct involvement or separate nodule" ], [ "8", "Not applicable: Information not collected for this case\n(If this information is required by your standard setter, use of code 8 may result in an edit error.)" ], [ "9", "Not documented in medical record\nIpsilateral adrenal gland not resected\nIpsilateral adrenal gland involvement not assessed or unknown if assessed\nNo surgical resection of primary site is performed" ] ], - "additional_info" : "**Source documents:** surgical pathology report\n\nFor further information, refer to the **Kidney** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Kidney*", - "coding_guidelines" : "**1)** Record ipsilateral adrenal gland involvement as documented in the surgical pathology report\n* Surgical resection of primary site must be done\n* Do not use imaging findings to code this data item.\n\n**2)** **Code 0**: There is no involvement of the ipsilateral adrenal gland\n* If surgical resection is done and tumor is “confined to kidney” and staging is based on size, then there is no involvement of the adrenal gland\n\n**3)** **Code 1**: Ipsilateral adrenal gland involved by direct extension (contiguous involvement)\n**4)** **Code 2**: Ipsilateral adrenal gland involved by separate nodule (discontiguous involvement)\n**5)** **Code 3**: Ipsilateral adrenal gland involvement by contiguous and discontiguous involvement\n**6)** **Code 4**: Ipsilateral adrenal gland involvement, unknown if contiguous or discontiguous involvement\n**7)** **Code 9** when\n* There is no documentation in the medical record\n* Clinical diagnosis only\n* Evaluation of ipsilateral adrenal gland involvement not done or unknown if done\n* Surgical resection of the primary site is performed, tumor is **not** confined to the kidney and there is no mention of ipsilateral adrenal gland involvement", + "additional_info" : "**Source documents:** surgical pathology report\n\nFor further information, refer to the **Kidney** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Kidney*.", + "coding_guidelines" : "**1)** Record ipsilateral adrenal gland involvement as documented in the surgical pathology report\n* Surgical resection of primary site must be done\n* Do not use imaging findings to code this data item.\n\n**2)** **Code 0**: There is no involvement of the ipsilateral adrenal gland\n* If surgical resection is done and tumor is “confined to kidney” and staging is based on size, then there is no involvement of the adrenal gland\n\n**3)** **Code 1**: Ipsilateral adrenal gland involved by direct extension (contiguous involvement)\n\n**4)** **Code 2**: Ipsilateral adrenal gland involved by separate nodule (discontiguous involvement)\n\n**5)** **Code 3**: Ipsilateral adrenal gland involvement by contiguous and discontiguous involvement\n\n**6)** **Code 4**: Ipsilateral adrenal gland involvement, unknown if contiguous or discontiguous involvement\n\n**7)** **Code 9** when\n* There is no documentation in the medical record\n* Clinical diagnosis only\n* Evaluation of ipsilateral adrenal gland involvement not done or unknown if done\n* Surgical resection of the primary site is performed, tumor is **not** confined to the kidney and there is no mention of ipsilateral adrenal gland involvement", "rationale" : "Ipsilateral adrenal gland involvement for Kidney is a Registry Data Collection Variable in AJCC. It was previously collected as Kidney, CS SSF #3." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/jak2_80148.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/jak2_80148.json index c3d51f475..d42193ab7 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/jak2_80148.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/jak2_80148.json @@ -6,7 +6,7 @@ "title" : "Janus Kinase 2", "description" : "Janus Kinase 2 (JAK2, JAK 2) is a gene mutation that increases susceptibility to several myeloproliferative neoplasms (MPNs). Testing for the JAK2 mutation is done on whole blood. Nearly all people with polycythemia vera, and about half of those with primary myelofibrosis and essential thrombocythemia, have the mutation. JAK2 analysis continues to increase in use for hematopoietic neoplasms.\n\nJAK2, a gene found in all humans, is involved in the development of blood cells. If JAK2 has mutated, the person is more susceptible to develop a myeloproliferative disorder (MPD). The JAK2 mutation, which is acquired rather than inherited, is found in as many as 90% of patients with polycythemia vera (PV), about half of patients with essential thrombocythemia (ET), and slightly fewer patients with primary myelofibrosis (also known as agnogenic myeloid metaplasia and other terms). JAK2 is used by clinicians to help classify MPDs. The most common histologies for which JAK-2 is tested are those listed above. Registrars can use JAK2 information to help determine whether the MPD is reportable. JAK2 positivity indicates a malignant (clonal, irreversible) reportable disease, but is not diagnostic of a specific MPD. Additional tests, such as a bone marrow biopsy, are necessary to determine the specific MPD histology. As the use of JAK2 increases and is investigated for other hematopoietic histologies, it also has future potential for development of targeted therapeutics for the MPDs.\n\nThe principal JAK2 test looks for a change (mutation) in an amino acid at a specific place on the JAK2 gene called V617F. If the V617F test is negative, other JAK2 mutation tests, such as those in exon 12 or 13 may be ordered to investigate a possible diagnosis of polycythemia vera. (An exon is a segment of a gene that contains instructions for making a protein.)", "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of JAK2 can be used to code this data item when no other information is available.\n\n**Note 2:** **Common histologies for JAK2**\n* Record JAK2 for any hematopoietic neoplasm. It is most commonly used for the following histologies listed below. Nearly all people with polycythemia vera, and about half of those with primary myelofibrosis and essential thrombocythemia, have the mutation.\n * Polycythemia Vera (9950/3)\n * Primary myelofibrosis (9961/3)\n * Essential Thrombocytopenia (9962/3)\n * Chronic myelomonocytic leukemia (9945/3)", - "last_modified" : "2025-03-24T14:28:40.222Z", + "last_modified" : "2025-11-06T22:01:04.867Z", "definition" : [ { "key" : "jak2", "name" : "Code", @@ -18,6 +18,6 @@ } ], "rows" : [ [ "0", "JAK2 result stated as negative" ], [ "1", "JAK2 positive for mutation V617F WITH or WITHOUT other mutations" ], [ "2", "JAK2 positive for exon 12 mutation" ], [ "3", "JAK2 positive for other specified mutation" ], [ "4", "JAK2 positive for more than one mutation other than V617F" ], [ "5", "JAK2 positive NOS \nSpecific mutation(s) not stated" ], [ "7", "Test ordered, results not in chart" ], [ "8", "Not applicable: Information not collected for this case \n(If this item is required by your standard setter, use of code 8 will result in an edit error.)" ], [ "9", "Not documented in medical record\nJAK2 not assessed or unknown if assessed" ] ], "additional_info" : "**Source documents:** clinical laboratory test (whole blood)\n\n**Other names include** Janus kinase 2 gene, JAK2 V617F, JAK2 exon 12, JAK2 exon13", - "coding_guidelines" : "**1)** Code the result of the JAK2 test as documented in a laboratory test or elsewhere in the medical record. \n**2)** Code this field for any hematopoietic, immunoproliferative, myeloproliferative, or myelodysplastic disease for which JAK2 is tested. \n**3)** **Code 0** when the JAK2 test result is stated as negative.\n**4)** **Code 1** when the JAK2 test was performed and was positive for mutation V617F in exon 14.\n**5)** **Code 2** when the JAK2 test was performed and was positive for mutation of exon 12.\n**6)** **Code 3** when the JAK2 test was performed and was positive for another specified mutation.\n**7)** **Code 4** when the JAK2 test was performed and was positive for more than one mutation.\n**8)** **Code 7** when there is a statement in the record that the test was ordered but the results are not available.\n**9)** **Code 9** when\n* There is no information in the medical record about JAK2 testing\n* The results of JAK2 testing are unknown\n* HemeRetic schema disease such as leukemia where JAK2 is not normally tested.", + "coding_guidelines" : "**1)** Code the result of the JAK2 test as documented in a laboratory test or elsewhere in the medical record. \n\n**2)** Code this field for any hematopoietic, immunoproliferative, myeloproliferative, or myelodysplastic disease for which JAK2 is tested. \n\n**3)** **Code 0** when the JAK2 test result is stated as negative.\n\n**4)** **Code 1** when the JAK2 test was performed and was positive for mutation V617F in exon 14.\n\n**5)** **Code 2** when the JAK2 test was performed and was positive for mutation of exon 12.\n\n**6)** **Code 3** when the JAK2 test was performed and was positive for another specified mutation.\n\n**7)** **Code 4** when the JAK2 test was performed and was positive for more than one mutation.\n\n**8)** **Code 7** when there is a statement in the record that the test was ordered but the results are not available.\n\n**9)** **Code 9** when\n* There is no information in the medical record about JAK2 testing\n* The results of JAK2 testing are unknown\n* HemeRetic schema disease such as leukemia where JAK2 is not normally tested.", "rationale" : "JAK2 can be collected by the surveillance community for myeloproliferative neoplasms. Prior to 2018, HemeRetic SSF#1 was used for JAK2." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ki67_8355.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ki67_8355.json index f4b00d430..daf03d94b 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ki67_8355.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ki67_8355.json @@ -6,7 +6,7 @@ "title" : "Ki-67 (MIB-1)", "description" : "Ki-67 (MIB-1) (Proliferative Index) is a marker of cell proliferation. A high value indicates a tumor that is proliferating more rapidly. Codes and coding instructions for this data item are site-specific.", "notes" : "**Note 1:** **Physician Statement**\n* Physician statement of Ki-67 (MIB-1), also referred to as the “Proliferative Index” can be used to code this data item when no other information is available.\n\n**Note 2:** **In-situ and Invasive components present**\n* If Ki-67 is done on both the in situ and invasive components in the primary tumor, code the Ki-67 value from the invasive component\n* If in situ and invasive components present and Ki-67 only done on the in-situ component in the primary tumor, code unknown\n\n**Note 3:** **Results from nodal or metastatic tissue**\n * Results from nodal or metastatic tissue may be used ONLY when there is no evidence of primary tumor\n * *Note:* In-situ is evidence of primary tumor\n\n**Note 4:** **Neoadjuvant Therapy**\n* Record the assay from tumor specimens prior to neoadjuvant therapy.\n* If neoadjuvant therapy is given and there are no Ki-67 results from pre-treatment specimens, report the findings from post-treatment specimens.", - "last_modified" : "2024-04-08T20:04:06.134Z", + "last_modified" : "2025-11-06T21:44:08.394Z", "definition" : [ { "key" : "ki67", "name" : "Code", @@ -17,7 +17,7 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "0.0-100.0", "0.0 to 100.0 percent positive: enter percent positive" ], [ "XXX.7", "Test done, actual percentage not stated" ], [ "XXX.8", "Not applicable: Information not collected for this case\n(If this item is required by your standard setter, use of code XXX.8 will result in an edit error.)" ], [ "XXX.9", "Not documented in medical record\nKi-67 (MIB-1) not assessed or unknown if assessed" ] ], - "additional_info" : "**Source documents:** pathology report\n\nFor further information, refer to the **Breast Biomarker Reporting** cancer protocols published by the College of American Pathologists for the AJCC Staging System *Breast*", - "coding_guidelines" : "Ki-67 results are reported as the percentage cell nuclei that stain positive. As of early 2017 there are no established standards for interpretation of results or for cutoffs for positive and negative. \n\n* ***Examples:***\n Ki-67 reported as 14%. Code 14.0\n Ki-67 reported as 8.6%. Code 8.6", + "additional_info" : "**Source documents:** pathology report\n\nFor further information, refer to the **Breast Biomarker Reporting** cancer protocols published by the College of American Pathologists for the AJCC Staging System *Breast*.", + "coding_guidelines" : "Ki-67 results are reported as the percentage cell nuclei that stain positive. As of early 2017 there are no established standards for interpretation of results or for cutoffs for positive and negative. \n\n* ***Examples:***\n\n * Ki-67 reported as 14%. Code 14.0\n * Ki-67 reported as 8.6%. Code 8.6", "rationale" : "Ki-67 (MIB-1) (Proliferative Index) is a Registry Data Collection Variable in AJCC. It was a new data item for breast cases diagnosed 1/1/2018+. It will apply to neuroendocrine tumors (NET) of the gastrointestinal tract (AJCC Chapters 29 – 34) for cases diagnosed 1/1/2021+. High Ki-67 is an adverse prognostic factor and Ki-67 is a component of grade for these tumors. NCCN guidelines recommend that tumor differentiation, mitotic rate and Ki-67 should be recorded in the pathology report for these tumors." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ki_67_67661.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ki_67_67661.json index ab7a1d7e4..93d69fac0 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ki_67_67661.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ki_67_67661.json @@ -6,7 +6,7 @@ "title" : "Ki-67", "description" : "Ki-67 (MIB-1) (Proliferative Index) is a marker of cell proliferation. A high value indicates a tumor that is proliferating more rapidly. Codes and coding instructions for this data item are site-specific.", "notes" : "**Note 1:** **Effective years**\n* This SSDI is effective for diagnosis years 2021+\n* For cases diagnosed 2018-2020, this SSDI must be blank\n\n**Note 2:** **Physician Statement**\n* Physician statement of Ki-67 (MIB-1), also referred to as the “Proliferative Index,” can be used to code this data item when no other information is available\n\n**Note 3:** **Priority order**\n* A specific value (0.0-100.0) takes priority over XXX.4, XXX.5 or XXX.6. \n* Code the exact percentage when provided\n* When the exact percentage is not given, including ranges or terms such as “less than” or “greater than” use the range value codes XXX.4, XXX.5, XXX.6.\n* XXX.4, XXX.5 and XXX.6 were added since they are listed on the CAP protocol\n\n**Note 4:** **Results from nodal or metastatic tissue**\n* May **not** be used\n * If the only information you have is a Ki-67 from a metastatic site, code to XXX.9 \n\n**Note 5:** **Neoadjuvant Therapy**\n* Record the assay from tumor specimens prior to neoadjuvant therapy.\n* If neoadjuvant therapy is given and there are no Ki-67 results from pre-treatment specimens, report the findings from post-treatment specimens.", - "last_modified" : "2025-08-20T11:13:10.087Z", + "last_modified" : "2025-11-06T15:59:28.810Z", "definition" : [ { "key" : "ki67", "name" : "Code", @@ -17,7 +17,7 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "0.0-100.0", "0.0 to 100.0 percent positive: enter percent positive" ], [ "XXX.4", "Ki-67 stated as less than 3%" ], [ "XXX.5", "Ki-67 stated as 3%-20%" ], [ "XXX.6", "Ki-67 stated as greater than 20%" ], [ "XXX.7", "Test done; actual percentage not stated" ], [ "XXX.8", "Not applicable: Information not collected for this case\n(If this item is required by your standard setter, use of code XXX.8 will result in an edit error.)" ], [ "XXX.9", "Not documented in medical record\nKi-67 (MIB-1) not assessed or unknown if assessed" ], [ "", "Must be blank if diagnosis year is before 2021" ] ], - "additional_info" : "**Source documents:** pathology report\n\n**Other names include** Proliferative index, MIB-1\n\nFor further information, refer to the **NET (Endocrine)** cancer protocols published by the College of American Pathologists", + "additional_info" : "**Source documents:** pathology report\n\n**Other names include** Proliferative index, MIB-1\n\nFor further information, refer to the **NET (Endocrine)** cancer protocols published by the College of American Pathologists.", "coding_guidelines" : "**1)** Ki-67 results are reported as the percentage cell nuclei that stain positive. As of early 2017 there are no established standards for interpretation of results or for cutoffs for positive and negative.\n\n***Examples:***\n* Ki-67 reported as 14%. Code 14.0\n* Ki-67 reported as 8.6%. Code 8.6\n* Ki-67 stated as less than 1%. Code XXX.4\n* Ki-67 stated as 5%-10%. Code XXX.5\n* Ki-67 stated as greater than 4%. Code XXX.5\n* Ki-67 stated as greater than 30%. Code XXX.6", "rationale" : "Ki-67 (MIB-1) (Proliferative Index) is a Registry Data Collection Variable in AJCC. It was a new data item for breast cases diagnosed 1/1/2018+. It will apply to neuroendocrine tumors (NET) of the gastrointestinal tract (AJCC Chapters 29 – 34) for cases diagnosed 1/1/2021+. \n\nHigh Ki-67 is an adverse prognostic factor and Ki-67 is a component of grade for these tumors. NCCN guidelines recommend that tumor differentiation, mitotic rate and Ki-67 should be recorded in the pathology report for these tumors." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/kras_79447.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/kras_79447.json index 621f7c72e..7cb1b7d01 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/kras_79447.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/kras_79447.json @@ -6,7 +6,7 @@ "title" : "KRAS", "description" : "KRAS is an important signaling intermediate in the growth receptor pathway which controls cell proliferation and survival. KRAS is a protein with production controlled by the K-ras gene. When the K-ras gene is activated through mutation during colorectal carcinogenesis, production of KRAS continuously stimulates cell proliferation and prevents cell deaths. Activating mutations in KRAS are an adverse prognostic factor for colorectal carcinoma and predict a poor response to monoclonal anti-EGFR antibody therapy in advanced colorectal carcinoma.\n\nKRAS is an oncogene (a gene that, when mutated or overexpressed, helps turn a normal cell into a cancer cell). Mutations of KRAS indicate that a patient may not respond to the anti-epidermal growth factor receptor drugs cetuximab (Erbitux) or panitumumab (Vectibix). ASCO recommends that Stage IV colorectal patients be tested for KRAS if anti-EGFR therapy is being considered. There are two types of KRAS genes: normal and mutated. The normal KRAS gene is also called the wild type allele; the mutated gene may be described as abnormal or having an abnormal codon (abnormal DNA sequence).", "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of KRAS can be used to code this data item when no other information is available. \n\n**Note 2:** **Applicable Stages**.\n* KRAS may be recorded for all stages; however, it is primarily performed for patients with metastatic disease. If information is not available, code 9\n\n**Note 3:** **Results from nodal or metastatic tissue**\n* Results from nodal or metastatic tissue may be used for KRAS.\n\n**Note 4:** **Timing**\n* Record the results of the KRAS from the initial workup (clinical and pathological workup).", - "last_modified" : "2025-02-24T13:40:52.784Z", + "last_modified" : "2025-11-14T15:58:42.112Z", "definition" : [ { "key" : "kras", "name" : "Code", @@ -17,7 +17,7 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "0", "Normal \nKRAS negative, KRAS wild type\nNegative for (somatic) mutations, no alterations, no (somatic) mutations identified, not present, not detected" ], [ "1", "Abnormal (mutated) in codon(s) 12, 13 and/or 61" ], [ "2", "Abnormal (mutated) in codon 146 only" ], [ "3", "Abnormal (mutated), but not in codon(s) 12, 13, 61, or 146" ], [ "4", "Abnormal (mutated), NOS, codon(s) not specified" ], [ "7", "Test ordered, results not in chart" ], [ "8", "Not applicable: Information not collected for this case\n(If this information is required by your standard setter, use of code 8 may result in an edit error.)" ], [ "9", "Not documented in medical record\nKRAS not assessed or unknown if assessed" ] ], - "additional_info" : "**Source documents:** pathology repot, clinical laboratory report\n\n**Other names include** K-Ras, K-ras, Ki-Ras\n\nFor further information, refer to the **Colon and Rectum Biomarker** Reporting cancer protocol published by the College of American Pathologists for the AJCC Staging System *Colon and Rectum*", - "coding_guidelines" : "There are 4 KRAS codons that are commonly mutated in colorectal cancers. This SSDI does not record the actual mutation, but instead records the codon or codon group that contains the mutation. If a specific KRAS mutation is reported, its codon may be identified from the following list of common KRAS mutations grouped by codon.\n\n**1)** **Codon 12 (see code 1)**\n* Gly12Asp (GGT>GAT)\n* Gly12Val (GGT>GTT)\n* Gly12Cys (GGT>TGT)\n* Gly12Ser (GGT>AGT)\n* Gly12Ala (GGT>GCT)\n* Gly12 Arg (GGT>CGT)\n* Codon 12 mutation, not otherwise specified\n\n**2)** **Codon 13 (see code 1)**\n* Gly13Asp (GGC>GAC)\n* Gly13Arg (GGC>CGC)\n* Gly13Cys (GGC>TGC)\n* Gly13Ala (GGC>GCC)\n* Gly13Val (GGC>GTC)\n* Codon 13 mutation, not otherwise specified\n\n**3)** **Codon 61 (see code 1)**\n* Gln61Leu (CAA>CTA)\n* Gln61His (CAA>CAC)\n* Codon 61 mutation, not otherwise specified\n\n**4)** **Codon 146 (See code 2)**\n* Ala146Thr (G436A) (GCA>ACA)\n* Codon 146 mutation, not otherwise specified\n* Other specified coding (excluding 12, 13, 61, 146) (See code 3)\n\n**5)** Other specified coding (excluding 12, 13, 61, 146) (See code 3)\n\n**6)** **Unknown codon (See code 4)**\n* KRAS positive, specific codon not mentioned \n\n**7)** **Code 9** when\n* Insufficient amount of tissue available to perform test\n* No microscopic confirmation of tumor\n* Pathology report available and there is no mention of KRAS\n* KRAS not ordered or not done, or unknown if ordered or done", + "additional_info" : "**Source documents:** pathology report, clinical laboratory report\n\n**Other names include** K-Ras, K-ras, Ki-Ras\n\nFor further information, refer to the **Colon and Rectum Biomarker** Reporting cancer protocol published by the College of American Pathologists for the AJCC Staging System *Colon and Rectum*.", + "coding_guidelines" : "There are 4 KRAS codons that are commonly mutated in colorectal cancers. This SSDI does not record the actual mutation, but instead records the codon or codon group that contains the mutation. If a specific KRAS mutation is reported, its codon may be identified from the following list of common KRAS mutations grouped by codon.\n\n**1)** **Codon 12 (see code 1)**\n* Gly12Asp (GGT>GAT)\n* Gly12Val (GGT>GTT)\n* Gly12Cys (GGT>TGT)\n* Gly12Ser (GGT>AGT)\n* Gly12Ala (GGT>GCT)\n* Gly12 Arg (GGT>CGT)\n* Codon 12 mutation, not otherwise specified\n\n**2)** **Codon 13 (see code 1)**\n* Gly13Asp (GGC>GAC)\n* Gly13Arg (GGC>CGC)\n* Gly13Cys (GGC>TGC)\n* Gly13Ala (GGC>GCC)\n* Gly13Val (GGC>GTC)\n* Codon 13 mutation, not otherwise specified\n\n**3)** **Codon 61 (see code 1)**\n* Gln61Leu (CAA>CTA)\n* Gln61His (CAA>CAC)\n* Codon 61 mutation, not otherwise specified\n\n**4)** **Codon 146 (See code 2)**\n* Ala146Thr (G436A) (GCA>ACA)\n* Codon 146 mutation, not otherwise specified\n\n**5)** **Other specified coding (excluding 12, 13, 61, 146) (See code 3)**\n\n**6)** **Unknown codon (See code 4)**\n* KRAS positive, specific codon not mentioned \n\n**7)** **Code 9** when\n* Insufficient amount of tissue available to perform test\n* No microscopic confirmation of tumor\n* Pathology report available and there is no mention of KRAS\n* KRAS not ordered or not done, or unknown if ordered or done", "rationale" : "KRAS is a Registry Data Collection Variable in AJCC. It was previously collected as Colon and Rectum CS SSF #9." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ldh_lab_value_85652.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ldh_lab_value_85652.json index 87550b9a1..ebee3a89c 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ldh_lab_value_85652.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ldh_lab_value_85652.json @@ -6,7 +6,7 @@ "title" : "LDH Lab Value", "description" : "LDH (Lactate Dehydrogenase) Lab Value, measured in serum, is a predictor of treatment response, progression-free survival, and overall survival for patients with Stage IV melanoma of the skin. \n\nWhen cells (normal or tumor) are damaged or destroyed, an enzyme called lactate dehydrogenase (LDH) is released into the bloodstream. LDH is an indirect indication of possible tumor burden or damage to an organ, which may be caused by metastatic involvement of liver or lung, or a myocardial infarction. The total LDH should be the test value that is coded, but there are five fractions of LDH that measure tissue specific cellular damage: LD1 and LD2: heart, red blood cells and kidneys; LD3: lung; LD4 and LD5: liver, skin, and skeletal muscles. LDH is elevated in 60% of patients with non-seminomatous germ cell tumors of the testis. LDH is not a screening test, nor is it diagnostic of melanoma, ocular adnexal lymphoma, or testicular cancer.\n\nLDH is important in melanoma staging in the setting of DISTANT metastasis. LDH level might only be ordered after re-excision/wide excision and/or nodal evaluation indicates a higher risk of distant metastasis. Imaging may then be performed and if distant metastasis are identified, LDH is ordered.", "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of LDH Lab Value can be used to code this data item when no other information is available. \n\n**Note 2:** **Pre systemic treatment results** \n* Record the lab value of the highest serum LDH test results documented in the medical record either before or after surgical resection of the primary tumor with or without regional lymph node dissection. \n* The LDH must be taken prior to systemic (chemo, immunotherapy, hormone), radiation therapy or surgery to a metastatic site. \n\n**Note 3:** **Related data item** \n* The same laboratory test should be used to record the related data items 3869: LDH Level and 3870: LDH Upper Limits of Normal.", - "last_modified" : "2025-02-24T16:14:55.645Z", + "last_modified" : "2025-11-06T18:46:06.278Z", "definition" : [ { "key" : "ldh_lab_value", "name" : "Code", @@ -18,6 +18,6 @@ } ], "rows" : [ [ "0.0", "0.0 (U/L)" ], [ "0.1-99999.9", "0.1 - 99,999.9 U/L" ], [ "XXXXX.1", "100,000 U/L or greater" ], [ "XXXXX.7", "Test ordered, results not in chart" ], [ "XXXXX.8", "Not applicable: Information not collected for this case\n(If this item is required by your standard setter, use of code XXXXX.8 will result in an edit error.)" ], [ "XXXXX.9", "Not documented in medical record\nLDH Lab Value not assessed or unknown if assessed" ] ], "additional_info" : "**Source documents:** clinical laboratory report; may be included in a liver or hepatic panel/profile, a cardiac panel, or a general metabolic panel of tests\n\n**Other names include:** LDH, Lactate dehydrogenase, lactase dehydrogenase, lactic acid dehydrogenase", - "coding_guidelines" : "**1)** Record the lab value of the highest serum LDH test results documented in the medical record **either before or after surgical resection** of the primary tumor with or without regional lymph node dissection.\n\n**2)** **Code 0.0** for a test result of 0 (U/L).\n\n**3)** **Code 0.1-99,999.9 for the highest exact LDH lab value** prior to systemic (chemo, immunotherapy, hormone), radiation therapy or surgery to a metastatic site \n \n**4)** **Code XXXXX.1** for a total LDH lab value of 100,000 or greater. \n**5)** **Code XXXXX.7** if the test was ordered and the results are not in the medical record. \n**6)** **Code XXXXX.9** when \n * There is no information in the medical record about the LDH lab value\n * Test is not done or unknown if the test was done", + "coding_guidelines" : "**1)** Record the lab value of the highest serum LDH test results documented in the medical record **either before or after surgical resection** of the primary tumor with or without regional lymph node dissection.\n\n**2)** **Code 0.0** for a test result of 0 (U/L).\n\n**3)** **Code 0.1-99,999.9 for the highest exact LDH lab value** prior to systemic (chemo, immunotherapy, hormone), radiation therapy or surgery to a metastatic site \n \n**4)** **Code XXXXX.1** for a total LDH lab value of 100,000 or greater. \n\n**5)** **Code XXXXX.7** if the test was ordered and the results are not in the medical record. \n\n**6)** **Code XXXXX.9** when \n * There is no information in the medical record about the LDH lab value\n * Test is not done or unknown if the test was done", "rationale" : "LDH Lab Value is a Registry Data Collection Variable in AJCC. It was previously collected as Melanoma Skin, CS SSF #5." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ldh_post_orchiectomy_range_38574.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ldh_post_orchiectomy_range_38574.json index f2b4f6741..06c5d21af 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ldh_post_orchiectomy_range_38574.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ldh_post_orchiectomy_range_38574.json @@ -6,7 +6,7 @@ "title" : "LDH (Lactate Dehydrogenase) Post-Orchiectomy Range", "description" : "LDH (Lactate Dehydrogenase) Post-Orchiectomy Range identifies the range category of the lowest LDH value measured post-orchiectomy. LDH is a nonspecific marker for testicular cancer that is elevated in some germ cell tumors. The Post-Orchiectomy lab value is used to monitor response to therapy.\n\nWhen cells (normal or tumor) are damaged or destroyed, an enzyme called lactate dehydrogenase (LDH) is released into the bloodstream. LDH is an indirect indication of possible tumor burden or damage to an organ, which may be caused by metastatic involvement of liver or lung, or a myocardial infarction. The total LDH should be the test value that is coded, but there are five fractions of LDH that measure tissue specific cellular damage: LD1 and LD2: heart, red blood cells and kidneys; LD3: lung; LD4 and LD5: liver, skin, and skeletal muscles. LDH is elevated in 60% of patients with non-seminomatous germ cell tumors of the testis. LDH is not a screening test, nor is it diagnostic of melanoma, ocular adnexal lymphoma, or testicular cancer.\n\nFor testis, only the LDH Range is coded. LDH is non-specific for testicular cancer. Although part of the criteria for the S category in the TNM system, LDH is not routinely performed unless the patient has evidence of bulky or distant disease.\nFor Testis, there are 2 related data items that record information on LDH.\n* 3867: LDH Post-Orchiectomy Range\n* 3868: LDH Pre-Orchiectomy Range", "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of the LDH (Lactate Dehydrogenase) Post-Orchiectomy Range can be used to code this data item when there is no other information available.\n\n**Note 2:** **Timing** \n* Record the range of the LDH test as documented in the medical record after orchiectomy but prior to adjuvant therapy. The lab value may be documented in a lab report, history and physical, or clinical statement in the pathology report.\n\n**Note 3:** **Calculating the upper limit** \n* To calculate whether the lab result is in a particular range, multiply the lab’s upper limit of normal (usually stated on the report) times the stated multiplier. If the test is elevated, determine whether it is less than 1.5 times the upper limit of normal (code 1), between 1.5 and 10 times the upper limit of normal (code 2), or more than 10 times the upper limit of normal (code 3) (*See coding guidelines for example*).\n\n **Note 4:** **Lab values elevated after orchiectomy** \n* If the initial post-orchiectomy LDH remains elevated, review subsequent tests, and record the lowest LDH value (normalization or plateau) prior to adjuvant therapy or before the value rises again.\n\n**Note 5:** **LDH and Testis** \n* Of the three tumor markers, lactate dehydrogenase (LDH) is the least specific for testicular cancer. The magnitude of LDH elevation directly correlates with Testis tumor burden.\n\n**Note 6:** **Related data item** \n* If the pre-orchiectomy LDH was normal, a post-orchiectomy LDH may not be performed. In this case, code 5 should be recorded.", - "last_modified" : "2024-04-10T16:45:53.934Z", + "last_modified" : "2025-11-06T21:08:49.727Z", "definition" : [ { "key" : "ldh_post_orch_range", "name" : "Code", @@ -17,7 +17,7 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "0", "Within normal limits" ], [ "1", "Less than 1.5 x N \n(Less than 1.5 times the upper limit of normal for LDH)" ], [ "2", "1.5 to 10 x N \n(Between 1.5 and 10 times the upper limit of normal for LDH)" ], [ "3", "Greater than 10 x N \n(Greater than 10 times the upper limit of normal for LDH)" ], [ "4", "Post-Orchiectomy lactate dehydrogenase (LDH) range stated to be elevated" ], [ "5", "Post-Orchiectomy lactate dehydrogenase (LDH) unknown or not done but pre-orchiectomy LDH was normal" ], [ "7", "Test ordered, results not in chart" ], [ "8", "Not applicable: Information not collected for this case\n(If this information is required by your standard setter, use of code 8 may result in an edit error.)" ], [ "9", "Not documented in medical record\nNo orchiectomy performed\nLDH (Lactate Dehydrogenase) Post-Orchiectomy Range not assessed or unknown if assessed" ] ], - "additional_info" : "**Source documents:** clinical laboratory report; may be included in a liver or hepatic panel/profile, a cardiac panel, or a general metabolic panel of tests\n\n**Other names include** LD, Lactate dehydrogenase, lactase dehydrogenase, lactic acid dehydrogenase\n\nFor further information, refer to the **Testis** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Testis*\n\n**Normal reference range** \n* Varies widely by laboratory, patient age, and the units of measurement.", - "coding_guidelines" : "***LDH Pre-Orchiectomy and Post-Orchiectomy Range***\n* For these examples, the lab’s normal reference range for LDH = 100-225\n * 1.5 X 225 (upper limit of normal) = 337.5 \n * 10 x 225 (upper limit of normal) = 2250\n* Therefore, for this lab, a value that is elevated and up to 337 = code 1, a value from 338 to 2250 = code 2, and a value greater than 2250 = code 3.", + "additional_info" : "**Source documents:** clinical laboratory report; may be included in a liver or hepatic panel/profile, a cardiac panel, or a general metabolic panel of tests\n\n**Other names include** LD, Lactate dehydrogenase, lactase dehydrogenase, lactic acid dehydrogenase\n\nFor further information, refer to the **Testis** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Testis*.\n\n**Normal reference range** \n* Varies widely by laboratory, patient age, and the units of measurement.", + "coding_guidelines" : "***LDH Pre-Orchiectomy and Post-Orchiectomy Range***\n\n* For these examples, the lab’s normal reference range for LDH = 100-225\n * 1.5 X 225 (upper limit of normal) = 337.5 \n * 10 x 225 (upper limit of normal) = 2250\n\n* Therefore, for this lab, a value that is elevated and up to 337 = code 1, a value from 338 to 2250 = code 2, and a value greater than 2250 = code 3.", "rationale" : "LDH (Lactate Dehydrogenase) is a Registry Data Collection Variable in AJCC. LDH (Lactate Dehydrogenase) Post-Orchiectomy Range is used to assign the S Category Pathological and was previously collected as Testis CS SSF #16." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ldh_pre_orchiectomy_range_42762.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ldh_pre_orchiectomy_range_42762.json index 6f81c219f..bb2f5d666 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ldh_pre_orchiectomy_range_42762.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ldh_pre_orchiectomy_range_42762.json @@ -4,9 +4,9 @@ "version" : "3.3", "name" : "LDH Pre-Orchiectomy Range", "title" : "LDH (Lactate Dehydrogenase) Pre-Orchiectomy Range", - "description" : "Lactate Dehydrogenase (LDH) Range identifies the range category of the highest LDH value measured prior to treatment. LDH is a nonspecific marker for testicular cancer that is elevated in some germ cell tumors. This data item refers to the Pre-Orchiectomy range.\n\nWhen cells (normal or tumor) are damaged or destroyed, an enzyme called lactate dehydrogenase (LDH) is released into the bloodstream. LDH is an indirect indication of possible tumor burden or damage to an organ, which may be caused by metastatic involvement of liver or lung, or a myocardial infarction. The total LDH should be the test value that is coded, but there are five fractions of LDH that measure tissue specific cellular damage: LD1 and LD2: heart, red blood cells and kidneys; LD3: lung; LD4 and LD5: liver, skin, and skeletal muscles. LDH is elevated in 60% of patients with non-seminomatous germ cell tumors of the testis. LDH is not a screening test, nor is it diagnostic of melanoma, ocular adnexal lymphoma, or testicular cancer.\n\nFor testis, only the LDH Range is coded. LDH is non-specific for testicular cancer. Although part of the criteria for the S category in the TNM system, LDH is not routinely performed unless the patient has evidence of bulky or distant disease.\nFor Testis, there are 2 related data items that record information on LDH.\n* 3867: LDH Post-Orchiectomy Range\n* 3868: LDH Pre-Orchiectomy Range", + "description" : "Lactate Dehydrogenase (LDH) Range identifies the range category of the highest LDH value measured prior to treatment. LDH is a nonspecific marker for testicular cancer that is elevated in some germ cell tumors. This data item refers to the Pre-Orchiectomy range.\n\nWhen cells (normal or tumor) are damaged or destroyed, an enzyme called lactate dehydrogenase (LDH) is released into the bloodstream. LDH is an indirect indication of possible tumor burden or damage to an organ, which may be caused by metastatic involvement of liver or lung, or a myocardial infarction. The total LDH should be the test value that is coded, but there are five fractions of LDH that measure tissue specific cellular damage: LD1 and LD2: heart, red blood cells and kidneys; LD3: lung; LD4 and LD5: liver, skin, and skeletal muscles. LDH is elevated in 60% of patients with non-seminomatous germ cell tumors of the testis. LDH is not a screening test, nor is it diagnostic of melanoma, ocular adnexal lymphoma, or testicular cancer.\n\nFor testis, only the LDH Range is coded. LDH is non-specific for testicular cancer. Although part of the criteria for the S category in the TNM system, LDH is not routinely performed unless the patient has evidence of bulky or distant disease.\n\nFor Testis, there are 2 related data items that record information on LDH.\n* 3867: LDH Post-Orchiectomy Range\n* 3868: LDH Pre-Orchiectomy Range", "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of the LDH (Lactate Dehydrogenase) Pre-Orchiectomy Range can be used to code this data item when no other information is available. \n\n**Note 2:** **Timing** \n* Record the range of the highest LDH test result documented in the medical record **prior to orchiectomy** or prior to any systemic treatment. The lab value may be documented in a lab report, history and physical, or clinical statement in the pathology report.\n\n**Note 3:** **Calculating the upper limit** \n* To calculate whether the lab result is in a particular range, multiply the lab’s upper limit of normal (usually stated on the report) times the stated multiplier. If the test is elevated, determine whether it is less than 1.5 times the upper limit of normal (code 1), between 1.5 and 10 times the upper limit of normal (code 2), or more than 10 times the upper limit of normal (code 3). (*See coding guidelines for example*).\n\n**Note 4:** **LDH and Testis** \n* Of the three tumor markers, lactate dehydrogenase (LDH) is the least specific for testicular cancer. The magnitude of LDH elevation directly correlates with Testis tumor burden.", - "last_modified" : "2024-04-10T16:46:12.764Z", + "last_modified" : "2025-11-06T21:09:48.826Z", "definition" : [ { "key" : "ldh_pre_orch_range", "name" : "Code", @@ -17,7 +17,7 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "0", "Within normal limits" ], [ "1", "Less than 1.5 x N \n(Less than 1.5 times the upper limit of normal for LDH)" ], [ "2", "1.5 to 10 x N \n(Between 1.5 and 10 times the upper limit of normal for LDH)" ], [ "3", "Greater than 10 x N \n(Greater than 10 times the upper limit of normal for LDH)" ], [ "4", "Pre-Orchiectomy lactate dehydrogenase (LDH) range stated to be elevated" ], [ "7", "Test ordered, results not in chart" ], [ "8", "Not applicable: Information not collected for this case\n(If this information is required by your standard setter, use of code 8 may result in an edit error.)" ], [ "9", "Not documented in medical record\nLDH (Lactate Dehydrogenase) Pre-Orchiectomy Range not assessed or unknown if assessed" ] ], - "additional_info" : "**Source documents:** clinical laboratory report; may be included in a liver or hepatic panel/profile, a cardiac panel, or a general metabolic panel of tests\n\n**Other names include** LD, Lactate dehydrogenase, lactase dehydrogenase, lactic acid dehydrogenase\n\nFor further information, refer to the **Testis** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Testis*\n\n**Normal reference range** \n* Varies widely by laboratory, patient age, and the units of measurement.", - "coding_guidelines" : "***Examples for LDH Pre-Orchiectomy and Post-Orchiectomy Range***\n* For these examples, the lab’s normal reference range for LDH = 100-225\n * 1.5 X 225 (upper limit of normal) = 337.5 \n * 10 x 225 (upper limit of normal) = 2250\n* Therefore, for this lab, a value that is elevated and up to 337 = code 1, a value from 338 to 2250 = code 2, and a value greater than 2250 = code 3.", + "additional_info" : "**Source documents:** clinical laboratory report; may be included in a liver or hepatic panel/profile, a cardiac panel, or a general metabolic panel of tests\n\n**Other names include** LD, Lactate dehydrogenase, lactase dehydrogenase, lactic acid dehydrogenase\n\nFor further information, refer to the **Testis** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Testis*.\n\n**Normal reference range** \n* Varies widely by laboratory, patient age, and the units of measurement.", + "coding_guidelines" : "***Examples for LDH Pre-Orchiectomy and Post-Orchiectomy Range***\n\n* For these examples, the lab’s normal reference range for LDH = 100-225\n * 1.5 X 225 (upper limit of normal) = 337.5 \n * 10 x 225 (upper limit of normal) = 2250\n\n* Therefore, for this lab, a value that is elevated and up to 337 = code 1, a value from 338 to 2250 = code 2, and a value greater than 2250 = code 3.", "rationale" : "LDH (Lactate Dehydrogenase) is a Registry Data Collection Variable in AJCC. LDH (Lactate Dehydrogenase) Pre-Orchiectomy Range is used to assign the S Category Clinical and was previously collected as Testis CS SSF #10." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ldh_upper_limits_of_normal_34244.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ldh_upper_limits_of_normal_34244.json index 8641ec83b..ec2bd451b 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ldh_upper_limits_of_normal_34244.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ldh_upper_limits_of_normal_34244.json @@ -6,7 +6,7 @@ "title" : "LDH (Lactate Dehydrogenase) Upper Limits of Normal", "description" : "LDH (Lactate Dehydrogenase), an enzyme involved in converting sugars to energy in the body, is elevated in some malignancies. LDH level is a prognostic factor for patients with Stage IV melanoma. This data Item refers to the Upper Limit of Normal in the laboratory test used to interpret the Serum LDH result.\n\nWhen cells (normal or tumor) are damaged or destroyed, an enzyme called lactate dehydrogenase (LDH) is released into the bloodstream. LDH is an indirect indication of possible tumor burden or damage to an organ, which may be caused by metastatic involvement of liver or lung, or a myocardial infarction. The total LDH should be the test value that is coded, but there are five fractions of LDH that measure tissue specific cellular damage: LD1 and LD2: heart, red blood cells and kidneys; LD3: lung; LD4 and LD5: liver, skin, and skeletal muscles. LDH is elevated in 60% of patients with non-seminomatous germ cell tumors of the testis. LDH is not a screening test, nor is it diagnostic of melanoma, ocular adnexal lymphoma, or testicular cancer.", "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of LDH (Lactate Dehydrogenase) Upper Limit of Normal can be used to code this data item when no other information is available.\n\n**Note 2:** **Recording upper limits** \n* Record the value of the highest serum LDH test results documented in the medical record either before or after surgical resection of the primary tumor with or without regional lymph node dissection. The LDH must be taken prior to systemic (chemo, immunotherapy, hormone), radiation therapy or surgery to a metastatic site. The lab value may be recorded in a lab report, history and physical, or clinical statement in the pathology report.\n\n**Note 3:** **Related data items** \n* The same laboratory test should be used to record the related data items 3932: LDH Lab Value and 3869: LDH Level.", - "last_modified" : "2024-04-08T16:58:27.973Z", + "last_modified" : "2025-11-06T15:49:42.721Z", "definition" : [ { "key" : "ldh_upper_limit", "name" : "Code", @@ -17,6 +17,6 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "001-999", "001 - 999 upper limit of normal \n(Exact upper limit of normal)" ], [ "XX8", "Not applicable: Information not collected for this case\n(If this information is required by your standard setter, use of code XX8 may result in an edit error.)" ], [ "XX9", "Not documented in medical record\nLDH Upper Limit not assessed or unknown if assessed" ] ], - "additional_info" : "**Source documents:** clinical laboratory report; may be included in a liver or hepatic panel/profile, a cardiac panel, or a general metabolic panel of tests\n\n**Other names include:** LDH, Lactate dehydrogenase, lactase dehydrogenase, lactic acid dehydrogenase\n\n**Normal reference range** varies widely by laboratory, patient age, and the units of measurement \n* Upper limits of normal for LDH vary widely depending on the lab. \n* Common upper limits can be 200, 250, 618, or other values.\n\n***Examples*** of reference range lab values:\n * Lab A Total LDH 71 – 207 U/L\n * Lab B Total LDH 300 – 600 U/L\n * Lab C LDH 45 – 90 U/L\n * Lab D Total LDH 150 – 250 U/L", + "additional_info" : "**Source documents:** clinical laboratory report; may be included in a liver or hepatic panel/profile, a cardiac panel, or a general metabolic panel of tests\n\n**Other names include:** LDH, Lactate dehydrogenase, lactase dehydrogenase, lactic acid dehydrogenase\n\n**Normal reference range** varies widely by laboratory, patient age, and the units of measurement.\n* Upper limits of normal for LDH vary widely depending on the lab. \n* Common upper limits can be 200, 250, 618, or other values.\n\n***Examples*** of reference range lab values:\n * Lab A Total LDH 71 – 207 U/L\n * Lab B Total LDH 300 – 600 U/L\n * Lab C LDH 45 – 90 U/L\n * Lab D Total LDH 150 – 250 U/L", "rationale" : "LDH (Lactate Dehydrogenase) Upper Limits of Normal is a Registry Data Collection Variable in AJCC. It was previously collected as Melanoma Skin, CS SSF #6." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ln_assessment_method_femoral_inguinal_48450.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ln_assessment_method_femoral_inguinal_48450.json index be4f17d26..a1cb7b805 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ln_assessment_method_femoral_inguinal_48450.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ln_assessment_method_femoral_inguinal_48450.json @@ -5,8 +5,8 @@ "name" : "LN Assessment Method Femoral-Inguinal", "title" : "Lymph Nodes Assessment Method Femoral-Inguinal", "description" : "This data item describes the method used to assess involvement of femoral-inguinal lymph nodes associated with certain female genital cancers.\n\nIn addition to assigning the N categories for vulva, vagina, and cervical cancers, the collection of specific lymph nodes and how they were assessed is important.\n* Status refers to positive or negative involvement\n* Assessment is the method by which the nodal status was determined\n\nThere are 3 related data items that collect assessment method information on regional lymph nodes, and 1 data item for distant lymph nodes. \n\nThe LN assessment data items collect how the lymph nodes were assessed for femoral-inguinal, para-aortic, and pelvic lymph nodes, and distant lymph nodes scalene and mediastinal. These related data items include\n* 3871: LN Assessment Method Femoral-Inguinal\n* 3872: LN Assessment Method Para-Aortic\n* 3873: LN Assessment Method Pelvic\n* 3874: LN Distant Assessment Method", - "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of the femoral-inguinal assessment methodcan be used to code this data item when no other information is available.\n\n**Note 2:** **Lower third of vagina**\n* Code this data item for the lower third of the vagina only.\n* Code 9 for upper two thirds of the vagina, or unknown whether it’s the lower third or upper two thirds\n\n**Note 3:** **Femoral-inguinal nodes** \n* Femoral\n* Inguinal, NOS\n * Inguinofemoral (groin)\n * Node of Cloquet or Rosenmuller (highest deep inguinal)\n * Superficial inguinal \n\n**Note 4:** **Isolated tumor cells**\n* For this data item, do not include isolated tumor cells (ITCs).\n\n**Note 5:** **Related data item**\n* The status of the lymph nodes is recorded in the related data item 3859: LN Status Femoral-Inguinal.", - "last_modified" : "2025-02-24T16:44:12.812Z", + "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of the femoral-inguinal assessment method can be used to code this data item when no other information is available.\n\n**Note 2:** **Lower third of vagina**\n* Code this data item for the lower third of the vagina only.\n* Code 9 for upper two thirds of the vagina, or unknown whether it’s the lower third or upper two thirds\n\n**Note 3:** **Femoral-inguinal nodes** \n* Femoral\n* Inguinal, NOS\n * Inguinofemoral (groin)\n * Node of Cloquet or Rosenmuller (highest deep inguinal)\n * Superficial inguinal \n\n**Note 4:** **Isolated tumor cells**\n* For this data item, do not include isolated tumor cells (ITCs).\n\n**Note 5:** **Related data item**\n* The status of the lymph nodes is recorded in the related data item 3859: LN Status Femoral-Inguinal.", + "last_modified" : "2025-11-06T20:21:47.166Z", "definition" : [ { "key" : "ln_assessment_femoral", "name" : "Code", @@ -18,6 +18,6 @@ } ], "rows" : [ [ "0", "Radiography, imaging \n(Ultrasound (US), computed tomography scan (CT), magnetic resonance imaging (MRI), positron emission tomography scan (PET))\n\nPhysical exam only" ], [ "1", "Incisional biopsy; fine needle aspiration (FNA)" ], [ "2", "Lymphadenectomy\nSentinel node biopsy\nExcisional biopsy or resection with microscopic confirmation" ], [ "7", "Femoral-inguinal lymph node(s) assessed, unknown assessment method" ], [ "8", "Not applicable: Information not collected for this case\n(If this item is required by your standard setter, use of code 8 will result in an edit error.)" ], [ "9", "Not documented in medical record\nFemoral-inguinal lymph node(s) not assessed or unknown if assessed" ] ], "additional_info" : "**Source documents:** pathology report, imaging, physical exam, other statement in record", - "coding_guidelines" : "**1)** Assign the highest applicable code (0-2) in the case of multiple assessments for the **lower third of the vagina only**\n**2)** **Code 0** when there is physical exam or imaging only\n**3)** **Code 1** when there is an incisional biopsy or FNA\n**4)** **Code 2** when there is an excisional biopsy, sentinel lymph node biopsy, or lymph node resection\n**5)** **Code 7** when lymph nodes are assessed, but it is unknown how\n**6)** **Code 9** when\n* Primary site location is **upper two thirds of the vagina**, or **unknown** whether it's the lower third or upper two thirds\n* Not documented in medical record\n* Regional/Distant lymph nodes not evaluated (assessed)\n* Unknown if regional/distant lymph nodes evaluated (assessed)", + "coding_guidelines" : "**1)** Assign the highest applicable code (0-2) in the case of multiple assessments for the **lower third of the vagina only**\n\n**2)** **Code 0** when there is physical exam or imaging only\n\n**3)** **Code 1** when there is an incisional biopsy or FNA\n\n**4)** **Code 2** when there is an excisional biopsy, sentinel lymph node biopsy, or lymph node resection\n\n**5)** **Code 7** when lymph nodes are assessed, but it is unknown how\n\n**6)** **Code 9** when\n* Primary site location is **upper two thirds of the vagina**, or **unknown** whether it's the lower third or upper two thirds\n* Not documented in medical record\n* Regional/Distant lymph nodes not evaluated (assessed)\n* Unknown if regional/distant lymph nodes evaluated (assessed)", "rationale" : "This data item describes the method used to assess involvement of femoral-inguinal lymph nodes associated with certain female genital cancers." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ln_assessment_method_pelvic_vulva_10928.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ln_assessment_method_pelvic_vulva_10928.json index b9e563b1e..4d443bda4 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ln_assessment_method_pelvic_vulva_10928.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ln_assessment_method_pelvic_vulva_10928.json @@ -6,7 +6,7 @@ "title" : "Lymph Nodes Assessment Method Pelvic", "description" : "This data item describes the method used to assess involvement of pelvic lymph nodes associated with certain female genital cancers.\n\nIn addition to assigning the N categories for vulva, vagina, and cervical cancers, the collection of specific lymph nodes and how they were assessed is important.\n* Status refers to positive or negative involvement\n* Assessment is the method by which the nodal status was determined\n\nThere are 3 related data items that collect assessment method information on regional lymph nodes, and 1 data item for distant lymph nodes. \n\nThe LN assessment data items collect how the lymph nodes were assessed for femoral-inguinal, para-aortic, and pelvic lymph nodes, and distant lymph nodes scalene and mediastinal. These related data items include\n\n* 3871: LN Assessment Method Femoral-Inguinal\n* 3872: LN Assessment Method Para-Aortic\n* 3873: LN Assessment Method Pelvic\n* 3874: LN Distant Assessment Method", "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of pelvic status can be used to code this data item when no other information is available. \n\n**Note 2:** **Vulva and pelvic lymph nodes**\n* For Vulva, pelvic lymph nodes are distant \n\n**Note 3:** **Pelvic lymph nodes** \n* Iliac, NOS\n * Common\n * External\n * Internal (hypogastric) (obturator)\n* Paracervical\n* Parametrial\n* Pelvic, NOS\n* Sacral, NOS\n * Lateral (laterosacral)\n * Middle (promontorial) (Gerota’s node)\n * Uterosacral\n\n**Note 4:** **Isolated tumor cells**\n* For this data item, do not include isolated tumor cells (ITCs).\n\n**Note 5:** **Related data item**\n* The status of the lymph nodes is recorded in the related data item 3957: LN Status: Pelvic", - "last_modified" : "2025-02-24T16:48:19.326Z", + "last_modified" : "2025-11-06T20:12:07.010Z", "definition" : [ { "key" : "ln_assessment_pelvic", "name" : "Code", @@ -18,6 +18,6 @@ } ], "rows" : [ [ "0", "Radiography, imaging \n(Ultrasound (US), computed tomography scan (CT), magnetic resonance imaging (MRI), positron emission tomography scan (PET))\n\nPhysical exam only" ], [ "1", "Incisional biopsy; fine needle aspiration (FNA)" ], [ "2", "Lymphadenectomy\nSentinel node biopsy\nExcisional biopsy or resection with microscopic confirmation" ], [ "7", "Pelvic lymph node(s) assessed, unknown assessment method" ], [ "8", "Not applicable: Information not collected for this case\n(If this item is required by your standard setter, use of code 8 will result in an edit error.)" ], [ "9", "Not documented in medical record\nPelvic lymph node(s) not assessed or unknown if assessed" ] ], "additional_info" : "**Source documents:** pathology report, imaging, physical exam, other statement in record", - "coding_guidelines" : "**1)** Assign the highest applicable code (0-2) in the case of multiple assessments.\n**2)** **Code 0** when there is physical exam or imaging only\n**3)** **Code 1** when there is an incisional biopsy or FNA\n**4)** **Code 2** when there is an excisional biopsy, sentinel lymph node biopsy, or lymph node resection\n**5)** **Code 7** when lymph nodes are assessed, but it is unknown how\n**6)** **Code 9** when\n* Not documented in medical record\n* Regional/Distant lymph nodes not evaluated (assessed)\n* Unknown if regional/distant lymph nodes evaluated (assessed)", + "coding_guidelines" : "**1)** Assign the highest applicable code (0-2) in the case of multiple assessments\n\n**2)** **Code 0** when there is physical exam or imaging only\n\n**3)** **Code 1** when there is an incisional biopsy or FNA\n\n**4)** **Code 2** when there is an excisional biopsy, sentinel lymph node biopsy, or lymph node resection\n\n**5)** **Code 7** when lymph nodes are assessed, but it is unknown how\n\n**6)** **Code 9** when\n* Not documented in medical record\n* Regional/Distant lymph nodes not evaluated (assessed)\n* Unknown if regional/distant lymph nodes evaluated (assessed)", "rationale" : "Method of assessment of regional nodal status is listed as a Registry Data Collection Variable in the AJCC GYN chapters. This data item was previously collected as Vulva, SSF #13." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ln_size_70140.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ln_size_70140.json index c58e0a004..2e739a869 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ln_size_70140.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ln_size_70140.json @@ -6,8 +6,8 @@ "title" : "LN Size", "subtitle" : "Lymph Nodes Size", "description" : "Lymph Node Size records the largest diameter of any involved regional lymph node(s). Pathological measurement takes precedence over a clinical measurement for the same node.\n\nThis data item is used to code the size of involved lymph nodes and is recorded in millimeters.", - "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of Lymph Nodes Size can be used to code this data item when no other information is available. \n\n**Note 2:** **Criteria for coding LN size** \n* The metric is the **size of the largest tumor deposit** in the lymph node, not the size of the overall lymph node that is involved. \n* For larger nodes however, the size of the deposit becomes essentially the size of the overall lymph node as the nodes become almost entirely overtaken with tumor. \n* Code the size of the largest deposit if pathology reports separately list the size of a deposit and the size of the overall lymph node that the deposit is involving.\n\n**Note 3:** **Clinical vs Pathological size** \n* Code the **clinical node size** when the largest involved node is not examined pathologically.\n* Code the **pathological node size** when the largest involved node (or same level) is examined clinically and pathologically, even if the pathological size is smaller.\n* Code the **size of the largest deposit** when the pathology report separately lists the size of a deposit and the size of the overall lymph node that the deposit is involving. \n * ***Example:*** Clinical evaluation shows 1.5 cm (15 mm) Level II lymph node, pathological examination shows positive Level II node 1.3 cm (13 mm), with size of largest nodal deposit 1.3 mm\n * Code 13.0.\n\n**Note 4:** **Regional vs. distant nodes**\n* Do not code the size of any distant nodes.", - "last_modified" : "2025-06-10T16:45:24.064Z", + "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of Lymph Nodes Size can be used to code this data item when no other information is available. \n\n**Note 2:** **Criteria for coding LN size** \n* The metric is the **size of the largest tumor deposit** in the lymph node, not the size of the overall lymph node that is involved. \n* For larger nodes however, the size of the deposit becomes essentially the size of the overall lymph node as the nodes become almost entirely overtaken with tumor. \n* Code the size of the largest deposit if pathology reports separately list the size of a deposit and the size of the overall lymph node that the deposit is involving.\n\n**Note 3:** **Clinical vs Pathological size** \n* Code the **clinical node size** when the largest involved node is not examined pathologically.\n* Code the **pathological node size** when the largest involved node (or same level) is examined clinically and pathologically, even if the pathological size is smaller.\n* Code the **size of the largest deposit** when the pathology report separately lists the size of a deposit and the size of the overall lymph node that the deposit is involving. \n * ***Example:*** Clinical evaluation shows 1.5 cm (15 mm) Level II lymph node, pathological examination shows positive Level II node 1.3 cm (13 mm), with size of largest nodal deposit 1.3 mm\n * Code 13.0.\n\n**Note 4:** **Regional vs. distant nodes**\n* Do not code the size of any distant nodes.", + "last_modified" : "2025-11-06T17:03:25.965Z", "definition" : [ { "key" : "ln_size_of_mets", "name" : "Code", @@ -19,6 +19,6 @@ } ], "rows" : [ [ "0.0", "No regional lymph node involvement\nNon-invasive neoplasm (behavior /2)" ], [ "0.1-99.9", "0.1 - 99.9 millimeters (mm)\n(Exact size of lymph node to nearest tenth of a mm)" ], [ "XX.1", "100 millimeters (mm) or greater" ], [ "XX.2", "Microscopic focus or foci only and no size of focus given" ], [ "XX.3", "Described as \"less than 1 centimeter (cm)\" or \"subcentimeter\"" ], [ "XX.4", "Described as \"at least\" 2 cm" ], [ "XX.5", "Described as \"at least\" 3 cm" ], [ "XX.6", "Described as \"at least\" 4 cm" ], [ "XX.7", "Described as greater than 5 cm" ], [ "XX.8", "Not applicable: Information not collected for this case\n(If this item is required by your standard setter, use of code XX.8 will result in an edit error)" ], [ "XX.9", "Not documented in medical record\nRegional lymph node(s) involved, size not stated\nLymph Nodes Size not assessed, or unknown if assessed" ] ], "additional_info" : "**Source documents:** pathology report, imaging reports, physical exam\n\n**Other names include** ENE, extracapsular extension, ECE\n\n**For further information**, refer to the **Head and Neck** cancer protocols published by the College of American Pathologist for the AJCC Staging Systems for *Head and Neck*.", - "coding_guidelines" : "**1)** Code the largest size in millimeters of any involved regional lymph nodes for head and neck (cervical lymph nodes). The measurement can be pathological, if available, or clinical. **See note 3.**\n * Record size in millimeters\n\n**2)** **Code 0.0** when no regional lymph nodes are involved\n**3)** **Code XX.1** for 100 millimeters (10 cm) or greater\n**4)** **Code XX.2** for microscopic focus or foci only and no size of focus given\n**5)** **Code XX.3** for lymph node met less than 1 cm (10 mm)\n * Lymph node described as “subcentimeter”\n\n**6) Code XX.9** when\n * Positive lymph nodes but size not stated\n * No information about regional lymph nodes\n * Lymph nodes not assessed or unknown if assessed\n\n**7)** In order to align with the CAP guidelines, additional codes have been added for “at least” categories which are used in the CAP protocols. Only use these codes when the pathologist has used this terminology to indicate the lymph node size. \n* **XX.4:** Describes a lymph node size at least 2 cm (20 mm)\n* **XX.5:** Described a lymph node size at least 3 cm (30 mm)\n* **XX.6:** Describes a lymph node size at least 4 cm (40 mm)\n* **XX.7:** Describes a lymph node size 5 cm (50 mm) or greater", + "coding_guidelines" : "**1)** Code the largest size in millimeters of any involved regional lymph nodes for head and neck (cervical lymph nodes). The measurement can be pathological, if available, or clinical. **See note 3.**\n * Record size in millimeters\n\n**2)** **Code 0.0** when no regional lymph nodes are involved\n\n**3)** **Code XX.1** for 100 millimeters (10 cm) or greater\n\n**4)** **Code XX.2** for microscopic focus or foci only and no size of focus given\n\n**5)** **Code XX.3** for lymph node met less than 1 cm (10 mm)\n * Lymph node described as “subcentimeter”\n\n**6) Code XX.9** when\n * Positive lymph nodes but size not stated\n * No information about regional lymph nodes\n * Lymph nodes not assessed or unknown if assessed\n\n**7)** In order to align with the CAP guidelines, additional codes have been added for “at least” categories which are used in the CAP protocols. Only use these codes when the pathologist has used this terminology to indicate the lymph node size. \n* **XX.4:** Describes a lymph node size at least 2 cm (20 mm)\n* **XX.5:** Described a lymph node size at least 3 cm (30 mm)\n* **XX.6:** Describes a lymph node size at least 4 cm (40 mm)\n* **XX.7:** Describes a lymph node size 5 cm (50 mm) or greater", "rationale" : "Lymph Nodes Size is a Registry Data Collection Variable in AJCC for several chapters. It was previously collected in the Head and Neck chapters as Size of Lymph Nodes, SSF #1." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ln_status_femoral_inguinal_vagina_64638.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ln_status_femoral_inguinal_vagina_64638.json index 789645df2..aad9a81b7 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ln_status_femoral_inguinal_vagina_64638.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ln_status_femoral_inguinal_vagina_64638.json @@ -6,7 +6,7 @@ "title" : "LN Status: Femoral-Inguinal", "description" : "This data item describes the status of femoral-inguinal lymph nodes associated with certain female genital cancers.\n\nIn addition to assigning the N categories for vulva, vagina, and cervical cancers, the collection of specific lymph nodes and how they were assessed is important.\n* Status refers to positive or negative involvement\n* Assessment is the method by which the nodal status was determined\n\nThere are 3 related data items that collect status information on regional lymph nodes, 1 data item for distant lymph nodes, and 1 data item for laterality. \n\nThe LN status data items collect the individual status (positive, negative, unknown) involvement of femoral-inguinal, para-aortic, and pelvic lymph nodes, and distant lymph nodes mediastinal and scalene. These related data items include \n\n* 3957: LN Status: Pelvic\n* 3958: LN Status: Para-Aortic\n* 3959: LN Status: Femoral-Inguinal\n* 3875: LN Distant: Mediastinal, Scalene", "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of the femoral-inguinal status can be used to code this data item when no other information is available.\n\n**Note 2:** **Lower third of vagina**\n* Code this data item for the lower third of the vagina only.\n* Code 9 for upper two thirds of the vagina, or unknown whether it’s the lower third or upper two thirds\n\n**Note 3:** **Femoral-inguinal nodes** \n* Femoral\n* Inguinal, NOS\n * Inguinofemoral (groin)\n * Node of Cloquet or Rosenmuller (highest deep inguinal)\n * Superficial inguinal \n\n**Note 4:** **Isolated tumor cells**\n* For this data item, do not include isolated tumor cells (ITCs).\n\n**Note 5:** **Related data item**\n* The assessment method is recorded in the related data item 3871: LN Assessment Method Femoral-Inguinal.", - "last_modified" : "2025-05-30T12:29:19.403Z", + "last_modified" : "2025-11-06T20:14:58.969Z", "definition" : [ { "key" : "ln_status_femoral_inguinal", "name" : "LN Status Femoral-Inguinal", @@ -18,6 +18,6 @@ } ], "rows" : [ [ "0", "Negative femoral-inguinal lymph nodes\nNon-invasive neoplasm (behavior /2)" ], [ "1", "Positive femoral-inguinal lymph nodes" ], [ "8", "Not applicable: Information not collected for this case\n(If this information is required by your standard setter, use of code 8 may result in an edit error.)" ], [ "9", "Not documented in medical record\nFemoral-Inguinal lymph node(s) not assessed or unknown if assessed" ] ], "additional_info" : "**Source documents:** pathology report, imaging, physical exam, other statement in record", - "coding_guidelines" : "**1)** Code this data item for the **lower third of the vagina** only.\n**2)** **Code 0** when \n* Non-invasive neoplasm (behavior /2) (in-situ)\n* All lymph nodes are negative and included an assessment of the femoral-inguinal lymph nodes\n* If there is no mention of femoral-inguinal lymph node involvement in the area being imaged, biopsied, or in the surgical field and there is no mention of involvement, then assume that the femoral-inguinal lymph nodes are negative\n\n**3)** **Code 9** when\n* Primary site location is **upper two thirds of the vagina**, or **unknown** whether it's the lower third or upper two thirds\n* When there is no imaging, biopsy, surgical workup, or a physical exam only\n* Not documented in medical record\n* Regional/Distant lymph nodes not evaluated (assessed)\n* Unknown if regional/distant lymph nodes evaluated (assessed)", + "coding_guidelines" : "**1)** Code this data item for the **lower third of the vagina** only.\n\n**2)** **Code 0** when \n* Non-invasive neoplasm (behavior /2) (in-situ)\n* All lymph nodes are negative and included an assessment of the femoral-inguinal lymph nodes\n* If there is no mention of femoral-inguinal lymph node involvement in the area being imaged, biopsied, or in the surgical field and there is no mention of involvement, then assume that the femoral-inguinal lymph nodes are negative\n\n**3)** **Code 9** when\n* Primary site location is **upper two thirds of the vagina**, or **unknown** whether it's the lower third or upper two thirds\n* When there is no imaging, biopsy, surgical workup, or a physical exam only\n* Not documented in medical record\n* Regional/Distant lymph nodes not evaluated (assessed)\n* Unknown if regional/distant lymph nodes evaluated (assessed)", "rationale" : "Specific regional lymph node involvement is listed as a Registry Data Collection Variable in AJCC. This information was previously collected as Vulva, SSF #14 and is now collected in Vagina." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/lymph_node_laterality_65685.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/lymph_node_laterality_65685.json index acbd202c3..fbee43e83 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/lymph_node_laterality_65685.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/lymph_node_laterality_65685.json @@ -6,7 +6,7 @@ "title" : "Lymph Nodes Laterality", "description" : "This data item describes whether positive regional lymph nodes are unilateral or bilateral.", "notes" : "**Note:** **Physician Statement** \n* Physician statement of lymph node laterality can be used to code this data item when no other information is available.", - "last_modified" : "2025-02-24T16:48:58.699Z", + "last_modified" : "2025-11-06T20:12:38.870Z", "definition" : [ { "key" : "ln_laterality", "name" : "Code", @@ -18,6 +18,6 @@ } ], "rows" : [ [ "0", "No regional lymph node involvement\nNon-invasive neoplasm (behavior /2)" ], [ "1", "Unilateral - all positive regional nodes with same laterality\nOR only one regional node positive" ], [ "2", "Bilateral - positive bilateral regional lymph nodes" ], [ "3", "Laterality unknown - positive regional lymph nodes with unknown laterality" ], [ "8", "Not applicable: Information not collected for this case\n(If this information is required by your standard setter, use of code 8 may result in an edit error.)" ], [ "9", "Not documented in medical record\nLymph node laterality not assessed or unknown if assessed" ] ], "additional_info" : "**Source documents:** pathology report, imaging, physical exam, other statement in record", - "coding_guidelines" : "**1)** Code the appropriate description of involved regional lymph nodes\n**2)** **Code 0** when all regional lymph nodes are negative\n**3)** **Code 1** when\n* All positive regional nodes are ipsilateral\n* Involved lymph nodes are described as unilateral\n* Only one regional node positive\n\n**4)** **Code 2** when\n* At least one regional lymph node is involved on each side of the body \n* Involvement is described as bilateral or contralateral\n\n**5)** **Code 3** when regional lymph node(s) are described as positive, but the laterality of the involved nodes is unknown\n\n**6)** **Code 9** when\n* Lymph nodes were not examined or assessed\n* There is no information in the medical record about regional lymph node involvement\n* The status of regional lymph nodes is unknown", + "coding_guidelines" : "**1)** Code the appropriate description of involved regional lymph nodes\n\n**2)** **Code 0** when all regional lymph nodes are negative\n\n**3)** **Code 1** when\n* All positive regional nodes are ipsilateral\n* Involved lymph nodes are described as unilateral\n* Only one regional node positive\n\n**4)** **Code 2** when\n* At least one regional lymph node is involved on each side of the body \n* Involvement is described as bilateral or contralateral\n\n**5)** **Code 3** when regional lymph node(s) are described as positive, but the laterality of the involved nodes is unknown\n\n**6)** **Code 9** when\n* Lymph nodes were not examined or assessed\n* There is no information in the medical record about regional lymph node involvement\n* The status of regional lymph nodes is unknown", "rationale" : "Laterality of regional node metastasis is a Registry Data Collection Variable in AJCC. This data item was previously collected as Vulva, CS SSF #11." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/lymph_nodes_assessment_method_femoral_46948.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/lymph_nodes_assessment_method_femoral_46948.json index 426ca46e9..1bb0775a5 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/lymph_nodes_assessment_method_femoral_46948.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/lymph_nodes_assessment_method_femoral_46948.json @@ -6,7 +6,7 @@ "title" : "Lymph Nodes Assessment Method Femoral-Inguinal", "description" : "This data item describes the method used to assess involvement of femoral-inguinal lymph nodes associated with certain female genital cancers.\n\nIn addition to assigning the N categories for vulva, vagina, and cervical cancers, the collection of specific lymph nodes and how they were assessed is important.\n* Status refers to positive or negative involvement\n* Assessment is the method by which the nodal status was determined\n\nThere are 3 related data items that collect assessment method information on regional lymph nodes, and 1 data item for distant lymph nodes. \n\nThe LN assessment data items collect how the lymph nodes were assessed for femoral-inguinal, para-aortic, and pelvic lymph nodes, and distant lymph nodes scalene and mediastinal. These related data items include\n* 3871: LN Assessment Method Femoral-Inguinal\n* 3872: LN Assessment Method Para-Aortic\n* 3873: LN Assessment Method Pelvic\n* 3874: LN Distant Assessment Method", "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of the femoral-inguinal assessment method can be used to code this data item when no other information is available.\n\n**Note 2:** **Femoral-inguinal nodes** \n* Femoral\n* Inguinal, NOS\n * Inguinofemoral (groin)\n * Node of Cloquet or Rosenmuller (highest deep inguinal)\n * Superficial inguinal \n\n**Note 3:** **Isolated tumor cells**\n* For this data item, do not include isolated tumor cells (ITCs).\n\n**Note 4:** **Related data item**\n* The status of the lymph nodes is recorded in the related data item 3859: LN Status Femoral-Inguinal.", - "last_modified" : "2024-04-08T20:22:54.018Z", + "last_modified" : "2025-11-06T20:11:23.472Z", "definition" : [ { "key" : "ln_assessment_femoral", "name" : "Code", @@ -18,6 +18,6 @@ } ], "rows" : [ [ "0", "Radiography, imaging \n(Ultrasound (US), computed tomography scan (CT), magnetic resonance imaging (MRI), positron emission tomography scan (PET))\n\nPhysical exam only" ], [ "1", "Incisional biopsy; fine needle aspiration (FNA)" ], [ "2", "Lymphadenectomy\nSentinel node biopsy\nExcisional biopsy or resection with microscopic confirmation" ], [ "7", "Femoral-inguinal lymph node(s) assessed, unknown assessment method" ], [ "8", "Not applicable: Information not collected for this case\n(If this item is required by your standard setter, use of code 8 will result in an edit error.)" ], [ "9", "Not documented in medical record\nFemoral-inguinal lymph node(s) not assessed or unknown if assessed" ] ], "additional_info" : "**Source documents:** pathology report, imaging, physical exam, other statement in record", - "coding_guidelines" : "**1)** Assign the highest applicable code (0-2) in the case of multiple assessments.\n**2)** **Code 0** when there is physical exam or imaging only\n**3)** **Code 1** when there is an incisional biopsy or FNA\n**4)** **Code 2** when there is an excisional biopsy or lymph node resection\n**5)** **Code 7** when lymph nodes are assessed, but it is unknown how\n**6)** **Code 9** when\n* Not documented in medical record\n* Regional/Distant lymph nodes not evaluated (assessed)\n* Unknown if regional/distant lymph nodes evaluated (assessed)", + "coding_guidelines" : "**1)** Assign the highest applicable code (0-2) in the case of multiple assessments\n\n**2)** **Code 0** when there is physical exam or imaging only\n\n**3)** **Code 1** when there is an incisional biopsy or FNA\n\n**4)** **Code 2** when there is an excisional biopsy or lymph node resection\n\n**5)** **Code 7** when lymph nodes are assessed, but it is unknown how\n\n**6)** **Code 9** when\n* Not documented in medical record\n* Regional/Distant lymph nodes not evaluated (assessed)\n* Unknown if regional/distant lymph nodes evaluated (assessed)", "rationale" : "Method of assessment of regional nodal status is listed as a Registry Data Collection Variable in the AJCC GYN chapters. This data item was previously collected as Vulva, SSF #15." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/lymph_nodes_assessment_method_para_aortic_56026.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/lymph_nodes_assessment_method_para_aortic_56026.json index 5ab41f05c..c87ee0d33 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/lymph_nodes_assessment_method_para_aortic_56026.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/lymph_nodes_assessment_method_para_aortic_56026.json @@ -6,7 +6,7 @@ "title" : "Lymph Nodes Assessment Method Para-aortic", "description" : "This data item describes the method used to assess involvement of para-aortic lymph nodes associated with certain female genital cancers.\n\nIn addition to assigning the N categories for vulva, vagina, and cervical cancers, the collection of specific lymph nodes and how they were assessed is important.\n* Status refers to positive or negative involvement\n* Assessment is the method by which the nodal status was determined\n\nThere are 3 related data items that collect assessment method information on regional lymph nodes, and 1 data item for distant lymph nodes. \n\nThe LN assessment data items collect how the lymph nodes were assessed for femoral-inguinal, para-aortic, and pelvic lymph nodes, and distant lymph nodes scalene and mediastinal. These related data items include\n* 3871: LN Assessment Method Femoral-Inguinal\n* 3872: LN Assessment Method Para-Aortic\n* 3873: LN Assessment Method Pelvic\n* 3874: LN Distant Assessment Method", "notes" : "**Note 1:** **Physician Statement**\n* Physician statement of para-aortic assessment method can be used to code this data item when no other information is available. \n\n**Note 2:** **Para-aortic lymph nodes**\n* Aortic\n* Lateral aortic/lumbar aortic\n* Para-aortic, NOS\n* Periaortic\n\n**Note 3:** **Isolated tumor cells**\n* For this data item, do not include isolated tumor cells (ITCs).\n\n**Note 4:** **Related data item**\n* The status of the lymph nodes is recorded in the related data item 3959: LN Status Para-aortic.", - "last_modified" : "2025-02-24T15:31:28.109Z", + "last_modified" : "2025-11-06T20:16:19.425Z", "definition" : [ { "key" : "ln_assessment_para_aortic", "name" : "Code", @@ -18,6 +18,6 @@ } ], "rows" : [ [ "0", "Radiography, imaging \n(Ultrasound (US), computed tomography scan (CT), magnetic resonance imaging (MRI), positron emission tomography scan (PET))\n\nPhysical exam only" ], [ "1", "Incisional biopsy; fine needle aspiration (FNA)" ], [ "2", "Lymphadenectomy\nSentinel node biopsy\nExcisional biopsy or resection with microscopic confirmation" ], [ "7", "Para-aortic lymph node(s) assessed, unknown assessment method" ], [ "8", "Not applicable: Information not collected for this case\n(If this item is required by your standard setter, use of code 8 will result in an edit error.)" ], [ "9", "Not documented in medical record\nPara-aortic lymph node(s) not assessed or unknown if assessed" ] ], "additional_info" : "**Source documents:** pathology report, imaging, physical exam, other statement in record", - "coding_guidelines" : "**1** Assign the highest applicable code (0-2) in the case of multiple assessments\n**2)** **Code 0** when there is physical exam or imaging only\n**3)** **Code 1** when there is an incisional biopsy or FNA\n**4)** **Code 2** when there is an excisional biopsy, sentinel lymph node biopsy, or lymph node resection\n**5)** **Code 7** when lymph nodes are assessed, but it is unknown how\n**6)** **Code 9** when\n* Not documented in medical record\n* Regional/Distant lymph nodes not evaluated (assessed)\n* Unknown if regional/distant lymph nodes evaluated (assessed)", + "coding_guidelines" : "**1** Assign the highest applicable code (0-2) in the case of multiple assessments\n\n**2)** **Code 0** when there is physical exam or imaging only\n\n**3)** **Code 1** when there is an incisional biopsy or FNA\n\n**4)** **Code 2** when there is an excisional biopsy, sentinel lymph node biopsy, or lymph node resection\n\n**5)** **Code 7** when lymph nodes are assessed, but it is unknown how\n\n**6)** **Code 9** when\n* Not documented in medical record\n* Regional/Distant lymph nodes not evaluated (assessed)\n* Unknown if regional/distant lymph nodes evaluated (assessed)", "rationale" : "Method of assessment of regional nodal status is listed as a Registry Data Collection Variable in the AJCC GYN chapters. This data item was previously collected as Vagina, CS SSF #5." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/lymph_nodes_assessment_method_pelvic_33476.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/lymph_nodes_assessment_method_pelvic_33476.json index fbd5372a4..d0b53b7b6 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/lymph_nodes_assessment_method_pelvic_33476.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/lymph_nodes_assessment_method_pelvic_33476.json @@ -6,7 +6,7 @@ "title" : "Lymph Nodes Assessment Method Pelvic", "description" : "This data item describes the method used to assess involvement of pelvic lymph nodes associated with certain female genital cancers.\n\nIn addition to assigning the N categories for vulva, vagina, and cervical cancers, the collection of specific lymph nodes and how they were assessed is important.\n* Status refers to positive or negative involvement\n* Assessment is the method by which the nodal status was determined\n\nThere are 3 related data items that collect assessment method information on regional lymph nodes, and 1 data item for distant lymph nodes. \n\nThe LN assessment data items collect how the lymph nodes were assessed for femoral-inguinal, para-aortic, and pelvic lymph nodes, and distant lymph nodes scalene and mediastinal. These related data items include\n\n* 3871: LN Assessment Method Femoral-Inguinal\n* 3872: LN Assessment Method Para-Aortic\n* 3873: LN Assessment Method Pelvic\n* 3874: LN Distant Assessment Method", "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of pelvic assessment method can be used to code this data item when no other information is available. \n\n**Note 2:** **Pelvic lymph nodes** \n* Iliac, NOS\n * Common\n * External\n * Internal (hypogastric) (obturator)\n* Paracervical\n* Parametrial\n* Pelvic, NOS\n* Sacral, NOS\n * Lateral (laterosacral)\n * Middle (promontorial) (Gerota’s node)\n * Uterosacral\n\n**Note 3:** **Isolated tumor cells**\n* For this data item, do not include isolated tumor cells (ITCs).\n\n**Note 4:** **Related data item**\n* The status of the lymph nodes is recorded in the related data item 3959: LN Status Pelvic.", - "last_modified" : "2025-02-24T15:33:02.550Z", + "last_modified" : "2025-11-06T20:17:00.773Z", "definition" : [ { "key" : "ln_assessment_pelvic", "name" : "Code", @@ -18,6 +18,6 @@ } ], "rows" : [ [ "0", "Radiography, imaging \n(Ultrasound (US), computed tomography scan (CT), magnetic resonance imaging (MRI), positron emission tomography scan (PET))\n\nPhysical exam only" ], [ "1", "Incisional biopsy; fine needle aspiration (FNA)" ], [ "2", "Lymphadenectomy\nSentinel node biopsy\nExcisional biopsy or resection with microscopic confirmation" ], [ "7", "Pelvic lymph node(s) assessed, unknown assessment method" ], [ "8", "Not applicable: Information not collected for this case\n(If this item is required by your standard setter, use of code 8 will result in an edit error.)" ], [ "9", "Not documented in medical record\nPelvic lymph node(s) not assessed or unknown if assessed" ] ], "additional_info" : "**Source documents:** pathology report, imaging, physical exam, other statement in record", - "coding_guidelines" : "**1)** Assign the highest applicable code (0-2) in the case of multiple assessments\n**2)** **Code 0** when there is physical exam or imaging only\n**3)** **Code 1** when there is an incisional biopsy or FNA\n**4)** **Code 2** when there is an excisional biopsy, sentinel lymph node biopsy, or lymph node resection\n**5)** **Code 7** when lymph nodes are assessed, but it is unknown how\n**6)** **Code 9** when\n* Not documented in medical record\n* Regional/Distant lymph nodes not evaluated (assessed)\n* Unknown if regional/distant lymph nodes evaluated (assessed)", + "coding_guidelines" : "**1)** Assign the highest applicable code (0-2) in the case of multiple assessments\n\n**2)** **Code 0** when there is physical exam or imaging only\n\n**3)** **Code 1** when there is an incisional biopsy or FNA\n\n**4)** **Code 2** when there is an excisional biopsy, sentinel lymph node biopsy, or lymph node resection\n\n**5)** **Code 7** when lymph nodes are assessed, but it is unknown how\n\n**6)** **Code 9** when\n* Not documented in medical record\n* Regional/Distant lymph nodes not evaluated (assessed)\n* Unknown if regional/distant lymph nodes evaluated (assessed)", "rationale" : "Specific regional lymph node involvement is listed as a Registry Data Collection Variable in AJCC. This information was previously collected as Cervix, SSF #2 and Vagina, SSF # 2." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/lymph_nodes_distant_assessment_method_24499.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/lymph_nodes_distant_assessment_method_24499.json index 7a671f11e..65dc3c5f1 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/lymph_nodes_distant_assessment_method_24499.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/lymph_nodes_distant_assessment_method_24499.json @@ -6,7 +6,7 @@ "title" : "Lymph Nodes Distant Assessment Method", "description" : "This data item describes the method used to assess involvement of Distant (mediastinal, scalene) nodes associated with certain female genital cancers.\n\nIn addition to assigning the N categories for vulva, vagina, and cervical cancers, the collection of specific lymph nodes and how they were assessed is important.\n* Status refers to positive or negative involvement\n* Assessment is the method by which the nodal status was determined\n\nThere are 3 related data items that collect assessment method information on regional lymph nodes, and 1 data item for distant lymph nodes. \n\nThe LN assessment data items collect how the lymph nodes were assessed for femoral-inguinal, para-aortic, and pelvic lymph nodes, and distant lymph nodes scalene and mediastinal. These related data items include\n* 3871: LN Assessment Method Femoral-Inguinal\n* 3872: LN Assessment Method Para-Aortic\n* 3873: LN Assessment Method Pelvic\n* 3874: LN Distant Assessment Method", "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of Mediastinal and Scalene assessment method can be used to code this data item when no other information is available.\n\n**Note 2:** **Related data item** \n* The status of the lymph nodes is recorded in the related data item 3875: LN Distant: Mediastinal, Scalene.", - "last_modified" : "2025-02-24T15:34:15.806Z", + "last_modified" : "2025-11-06T20:17:43.564Z", "definition" : [ { "key" : "ln_distant_assessment", "name" : "Code", @@ -18,6 +18,6 @@ } ], "rows" : [ [ "0", "Radiography, imaging \n(Ultrasound (US), computed tomography scan (CT), magnetic resonance imaging (MRI), positron emission tomography scan (PET))\n\nPhysical exam only" ], [ "1", "Incisional biopsy; fine needle aspiration (FNA)" ], [ "2", "Lymphadenectomy\nExcisional biopsy or resection with microscopic confirmation" ], [ "7", "Distant lymph node(s) assessed, unknown assessment method" ], [ "8", "Not applicable: Information not collected for this case\n(If this item is required by your standard setter, use of code 8 will result in an edit error.)" ], [ "9", "Not documented in medical record\nDistant lymph node(s) not assessed or unknown if assessed" ] ], "additional_info" : "**Source documents:** pathology report, imaging, physical exam, other statement in record", - "coding_guidelines" : "**1)** Assign the highest applicable code (0-2) in the case of multiple assessments\n**2)** **Code 0** when there is physical exam or imaging only\n**3)** **Code 1** when there is an incisional biopsy or FNA\n**4)** **Code 2** when there is an excisional biopsy, sentinel lymph node biopsy, or lymph node resection\n**5)** **Code 7** when lymph nodes are assessed, but it is unknown how\n**6)** **Code 9** when\n* Not documented in medical record\n* Regional/Distant lymph nodes not evaluated (assessed)\n* Unknown if regional/distant lymph nodes evaluated (assessed)", + "coding_guidelines" : "**1)** Assign the highest applicable code (0-2) in the case of multiple assessments\n\n**2)** **Code 0** when there is physical exam or imaging only\n\n**3)** **Code 1** when there is an incisional biopsy or FNA\n\n**4)** **Code 2** when there is an excisional biopsy, sentinel lymph node biopsy, or lymph node resection\n\n**5)** **Code 7** when lymph nodes are assessed, but it is unknown how\n\n**6)** **Code 9** when\n* Not documented in medical record\n* Regional/Distant lymph nodes not evaluated (assessed)\n* Unknown if regional/distant lymph nodes evaluated (assessed)", "rationale" : "Method of assessment of distant nodal status is listed as a Registry Data Collection Variable in the AJCC GYN chapters. This data item was previously collected as Vagina, CS SSF #7." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/lymph_nodes_head_and_neck_levels_i_iii_19222.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/lymph_nodes_head_and_neck_levels_i_iii_19222.json index 01efb1857..e8af40e73 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/lymph_nodes_head_and_neck_levels_i_iii_19222.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/lymph_nodes_head_and_neck_levels_i_iii_19222.json @@ -4,9 +4,9 @@ "version" : "3.3", "name" : "LN Head and Neck Levels I-III", "title" : "Lymph Nodes Head and Neck Levels I-III", - "description" : "Lymph Nodes for Head and Neck, Levels I-III records the involvement of Levels I-III lymph nodes.\n\nThis data item is used to code the presence or absence of lymph node involvement in head and neck levels I-III. The definitions of the levels are the same for all applicable head and neck sites. \n* Note: This data item was previously collected for all head and neck sites. It is now only clinically relevant for unknown head and neck primaries with positive cervical (head and neck) lymph nodes and mucosal melanomas of the head and neck.\n\n**Level I** is subdivided into levels IA and IB, which contain the submental and submandibular triangles bounded by the anterior and posterior bellies of the digastric muscle, the hyoid bone inferiorly, and the body of the mandible superiorly. Lymph node chains at this level:\n* Submental (Level IA), submandibular (Level IB), submaxillary (Level IB)\n\n**Level II** is subdivided into levels IIA and IIB, which contain the upper jugular lymph nodes and extend from the level of the skull base superiorly to the hyoid bone inferiorly. A vertical plane defined by the spinal accessory nerve is the boundary between level IIA (anterior to spinal accessory nerve) and IIB (posterior to spinal accessory nerve). Lymph node chains at this level:\n* Jugulodigastric (subdigastric), upper deep cervical, upper jugular\n\n**Level III** contains the middle jugular lymph nodes from the hyoid bone superiorly to the level of the lower border of the cricoid cartilage inferiorly. Lymph node chains at this level:\n* Middle deep cervical, mid-jugular", + "description" : "Lymph Nodes for Head and Neck, Levels I-III records the involvement of Levels I-III lymph nodes.\n\nThis data item is used to code the presence or absence of lymph node involvement in head and neck levels I-III. The definitions of the levels are the same for all applicable head and neck sites. \n* **Note:** This data item was previously collected for all head and neck sites. It is now only clinically relevant for unknown head and neck primaries with positive cervical (head and neck) lymph nodes and mucosal melanomas of the head and neck.\n\n**Level I** is subdivided into levels IA and IB, which contain the submental and submandibular triangles bounded by the anterior and posterior bellies of the digastric muscle, the hyoid bone inferiorly, and the body of the mandible superiorly. Lymph node chains at this level:\n* Submental (Level IA), submandibular (Level IB), submaxillary (Level IB)\n\n**Level II** is subdivided into levels IIA and IIB, which contain the upper jugular lymph nodes and extend from the level of the skull base superiorly to the hyoid bone inferiorly. A vertical plane defined by the spinal accessory nerve is the boundary between level IIA (anterior to spinal accessory nerve) and IIB (posterior to spinal accessory nerve). Lymph node chains at this level:\n* Jugulodigastric (subdigastric), upper deep cervical, upper jugular\n\n**Level III** contains the middle jugular lymph nodes from the hyoid bone superiorly to the level of the lower border of the cricoid cartilage inferiorly. Lymph node chains at this level:\n* Middle deep cervical, mid-jugular", "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of Levels I-III lymph node involvement can be used to code this data item when no other information is available.\t\n\n**Note 2:** **Related data items** \n* 3876: LN Head and Neck Levels I-III \n* 3877: LN Head and Neck Levels IV-V \n* 3878: LN Head and Neck Levels VI-VII \n* 3879: LN Head and Neck Other \n\n**Note 3:** **Priority order**\n* Pathological information takes priority over clinical.", - "last_modified" : "2025-04-09T14:15:24.197Z", + "last_modified" : "2025-11-06T17:08:13.650Z", "definition" : [ { "key" : "ln_hn_1_2_3", "name" : "Code", @@ -17,7 +17,7 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "0", "No involvement in Levels I, II, or III lymph nodes\nNon-invasive neoplasm (behavior /2)" ], [ "1", "Level I lymph node(s) involved" ], [ "2", "Level II lymph node(s) involved" ], [ "3", "Level III lymph node(s) involved" ], [ "4", "Levels I and II lymph nodes involved" ], [ "5", "Levels I and III lymph nodes involved" ], [ "6", "Levels II and III lymph nodes involved" ], [ "7", "Levels I, II and III lymph nodes involved" ], [ "8", "Not applicable: Information not collected for this case\n(If this item is required by your standard setter, use of code 8 will result in an edit error)" ], [ "9", "Not documented in medical record\nPositive nodes, but level of positive node(s) unknown\nLymph node levels I-III not assessed, or unknown if assessed" ] ], - "additional_info" : "**Source documents:** pathology report, imaging\n\nFor more information on **Head and Neck levels**, see AJCC 8th edition, Chapter 5: Staging Head and Neck Cancers, Table 5.1", + "additional_info" : "**Source documents:** pathology report, imaging\n\nFor more information on **Head and Neck levels**, see AJCC 8th edition, Chapter 5: Staging Head and Neck Cancers, Table 5.1.", "coding_guidelines" : "**1)** Code all applicable levels that are involved\n* ***Example:*** A carcinoma of the base of tongue involves bilateral submandibular nodes and left upper, mid-, and lower jugular nodes, the largest measuring 4 cm. There is no extracapsular extension. These are level I, II, III, and IV lymph nodes according to AJCC definitions. \n * Levels I-III: Code 7 (Levels I, II and III lymph nodes involved) to show that levels I, II, and III are involved\n * Levels IV-V: Code 1 to show that level IV is involved\n * Levels VI-VII: Code 0 for no other nodes involved\n * Head and Neck, Other: Code 0 for no other nodes involved\n\n**2)** If information is available on some nodes, but the others are unknown, code what is known. \n* ***Example:*** Multiple lymph nodes involved, level II documented, but the other levels not mentioned. Code 2 to indicate level II involvement.\n\n**3)** If a lymph node is described as involving two levels, or documented as a range, code both levels.\n* ***Example:*** Physical examination for a floor of mouth cancer describes a large lymph node mass low in level II stretching into Level III. Code 6 for Levels II-III because both Level II and Level III are mentioned.\n\n**4)** Code 9 when the only information available is “Regional nodes, NOS” or “Cervical nodes, NOS” or “Internal jugular nodes, NOS” or “Lymph nodes, NOS. In other words, if regional nodes are known to be positive but the level(s) of nodes involved is unknown, code 9.\n* ***Example:*** Patient diagnosed elsewhere with carcinoma of oropharynx with cervical lymph node involvement. No other information available. All Head and Neck Level data items are coded to 9 since there is no specific information about the levels. \n * Levels I-III: Code 9\n * Levels IV-V: Code 9\n * Levels VI-VII: Code 9\n * Head and Neck, Other: Code 9", "rationale" : "Level of nodal involvement is a Registry Data Collection Variable in AJCC for several head and neck chapters. This data item was previously collected as Head and Neck SSF #3 (common SSF)." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/lymph_nodes_head_and_neck_levels_iv_v_55093.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/lymph_nodes_head_and_neck_levels_iv_v_55093.json index c33267a3f..de96f6c47 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/lymph_nodes_head_and_neck_levels_iv_v_55093.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/lymph_nodes_head_and_neck_levels_iv_v_55093.json @@ -6,7 +6,7 @@ "title" : "Lymph Nodes Head and Neck Levels IV-V", "description" : "Lymph Nodes for Head and Neck, Levels IV-V records the involvement of Levels IV-V lymph nodes.\n\nThis data item is used to code the presence or absence of lymph node involvement in head and neck levels I-III. The definitions of the levels are the same for all applicable head and neck sites. \n* Note: This data item was previously collected for all head and neck sites. It is now only clinically relevant for unknown head and neck primaries with positive cervical (head and neck) lymph nodes and mucosal melanomas of the head and neck.\n\n**Level IV** contains the lower jugular lymph nodes from the level of the cricoid cartilage superiorly to the clavicle inferiorly. Lymph node chains at this level:\n* Jugulo-omohyoid (supraomohyoid), lower deep cervical, lower jugular\n\n**Level V** is subdivided into levels VA and VB, which contain the lymph nodes in the posterior triangle bounded by the anterior border of the trapezius muscle posteriorly, the posterior border of the sternocleidomastoid muscle anteriorly, and the clavicle inferiorly. For descriptive purposes, Level V may be further subdivided into upper (VA) and lower (VB) levels corresponding to a plane defined by the inferior border of the cricoid cartilage. Lymph node chains at this level:\n* Posterior cervical, posterior triangle (spinal accessory, transverse cervical [upper, middle, and lower, corresponding to the levels that define upper, middle, and lower jugular nodes]), supraclavicular", "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of Levels IV-V lymph node involvement can be used to code this data item when no other information is available.\n\n**Note 2:** **Related data items** \n* 3876: LN Head and Neck Levels I-III \n* 3877: LN Head and Neck Levels IV-V \n* 3878: LN Head and Neck Levels VI-VII \n* 3879: LN Head and Neck Other \n\n**Note 3:** **Priority order**\n* Pathological information takes priority over clinical.\n\n**Note 4:** **Supraclavicular nodes** \n* If lymph nodes are described only as “supraclavicular,” try to determine if they are in Level IV (deep to the sternocleidomastoid muscle, in the lower jugular chain) or Level V (in the posterior triangle, inferior to the transverse cervical artery) and code appropriately. \n * If the specific level cannot be determined, or is documented as supraclavicular with no further information, code them as Level V nodes\n\n**Note 5:** **Priority order**\n* Pathological information takes priority over clinical.", - "last_modified" : "2025-04-09T14:21:44.629Z", + "last_modified" : "2025-11-05T21:32:30.696Z", "definition" : [ { "key" : "ln_hn_4_5", "name" : "Code", @@ -17,7 +17,7 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "0", "No involvement in Levels I, II, or III lymph nodes\nNon-invasive neoplasm (behavior /2)" ], [ "1", "Level IV lymph node(s) involved" ], [ "2", "Level V lymph node(s) involved" ], [ "3", "Levels IV and V lymph node(s) involved" ], [ "8", "Not applicable: Information not collected for this case\n(If this item is required by your standard setter, use of code 8 will result in an edit error)" ], [ "9", "Not documented in medical record\nPositive nodes, but level of positive node(s) unknown\nLymph node levels IV-V not assessed, or unknown if assessed" ] ], - "additional_info" : "**Source documents:** pathology report, imaging\n\nFor more information on **Head and Neck levels**, see AJCC 8th edition, Chapter 5: Staging Head and Neck Cancers, Table 5.1", + "additional_info" : "**Source documents:** pathology report, imaging\n\nFor more information on **Head and Neck levels**, see AJCC 8th edition, Chapter 5: Staging Head and Neck Cancers, Table 5.1.", "coding_guidelines" : "**1)** Code all applicable levels that are involved\n* ***Example:*** A carcinoma of the base of tongue involves bilateral submandibular nodes and left upper, mid-, and lower jugular nodes, the largest measuring 4 cm. There is no extracapsular extension. These are level I, II, III, and IV lymph nodes according to AJCC definitions. \n * Levels I-III: Code 7 (Levels I, II and III lymph nodes involved) to show that levels I, II, and III are involved\n * Levels IV-V: Code 1 to show that level IV is involved\n * Levels VI-VII: Code 0 for no other nodes involved\n * Head and Neck, Other: Code 0 for no other nodes involved\n\n**2)** If information is available on some nodes, but the others are unknown, code what is known. \n* ***Example:*** Multiple lymph nodes involved, level II documented, but the other levels not mentioned. Code 2 to indicate level II involvement.\n\n**3)** If a lymph node is described as involving two levels, or documented as a range, code both levels.\n* ***Example:*** Physical examination for a floor of mouth cancer describes a large lymph node mass low in level II stretching into Level III. Code 6 for Levels II-III because both Level II and Level III are mentioned.\n\n**4)** **Code 9** when the only information available is “Regional nodes, NOS” or “Cervical nodes, NOS” or “Internal jugular nodes, NOS” or “Lymph nodes, NOS. In other words, if regional nodes are known to be positive but the level(s) of nodes involved is unknown, code 9.\n* ***Example:*** Patient diagnosed elsewhere with carcinoma of oropharynx with cervical lymph node involvement. No other information available. All Head and Neck Level data items are coded to 9 since there is no specific information about the levels. \n * Levels I-III: Code 9\n * Levels IV-V: Code 9\n * Levels VI-VII: Code 9\n * Head and Neck, Other: Code 9", "rationale" : "Level of nodal involvement is a Registry Data Collection Variable in AJCC. This data item was previously collected as Head and Neck SSF #4 (common SSF)." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/lymph_nodes_head_and_neck_levels_vi_vii_32325.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/lymph_nodes_head_and_neck_levels_vi_vii_32325.json index 748cd713c..e10ff9841 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/lymph_nodes_head_and_neck_levels_vi_vii_32325.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/lymph_nodes_head_and_neck_levels_vi_vii_32325.json @@ -6,7 +6,7 @@ "title" : "Lymph Nodes Head and Neck Levels VI-VII", "description" : "Lymph Nodes for Head and Neck, Levels VI-VII records the involvement of Levels VI-VII lymph nodes.\n\nThis data item is used to code the presence or absence of lymph node involvement in head and neck levels I-III. The definitions of the levels are the same for all applicable head and neck sites. \n\n**Level VI** contains the lymph nodes of the anterior central compartment from the hyoid bone superiorly to the suprasternal notch inferiorly. On each side, the lateral boundary is formed by the medial border of the carotid sheath. Lymph node chains at this level:\n* Laterotracheal, Paralaryngeal, paratracheal (above suprasternal notch), perithyroidal, Precricoid (Delphian), Prelaryngeal, recurrent laryngeal)\n\n**Level VII** contains the lymph nodes inferior to the suprasternal notch in the superior mediastinum. Lymph node chains at this level:\n* Esophageal groove, paratracheal (below suprasternal notch), Pretracheal (below suprasternal notch)", "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of Levels IV-V lymph node involvement can be used to code this data item when no other information is available.\n\n**Note 2:** **Related data items** \n* 3876: LN Head and Neck Levels I-III \n* 3877: LN Head and Neck Levels IV-V \n* 3878: LN Head and Neck Levels VI-VII \n* 3879: LN Head and Neck Other \n\n**Note 3:** **Priority order**\n* Pathological information takes priority over clinical.", - "last_modified" : "2025-04-09T14:23:03.894Z", + "last_modified" : "2025-11-05T21:32:28.189Z", "definition" : [ { "key" : "ln_hn_6_7", "name" : "Code", @@ -17,7 +17,7 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "0", "No involvement in Levels VI or VII lymph nodes\nNon-invasive neoplasm (behavior /2)" ], [ "1", "Level VI lymph node(s) involved" ], [ "2", "Level VII lymph node(s) involved" ], [ "3", "Levels VI and VII lymph node(s) involved" ], [ "8", "Not applicable: Information not collected for this case\n(If this item is required by your standard setter, use of code 8 will result in an edit error)" ], [ "9", "Not documented in medical record\nPositive nodes, but level of positive node(s) unknown\nLymph nodes levels VI-VII not assessed, or unknown if assessed" ] ], - "additional_info" : "**Source documents:** pathology report, imaging\n\nFor more information on **Head and Neck levels**, see AJCC 8th edition, Chapter 5: Staging Head and Neck Cancers, Table 5.1", + "additional_info" : "**Source documents:** pathology report, imaging\n\nFor more information on **Head and Neck levels**, see AJCC 8th edition, Chapter 5: Staging Head and Neck Cancers, Table 5.1.", "coding_guidelines" : "**1)** Code all applicable levels that are involved\n* ***Example:*** A carcinoma of the base of tongue involves bilateral submandibular nodes and left upper, mid-, and lower jugular nodes, the largest measuring 4 cm. There is no extracapsular extension. These are level I, II, III, and IV lymph nodes according to AJCC definitions. \n * Levels I-III: Code 7 (Levels I, II and III lymph nodes involved) to show that levels I, II, and III are involved\n * Levels IV-V: Code 1 to show that level IV is involved\n * Levels VI-VII: Code 0 for no other nodes involved\n * Head and Neck, Other: Code 0 for no other nodes involved\n\n**2)** If information is available on some nodes, but the others are unknown, code what is known. \n* ***Example:*** Multiple lymph nodes involved, level II documented, but the other levels not mentioned. Code 2 to indicate level II involvement.\n\n**3)** If a lymph node is described as involving two levels, or documented as a range, code both levels.\n* ***Example:*** Physical examination for a floor of mouth cancer describes a large lymph node mass low in level II stretching into Level III. Code 6 for Levels II-III because both Level II and Level III are mentioned.\n\n**4)** **Code 9** when the only information available is “Regional nodes, NOS” or “Cervical nodes, NOS” or “Internal jugular nodes, NOS” or “Lymph nodes, NOS. In other words, if regional nodes are known to be positive but the level(s) of nodes involved is unknown, code 9.\n* ***Example:*** Patient diagnosed elsewhere with carcinoma of oropharynx with cervical lymph node involvement. No other information available. All Head and Neck Level data items are coded to 9 since there is no specific information about the levels. \n * Levels I-III: Code 9\n * Levels IV-V: Code 9\n * Levels VI-VII: Code 9\n * Head and Neck, Other: Code 9", "rationale" : "Level of nodal involvement is a Registry Data Collection Variable in AJCC. This data item was previously collected as Head and Neck SSF #5 (common SSF)." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/lymph_nodes_head_and_neck_other_31141.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/lymph_nodes_head_and_neck_other_31141.json index e716c1ac9..7eb27131d 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/lymph_nodes_head_and_neck_other_31141.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/lymph_nodes_head_and_neck_other_31141.json @@ -6,7 +6,7 @@ "title" : "Lymph Nodes Head and Neck Other", "description" : "Lymph Nodes for Head and Neck, Other records the involvement of lymph nodes other than Levels I-III, IV-V, and VI-VII.\n\nThis data item is used to code the presence or absence of lymph node involvement in head and neck levels I-III. The definitions of the levels are the same for all applicable head and neck sites. \n\n**Other head and neck lymph nodes**: \n* Cervical, NOS; deep cervical (NOS), facial, buccinator (buccal), infraauricular, internal jugular (NOS), intraparotid, mandibular, nasolabial, parapharyngeal, parotid, periparotid, preauricular, retroauricular (mastoid), retropharyngeal, suboccipital", "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of other head and neck lymph node involvement can be used to code this data item when no other information is available.\n\n**Note 2:** **Related data items** \n* 3876: LN Head and Neck Levels I-III \n* 3877: LN Head and Neck Levels IV-V \n* 3878: LN Head and Neck Levels VI-VII \n* 3879: LN Head and Neck Other \n\n**Note 3:** **Priority order**\n* Pathological information takes priority over clinical.", - "last_modified" : "2025-04-09T14:25:02.778Z", + "last_modified" : "2025-11-05T21:32:25.373Z", "definition" : [ { "key" : "ln_hn_other", "name" : "Code", @@ -17,7 +17,7 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "0", "No involvement in other head and neck lymph node regions\nNon-invasive neoplasm (behavior /2)" ], [ "1", "Buccinator (facial) lymph node(s) involved" ], [ "2", "Parapharyngeal lymph node(s) involved" ], [ "3", "Periparotid and intraparotid lymph node(s) involved" ], [ "4", "Preauricular lymph node(s) involved" ], [ "5", "Retropharyngeal lymph node(s) involved" ], [ "6", "Suboccipital/retroauricular lymph node(s) involved" ], [ "7", "Any combination of codes 1-6" ], [ "8", "Not applicable: Information not collected for this case\n(If this item is required by your standard setter, use of code 8 will result in an edit error.)" ], [ "9", "Not documented in medical record\nPositive nodes, but level of positive node(s) unknown\nOther Head and Neck lymph nodes not assessed, or unknown if assessed" ] ], - "additional_info" : "**Source documents:** pathology report, imaging\n\nFor more information on **Head and Neck levels**, see AJCC 8th edition, Chapter 5: Staging Head and Neck Cancers, Table 5.1", + "additional_info" : "**Source documents:** pathology report, imaging\n\nFor more information on **Head and Neck levels**, see AJCC 8th edition, Chapter 5: Staging Head and Neck Cancers, Table 5.1.", "coding_guidelines" : "**1)** Code all applicable levels that are involved\n* ***Example 1:*** A carcinoma of the base of tongue involves bilateral submandibular nodes and left upper, mid-, and lower jugular nodes, the largest measuring 4 cm. There is no extracapsular extension. These are level I, II, III, and IV lymph nodes according to AJCC definitions. \n * Levels I-III: Code 7 (Levels I, II and III lymph nodes involved) to show that levels I, II, and III are involved\n * Levels IV-V: Code 1 to show that level IV is involved\n * Levels VI-VII: Code 0 for no other nodes involved\n * Head and Neck, Other: Code 0 for no other nodes involved\n\n**2)** If information is available on some nodes, but the others are unknown, code what is known. \n* ***Example:*** Multiple lymph nodes involved, level II documented, but the other levels not mentioned. Code 2 to indicate level II involvement.\n\n**3)** If a lymph node is described as involving two levels, or documented as a range, code both levels.\n* ***Example:*** Physical examination for a floor of mouth cancer describes a large lymph node mass low in level II stretching into Level III. Code 6 for Levels II-III because both Level II and Level III are mentioned.\n\n**4)** **Code 9** when the only information available is “Regional nodes, NOS” or “Cervical nodes, NOS” or “Internal jugular nodes, NOS” or “Lymph nodes, NOS. In other words, if regional nodes are known to be positive but the level(s) of nodes involved is unknown, code 9.\n* ***Example:*** Patient diagnosed elsewhere with carcinoma of oropharynx with cervical lymph node involvement. No other information available. All Head and Neck Level data items are coded to 9 since there is no specific information about the levels. \n * Levels I-III: Code 9\n * Levels IV-V: Code 9\n * Levels VI-VII: Code 9\n * Head and Neck, Other: Code 9", "rationale" : "Level of nodal involvement is a Registry Data Collection Variable in AJCC. This data item was previously collected as Head and Neck SSF #6 (common SSF)." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/lymph_nodes_isolated_tumor_cells_67876.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/lymph_nodes_isolated_tumor_cells_67876.json index 5d409e0ef..b4b79a5e9 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/lymph_nodes_isolated_tumor_cells_67876.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/lymph_nodes_isolated_tumor_cells_67876.json @@ -4,9 +4,9 @@ "version" : "3.3", "name" : "LN Isolated Tumor Cells", "title" : "Lymph Nodes Isolated Tumor Cells (ITC)", - "description" : "Lymph Nodes Isolated Tumor Cells (ITC), the presence of isolated tumor cells in regional lymph node(s) that may be detected by hematoxylin and eosin or by immunohistochemical staining, is a potential prognostic factor for Merkel Cell Carcinoma.\n\nIsolated tumor cells (ITCs) for Merkel cell carcinoma are defined as single tumor cells or small clusters of tumor cells not more than 0.2 mm in greatest dimension. ITCs are usually detected by immunohistochemistry on sentinel lymph node biopsies. \n* Note: Examples of immunohistochemical staining methods are Cytokeratin 20 (CK20), CAM 5.2, pancytokeratin, and AE1/3. ITCs may be detected by routine H&E stains.\n\nITCs may be identified in lymph nodes by hematoxylin and eosin staining or by specialized pathological techniques, such as IHC for cytokeratin proteins for carcinomas. Specialized pathology techniques such IHC and molecular techniques are not recommended for routine examination of lymph nodes.\n\nThese cells usually are found in the subcapsular nodal sinuses but may be seen within the nodal parenchyma.", + "description" : "Lymph Nodes Isolated Tumor Cells (ITC), the presence of isolated tumor cells in regional lymph node(s) that may be detected by hematoxylin and eosin or by immunohistochemical staining, is a potential prognostic factor for Merkel Cell Carcinoma.\n\nIsolated tumor cells (ITCs) for Merkel cell carcinoma are defined as single tumor cells or small clusters of tumor cells not more than 0.2 mm in greatest dimension. ITCs are usually detected by immunohistochemistry on sentinel lymph node biopsies. \n* **Note:** Examples of immunohistochemical staining methods are Cytokeratin 20 (CK20), CAM 5.2, pancytokeratin, and AE1/3. ITCs may be detected by routine H&E stains.\n\nITCs may be identified in lymph nodes by hematoxylin and eosin staining or by specialized pathological techniques, such as IHC for cytokeratin proteins for carcinomas. Specialized pathology techniques such IHC and molecular techniques are not recommended for routine examination of lymph nodes.\n\nThese cells usually are found in the subcapsular nodal sinuses but may be seen within the nodal parenchyma.", "notes" : "**Note:** **Physician statement** \n* Physician statement of Isolated Tumor Cells (ITCs) can be used to code this data item when no other information is available.", - "last_modified" : "2024-04-30T19:13:16.392Z", + "last_modified" : "2025-11-06T18:40:54.261Z", "definition" : [ { "key" : "ln_itc", "name" : "Code", @@ -17,7 +17,7 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "0", "Regional lymph nodes negative for ITCs" ], [ "1", "Regional lymph nodes positive for ITCs \n(Tumor cell clusters not greater than 0.2 millimeter (mm))" ], [ "8", "Not applicable: Information not collected for this case\n(If this information is required by your standard setter, use of code 8 may result in an edit error.)" ], [ "9", "Not documented in medical record\nCannot be determined by pathologist\nITCs not assessed or unknown if assessed" ] ], - "additional_info" : "**Source documents:** pathology report\n\nFor further information, refer to the **Merkel Cell Carcinoma** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Merkel Cell Carcinoma*", + "additional_info" : "**Source documents:** pathology report\n\nFor further information, refer to the **Merkel Cell Carcinoma** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Merkel Cell Carcinoma*.", "coding_guidelines" : "Record the status of ITCs as documented by the pathologist", "rationale" : "Lymph Nodes, Isolated Tumor Cells (ITC) is a Registry Data Collection Variable in AJCC. This data item was previously collected for Merkel Cell Skin, SSF #18." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/major_vein_involvement_87947.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/major_vein_involvement_87947.json index cee59f86c..f8ad52580 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/major_vein_involvement_87947.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/major_vein_involvement_87947.json @@ -6,7 +6,7 @@ "title" : "Major Vein Involvement", "description" : "Major vein involvement pertains to the invasion of the kidney tumor into major veins.\n\nInvolvement of veins from a renal cancer has prognostic implications because tumor cells can more easily disseminate through the bloodstream. This data item records information about the presence and level of involvement of specific major blood vessels. Do not code microscopically identified involvement of small unnamed blood vessels within the kidney; this information is coded in the field Lymph-Vascular Invasion (LVI). The tumor may be described as a thrombus, a cluster of tumor cells presents in the center of the vein but not attached to the wall of the vein. Tumor spread may resemble mud extruding along the inside of a pipe. Direct tumor invasion of the wall of the inferior vena cava is not coded in this field.\nRecord the code that best describes involvement of the renal vein and/or inferior vena cava (IVC) as described in the pathology report. Do not include clinical findings in this field.", "notes" : "**Note 1:** **Physician Statement**\n* Physician statement of Major Vein Involvement can be used to code this data item when no other information is available. \n* The major veins include the renal vein or its segmental branches, and the inferior vena cava.\n\n**Note 2:** **Relevance to Staging**\n* Information about major vein involvement beyond the kidney is collected in primary tumor as an element in anatomic staging. It is also collected in this field as it may have an independent effect on prognosis. \n\n**Note 3:** **Major Vein Involvement**\n* Record the involvement of specific named veins as documented in the pathology report. Do not code invasion of small unnamed vein(s) of the type collected as lymph-vascular invasion. Lymph-vascular invasion is usually only seen microscopically.", - "last_modified" : "2025-02-24T15:47:58.969Z", + "last_modified" : "2025-11-06T21:18:43.177Z", "definition" : [ { "key" : "major_vein_involv", "name" : "Code", @@ -17,7 +17,7 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "0", "Major vein involvement not present/not identified" ], [ "1", "Renal vein or its segmental branches" ], [ "2", "Inferior vena cava (IVC)" ], [ "3", "Major vein invasion, NOS" ], [ "4", "Any combination of codes 1-3" ], [ "8", "Not applicable: Information not collected for this case\n(If this information is required by your standard setter, use of code 8 may result in an edit error.)" ], [ "9", "Not documented in medical record\nVein involvement not assessed or unknown if assessed\nNo surgical resection of primary site is performed" ] ], - "additional_info" : "**Source documents:** surgical pathology report\n\nFor further information, refer to the **Kidney** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Kidney*", - "coding_guidelines" : "**1)** Record major vein involvement as documented in the surgical pathology report\n* Surgical resection of primary site must be done \n* Do not use imaging findings to code this data item.\n\n**2)** **Code 0**: There is no involvement of the major veins\n* If surgical resection is done and tumor is “confined to kidney” and staging is based on size, then there is no involvement of major veins\n\n**3)** **Code 1**: Involvement of the renal vein or segmental branches\n**4)** **Code 2**: Involvement of the inferior vena cava (IVC)\n**5)** **Code 3**: Involvement of major veins, but not specified which one (renal vein, segmental branches, or inferior vena cava (IVC))\n**6)** **Code 4**: Involvement of more than one vein (any combination of codes 1-3)\n**7)** **Code 9** when\n* There is no documentation in the medical record\n* Clinical diagnosis only\n* Evaluation of major vein involvement not done or unknown if done\n* Surgical resection of the primary site is performed, tumor is **not** confined to the kidney and there is no mention of major vein involvement", + "additional_info" : "**Source documents:** surgical pathology report\n\nFor further information, refer to the **Kidney** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Kidney*.", + "coding_guidelines" : "**1)** Record major vein involvement as documented in the surgical Pathology report\n* Surgical resection of primary site must be done \n* Do not use imaging findings to code this data item.\n\n**2)** **Code 0**: There is no involvement of the major veins\n* If surgical resection is done and tumor is “confined to kidney” and staging is based on size, then there is no involvement of major veins\n\n**3)** **Code 1**: Involvement of the renal vein or segmental branches\n\n**4)** **Code 2**: Involvement of the inferior vena cava (IVC)\n\n**5)** **Code 3**: Involvement of major veins, but not specified which one (renal vein, segmental branches, or inferior vena cava (IVC))\n\n**6)** **Code 4**: Involvement of more than one vein (any combination of codes 1-3)\n\n**7)** **Code 9** when\n* There is no documentation in the medical record\n* Clinical diagnosis only\n* Evaluation of major vein involvement not done or unknown if done\n* Surgical resection of the primary site is performed, tumor is **not** confined to the kidney and there is no mention of major vein involvement", "rationale" : "Involvement of major veins for Kidney is a Registry Data Collection Variable in AJCC. It was previously collected as Kidney, CS SSF #2." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/measured_basal_diameter_70699.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/measured_basal_diameter_70699.json index ae43cc971..63acf3cf1 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/measured_basal_diameter_70699.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/measured_basal_diameter_70699.json @@ -6,7 +6,7 @@ "title" : "Measured Basal Diameter", "description" : "Measured Basal Diameter, the largest basal diameter of a uveal melanoma, is a prognostic indicator for this tumor.\n\nThe basal diameter is the width (horizontal measurement) of the melanoma at its base (in contact with sclera). This is not the same as the depth of invasion (see NAACCR Data Item #3888-Measured Thickness). Clinical research has shown that as a uveal tumor becomes larger, the risk of hematogenous metastases and death increases. In addition, knowing the size of the melanoma is important for treatment planning.\n\nPer the CAP guidelines for Uveal Melanoma, “in clinical practice, the largest tumor basal diameter may be estimated in optic disc diameters (dd, average: 1 dd = 1.5 mm). Techniques such as ultrasonography and fundus photography are used to provide more accurate measurement. When histopathological measurements are recorded after fixation, tumor diameter and thickness may be underestimated because of tissue shrinkage.”", "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of measured basal diameter can be used to code this data item when no other information is available. \n\n**Note 2:** **Code measured basal diameter of tumor not Tumor size** \n* Record actual measurement in millimeters (mm) to nearest tenth from clinical documentation, or from a pathology report if surgery performed", - "last_modified" : "2024-04-07T17:53:57.290Z", + "last_modified" : "2025-11-06T15:26:35.359Z", "definition" : [ { "key" : "measured_basal_diameter", "name" : "Code", @@ -17,6 +17,6 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "0.0", "No mass/tumor found" ], [ "0.1-99.9", "0.1 - 99.9 millimeters (mm)\n(Exact measurement to nearest tenth of mm)" ], [ "XX.0", "100 millimeters (mm) or larger " ], [ "XX.1", "Described as \"less than 3 mm\"" ], [ "XX.2", "Described as \"at least\" 3 mm" ], [ "XX.3", "Described as \"at least\" 6 mm" ], [ "XX.4", "Described as \"at least\" 9 mm" ], [ "XX.5", "Described as \"at least\" 12 mm" ], [ "XX.6", "Described as \"at least\" 15 mm" ], [ "XX.7", "Described as \"at least\" 18 mm" ], [ "XX.8", "Not applicable: Information not collected for this case\n(If this information is required by your standard setter, use of code XX.8 may result in an edit error.)" ], [ "XX.9", "Not documented in medical record\nCannot be determined by pathologist\nMeasured Basal Diameter not assessed or unknown if assessed" ] ], - "additional_info" : "**Source documents:** High-frequency ultrasonography (ultrasound biomicroscopy) report, pathology report, wide-angle fundus camera measurement, clinician report or other documentation in medical record\n\n**Other names include** largest tumor diameter (LTD), tumor basal size; do not code tumor basal area (measured in square millimeters)\n\nFor further information, refer to the **Uveal Melanoma** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Uveal Melanoma*", + "additional_info" : "**Source documents:** High-frequency ultrasonography (ultrasound biomicroscopy) report, pathology report, wide-angle fundus camera measurement, clinician report or other documentation in medical record\n\n**Other names include** largest tumor diameter (LTD), tumor basal size; do not code tumor basal area (measured in square millimeters)\n\nFor further information, refer to the **Uveal Melanoma** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Uveal Melanoma*.", "rationale" : "Measured Basal Diameter is listed as a Registry Data Collection Variable in AJCC. It was previously collected as Uveal Melanoma, CS SSF #2." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/measured_thickness_84907.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/measured_thickness_84907.json index 8a4e2ca56..79e132eff 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/measured_thickness_84907.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/measured_thickness_84907.json @@ -6,7 +6,7 @@ "title" : "Measured Thickness", "description" : "Measured Thickness, or height, the thickness of a uveal melanoma, is a prognostic indicator for this tumor.\n\nThis data items measures tumor thickness, height, or depth (vertical dimension), rather than size (lateral dimension) or basal diameter (horizontal dimension). (For basal diameter, see NAACCR Data Item #3887-Measured Basal Diameter). \n\nThe depth of invasion or tumor thickness measurement for melanomas of the choroid, ciliary body, and iris is collected in tenths of millimeters as stated in the pathology report for the resected specimen. (This is similar to, but not the same as, Breslow depth of invasion, which is measured in hundredths of millimeters.) Code a measurement specifically labeled as “thickness” “height” or “depth” in the pathology report. In the absence of this label, a measurement described as taken from the cut surface of the specimen can be coded. And in the absence of either of these labels, the third dimension in a statement of tumor size (length x width x depth) can be used by the registrar to code this field.\n\nPer the CAP guidelines for Uveal Melanoma, “in clinical practice, tumor thickness may be estimated in diopters (average: 2.5 diopters = 1 mm). Techniques such as ultrasonography and fundus photography are used to provide more accurate measurement. When histopathological measurements are recorded after fixation, tumor diameter and thickness may be underestimated because of tissue shrinkage.”", "notes" : "**Note 1:** **Physician Statement**\n* Physician statement of measured thickness, or height, can be used to code this data item when no other information is available. \n\n**Note 2:** **Code height not Tumor Size** \n* Record actual measurement in millimeters (mm) from clinical documentation, or from a pathology report if surgery performed.", - "last_modified" : "2024-04-07T17:52:34.996Z", + "last_modified" : "2025-11-06T15:26:15.468Z", "definition" : [ { "key" : "measured_thickness", "name" : "Code", @@ -17,6 +17,6 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "0.0", "No mass/tumor found" ], [ "0.1-99.9", "0.1 - 99.9 millimeters (mm)\n(Exact measurement to nearest tenth of mm)" ], [ "XX.0", "100 millimeters (mm) or larger " ], [ "XX.1", "Described as \"less than 3 mm\"" ], [ "XX.2", "Described as \"at least\" 3 mm " ], [ "XX.3", "Described as \"at least\" 6 mm" ], [ "XX.4", "Described as \"at least\" 9 mm" ], [ "XX.5", "Described as \"at least\" 12 mm" ], [ "XX.6", "Described as \"greater than\" 15 mm" ], [ "XX.8", "Not applicable: Information not collected for this case\n(If this information is required by your standard setter, use of code XX.8 may result in an edit error.)" ], [ "XX.9", "Not documented in medical record\nCannot be determined \nMeasured Thickness not assessed or unknown if assessed" ] ], - "additional_info" : "**Source Documents:** High-frequency ultrasonography (ultrasound biomicroscopy) report, pathology report, wide-angle fundus camera measurement, clinician report or other documentation in medical record. \n\n**Other names include** maximum tumor thickness, depth of invasion, perpendicular tumor diameter (PTD), tumor height\n\nFor further information, refer to the **Uveal Melanoma** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Uveal Melanoma*", + "additional_info" : "**Source Documents:** High-frequency ultrasonography (ultrasound biomicroscopy) report, pathology report, wide-angle fundus camera measurement, clinician report or other documentation in medical record\n\n**Other names include** maximum tumor thickness, depth of invasion, perpendicular tumor diameter (PTD), tumor height\n\nFor further information, refer to the **Uveal Melanoma** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Uveal Melanoma*.", "rationale" : "Measured Thickness is listed as a Registry Data Collection Variable in AJCC. It was previously collected as Uveal Melanoma, CS SSF #3." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/melanoma_ciliary_body_melanoma_iris_79773.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/melanoma_ciliary_body_melanoma_iris_79773.json index fd3c6799e..58fa86122 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/melanoma_ciliary_body_melanoma_iris_79773.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/melanoma_ciliary_body_melanoma_iris_79773.json @@ -5,8 +5,8 @@ "name" : "Schema Discriminator 1", "title" : "Schema Discriminator 1: Melanoma Ciliary Body/Melanoma Iris", "description" : "Iris and ciliary body have the same ICD-O topography code (C694). However, for purposes of stage grouping AJCC 8th edition, they each have different definitions for T or primary tumor extension. A schema discriminator is necessary to distinguish between these primary sites so that the appropriate sub(chapter)/schema is used.", - "notes" : "**Note:** **Schema discriminator for C694** \n* A schema discriminator is used to discriminate between melanoma tumors with primary site code C694: Ciliary Body/Iris. Code the site in which the tumor arose. \n* **00672: Melanoma Ciliary Body (see code 1)**\nSubsites include Ciliary body, crystalline lens, sclera, uveal tract, intraocular, eyeball\n* **00671: Melanoma Iris (see code 2)**\nSubsite includes Iris", - "last_modified" : "2024-04-30T19:08:01.698Z", + "notes" : "**Note:** **Schema discriminator for C694** \n\n* A schema discriminator is used to discriminate between melanoma tumors with primary site code C694: Ciliary Body/Iris. Code the site in which the tumor arose. \n\n* **00672: Melanoma Ciliary Body (see code 1)**\n\n Subsites include Ciliary body, crystalline lens, sclera, uveal tract, intraocular, eyeball\n\n* **00671: Melanoma Iris (see code 2)**\n\n Subsite includes Iris", + "last_modified" : "2025-11-06T21:24:29.631Z", "definition" : [ { "key" : "discriminator_1", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hab.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hab.json index e7565bc23..85daf3a6c 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hab.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hab.json @@ -6,7 +6,7 @@ "title" : "EOD Mets", "notes" : "**Note:** **Pleural and pericardial effusions**\n* Most pleural and pericardial effusions with lung cancer are due to tumor\n* In a few patients, however, multiple cytopathological examinations of pleural and/or pericardial fluid are negative for tumor, and the fluid is non-bloody and is not an exudate. Where these elements and clinical judgment dictate that the effusion is not related to the tumor, the effusion should be excluded as a staging element. \n * Code 00 in the absence of any other metastasis.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Rami-Porta, R., Asamura, H., Travis, W.D., Rusch, V.W. **Lung**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:53.747Z", + "last_modified" : "2025-11-14T20:06:09.038Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hac.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hac.json index bde223632..be74a8021 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hac.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hac.json @@ -6,7 +6,7 @@ "title" : "EOD Mets", "notes" : "**Note 1:** **Nodules on peritoneal surface** \n* Nodules implanted on peritoneal surfaces are classified as metastatic disease (code 70).\n\n**Note 2:** **Hepatoduodenal and Pancreaticoduodenal lymph nodes**\n* These nodes have been moved to EOD Regional Nodes for all sites.\n* **Note:** They are still distant for Summary Stage", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Ajani, J.A., In, H., Sano, T., Hofstetter, W.L., et al. **Stomach**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:48.286Z", + "last_modified" : "2025-11-14T20:05:10.720Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_had.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_had.json index 8c1d67870..b6f2f159f 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_had.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_had.json @@ -6,7 +6,7 @@ "title" : "EOD Mets", "notes" : "**Note 1:** **LDH and Metastatic disease** \n* For cases with positive metastases, Serum LDH is an additional data item that is predictor of survival outcome. \n* Serum LDH is coded in data item LDH (Lactate Dehydrogenase) Level [#3869]\n\n**Note 2:** **Distant metastasis** \n* Use code 70 when the only information is “distant metastasis, NOS,” and there is no documentation regarding the specific metastases. \n* If there are specific metastasis documented that are not listed in codes 10, 20, 30, or 40, assign code 50 for “other specified distant metastasis.”", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Gershenwald, J.E., Scolyer, R.A., et al. **Melanoma of the Skin**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:44.119Z", + "last_modified" : "2025-11-14T20:06:16.523Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hae.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hae.json index 674fffc79..9c1796962 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hae.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hae.json @@ -6,7 +6,7 @@ "title" : "EOD Mets", "notes" : "**Note 1:** **Distant metastasis, NOS** \n* Use code 70 when the only information is \n - Distant lymph nodes are involved, but not stated as single or multiple lymph node chains\n - Distant metastasis is present, but not stated as single or multiple organ involvement\n\n**Note 2:** **Peritoneal involvement** \n* Peritoneal involvement, WITH or WITHOUT any other involvement, is code 50.\n\n**Note 3:** **Distant lymph node(s) for Colon, Rectum and Rectosigmoid include**\n\n**Colon**\n- Iliac (common, external, hypogastric, internal, obturator, NOS)\n- Inferior mesenteric (cecum, ascending colon, hepatic flexure, transverse colon)\n- Para-aortic\n- Retroperitoneal\n- Superior mesenteric\n\n**Rectosigmoid**\n- Hemorrhoidal, inferior (rectosigmoid)\n- Iliac (common, external, hypogastric, internal, obturator)\n- Rectal, inferior \n- Superior mesenteric\n\n**Rectum**\n- Colic (left) (rectum)\n- Iliac (common, external, NOS)\n- Superior mesenteric", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Jessup, J.M., Goldberg, R.M., et al. **Colon and Rectum**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:40.206Z", + "last_modified" : "2025-11-14T20:06:08.248Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_haf.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_haf.json index 61952172b..643726c9e 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_haf.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_haf.json @@ -5,7 +5,7 @@ "name" : "EOD Mets", "title" : "EOD Mets", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Abou-Alfa, G.K., Pawlik, T.M., Vauthey, J.N., et al. **Liver**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:42:00.564Z", + "last_modified" : "2025-11-14T20:05:18.130Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hah.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hah.json index 992f054b0..5561e70de 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hah.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hah.json @@ -5,7 +5,7 @@ "name" : "EOD Mets", "title" : "EOD Mets", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) **Introduction to Female Reproductive Organs**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Prat, J., Olawaiye, A.B., Mutch, D.G., et al. **Ovary, Fallopian Tube, and Primary Peritoneal Carcinoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:31.988Z", + "last_modified" : "2025-11-14T20:05:16.058Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_haj.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_haj.json index 14428f227..3523b1f5d 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_haj.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_haj.json @@ -6,7 +6,7 @@ "title" : "EOD Mets", "notes" : "**Note:** **FIGO and metastatic detail** \n* When both the Federation Internationale de Gynecologie et d'Obstetrique (FIGO) stage and metastatic detail are available, record the code with metastatic detail in preference to a statement of FIGO stage.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05.** American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging.** In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) **Introduction to Female Reproductive Organs**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Gibb, R.K., Olawaiye, A.B., Mutch, D.G., et al. **Vagina**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:48.051Z", + "last_modified" : "2025-11-14T20:06:11.336Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hak.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hak.json index d12137310..c4698c3a3 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hak.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hak.json @@ -6,7 +6,7 @@ "title" : "EOD Mets", "notes" : "**Note 1:** **FIGO and metastatic detail** \n* When both the Federation Internationale de Gynecologie et d'Obstetrique (FIGO) stage and metastatic detail are available, record the code with metastatic detail in preference to a statement of FIGO stage.\n\n**Note 2:** **Distant metastasis** \n* Use code 70 when the only information is “distant metastasis, NOS,” and there is no documentation regarding the specific metastases. \n+ If there are specific metastasis documented that are not listed in codes 10, 30, or 50, assign code 50 for “other specified distant metastasis.”", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) **Introduction to Female Reproductive Organs**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Chen, L., Olawaiye, A.B., Mutch, D.G., et al. **Gestational Trophoblastic Neoplasms**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-19T18:52:43.725Z", + "last_modified" : "2025-11-14T20:06:14.404Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hal.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hal.json index b0383cfd5..8e1ed94dd 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hal.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hal.json @@ -6,7 +6,7 @@ "title" : "EOD Mets", "notes" : "**Note:** **Distant metastasis, NOS** \n* Use code 70 when the only information is “distant metastasis, NOS,” and there is no documentation regarding the specific metastases. \n+ If there are specific metastasis documented that are not listed in codes 10, 30, or 50, assign code 50 for “other specified distant metastasis.”", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Buyyounouski, M.K., Lin, D.W., et al. **Prostate**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:42:27.246Z", + "last_modified" : "2025-11-14T20:05:51.071Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_han.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_han.json index e7ff6ff17..12e9e2321 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_han.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_han.json @@ -6,7 +6,7 @@ "title" : "EOD Mets", "notes" : "**Note:** **FIGO and metastatic disease detail** \n* When both the Federation Internationale de Gynecologie et d'Obstetrique (FIGO) stage and metastatic detail are available, record the code with metastatic detail in preference to a statement of FIGO stage.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) **Introduction to Female Reproductive Organs**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Erickson, B.A., Olawaiye, A.B., Mutch, D.G., et al. **Cervix Uteri**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:42:15.348Z", + "last_modified" : "2025-11-14T20:05:20.135Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_har.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_har.json index 371047e2f..32ffd5746 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_har.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_har.json @@ -5,7 +5,7 @@ "name" : "EOD Mets", "title" : "EOD Mets", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Herman, J.M., Pawlik, T.M., Vauthey, J.N., et al. **Ampulla of Vater**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:45.282Z", + "last_modified" : "2025-11-14T20:05:36.692Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hat.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hat.json index a9b8b8d71..dcdbeff56 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hat.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hat.json @@ -6,7 +6,7 @@ "title" : "EOD Mets", "notes" : "**Note 1:** **Pleural effusion** \n* A physician’s statement of positive (malignant) pleural effusion or a positive cytology confirming a malignant pleural effusion must be used to code 05. \n * If the physician feels the pleural effusion is due to tumor, despite negative cytology, the physician’s assessment can be used to code EOD Mets\n* If pleural fluid cytology is described as suspicious/suspicious for mesothelioma, code 05\n* A positive pleural effusion (code 05) should not be coded as present under the Mets at Dx-Other field. \n * Code 0 for Mets at Dx-Other when code 05 is coded in EOD Mets.\n\n**Note 2:** **Additional data item for staging** \n* In addition to EOD Mets, the following data item is also collected to determine the results of the Pleural Effusion, which include negative, atypical, or Pleural effusion, NOS\n* Pleural effusion [NAACCR Data Item #3913]\n\n**Note 3:** **Pleural effusion with other mets** \n* If there is a malignant pleural effusion WITH other mets, code 70.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Rusch, V.W., et al. **Malignant Plural Mesothelioma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:33.986Z", + "last_modified" : "2025-11-14T20:05:34.084Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hau.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hau.json index f402e3e06..93074cca1 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hau.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hau.json @@ -6,7 +6,7 @@ "title" : "EOD Mets", "notes" : "**Note:** **Bone marrow micrometastasis** \n* For bone marrow micrometastasis, circulating tumor cells (CTCs) or disseminated tumor cells and clusters (DTCs) are less than or equal to 0.2 mm and assigned code 05.\n* Circulating tumor cells (CTCs) or disseminated tumor cells and clusters (DTCs) should not be coded as present under the Mets at Dx-Other field. Code 0 for Mets at Dx-Other when code 05 is coded in EOD mets.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Hortobagyi, G.N., Giuliano, A., et al. **Breast**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:41.296Z", + "last_modified" : "2025-11-14T20:06:13.158Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hav.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hav.json index 97db63abf..ad355adf9 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hav.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hav.json @@ -6,7 +6,7 @@ "title" : "EOD Mets", "notes" : "**Note:** **Distant metastasis, NOS** \n* Use code 70 when the only information is “distant metastasis, NOS,” and there is no documentation regarding the specific metastases. \n* If there are specific metastasis documented that are not listed in codes 10, 30, or 50, assign code 50 for “other specified distant metastasis.”", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Kneisl, J.S., Rosenberg, A.E., et al. **Bone**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:44.498Z", + "last_modified" : "2025-11-14T20:05:19.276Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_haw.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_haw.json index d759dcc50..ec2054e21 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_haw.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_haw.json @@ -6,7 +6,7 @@ "title" : "EOD Mets", "notes" : "**Note 1:** **Benign/borderline tumors** \n* Code 00 for benign (behavior /0) and borderline (behavior /1) tumors.\n\n**Note 2:** **Leptomeningeal metastases** \n* Leptomeningeal metastases, also known as carcinomatous meningitis and meningeal carcinomatosis, refers to the spread of malignant cells through the CSF space. \n* These cells can originate from primary CNS tumors (e.g., in the form of drop metastases), as well as from distant tumors that have metastasized via hematogenous spread (code 70).", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Laws, E.R., Curran, W.J., et al. **Brain and Spinal Cord**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:27.739Z", + "last_modified" : "2025-11-14T20:05:14.875Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_haz.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_haz.json index 161547a08..b4b7490a9 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_haz.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_haz.json @@ -6,7 +6,7 @@ "title" : "EOD Mets", "notes" : "**Note 1:** **Definition of viscera** \n* For the purpose of coding EOD Mets, the definition of viscera is the soft internal organs of the body, specifically of the abdominal and thoracic cavity.\n\n**Note 2:** **Visceral involvement** \n* Visceral involvement is metastatic disease and should be questioned in the absence of node or blood involvement.\n\n**Note 3:** **Distant lymph nodes** \n* For this schema, distant lymph nodes are collected in EOD Regional Nodes.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) **Introduction to Hematologic Malignancies**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Rosen, S.T., Jaffe, E.S., Leonard, J.P., et al. **Primary Cutaneous Lymphomas**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:42:20.447Z", + "last_modified" : "2025-11-14T20:05:46.731Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hba.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hba.json index e33bdeb91..8eedf8db9 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hba.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hba.json @@ -6,7 +6,7 @@ "title" : "EOD Mets", "notes" : "**Note:** **FIGO and metastatic detail** \n* When both the Federation Internationale de Gynecologie et d'Obstetrique (FIGO) stage and metastatic detail are available, record the code with metastatic detail in preference to a statement of FIGO stage.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) **Introduction to Female Reproductive Organs**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Gibb, R.K., Olawaiye, A.B., Mutch, D.G., et al. **Vulva**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(7) **Vulva,** from the AJCC Cancer Staging System Version 9 (2023). Used with permission of the American College of Surgeons, Chicago, Illinois.", - "last_modified" : "2025-09-18T20:41:38.697Z", + "last_modified" : "2025-11-14T20:06:01.419Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hbb.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hbb.json index 41bc8030a..24822e50a 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hbb.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hbb.json @@ -6,7 +6,7 @@ "title" : "EOD Mets", "notes" : "**Note 1:** **Previous scrotal surgery and lymph nodes** \n* Involvement of inguinal, pelvic, or external iliac lymph nodes with previous scrotal or inguinal surgery prior to presentation of the testis tumor are coded in EOD Regional Nodes.\n\n**Note 2:** **Distant metastasis** \n* Use code 70 when the only information is “distant metastasis, NOS,” and there is no documentation regarding the specific metastases. \n * If there are specific metastasis documented that are not listed in codes 10, 30, or 50, assign code 60 for “other specified distant metastasis.”", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Brimo, F., Srigley, J.R., Lin, D.W., et al. **Testis**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:37.735Z", + "last_modified" : "2025-11-14T20:05:51.463Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hbe.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hbe.json index 6293212f7..cfe30c7e2 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hbe.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hbe.json @@ -5,7 +5,7 @@ "name" : "EOD Mets", "title" : "EOD Mets", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Zhu, A.X., Pawlik, T.M., Vauthey, J.N., et al. **Gallbladder**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:42:12.668Z", + "last_modified" : "2025-11-14T20:05:39.674Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hbg.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hbg.json index 9b1054ee5..9ad45df2f 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hbg.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hbg.json @@ -5,7 +5,7 @@ "name" : "EOD Mets", "title" : "EOD Mets", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Rice, T.W., Kelsen, D., Hofstetter, W.L., et al. **Esophagus and Esophagogastric Junction**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:42:01.327Z", + "last_modified" : "2025-11-14T20:05:35.710Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hbo.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hbo.json index 1d326f4f8..dd1b71e7c 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hbo.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hbo.json @@ -5,7 +5,7 @@ "name" : "EOD Mets", "title" : "EOD Mets", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Coit, D.G., Kelsen, D., Hofstetter, W.L., et al. **Small Intestine**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:42.407Z", + "last_modified" : "2025-11-14T20:05:41.065Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hbv.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hbv.json index d9aaee966..4e898a5e9 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hbv.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hbv.json @@ -6,7 +6,7 @@ "title" : "EOD Mets", "notes" : "**Note:** **Location of metastases** \n* Metastases for the parathyroid is anything beyond the central and lateral part of the neck.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Kakar, S., Pawlik, T.M., Vauthey, J.N., et al. **Exocrine Pancreas**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:48.532Z", + "last_modified" : "2025-11-14T20:05:21.381Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hbx.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hbx.json index 4bbf2b987..ec3256548 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hbx.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hbx.json @@ -6,7 +6,7 @@ "title" : "EOD Mets", "notes" : "**Note 1:** **Liver mets WITH other metastatic involvement** \n* Use code 50 only when there are liver metastasis WITH other metastatic involvement. \n * If there are multiple distant mets but liver is not one of them, code 30.\n\n**Note 2:** **Distant metastasis, NOS** \n* Use code 70 when the only information is “distant metastasis, NOS,” and there is no documentation regarding the specific metastases. \n * If there are specific metastasis documented that are not listed in codes 10, 20, or 30, assign code 30 for “other specified distant metastasis.”", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Woltering, E.A., Bergsland, E.K., et al. **Neuroendocrine Tumors of the Appendix**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) **Neuroendocrine Tumors of the Appendix**, from the AJCC Cancer Staging System Version 9 (2023). Used with permission of the American College of Surgeons, Chicago, Illinois.", - "last_modified" : "2025-09-18T20:41:36.908Z", + "last_modified" : "2025-11-14T20:05:47.248Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hbz.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hbz.json index adcd68d12..4b1d6fc13 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hbz.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hbz.json @@ -5,7 +5,7 @@ "name" : "EOD Mets", "title" : "EOD Mets", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Aloia, T., Pawlik, T.M., Vauthey, J.N., et al. **Intrahepatic Bile Ducts**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:34.973Z", + "last_modified" : "2025-11-14T20:05:37.998Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hcf.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hcf.json index e82745a69..005f0b31e 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hcf.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hcf.json @@ -6,7 +6,7 @@ "title" : "EOD Mets", "notes" : "**Note 1:** **Peritoneal spread and Peritoneal implants** \n* Peritoneal spread is common in appendiceal tumors and is coded as 30 if limited to the peritoneum. \n* Peritoneal implants involving abdominopelvic organs, such as the serosa of the small or large bowel and the surface of the ovary, spleen, or liver, should be coded as 30, regardless of whether implants demonstrate infiltration of underlying tissue, manifested as invasion. \n* Nonperitoneal metastasis, such as pleuropulmonary involvement is rare and would be coded as 50.\n\n**Note 2:** **Distant metastasis, NOS** \n* Use code 70 when the only information is “distant metastasis, NOS,” and there is no documentation regarding the specific metastases. \n* If there are specific metastasis documented that are not listed in codes 10, 30, 40, or 50, assign code 50 for “other specified distant metastasis.”", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Overman, M.J., Jessup, J.M., et al. **Appendix - Carcinoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:42:14.319Z", + "last_modified" : "2025-11-14T20:05:04.571Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hcg.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hcg.json index 2630fcf53..927cbbb70 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hcg.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hcg.json @@ -5,7 +5,7 @@ "name" : "EOD Mets", "title" : "EOD Mets", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Rini, B.I., McKiernan, J.M., Stadler, W.M., et al. **Kidney**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:36.267Z", + "last_modified" : "2025-11-14T20:05:40.161Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hch.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hch.json index a0bb08614..a7db1fb8d 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hch.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hch.json @@ -5,7 +5,7 @@ "name" : "EOD Mets", "title" : "EOD Mets", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Pollock, R.E., Maki, R.G. **Introduction to Soft Tissue Sarcoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) DeMatteo, R.P., Maki, R.G., Pollock, R.E., et al. **Gastrointestinal Stromal Tumor**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:30.637Z", + "last_modified" : "2025-11-14T20:05:11.222Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hci.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hci.json index dc38e03d9..900f57f72 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hci.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hci.json @@ -6,7 +6,7 @@ "title" : "EOD Mets", "notes" : "**Note 1:** **Liver mets WITH other metastatic involvement** \n* Use code 50 only when there are liver metastasis WITH other metastatic involvement. \n * If there are multiple distant mets but liver is not one of them, code 30.\n\n**Note 2:** **Distant metastasis, NOS** \n* Use code 70 when the only information is “distant metastasis, NOS,” and there is no documentation regarding the specific metastases. \n * If there are specific metastasis documented that are not listed in codes 10, 20, or 30, assign code 30 for “other specified distant metastasis.”", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Shi, C., Woltering, E.A., Washington, M.K., et al. **Neuroendocrine Tumors of the Colon and Rectum**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) **Neuroendocrine Tumors of the Colon and Rectum**, from the AJCC Cancer Staging System Version 9 (2023). Used with permission of the American College of Surgeons, Chicago, Illinois.", - "last_modified" : "2025-09-18T20:41:33.560Z", + "last_modified" : "2025-11-14T20:05:27.291Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hck.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hck.json index 416e086e0..956ef88e3 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hck.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hck.json @@ -6,7 +6,7 @@ "title" : "EOD Mets", "notes" : "**Note 1:** **Liver mets WITH other metastatic involvement** \n* Use code 50 only when there are liver metastasis WITH other metastatic involvement. \n * If there are multiple distant mets but liver is not one of them, code 30.\n\n**Note 2:** **Hepatoduodenal and Pancreaticoduodenal lymph nodes**\n* These nodes have been moved to EOD Regional Nodes for all subsites.\n* **Note:** They are still distant for Summary Stage\n\n**Note 3:** **Distant metastasis, NOS** \n* Use code 70 when the only information is “distant metastasis, NOS,” and there is no documentation regarding the specific metastases. \n * If there are specific metastasis documented that are not listed in codes 10, 20, or 30, assign code 30 for “other specified distant metastasis.”", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Woltering, E.A., Bergsland, E.K., et al. **Neuroendocrine Tumors of the Stomach**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) **Neuroendocrine Tumors of the Stomach,** from the AJCC Cancer Staging System Version 9 (2023). Used with permission of the American College of Surgeons, Chicago, Illinois.", - "last_modified" : "2025-09-18T20:41:56.488Z", + "last_modified" : "2025-11-14T20:05:48.305Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hcp.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hcp.json index 90eafb3ed..9cc1c1f79 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hcp.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hcp.json @@ -6,7 +6,7 @@ "title" : "EOD Mets", "notes" : "**Note 1:** **Liver mets WITH other metastatic involvement** \n* Use code 50 only when there are liver metastasis WITH other metastatic involvement. \n * If there are multiple distant mets but liver is not one of them, code 30.\n\n**Note 2:** **Distant metastasis, NOS** \n* Use code 70 when the only information is “distant metastasis, NOS,” and there is no documentation regarding the specific metastases. \n * If there are specific metastasis documented that are not listed in codes 10, 20, or 30, assign code 30 for “other specified distant metastasis.”", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Woltering, E.A., Bergsland, E.K., et al. **Neuroendocrine Tumors of the Jejunum and Ileum**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) **Neuroendocrine Tumors of the Jejunum and Ileum**, from the AJCC Cancer Staging System Version 9 (2023). Used with permission of the American College of Surgeons, Chicago, Illinois.", - "last_modified" : "2025-09-18T20:41:38.290Z", + "last_modified" : "2025-11-14T20:05:47.763Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hcq.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hcq.json index 1e85f1e18..859d81565 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hcq.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hcq.json @@ -5,7 +5,7 @@ "name" : "EOD Mets", "title" : "EOD Mets", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Krasinskas, A., Pawlik, T.M., Vauthey, J.N., et al. **Distal Bile Duct**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:34.747Z", + "last_modified" : "2025-11-14T20:05:37.585Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hcr.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hcr.json index e7a715e04..8f59bccaa 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hcr.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hcr.json @@ -5,7 +5,7 @@ "name" : "EOD Mets", "title" : "EOD Mets", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Nagorney, D.M., Pawlik, T.M., Vauthey, J.N., et al. **Perihilar Bile Ducts**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:35.417Z", + "last_modified" : "2025-11-14T20:05:38.368Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hcu.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hcu.json index 5aab35c11..54b80da52 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hcu.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hcu.json @@ -5,7 +5,7 @@ "name" : "EOD Mets", "title" : "EOD Mets", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Esmaeli, B., Finger, P.T., et al. **Eyelid Carcinoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:42:17.452Z", + "last_modified" : "2025-11-14T20:05:32.119Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hcv.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hcv.json index 902f65028..e917ecd63 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hcv.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hcv.json @@ -5,7 +5,7 @@ "name" : "EOD Mets", "title" : "EOD Mets", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05.** American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging.** In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Zhu, A.X., Pawlik, T.M., Vauthey, J.N., et al. **Gallbladder**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:35.852Z", + "last_modified" : "2025-11-14T20:05:39.211Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hna.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hna.json index e8454eed5..c77aafeca 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hna.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hna.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "EOD Mets", "title" : "EOD Mets", - "last_modified" : "2025-09-18T20:41:28.132Z", + "last_modified" : "2025-11-14T20:05:03.500Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hph.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hph.json index e952b0e65..d333ecebc 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hph.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mets_hph.json @@ -6,7 +6,7 @@ "title" : "EOD Mets", "notes" : "**Note:** **Distant metastasis, NOS** \n* Use code 70 when the only information is “distant metastasis, NOS,” and there is no documentation regarding the specific metastases. \n* If there are specific metastasis documented that are not listed in codes 10, 20, or 30, assign code 50 for “other specified distant metastasis.”", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Bichakjian, C.K., Nghiem, P., Sober, A.J., et al. **Merkel Cell Carcinoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:42:17.046Z", + "last_modified" : "2025-11-14T20:05:30.139Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mgmt_17454.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mgmt_17454.json index fcd14f62e..5b5c22235 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mgmt_17454.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mgmt_17454.json @@ -6,7 +6,7 @@ "title" : "Methylation of O6-Methylguanine-Methyltransferase (MGMT)", "description" : "O6-Methylguanine-Methyltransferase (MGMT) is an enzyme in cells that repairs DNA. Methylation of the MGMT gene reduces production of the MGMT enzyme and the ability of tumor cells to repair damage caused by chemotherapy. Methylation of MGMT is a prognostic and predictive factor for high grade gliomas.\n\nO6-Methylguanine-Methyltransferase (MGMT) is an enzyme in cells that repairs DNA. DNA repair is undesirable in tumors, because it may enable them to overcome the DNA damage done by chemotherapy. With methylation, less MGMT enzyme is produced, which may lead to prolonged survival compared to unmethylated MGMT.\n\nA patient with increased MGMT methylation is more likely to respond to alkylating agents such as temozolomide (Temodar) and the nitrosoureas, some of the few drugs effective for brain tumors. MGMT methylation is a special (not routine) molecular test done on tumor tissue. It is used primarily for anaplastic oligodendroglioma, anaplastic astrocytoma and glioblastoma multiforme, but can also be done for low grade malignant central nervous system tumors.", "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of the methylation status of the MGMT, also termed MGMT promoter, gene can be used to code this data item when no other information is available.\n\n**Note 2:** **Applicable histologies**\n* Below is a list of histologies/terms for which the MGMT test is commonly done. If the test was done, record the results, regardless of the histology. If the histology is not listed among those for which the MGMT test is commonly done, and the test result is not readily available, assume it was not done and code 9 for unknown.\n * 9382/3: Anaplastic oligoastrocytoma, NOS\n * 9382/3: Oligoastrocytoma, NOS\n * 9400/3: Diffuse astrocytoma (IDH mutant, IDH wild type, NOS)\n * 9401/3: Anaplastic astrocytoma (IDH mutant, IDH wild type, NOS)\n * 9411/3: Gemistocytic astrocytoma, IDH mutant\n * 9424/3: Anaplastic pleomorphic xanthoastrocytoma\n * 9440/3: Glioblastoma (epithelioid, IDH wild type, NOS)\n * 9441/3: Giant cell glioblastoma\n * 9442/3: Gliosarcoma\n * 9445/3: Glioblastoma, IDH mutant\n * 9450/3: Oligodendroglioma (IDH mutant and 1p/19q codeleted, NOS)\n * 9451/3: Anaplastic oligodendroglioma (IDH mutant and 1p/19 codeleted, NOS)\n * 9505/3: Anaplastic ganglioglioma\n * 9530/3: Anaplastic (malignant)meningioma", - "last_modified" : "2024-04-07T18:46:49.965Z", + "last_modified" : "2025-11-06T21:33:16.327Z", "definition" : [ { "key" : "mgmt", "name" : "Code", @@ -18,6 +18,6 @@ } ], "rows" : [ [ "0", "MGMT methylation absent/not present, unmethylated MGMT" ], [ "1", "MGMT methylation present, low level\nHypomethylated\nPartial methylated" ], [ "2", "MGMT methylation present, high level\nHypermethylated" ], [ "3", "MGMT methylation present, level unspecified" ], [ "6", "Benign or borderline tumor" ], [ "7", "Test ordered, result not in chart" ], [ "8", "Not applicable: Information not collected for this case\n(If this item is required by your standard setter, use of code 8 will result in an edit error.)" ], [ "9", "Not documented in medical record\nCannot be determined by the pathologist\nMGMT not assessed or unknown if assessed" ] ], "additional_info" : "**Source documents:** pathology report, specialty, or reference laboratory report\n\n**Other names include** MGMT promoter methylation, methylation status", - "coding_guidelines" : "**1)** **Code 0** when the MGMT is not identified/not present \n**2)** **Code 1** when the MGMT is low\n**3)** **Code 2** when the MGMT is high\n**4)** **Code 3** when the MGMT is mentioned, but not stated as low or high\n**5)** **Code 6** for a **Benign (/0)** or **Borderline (/1) tumor**\n**6)** **Code 9** when\n* **a.** No information in the medical record about MGMT\n* **b.** MGMT test not done (not assessed)\n* **c.** Unknown if MGMT test was performed (unknown if assessed)", + "coding_guidelines" : "**1)** **Code 0** when the MGMT is not identified/not present \n\n**2)** **Code 1** when the MGMT is low\n\n**3)** **Code 2** when the MGMT is high\n\n**4)** **Code 3** when the MGMT is mentioned, but not stated as low or high\n\n**5)** **Code 6** for a **Benign (/0)** or **Borderline (/1) tumor**\n\n**6)** **Code 9** when\n* No information in the medical record about MGMT\n* MGMT test not done (not assessed)\n* Unknown if MGMT test was performed (unknown if assessed)", "rationale" : "Methylation of O6-Methylguanine-Methyltransferase (MGMT) is a Registry Data Collection Variable in AJCC. It was previously collected as Brain, CS SSF #4." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/microsatellite_instability_35598.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/microsatellite_instability_35598.json index 80bd7a88c..87fcd5314 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/microsatellite_instability_35598.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/microsatellite_instability_35598.json @@ -6,7 +6,7 @@ "title" : "Microsatellite Instability (MSI)", "description" : "The microsatellite instability (MSI) test is a genetic test performed on tumor tissue to look for differences in length of certain non-functioning sections of DNA. The differences are caused by problems with the genes that encode proteins that normally repair certain types of DNA damage. Knowing whether cancer is microsatellite instability high may help plan the best treatment\n\nMicrosatellites are short, repeated, sequences of DNA. Cancer cells that have large numbers of microsatellites that may have defects in the ability to correct mistakes that occur when DNA is copied in the cell. Microsatellite instability is found most often in colorectal cancer, other types of gastrointestinal cancer, and endometrial cancer. It may also be found in cancers of the breast, prostate, bladder, and thyroid.", "notes" : "**Note 1:** **Effective years**\n* This SSDI is effective for diagnosis years 2026+\n* For cases diagnosed 2018-2025, this SSDI must be blank\n\n**Note 2:** **Physician Statement**\n* Physician statement of MSI can be used to code this data item when no other information is available.\n\n**Note 3:** **Applicable stages**\n* MSI may be recorded for all stages; however, it is primarily performed for invasive neoplasms\n* For non-invasive neoplasms (behavior /2), code to 9 if no information available.\n\n**Note 4:** **Results from nodal or metastatic tissue**\n* Results from nodal or metastatic tissue may be used for Microsatellite Instability.", - "last_modified" : "2025-04-18T16:11:03.927Z", + "last_modified" : "2025-11-06T20:29:58.569Z", "definition" : [ { "key" : "msi", "name" : "Code", @@ -17,6 +17,6 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "0", "Microsatellite instability (MSI) stable; microsatellite stable (MSS); negative, NOS\nAND/OR\nMismatch repair (MMR) intact, no loss of nuclear expression of MMR proteins\nMMR proficient (pMMR or MMR-P)" ], [ "1", "MSI unstable low (MSI-L)" ], [ "2", "MSI unstable high (MSI-H)\nAND/OR\nMMR deficient (dMMR or MMR-D) loss of nuclear expression of one or more MMR proteins, MMR protein deficient)" ], [ "8", "Not applicable: Information not collected for this case\n(If this information is required by your standard setter, use of code 8 may result in an edit error.)" ], [ "9", "Not documented in medical record\nMSI-indeterminate \nMSI-equivocal\nMicrosatellite instability not assessed or unknown if assessed" ], [ "", "Must be blank if diagnosis year is before 2026" ] ], - "additional_info" : "**Source documents:** pathology report\n\n**Other names include** MSI, Mismatch repair, MMR, MSI-H\n\nFor further information, refer to the **Carcinoma of the Endometrium** Reporting cancer protocol published by the College of American Pathologists for the AJCC Staging System *Corpus Uteri-Carcinoma and Adenocarcinoma*", - "coding_guidelines" : "**Microsatellite Instability (MSI)**\n* Testing for MSI may be done by immunology or genetic testing. Only genetic testing results will specify whether the MSI is low or high.\n* MSI is looking at instability in informative markers\n\n\n**1)** **Code 0**\n* MSS (Code 0)\n * Stable (Code 0)\n * Negative (Code 0)\n * Low probability of MSI-H (Code 0)\n* MSS/MSI-L (Code 0)\n\n **2)** **Code 1**\n* MSI-L (Code 1)\n\n**3)** **Code 2**\n* Unstable, high (Code 2)\n* Unstable, NOS (no designation of high or low) (Code 2)\n * MSI-H (Code 2)\n\n**4)** **Code 9**\n* MSI-I (intermediate) (Code 9)\n\n**Mismatch Repair (MMR)**\n* Testing for Mismatch Repair (MMR) is usually done by immunohistochemistry (IHC).\n* Most common markers are MLH1, MSH2, MSH6, PMS2\n\n \n **1)** **Code 0**\n* No loss of nuclear expression (code 0)\n* Mismatch repair (MMR) intact (code 0)\n* MMR proficient (pMMR or MMR-P) (code 0)\n * MMR normal (code 0)\n\n **2)** **Code 2**\n* Loss of nuclear expression (code 2)\n* MMR deficient (dMMR or MMR-D) (code 2)\n * MMR abnormal (code 2)\n\n**MSI and MMR**\n **1)** **Code 0** If all tests done are negative\n**2)** **Code 2** If both tests are done and one or both are positive" + "additional_info" : "**Source documents:** pathology report\n\n**Other names include** MSI, Mismatch repair, MMR, MSI-H\n\nFor further information, refer to the **Carcinoma of the Endometrium** Reporting cancer protocol published by the College of American Pathologists for the AJCC Staging System *Corpus Uteri-Carcinoma and Adenocarcinoma*.", + "coding_guidelines" : "**Microsatellite Instability (MSI)**\n* Testing for MSI may be done by immunology or genetic testing. Only genetic testing results will specify whether the MSI is low or high.\n* MSI is looking at instability in informative markers\n\n**1)** **Code 0**\n* MSS (Code 0)\n * Stable (Code 0)\n * Negative (Code 0)\n * Low probability of MSI-H (Code 0)\n* MSS/MSI-L (Code 0)\n\n**2)** **Code 1**\n* MSI-L (Code 1)\n\n**3)** **Code 2**\n* Unstable, high (Code 2)\n* Unstable, NOS (no designation of high or low) (Code 2)\n * MSI-H (Code 2)\n\n**4)** **Code 9**\n* MSI-I (intermediate) (Code 9)\n\n\n**Mismatch Repair (MMR)**\n* Testing for Mismatch Repair (MMR) is usually done by immunohistochemistry (IHC).\n* Most common markers are MLH1, MSH2, MSH6, PMS2\n \n**1)** **Code 0**\n* No loss of nuclear expression (code 0)\n* Mismatch repair (MMR) intact (code 0)\n* MMR proficient (pMMR or MMR-P) (code 0)\n * MMR normal (code 0)\n\n**2)** **Code 2**\n* Loss of nuclear expression (code 2)\n* MMR deficient (dMMR or MMR-D) (code 2)\n * MMR abnormal (code 2)\n\n\n**MSI and MMR**\n\n**1)** **Code 0** If all tests done are negative\n\n**2)** **Code 2** If both tests are done and one or both are positive" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/microsatellite_instability_7008.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/microsatellite_instability_7008.json index e195b312b..ddd7029f4 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/microsatellite_instability_7008.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/microsatellite_instability_7008.json @@ -6,7 +6,7 @@ "title" : "Microsatellite Instability (MSI)", "description" : "The microsatellite instability (MSI) test is a genetic test performed on tumor tissue to look for differences in length of certain non-functioning sections of DNA. The differences are caused by problems with the genes that encode proteins that normally repair certain types of DNA damage. Knowing whether cancer is microsatellite instability high may help plan the best treatment\n\nMicrosatellites are short, repeated, sequences of DNA. Cancer cells that have large numbers of microsatellites that may have defects in the ability to correct mistakes that occur when DNA is copied in the cell. Microsatellite instability is found most often in colorectal cancer, other types of gastrointestinal cancer, and endometrial cancer. It may also be found in cancers of the breast, prostate, bladder, and thyroid. \n\nHigh MSI, found in about 15% of colorectal carcinomas, is an adverse prognostic factor for colorectal carcinomas and predicts poor response to 5-FU chemotherapy (although the addition of oxaliplatin in FOLFOX regimens negates the adverse effects. High MSI is a hallmark of hereditary nonpolyposis colorectal carcinoma, also known as Lynch syndrome.\n\nA high proportion of colon cancers arising in patients with hereditary nonpolyposis colorectal cancer (HNPCC) (also known as Lynch syndrome) have high MSI and a smaller percentage of colon cancers not associated with Lynch syndrome have high MSI. Patients with colon cancers with high MSI may be further tested to determine if they have HNPCC. In addition, MSI is a useful prognostic marker in that patients with high MSI colon cancers have better response to surgery and survival.", "notes" : "**Note 1:** **Physician Statement**\n* Physician statement of MSI can be used to code this data item when no other information is available.\n\n**Note 2:** **Applicable stages**\n* MSI may be recorded for all stages; however, it is primarily performed for invasive neoplasms\n* For non-invasive neoplasms (behavior /2), code to 9 if no information available.\n\n**Note 3:** **Results from nodal or metastatic tissue**\n* Results from nodal or metastatic tissue may be used for Microsatellite Instability.", - "last_modified" : "2025-03-24T16:44:03.312Z", + "last_modified" : "2025-11-06T18:04:16.825Z", "definition" : [ { "key" : "msi", "name" : "Code", @@ -17,7 +17,7 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "0", "Microsatellite instability (MSI) stable; microsatellite stable (MSS); negative, NOS\nAND/OR\nMismatch repair (MMR) intact, no loss of nuclear expression of MMR proteins\nMMR proficient (pMMR or MMR-P)" ], [ "1", "MSI unstable low (MSI-L)" ], [ "2", "MSI unstable high (MSI-H)\nAND/OR\nMMR deficient (dMMR or MMR-D) loss of nuclear expression of one or more MMR proteins, MMR protein deficient)" ], [ "8", "Not applicable: Information not collected for this case\n(If this information is required by your standard setter, use of code 8 may result in an edit error.)" ], [ "9", "Not documented in medical record\nMSI-indeterminate \nMSI-equivocal\nMicrosatellite instability not assessed or unknown if assessed" ] ], - "additional_info" : "**Source documents:** pathology report\n\n**Other names include** MSI, Mismatch repair, MMR, MSI-H\n\nFor further information, refer to the **Colon and Rectum Biomarker** Reporting cancer protocol published by the College of American Pathologists for the AJCC Staging System *Colon and Rectum*", - "coding_guidelines" : "**Microsatellite Instability (MSI)**\n* Testing for MSI may be done by immunology or genetic testing. Only genetic testing results will specify whether the MSI is low or high.\n* MSI is looking at instability in informative markers\n\n\n**1)** **Code 0**\n* MSS (Code 0)\n * Stable (Code 0)\n * Negative (Code 0)\n * Low probability of MSI-H (Code 0)\n* MSS/MSI-L (Code 0)\n\n **2)** **Code 1**\n* MSI-L (Code 1)\n\n**3)** **Code 2**\n* Unstable, high (Code 2)\n* Unstable, NOS (no designation of high or low) (Code 2)\n * MSI-H (Code 2)\n\n**4)** **Code 9**\n* MSI-I (intermediate) (Code 9)\n\n**Mismatch Repair (MMR)**\n* Testing for Mismatch Repair (MMR) is usually done by immunohistochemistry (IHC).\n* Most common markers are MLH1, MSH2, MSH6, PMS2\n\n \n **1)** **Code 0**\n* No loss of nuclear expression (code 0)\n* Mismatch repair (MMR) intact (code 0)\n* MMR proficient (pMMR or MMR-P) (code 0)\n * MMR normal (code 0)\n\n **2)** **Code 2**\n* Loss of nuclear expression (code 2)\n* MMR deficient (dMMR or MMR-D) (code 2)\n * MMR abnormal (code 2)\n\n**MSI and MMR**\n **1)** **Code 0** If all tests done are negative\n**2)** **Code 2** If both tests are done and one or both are positive", + "additional_info" : "**Source documents:** pathology report\n\n**Other names include** MSI, Mismatch repair, MMR, MSI-H\n\nFor further information, refer to the **Colon and Rectum Biomarker** Reporting cancer protocol published by the College of American Pathologists for the AJCC Staging System *Colon and Rectum*.", + "coding_guidelines" : "**Microsatellite Instability (MSI)**\n* Testing for MSI may be done by immunology or genetic testing. Only genetic testing results will specify whether the MSI is low or high.\n* MSI is looking at instability in informative markers\n\n**1)** **Code 0**\n* MSS (Code 0)\n * Stable (Code 0)\n * Negative (Code 0)\n * Low probability of MSI-H (Code 0)\n* MSS/MSI-L (Code 0)\n\n **2)** **Code 1**\n* MSI-L (Code 1)\n\n**3)** **Code 2**\n* Unstable, high (Code 2)\n* Unstable, NOS (no designation of high or low) (Code 2)\n * MSI-H (Code 2)\n\n**4)** **Code 9**\n* MSI-I (intermediate) (Code 9)\n\n\n**Mismatch Repair (MMR)**\n* Testing for Mismatch Repair (MMR) is usually done by immunohistochemistry (IHC).\n* Most common markers are MLH1, MSH2, MSH6, PMS2\n \n**1)** **Code 0**\n* No loss of nuclear expression (code 0)\n* Mismatch repair (MMR) intact (code 0)\n* MMR proficient (pMMR or MMR-P) (code 0)\n * MMR normal (code 0)\n\n**2)** **Code 2**\n* Loss of nuclear expression (code 2)\n* MMR deficient (dMMR or MMR-D) (code 2)\n * MMR abnormal (code 2)\n\n\n**MSI and MMR**\n\n**1)** **Code 0** If all tests done are negative\n\n**2)** **Code 2** If both tests are done and one or both are positive", "rationale" : "Microsatellite Instability (MSI) is a Registry Data Collection Variable in AJCC. It was previously collected as Colon and Rectum, CS SSF #7." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/microvascular_density_70589.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/microvascular_density_70589.json index 496e2288e..ea160ebf0 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/microvascular_density_70589.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/microvascular_density_70589.json @@ -6,7 +6,7 @@ "title" : "Microvascular Density (MVD)", "description" : "Microvascular Density, a quantitative measure of tumor vascularity, is a prognostic factor for uveal melanoma.\n\nA high density of microvessels, identified immunohistochemically using antibodies for vascular endothelial cells (such as Factor VIII-associated antigen, CD34 epitope, etc.), has prognostic significance in a melanoma of the uvea. Higher counts have more unfavorable outcome. To obtain microvascular density, the pathologist, using a microscope with an eyepiece graticule (grid) of approximately 0.3 square mm and X200 magnification, counts microvessels from the most highly vascularized areas (“hot spots”) of the tumor, identified by scanning the entire immunostained tumor at lower magnification. Any immunolabeled element, clearly separate from an adjacent one and either totally inside the graticule or touching its top or left border, is counted as a microvessel. In several studies, the range of microvascular density was from 5 to 121 vessels, although this will vary depending on the type of immunostaining and area of graticule used.", "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of microvascular density (MVD) can be used to code this data item when no other information is available.\n\n**Note 2:** **Recording the results** \n* Record the results as expressed on the laboratory test\n* Record the information based on quartiles for laboratory standards if this is the only expression of results.\n* Code the microvascular density (number of microvessels) in whole numbers as stated in the pathology report in the code range 001 (1 vessel per 0.3 square millimeters) to 500 (500 vessels per 0.3 square millimeters).", - "last_modified" : "2024-04-07T17:59:52.245Z", + "last_modified" : "2025-11-06T15:27:10.445Z", "definition" : [ { "key" : "mvd", "name" : "Code", @@ -17,6 +17,6 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "00", "No vessels involved" ], [ "01-99", "01-99 vessels per 0.3 square millimeter (mm2)" ], [ "X1", "Greater than or equal to 100 vessels per 0.3 square millimeter (mm2)" ], [ "X2", "Lowest quartile for laboratory" ], [ "X3", "Second quartile for laboratory" ], [ "X4", "Third quartile for laboratory" ], [ "X5", "Highest quartile for laboratory" ], [ "X7", "Test ordered, results not in chart" ], [ "X8", "Not applicable: Information not collected for this case\n(If this information is required by your standard setter, use of code 8 may result in an edit error.)" ], [ "X9", "Not documented in medical record\nMicrovascular Density (MVD) not assessed or unknown if assessed" ] ], - "additional_info" : "**Source documents:** pathology report\n\nFor further information, refer to the **Uveal Melanoma** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Uveal Melanoma*", + "additional_info" : "**Source documents:** pathology report\n\nFor further information, refer to the **Uveal Melanoma** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Uveal Melanoma*.", "rationale" : "Microvascular Density is a Registry Data Collection Variable in AJCC. This data item was previously collected as Uveal Melanoma, CS SSF #13." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mitotic_count_uveal_melanoma_26990.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mitotic_count_uveal_melanoma_26990.json index 0bd9d4049..f25f4dbe0 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mitotic_count_uveal_melanoma_26990.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mitotic_count_uveal_melanoma_26990.json @@ -6,7 +6,7 @@ "title" : "Mitotic Count Uveal Melanoma", "description" : "Mitotic Count Uveal Melanoma, the number of mitoses per 40 high-power fields (HPF) based on pathological evaluation, is a prognostic factor for uveal melanoma.\n\nMitotic count is collected for several different types of cancers. For melanomas of the choroids, ciliary body and iris, the standard measurement is the total number of mitoses per 40 high power fields (HPF at 40 times magnification) per 0.152 square millimeters.", "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of mitotic count for a uveal melanoma can be used to code this data item when no other information is available. \n\n**Note 2:** **Mitotic count defined** \n* The number of mitoses per 40 high-power fields (HPF), reflects the potential aggressiveness or prognosis of uveal melanomas\n* This data item presumes the denominator of 40 HPF, so just the numerator (the mitotic count) is coded here. \n* For other schemas in which mitotic count is collected, the denominator may vary.\n\n**Note 3:** **High Power Field (HPF) defined** \n* An HPF usually has a magnification objective of 40 (a 40x field) \n* As described in the AJCC chapter on Uveal Melanomas, the typical field area is 0.152 square millimeters (mm2).\n\n**Note 4:** **Recording the results** \n* Record mitotic count to the nearest tenth as documented in the pathology report. \n* For example, a mitotic count of 6/40 HPF would be coded 6.0.", - "last_modified" : "2024-04-07T18:00:17.861Z", + "last_modified" : "2025-11-06T15:27:24.605Z", "definition" : [ { "key" : "mitotic_count_uveal_mel", "name" : "Code", @@ -17,6 +17,6 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "0.0", "0 mitoses per 40 high-power fields (HPF) \nMitoses absent, no mitoses present, no mitotic activity" ], [ "0.1-99.9", "0.1-99.9 mitosis per 40 HPF " ], [ "XX.1", "100 or more mitoses per 40 HPF" ], [ "XX.2", "Stated as low mitotic count or rate with no specific number" ], [ "XX.3", "Stated as high mitotic count or rate with no specific number" ], [ "XX.4", "Mitotic count described with denominator other than 40 HPF " ], [ "XX.7", "Test ordered, results not in chart" ], [ "XX.8", "Not applicable: Information not collected for this case\n(If this information is required by your standard setter, use of code XX.8 may result in an edit error.)" ], [ "XX.9", "Not documented in medical record\nMitotic Count Uveal Melanoma not assessed or unknown if assessed" ] ], - "additional_info" : "**Source documents:** pathology report\n\nFor further information, refer to the **Uveal Melanoma** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Uveal Melanoma*", + "additional_info" : "**Source documents:** pathology report\n\nFor further information, refer to the **Uveal Melanoma** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Uveal Melanoma*.", "rationale" : "Mitotic Count Uveal Melanoma is listed as a Registry Data Collection Variable in AJCC. It was previously collected as Uveal Melanoma, CS SSF #9." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mitotic_rate_melanoma_88184.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mitotic_rate_melanoma_88184.json index 7c43d2eb8..a169878b8 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mitotic_rate_melanoma_88184.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/mitotic_rate_melanoma_88184.json @@ -6,7 +6,7 @@ "title" : "Mitotic Rate Melanoma", "description" : "Mitotic Rate Melanoma, the number of mitoses per square millimeter based on pathological evaluation, is a prognostic factor for melanoma of the skin.\n\nMitotic count is a way of describing the potential aggressiveness of a tumor. Record the number of cells actively dividing as determined by the pathologist. The count will vary according to the type of tumor.", "notes" : "**Note:** **Physician Statement** \n* Physician statement of the Mitotic Rate Melanoma can be used to code this data item when no other information is available.", - "last_modified" : "2024-04-08T16:53:36.857Z", + "last_modified" : "2025-11-06T15:49:05.158Z", "definition" : [ { "key" : "mitotic_rate_melanoma", "name" : "Code", @@ -17,7 +17,7 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "00", "0 mitoses per square millimeter (mm)\nMitoses absent\nNo mitoses present" ], [ "01-99", "1 - 99 mitoses/square mm\n(Exact measurement in mitoses/square mm)" ], [ "X1", "100 mitoses/square mm or more" ], [ "X2", "Stated as \"less than 1 mitosis/square mm\"\nStated as \"nonmitogenic\"" ], [ "X3", "Stated as \"at least 1 mitosis/square mm\"\nStated as \"mitogenic\"" ], [ "X4", "Mitotic rate described with denominator other than square millimeter (mm)" ], [ "X7", "Test ordered, results not in chart" ], [ "X8", "Not applicable: Information not collected for this case\n(If this information is required by your standard setter, use of code X8 may result in an edit error.)" ], [ "X9", "Not documented in medical record\nMitotic Rate Melanoma not assessed or unknown if assessed" ] ], - "additional_info" : "**Source documents:** pathology report\n\n**Other names include** mitotic rate, mitotic index (a ratio—do not record this measurement), mitotic activity\n\nFor further information, refer to the **Melanoma of the Skin** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Melanoma of the Skin*", + "additional_info" : "**Source documents:** pathology report\n\n**Other names include** mitotic rate, mitotic index (a ratio—do not record this measurement), mitotic activity\n\nFor further information, refer to the **Melanoma of the Skin** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Melanoma of the Skin*.", "coding_guidelines" : "**1)** Record the mitotic rate/count as documented in the pathology report. \n\n**2)** If there is more than one pathology report for the same melanoma at initial diagnosis and different mitotic counts are documented, code the highest mitotic count from any of the pathology reports.\n\n**3)** The term \"mitotic figures\" is the same as mitoses.", "rationale" : "Mitotic Rate Melanoma is a Registry Data Collection Variable in AJCC. It was previously collected as Melanoma Skin, CS SSF #7." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/multigene_signature_method_85043.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/multigene_signature_method_85043.json index 35e8016d6..e2fbde09b 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/multigene_signature_method_85043.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/multigene_signature_method_85043.json @@ -6,7 +6,7 @@ "title" : "Multigene Signature Method", "description" : "Multigene signatures or classifiers are assays of a panel of genes from a tumor specimen, intended to provide a quantitative assessment of the likelihood of response to chemotherapy and to evaluate prognosis or the likelihood of future metastasis. This data item identifies the multigene signature method used. Oncotype Dx is coded elsewhere.\n\nMultigene testing is usually done for node-negative female breast cancer patients to predict risk of recurrence within a specified time period or to predict the likelihood that the patient will respond to specific types of chemotherapy. Multigene testing helps tailor treatment for the woman’s specific cancer characteristics. Recent studies indicate that these tests may also be helpful in planning treatment and predicting recurrence in node positive women with small tumors. Some types of tests may be specific to ER positive or negative patients or women in a certain age range. Many different types of genetic testing are available, including IHC-, FISH-, RT-PCR-, and genomic microarray-based multigene predictors.\n\nInformation is collected on the following tests \n* **MammaPrint:** A genomic test that analyzes the activity of certain genes in early-stage breast cancer. Developed to help make treatment decisions based on the cancer's risk of coming back (recurrence) within 10 years after diagnosis. \n* **PAM 50 (Prosigna):** PAM50 stands for Prediction Analysis of Microarray 50. It tests a sample of the tumor (removed during a biopsy or surgery) for a group of 50 genes. Along with other factors, the results of the PAM50 (Prosigna) test help predict the chance of metastasis (when cancer spreads to other organs). Prosigna also helps to determine the molecular subtype of breast cancer.\n* **Breast Cancer Index:** Analyzes the activity of seven genes to help predict the risk of node-negative, hormone-receptor-positive breast cancer coming back 5 to 10 years after diagnosis. The test can help women and their doctors decide if extending hormonal therapy 5 more years (for a total of 10 years of hormonal therapy) would be beneficial. The Breast Cancer Index reports two scores: how likely the cancer is to recur 5 to 10 years after diagnosis and how likely a woman is to benefit from taking hormonal therapy for a total of 10 years. \n* **EndoPredict:** A genomic test for people newly diagnosed with early-stage, estrogen-receptor-positive, HER2-negative breast cancer. May be used to help make treatment decisions based on the cancer's risk of coming back in a part of the body away from the breast (distant metastasis) within 10 years after diagnosis. The EndoPredict test provides a risk score that is either low-risk or high-risk of breast cancer recurring as distant metastasis. Knowing if the cancer has a high or low risk of recurrence can help women and their doctors decide if chemotherapy or other treatments to reduce risk after surgery are needed. \n\nFor the Breast cases, there are 2 related data items that record information on Multigene testing.\n* 3894: Multigene Signature Method\n* 3895: Multigene Signature Results\n\nThese two fields record the type of multigene signature test that was performed. Both fields should be coded from the same test, which may not be available at the time of diagnosis.", "notes" : "**Note 1:** **Physician Statement**\n* Physician statement of the Multigene Signature Method can be used to code this data item when no other information is available.\n\n**Note 2:** **Multigene signatures/classifiers**\n* Multigene signatures or classifiers are assays of a panel of genes from a tumor specimen, intended to provide a quantitative assessment of the likelihood of response to chemotherapy and to evaluate prognosis or the likelihood of future metastasis.\n* Only record tests done on tumor tissue that help determine if the cancer is likely to recur.\n * Don’t include other tests, such as those that evaluate hereditary mutations that influence a patient’s risk of developing cancer (e.g. myRisk, BRCA)\n* Only record tests that are based on gene assays.\n* Don’t include other tests which use a multivariate data model to eliminate the need for genetic assays\n\n**Note 3:** **Oncotype Dx tests**\n* Oncotype Dx tests are not recorded in this data item. See the following related data items for Oncotype Dx.\n * 3903: Oncotype Dx Recurrence Score-DCIS\n * 3904: Oncotype Dx Recurrence Score-Invasive\n * 3905: Oncotype Dx Risk Level-DCIS\n * 3906: Oncotype Dx Risk Level-Invasive\n\n**Note 4:** **Related data item** \n* Code the type of test performed. The same test should be used to record the related data item 3895: Multigene Signature Results.", - "last_modified" : "2024-04-08T20:07:22.056Z", + "last_modified" : "2025-11-05T21:02:29.129Z", "definition" : [ { "key" : "multigene_signature_method", "name" : "Code", @@ -17,6 +17,6 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "1", "MammaPrint" ], [ "2", "PAM50 (Prosigna)" ], [ "3", "Breast Cancer Index" ], [ "4", "EndoPredict" ], [ "5", "Test performed, type of test unknown" ], [ "6", "Multiple tests, any tests in codes 1-4" ], [ "7", "Test ordered, results not in chart" ], [ "8", "Not applicable: Information not collected for this case\n(If this item is required by your standard setter, use of code 8 will result in an edit error.)" ], [ "9", "Not documented in medical record\nMultigene Signature Method not assessed or unknown if assessed" ] ], - "additional_info" : "**Source documents:** specialty reference laboratories (private companies with proprietary testing methods); the actual report may be included in the medical record or may be referenced by the clinician.\n\n**Other names include:** genomic profiling, multigene testing, multigene assay, microarray assay, molecular diagnostics for treatment planning", + "additional_info" : "**Source documents:** specialty reference laboratories (private companies with proprietary testing methods); the actual report may be included in the medical record or may be referenced by the clinician\n\n**Other names include:** genomic profiling, multigene testing, multigene assay, microarray assay, molecular diagnostics for treatment planning", "rationale" : "Rationale\nMultigene Signature Method is a Registry Data Collection Variable in AJCC. It was previously collected as Breast, CS SSF #22. See also Multigene Signature Results." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/multigene_signature_result_37000.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/multigene_signature_result_37000.json index f4cf36960..52bf6eedd 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/multigene_signature_result_37000.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/multigene_signature_result_37000.json @@ -6,7 +6,7 @@ "title" : "Multigene Signature Result", "description" : "Multigene signatures or classifiers are assays of a panel of genes from a tumor specimen, intended to provide a quantitative assessment of the likelihood of response to chemotherapy and to evaluate prognosis or the likelihood of future metastasis. This data item identifies the multigene signature result. Oncotype Dx is coded elsewhere.", "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of the Multigene Signature Results can be used to code this data item when no other information is available.\n\n**Note 2:** **Score or Risk** \n* Code the score or risk for the test performed. The same test should be used to record the related data item 3894: Multigene Signature Method.\n\n**Note 3:** **Oncotype Dx tests** \n* Oncotype Dx tests are not recorded in this data item. See the following related data items for Oncotype Dx.\n * 3903: Oncotype Dx Recurrence Score-DCIS\n * 3904: Oncotype Dx Recurrence Score-Invasive\n * 3905: Oncotype Dx Risk Level-DCIS\n * 3906: Oncotype Dx Risk Level-Invasive", - "last_modified" : "2024-04-08T20:08:11.551Z", + "last_modified" : "2025-11-05T21:03:11.920Z", "definition" : [ { "key" : "multigene_signature_result", "name" : "Code", @@ -17,6 +17,6 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "00-99", "Enter actual recurrence score \nNote: Depending on the test, the range of values may be different" ], [ "X1", "Score 100" ], [ "X2", "Low risk" ], [ "X3", "Moderate [intermediate] risk" ], [ "X4", "High risk" ], [ "X7", "Test done, results not in chart" ], [ "X8", "Not applicable: Information not collected for this case\n(If this item is required by your standard setter, use of code X8 will result in an edit error.)" ], [ "X9", "Not documented in medical record\nMultigene Signature Results not assessed or unknown if assessed" ] ], - "additional_info" : "**Source documents:** specialty reference laboratories (private companies with proprietary testing methods); the actual report may be included in the medical record or may be referenced by the clinician.\n\n**Other names include:** genomic profiling, multigene testing, multigene assay, microarray assay, molecular diagnostics for treatment planning", + "additional_info" : "**Source documents:** specialty reference laboratories (private companies with proprietary testing methods); the actual report may be included in the medical record or may be referenced by the clinician\n\n**Other names include:** genomic profiling, multigene testing, multigene assay, microarray assay, molecular diagnostics for treatment planning", "rationale" : "Multigene Signature Results is a Registry Data Collection Variable in AJCC. It was previously collected as Breast, CS SSF #23. See also Multigene Signature Method." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/multiple_myeloma_terminology_20875.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/multiple_myeloma_terminology_20875.json index 7fcdd0f8b..6cc8aea13 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/multiple_myeloma_terminology_20875.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/multiple_myeloma_terminology_20875.json @@ -6,7 +6,7 @@ "title" : "Schema Discriminator 1: Myeloma Terminology", "description" : "A variety of descriptive terms refer to early phases of plasma cell myeloma, all of which are coded to 9732, and reportable based on the 2010 Hematopoietic and Lymphoid Neoplasms coding rules. \n\nPer AJCC 8th edition, not all terms are applicable for the Revised International Staging System (RISS or R-ISS) stage. This schema discriminators collects the specific terminology used to describe the plasma cell myeloma at the time of diagnosis.", "notes" : "**Note 1:** **Code Selection** \n* Select the code based on the terminology specified by the physician in the record. Do not attempt to determine the correct terminology based on the diagnostic criteria in the AJCC 8th table 82.1\n* Do not change the discriminator code if a term used later indicates progression to a more aggressive disease course.\n\n**Note 2:** **Plasma cell leukemia** \n* Code 0 if diagnosis is plasma cell leukemia variant and is diagnosed concomitant with plasma cell myeloma", - "last_modified" : "2025-04-16T17:06:46.267Z", + "last_modified" : "2025-11-06T22:00:04.436Z", "definition" : [ { "key" : "discriminator_1", "name" : "Code", @@ -20,7 +20,7 @@ "name" : "Staging", "type" : "DESCRIPTION" } ], - "rows" : [ [ "0", "**Multiple myeloma**\n* Myeloma, NOS\n* Non-secretory myeloma\n* Plasma cell myeloma (PCM)\n* Ultra-High-Risk Smoldering MM (SMM)", "RISS Stage" ], [ "1", "Smoldering plasma cell myeloma (SPCM)\n Asymptomatic plasma cell myeloma\n Early myeloma\n Evolving myeloma", "No RISS Stage" ], [ "9", "**Other terminology describing myeloma**\nUnknown terminology used", "No RISS Stage" ] ], + "rows" : [ [ "0", "**Multiple myeloma**\n* Myeloma, NOS\n* Non-secretory myeloma\n* Plasma cell myeloma (PCM)\n* Ultra-High-Risk Smoldering MM (SMM)", "RISS Stage" ], [ "1", "Smoldering plasma cell myeloma (SPCM)\n Asymptomatic plasma cell myeloma\n Early myeloma\n Evolving myeloma", "No RISS Stage" ], [ "9", "**Other terminology describing myeloma**\n Unknown terminology used", "No RISS Stage" ] ], "additional_info" : "**Source documents:** pathology report, clinician’s statement", "rationale" : "A schema discriminator is used to assign AJCC ID when site and histology alone are insufficient to identify the applicable AJCC staging method and to assign Schema ID, which links each case to the appropriate SSDIs, Grade, Summary Stage and EOD data collection system." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nasopharynx_pharyngealtonsil_84756.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nasopharynx_pharyngealtonsil_84756.json index f7fdc2ad3..4a2993c12 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nasopharynx_pharyngealtonsil_84756.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nasopharynx_pharyngealtonsil_84756.json @@ -5,8 +5,8 @@ "name" : "Schema Discriminator 1", "title" : "Schema Discriminator 1: Nasopharynx/PharyngealTonsil", "description" : "Nasopharynx and pharyngeal tonsil have the same ICD-O topography code (C111). However, for purposes of stage grouping AJCC 8th edition, nasopharynx and pharyngeal tonsil are staged in different chapters. A schema discriminator is necessary to distinguish between these primary sites so that the appropriate chapter/schema is used.\n\n**Note: This schema discriminator is only needed for diagnosis years 2018-2024. It should be left blank for diagnosis years 2025 and after.**", - "notes" : "**Note:** **Schema discriminator for C111** \n* A schema discriminator is used to discriminate for primary site C111: Posterior wall of nasopharynx. Code the specific site in which the tumor arose.\n\n* **This schema discriminator is only needed for diagnosis years 2018-2024. It should be left blank for diagnosis years 2025 and after.**\n\n* **00090: Nasopharynx (see code 1)**\n Used to stage for the following primary site description: posterior wall of nasopharynx (NOS)\n\n* **00100 (Oropharyngeal HPV-Associated) or 00111 (Oropharyngeal HPV-Independent) (see code 2)**\nOropharynx Staging Systems are used for the following primary site descriptions. An additional schema discriminator will be used to distinguish between the AJCC HPV-Mediated (p16+) Oropharyngeal Cancer and Oropharynx (p16-) and Hypopharynx Staging System \n * Adenoid\n * Pharyngeal tonsil", - "last_modified" : "2025-06-10T16:55:30.518Z", + "notes" : "**Note:** **Schema discriminator for C111** \n* A schema discriminator is used to discriminate for primary site C111: Posterior wall of nasopharynx. Code the specific site in which the tumor arose.\n\n* **This schema discriminator is only needed for diagnosis years 2018-2024. It should be left blank for diagnosis years 2025 and after.**\n\n* **00090: Nasopharynx (see code 1)**\n\n Used to stage for the following primary site description: posterior wall of nasopharynx (NOS)\n\n* **00100 (Oropharyngeal HPV-Associated) or \n00111 (Oropharyngeal HPV-Independent) (see code 2)**\n\n Oropharynx Staging Systems are used for the following primary site descriptions. An additional schema discriminator will be used to distinguish between the AJCC HPV-Mediated (p16+) Oropharyngeal Cancer and Oropharynx (p16-) and Hypopharynx Staging System \n * Adenoid\n * Pharyngeal tonsil", + "last_modified" : "2025-11-06T17:16:57.484Z", "definition" : [ { "key" : "discriminator_1", "name" : "Code", @@ -21,6 +21,6 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "1", "Posterior wall of nasopharynx, NOS ", "00090: Nasopharynx 8th (2018-2024)" ], [ "2", "Adenoid\nPharyngeal tonsil", "3927: Schema discriminator 2: Oropharyngeal p16" ], [ "", "Primary Site is NOT C111, Discriminator is not necessary\nYear of Diagnosis is 2025 or later, Discriminator is not necessary", "" ] ], - "additional_info" : "**Source documents:** pathology report, imaging, clinician’s statement\n\nFor further information, refer to the **Pharynx** cancer protocol published by the College of American Pathologist for the AJCC Staging Systems *Nasopharynx, Oropharynx (p16-) and Oropharynx HPV-mediated (p16+)*", + "additional_info" : "**Source documents:** pathology report, imaging, clinician’s statement\n\nFor further information, refer to the **Pharynx** cancer protocol published by the College of American Pathologist for the AJCC Staging Systems *Nasopharynx, Oropharynx (p16-) and Oropharynx HPV-mediated (p16+)*.", "rationale" : "A schema discriminator is used to assign AJCC ID when site and histology alone are insufficient to identify the applicable AJCC staging method and to assign Schema ID, which links each case to the appropriate SSDIs, Summary Stage and EOD data collection system." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_daa.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_daa.json index 0c512238a..d1ae6f1e4 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_daa.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_daa.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Definition of Head and Neck Lymph Nodes** \n* For head and neck schemas, this field includes all lymph nodes defined as Levels I-VII and Other by TNM. \n\n**Note 2:** **CLINICAL AND PATHOLOGICAL codes** \n* This schema has lymph node codes that are defined as **CLINICAL** assessment only or **PATHOLOGICAL** assessment only.\n\n**No surgical resection**\n* Use **CLINICAL** assessment only codes (450) when there is a clinical work up only and there is **NO surgical resection of the primary tumor or site** WITH \n * Any microscopic examination of regional lymph nodes, which includes FNA, core biopsy, sentinel node biopsy, lymph node excision, or lymph node dissection done during the clinical work up. \n\n**Surgical resection without neoadjuvant therapy**\n* Use **PATHOLOGICAL** assessment only codes (150, 500, 600, 700) when there is a **surgical resection of the primary tumor or site** WITH \n * Any microscopic examination of regional lymph nodes, which includes FNA, core biopsy, sentinel node biopsy, lymph node excision done or lymph node dissection performed.\n\n**Surgical resection after neoadjuvant therapy**\n* If patient has neoadjuvant therapy, and the clinical assessment is equal to or greater than the pathological assessment, then the clinical assessment codes take priority. Otherwise, code the pathologic assessment. \n * See ***EOD 2018 General Instructions*** for further instructions on coding cases with neoadjuvant therapy, https://seer.cancer.gov/tools/staging/eod/.\n\n \n**Note 3:** **Laterality** \n* If laterality of lymph nodes is not specified, assume nodes are ipsilateral. Midline nodes are ipsilateral.\n\n**Note 4:** **Supraclavicular lymph nodes**\n* Supraclavicular lymph nodes can be either Level IV or Level V\n * Level IV: deep to the sternocleidomastoid muscle, in the lower jugular chain\n * Level V: in the posterior triangle, inferior to the transverse cervical artery, supraclavicular lymph nodes, NOS\n\n**Note 5:** **Extranodal Extension** \n* Extranodal extension (ENE) is defined as the extension of a nodal metastasis through the lymph node capsule into adjacent tissue. The following codes record the status of the lymph nodes with positive ENE\n * Code 150: Pathological only: single ipsilateral node, less than or equal to 3 cm\n * Code 450: Clinical only: overt ENE\n * Code 500: Pathological only: single ipsilateral node, greater than 3 cm\n * Code 600: Pathological only: multiple ipsilateral, bilateral or contralateral nodes\n * Code 700: Pathological only: Single contralateral node\n\n**Note 6:** **Regional lymph nodes for Head and Neck tumors** \n* **Note:** For codes 100-700, use the list below for named regional lymph nodes. If the only information available is \"regional lymph nodes, NOS\" or \"lymph nodes,\" code 800.\n\n**Level I**\nLevel IA - Submental\nLevel IB - Submandibular (submaxillary), sublingual\n\n**Level II - Upper jugular** \nJugulodigastric (subdigastric)\nUpper deep cervical \nLevel IIA - Anterior\nLevel IIB - Posterior \n\n**Level III - Middle jugular**\nMiddle deep cervical\n\n**Level IV - Lower jugular**\nJugulo-omohyoid (supraomohyoid)\nLower deep cervical \nVirchow node\n\n**Level V - Posterior triangle group**\nPosterior cervical\nLevel VA - Spinal accessory \nLevel VB - Transverse cervical, supraclavicular \n\n**Level VI - Anterior compartment group**\nLaterotracheal\nParalaryngeal\nParatracheal - above suprasternal notch\nPerithyroidal\nPrecricoid (Delphian)\nPrelaryngeal\nPretracheal - above suprasternal notch\nRecurrent laryngeal\n\n**Level VII - Superior mediastinal group (for other mediastinal node(s) see EOD Mets)**\nEsophageal groove\nParatracheal - below suprasternal notch\nPretracheal - below suprasternal notch \n\n**Other groups**\nCervical, NOS\nDeep cervical, NOS\nFacial\n- Buccinator (buccal)\n- Mandibular\n- Nasolabial\n\nInternal jugular, NOS\nParapharyngeal \nParotid\n- Infraauricular\n- Intraparotid\n- Periparotid\n- Preauricular\n\nRetroauricular (mastoid)\nRetropharyngeal\nSuboccipital", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Lydiatt, W.M., Patel, S.G., Shah, J.P., et al. **Staging Head and Neck Cancers**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Ridge, J.A., Lydiatt, W.M., Shah, J.P., et al. **Oral Cavity**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:39.331Z", + "last_modified" : "2025-11-14T20:05:17.217Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dab.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dab.json index 77f5ea481..03c89d637 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dab.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dab.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n\n**Note 2:** **Lymph nodes, NOS** \n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Welton, M.L., Jessup, J.M., et al. **Anus**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:58.196Z", + "last_modified" : "2025-11-14T20:05:37.022Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dai.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dai.json index 35723a8b2..849abf9fd 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dai.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dai.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS**\n* Code only regional nodes and nodes, NOS, in this field. \n* Distant nodes are coded in EOD Mets.\n\n**Note 2:** **\"Vocal cord paralysis\" or \"Superior vena cava syndrome\"** \n* \"Vocal cord paralysis,\" \"superior vena cava syndrome,\" and \"compression of the trachea or the esophagus\" are classified as either direct extension from the primary tumor or mediastinal lymph node involvement\n\n* **Caused by direct extension of the primary tumor**\n * Code as primary tumor involvement (EOD Primary Tumor, code 650)\n* **Primary tumor is peripheral and clearly unrelated to vocal cord paralysis, SVC obstruction, or compression of the trachea, or the esophagus**\n * These manifestations are secondary to lymph node involvement; code as mediastinal lymph node involvement (EOD Lymph Nodes, code 400)\n* **Unable to determine if manifestations due to direct extension or mediastinal lymph node involvement**\n * Record as mediastinal lymph node involvement (EOD Lymph Nodes, code 400)\n\n**Note 3:** **Lymph nodes, NOS**\n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Rami-Porta, R., Asamura, H., Travis, W.D., Rusch, V.W. **Lung**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:53.546Z", + "last_modified" : "2025-11-14T20:06:08.954Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_daj.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_daj.json index 806c32476..b3cea207b 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_daj.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_daj.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n\n**Note 2:** **CLINICAL AND PATHOLOGICAL codes**\n* This schema has lymph node codes that are defined as **CLINICAL** assessment only or **PATHOLOGICAL** assessment only.\n\n**No surgical resection**\n* Use **CLINICAL** assessment only codes (000, 150, 350, 400) when there is a clinical work up only and there is **NO surgical resection of the primary tumor or site** WITH \n * Any microscopic examination of regional lymph nodes, which includes FNA, core biopsy, sentinel node biopsy, lymph node excision, or lymph node dissection done during the clinical work up. \n\n**Surgical resection without neoadjuvant therapy**\n* Use **PATHOLOGICAL** assessment only codes (030, 050, 070, 200, 250, 300) when there is a **surgical resection of the primary tumor or site** WITH \n * Any microscopic examination of regional lymph nodes, which includes FNA, core biopsy, sentinel node biopsy, lymph node excision done or lymph node dissection performed.\n\n**Surgical resection after neoadjuvant therapy**\n* If patient has neoadjuvant therapy, and the clinical assessment is equal to or greater than the pathological assessment, then the clinical assessment codes take priority. Otherwise, code the pathologic assessment. \n * See ***EOD 2018 General Instructions*** for further instructions on coding cases with neoadjuvant therapy, https://seer.cancer.gov/tools/staging/eod/.\n\n \n**Note 3:** **Size of metastasis not stated**\n* If the pathology report indicates that nodes are positive, but size of the metastases is not stated, assume the metastases are greater than 0.2 mm and code the lymph nodes as positive in this field.\n\n**Note 4:** **Level of lymph nodes not specified**\n* If regional nodes are removed and there is no mention of the level or another specific type, assume these are Level I-II and code appropriately.\n\n**Note 5:** **Isolated tumor cells (ITC)** \n* Isolated tumor cells (ITCs) are defined as single tumor cells or small clusters not greater than 0.2 mm, usually detected by immunohistochemical (IHC) or molecular methods. ITCs do not usually show evidence of malignant activity (e.g., proliferation or stromal reaction). Lymph nodes with ITCs only are not counted as positive nodes. RT-PCR is a molecular method designed to find evidence of unique tumor or epithelial cell markers. \n + Codes 030, 050, and 070 are for nodes that are **pathologically negative** but are **positive** for ITCs or RT-PCR\n - **Code 030:** Negative nodes pathologically with positive ITCs OR positive ITCs AND positive RT-PCR\n - **Code 050:** Negative nodes pathologically with positive RT-PCR, negative ITCs\n - **Code 070:** Negative nodes pathologically, unknown if ITCs or RT-PCR\n - ***Note:** **Code 000** is only for clinical evaluation of lymph nodes (physical exam, imaging)*\n\n**Note 6:** **Internal mammary nodes** \n* Internal mammary nodes (codes 250, 300, 400, 600) are not routinely removed unless there was an uptake during a sentinel lymph node biopsy, or they were clinically apparent on imaging. Before assigning one of these codes, make sure that the documentation clearly states that internal mammary nodes are involved. \n + Do not confuse **internal mammary** nodes with **intramammary nodes**, which are routinely evaluated\n\n**Note 7:** **Axillary Level I and II lymph nodes** \n* Codes 100-200 and 350 only apply to involved axillary level I and II lymph nodes. \n* If internal mammary, infraclavicular (subclavicular, level III axillary, apical), or supraclavicular lymph nodes are involved, codes 100-200 and 350 may not be used.\n\n**Note 8:** **Regional lymph nodes include**\n\n- Axillary, NOS (ipsilateral)\n - Level I (low-axilla) (low) (superficial), NOS [adjacent to tail of breast]\n + Anterior (pectoral)\n + Lateral (brachial)\n + Posterior (subscapular)\n - Level II (mid-axilla) (central), NOS\n + Interpectoral (Rotter's)\n - Level III (high) (deep), NOS\n + Apical (subclavian)\n + Axillary vein\n- Fixed/matted axillary (level I and II) (ipsilateral)\n- Infraclavicular (subclavicular) (ipsilateral)\n- Internal mammary (parasternal) (ipsilateral)\n- Intramammary (ipsilateral)\n- Supraclavicular (transverse cervical) (ipsilateral)\n\n**Note 9:** **Lymph nodes, NOS** \n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Hortobagyi, G.N., Giuliano, A., et al. **Breast**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-19T18:33:51.778Z", + "last_modified" : "2025-11-14T20:06:13.057Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dak.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dak.json index d900dd206..0f80346b1 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dak.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dak.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n\n**Note 2:** **Hepatoduodenal and Pancreaticoduodenal lymph nodes** \n* Per AJCC, Hepatoduodenal nodes are regional for **all subsites** of the stomach. Previously they were regional only for the lesser curvature and the greater curvature.\n\n**Note 3:** **Metastatic nodules in the fat** \n* Metastatic nodules in the fat adjacent to a gastric carcinoma, without evidence of residual lymph node tissue, are classified as regional node metastases, but nodules implanted on peritoneal surfaces are classified as distant metastases (see EOD Mets).\n\n**Note 4:** **CLINICAL AND PATHOLOGICAL codes** \n* This schema has lymph node codes that are defined as **CLINICAL** assessment only or **PATHOLOGICAL** assessment only. \n\n**No surgical resection**\n* Use **CLINICAL** assessment only codes (400, 450, 500, 600, 700) when there is a clinical work up only and there is **NO surgical resection of the primary tumor or site** WITH \n * Any microscopic examination of regional lymph nodes, which includes FNA, core biopsy, sentinel node biopsy, lymph node excision, or lymph node dissection done during the clinical work up. \n\n**Surgical resection without neoadjuvant therapy**\n* Use **PATHOLOGICAL** assessment only codes (300) when there is a **surgical resection of the primary tumor or site** WITH \n * Any microscopic examination of regional lymph nodes, which includes FNA, core biopsy, sentinel node biopsy, lymph node excision done or lymph node dissection performed.\n\n**Surgical resection after neoadjuvant therapy**\n* If patient has neoadjuvant therapy, and the clinical assessment is equal to or greater than the pathological assessment, then the clinical assessment codes take priority. Otherwise, code the pathologic assessment. \n * See ***EOD 2018 General Instructions*** for further instructions on coding cases with neoadjuvant therapy, https://seer.cancer.gov/tools/staging/eod/.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Ajani, J.A., In, H., Sano, T., Hofstetter, W.L., et al. **Stomach**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:48.194Z", + "last_modified" : "2025-11-14T20:05:10.620Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dam.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dam.json index 83c5b0be6..92cbc7cab 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dam.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dam.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n\n**Note 2:** **Coding no regional lymph node involvement** \n* Code 000 may be used when\n * Pathology report **only** with a localized tumor based on Breslow's depth and/or Clark's Level (see EOD Primary Tumor or Summary Stage) AND\n * No information on regional lymph nodes or mets\n * **Note:** If the tumor is noted to be regional or distant based on Breslow’s Depth and/or Clark’s (see EOD Primary Tumor, EOD Mets or Summary Stage) then you cannot assume that the nodes are negative and would need to assign 999. \n\n**Note 3:** **Criteria for coding nodes** \n* Codes 100-750 are based on the following criteria\n + How the nodes were determined\n * Clinically occult (not clinically apparent) and found to be positive on microscopic examination (e.g., on sentinel lymph node procedure)\n * Clinically detected (clinically apparent) WITH or WITHOUT microscopic confirmation\n + Number of nodes involved\n + Presence of in-transit, satellite or microsatellite mets (see Note 4)\n\n**Note 4:** **Isolated tumor cells** \n* Isolated tumor cells (ITCs) are defined as single tumor cells or small clusters not greater than 0.2 mm, usually detected by immunohistochemical (IHC) or molecular methods. \nITCs do not usually show evidence of malignant activity (e.g., proliferation or stromal reaction). \n* Lymph nodes with isolated tumor cells (ITCs) are counted as positive lymph nodes\n\n**Note 5:** **In-transit, satellite and/r microsatellite metastasis** \n* In-transit, satellite, and/or microsatellite metastasis are metastasis that have occurred via lymphatic or angiolymphatic spread. \n* Satellite nodules are subcutaneous metastasis that occur within 2 cm of the primary tumor. \n* Microsatellite metastasis are microscopic cutaneous metastasis found adjacent or deep to a primary melanoma tumor.\n * Code 300 if there are in-transit, satellite, and/or microsatellite metastasis WITHOUT regional lymph node involvement\n * Code 500 if there are in-transit, satellite, and/or microsatellite metastasis WITH 1 positive lymph node\n * Code 700 if there are in-transit, satellite, and/or microsatellite metastasis WITH 2 or more positive lymph nodes\n\n**Note 6:** **Bilateral or contralateral nodes** \n* Bilateral or contralateral nodes are classified as regional nodes for head, neck, and truncal tumors with bidirectional drainage to primary nodal basins, as shown on lymphoscintigraphy. \n* Truncal tumors may also drain to both cephalad and caudal primary nodal basins as shown on lymphoscintigraphy.\n * Clinical assessment of bilateral/contralateral or cephalad/caudal regional nodal involvement is required for tumors where lymphoscintigraphy is not performed\n\n**Note 7:** **Nodal basins** \n* Contiguous or secondary nodal basins are the next nodal drainage basins beyond the primary nodal basins and are coded as regional nodes. \n\n**Note 8:** **Regional lymph nodes for skin**\n* Single, Multiple, Ipsilateral, Bilateral or Contralateral lymph nodes\n\n**Skin of head and neck (C000-C002, C006, C440-C444)**\n- Levels I-VII \n- Axillary (neck only, C444)\n- Cervical, NOS\n- Deep cervical, NOS\n- Facial (buccinator, buccal, nasolabial)\n- Internal jugular, NOS\n- Parapharyngeal \n- Parotid (infraauricular, intraparotid, periparotid, preauricular)\n- Retroauricular (mastoid)\n- Retropharyngeal\n- Suboccipital\n\n**Skin of trunk (C445)**\n* Upper trunk\n * Axillary\n * Cervical\n * Internal mammary\n * Supraclavicular\n* Lower trunk\n * Superficial inguinal (femoral) \n\n\n**Skin of upper limb and shoulder (C446)**\n- Axillary\n- Cervical\n- Epitrochlear for hand/forearm\n- Internal mammary (parasternal)\n- Spinal accessory for shoulder\n- Supraclavicular (transverse cervical)\n\n**Skin of lower limb and hip (C447)**\n- Femoral (superficial inguinal)\n- Inguinal \n- Popliteal for heel and calf\n\n**Vulva (C510-C512, C518-C519)**\n- Deep inguinal, NOS\n- Femoral\n- Inguinal, NOS\n- Inguinofemoral (groin)\n- Node of Cloquet or Rosenmuller (highest deep inguinal)\n- Superficial inguinal (femoral)\n\n**Penis (C600-C602, C608-C609)**\n- Iliac, NOS\n + External\n + Internal (hypogastric, obturator)\n- Inguinal, NOS\n + Node of Cloquet or Rosenmuller (highest deep inguinal)\n + Superficial [femoral] \n- Pelvic, NOS\n\n**Scrotum (C632)**\n- Iliac, NOS\n + External\n + Internal (hypogastric), NOS\n * Obturator\n- Inguinal, NOS\n + Deep inguinal, NOS\n * Node of Cloquet or Rosenmuller (highest deep inguinal)\n + Superficial inguinal (femoral)\n\n**Note 9:** **Lymph nodes, NOS** \n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Gershenwald, J.E., Scolyer, R.A., et al. **Melanoma of the Skin**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-19T18:44:55.040Z", + "last_modified" : "2025-11-14T20:06:16.436Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dan.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dan.json index 46bb218b5..ad16912f9 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dan.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dan.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n\n**Note 2:** **Unnamed nodes** \n* **For Colon and Rectum ONLY**, any unnamed nodes that are removed with a colon or rectal resection are presumed to be regional pericolic or perirectal lymph nodes and are included in the EOD Regional Nodes code 300 (pericolic for sites C180 - C189, C199 and perirectal for sites C199 or C209). \n* This site-specific instruction applies only to colon and rectum tumors and was verified with subject matter experts.\n\n**Note 3:** **CLINICAL AND PATHOLOGICAL codes** \n* This schema has lymph node codes that are defined as **CLINICAL** assessment only or **PATHOLOGICAL** assessment only. \n\n**No surgical resection**\n* Use **CLINICAL** assessment only codes (350, 400, 450, 500, 550, 600) when there is a clinical work up only and there is **NO surgical resection of the primary tumor or site** WITH \n * Any microscopic examination of regional lymph nodes, which includes FNA, core biopsy, sentinel node biopsy, lymph node excision, or lymph node dissection done during the clinical work up. \n\n**Surgical resection without neoadjuvant therapy**\n* Use **PATHOLOGICAL** assessment only codes (300) when there is a **surgical resection of the primary tumor or site** WITH \n * Any microscopic examination of regional lymph nodes, which includes FNA, core biopsy, sentinel node biopsy, lymph node excision done or lymph node dissection performed.\n\n**Surgical resection after neoadjuvant therapy**\n* If patient has neoadjuvant therapy, and the clinical assessment is equal to or greater than the pathological assessment, then the clinical assessment codes take priority. Otherwise, code the pathologic assessment. \n * See ***EOD 2018 General Instructions*** for further instructions on coding cases with neoadjuvant therapy, https://seer.cancer.gov/tools/staging/eod/.\n\n**Note 4:** **Tumor Deposits** \n* Code 200 is defined as **PATHOLOGICAL** assessment only. This is used when\n* Primary tumor or site surgically resected with\n * Any positive microscopic examination of tumor deposits WITHOUT positive lymph nodes\n * If there are also positive lymph nodes, code 300", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Jessup, J.M., Goldberg, R.M., et al. **Colon and Rectum**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:40.114Z", + "last_modified" : "2025-11-14T20:06:08.160Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_daq.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_daq.json index 3083ccc59..1ca17c2f3 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_daq.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_daq.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Definition of Head and Neck Lymph Nodes** \n* For head and neck schemas, this field includes all lymph nodes defined as Levels I-VII and Other. \n\n**Note 2:** **Laterality** \n* If laterality of lymph nodes is not specified, assume nodes are ipsilateral. Midline nodes are ipsilateral.\n\n**Note 3:** **Supraclavicular Lymph Nodes** \n* Supraclavicular lymph nodes can be either Level IV or Level V\n * Level IV: deep to the sternocleidomastoid muscle, in the lower jugular chain\n * Level V: in the posterior triangle, inferior to the transverse cervical artery, supraclavicular lymph nodes, NOS\n\n**Note 4:** **Lymph nodes, NOS** \n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)", - "last_modified" : "2025-09-18T20:41:26.896Z", + "last_modified" : "2025-11-14T20:05:14.042Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dat.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dat.json index 90ba12a2d..d90d1919d 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dat.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dat.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n\n**Note 2:** **Gastrohepatic ligament or gastrohepatic level nodes** \n* Imaging studies often refer to involved nodes in the gastrohepatic ligament or at the gastrohepatic level for esophageal primaries. Code as left gastric nodes if there is no more specific information.\n\n**Note 3:** **CLINICAL AND PATHOLOGICAL codes** \n* This schema has lymph node codes that are defined as **CLINICAL** assessment only or **PATHOLOGICAL** assessment only. \n\n**No surgical resection**\n* Use **CLINICAL** assessment only codes (725, 750, 775) when there is a clinical work up only and there is **NO surgical resection of the primary tumor or site** WITH \n * Any microscopic examination of regional lymph nodes, which includes FNA, core biopsy, sentinel node biopsy, lymph node excision, or lymph node dissection done during the clinical work up. \n\n**Surgical resection without neoadjuvant therapy**\n* Use **PATHOLOGICAL** assessment only codes (300, 700) when there is a **surgical resection of the primary tumor or site** WITH \n * Any microscopic examination of regional lymph nodes, which includes FNA, core biopsy, sentinel node biopsy, lymph node excision done or lymph node dissection performed.\n\n**Surgical resection after neoadjuvant therapy**\n* If patient has neoadjuvant therapy, and the clinical assessment is equal to or greater than the pathological assessment, then the clinical assessment codes take priority. Otherwise, code the pathologic assessment. \n * See ***EOD 2018 General Instructions*** for further instructions on coding cases with neoadjuvant therapy, https://seer.cancer.gov/tools/staging/eod/.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Rice, T.W., Kelsen, D., Hofstetter, W.L., et al. **Esophagus and Esophagogastric Junction**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:42:01.251Z", + "last_modified" : "2025-11-14T20:05:35.590Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dau.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dau.json index 51babb4fe..60ec92b67 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dau.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dau.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n\n**Note 2:** **Lymph nodes, NOS** \n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Abou-Alfa, G.K., Pawlik, T.M., Vauthey, J.N., et al. **Liver**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:42:00.479Z", + "last_modified" : "2025-11-14T20:05:18.041Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", @@ -20,5 +20,5 @@ "name" : "SS2018 N", "type" : "ENDPOINT" } ], - "rows" : [ [ "000", "No regional lymph node involvement", "VALUE:NONE" ], [ "300", "Caval\nHepatic, NOS\n- Hepatic artery\n- Hepatic pedicle\n- Inferior vena cava\n- Porta hepatis (portal) (hilar) [in hilus of liver]\n\nHepatoduodenal ligament\nPeriportal\nPortal vein", "VALUE:RN" ], [ "700", "Inferior phrenic nodes", "VALUE:D" ], [ "800", "Regional lymph node(s), NOS\nLymph node(s), NOS", "VALUE:RN" ], [ "999", "Unknown; regional lymph node(s) not stated\nRegional lymph node(s) cannot be assessed\nNot documented in medical record\n\nDeath Certificate Only", "VALUE:U" ] ] + "rows" : [ [ "000", "No regional lymph node involvement", "VALUE:NONE" ], [ "300", "Caval\nCeliac axis\nHepatic, NOS\n- Hepatic artery\n- Hepatic pedicle\n- Inferior vena cava\n- Porta hepatis (portal) (hilar) [in hilus of liver]\n\nHepatoduodenal ligament\nPeriportal\nPortal vein", "VALUE:RN" ], [ "700", "Inferior phrenic nodes", "VALUE:D" ], [ "800", "Regional lymph node(s), NOS\nLymph node(s), NOS", "VALUE:RN" ], [ "999", "Unknown; regional lymph node(s) not stated\nRegional lymph node(s) cannot be assessed\nNot documented in medical record\n\nDeath Certificate Only", "VALUE:U" ] ] } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dav.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dav.json index 10d5d023a..1be187a53 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dav.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dav.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n\n**Note 2:** **CLINICAL AND PATHOLOGICAL codes** \n* This schema has lymph node codes that are defined as **CLINICAL** assessment only or **PATHOLOGICAL** assessment only. \n\n**No surgical resection**\n* Use **CLINICAL** assessment only codes (725, 775) when there is a clinical work up only and there is **NO surgical resection of the primary tumor or site** WITH \n * Any microscopic examination of regional lymph nodes, which includes FNA, core biopsy, sentinel node biopsy, lymph node excision, or lymph node dissection done during the clinical work up. \n\n**Surgical resection without neoadjuvant therapy**\n* Use **PATHOLOGICAL** assessment only codes (300) when there is a **surgical resection of the primary tumor or site** WITH \n * Any microscopic examination of regional lymph nodes, which includes FNA, core biopsy, sentinel node biopsy, lymph node excision done or lymph node dissection performed.\n\n**Surgical resection after neoadjuvant therapy**\n* If patient has neoadjuvant therapy, and the clinical assessment is equal to or greater than the pathological assessment, then the clinical assessment codes take priority. Otherwise, code the pathologic assessment. \n * See ***EOD 2018 General Instructions*** for further instructions on coding cases with neoadjuvant therapy, https://seer.cancer.gov/tools/staging/eod/.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Zhu, A.X., Pawlik, T.M., Vauthey, J.N., et al. **Gallbladder**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:42:12.580Z", + "last_modified" : "2025-11-14T20:05:39.577Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_daw.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_daw.json index 8bda7edb3..984ac0b8f 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_daw.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_daw.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n\n**Note 2:** **Pericholedochal nodes** \n* Pericholedochal nodes are coded in EOD Mets for jejunum and ileum primaries.\n\n**Note 3:** **CLINICAL AND PATHOLOGICAL codes** \n* This schema has lymph node codes that are defined as **CLINICAL** assessment only or **PATHOLOGICAL** assessment only. \n\n**No surgical resection**\n* Use **CLINICAL** assessment only codes (600, 700) when there is a clinical work up only and there is **NO surgical resection of the primary tumor or site** WITH \n * Any microscopic examination of regional lymph nodes, which includes FNA, core biopsy, sentinel node biopsy, lymph node excision, or lymph node dissection done during the clinical work up. \n\n**Surgical resection without neoadjuvant therapy**\n* Use **PATHOLOGICAL** assessment only codes (300) when there is a **surgical resection of the primary tumor or site** WITH \n * Any microscopic examination of regional lymph nodes, which includes FNA, core biopsy, sentinel node biopsy, lymph node excision done or lymph node dissection performed.\n\n**Surgical resection after neoadjuvant therapy**\n* If patient has neoadjuvant therapy, and the clinical assessment is equal to or greater than the pathological assessment, then the clinical assessment codes take priority. Otherwise, code the pathologic assessment. \n * See ***EOD 2018 General Instructions*** for further instructions on coding cases with neoadjuvant therapy, https://seer.cancer.gov/tools/staging/eod/.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Coit, D.G., Kelsen, D., Hofstetter, W.L., et al. **Small Intestine**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:42.317Z", + "last_modified" : "2025-11-14T20:05:40.977Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_day.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_day.json index 83c28eb5a..7fce9386b 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_day.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_day.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n\n**Note 2:** **Inguinal lymph nodes**\n* Inguinal lymph nodes are no longer coded as regional lymph nodes. See EOD Mets.\n\n**Note 3:** **Isolated tumor cells**\n* Isolated tumor cells (ITCs) are defined as single tumor cells or small clusters not greater than 0.2 mm, usually detected by immunohistochemical (IHC) or molecular methods. ITCs do not usually show evidence of malignant activity (e.g., proliferation or stromal reaction). Lymph nodes with ITCs only are not counted as positive nodes. \n* For positive ITCs with NO regional lymph node involvement, code 050\n\n**Note 4:** **Regional lymph nodes include (bilateral and contralateral)**\n\n- Intrabdominal \n- Para-aortic, NOS\n + Aortic\n + Lateral aortic/lateral lumbar\n + Periaortic\n- Pelvic, NOS\n + Iliac, NOS\n + Common\n + External\n + Internal (hypogastric) (obturator)\n + Paracervical\n + Parametrial\n + Sacral, NOS\n + Lateral (laterosacral)\n + Middle (promontorial) (Gerota's node)\n + Presacral\n + Uterosacral\n- Retroperitoneal, NOS\n- Subdiaphragmatic\n\n**Note 5:** **Lymph nodes, NOS** \n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05.** American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) **Introduction to Female Reproductive Organs**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Prat, J., Olawaiye, A.B., Mutch, D.G., et al. **Ovary, Fallopian Tube, and Primary Peritoneal Carcinoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:47.616Z", + "last_modified" : "2025-11-14T20:06:10.304Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dba.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dba.json index d0d17bdf5..96340242d 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dba.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dba.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n\n**Note 2:** **FIGO and lymph node detail** \n* When both the Federation Internationale de Gynecologie et d'Obstetrique (FIGO) stage and lymph node detail are available, record the code with lymph node detail in preference to a statement of FIGO stage.\n\n**Note 3:** **Isolated tumor cells** \n* Isolated tumor cells (ITCs) are defined as single tumor cells or small clusters not greater than 0.2 mm, usually detected by immunohistochemical (IHC) or molecular methods. ITCs do not usually show evidence of malignant activity (e.g., proliferation or stromal reaction). Lymph nodes with ITCs only are not counted as positive nodes. \n* For positive ITCs with NO regional lymph node involvement, code 050\n\n**Note 4:** **Lymph nodes, NOS** \n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05.** American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging.** In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) **Introduction to Female Reproductive Organs**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Gibb, R.K., Olawaiye, A.B., Mutch, D.G., et al. **Vagina**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:47.965Z", + "last_modified" : "2025-11-14T20:06:11.242Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dbb.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dbb.json index e86a971bd..2c1d020ca 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dbb.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dbb.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n\n**Note 2:** **FIGO and lymph node detail** \n* When both the Federation Internationale de Gynecologie et d'Obstetrique (FIGO) stage and lymph node detail are available, record the code with lymph node detail in preference to a statement of FIGO stage.\n\n**Note 3:** **Isolated tumor cells** \n* Isolated tumor cells (ITCs) are defined as single tumor cells or small clusters not greater than 0.2 mm, usually detected by immunohistochemical (IHC) or molecular methods. ITCs do not usually show evidence of malignant activity (e.g., proliferation or stromal reaction). Lymph nodes with ITCs only are not counted as positive nodes. \n* For positive ITCs with NO regional lymph node involvement, code 050\n\n**Note 4:** **Regional lymph nodes include**\n- Femoral\n- Inguinal, NOS\n + Inguinofemoral (groin)\n + Node of Cloquet or Rosenmuller (highest deep inguinal)\n + Superficial inguinal\n\n**Note 5:** **Lymph nodes, NOS** \n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) **Introduction to Female Reproductive Organs**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Gibb, R.K., Olawaiye, A.B., Mutch, D.G., et al. **Vulva**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:38.610Z", + "last_modified" : "2025-11-14T20:06:01.362Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dbc.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dbc.json index 8670a3119..eaf3088c7 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dbc.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dbc.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS**\n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n\n**Note 2:** **Para-aortic nodes** \n* Para-aortic nodes are now regional instead of distant.\n\n**Note 3:** **FIGO and lymph node detail** \n* When both the Federation Internationale de Gynecologie et d'Obstetrique (FIGO) stage and lymph node detail are available, record the code with lymph node detail in preference to a statement of FIGO stage.\n\n**Note 4:** **Isolated tumor cells** \n* Isolated tumor cells (ITCs) are defined as single tumor cells or small clusters not greater than 0.2 mm, usually detected by immunohistochemical (IHC) or molecular methods. ITCs do not usually show evidence of malignant activity (e.g., proliferation or stromal reaction). \n* Lymph nodes with ITCs only are not counted as positive nodes \n * For positive ITCs with NO regional lymph node involvement, code 050\n\n**Note 5:** **Lymph nodes, NOS**\n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) **Introduction to Female Reproductive Organs**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Erickson, B.A., Olawaiye, A.B., Mutch, D.G., et al. **Cervix Uteri**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:42:15.245Z", + "last_modified" : "2025-11-14T20:05:20.048Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dbd.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dbd.json index 39ac50dc9..4d6692c05 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dbd.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dbd.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n\n**Note 2:** **FIGO and lymph node detail** \n* When both the Federation Internationale de Gynecologie et d'Obstetrique (FIGO) stage and lymph node detail are available, record the code with lymph node detail in preference to a statement of FIGO stage.\n\n**Note 3:** **Isolated tumor cells** \n* Isolated tumor cells (ITCs) are defined as single tumor cells or small clusters not greater than 0.2 mm, usually detected by immunohistochemical (IHC) or molecular methods. ITCs do not usually show evidence of malignant activity (e.g., proliferation or stromal reaction). Lymph nodes with ITCs only are not counted as positive nodes. \n* For positive ITCs with NO regional lymph node involvement, code 050\n\n**Note 4:** **Regional lymph nodes include**\n* Pelvic, NOS (codes 100-300)\n - Iliac, NOS \n + Common\n + External\n + Internal (hypogastric) (obturator)\n - Paracervical\n - Parametrial\n - Pelvic, NOS\n - Sacral, NOS \n + Lateral (laterosacral)\n + Middle (promontorial) (Gerota's node)\n + Presacral\n + Uterosacral\n \n* Para-aortic, NOS (WITH or WITHOUT pelvic lymph nodes) (codes 400-600)\n - Aortic\n - Lateral aortic/lateral lumbar\n - Periaortic\n\n**Note 5:** **Lymph nodes, NOS** \n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05.** American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging.** In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) **Introduction to Female Reproductive Organs**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Powell, M.A., Olawaiye, A.B., Mutch, D.G., et al. **Corpus Uteri - Carcinoma and Carcinosarcoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:42:00.125Z", + "last_modified" : "2025-11-14T20:05:04.034Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dbe.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dbe.json index dba026328..4e65c8961 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dbe.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dbe.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n* Regional nodes include bilateral and contralateral involvement of named nodes.\n\n**Note 2:** **Regional lymph nodes include**\n\n**All sites**\n- Lateral aortic (lumbar)\n- Paracaval\n- Renal hilar\n- Retroperitoneal, NOS\n\n**Renal Pelvis**\n- Aortic (para-aortic, periaortic, NOS)\n\n**Ureter**\n- Iliac (common, external, NOS)\n- Internal (hypogastric) (obturator)\n- Pelvic, NOS\n- Periureteral\n\n**Note 3:** **Lymph nodes, NOS** \n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) McKiernan, J.M., Hansel, D.E., Stadler, W.M., et al. **Renal Pelvis and Ureter**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:37.236Z", + "last_modified" : "2025-11-14T20:05:49.151Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dbf.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dbf.json index 504a50877..910cb4859 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dbf.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dbf.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n* Regional nodes include contralateral or bilateral nodes.\n\n**Note 2:** **Lymph nodes, NOS** \n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.\n\n**Note 3:** **Path only cases** \n* Code 000 for \"path only\" cases\n* “Path only” cases are where the only information available is the pathology report, it is a localized cancer (no evidence of extraprostatic extension), there is no information on lymph nodes, no imaging and no statement from the physician on lymph node status\n * These types of cases are usually for central registries only; however, a hospital registry may use this rule when all they have is a pathology report \n* This instruction is only for prostate. Do not apply this instruction to any other primary site", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Buyyounouski, M.K., Lin, D.W., et al. **Prostate**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:42:25.608Z", + "last_modified" : "2025-11-14T20:05:50.978Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dbg.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dbg.json index f813a42a9..fe0e8205f 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dbg.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dbg.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n* Regional nodes include bilateral and contralateral involvement of named nodes.\n\n**Note 2:** **Lymph nodes, NOS** \n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Rini, B.I., McKiernan, J.M., Stadler, W.M., et al. **Kidney**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:36.179Z", + "last_modified" : "2025-11-14T20:05:40.072Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dbh.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dbh.json index 782d9eacd..58fe404e5 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dbh.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dbh.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n\n**Note 2:** **Definition of Regional lymph nodes**\n* Regional lymph nodes are defined as those in the vicinity of the primary tumor.\n\n**Note 3:** **Lymph node involvement in bone is rare**\n* Regional lymph node involvement is rare. \n* If there is no mention of lymph node involvement clinically, assume that lymph nodes are negative and code 000.\n\n**Note 4:** **Lymph nodes, NOS** \n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Kneisl, J.S., Rosenberg, A.E., et al. **Bone**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:44.385Z", + "last_modified" : "2025-11-14T20:05:19.096Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dbi.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dbi.json index 54b3552b0..afab90c06 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dbi.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dbi.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n\n**Note 2:** **Nodal metastasis rare** \n* Regional lymph node involvement is rare. For this schema, if there is no mention of lymph node involvement clinically, assume that lymph nodes are negative. \n* Code 999 (Unknown) only when there is no available information on the extent of the patient's disease, for example when a lab-only case is abstracted from a biopsy report and no clinical history is available.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Pollock, R.E., Maki, R.G. **Introduction to Soft Tissue Sarcoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Maki, R.G., Pollock, R.E., et al. **Soft Tissue Sarcoma - Unusual Histologies and Sites**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:40.842Z", + "last_modified" : "2025-11-14T20:06:10.758Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dbj.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dbj.json index 47946bc3f..94b61f42f 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dbj.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dbj.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n\n**Note 2:** **CLINICAL AND PATHOLOGICAL** \n* This schema has lymph node codes that are defined as **CLINICAL** assessment only or **PATHOLOGICAL** assessment only.\n\n**No surgical resection**\n* Use **CLINICAL** assessment only codes (100, 200, 300) when there is a clinical work up only and there is **NO surgical resection of the primary tumor or site** WITH\n * Any microscopic examination of regional lymph nodes, which includes FNA, core biopsy, sentinel node biopsy, lymph node excision, or lymph node dissection done during the clinical work up.\n\n**Surgical resection without neoadjuvant therapy**\n* Use **PATHOLOGICAL** assessment only codes (400, 500) when there is a **surgical resection of the primary tumor or site** WITH\n * Any microscopic examination of regional lymph nodes, which includes FNA, core biopsy, sentinel node biopsy, lymph node excision done or lymph node dissection performed.\n\n**Surgical resection after neoadjuvant therapy**\n* If patient has neoadjuvant therapy, and the clinical assessment is equal to or greater than the pathological assessment, then the clinical assessment codes take priority. Otherwise, code the pathologic assessment.\n * See ***EOD 2018 General Instructions*** for further instructions on coding cases with neoadjuvant therapy, https://seer.cancer.gov/tools/staging/eod/.\n\n**Note 3:** **Regional lymph nodes include**\n- Iliac, NOS\n + External\n + Internal (hypogastric, obturator)\n- Inguinal, NOS\n + Node of Cloquet or Rosenmuller (highest deep inguinal)\n + Superficial [femoral] \n- Pelvic, NOS\n\n**Note 4:** **Lymph nodes, NOS** \n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Pettaway, C.A., Srigley, J.R., Amin, M.B., et al. **Penis**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:42:11.593Z", + "last_modified" : "2025-11-14T20:05:48.693Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dbo.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dbo.json index d1b2916f3..77869c421 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dbo.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dbo.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n\n**Note 2:** **Splenic lymph nodes** \n* Splenic lymph nodes and those located at the tail of the pancreas are not regional and should be coded in EOD Mets.\n\n**Note 3:** **Regional lymph nodes include** \n- Anterior to ampulla of Vater \n- Inferior to ampulla of Vater\n- Posterior to ampulla of Vater\n- Superior to ampulla of Vater\n- Celiac\n- Hepatic \n- Hepatic artery\n- Lateral aortic (lumbar)\n- Node of foramen of Winslow (epiploic) (omental)\n- Pancreaticoduodenal\n- Peripancreatic (excluding nodes at tail of pancreas)\n- Periportal (portal vein)\n- Proximal mesenteric\n- Pyloric (infrapyloric, subpyloric)\n- Retroperitoneal\n- Superior mesenteric\n\n**Note 4:** **Lymph nodes, NOS** \n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Herman, J.M., Pawlik, T.M., Vauthey, J.N., et al. **Ampulla of Vater**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:45.185Z", + "last_modified" : "2025-11-14T20:05:36.595Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dbq.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dbq.json index ee7b05f29..2d719bd32 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dbq.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dbq.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n\n**Note 2:** **Lymph nodes, NOS** \n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Rusch, V.W., et al. **Malignant Plural Mesothelioma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:33.895Z", + "last_modified" : "2025-11-14T20:05:34.033Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dbu.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dbu.json index 3823cccf3..bbf5878a9 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dbu.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dbu.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n\n**Note 2:** **Nodal basins** \n* Nodes in contiguous (secondary) and bidirectional (cephalad/caudal) primary nodal basins are coded in EOD Regional Nodes.\n\n**Note 3:** **Regional lymph nodes include**\n- Iliac (common, external, internal [hypogastric] [obturator], NOS)\n- Inguinal (superficial [femoral], NOS)\n- Inguinal, deep (Node of Cloquet or Rosenmuller [highest deep inguinal], NOS) \n- Pelvic, NOS (including true pelvis)\n- Perivesical\n- Presacral\n- Sacral, NOS\n\n**Note 4:** **Lymph nodes, NOS** \n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Hansel, D.E., Reuter, V.E., McKiernan, J.M., et al. **Urethra**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:42:14.875Z", + "last_modified" : "2025-11-14T20:05:11.624Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dbv.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dbv.json index 0d0a8a41c..76b80f134 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dbv.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dbv.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n* Regional nodes include bilateral and contralateral involvement of named nodes.\n\n**Note 2:** **Lymph nodes, NOS** \n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)", - "last_modified" : "2025-09-18T20:41:44.823Z", + "last_modified" : "2025-11-14T20:05:09.851Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dbw.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dbw.json index dbc77f17c..272850b4e 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dbw.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dbw.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n\n**Note 2:** **Lymph nodes, NOS** \n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)", - "last_modified" : "2025-09-18T20:41:36.424Z", + "last_modified" : "2025-11-14T20:05:43.603Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dbx.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dbx.json index 819cfa956..181725620 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dbx.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dbx.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n* Regional nodes include bilateral and contralateral involvement of named nodes.\n\n**Note 2:** **Lymph nodes, NOS** \n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)", - "last_modified" : "2025-09-18T20:42:25.027Z", + "last_modified" : "2025-11-14T20:05:45.488Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dby.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dby.json index c6d8fd418..c76d0b689 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dby.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dby.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note:** **All lymph node (regional and distant)** \n* Coded in this field \n* Code 700 for any involvement of distant lymph nodes (includes regional lymph node and distant lymph node involvement)", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions,** National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05.** American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Pollock, R.E., Maki, R.G. **Introduction to Soft Tissue Sarcoma** In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Maki, R.G., Pollock, R.E., et al. **Soft Tissue Sarcoma - Unusual Histologies and Sites**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:27.975Z", + "last_modified" : "2025-11-14T20:05:43.229Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dca.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dca.json index b7619a959..4e27123b1 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dca.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dca.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n* Regional nodes include bilateral and contralateral involvement of named nodes.\n\n**Note 2:** **Lymph nodes, NOS** \n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)", - "last_modified" : "2025-09-18T20:41:29.196Z", + "last_modified" : "2025-11-14T20:05:08.585Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dcb.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dcb.json index 743470d7d..045199296 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dcb.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dcb.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n\n**Note 2:** **Lymph nodes, NOS** \n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)", - "last_modified" : "2025-09-18T20:42:16.613Z", + "last_modified" : "2025-11-14T20:05:08.208Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dcc.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dcc.json index 4b84730d1..820b66224 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dcc.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dcc.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n* Regional nodes include bilateral and contralateral involvement of named nodes.\n\n**Note 2:** **Lymph nodes, NOS** \n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)", - "last_modified" : "2025-09-18T20:42:08.566Z", + "last_modified" : "2025-11-14T20:05:07.051Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dcd.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dcd.json index aee30f5b5..0f2b73f68 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dcd.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dcd.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n* Regional nodes include bilateral and contralateral involvement of named nodes.\n\n**Note 2:** **Lymph nodes, NOS** \n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)", - "last_modified" : "2025-09-18T20:42:22.976Z", + "last_modified" : "2025-11-14T20:05:07.953Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dce.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dce.json index 87deadea6..b7682c1af 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dce.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dce.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **All lymph node (regional and distant) involvement is coded in this field.**\n* Peripheral nodes (e.g., palpable/accessible nodes) may be used to code this. \n* Central nodes (code 700) (deep/non-palpable nodes) are only included when they are microscopically proven\n\n**Note 2:** **Clinical involvement** \n* Regional node involvement (clinical abnormal peripheral lymph nodes) can be clinically involved despite negative biopsy or a lack of microscopic confirmation. \n\n**Note 3:** **Dutch grade system includes**\n- Grade 1 - Dermatopathic lymphadenopathy (DL)\n- Grade 2 - Early involvement by mycosis fungoides (MF), (presence of cerebriform nuclei larger than 7.5 micrometers (um))\n- Grade 3 - Partial effacement of lymph node architecture; many atypical cerebriform mononuclear cells (CMCs)\n- Grade 4 - Complete effacement of lymph node architecture\n\n**Note 4:** **National Cancer Institute - Lymph Nodes (NCI LN) grade system includes**\n- LN 0 - No atypical lymphocytes\n- LN 1 - Occasional and isolated atypical lymphocytes not arranged in clusters\n- LN 2 - Many atypical lymphocytes or in 3-6 cell clusters\n- LN 3 - Aggregates of atypical lymphocytes; nodal architecture preserved\n- LN 4 - Partial/complete effacement of nodal architecture by atypical lymphocytes or frankly neoplastic cells\n\n**Note 5:** **T-cell clone**\n* A T-cell clone (clone negative or clone positive) is defined by polymerase chain reaction (PCR) or Southern blot analysis of the T-cell receptor gene (TCR).", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) **Introduction to Hematologic Malignancies**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Rosen, S.T., Jaffe, E.S., Leonard, J.P., et al. **Primary Cutaneous Lymphomas**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:42:20.351Z", + "last_modified" : "2025-11-14T20:05:46.646Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dck.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dck.json index fb5f5b4df..c04b96f19 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dck.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dck.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n\n**Note 2:** **Regional lymph nodes include**\n- Iliac, NOS\n + Common\n + External\n + Internal (hypogastric)\n- Obturator\n- Pelvic, NOS\n- Perivesical pelvic, NOS\n- Sacral, NOS\n + Lateral (laterosacral)\n + Presacral\n + Sacral promontory (Gerota's)\n\n**Note 3:** **Lymph nodes, NOS** \n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Bochner, B.H., Hansel, D.E., Stadler, W.M., et al. **Urinary Bladder**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:42:03.448Z", + "last_modified" : "2025-11-14T20:05:38.667Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dcl.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dcl.json index 04ab7ffd7..05d98399a 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dcl.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dcl.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n* Regional nodes include bilateral and contralateral involvement of named nodes.\n\n**Note 2:** **Lymph nodes, NOS** \n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)", - "last_modified" : "2025-09-18T20:41:28.648Z", + "last_modified" : "2025-11-14T20:05:07.583Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dcn.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dcn.json index 946c4c10b..87838bb96 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dcn.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dcn.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Definition of Head and Neck Lymph Nodes** \n* For head and neck schemas, this field includes all lymph nodes defined as Levels I-VII and Other by TNM.\n\n**Note 2:** **Laterality** \n* If laterality of lymph nodes is not specified, assume nodes are ipsilateral. Midline nodes are ipsilateral.\n\n**Note 3:** **Supraclavicular lymph nodes** \n* Supraclavicular lymph nodes can be either Level IV or Level V\n * Level IV: deep to the sternocleidomastoid muscle, in the lower jugular chain\n * Level V: in the posterior triangle, inferior to the transverse cervical artery, supraclavicular lymph nodes, NOS\n\n**Note 4:** **Regional lymph nodes for Head and Neck tumors** \n* For nasopharynx, Levels I, II, III, V, VI, are assigned code 300 or 400 based on size and/or unilateral vs bilateral. \n* For Levels IV, VB, and VII, see code 600. If the only information available is \"regional lymph nodes, NOS\" or \"lymph nodes,\" code 800.\n\n **Level I**\n Level IA - Submental\n Level IB - Submandibular (submaxillary), sublingual\n\n**Level II - Upper jugular** \n Jugulodigastric (subdigastric)\n Upper deep cervical \n Level IIA - Anterior\n Level IIB - Posterior \n\n**Level III - Middle jugular**\nMiddle deep cervical\n\n**Level IV - Lower jugular**\nJugulo-omohyoid (supraomohyoid)\nLower deep cervical \nVirchow node\n\n**Level V - Posterior triangle group**\nPosterior cervical\nLevel VA - Spinal accessory \nLevel VB - Transverse cervical, supraclavicular \n\n**Level VI - Anterior compartment group**\nLaterotracheal\nParalaryngeal\nParatracheal - above suprasternal notch\nPerithyroidal\nPrecricoid (Delphian)\nPrelaryngeal\nPretracheal - above suprasternal notch\nRecurrent laryngeal\n\n**Level VII - Superior mediastinal group (for other mediastinal node(s) see EOD Mets)**\nEsophageal groove\nParatracheal - below suprasternal notch\nPretracheal - below suprasternal notch \n\n**Other groups**\nCervical, NOS\nDeep cervical, NOS\nFacial\n- Buccinator (buccal)\n- Mandibular\n- Nasolabial\n\nInternal jugular, NOS\nParapharyngeal \nParotid\n- Infraauricular\n- Intraparotid\n- Periparotid\n- Preauricular\n\nRetroauricular (mastoid)\nRetropharyngeal\nSuboccipital\n\n**Note 5:** **Lymph nodes, NOS** \n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Lydiatt, W.M., Patel, S.G., Shah, J.P., et al. **Staging Head and Neck Cancers**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Lee, A.W.M., Lydiatt, W.M., Shah, J.P., et al. **Nasopharynx**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:42:19.915Z", + "last_modified" : "2025-11-14T20:06:04.113Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dcu.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dcu.json index f27af4af9..ae6b708a4 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dcu.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dcu.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Definition of Head and Neck Lymph Nodes** \n* For head and neck schemas, this field includes all lymph nodes defined as Levels I-VII and Other by TNM. \n\n**Note 2:** **CLINICAL AND PATHOLOGICAL codes** \n* This schema has lymph node codes that are defined as **CLINICAL** assessment only or **PATHOLOGICAL** assessment only.\n\n**No surgical resection**\n* Use **CLINICAL** assessment only codes (300, 400) when there is a clinical work up only and there is **NO surgical resection of the primary tumor or site** WITH \n * Any microscopic examination of regional lymph nodes, which includes FNA, core biopsy, sentinel node biopsy, lymph node excision, or lymph node dissection done during the clinical work up. \n\n**Surgical resection without neoadjuvant therapy**\n* Use **PATHOLOGICAL** assessment only codes (500) when there is a **surgical resection of the primary tumor or site** WITH \n * Any microscopic examination of regional lymph nodes, which includes FNA, core biopsy, sentinel node biopsy, lymph node excision done or lymph node dissection performed.\n\n**Surgical resection after neoadjuvant therapy**\n* If patient has neoadjuvant therapy, and the clinical assessment is equal to or greater than the pathological assessment, then the clinical assessment codes take priority. Otherwise, code the pathologic assessment. \n * See ***EOD 2018 General Instructions*** for further instructions on coding cases with neoadjuvant therapy, https://seer.cancer.gov/tools/staging/eod/.\n\n\n**Note 3:** **Laterality** \n* If laterality of lymph nodes is not specified, assume nodes are ipsilateral. Midline nodes are ipsilateral.\n\n**Note 4:** **Supraclavicular lymph nodes** \n* Supraclavicular lymph nodes can be either Level IV or Level V\n * Level IV: deep to the sternocleidomastoid muscle, in the lower jugular chain\n * Level V: in the posterior triangle, inferior to the transverse cervical artery, supraclavicular lymph nodes, NOS\n\n**Note 5:** **Regional lymph nodes for Head and Neck tumors** \n* **Note:** For codes 300, 400, or 500, use the list below for named regional lymph nodes. If the only information available is \"regional lymph nodes, NOS\" or \"lymph nodes,\" code 800.\n\n**Level I**\n- Level IA - Submental\n- Level IB - Submandibular (submaxillary), sublingual\n\n**Level II - Upper jugular** \n- Jugulodigastric (subdigastric)\n- Upper deep cervical \n- Level IIA - Anterior\n- Level IIB - Posterior \n\n**Level III - Middle jugular**\n- Middle deep cervical\n\n**Level IV - Lower jugular**\n- Jugulo-omohyoid (supraomohyoid)\n- Lower deep cervical \n- Virchow node\n\n**Level V - Posterior triangle group**\n- Posterior cervical\n- Level VA - Spinal accessory \n- Level VB - Transverse cervical, supraclavicular \n\n**Level VI - Anterior compartment group**\n- Laterotracheal\n- Paralaryngeal\n- Paratracheal - above suprasternal notch\n- Perithyroidal\n- Precricoid (Delphian)\n- Prelaryngeal\n- Pretracheal - above suprasternal notch\n- Recurrent laryngeal\n\n**Level VII - Superior mediastinal group (for other mediastinal node(s), see EOD Mets)**\n- Esophageal groove\n- Paratracheal - below suprasternal notch\n- Pretracheal - below suprasternal notch \n\n**Other groups**\n- Cervical, NOS\n- Deep cervical, NOS\n- Facial\n + Buccinator (buccal)\n + Mandibular\n + Nasolabial\n- Internal jugular, NOS\n- Parapharyngeal \n- Parotid\n + Infraauricular\n + Intraparotid\n + Periparotid\n + Preauricular\n- Retroauricular (mastoid)\n- Retropharyngeal\n- Suboccipital\n- Regional lymph node(s), NOS\n- Lymph node(s), NOS\n\n**Note 6:** **Lymph nodes, NOS** \n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Lydiatt, W.M., Patel, S.G., Shah, J.P., et al. **Staging Head and Neck Cancers**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) O'Sullivan, B., Lydiatt, W.M., Shah, J.P., et al. **HPV-Mediated (p16+) Oropharyngeal Cancer**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-19T18:45:23.406Z", + "last_modified" : "2025-11-14T20:06:05.594Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dcz.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dcz.json index 2401c6c59..991968fc4 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dcz.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dcz.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n* Regional nodes include bilateral and contralateral involvement of named nodes.\n\n**Note 2:** **Lymph nodes, NOS** \n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)", - "last_modified" : "2025-09-18T20:41:59.305Z", + "last_modified" : "2025-11-14T20:05:41.388Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dde.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dde.json index 8cb276cbe..81d12c72d 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dde.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dde.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n\n**Note 2:** **Regional lymph nodes include**\n- Buccinator (buccal)\n- Cervical, NOS\n- Facial, NOS\n- Intraparotid\n- Nasolabial\n- Parotid\n + Infra-auricular\n + Preauricular\n- Submandibular [submaxillary]\n- Submental\n- Supraclavicular, NOS\n\n**Note 3:** **Lymph nodes, NOS** \n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Esmaeli, B., Finger, P.T., et al. **Eyelid Carcinoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:42:17.360Z", + "last_modified" : "2025-11-14T20:05:30.522Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_ddf.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_ddf.json index b7e7b6697..00dac5890 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_ddf.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_ddf.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n\n**Note 2:** **CLINICAL AND PATHOLOGICAL codes** \n* This schema has lymph node codes that are defined as **CLINICAL** assessment only or **PATHOLOGICAL** assessment only.\n\n**No surgical resection**\n* Use **CLINICAL** assessment only codes (100, 300) when there is a clinical work up only and there is **NO surgical resection of the primary tumor or site** WITH \n * Any microscopic examination of regional lymph nodes, which includes FNA, core biopsy, sentinel node biopsy, lymph node excision, or lymph node dissection done during the clinical work up. \n\n**Surgical resection without neoadjuvant therapy**\n* Use **PATHOLOGICAL** assessment only codes (200, 400, 500) when there is a **surgical resection of the primary tumor or site** WITH \n * Any microscopic examination of regional lymph nodes, which includes FNA, core biopsy, sentinel node biopsy, lymph node excision done or lymph node dissection performed.\n\n**Surgical resection after neoadjuvant therapy**\n* If patient has neoadjuvant therapy, and the clinical assessment is equal to or greater than the pathological assessment, then the clinical assessment codes take priority. Otherwise, code the pathologic assessment. \n * See ***EOD 2018 General Instructions*** for further instructions on coding cases with neoadjuvant therapy, https://seer.cancer.gov/tools/staging/eod/.\n \n**Note 3:** **Previous scrotal surgery and lymph nodes** \n* Involvement of inguinal, pelvic, or external iliac lymph nodes WITHOUT or unknown if previous scrotal or inguinal surgery prior to presentation of the testis tumor is coded in EOD Mets as distant lymph node involvement.\n\n**Note 4:** **Regional lymph nodes include**\n\nAortic, NOS\n- Lateral (lumbar)\n- Para-aortic\n- Periaortic\n- Preaortic \n- Retroaortic\n\nPericaval, NOS\n- Interaortocaval\n- Paracaval\n- Precaval\n- Retrocaval\n\nRetroperitoneal below the diaphragm or NOS\nSpermatic vein\n\nLymph nodes **WITH** previous scrotal or inguinal surgery\n- External iliac\n- Inguinal nodes, NOS\n + Deep, NOS\n + Node of Cloquet or Rosenmuller (highest deep inguinal)\n + Superficial (femoral)\n- Pelvic\n\n**Note 5:** **Lymph nodes, NOS** \n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Brimo, F., Srigley, J.R., Lin, D.W., et al. **Testis**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:37.638Z", + "last_modified" : "2025-11-14T20:05:51.361Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_ddj.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_ddj.json index e49c15886..896667a7e 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_ddj.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_ddj.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n\n**Note 2:** **Bilateral or Contralateral nodes** \n* Bilateral or contralateral nodes are classified as regional nodes for truncal tumors (C445) with bidirectional drainage to primary nodal basins, as shown on lymphoscintigraphy. \n * Truncal tumors may also drain to both cephalad and caudal primary nodal basins as shown on lymphoscintigraphy.\n* Clinical assessment of bilateral/contralateral or cephalad/caudal regional nodal involvement is required for tumors where lymphoscintigraphy is not performed\n\n**Note 3:** **Nodal basins** \n* Contiguous or secondary nodal basins are the next nodal drainage basins beyond the primary nodal basins and are coded as regional nodes.\n\n**Note 4:** **Lymph nodes, NOS** \n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)", - "last_modified" : "2025-09-18T20:41:30.158Z", + "last_modified" : "2025-11-14T20:05:10.234Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_ddn.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_ddn.json index 396c5e2d8..737f13bf2 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_ddn.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_ddn.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n\n**Note 2:** **CLINICAL AND PATHOLOGICAL codes** \n* This schema has lymph node codes that are defined as **CLINICAL** assessment only or **PATHOLOGICAL** assessment only.\n\n**No surgical resection**\n* Use **CLINICAL** assessment only codes (100, 200, 600, 650) when there is a clinical work up only and there is **NO surgical resection of the primary tumor or site** WITH\n * Any microscopic examination of regional lymph nodes, which includes FNA, core biopsy, sentinel node biopsy, lymph node excision, or lymph node dissection done during the clinical work up.\n\n**Surgical resection without neoadjuvant therapy**\n* Use **PATHOLOGICAL** assessment only codes (300, 350, 400, 500, 700, 750) when there is a **surgical resection of the primary tumor or site** WITH\n * Any microscopic examination of regional lymph nodes, which includes FNA, core biopsy, sentinel node biopsy, lymph node excision done or lymph node dissection performed.\n\n**Surgical resection after neoadjuvant therapy**\n* If patient has neoadjuvant therapy, and the clinical assessment is equal to or greater than the pathological assessment, then the clinical assessment codes take priority. Otherwise, code the pathologic assessment.\n * See ***EOD 2018 General Instructions*** for further instructions on coding cases with neoadjuvant therapy, https://seer.cancer.gov/tools/staging/eod/.\n\n**Note 3:** **Isolated tumor cells** \n* Isolated tumor cells (ITCs) are defined as single tumor cells or small clusters not greater than 0.2 mm, usually detected by immunohistochemical (IHC) or molecular methods. \n* ITCs do not usually show evidence of malignant activity (e.g., proliferation or stromal reaction).\n * Lymph nodes with isolated tumor cells (ITCs) are counted as positive lymph nodes\n\n**Note 4:** **In transit metastasis** \n* In transit metastasis is defined as a tumor distinct from the primary lesion and located either between the primary lesion and the draining regional lymph node(s) or distal to the primary lesion. \n* In transit metastasis with positive lymph node(s) are coded under regional lymph nodes.\n* Code 600 if there are **clinically** in-transit metastasis WITHOUT regional lymph node involvement\n* Code 650 if there are **clinically** in-transit metastasis WITH regional lymph node involvement\n* Code 700 if there are **pathologically** in-transit metastasis WITHOUT regional lymph node involvement\n* Code 750 if there are **pathologically** in-transit metastasis WITH regional lymph node involvement\n\n**Note 5:** **Regional lymph nodes for skin**\n* Single, Multiple, Ipsilateral, Bilateral or Contralateral lymph nodes\n\n**Skin of head and neck (C000-C006, C008-C009, C440-C444)**\n- Levels I-VII \n- Axillary (neck only, C444)\n- Cervical, NOS\n- Deep cervical, NOS\n- Facial (buccinator, buccal, nasolabial)\n- Internal jugular, NOS\n- Parapharyngeal \n- Parotid (infraauricular, intraparotid, periparotid, preauricular)\n- Retroauricular (mastoid)\n- Retropharyngeal\n- Suboccipital\n\n**Skin of trunk (C445)**\n- Upper trunk \n + Axillary\n + Cervical\n + Internal mammary\n + Supraclavicular\n- Lower trunk \n + Superficial inguinal (femoral)\n\n**Skin of upper limb and shoulder (C446)**\n- Axillary\n- Cervical\n- Epitrochlear for hand/forearm\n- Internal mammary (parasternal)\n- Spinal accessory for shoulder\n- Supraclavicular (transverse cervical)\n\n**Skin of lower limb and hip (C447)**\n- Femoral (superficial inguinal)\n- Inguinal\n- Popliteal for heel and calf\n\n**Vulva (C510-C512, C518-C519)**\n- Deep inguinal, NOS\n- Femoral\n- Inguinal, NOS\n- Inguinofemoral (groin)\n- Node of Cloquet or Rosenmuller (highest deep inguinal)\n- Superficial inguinal (femoral)\n\n**Penis (C600-C602, C608-C609)**\n- Iliac, NOS\n + External\n + Internal (hypogastric, obturator)\n- Inguinal, NOS\n + Node of Cloquet or Rosenmuller (highest deep inguinal)\n + Superficial [femoral] \n- Pelvic, NOS\n\n**Scrotum (C632)**\n- Iliac, NOS\n + External\n + Internal (hypogastric), NOS\n * Obturator\n- Inguinal, NOS\n + Deep inguinal, NOS\n * Node of Cloquet or Rosenmuller (highest deep inguinal)\n + Superficial inguinal (femoral)\n\n**Note 6:** **Lymph nodes, NOS** \n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Bichakjian, C.K., Nghiem, P., Sober, A.J., et al. **Merkel Cell Carcinoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-19T18:45:12.645Z", + "last_modified" : "2025-11-14T20:05:30.050Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_ddp.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_ddp.json index 6712b3afe..2b66b6149 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_ddp.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_ddp.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n\n**Note 2:** **Lymph nodes, NOS** \n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Woltering, E.A., Bergsland, E.K., et al. **Neuroendocrine Tumors of the Appendix**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) **Neuroendocrine Tumors of the Appendix**, from the AJCC Cancer Staging System Version 9 (2023). Used with permission of the American College of Surgeons, Chicago, Illinois.", - "last_modified" : "2025-09-18T20:41:36.801Z", + "last_modified" : "2025-11-14T20:05:47.144Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dew.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dew.json index f6e680d82..79c97931b 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dew.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dew.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n\n**Note 2:** **Lymph nodes, NOS** \n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Aloia, T., Pawlik, T.M., Vauthey, J.N., et al. **Intrahepatic Bile Ducts**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:34.886Z", + "last_modified" : "2025-11-14T20:05:37.957Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dfc.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dfc.json index 0afc2c664..6a39c3af6 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dfc.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dfc.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n\n**Note 2:** **LAMN tumors** \n* Nodal metastasis is very rare in low-grade appendiceal neoplasms (LAMN). If there is no mention of lymph nodes in the pathology report for a LAMN, code as none (000). \n\n**Note 3:** **CLINICAL and PATHOLOGICAL codes** \n* This schema has lymph node codes that are defined as **CLINICAL** assessment only or **PATHOLOGICAL** assessment only. \n\n**No surgical resection**\n* Use **CLINICAL** assessment only codes (450, 500, 550, 600, 650, 700) when there is a clinical work up only and there is **NO surgical resection of the primary tumor or site** WITH \n * Any microscopic examination of regional lymph nodes, which includes FNA, core biopsy, sentinel node biopsy, lymph node excision, or lymph node dissection done during the clinical work up. \n\n**Surgical resection without neoadjuvant therapy**\n* Use **PATHOLOGICAL** assessment only codes (300, 400) when there is a **surgical resection of the primary tumor or site** WITH \n * Any microscopic examination of regional lymph nodes, which includes FNA, core biopsy, sentinel node biopsy, lymph node excision done or lymph node dissection performed.\n\n**Surgical resection after neoadjuvant therapy**\n* If patient has neoadjuvant therapy, and the clinical assessment is equal to or greater than the pathological assessment, then the clinical assessment codes take priority. Otherwise, code the pathologic assessment. \n * See ***EOD 2018 General Instructions*** for further instructions on coding cases with neoadjuvant therapy, https://seer.cancer.gov/tools/staging/eod/.\n\n**Note 4:** **Tumor Deposits** \n* Code 400 is defined as **PATHOLOGICAL** assessment only. This is used when\n * Primary tumor or site surgically resected with\n * Any positive microscopic examination of tumor deposits WITHOUT positive lymph nodes\n * If there are also positive lymph nodes, code 300", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Overman, M.J., Jessup, J.M., et al. **Appendix - Carcinoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:42:14.233Z", + "last_modified" : "2025-11-14T20:05:04.476Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dfd.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dfd.json index 84f76106c..b2885f992 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dfd.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dfd.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n\n**Note 2:** **Nodal metastasis rare** \n* Nodal metastasis is very rare in gastrointestinal stromal tumors (GISTs) and surgeons generally agree that nodal dissection is not indicated. In the absence of information on regional lymph node status for a localized tumor, code as none (000).\n\n**Note 3:** **EOD references** \n* See the chapter (schema) corresponding to the primary site for information about regional nodes. \n* *For example*: For primary colon GIST, see the colon chapter (schema) for regional nodes information.\n * **Esophagus**: C150-C155, C158-C159\n * **Small Intestine**: C170-C172, C178-C17\n * **Stomach**: C160-C166, C168-C169 \n * **Appendix**: C181 \n * **Colon and Rectum**: C180, C182-C189, C199, C209\n * **Retroperitoneum**: C480-C482, C488\n\n**Note 4:** **Lymph nodes, NOS** \n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Pollock, R.E., Maki, R.G. **Introduction to Soft Tissue Sarcoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) DeMatteo, R.P., Maki, R.G., Pollock, R.E., et al. **Gastrointestinal Stromal Tumor**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:30.544Z", + "last_modified" : "2025-11-14T20:05:11.136Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dfe.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dfe.json index b7b5de441..0461282ca 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dfe.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dfe.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n\n**Note 2:** **Unnamed nodes** \n* For Colon and Rectum ONLY, any unnamed nodes that are removed with a colon or rectal resection are presumed to be regional pericolic or perirectal lymph nodes and are included in the EOD Regional Nodes code 300 (pericolic for sites C180 - C189, C199 and perirectal for sites C199 or C209). \n* This site-specific instruction applies only to colon and rectum tumors and was verified with subject matter experts.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Shi, C., Woltering, E.A., Washington, M.K., et al. **Neuroendocrine Tumors of the Colon and Rectum**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) **Neuroendocrine Tumors of the Colon and Rectum**, from the AJCC Cancer Staging System Version 9 (2023). Used with permission of the American College of Surgeons, Chicago, Illinois.", - "last_modified" : "2025-09-18T20:41:33.459Z", + "last_modified" : "2025-11-14T20:05:27.178Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dfg.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dfg.json index f1ca1f9d0..6002c11e1 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dfg.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dfg.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n\n**Note 2:** **Hepatoduodenal and Pancreaticoduodenal lymph nodes**\n* Per AJCC, Hepatoduodenal and Pancreaticoduodenal nodes are regional for all subsites of the stomach. Previously they were regional only for the lesser curvature and greater curvature.\n\n**Note 3:** **Lymph nodes, NOS** \n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Woltering, E.A., Bergsland, E.K., et al. **Neuroendocrine Tumors of the Stomach**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) **Neuroendocrine Tumors of the Stomach,** from the AJCC Cancer Staging System Version 9 (2023). Used with permission of the American College of Surgeons, Chicago, Illinois.", - "last_modified" : "2025-09-18T20:41:56.376Z", + "last_modified" : "2025-11-14T20:05:48.187Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dfh.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dfh.json index 1eb7687ba..69e4beb8d 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dfh.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dfh.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n\n**Note 2:** **FIGO and lymph node detail** \n* When both the Federation Internationale de Gynecologie et d'Obstetrique (FIGO) stage and lymph node detail are available, record the code with lymph node detail in preference to a statement of FIGO stage.\n\n**Note 3:** **Isolated Tumor Cells** \n* Isolated tumor cells (ITCs) are defined as single tumor cells or small clusters not greater than 0.2 mm, usually detected by immunohistochemical (IHC) or molecular methods. ITCs do not usually show evidence of malignant activity (e.g., proliferation or stromal reaction). Lymph nodes with ITCs only are not counted as positive nodes. \n* For positive ITCs with NO regional lymph node involvement, code 050\n\n**Note 4:** **Lymph nodes, NOS** \n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05.** American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging.** In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) **Introduction to Female Reproductive Organs**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Dizon, D.S., Olawaiye, A.B., Mutch, D.G., et al. **Corpus Uteri - Sarcoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:42:12.050Z", + "last_modified" : "2025-11-14T20:05:26.651Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dfl.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dfl.json index c39ba535b..8957c8798 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dfl.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dfl.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n\n**Note 2:** **Lymph nodes, NOS** \n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Woltering, E.A., Bergsland, E.K., et al. **Neuroendocrine Tumors of the Jejunum and Ileum**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) **Neuroendocrine Tumors of the Jejunum and Ileum**, from the AJCC Cancer Staging System Version 9 (2023). Used with permission of the American College of Surgeons, Chicago, Illinois.", - "last_modified" : "2025-09-18T20:41:38.187Z", + "last_modified" : "2025-11-14T20:05:47.656Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dfm.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dfm.json index 40d2d930d..9285cad5e 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dfm.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dfm.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note:** **Lymph nodes, NOS** \n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) **Introduction to Female Reproductive Organs**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Chen, L., Olawaiye, A.B., Mutch, D.G., et al. **Gestational Trophoblastic Neoplasms**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-19T18:52:43.627Z", + "last_modified" : "2025-11-14T20:06:14.317Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dfn.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dfn.json index 8fd8cff47..cff5715ce 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dfn.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dfn.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n\n**Note 2:** **CLINICAL AND PATHOLOGICAL codes** \n* This schema has lymph node codes that are defined as **CLINICAL** assessment only or **PATHOLOGICAL** assessment only. \n\n**No surgical resection**\n* Use **CLINICAL** assessment only codes (700, 725, 775) when there is a clinical work up only and there is **NO surgical resection of the primary tumor or site** WITH \n * Any microscopic examination of regional lymph nodes, which includes FNA, core biopsy, sentinel node biopsy, lymph node excision, or lymph node dissection done during the clinical work up. \n\n**Surgical resection without neoadjuvant therapy**\n* Use **PATHOLOGICAL** assessment only codes (300) when there is a **surgical resection of the primary tumor or site** WITH \n * Any microscopic examination of regional lymph nodes, which includes FNA, core biopsy, sentinel node biopsy, lymph node excision done or lymph node dissection performed.\n\n**Surgical resection after neoadjuvant therapy**\n* If patient has neoadjuvant therapy, and the clinical assessment is equal to or greater than the pathological assessment, then the clinical assessment codes take priority. Otherwise, code the pathologic assessment. \n * See ***EOD 2018 General Instructions*** for further instructions on coding cases with neoadjuvant therapy, https://seer.cancer.gov/tools/staging/eod/.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Krasinskas, A., Pawlik, T.M., Vauthey, J.N., et al. **Distal Bile Duct**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:34.657Z", + "last_modified" : "2025-11-14T20:05:37.499Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dfo.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dfo.json index af3b85195..41dd61a23 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dfo.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dfo.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n\n**Note 2:** **CLINICAL AND PATHOLOGICAL codes** \n* This schema has lymph node codes that are defined as **CLINICAL** assessment only or **PATHOLOGICAL** assessment only. \n\n**No surgical resection**\n* Use **CLINICAL** assessment only codes (700, 725, 775) when there is a clinical work up only and there is **NO surgical resection of the primary tumor or site** WITH \n * Any microscopic examination of regional lymph nodes, which includes FNA, core biopsy, sentinel node biopsy, lymph node excision, or lymph node dissection done during the clinical work up. \n\n**Surgical resection without neoadjuvant therapy**\n* Use **PATHOLOGICAL** assessment only codes (300) when there is a **surgical resection of the primary tumor or site** WITH \n * Any microscopic examination of regional lymph nodes, which includes FNA, core biopsy, sentinel node biopsy, lymph node excision done or lymph node dissection performed.\n\n**Surgical resection after neoadjuvant therapy**\n* If patient has neoadjuvant therapy, and the clinical assessment is equal to or greater than the pathological assessment, then the clinical assessment codes take priority. Otherwise, code the pathologic assessment. \n * See ***EOD 2018 General Instructions*** for further instructions on coding cases with neoadjuvant therapy, https://seer.cancer.gov/tools/staging/eod/.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Nagorney, D.M., Pawlik, T.M., Vauthey, J.N., et al. **Perihilar Bile Ducts**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:35.316Z", + "last_modified" : "2025-11-14T20:05:38.281Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dfq.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dfq.json index 9bf74c3aa..b884b30f4 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dfq.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dfq.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n\n**Note 2:** **Lymph node involvement rare**\n* Regional lymph node involvement is rare. \n* For this schema, if there is no mention of lymph node involvement clinically, assume that lymph nodes are negative. \n* Code unknown (999) only when there is no available information on the extent of the patient's disease\n * ***Example***: lab-only case is abstracted from a biopsy report and no clinical history is available.\n\n**Note 3:** **Lymph nodes, NOS** \n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Pollock, R.E., Maki, R.G. **Introduction to Soft Tissue Sarcoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Pollock, R.E., Maki, R.G., et al. **Soft Tissue Sarcoma of the Retroperitoneum**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:42:20.848Z", + "last_modified" : "2025-11-14T20:05:18.776Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dfr.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dfr.json index 3eec25895..f5a4fbd5a 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dfr.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dfr.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n\n**Note 2:** **CLINICAL AND PATHOLOGICAL codes** \n* This schema has lymph node codes that are defined as **CLINICAL** assessment only or **PATHOLOGICAL** assessment only. \n\n**No surgical resection**\n* Use **CLINICAL** assessment only codes (700, 725, 775) when there is a clinical work up only and there is **NO surgical resection of the primary tumor or site** WITH \n * Any microscopic examination of regional lymph nodes, which includes FNA, core biopsy, sentinel node biopsy, lymph node excision, or lymph node dissection done during the clinical work up. \n\n**Surgical resection without neoadjuvant therapy**\n* Use **PATHOLOGICAL** assessment only codes (300) when there is a **surgical resection of the primary tumor or site** WITH \n * Any microscopic examination of regional lymph nodes, which includes FNA, core biopsy, sentinel node biopsy, lymph node excision done or lymph node dissection performed.\n\n**Surgical resection after neoadjuvant therapy**\n* If patient has neoadjuvant therapy, and the clinical assessment is equal to or greater than the pathological assessment, then the clinical assessment codes take priority. Otherwise, code the pathologic assessment. \n * See ***EOD 2018 General Instructions*** for further instructions on coding cases with neoadjuvant therapy, https://seer.cancer.gov/tools/staging/eod/.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05.** American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging.** In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Zhu, A.X., Pawlik, T.M., Vauthey, J.N., et al. **Gallbladder**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:35.754Z", + "last_modified" : "2025-11-14T20:05:39.121Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dna.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dna.json index f6fe8b0a2..85934fa94 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dna.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nodes_dna.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "EOD Regional Nodes", "title" : "EOD Regional Nodes", - "last_modified" : "2025-09-18T20:41:27.381Z", + "last_modified" : "2025-11-14T20:05:02.844Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nras_mutational_analysis_16621.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nras_mutational_analysis_16621.json index c718e6ccd..a2cde61c6 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nras_mutational_analysis_16621.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/nras_mutational_analysis_16621.json @@ -6,7 +6,7 @@ "title" : "NRAS Mutational Analysis", "description" : "NRAS is a signaling intermediate in the growth receptor pathway. Certain NRAS mutations predict poor response to anti-EGFR therapy in patients with metastatic colorectal cancer.\n\nKRAS (NAACCR Data Item # 3866) and NRAS are important signaling intermediates in the growth receptor pathway, which controls cell proliferation and survival. Both KRAS and NRAS may be constitutively activated through mutation during colorectal carcinogenesis so that they continuously stimulate cell proliferation and prevent cell death (reference AJCC 8, pg. 266). KRAS and NRAS mutations predict poor response to anti-EGFR therapy in patients with metastatic colon cancer. AJCC 8 estimates that KRAS may be activated in up to 40% and NRAS in about 7% of colorectal carcinomas.", "notes" : "**Note 1:** **Effective years**\n* This SSDI is effective for diagnosis years 2021+\n* For cases diagnosed 2018-2020, this SSDI must be blank\n\n**Note 2:** **Physician Statement** \n* Physician statement of NRAS can be used to code this data item when no other information is available.\n\n**Note 3:** **Applicable stages**\n* NRAS may be recorded for all stages; however, it is primarily performed for patients with metastatic disease. If information is not available, code 9.\n\n**Note 4:** **Results from nodal or metastatic tissue**\n* Results from nodal or metastatic tissue may be used for NRAS.\n\n**Note 5:** **Neoadjuvant Therapy** \n* Record the assay from tumor specimens prior to neoadjuvant therapy.\n* If neoadjuvant therapy is given and there are no NRAS results from pre-treatment specimens, report the findings from post-treatment specimens.", - "last_modified" : "2025-02-24T13:46:52.827Z", + "last_modified" : "2025-11-05T21:37:28.215Z", "definition" : [ { "key" : "nras_mutational_analysis", "name" : "Code", @@ -17,7 +17,7 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "0", "Normal\nNRAS negative; NRAS wild type\nNegative for (somatic) mutations, no alterations, no (somatic) mutations identified, not present, not detected" ], [ "1", "Abnormal (mutated)/detected in codon(s) 12, 13, and/or 61" ], [ "2", "Abnormal (mutated)/detected, codon(s) specified but not in codon(s) 12, 13, or 61" ], [ "4", "Abnormal (mutated), NOS, codon(s) not specified" ], [ "7", "Test ordered, results not in chart" ], [ "8", "Not applicable: Information not collected for this case\n(If this information is required by your standard setter, use of code 8 may result in an edit error.)" ], [ "9", "Not documented in medical record\nNRAS not assessed or unknown if assessed" ], [ "", "Must be blank if diagnosis year is before 2021" ] ], - "additional_info" : "**Source documents:** pathology report, clinical laboratory report\n\nFor further information, refer to the **Colon and Rectum Biomarker** Reporting cancer protocol published by the College of American Pathologists for the AJCC Staging System *Colon and Rectum*", + "additional_info" : "**Source documents:** pathology report, clinical laboratory report\n\nFor further information, refer to the **Colon and Rectum Biomarker** Reporting cancer protocol published by the College of American Pathologists for the AJCC Staging System *Colon and Rectum*.", "coding_guidelines" : "There are 3 NRAS codons that are commonly mutated in colorectal cancers. This SSDI does not record the actual mutation, but instead records the codon or codon group that contains the mutation. If a specific NRAS mutation is reported, its codon may be identified from the following list of common NRAS mutations grouped by codon.\n\n**1)** **Codon 12 (See code 1)**\n* Gly12Asp (GGT>GAT)\n* Gly12Val (GGT>GTT)\n* Gly12Cys (GGT>TGT)\n* Gly12Ser (GGT>AGT)\n* Gly12Ala (GGT>GCT)\n* Gly12Arg (GGT>CGT)\n* Codon 12 mutation, not otherwise specified\n\n**2)** **Codon 13 (See code 1)**\n* Codon 13 mutation, not otherwise specified\n\n**3)** **Codon 61 (See code 1)**\n* Gln61Lys (CAA>AAA)\n* Gln61Arg (CAA>CGA)\n* Codon 61 mutation, not otherwise specified\n\n**4)** **Other specified codons (excluding 12, 13, 61) (See code 2)**\n\n**5)** **Unknown codon (See code 4)**\n * NRAS positive, specific codon not mentioned\n\n**6)** **Code 9** when\n* Insufficient amount of tissue available to perform test\n* No microscopic confirmation of tumor \n* Pathology report available and there is no mention of NRAS\n* NRAS not ordered or not done, or unknown if ordered or done", "rationale" : "NRAS mutational analysis is recommended in clinical guidelines for patients with metastatic colon cancer who are being considered for anti-EGFR therapy. It is a new data item for cases diagnosed 1/1/2021+." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/number_of_cores_examined_64985.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/number_of_cores_examined_64985.json index 9da97788d..7d53a9f7b 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/number_of_cores_examined_64985.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/number_of_cores_examined_64985.json @@ -6,7 +6,7 @@ "title" : "Number of Cores Examined", "description" : "This data item represents the number of cores examined as documented in the pathology report from a needle core biopsy of the prostate gland.\n\nTwo data items record the number of positive and examined cores that are microscopically confirmed. A diagnostic procedure, such as a needle core biopsy, can take as many as 20 or more core biopsies to determine the extent of the cancer within the prostate. \n\nTogether these two data items can provide researchers with a surrogate estimate of the percentage of the prostate involved by tumor, if that figure is not stated in the pathology report\n\nNumber of Cores Positive must ALWAYS be less than or equal to Number of Cores Examined.\n\nFor Prostate, there are 2 data items that record information on the number of cores positive and examined. These related data items should be coded from the same test. \n* 3897: Number of Cores Examined\n* 3898: Number of Cores Positive\n\n***Note:*** Do not make assumptions about the number of cores positive or examined based on the number of areas biopsied within the prostate (laterality, lobes, apex, base, or mid-prostate). Several cores may be taken from each area.", "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of Number of Cores Examined can be used to code this data item when there is no other information available, provided the priority order has been met (See Note 2).\n\n**Note 2:** **Priority order**\n* **Final diagnosis**\n * If the core biopsy pathology report contains a summary of the number of cores examined from all specimens, use the summary provided\n * Do not include cores of other areas like seminal vesicles\n* **Gross description**\n * Information from the gross description of the core biopsy pathology report can be used to code this data item when the final diagnosis is not available and the gross findings provide the actual number of cores and not pieces, chips, fragments, etc.\n* **Physician statement (see Note 1)**\n\n**Note 3:** **Transperineal template-guided saturation biopsy (TTSB)**\n* A stereotactic prostate biopsy technique that typically produces 30 to 80 core biopsies. This is an alternative biopsy technique used for some high-risk patients including men with persistently elevated PSA, those who have atypia on prior prostate biopsies, or men with biopsies showing high grade prostatic intraepithelial neoplasia (PIN).\n\n**Note 4:** If there is a targeted biopsy or a region of interest (ROI) biopsy done, count as 1 core positive/1 core examined, regardless of how many cores are actually taken from the targeted/ROI location. \n * When doing a targeted or ROI biopsy, the region being biopsied is suspected of cancer (usually based on an MRI). Since the area is targeted, there will be many more cores removed. To record all these cores would be inflating the numbers.\n * ***Example:*** Standard/systematic core biopsy done, 2/16 cores positive, targeted biopsy done, 6/8 cores positive. \n * The total cores positive would be 2 + 1 (from the targeted biopsy), and total cores examined would be 16 + 1 (from the targeted biopsy).\n * If there are multiple targeted or region of interest's biopsies done, count each one as 1/1 cores positive/examined.\n\n * ***Example:*** Standard/systematic core biopsy done, 3/8 cores positive. Two targeted biopsies done, one 5/11 cores positive and the other 7/10 cores positive. \n * The total cores positive would be 3 + 2 (for the two targeted biopsies) and total cores examined would be 8 + 2 (for the two targeted biopsies)\n\n**Note 5:** **Related data item** \n* The number of cores positive are recorded in the related data item 3898: Number of Cores Positive.", - "last_modified" : "2025-06-11T19:15:43.023Z", + "last_modified" : "2025-11-06T20:42:32.366Z", "definition" : [ { "key" : "number_cores_exam", "name" : "Code", @@ -17,7 +17,7 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "01-99", "1 - 99 cores examined\n(Exact number of cores examined)" ], [ "X1", "100 or more cores examined" ], [ "X6", "Biopsy cores examined; number unknown" ], [ "X7", "No needle core biopsy performed" ], [ "X8", "Not applicable: Information not collected for this case\n(If this information is required by your standard setter, use of code X8 may result in an edit error.)" ], [ "X9", "Not documented in medical record\nNumber of cores examined not assessed or unknown if assessed" ] ], - "additional_info" : "**Source documents:** pathology reports from core needle biopsies\n\n**Other names for procedures include** needle core biopsy, needle biopsy, core biopsy, prostate biopsy, sextant biopsy, transrectal biopsy, ultrasound-guided biopsy, transperineal prostate biopsy, triggered-needle biopsy.\n\nFor further information, refer to the **Prostate** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Prostate*", - "coding_guidelines" : "**1)** Record the number of positive prostate core biopsies from the **first prostate core biopsy** diagnostic for cancer. \n* Information from the first core biopsy is preferred since the physician is usually examining the entire prostate. \n* If a second core biopsy is done, this is usually done on a specified area, so more cores will be found to be positive\n\n**2) Code 01-99** for the exact number of examined cores\n**3) Code X1** for 100 or more examined cores\n**4) Code X6** for examined cores, and the number of examined cores are not specifically identified, this includes descriptions such as pieces, chips, or fragments\n**5) Code X9** when \n* Not documented in the medical record\n* Cores not evaluated (assessed)\n* Unknown if Cores evaluated (assessed)", + "additional_info" : "**Source documents:** pathology reports from core needle biopsies\n\n**Other names for procedures include** needle core biopsy, needle biopsy, core biopsy, prostate biopsy, sextant biopsy, transrectal biopsy, ultrasound-guided biopsy, transperineal prostate biopsy, triggered-needle biopsy\n\nFor further information, refer to the **Prostate** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Prostate*.", + "coding_guidelines" : "**1)** Record the number of positive prostate core biopsies from the **first prostate core biopsy** diagnostic for cancer. \n* Information from the first core biopsy is preferred since the physician is usually examining the entire prostate. \n* If a second core biopsy is done, this is usually done on a specified area, so more cores will be found to be positive\n\n**2) Code 01-99** for the exact number of examined cores\n\n**3) Code X1** for 100 or more examined cores\n\n**4) Code X6** for examined cores, and the number of examined cores are not specifically identified, this includes descriptions such as pieces, chips, or fragments\n\n**5) Code X9** when \n* Not documented in the medical record\n* Cores not evaluated (assessed)\n* Unknown if Cores evaluated (assessed)", "rationale" : "Number of Cores Examined is a Registry Data Collection Variable for AJCC. This data item was previously collected as Prostate, CS SSF #13." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/number_of_cores_positive_87819.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/number_of_cores_positive_87819.json index 16350d71e..a5ecaebf5 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/number_of_cores_positive_87819.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/number_of_cores_positive_87819.json @@ -6,7 +6,7 @@ "title" : "Number of Cores Positive", "description" : "This data item represents the number of positive cores documented in the pathology report from a needle core biopsy of the prostate gland.\n\nTwo data items record the number of positive and examined cores that are microscopically confirmed. A diagnostic procedure, such as a needle core biopsy, can take as many as 20 or more core biopsies to determine the extent of the cancer within the prostate. \n\nTogether these two data items can provide researchers with a surrogate estimate of the percentage of the prostate involved by tumor, if that figure is not stated in the pathology report\n\nNumber of Cores Positive must ALWAYS be less than or equal to Number of Cores Examined.\n\nFor Prostate, there are 2 data items that record information on the number of cores positive and examined. These related data items should be coded from the same test. \n* 3897: Number of Cores Examined\n* 3898: Number of Cores Positive\n\n***Note:*** Do not make assumptions about the number of cores positive or examined based on the number of areas biopsied within the prostate (laterality, lobes, apex, base, or mid-prostate). Several cores may be taken from each area.", "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of Number of Cores Positive can be used to code this data item when there is no other information available, provided the priority order has been met (See Note 2).\n\n**Note 2:** **Priority order**\n* **Final diagnosis**\n * If the core biopsy pathology report contains a summary of the number of cores positive, use the summary provided\n * Do not include cores of other areas like seminal vesicles\n* **Gross description**\n * Information from the gross description of the core biopsy pathology report can be used to code this data item when the final diagnosis is not available and the gross findings provide the actual number of cores and not pieces, chips, fragments, etc.\n* **Physician statement (see Note 1)**\n\n\n**Note 3:** **Transperineal template-guided saturation biopsy (TTSB)**\n* A stereotactic prostate biopsy technique that typically produces 30 to 80 core biopsies. This is an alternative biopsy technique used for some high-risk patients including men with persistently elevated PSA, those who have atypia on prior prostate biopsies, or men with biopsies showing high grade prostatic intraepithelial neoplasia (PIN).\n\n**Note 4:** If there is a targeted biopsy or a region of interest (ROI) biopsy done, count as 1 core positive/1 core examined, regardless of how many cores are actually taken from the targeted/ROI location.\n * When doing a targeted or ROI biopsy, the region being biopsied is suspected of cancer (usually based on an MRI). Since the area is targeted, there will be many more cores removed. To record all these cores would be inflating the numbers.\n * ***Example:*** Standard/systematic core biopsy done, 2/16 cores positive, targeted biopsy done, 6/8 cores positive. \n * The total cores positive would be 2 + 1 (from the targeted biopsy), and total cores examined would be 16 + 1 (from the targeted biopsy).\n * If there are multiple targeted or region of interest's biopsies done, count each one as 1/1 cores positive/examined.\n\n * ***Example:*** Standard/systematic core biopsy done, 3/8 cores positive. Two targeted biopsies done, one 5/11 cores positive and the other 7/10 cores positive. \n * The total cores positive would be 3 + 2 (for the two targeted biopsies) and total cores examined would be 8 + 2 (for the two targeted biopsies)\n\n**Note 5:** **Related data item** \n* The number of cores examined is recorded in the related data item 3897: Number of Cores Examined.", - "last_modified" : "2025-06-11T19:15:17.381Z", + "last_modified" : "2025-11-06T20:42:12.019Z", "definition" : [ { "key" : "number_cores_pos", "name" : "Code", @@ -17,7 +17,7 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "00", "All examined cores negative" ], [ "01-99", "1 - 99 cores positive \n(Exact number of cores positive)" ], [ "X1", "100 or more cores positive" ], [ "X6", "Biopsy cores positive, number unknown" ], [ "X7", "No needle core biopsy performed " ], [ "X8", "Not applicable: Information not collected for this case\n(If this information is required by your standard setter, use of code X8 may result in an edit error.)" ], [ "X9", "Not documented in medical record\nNumber of cores positive not assessed or unknown if assessed" ] ], - "additional_info" : "**Source documents:** pathology reports from core needle biopsies\n\n**Other names for procedures include** needle core biopsy, needle biopsy, core biopsy, prostate biopsy, sextant biopsy, transrectal biopsy, ultrasound-guided biopsy, transperineal prostate biopsy, triggered-needle biopsy.\n\nFor further information, refer to the **Prostate** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Prostate*", - "coding_guidelines" : "**1)** Record the number of positive prostate core biopsies from the **first prostate core biopsy** diagnostic for cancer. \n* Information from the first core biopsy is preferred since the physician is usually examining the entire prostate. \n* If a second core biopsy is done, this is usually done on a specified area, so more cores will be found to be positive\n\n**2)** **Code 00** for all cores negative\n**3)** **Code 01-99** for the exact number of positive cores\n**4)** **Code X1** for 100 or more positive cores\n**5)** **Code X6** if positive cores are identified, and the number of positive cores are not specifically identified, this includes descriptions such as pieces, chips, or fragments\n**6) Code X9** when \n* Not documented in the medical record\n* Cores not evaluated (assessed)\n* Unknown if Cores evaluated (assessed)", + "additional_info" : "**Source documents:** pathology reports from core needle biopsies\n\n**Other names for procedures include** needle core biopsy, needle biopsy, core biopsy, prostate biopsy, sextant biopsy, transrectal biopsy, ultrasound-guided biopsy, transperineal prostate biopsy, triggered-needle biopsy\n\nFor further information, refer to the **Prostate** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Prostate*.", + "coding_guidelines" : "**1)** Record the number of positive prostate core biopsies from the **first prostate core biopsy** diagnostic for cancer. \n* Information from the first core biopsy is preferred since the physician is usually examining the entire prostate. \n* If a second core biopsy is done, this is usually done on a specified area, so more cores will be found to be positive\n\n**2)** **Code 00** for all cores negative\n\n**3)** **Code 01-99** for the exact number of positive cores\n\n**4)** **Code X1** for 100 or more positive cores\n\n**5)** **Code X6** if positive cores are identified, and the number of positive cores are not specifically identified, this includes descriptions such as pieces, chips, or fragments\n\n**6) Code X9** when \n* Not documented in the medical record\n* Cores not evaluated (assessed)\n* Unknown if Cores evaluated (assessed)", "rationale" : "Number of Cores Positive is a Registry Data Collection Variable for AJCC. This data item was previously collected as Prostate, CS SSF #12." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/number_of_examined_para_aortic_nodes_38078.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/number_of_examined_para_aortic_nodes_38078.json index a818a728a..4567118fa 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/number_of_examined_para_aortic_nodes_38078.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/number_of_examined_para_aortic_nodes_38078.json @@ -6,7 +6,7 @@ "title" : "Number of Examined Para-Aortic Nodes", "description" : "Number of Examined Para-Aortic nodes is the number of nodes examined based on para-aortic nodal dissection.\n\nInformation on the number of positive and examined para-aortic and pelvic lymph nodes. These related data items should be coded from the same procedure.\n* 3899: Number of Examined Para-Aortic Nodes\n* 3900: Number of Examined Pelvic Nodes\n* 3901: Number of Positive Para-Aortic Nodes\n* 3902: Number of Positive Pelvic Nodes", "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of examined para-aortic nodes can be used to code this data item when no other information is available.\n\n**Note 2:** **Para-aortic nodes** \n* Aortic\n* Lateral aortic/lateral lumbar\n* Para-aortic, NOS\n* Periaortic\n\n**Note 3:** **Related data item** \n* The number of para-aortic nodes positive is recorded in the related data item 3901: Number of Positive Para-aortic Nodes.\n\n**Note 4:** **Related data item**\n* The number of examined pelvic nodes is recorded in the related data item 3899: Number of Examined Para-Aortic Nodes.", - "last_modified" : "2025-05-15T12:34:09.971Z", + "last_modified" : "2025-11-06T20:25:49.351Z", "definition" : [ { "key" : "num_exam_para_aortic_nodes", "name" : "Code", @@ -18,6 +18,6 @@ } ], "rows" : [ [ "00", "No para-aortic nodes examined" ], [ "01-99", "1 - 99 para-aortic nodes examined \n(Exact number of para-aortic lymph nodes examined)" ], [ "X1", "100 or more para-aortic nodes examined" ], [ "X2", "Para-aortic nodes examined; number unknown" ], [ "X6", "No para-aortic lymph nodes removed, but aspiration or core biopsy of para-aortic node(s) only" ], [ "X8", "Not applicable: Information not collected for this case\n(If this item is required by your standard setter, use of code X8 will result in an edit error.)" ], [ "X9", "Not documented in medical record\nCannot be determined, indeterminate if examined para-aortic nodes present \nPara-aortic lymph nodes not assessed or unknown if assessed" ] ], "additional_info" : "**Source documents:** pathology report, imaging reports, physical exam, other statements in medical record", - "coding_guidelines" : "**1)** Record the number of examined pelvic lymph nodes documented in the medical record.\n* Number of nodes examined must ALWAYS be **equal to or greater** than the number of nodes positive.\n* If a lymph node dissection is done and only “nodes” are documented without specifying pelvic or para-aortic, assume they are pelvic\n * Para-aortic nodes are not routinely examined unless there is suspected involvement\n\n**2)** **Code 00** when no lymph nodes are examined by FNA, core biopsy or removal of lymph node(s) (e.g., sentinel lymph node biopsy or lymph node dissection)\n**3)** **Code 01-99** for the exact number of examined \n**4)** **Code X1** for 100 or more examined nodes\n**5)** **Code X2** for nodes examined, but unknown how many\n**6)** **Code X6** for aspiration or core biopsy of para-aortic node(s) \n**7)** **Code X9** when\n* Not documented in the medical record\n* Para-aortic lymph nodes not evaluated (assessed)\n* Unknown if Para-aortic lymph nodes not evaluated (assessed)", + "coding_guidelines" : "**1)** Record the number of examined pelvic lymph nodes documented in the medical record.\n* Number of nodes examined must ALWAYS be **equal to or greater** than the number of nodes positive.\n* If a lymph node dissection is done and only “nodes” are documented without specifying pelvic or para-aortic, assume they are pelvic\n * Para-aortic nodes are not routinely examined unless there is suspected involvement\n\n**2)** **Code 00** when no lymph nodes are examined by FNA, core biopsy or removal of lymph node(s) (e.g., sentinel lymph node biopsy or lymph node dissection)\n\n**3)** **Code 01-99** for the exact number of examined \n\n**4)** **Code X1** for 100 or more examined nodes\n\n**5)** **Code X2** for nodes examined, but unknown how many\n\n**6)** **Code X6** for aspiration or core biopsy of para-aortic node(s) \n\n**7)** **Code X9** when\n* Not documented in the medical record\n* Para-aortic lymph nodes not evaluated (assessed)\n* Unknown if Para-aortic lymph nodes not evaluated (assessed)", "rationale" : "Number of Examined Para-Aortic Nodes is listed as a Registry Data Collection Variable in AJCC. This data item was previously collected as Corpus, CS SSF #6." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/number_of_examined_pelvic_nodes_60771.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/number_of_examined_pelvic_nodes_60771.json index 9220d6e58..07aca25b2 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/number_of_examined_pelvic_nodes_60771.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/number_of_examined_pelvic_nodes_60771.json @@ -5,8 +5,8 @@ "name" : "Number of Examined Pelvic Nodes", "title" : "Number of Examined Pelvic Nodes", "description" : "Number of Examined Pelvic Nodes is the number of nodes examined based on pelvic nodal dissection.\n\nFor the Corpus schemas (3) and the Cervix Sarcoma schema, there are 4 data items that record information on the number of positive and examined para-aortic and pelvic lymph nodes. These related data items should be coded from the same procedure\n* 3899: Number of Examined Para-Aortic Nodes\n* 3900: Number of Examined Pelvic Nodes\n* 3901: Number of Positive Para-Aortic Nodes\n* 3902: Number of Positive Pelvic Nodes", - "notes" : "**Note 1:** **Physician Statement**\n* Physician statement of examined pelvic nodes can be used to code this data item when no other information is available \n\n**Note 2:** **Pelvic lymph nodes** \n* Iliac, NOS\n * Common\n * External\n * Internal (hypogastric) (obturator)\n* Paracervical\n* Parametrial\n* Pelvic, NOS\n* Sacral, NOS\n * Lateral (laterosacral)\n * Middle (promontorial) (Gerota’s node)\n * Uterosacral\n\n**Note 3:** **Isolated tumor cells**\n* For this data item, do not include isolated tumor cells (ITCs).\n\n**Note 4:** **Related data item**\n* The number of positive pelvic nodes is recorded in in the related data item 3902: Number of Positive Pelvic Nodes.", - "last_modified" : "2025-03-21T17:58:51.354Z", + "notes" : "**Note 1:** **Physician Statement**\n* Physician statement of examined pelvic nodes can be used to code this data item when no other information is available \n\n**Note 2:** **Pelvic lymph nodes** \n* Iliac, NOS\n * Common\n * External\n * Internal (hypogastric) (obturator)\n* Paracervical\n* Parametrial\n* Pelvic, NOS\n* Sacral, NOS\n * Lateral (laterosacral)\n * Middle (promontorial) (Gerota’s node)\n * Uterosacral\n\n**Note 3:** **Isolated tumor cells**\n* For this data item, do not include isolated tumor cells (ITCs).\n\n**Note 4:** **Related data item**\n* The number of positive pelvic nodes is recorded in the related data item 3902: Number of Positive Pelvic Nodes.", + "last_modified" : "2025-11-06T20:24:36.143Z", "definition" : [ { "key" : "num_exam_pelvic_nodes", "name" : "Code", @@ -18,6 +18,6 @@ } ], "rows" : [ [ "00", "No pelvic lymph nodes examined" ], [ "01-99", "1 - 99 pelvic lymph nodes examined \n(Exact number of pelvic lymph nodes examined)" ], [ "X1", "100 or more pelvic nodes examined" ], [ "X2", "Pelvic nodes examined; number unknown" ], [ "X6", "No pelvic lymph nodes removed, but aspiration or core biopsy of pelvic node(s) only" ], [ "X8", "Not applicable: Information not collected for this case\n(If this item is required by your standard setter, use of code X8 will result in an edit error.)" ], [ "X9", "Not documented in medical record\nCannot be determined, indeterminate if examined pelvic nodes present\nPelvic lymph nodes not assessed or unknown if assessed" ] ], "additional_info" : "**Source documents:** pathology report, imaging reports, physical exam, other statements in medical record", - "coding_guidelines" : "**1)** Record the number of examined pelvic lymph nodes documented in the medical record.\n* Number of nodes examined must ALWAYS be **equal to or greater** than the number of nodes positive.\n* If a lymph node dissection is done and only “nodes” are documented without specifying pelvic or para-aortic, assume they are pelvic\n\n**2)** **Code 00** when no lymph nodes are examined by FNA, core biopsy or removal of lymph node(s) (e.g., sentinel lymph node biopsy or lymph node dissection)\n**3)** **Code 01-99** for the exact number of examined \n**4)** **Code X1** for 100 or more examined nodes\n**5)** **Code X2** for nodes examined, but unknown how many\n**6)** **Code X6** for aspiration or core biopsy of pelvic node(s) \n**7)** **Code X9** when\n* Not documented in the medical record\n* Pelvic lymph nodes not evaluated (assessed)\n* Unknown if Pelvic lymph nodes not evaluated (assessed)", + "coding_guidelines" : "**1)** Record the number of examined pelvic lymph nodes documented in the medical record.\n* Number of nodes examined must ALWAYS be **equal to or greater** than the number of nodes positive.\n* If a lymph node dissection is done and only “nodes” are documented without specifying pelvic or para-aortic, assume they are pelvic\n\n**2)** **Code 00** when no lymph nodes are examined by FNA, core biopsy or removal of lymph node(s) (e.g., sentinel lymph node biopsy or lymph node dissection)\n\n**3)** **Code 01-99** for the exact number of examined \n\n**4)** **Code X1** for 100 or more examined nodes\n\n**5)** **Code X2** for nodes examined, but unknown how many\n\n**6)** **Code X6** for aspiration or core biopsy of pelvic node(s) \n\n**7)** **Code X9** when\n* Not documented in the medical record\n* Pelvic lymph nodes not evaluated (assessed)\n* Unknown if Pelvic lymph nodes not evaluated (assessed)", "rationale" : "Number of Examined Pelvic Nodes is listed as a Registry Data Collection Variable in AJCC. This data item was previously collected as Corpus, CS SSF #4." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/number_of_positive_ipsilateral_level_i_ii_axillary_lymph_nodes_79439.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/number_of_positive_ipsilateral_level_i_ii_axillary_lymph_nodes_79439.json index f9f9111a6..0334c5fec 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/number_of_positive_ipsilateral_level_i_ii_axillary_lymph_nodes_79439.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/number_of_positive_ipsilateral_level_i_ii_axillary_lymph_nodes_79439.json @@ -5,8 +5,8 @@ "name" : "LN Positive Axillary Level I-II", "title" : "Lymph Nodes Positive Axillary Level I-II", "description" : "This data item pertains to the number of positive ipsilateral level I and II axillary lymph nodes and intramammary lymph nodes based on pathological information.\n\nThis data items records the low axillary (level I and intramammary) and mid-axillary (level II, also called interpectoral or Rotter’s nodes).\n\nThis data item excludes level III (high axillary, also called apical or infraclavicular), internal mammary and supraclavicular lymph nodes.\n\nDo not confuse intramammary nodes, which are within breast tissue and are included in level I, with internal mammary nodes, which are along the sternum.\n\nThis field is based on pathological examination of ipsilateral (same side as the primary cancer) level I and II axillary lymph nodes, so pathological information is included even if the patient had neoadjuvant therapy prior to lymph node removal.\n\nDo not include lymph nodes containing only isolated tumor cells (ITCs—metastases less than 0.2 mm in size) in the count of positive nodes.", - "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of number of positive ipsilateral Level I-II axillary nodes can be used to code this data item, when no other specific information is available.\n\n**Note 2:** **Axillary Level I and II lymph nodes** \n* Include only the number of positive ipsilateral level I and II axillary lymph nodes and intramammary lymph nodes in this field. Intramammary nodes, located within the breast, are not the same as internal mammary nodes, located along the sternum.\n\n**Note 3:** **Microscopic confirmation** \n* This field is based on microscopic information only. If no ipsilateral axillary nodes are examined, or if an ipsilateral axillary lymph node drainage area is removed but no lymph nodes are found, code X9.\n\n**Note 4:** **Isolated tumor cells** \n* Lymph nodes with only isolated tumor cells (ITCs) are not counted as positive lymph nodes. Only lymph nodes with metastases greater than 0.2 mm (micrometastases or larger) should be counted as positive. If the pathology report indicates that axillary nodes are positive, but size of the metastases is not stated, assume the metastases are greater than 0.2 mm and code the lymph nodes as positive in this field.\n\n**Note 5:** **Positive Axillary lymph nodes compared to Regional Nodes Positive** \n* When positive ipsilateral axillary lymph nodes are coded in this field, the number of positive ipsilateral axillary lymph nodes must be less than or equal to the number coded in Regional Nodes Positive (i.e., the number of positive ipsilateral axillary nodes will always be a subset of the number of positive regional nodes.)\n\n**Note 6:** **Neoadjuvant Therapy:** \n+ If clinical nodal involvement is more extensive, include only those nodes that are positive during clinical workup\n - Positive nodes can be from an FNA, core biopsy or sentinel lymph node biopsy\n - ***Example:*** Patient with positive FNA of axillary lymph node, neoadjuvant therapy administered. Lymph node dissection revealed negative lymph nodes. Code X6 for the positive FNA.\n+ If the post-neoadjuvant nodal involvement is more extensive, include only those nodes positive during surgery\n - Positive nodes can be from an FNA, core biopsy, sentinel lymph node biopsy or lymph node dissection\n - ***Example:*** Patient with large breast mass, lymph node negative on clinical exam. Neoadjuvant therapy administered. Mastectomy and sentinel lymph node biopsy done, 1 of 2 SLN’s positive. Code 01.", - "last_modified" : "2024-04-08T19:50:40.274Z", + "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of number of positive ipsilateral Level I-II axillary nodes can be used to code this data item, when no other specific information is available.\n\n**Note 2:** **Axillary Level I and II lymph nodes** \n* Include only the number of positive ipsilateral level I and II axillary lymph nodes and intramammary lymph nodes in this field. Intramammary nodes, located within the breast, are not the same as internal mammary nodes, located along the sternum.\n\n**Note 3:** **Microscopic confirmation** \n* This field is based on microscopic information only. If no ipsilateral axillary nodes are examined, or if an ipsilateral axillary lymph node drainage area is removed but no lymph nodes are found, code X9.\n\n**Note 4:** **Isolated tumor cells** \n* Lymph nodes with only isolated tumor cells (ITCs) are not counted as positive lymph nodes. Only lymph nodes with metastases greater than 0.2 mm (micrometastases or larger) should be counted as positive. If the pathology report indicates that axillary nodes are positive, but size of the metastases is not stated, assume the metastases are greater than 0.2 mm and code the lymph nodes as positive in this field.\n\n**Note 5:** **Positive Axillary lymph nodes compared to Regional Nodes Positive** \n* When positive ipsilateral axillary lymph nodes are coded in this field, the number of positive ipsilateral axillary lymph nodes must be less than or equal to the number coded in Regional Nodes Positive (i.e., the number of positive ipsilateral axillary nodes will always be a subset of the number of positive regional nodes.)\n\n**Note 6:** **Neoadjuvant Therapy:** \n* If clinical nodal involvement is more extensive, include only those nodes that are positive during clinical workup\n * Positive nodes can be from an FNA, core biopsy or sentinel lymph node biopsy\n * ***Example:*** Patient with positive FNA of axillary lymph node, neoadjuvant therapy administered. Lymph node dissection revealed negative lymph nodes. Code X6 for the positive FNA.\n* If the post-neoadjuvant nodal involvement is more extensive, include only those nodes positive during surgery\n * Positive nodes can be from an FNA, core biopsy, sentinel lymph node biopsy or lymph node dissection\n * ***Example:*** Patient with large breast mass, lymph node negative on clinical exam. Neoadjuvant therapy administered. Mastectomy and sentinel lymph node biopsy done, 1 of 2 SLN’s positive. Code 01.", + "last_modified" : "2025-11-06T18:48:05.729Z", "definition" : [ { "key" : "ln_pos_axillary_level_1_2", "name" : "Code", @@ -17,7 +17,7 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "00", "All ipsilateral axillary nodes examined negative" ], [ "01-99", "1 - 99 nodes positive \n(Exact number of nodes positive)" ], [ "X1", "100 or more nodes positive" ], [ "X5", "Positive nodes, number unspecified" ], [ "X6", "Positive aspiration or needle core biopsy of lymph node(s)" ], [ "X8", "Not applicable: Information not collected for this case\n(If this item is required by your standard setter, use of code X8 will result in an edit error.)" ], [ "X9", "Not documented in medical record\nLevel I-II axillary nodes not assessed or unknown if assessed" ] ], - "additional_info" : "**Required for Staging:** EOD only.\n\n**Source documents:** pathology report", - "coding_guidelines" : "**1)** **Code 00** when all level I and II axillary lymph nodes are negative on pathological examination\n**2)** **Code 01-99** for the exact number of positive nodes for levels I and II\n**3)** **Code X1** if more than 99 level I and II axillary lymph nodes are positive\n**4)** **Code X5** if level I and II axillary lymph nodes were positive, but the number is not specified\n**5)** **Code X6** if there was only a positive aspiration of level I or II axillary lymph node(s)\n**6)** **Code X9** when\n* **a.** No axillary nodes were examined\n* **b.** Axillary dissection was performed but no axillary lymph nodes were found\n* **c.** Clinical diagnosis only (no axillary lymph nodes were removed)\n* **d.** Unknown whether axillary lymph nodes are positive", + "additional_info" : "**Required for Staging:** EOD only\n\n**Source documents:** pathology report", + "coding_guidelines" : "**1)** **Code 00** when all level I and II axillary lymph nodes are negative on pathological examination\n\n**2)** **Code 01-99** for the exact number of positive nodes for levels I and II\n\n**3)** **Code X1** if more than 99 level I and II axillary lymph nodes are positive\n\n**4)** **Code X5** if level I and II axillary lymph nodes were positive, but the number is not specified\n\n**5)** **Code X6** if there was only a positive aspiration of level I or II axillary lymph node(s)\n\n**6)** **Code X9** when\n* No axillary nodes were examined\n* Axillary dissection was performed but no axillary lymph nodes were found\n* Clinical diagnosis only (no axillary lymph nodes were removed)\n* Unknown whether axillary lymph nodes are positive", "rationale" : "Lymph Nodes Positive Axillary Level I-II can be collected by the surveillance community for breast cancers. Prior to 2018, Breast SSF#3 was used for Lymph Nodes Positive Axillary Level I-II." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/number_of_positive_para_aortic_nodes_62533.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/number_of_positive_para_aortic_nodes_62533.json index f4e8d4c4b..963506bd6 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/number_of_positive_para_aortic_nodes_62533.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/number_of_positive_para_aortic_nodes_62533.json @@ -6,7 +6,7 @@ "title" : "Number of Positive Para-Aortic Nodes", "description" : "Number of Positive Para-Aortic Nodes is the number of positive nodes based on para-aortic nodal dissection.\n\nInformation on the number of positive and examined para-aortic and pelvic lymph nodes. These related data items should be coded from the same procedure.\n* 3899: Number of Examined Para-Aortic Nodes\n* 3900: Number of Examined Pelvic Nodes\n* 3901: Number of Positive Para-Aortic Nodes\n* 3902: Number of Positive Pelvic Nodes", "notes" : "**Note 1:** **Physician Statement**\n* Physician statement of positive para-aortic nodes can be used to code this data item when no other information is available.\n\n**Note 2:** **Para-aortic nodes** \n* Aortic\n* Lateral aortic/lateral lumbar\n* Para-aortic, NOS\n* Periaortic\n\n**Note 3:** **Isolated tumor cells**\n* For this data item, do not include isolated tumor cells (ITCs).\n\n**Note 4:** **Micrometastasis and macrometastasis**\n* Micrometastasis and macrometastasis may be listed separately on the pathology report. Add these two together to get the total number of positive nodes. \n\n**Note 5:** **Related data item**\n* The number of examined pelvic nodes is recorded in the related data item 3899: Number of Examined Para-Aortic Nodes.", - "last_modified" : "2025-03-21T18:00:04.351Z", + "last_modified" : "2025-11-06T20:25:21.161Z", "definition" : [ { "key" : "num_pos_para_aortic_nodes", "name" : "Code", @@ -17,7 +17,7 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "00", "All para-aortic lymph nodes examined negative" ], [ "01-99", "1-99 para-aortic lymph nodes positive\n(Exact number of nodes positive)" ], [ "X1", "100 or more para-aortic nodes positive" ], [ "X2", "Positive para-aortic nodes identified; number unknown" ], [ "X6", "Positive aspiration or core biopsy of para-aortic lymph node(s)" ], [ "X8", "Not applicable: Information not collected for this case\n(If this item is required by your standard setter, use of code X8 will result in an edit error.)" ], [ "X9", "Not documented in medical record\nCannot be determined, indeterminate if positive para-aortic nodes present\nNo lymph nodes removed\nPara-aortic lymph nodes not assessed or unknown if assessed" ] ], - "additional_info" : "**Source documents:** pathology report, imaging reports, physical exam, other statements in medical record\nNotes", - "coding_guidelines" : "**1)** Record the number of positive para-aortic lymph nodes documented in the medical record.\n**2)** **Code 00** for when there are no positive nodes\n**3)** **Code 01-99** for the exact number of positive nodes \n**4)** **Code X1** for 100 or more positive nodes\n**5)** **Code X2** for positive nodes, but unknown how many\n**6)** **Code X6** if only a FNA or core biopsy is done, and it is positive\n**7)** **Code X9** when\n* If only a FNA or core biopsy is done, and it is negative\n* Not documented in the medical record\n* Para-aortic lymph nodes not evaluated (assessed)\n* No lymph nodes removed\n* Unknown if Para-aortic lymph nodes evaluated (assessed)", + "additional_info" : "**Source documents:** pathology report, imaging reports, physical exam, other statements in medical record", + "coding_guidelines" : "**1)** Record the number of positive para-aortic lymph nodes documented in the medical record.\n\n**2)** **Code 00** for when there are no positive nodes\n\n**3)** **Code 01-99** for the exact number of positive nodes \n\n**4)** **Code X1** for 100 or more positive nodes\n\n**5)** **Code X2** for positive nodes, but unknown how many\n\n**6)** **Code X6** if only a FNA or core biopsy is done, and it is positive\n\n**7)** **Code X9** when\n* If only a FNA or core biopsy is done, and it is negative\n* Not documented in the medical record\n* Para-aortic lymph nodes not evaluated (assessed)\n* No lymph nodes removed\n* Unknown if Para-aortic lymph nodes evaluated (assessed)", "rationale" : "Number of Positive Para-Aortic Nodes is listed as a Registry Data Collection Variable in AJCC. This data item was previously collected as Corpus, CS SSF #5." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/number_of_postive_pelvic_nodes_94512.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/number_of_postive_pelvic_nodes_94512.json index f71edb2cc..17f9281bb 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/number_of_postive_pelvic_nodes_94512.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/number_of_postive_pelvic_nodes_94512.json @@ -6,7 +6,7 @@ "title" : "Number of Positive Pelvic Nodes", "description" : "Number of Positive Pelvic Nodes is the number of positive nodes based on pelvic nodal dissection.\n\nFor the Corpus schemas (3) and the Cervix Sarcoma schema, there are 4 data items that record information on the number of positive and examined para-aortic and pelvic lymph nodes. These related data items should be coded from the same procedure\n* 3899: Number of Examined Para-Aortic Nodes\n* 3900: Number of Examined Pelvic Nodes\n* 3901: Number of Positive Para-Aortic Nodes\n* 3902: Number of Positive Pelvic Nodes", "notes" : "**Note 1:** **Physician Statement**\n* Physician statement of positive pelvic nodes can be used to code this data item when no other information is available.\n\n**Note 2:** **Pelvic lymph nodes** \n* Iliac, NOS\n * Common\n * External\n * Internal (hypogastric) (obturator)\n* Paracervical\n* Parametrial\n* Pelvic, NOS\n* Sacral, NOS\n * Lateral (laterosacral)\n * Middle (promontorial) (Gerota’s node)\n * Uterosacral\n\n**Note 3:** **Isolated tumor cells**\n* For this data item, do not include isolated tumor cells (ITCs).\n\n**Note 4:** **Micrometastasis and macrometastasis**\n* Micrometastasis and macrometastasis may be listed separately on the pathology report. Add these two together to get the total number of positive nodes. \n\n**Note 5:** **Related data item**\n* The number of examined pelvic nodes is recorded in the related data item 3900: Number of Examined Pelvic Nodes.", - "last_modified" : "2025-02-24T15:37:48.088Z", + "last_modified" : "2025-11-06T20:23:55.754Z", "definition" : [ { "key" : "num_pos_pelvic_nodes", "name" : "Code", @@ -18,6 +18,6 @@ } ], "rows" : [ [ "00", "All pelvic nodes examined negative" ], [ "01-99", "1 - 99 pelvic nodes positive \n(Exact number of nodes positive)" ], [ "X1", "100 or more pelvic nodes positive" ], [ "X2", "Positive pelvic nodes identified; number unknown" ], [ "X6", "Positive aspiration or core biopsy of pelvic lymph node(s)" ], [ "X8", "Not applicable: Information not collected for this case\n(If this item is required by your standard setter, use of code X8 will result in an edit error.)" ], [ "X9", "Not documented in medical record\nCannot be determined, indeterminate if positive pelvic nodes present\nNo lymph nodes removed\nPelvic lymph nodes not assessed or unknown if assessed" ] ], "additional_info" : "**Source documents:** pathology report, imaging reports, physical exam, other statements in medical record", - "coding_guidelines" : "**1)** Record the number of positive pelvic lymph nodes documented in the medical record.\n* Number of nodes positive must ALWAYS be less than or equal to number of nodes examined\n\n**2)** Record the number of positive pelvic lymph nodes documented in the medical record.\n**3)** **Code 00** for when there are no positive nodes\n**4)** **Code 01-99** for the exact number of positive nodes \n**5)** **Code X1** for 100 or more positive nodes\n**6)** **Code X2** for positive nodes, but unknown how many\n**7)** **Code X6** if only a FNA or core biopsy is done, and it is positive\n**8)** **Code X9** when\n* If only a FNA or core biopsy is done, and it is negative\n* Not documented in the medical record\n* Pelvic lymph nodes not evaluated (assessed)\n* No lymph nodes removed\n* Unknown if Pelvic lymph nodes evaluated (assessed)", + "coding_guidelines" : "**1)** Record the number of positive pelvic lymph nodes documented in the medical record.\n* Number of nodes positive must ALWAYS be less than or equal to number of nodes examined\n\n**2)** Record the number of positive pelvic lymph nodes documented in the medical record.\n\n**3)** **Code 00** for when there are no positive nodes\n\n**4)** **Code 01-99** for the exact number of positive nodes \n\n**5)** **Code X1** for 100 or more positive nodes\n\n**6)** **Code X2** for positive nodes, but unknown how many\n\n**7)** **Code X6** if only a FNA or core biopsy is done, and it is positive\n\n**8)** **Code X9** when\n* If only a FNA or core biopsy is done, and it is negative\n* Not documented in the medical record\n* Pelvic lymph nodes not evaluated (assessed)\n* No lymph nodes removed\n* Unknown if Pelvic lymph nodes evaluated (assessed)", "rationale" : "Number of Positive Pelvic Nodes is the number of positive nodes based on pelvic nodal dissection." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/occult_head_and_neck_lymph_nodes_10277.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/occult_head_and_neck_lymph_nodes_10277.json index f8c6b4049..a571f2a61 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/occult_head_and_neck_lymph_nodes_10277.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/occult_head_and_neck_lymph_nodes_10277.json @@ -5,8 +5,8 @@ "name" : "Schema Discriminator 1", "title" : "Schema Discriminator 1: Occult Head and Neck Lymph Nodes", "description" : "In AJCC 8th edition, a new chapter was introduced for situations when there are positive cervical nodes (head and neck nodes for Levels I-VII, and other group), however, the primary tumor is not evident (occult tumor), and the primary tumor is suspected to be from the head and neck region (primary sites C00-C14, C30-32). \n* If the differential diagnosis includes non-head and neck sites, the primary site should be coded to C809\n * ***Example***: path report states metastasis to the cervical lymph node could be from a head and neck primary, lung primary, or gynecologic primary\n* If there is no indication that the cervical lymph node is from a head and neck site, then the primary site should be coded to C809 \n* If the tumor is found to be EBV+ or p16+. See Coding Guidelines below.\n* If the tumor is suspected to be from a head and neck site, or a potential head and neck site is indicated by the physician, see Coding Guidelines below.\n\nTo develop a software algorithm that can be used to send the registrar to the right chapter/schema, this schema discriminator was developed. \nTo get to this schema discriminator, the registrar will code C760 (head and neck, NOS) when there is a suspected head and neck tumor, yet the primary site is not known, and/or the primary tumor was not identified. The schema discriminator will then be brought up. \n\n* Note: If the physician “suspects” or “assigns” a specific head and neck subsite, the registrar is still to assign C760 so that the correct staging information can be abstracted. \n * ***Example***: FNA of cervical lymph node metastases shows squamous cell carcinoma, p16 negative. Workup shows no evidence of primary tumor, although physician states this may be a laryngeal primary based on “best guess”. \n\n* Even though the primary site is suspected to be larynx, primary site would still be coded to C760. For all head and neck sites, except for Oropharynx HPV-Associated and Nasopharynx EBV positive, no evidence of primary tumor (T0) does not exist in the individual AJCC chapters or EOD schemas. These cases are collected as unknown head and neck primary (C760), which will have no evidence of primary tumor. This Schema ID was designed specifically to group together these cases of an occult primary, a tumor that is not identified on physical exam or imaging techniques.", - "notes" : "**Note:** **Schema Discriminator for C760** \n* This schema discriminator is used to discriminate between head and neck tumors with unknown primary site coded as C760. \n\t\n* **00060: Cervical Lymph Nodes and Unknown Primary**\n \n Occult head and neck tumor with cervical metastasis in Levels I-VII, and other group lymph nodes without a p16 immunostaining or with negative results and without an Epstein-Barr virus (EBV) encoded small RNAs (EBER) by in situ hybridization performed or with negative results are staged using the AJCC Cervical Lymph Nodes and Unknown Primary Tumors of the Head and Neck Staging System. **Assign primary site C760; code the schema discriminator accordingly.**\n\n* **00090: Nasopharynx 8th (2018-2024) and \n09090: Nasopharynx V9 (2025+)**\n \n Occult head and neck tumors with cervical metastasis in Levels I-VII, and other group lymph nodes that is positive for Epstein-Barr virus (EBV+) (regardless of p16 status) encoded small RNAs (EBER) identified by in situ hybridization are staged using the AJCC Nasopharynx Staging System. **Assign primary site C119; do NOT code this discriminator**\n\n* **00100: Oropharynx HPV-Associated 8th (2018-2025) and 09100: Oropharynx HPV-Associated V9 (2026+)**\n \n Occult head and neck tumors with cervical metastasis in Levels I-VII, and other group lymph nodes, p16 positive with histology consistent with HPV-associated oropharyngeal carcinoma (OPC), are staged using the AJCC Oropharynx HPV-Associated Staging System. **Assign primary site C109; do NOT code this discriminator**\n\n* **99999: Ill-Defined Other**\n\n If the tumor is not occult or does not have cervical metastasis in Levels I-VII, and other group lymph nodes, it is not included in the AJCC Cervical Lymph Nodes and Unknown Primary Tumors of the Head and Neck Staging System and will be classified as Ill-Defined Other for Summary Staging", - "last_modified" : "2025-08-12T15:46:32.655Z", + "notes" : "**Note:** **Schema Discriminator for C760** \n* This schema discriminator is used to discriminate between head and neck tumors with unknown primary site coded as C760. \n\t\n* **00060: Cervical Lymph Nodes and Unknown Primary**\n\n Occult head and neck tumor with cervical metastasis in Levels I-VII, and other group lymph nodes without a p16 immunostaining or with negative results and without an Epstein-Barr virus (EBV) encoded small RNAs (EBER) by in situ hybridization performed or with negative results are staged using the AJCC Cervical Lymph Nodes and Unknown Primary Tumors of the Head and Neck Staging System. **Assign primary site C760; code the schema discriminator accordingly.**\n\n* **00090: Nasopharynx 8th (2018-2024) and \n09090: Nasopharynx V9 (2025+)**\n\n Occult head and neck tumors with cervical metastasis in Levels I-VII, and other group lymph nodes that is positive for Epstein-Barr virus (EBV+) (regardless of p16 status) encoded small RNAs (EBER) identified by in situ hybridization are staged using the AJCC Nasopharynx Staging System. **Assign primary site C119; do NOT code this discriminator**\n\n* **00100: Oropharynx HPV-Associated 8th (2018-2025) and \n09100: Oropharynx HPV-Associated V9 (2026+)**\n\n Occult head and neck tumors with cervical metastasis in Levels I-VII, and other group lymph nodes, p16 positive with histology consistent with HPV-associated oropharyngeal carcinoma (OPC), are staged using the AJCC Oropharynx HPV-Associated Staging System. **Assign primary site C109; do NOT code this discriminator**\n\n* **99999: Ill-Defined Other**\n\n If the tumor is not occult or does not have cervical metastasis in Levels I-VII, and other group lymph nodes, it is not included in the AJCC Cervical Lymph Nodes and Unknown Primary Tumors of the Head and Neck Staging System and will be classified as Ill-Defined Other for Summary Staging", + "last_modified" : "2025-11-06T16:45:50.486Z", "definition" : [ { "key" : "discriminator_1", "name" : "Code", @@ -21,7 +21,7 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "0", "Not Occult", "99999: Ill Defined Other\n00459: Soft Tissue Other (8941/3 only)" ], [ "1", "Occult, Negative cervical nodes (regional head and neck nodes)", "99999: Ill Defined Other\n00459: Soft Tissue Other (8941/3 only)" ], [ "2", "Not tested for EBV or p16 in head and neck regional nodes (EBV and p16 both unknown)", "00060: Cervical Lymph Nodes and Unknown Primary" ], [ "3", "Unknown EBV, p16 negative in head and neck regional nodes", "00060: Cervical Lymph Nodes and Unknown Primary" ], [ "4", "Unknown p16, EBV negative in head and neck regional nodes", "00060: Cervical Lymph Nodes and Unknown Primary" ], [ "5", "Negative for both EBV and p16 in head and neck regional nodes", "00060: Cervical Lymph Nodes and Unknown Primary" ], [ "", "Not C760, discriminator does not apply\n\nPositive p16 in head and neck regional nodes, EBV unknown or negative\nAssign primary site C109\n\nPositive EBV in head and neck regional nodes, p16 positive, negative, or unknown\nAssign primary site C119", "Various \n\n00100: Oropharynx HPV-Associated 8th (2018-2025)\n09100: Oropharynx HPV-Associated V9 (2026+)\n\n00090: Nasopharynx 8th (2018-2024)\n09090: Nasopharynx V9 (2025+)" ] ], - "additional_info" : "**Source documents:** imaging, pathology report, p16 results, EBV results.", + "additional_info" : "**Source documents:** imaging, pathology report, p16 results, EBV results", "coding_guidelines" : "**1)** **Code 0: Not occult**\n* Primary tumor is evident in the head and neck region; however, a specific primary site cannot be identified. \n* If overlapping lesions are evident and the primary site cannot be determined, this would not be a C760, but C148 (overlapping lesions) (Schema ID 00118: Pharynx Other)\n* For tumors in this category, C760 should be used sparingly. If C760 is assigned, this would be collected in the following schemas: Schema ID 99999: Ill-Defined Other OR Schema ID 00450: Soft Tissue Other (if specified sarcoma) \n * ***Examples include*** Cases with limited information, historical case\n\n**2)** **Code 1: Occult, Negative cervical nodes (regional head and neck nodes** \n* No evidence of primary tumor or positive cervical lymph nodes (head and neck regional lymph nodes), suspected head and neck primary. \n* This type of situation would be rare but would probably be diagnosed based on metastatic disease, including distant lymph nodes (Mediastinal [excluding superior mediastinal node(s)])\n* This case would be collected in the **Ill-Defined Other** schema, or **Soft Tissue Other** (if specified sarcoma).\n\n**3)** **Code 2: Not tested for EBV or p16 in head and neck regional nodes (EBV and p16 both unknown)** \n* There is no documentation in the record regarding p16 or EBV.\n\n**4)** **Code 3: Unknown EBV, p16 negative in head and neck regional nodes** \n* p16 is done and reported as negative. No documentation in the medical record regarding EBV. \n\n**5)** **Code 4: Unknown p16, EBV negative in head and neck regional nodes** \n* EBV done and reported as negative. No documentation in the medical record regarding p16. \n\n**6)** **Code 5: Negative for both EBV and p16 in head and neck regional nodes** \n* Both EBV and p16 done and reported as negative", "rationale" : "A schema discriminator is used to assign AJCC ID when site and histology alone are insufficient to identify the applicable AJCC staging method and to assign Schema ID, which links each case to the appropriate SSDIs, Summary Stage and EOD data collection system." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/oncotype_dx_recur_score_73667.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/oncotype_dx_recur_score_73667.json index dba3f0ecb..7d7486aa0 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/oncotype_dx_recur_score_73667.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/oncotype_dx_recur_score_73667.json @@ -6,7 +6,7 @@ "title" : "Oncotype Dx Recurrence Score - Invasive", "description" : "Oncotype Dx Recurrence Score-Invasive is a numeric score of a genomic test to predict the likelihood of distant recurrence of invasive breast cancer based on the assessment of 21 genes. \n\nThe Oncotype DX Breast Recurrence Score test (Oncotype DX) test is a genomic test that predicts the risk of distant recurrence and likelihood of benefit chemotherapy for early-stage breast cancers. It is required for assigning prognostic stage in AJCC 8th edition for patients with T1-2 N0, M0, ER-positive, HER2 negative breast cancers. Oncotype DX provides a quantitative score, based on a continuous scale from 0-100, with higher scores reflecting higher risk of distant recurrence and higher likelihood of chemotherapy benefit.", "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of Oncotype Dx Recurrence Score-Invasive score can be used to code this data item when no other information is available.\n\n**Note 2:** **Type of Test**\n* Record only the results of an Oncotype Dx-Invasive recurrence score in this data item. If some other test is used for scoring, assign code XX9.\n* Predicted Oncotype Dx Recurrence Score based on linear regression models and Magee equations should not be reported in this field.\n * Code unknown If the only information you have on Oncotype Dx is based on a linear regression model and Magee score\n\n**Note 3:** **Staging related** \n* Staging for Breast cancer now depends on the Oncotype-Dx-Invasive recurrence score. Score of less than 11 indicates a pertinent cut off value for staging purposes. \n\n**Note 4:** **Results from nodal or metastatic tissue**\n* May be used, ONLY when there is no evidence of primary tumor\n * **Note:** In-situ is evidence of primary tumor\n\n**Note 5:** **Multiple tests, multiple results**\n* In cases where Oncotype DX is reported on more than one breast tumor specimen, record the highest value. \n\n**Note 6:** **Related data item** \n* Code this data item using the same report used to record the related data item 3906: Oncotype Dx Risk Level-Invasive.", - "last_modified" : "2025-02-24T14:50:57.182Z", + "last_modified" : "2025-11-06T18:52:03.561Z", "definition" : [ { "key" : "oncotype_dx_score", "name" : "Code", @@ -18,6 +18,6 @@ } ], "rows" : [ [ "000-100", "Enter actual recurrence score between 0 and 100" ], [ "XX4", "Stated as less than 11" ], [ "XX5", "Stated as equal to or greater than 11" ], [ "XX6", "Not applicable, in situ case" ], [ "XX7", "Test ordered, results not in chart" ], [ "XX9", "Not documented in medical record\nOncotype Dx Recurrence Score-Invasive not assessed or unknown if assessed" ] ], "additional_info" : "**Source documents:** Oncotype Dx Breast Recurrence Score laboratory report, other statements in medical record", - "coding_guidelines" : "**1)** Code 01-100 for the actual recurrence score\n* The actual recurrence score takes priority over codes XX4 and XX5.\n\n**2)** Code XX6 if the case is in-situ (/2)\n**3)** Code XX7 If the only information available is the Oncotype Dx-Invasive Risk Level\n**4)** Code XX9 when Oncotype DX recurrence score\n* Cannot be determined by the pathologist (e.g., inadequate specimen)\n* It is unknown whether the Oncotype DX recurrence score test was performed\n* The patient has only a clinical diagnosis of breast cancer (no tissue diagnosis)", + "coding_guidelines" : "**1)** Code 01-100 for the actual recurrence score\n* The actual recurrence score takes priority over codes XX4 and XX5.\n\n**2)** Code XX6 if the case is in-situ (/2)\n\n**3)** Code XX7 If the only information available is the Oncotype Dx-Invasive Risk Level\n\n**4)** Code XX9 when Oncotype DX recurrence score\n* Cannot be determined by the pathologist (e.g., inadequate specimen)\n* It is unknown whether the Oncotype DX recurrence score test was performed\n* The patient has only a clinical diagnosis of breast cancer (no tissue diagnosis)", "rationale" : "Oncotype Dx Recurrence Score-Invasive is a Registry Data Collection Variable in AJCC. It is a new data item for cases diagnosed 1/1/2018+." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/oncotype_dx_recurrence_score_dcis_70549.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/oncotype_dx_recurrence_score_dcis_70549.json index 2525bdf89..55077f702 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/oncotype_dx_recurrence_score_dcis_70549.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/oncotype_dx_recurrence_score_dcis_70549.json @@ -6,7 +6,7 @@ "title" : "Oncotype Dx Recurrence Score - DCIS", "description" : "Oncotype Dx Recurrence Score-DCIS is a numeric score of a genomic test to predict the likelihood of distant recurrence of invasive breast cancer based on the assessment of 21 genes.\n\nThe Oncotype DX DCIS score is a genomic test that estimates the likelihood of local recurrence (DCIS or invasive) for a patient with DCIS. The results may be used clinically to evaluate benefits of radiation therapy following surgery.", "notes" : "**Note 1:** **Physician statement**\n* Physician statement of Oncotype Dx Recurrence Score-DCIS can be used to code this data item when no other is available.\n\n**Note 2:** **Type of Test**\n* Record only the results of an Oncotype Dx-DCIS recurrence score in this data item. If some other test is used for scoring, assign code XX9.\n\n**Note 3:** **Multiple tests, multiple results**\n* In cases where Oncotype Dx-DCIS is reported on more than one in situ breast tumor specimen, record the highest value.\n\n**Note 4:** **Related data item** \n* Code this data item using the same report used to record the related data item 3905: Oncotype Dx Risk Level-DCIS.", - "last_modified" : "2025-02-24T14:52:14.338Z", + "last_modified" : "2025-11-06T19:57:41.681Z", "definition" : [ { "key" : "oncotype_dx_score_dcis", "name" : "Code", @@ -18,6 +18,6 @@ } ], "rows" : [ [ "000-100", "Enter actual recurrence score between 0 and 100" ], [ "XX6", "Not applicable, invasive case" ], [ "XX7", "Test ordered, results not in chart" ], [ "XX8", "Not applicable: Information not collected for this case\n(If this item is required by your standard setter, use of code XX8 will result in an edit error.)" ], [ "XX9", "Not documented in medical record\nOncotype Dx recurrence score-DCIS not assessed or unknown if assessed" ] ], "additional_info" : "**Source documents:** Oncotype Dx DCIS laboratory report, other statements in medical record", - "coding_guidelines" : "**1)** **Code 01-100** for the actual recurrence score\n* The actual recurrence score takes priority over codes XX4 and XX5\n\n**2)** **Code XX6** if the case is invasive (/3)\n**3)** **Code XX7** If the only information available is the Oncotype Dx-DCIS Risk Level\n**4)** **Code XX9** when Oncotype DX recurrence score\n* LCIS tumors\n* Cannot be determined by the pathologist (e.g., inadequate specimen)\n* It is unknown whether the Oncotype DX recurrence-DCIS score test was performed\n* The patient has only a clinical diagnosis of breast cancer (no tissue diagnosis)", + "coding_guidelines" : "**1)** **Code 01-100** for the actual recurrence score\n* The actual recurrence score takes priority over codes XX4 and XX5\n\n**2)** **Code XX6** if the case is invasive (/3)\n\n**3)** **Code XX7** If the only information available is the Oncotype Dx-DCIS Risk Level\n\n**4)** **Code XX9** when Oncotype DX recurrence score\n* LCIS tumors\n* Cannot be determined by the pathologist (e.g., inadequate specimen)\n* It is unknown whether the Oncotype DX recurrence-DCIS score test was performed\n* The patient has only a clinical diagnosis of breast cancer (no tissue diagnosis)", "rationale" : "Oncotype Dx Recurrence Score-DCIS is a Registry Data Collection Variable in AJCC. It is a new data item for cases diagnosed 1/1/2018+." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/oncotype_dx_risk_level_11033.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/oncotype_dx_risk_level_11033.json index 389a3ad38..0c7645271 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/oncotype_dx_risk_level_11033.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/oncotype_dx_risk_level_11033.json @@ -4,9 +4,9 @@ "version" : "3.3", "name" : "Oncotype DX Risk Level-Invasive", "title" : "Oncotype Dx Risk Level-Invasive", - "description" : "Oncotype Dx Risk Level-Invasive stratifies Oncotype Dx recurrence scores into low, intermediate, and high risk of distant recurrence. \n\nThe numeric value of the recurrence score is coded in Data Item #3906. When the actual recurrence score is not available, there is an option for coding recurrence scores stated as less than 11 or greater than equal to 11 as this the cut point determined to be clinically relevant for stage group in AJCC8. Oncotype DX Risk Level -Invasive, coded in NAACCR Data Item #3906, stratifies the Oncotype DX recurrence score into three risk levels \n* **Low risk: Recurrence Score result less than 18:** The patient has a lower risk of having a recurrence, assuming 5 years of hormonal therapy is given. Chemotherapy is likely to have little or no benefit.\n* **Intermediate Risk: Recurrence Score result between 18 and 30:** The patient has a tumor that is in the middle of the risk spectrum reflecting that biology is continuous and not all patients have a low or a high recurrence risk, assuming 5 years of hormonal therapy is given. The likelihood of distant recurrence and benefit from chemotherapy increases with an increase in the Recurrence Score result.\n* **High risk: Recurrence Score result greater than or equal to 31:** The patient has a high risk of distant recurrence, assuming 5 years of hormonal therapy and is likely to benefit from\n.", + "description" : "Oncotype Dx Risk Level-Invasive stratifies Oncotype Dx recurrence scores into low, intermediate, and high risk of distant recurrence. \n\nThe numeric value of the recurrence score is coded in Data Item #3906. When the actual recurrence score is not available, there is an option for coding recurrence scores stated as less than 11 or greater than equal to 11 as this the cut point determined to be clinically relevant for stage group in AJCC8. Oncotype DX Risk Level -Invasive, coded in NAACCR Data Item #3906, stratifies the Oncotype DX recurrence score into three risk levels \n* **Low risk: Recurrence Score result less than 18:** The patient has a lower risk of having a recurrence, assuming 5 years of hormonal therapy is given. Chemotherapy is likely to have little or no benefit.\n* **Intermediate Risk: Recurrence Score result between 18 and 30:** The patient has a tumor that is in the middle of the risk spectrum reflecting that biology is continuous and not all patients have a low or a high recurrence risk, assuming 5 years of hormonal therapy is given. The likelihood of distant recurrence and benefit from chemotherapy increases with an increase in the Recurrence Score result.\n* **High risk: Recurrence Score result greater than or equal to 31:** The patient has a high risk of distant recurrence, assuming 5 years of hormonal therapy and is likely to benefit from chemotherapy.\n.", "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of Oncotype Dx Risk Level-Invasive can be used to code this data item when no other information is available.\n\n**Note 2:** **Related data item** \n* Code this data item using the same report used to record the related data item 3904: Oncotype Dx Recurrence Score-Invasive.", - "last_modified" : "2024-04-08T20:06:25.489Z", + "last_modified" : "2025-11-14T15:55:36.053Z", "definition" : [ { "key" : "oncotype_dx_risk_level", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/oropharyngeal_p16_44685.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/oropharyngeal_p16_44685.json index e296c82e0..ef3759d60 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/oropharyngeal_p16_44685.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/oropharyngeal_p16_44685.json @@ -4,9 +4,9 @@ "version" : "3.3", "name" : "Schema Discriminator 2", "title" : "Schema Discriminator 2: Oropharyngeal p16", - "description" : "Staging for oropharyngeal cancers changed in the AJCC 8th edition. Oropharynx was divided into **Oropharynx HPV-Associated (p16+)** and **Oropharynx HPV-Independent (p16-).** A schema discriminator is necessary to determine the HPV status so that the appropriate protocol/schema is used.\n\nThere are several methods for determination of HPV status. The most frequent, and preferred test is IHC for p16 expression, which is a surrogate marker for transcriptionally active high-risk HPV\n* Other tests that may be used for this data item **in addition to p16 or when p16 is not available** include (but are not limited to)\n * High-risk HPV RNA ISH\n * High-risk HPV DNA ISH\n* Other tests that may be used for this data item **in addition to p16 include** but are not limited to\n * High-risk HPV DNA PCR\n\n**High-risk** HPV types include: 16, 18, 26, 31, 33, 34, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 70, 73, and 82.\n\n**Low-risk (cannot be used to determine HPV status)** HPV types include: 6, 11, 42, 43, and 44.", + "description" : "Staging for oropharyngeal cancers changed in the AJCC 8th edition. Oropharynx was divided into **Oropharynx HPV-Associated (p16+)** and **Oropharynx HPV-Independent (p16-).** A schema discriminator is necessary to determine the HPV status so that the appropriate protocol/schema is used.\n\nThere are several methods for determination of HPV status. The most frequent, and preferred test is IHC for p16 expression, which is a surrogate marker for transcriptionally active high-risk HPV.\n* Other tests that may be used for this data item **in addition to p16 or when p16 is not available** include (but are not limited to)\n * High-risk HPV RNA ISH\n * High-risk HPV DNA ISH\n* Other tests that may be used for this data item **in addition to p16 include** but are not limited to\n * High-risk HPV DNA PCR\n\n**High-risk** HPV types include: 16, 18, 26, 31, 33, 34, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 70, 73, and 82.\n\n**Low-risk (cannot be used to determine HPV status)** HPV types include: 6, 11, 42, 43, and 44.", "notes" : "**Note 1:** **Schema discriminator for Oropharynx** \n* A schema discriminator is used to discriminate between oropharyngeal tumors that are p16 positive and oropharyngeal tumors that are p16 negative OR p16 status unknown. \n\n**Note 2:** **p16 testing** \n* p16 testing will guide classification of most patients but some will have HPV-specific testing that should be used in conjunction for classification when the pathologist performs it.\n\n* **00100: Oropharynx HPV-Associated (p16+) (see code 2)**\n * p16 positive and it is the only test performed\n * p16 positive when subsequent high-risk HPV-specific testing is performed and is positive\n * p16 equivocal (50-70% staining) when subsequent high-risk HPV-specific testing is performed and is positive\n * p16 not performed but when high-risk HPV-specific testing is positive (High-risk HPV RNA ISH or high-risk HPV DNA ISH when performed alone). \n * High-risk HPV DNA PCR testing if used alone is not reliable to assign HPV status.\n * Stated as **HPV-associated** or **High-risk HPV**\n\n* **00111: Oropharynx HPV-Independent (p16-) (see code 1)**\n * p16 negative and it is the only test performed\n * p16 expression of limited (<50%) distribution only \n * p16 positive but when subsequent reliable high-risk HPV-specific testing is performed and is negative (reliable high-risk HPV-specific tests include high-risk HPV RNA ISH and high-risk HPV DNA PCR)\n * Stated as **Oropharynx-Independent**\n\n* **HPV testing not done or unknown if done (see code 9)**\n * Cases coded as unknown will be included with the Oropharynx HPV-Independent (p16-) schema\n * Stated as **HPV positive** and no indication if it’s p16, low risk or high risk\n * Stated as **low risk HPV**", - "last_modified" : "2025-08-12T12:53:41.352Z", + "last_modified" : "2025-11-06T17:19:04.985Z", "definition" : [ { "key" : "discriminator_2", "name" : "Code", @@ -21,6 +21,6 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "1", "p16 Negative; Nonreactive", "00111: Oropharynx HPV-Independent" ], [ "2", "p16 positive with **extensive** (>70%) moderate to strong reactivity\n* WITH or WITHOUT positive high-risk HPV-specific testing\n\nOr in rare instances, high-risk HPV specific testing positive alone", "00100: Oropharynx HPV-Associated 8th (2018-2025)\n09100: Oropharynx HPV-Associated V9 (2026+)" ], [ "9", "Not tested for p16; Unknown", "00111: Oropharynx HPV-Independent" ] ], - "additional_info" : "**Source documents:** pathology report, clinician's statement\n\nFor further information, refer to the **HPV-associated Squamous Cell Carcinoma of the Oropharynx** or the **HPV-independent Oropharynx and Hypopharynx** cancer protocols published by the College of American Pathologist for the AJCC Staging Systems *Oropharynx-Associated* and *Oropharynx-Independent*", + "additional_info" : "**Source documents:** pathology report, clinician's statement\n\nFor further information, refer to the **HPV-associated Squamous Cell Carcinoma of the Oropharynx** or the **HPV-independent Oropharynx and Hypopharynx** cancer protocols published by the College of American Pathologist for the AJCC Staging Systems *Oropharynx-Associated* and *Oropharynx-Independent*.", "rationale" : "A schema discriminator is used to assign AJCC ID when site and histology alone are insufficient to identify the applicable AJCC staging method and to assign Schema ID, which links each case to the appropriate SSDIs, Grade, Summary Stage and EOD data collection system." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/p16_831.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/p16_831.json index 9d1272f70..8d03c999b 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/p16_831.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/p16_831.json @@ -4,9 +4,9 @@ "version" : "3.3", "name" : "p16", "title" : "p16", - "description" : "The p16 biomarker is overexpressed (produced) in response to HPV. It is therefore a surrogate marker for HPV disease.\np16 is a tumor suppressor protein also known as cyclin-dependent kinase inhibitor 2A. The p16 biomarker is overexpressed (produced) in response to HPV. It is therefore a surrogate marker for HPV disease.", + "description" : "The p16 biomarker is overexpressed (produced) in response to HPV. It is therefore a surrogate marker for HPV disease.\n\np16 is a tumor suppressor protein also known as cyclin-dependent kinase inhibitor 2A. The p16 biomarker is overexpressed (produced) in response to HPV. It is therefore a surrogate marker for HPV disease.", "notes" : "**Note 1:** **Effective years**\n* This SSDI is effective for diagnosis years 2024+\n* For cases diagnosed 2018-2023, this SSDI must be blank\n\n**Note 2:** **p16 Results ONLY**\n* This data item must be based on testing results for p16 overexpression.\n* Testing for HPV by DNA, mRNA, antibody, or other methods should not be coded in this data item\n* Do not confuse p16 with HPV, which is a specific strain of virus. A statement of a patient being HPV positive, or negative is not enough to code this data item\n* Code 0 for p16 expression of weak intensity or limited distribution.", - "last_modified" : "2024-04-06T14:17:04.159Z", + "last_modified" : "2025-11-06T20:13:12.313Z", "definition" : [ { "key" : "p16", "name" : "p16", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/p16_anus_2709.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/p16_anus_2709.json index 0cd8e1d73..5ec26030e 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/p16_anus_2709.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/p16_anus_2709.json @@ -6,7 +6,7 @@ "title" : "p16", "description" : "The p16 biomarker is overexpressed (produced) in response to HPV. It is therefore a surrogate marker for HPV disease.\n\np16 is a tumor suppressor protein also known as cyclin-dependent kinase inhibitor 2A.\n\nThe p16 biomarker is overexpressed (produced) in response to HPV. It is therefore a surrogate marker for HPV disease.", "notes" : "**Note 1:** **Effective years**\n* This SSDI is effective for diagnosis years 2023+\n* For cases diagnosed 2018-2022, this SSDI must be blank\n\n**Note 2:** **p16 Results ONLY**\n* This data item must be based on testing results for p16 overexpression.\n* Testing for HPV by DNA, mRNA, antibody, or other methods should not be coded in this data item\n* Do not confuse p16 with HPV, which is a specific strain of virus. A statement of a patient being HPV positive or negative is not enough to code this data item.", - "last_modified" : "2024-04-04T19:04:00.023Z", + "last_modified" : "2025-11-06T18:08:19.641Z", "definition" : [ { "key" : "p16", "name" : "p16", @@ -18,6 +18,6 @@ } ], "rows" : [ [ "0", "p16 Negative; Nonreactive" ], [ "1", "p16 Positive; Diffuse, Strong reactivity" ], [ "8", "Not applicable: Information not collected for this case\n(If this time is required by your standard setter, use of code 8 will result in an edit error)" ], [ "9", "Not tested for p16; Unknown" ], [ "", "Must be blank if diagnosis year is before 2023" ] ], "additional_info" : "**Source documents:** pathology report, physician's statement", - "coding_guidelines" : "* **Code 0** for p16 expression of weak intensity or limited distribution.", + "coding_guidelines" : "**Code 0** for p16 expression of weak intensity or limited distribution.", "rationale" : "Patients with HPV have a different survival or outcome, so it is important to be able to distinguish this by documenting the p16 results. Testing is performed by immunohistochemistry (IHC) which is inexpensive and has near universal availability. It has an easily standardized interpretation. HPV testing is usually performed through DNA testing which is more expensive and less widely available. HPV testing also has technically more variability with the interpretation." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/pd_l1_61573.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/pd_l1_61573.json index 47efc190f..d36ac8f03 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/pd_l1_61573.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/pd_l1_61573.json @@ -6,7 +6,7 @@ "title" : "PD-L1", "description" : "The absence or presence of PD-L1 expression determines if the tumor will respond to treatment with a targeted inhibitor (immunotherapy). PD-L1 is done for Non-Small Cell lung cancers (NSCLC).\n\nThis test is usually done on metastatic non-small cell lung cancer (NSCLC) patients. An assay is performed on formalin-fixed, paraffin-embedded (FFPE) tissue specimen of at least 100 cells taken from the patient. The assay is used to determine the PD-L1 expression by IHC. Then the pathologist determines the tumor proportion score. The treating physician uses that information to determine what type of treatment the patient will receive.", "notes" : "**Note 1:** **Effective years**\n* This SSDI is effective for diagnosis years 2025+\n* For cases diagnosed 2018-2024, this SSDI must be blank\n\n**Note 2:** **Physician Statement** \n* Physician statement PD-L1 can be used to code this data item when no other information is available.\n\n**Note 3:** **Purpose of PD-L1** \n* The absence or presence of PD-L1 expression determines if the tumor will respond to treatment with a targeted inhibitor (immunotherapy). PD-L1 is done for Non-Small Cell lung cancers (NSCLC). \n\n**Note 4:** **Tumor Proportion Score**\n* PD-L1 is documented by the tumor proportion score. Record the actual Tumor Proportion Score (0.0-100.0) as stated from the pathology report.\n* An actual tumor proportion score (0.1-100.0) takes priority over XXX.2 (Stated as negative), XXX.3 (Stated as low), or XXX.4 (Stated as high/positive)\n\n**Note 5:** **Combined Proportion Score (CPS)**\n* Do not record the CPS score (0.0-100.0) in this data item. \n * If you have a CPS score WITH an interpretation, record the interpretation. \n * ***Example:*** Squamous cell carcinoma: NEGATIVE for PD-L1 Expression, CPS score <1. Record as XXX.2 for negative\n * If you have a CPS score WITHOUT an interpretation, record unknown (XXX.9). \n * ***Example:*** Squamous cell carcinoma: PD-L1, CPS score <1. Record as XXX.9 for unknown (interpretation not provided)\n\n**Note 6:** **Neoadjuvant therapy** If neoadjuvant therapy is given, record the assay from tumor specimens prior to neoadjuvant therapy. \n* If neoadjuvant therapy is given and there are no PD-L1 results from pre-treatment specimens, report the findings from post-treatment specimens", - "last_modified" : "2025-09-15T13:54:51.246Z", + "last_modified" : "2025-11-06T18:31:00.147Z", "definition" : [ { "key" : "pdl1", "name" : "Code", @@ -17,6 +17,6 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "0.0", "No PD-L1 expression identified\nTumor Proportion Score (TPS) = 0%" ], [ "0.1-100.0", "0.1-100.0 PD-L1 expression\nTumor Proportion Score (TPS) = 0.1%-100.0%" ], [ "XXX.2", "PD-L1 expression absent **AND**\nTumor Proportion Score (TPS) stated as negative" ], [ "XXX.3", "PD-L1 expression present **AND**\nTumor Proportion Score (TPS) stated as low" ], [ "XXX.4", "PD-L1 expression present **AND**\nTumor Proportion Score (TPS) stated as high/positive" ], [ "XXX.7", "Test ordered, results not in chart" ], [ "XXX.8", "Not applicable: Information not collected for this case\n(If this item is required by your standard setter, use of code 8 will result in an edit error)" ], [ "XXX.9", "Not documented in medical record\nNo microscopic confirmation of tumor\nPD-L1 cannot be determined\nPD-L1 not assessed or unknown if assessed" ], [ "", "N/A - Diagnosis year is prior to 2025" ] ], - "additional_info" : "**Source documents**: pathology report\n\nFor further information, refer to the **Lung Biomarker Reporting** cancer protocol published by the College of American Pathologists", + "additional_info" : "**Source documents**: pathology report\n\nFor further information, refer to the **Lung Biomarker Reporting** cancer protocol published by the College of American Pathologists.", "rationale" : "PD-L1 is recommended by treatment guidelines for lung cancer to determine if the patient may benefit from checkpoint inhibitor drugs (immunotherapy). **It is a new data item for cases diagnosed 1/1/2025+.**" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/perineural_invasion_27557.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/perineural_invasion_27557.json index b379cb327..720bf1c21 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/perineural_invasion_27557.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/perineural_invasion_27557.json @@ -6,7 +6,7 @@ "title" : "Perineural Invasion", "description" : "Perineural Invasion, within or adjacent to the primary tumor, is a negative prognostic factor for cutaneous squamous cell carcinomas of the head and neck and carcinomas of the colon and rectum, eyelid, and lacrimal gland.\n\nPerineural invasion is infiltration of nerves in the area of the lesion by tumor cells or spread of tumor along the nerve pathway. The presence of perineural invasion has been shown in several studies to be an indicator of poor patient prognosis. If perineural invasion is not mentioned in the pathology report, do not assume that there is no perineural invasion.", "notes" : "**Note 1:** **Physician Statement**\n* Physician statement of microscopically confirmed perineural invasion can be used to code this data item when no other information is available.\n\n**Note 2:** **Pathology report from a biopsy or surgical resection**\n* Information on **presence** of perineural invasion **must be from a pathology report** (biopsy or surgical resection) \n* Absence of perineural invasion **can only be taken from a surgical resection pathology report**\n\n**Note 3:** **Perineural Invasion not documented on pathology report**\n* Code 9 if surgical resection of the primary site is performed and there is no mention of perineural invasion.\n* Do not assume that there is no perineural invasion when there is no mention of it on the pathology report", - "last_modified" : "2024-05-08T21:22:56.425Z", + "last_modified" : "2025-11-05T21:38:15.231Z", "definition" : [ { "key" : "perineural_invasion", "name" : "Code", @@ -17,7 +17,7 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "0", "Perineural invasion not identified/not present\nNon-invasive neoplasm (behavior /2)" ], [ "1", "Perineural invasion identified/present" ], [ "8", "Not applicable: Information not collected for this case\n(If this information is required by your standard setter, use of code 8 may result in an edit error.)" ], [ "9", "Not documented in medical record\nPathology report does not mention perineural invasion\nCannot be determined by the pathologist\nPerineural invasion not assessed or unknown if assessed" ] ], - "additional_info" : "**Source documents:** pathology report\n\n**Other names include** PIN, neurotropism \n\nFor further information refer to the **Colon and Rectum** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Colon and Rectum*", + "additional_info" : "**Source documents:** pathology report\n\n**Other names include** PIN, neurotropism \n\nFor further information refer to the **Colon and Rectum** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Colon and Rectum*.", "coding_guidelines" : "**Code 0 when there is an in situ/non-invasive neoplasm (behavior /2)**\n* By definition, in situ tumors cannot have perineural invasion\n* There are no surgical requirements for an in situ tumor", "rationale" : "Perineural Invasion is a Registry Data Collection Variable in AJCC. It was previously collected as Colon and Rectum CS SSF #8." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/perineural_invasion_84622.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/perineural_invasion_84622.json index 5891af7cf..57f2a82f7 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/perineural_invasion_84622.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/perineural_invasion_84622.json @@ -6,7 +6,7 @@ "title" : "Perineural Invasion", "description" : "Perineural Invasion, within or adjacent to the primary tumor, is a negative prognostic factor for cutaneous squamous cell carcinomas of the head and neck and carcinomas of the colon and rectum, eyelid, and lacrimal gland.\n\nPerineural invasion is infiltration of nerves in the area of the lesion by tumor cells or spread of tumor along the nerve pathway. The presence of perineural invasion has been shown in several studies to be an indicator of poor patient prognosis. If perineural invasion is not mentioned in the pathology report, do not assume that there is no perineural invasion.", "notes" : "**Note 1:** **Physician Statement**\n* Physician statement of microscopically confirmed perineural invasion can be used to code this data item when no other information is available.\n\n**Note 2:** **Pathology report from a biopsy or surgical resection**\n* Information on **presence** of perineural invasion **must be from a pathology report** (biopsy or surgical resection) \n* Absence of perineural invasion **can only be taken from a surgical resection pathology report**\n\n**Note 3:** **Perineural Invasion not documented on pathology report**\n* Code 9 if surgical resection of the primary site is performed and there is no mention of perineural invasion.\n* Do not assume that there is no perineural invasion", - "last_modified" : "2024-04-08T15:31:38.650Z", + "last_modified" : "2025-11-05T21:40:40.227Z", "definition" : [ { "key" : "perineural_invasion", "name" : "Code", @@ -17,6 +17,6 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "0", "Perineural invasion not identified/not present\nNon-invasive neoplasm (behavior /2)" ], [ "1", "Perineural invasion identified/present" ], [ "8", "Not applicable: Information not collected for this case\n(If this information is required by your standard setter, use of code 8 may result in an edit error.)" ], [ "9", "Not documented in medical record\nPathology report does not mention perineural invasion\nCannot be determined by the pathologist\nPerineural invasion not assessed or unknown if assessed" ] ], - "additional_info" : "**Source documents:** pathology report\n\n**Other names include** PNI, neurotropism\n\nFor further information, refer to the **Cutaneous Carcinoma of Head and Neck** cancer protocols published by the College of American Pathologist for the AJCC Staging Systems for *Cutaneous Carcinoma of Head and Neck*", + "additional_info" : "**Source documents:** pathology report\n\n**Other names include** PNI, neurotropism\n\nFor further information, refer to the **Cutaneous Carcinoma of Head and Neck** cancer protocols published by the College of American Pathologist for the AJCC Staging Systems for *Cutaneous Carcinoma of Head and Neck*.", "rationale" : "Perineural Invasion is a Registry Data Collection Variable in AJCC. It was previously collected as Skin, SSF #11." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/peritoneal_cytology_38674.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/peritoneal_cytology_38674.json index 61ff6836a..43f6875d6 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/peritoneal_cytology_38674.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/peritoneal_cytology_38674.json @@ -6,7 +6,7 @@ "title" : "Peritoneal Cytology", "description" : "Peritoneal cytology pertains to the results of cytologic examination for malignant cells performed on fluid that is obtained from the peritoneal cavity.\n\nPeritoneal cytology looks for malignant cells in the fluid in the pelvic and peritoneal cavities. Excess natural fluid accumulation is called ascites. If, at laparotomy an analyzable amount of ascites is not present, the surgeon may flood the pelvis and abdomen with saline solution then suction it out and send the fluid for cytologic examination.", "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of Peritoneal Cytology can be used to code this data item when no other information is available.\n\n**Note 2:** **Other names for Peritoneal cytology**\n* Peritoneal cytology may also be called peritoneal ascitic fluid instead of peritoneal washing or pelvic washing (see also Additional information)\n\n**Note 3:** **Ascites examination**\n* Cytologic examination for malignant cells may be performed on ascites (fluid that has accumulated in the peritoneal cavity in excess amount) or the fluid (saline) that is introduced into the peritoneal cavity or pelvis, and then removed by suction. The introduction of fluid may be termed peritoneal or pelvic washing or peritoneal lavage", - "last_modified" : "2025-02-24T15:40:18.884Z", + "last_modified" : "2025-11-06T20:26:27.011Z", "definition" : [ { "key" : "peritoneal_cytology", "name" : "Code", @@ -17,7 +17,7 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "0", "Peritoneal cytology/washing negative for malignancy" ], [ "1", "Peritoneal cytology/washing atypical and/or suspicious" ], [ "2", "Peritoneal cytology/washing malignant (positive for malignancy)" ], [ "3", "Unsatisfactory/nondiagnostic" ], [ "7", "Test ordered, results not in chart" ], [ "8", "Not applicable: Information not collected for this case\n(If this item is required by your standard setter, use of code 8 will result in an edit error.)" ], [ "9", "Not documented in medical record\nPeritoneal cytology not assessed or unknown if assessed" ] ], - "additional_info" : "**Source documents:** cytology reports (look for multiple reports), pathology report\n\n**Other names include** peritoneal washings, peritoneal lavage, possibly paracentesis (if no surgery), peritoneal ascitic fluid instead of peritoneal washing or pelvic washing.", - "coding_guidelines" : "**1)** **Code 0** when the peritoneal cytology is reported as negative or normal\n**2)** **Code 1** when the peritoneal cytology test was done, and the results were reported as suspicious, undetermined if negative or positive\n**3)** **Code 2** when the peritoneal cytology is reported as positive\n**4)** **Code 7** when test was ordered but the results are not in the medical record\n**5)** **Code 9** when\n* No cytological specimen is available\n* Peritoneal cytology not evaluated (assessed)\n* Unknown if Peritoneal Cytology evaluated (assessed)", + "additional_info" : "**Source documents:** cytology reports (look for multiple reports), pathology report\n\n**Other names include** peritoneal washings, peritoneal lavage, possibly paracentesis (if no surgery), peritoneal ascitic fluid instead of peritoneal washing or pelvic washing", + "coding_guidelines" : "**1)** **Code 0** when the peritoneal cytology is reported as negative or normal\n\n**2)** **Code 1** when the peritoneal cytology test was done, and the results were reported as suspicious, undetermined if negative or positive\n\n**3)** **Code 2** when the peritoneal cytology is reported as positive\n\n**4)** **Code 7** when test was ordered but the results are not in the medical record\n\n**5)** **Code 9** when\n* No cytological specimen is available\n* Peritoneal cytology not evaluated (assessed)\n* Unknown if Peritoneal Cytology evaluated (assessed)", "rationale" : "Peritoneal Cytology is listed as a Registry Data Collection Variable in AJCC. This data item was previously collected as Corpus, CS SSF #2." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/post_neoadj_chemo_percent_necrosis_15912.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/post_neoadj_chemo_percent_necrosis_15912.json index 014446990..73652c658 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/post_neoadj_chemo_percent_necrosis_15912.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/post_neoadj_chemo_percent_necrosis_15912.json @@ -6,7 +6,7 @@ "title" : "Percent Necrosis Post Neoadjuvant", "description" : "Percent Necrosis Post Neoadjuvant is a prognostic factor for bone sarcomas. \n\nFor osteosarcoma and Ewing’s sarcoma/PNET, response to neoadjuvant chemotherapy is a prognostic factor. Patients with more than 90% tumor necrosis have a more favorable prognosis than those with less response. The CAP protocol for bone tumor resection provides the pathologist with specific instructions for determining the percentage of tumor necrosis. A separate method (system of Picci) may describe response to treatment in grades: grade I (macroscopic viable tumor), grade II (microscopic viable tumor), or grade III (no viable tumor). Do not code the Picci grade system in this data item.", "notes" : "**Note:** **Physician Statement** \n* Physician statement of microscopically confirmed Percent Necrosis Post Neoadjuvant Chemotherapy can be used to code this data item if no other documentation is available.", - "last_modified" : "2025-04-09T14:10:29.289Z", + "last_modified" : "2025-11-05T20:46:50.873Z", "definition" : [ { "key" : "post_neoadj_chemo_percent_necrosis", "name" : "Code", @@ -17,7 +17,7 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "0.0", "Tumor necrosis not identified/not present" ], [ "0.1-100.0", "0.1 - 100.0 percent tumor necrosis\n(Percentage of tumor necrosis to nearest tenth of a percent)" ], [ "XXX.2", "Tumor necrosis present, percent not stated" ], [ "XXX.8", "Not applicable: Information not collected for this case\nIf this item is required by your standard setter, use of code XXX.8 will result in an edit error." ], [ "XXX.9", "Not documented in medical record\nNo histologic examined of primary site\nNo neoadjuvant therapy\nNo surgical resection of primary site is performed" ] ], - "additional_info" : "**Source documents:** pathology report\n\n**Other names include** Histologic treatment response, therapy response, chemotherapy effect\n\n**For further information**, refer to the **Bone** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Bone*", + "additional_info" : "**Source documents:** pathology report\n\n**Other names include** Histologic treatment response, therapy response, chemotherapy effect\n\n**For further information**, refer to the **Bone** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Bone*.", "coding_guidelines" : "**1)** Record the highest percentage value of the tumor necrosis post neo-adjuvant therapy as stated by the pathologist or in the pathology report.\n* Code the value of the tumor necrosis to the nearest tenth of a percent\n\n**2)** **Codes 001.0-100.0**. Record the percentage value of tumor necrosis post neo-adjuvant chemotherapy as stated by the pathologist in the pathology report\n\n**3)** **Code XXX.9** when\n* Surgical resection of the primary site is the initial therapy; therefore, no neoadjuvant therapy was performed\n* Surgical resection of the primary site after neoadjuvant therapy is performed and there is no mention of percent necrosis", "rationale" : "Percent Necrosis Post Neoadjuvant is a Registry Data Collection Variable for AJCC. It was previously collected as Bone, CS SSF #3." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/pr_allred_score_83938.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/pr_allred_score_83938.json index b10b0236b..76dc56658 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/pr_allred_score_83938.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/pr_allred_score_83938.json @@ -6,7 +6,7 @@ "title" : "PR (Progesterone Receptor) Total Allred Score", "description" : "Progesterone Receptor, Total Allred Score is based on the percentage of cells that stain by IHC for progesterone receptor (PR) and the intensity of that staining.\n\nThe Allred Score is a method of quantifying ER and PR using both intensity and percentage of positive cells. The Allred Score is calculated by adding the Proportion Score and the Intensity Score, as defined in the tables below.\n\nThe Allred score combines the percentage of positive cells (proportion score) and the intensity score of the reaction product in most of the carcinoma. The 2 scores are added together for a final score with 8 possible values (00-08). \n\nPositive cells = 0; Proportion score = 0\nPositive cells = <1; Proportion score = 1\nPositive cells = 1 to 10; Proportion score = 2\nPositive cells = 11 to 33; Proportion score = 3\nPositive cells = 34 to 66; Proportion score = 4\nPositive cells = 67 or greater; Proportion score = 5\n\nIntensity = None; Intensity Score = 0\nIntensity = Weak; Intensity Score = 1\nIntensity = Intermediate/Moderate; Intensity Score = 2\nIntensity = Strong; Intensity Score = 3", "notes" : "**Note 1:** **No longer required by any standard setter** \n* This SSDI is no longer required by any of the standard setters starting with 2023 diagnoses\n* For cases diagnosed 2023+, this SSDI may be left blank\n\n**Note 2:** **Physician Statement** \n* Physician statement of PR (Progesterone Receptor) Total Allred Score can be used to code this data item when no other information is available.\n\n**Note 3:** **Related data item** \n* Code this data item using the same report used to record the related data item 3915: Progesterone Receptor Summary.", - "last_modified" : "2024-04-08T19:57:37.092Z", + "last_modified" : "2025-11-05T21:00:49.473Z", "definition" : [ { "key" : "pr_allred_score", "name" : "Code", @@ -17,7 +17,7 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "00", "Total PR Allred score of 0 " ], [ "01", "Total PR Allred score of 1" ], [ "02", "Total PR Allred score of 2" ], [ "03", "Total PR Allred score of 3" ], [ "04", "Total PR Allred score of 4" ], [ "05", "Total PR Allred score of 5" ], [ "06", "Total PR Allred score of 6" ], [ "07", "Total PR Allred score of 7" ], [ "08", "Total PR Allred score of 8" ], [ "X8", "Not applicable: Information not collected for this case\n(If this item is required by your standard setter, use of code X8 will result in an edit error.)" ], [ "X9", "Not documented in medical record\nPR (Progesterone Receptor) Total Allred Score not assessed, or unknown if assessed" ], [ "", "May be blank if diagnosis year is after 2022" ] ], - "additional_info" : "**Source documents:** pathology report\n\nFor further information, refer to the **Breast Biomarker Reporting** cancer protocols published by the College of American Pathologists for the AJCC Staging System *Breast*", + "additional_info" : "**Source documents:** pathology report\n\nFor further information, refer to the **Breast Biomarker Reporting** cancer protocols published by the College of American Pathologists for the AJCC Staging System *Breast*.", "coding_guidelines" : "**1)** Registrar should not calculate the Allred Score unless both components are available (proportion score and intensity)\n\n**2)** **Code X9** if PR test is performed, but Allred score is not documented, or cannot be calculated", "rationale" : "Progesterone Receptor, Total Allred Score is a Registry Data Collection Variable in AJCC. It is a new data item for cases diagnosed 1/1/2018+." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/pr_percent_positive_94563.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/pr_percent_positive_94563.json index 825cdab03..38ac81062 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/pr_percent_positive_94563.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/pr_percent_positive_94563.json @@ -6,7 +6,7 @@ "title" : "PR (Progesterone Receptor) Percent Positive or Range", "description" : "Progesterone Receptor Percent Positive or Range is the percent of cells staining progesterone receptor positive measured by IHC.\n\nThe two most common ways to report ER and PR results are the percentage of cells with nuclear positivity and the average intensity of staining. Both the PS and IS are based on immunohistochemical staining of tumor cells. \n\nER and PR status, the percentage of tumor cells with positive nuclear staining, may be reported as a specific number or a range if more than 10%. Intensity refers to degree of nuclear positivity (i.e., pale to dark); average intensity of staining is recorded as weak, moderate, or strong.", "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of PR (Progesterone Receptor) Percent Positive or Range can be used to code this data item when no other information is available.\n\n**Note 2:** **Related Data Item** \n* Code this data item using the same report used to record the related data item 3915: Progesterone Receptor Summary.", - "last_modified" : "2025-02-24T14:47:11.881Z", + "last_modified" : "2025-11-06T18:57:00.719Z", "definition" : [ { "key" : "pr_percent_positive", "name" : "Code", @@ -17,7 +17,7 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "000", "PR negative, or stated as less than 1%" ], [ "001-100", "1-100 percent" ], [ "R10", "Stated as 1-10%" ], [ "R20", "Stated as 11-20%" ], [ "R30", "Stated as 21-30%" ], [ "R40", "Stated as 31-40%" ], [ "R50", "Stated as 41-50%" ], [ "R60", "Stated as 51-60%" ], [ "R70", "Stated as 61-70%" ], [ "R80", "Stated as 71-80%" ], [ "R90", "Stated as 81-90%" ], [ "R99", "Stated as 91-100%" ], [ "XX7", "Test done, results not in chart " ], [ "XX8", "Not applicable: Information not collected for this case\n(If this item is required by your standard setter, use of code XX8 will result in an edit error.)" ], [ "XX9", "Not documented in medical record\nPR (Progesterone Receptor) Percent Positive or Range not assessed or unknown if assessed" ] ], - "additional_info" : "**Source documents:** pathology report\n\nFor further information, refer to the **Breast Biomarker Reporting** cancer protocols published by the College of American Pathologists for the AJCC Staging System *Breast*", - "coding_guidelines" : "**1)** **Code 000** when PR is negative, or percentage is less than 1%\n**2)** **Code 01-100** for the actual percentage\n* The actual PR (1-100%) percent takes priority over the range codes\n\n**3)** **Code XX7** if PR is positive, but percentage is unknown\n**4)** **R10-R99** Ranges for the codes in this data item are defined in steps of 10 which correspond to the CAP protocol. If a range in a report is given in steps other than those provided in the R codes, code per the following.\n* If the range is less than or equal to 10, then code the appropriate R code based on the lower number\n * ***Example 1***: Report documents 1-5%. Code R10 (1-10%)\n * ***Example 2***: Report documents 25-34%. Code R30 (21-30%)\n* If the range is greater than 10, then code to unknown\n * ***Example 1***: Report documents 10-25%. Code XX9\n * ***Example 2:*** Report documents 67-100%. Code XX9", + "additional_info" : "**Source documents:** pathology report\n\nFor further information, refer to the **Breast Biomarker Reporting** cancer protocols published by the College of American Pathologists for the AJCC Staging System *Breast*.", + "coding_guidelines" : "**1)** **Code 000** when PR is negative, or percentage is less than 1%\n\n**2)** **Code 01-100** for the actual percentage\n* The actual PR (1-100%) percent takes priority over the range codes\n\n**3)** **Code XX7** if PR is positive, but percentage is unknown\n\n**4)** **R10-R99** Ranges for the codes in this data item are defined in steps of 10 which correspond to the CAP protocol. If a range in a report is given in steps other than those provided in the R codes, code per the following.\n* If the range is less than or equal to 10, then code the appropriate R code based on the lower number\n * ***Example 1***: Report documents 1-5%. Code R10 (1-10%)\n * ***Example 2***: Report documents 25-34%. Code R30 (21-30%)\n* If the range is greater than 10, then code to unknown\n * ***Example 1***: Report documents 10-25%. Code XX9\n * ***Example 2:*** Report documents 67-100%. Code XX9", "rationale" : "Progesterone Receptor Percent Positive or Range is a Registry Data Collection Variable in AJCC. It is a new data item for cases diagnosed 1/1/2018+." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/pr_summary_49534.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/pr_summary_49534.json index fbaedfd1e..ba299636f 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/pr_summary_49534.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/pr_summary_49534.json @@ -4,9 +4,9 @@ "version" : "3.3", "name" : "Progesterone Receptor Summary", "title" : "PR (Progesterone Receptor) Summary", - "description" : "Progesterone Receptor Summary is a summary of results from the progesterone receptor (PR) assay.\n\nEstrogen receptor (ER) positivity and progesterone receptor (PR) positivity are favorable prognostic factors in breast cancer, as well as endometrial carcinoma and meningioma. Positive results predict a favorable response to endocrine (hormonal) therapy. Combined ER and PR positivity is associated with increased response to antiestrogen therapies. \nThere are a variety of ways to report information on ER and PR results, but there is almost always a summary statement that the result is positive or negative.", - "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of PR (Progesterone Receptor) Summary status can be used to code this data item when no other information is available.\n\n**Note 2:** **In-situ and Invasive components present**\n* If PR is positive on an in-situ component and PR is negative on all tested invasive components in the primary tumor, code PR as negative (code 0)\n* If in situ and invasive components present and PR only done on the in-situ component in the primary tumor, code unknown (code 9)\n\n**Note 3:** **Single tumor, multiple biopsies or surgical resection, different results**\n* Use the highest (positive versus negative)\n\n**Note 4:** **Multiple tumors, different results**\n* Code the results from the largest tumor size (determined either clinically or pathologically) when multiple tumors are present.\n * Do not use specimen size to determine the largest tumor size\n\n**Note 5:** **Results from nodal or metastatic tissue**\n* May be used ONLY when there is no evidence of primary tumor\n * **Note:** In-situ is evidence of primary tumor\n\n**Note 6:** **Neoadjuvant Therapy**\n* Record the assay from tumor specimens prior to neoadjuvant therapy.\n* If neoadjuvant therapy is given and there are no ER results from pre-treatment specimens, report the findings from post-treatment specimens\n\n**Note 7:** **Others tests for PR**\n* Do not use results from the following tests to record PR results\n * MammaPrint\n * EndoPredict\n * PAM 50 (Prosigna)\n * Any other test that records PR", - "last_modified" : "2025-02-24T14:48:18.781Z", + "description" : "Progesterone Receptor Summary is a summary of results from the progesterone receptor (PR) assay.\n\nEstrogen receptor (ER) positivity and progesterone receptor (PR) positivity are favorable prognostic factors in breast cancer, as well as endometrial carcinoma and meningioma. Positive results predict a favorable response to endocrine (hormonal) therapy. Combined ER and PR positivity is associated with increased response to antiestrogen therapies.\n\nThere are a variety of ways to report information on ER and PR results, but there is almost always a summary statement that the result is positive or negative.", + "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of PR (Progesterone Receptor) Summary status can be used to code this data item when no other information is available.\n\n**Note 2:** **In-situ and Invasive components present**\n* If PR is positive on an in-situ component and PR is negative on all tested invasive components in the primary tumor, code PR as negative (code 0)\n* If in situ and invasive components present and PR only done on the in-situ component in the primary tumor, code unknown (code 9)\n\n**Note 3:** **Single tumor, multiple biopsies or surgical resection, different results**\n* Use the highest (positive versus negative)\n\n**Note 4:** **Multiple tumors, different results**\n* Code the results from the largest tumor size (determined either clinically or pathologically) when multiple tumors are present.\n * Do not use specimen size to determine the largest tumor size\n\n**Note 5:** **Results from nodal or metastatic tissue**\n* May be used ONLY when there is no evidence of primary tumor\n * **Note:** In-situ is evidence of primary tumor\n\n**Note 6:** **Neoadjuvant Therapy**\n* Record the assay from tumor specimens prior to neoadjuvant therapy.\n* If neoadjuvant therapy is given and there are no ER results from pre-treatment specimens, report the findings from post-treatment specimens\n\n**Note 7:** **Other tests for PR**\n* Do not use results from the following tests to record PR results\n * MammaPrint\n * EndoPredict\n * PAM 50 (Prosigna)\n * Any other test that records PR", + "last_modified" : "2025-11-06T18:49:57.558Z", "definition" : [ { "key" : "pr", "name" : "Code", @@ -17,7 +17,7 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "0", "PR negative (0.0% or less than 1%)" ], [ "1", "PR positive" ], [ "7", "Test ordered, results not in chart" ], [ "9", "Not documented in medical record\nCannot be determined (indeterminate)\nPR (Progesterone Receptor) Summary status not assessed or unknown if assessed" ] ], - "additional_info" : "**Source documents:** pathology report\n\n**For further information**, refer to the **Breast Biomarker Reporting** cancer protocols published by the College of American Pathologists for the AJCC Staging System Breast", - "coding_guidelines" : "**1)** **Code 0** when the PR is reported as negative or normal\n**2)** **Code 1** when the PR is reported as positive or elevated\n**3)** **Code 7** when the PR test was ordered but the results are not available\n**4)** **Code 9** when the PR is \n * Reported as borderline; undetermined whether positive or negative \n * Cannot be determined by the pathologist (e.g., inadequate specimen)\n * It is unknown whether the PR test was performed\n * The patient has only a clinical diagnosis of breast cancer (no tissue diagnosis)", + "additional_info" : "**Source documents:** pathology report\n\n**For further information**, refer to the **Breast Biomarker Reporting** cancer protocols published by the College of American Pathologists for the AJCC Staging System Breast.", + "coding_guidelines" : "**1)** **Code 0** when the PR is reported as negative or normal\n\n**2)** **Code 1** when the PR is reported as positive or elevated\n\n**3)** **Code 7** when the PR test was ordered but the results are not available\n\n**4)** **Code 9** when the PR is \n * Reported as borderline; undetermined whether positive or negative \n * Cannot be determined by the pathologist (e.g., inadequate specimen)\n * It is unknown whether the PR test was performed\n * The patient has only a clinical diagnosis of breast cancer (no tissue diagnosis)", "rationale" : "This data item is required for prognostic stage grouping in AJCC 8th edition, Chapter 48 Breast. It was previously collected as Breast CS SSF # 2." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/primary_peritoneum_tumor_19475.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/primary_peritoneum_tumor_19475.json index 9a1ec394b..5342047a4 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/primary_peritoneum_tumor_19475.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/primary_peritoneum_tumor_19475.json @@ -6,7 +6,7 @@ "title" : "Schema Discriminator 1: Primary Peritoneum Tumor", "description" : "The GIST chapter includes a schema discriminator for C481 for location of the primary tumor because all the peritoneum structures are coded to C481, but two separate stage tables are used to derive the TNM values.", "notes" : "**Note:** **Schema discriminator for C481**\n* Since both omental and peritoneal gastrointestinal stromal tumors (GIST) are coded with the same ICD-O-3 topography code (C481), this data item must be used to identify the appropriate AJCC stage table.", - "last_modified" : "2024-04-30T19:00:18.389Z", + "last_modified" : "2025-11-06T18:36:24.035Z", "definition" : [ { "key" : "discriminator_1", "name" : "Code", @@ -20,7 +20,7 @@ "name" : "Stage Table", "type" : "DESCRIPTION" } ], - "rows" : [ [ "1", "Mesentery\nMesoappendix\nMesocolon\nPelvic peritoneum\nRectouterine pouch\n- Cul de sac\n- Pouch of Douglas\n\nOther specified peritoneal site", "Small Intestinal, Esophageal, Colorectal, Mesenteric and Peritoneal GIST" ], [ "2", "Omentum", "Gastic and Omental GIST" ], [ "9", "Unknown or no information\nNot documented in medical record", "Small Intestinal, Esophageal, Colorectal, Mesenteric and Peritoneal GIST" ], [ "", "Primary Site is NOT C481, Discriminator is not necessary", "" ] ], + "rows" : [ [ "1", "Mesentery\nMesoappendix\nMesocolon\nPelvic peritoneum\nRectouterine pouch\n- Cul de sac\n- Pouch of Douglas\n\nOther specified peritoneal site", "Small Intestinal, Esophageal, Colorectal, Mesenteric and Peritoneal GIST" ], [ "2", "Omentum", "Gastric and Omental GIST" ], [ "9", "Unknown or no information\nNot documented in medical record", "Small Intestinal, Esophageal, Colorectal, Mesenteric and Peritoneal GIST" ], [ "", "Primary Site is NOT C481, Discriminator is not necessary", "" ] ], "additional_info" : "**Source documents:** pathology report, imaging, physician documentation, physician staging", "rationale" : "A schema discriminator is used to assign AJCC ID when site and histology alone are insufficient to identify the applicable AJCC staging method and to assign Schema ID, which links each case to the appropriate SSDIs, Grade, Summary Stage and EOD data collection system." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/primary_scleros_cholangitis_86402.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/primary_scleros_cholangitis_86402.json index 3f1a0af96..c22a231fe 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/primary_scleros_cholangitis_86402.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/primary_scleros_cholangitis_86402.json @@ -6,7 +6,7 @@ "title" : "Primary Sclerosing Cholangitis (PSC)", "description" : "Primary sclerosing cholangitis denotes a chronic autoimmune inflammation of the bile ducts that leads to scar formation and narrowing of the ducts over time. It is a prognostic factor for intrahepatic bile duct cancer.\n\nPrimary sclerosing cholangitis is an idiopathic liver disease characterized by inflammation and fibrosis of the entire biliary tree. The chronic inflammation and injury to ducts may lead to cirrhosis and predispose to cholangiocarcinoma at any site in the biliary tree. \n\nPatients with primary sclerosing cholangitis are advised to receive neoadjuvant chemoradiation and liver transplantation.", "notes" : "**Note:** **Physician Statement** \n* Physician statement of Primary Sclerosing Cholangitis (PSC) can be used to code this data item when no other information is available.", - "last_modified" : "2025-02-24T13:51:40.688Z", + "last_modified" : "2025-11-06T18:15:18.622Z", "definition" : [ { "key" : "prim_scleros_cholangitis", "name" : "Code", @@ -18,6 +18,6 @@ } ], "rows" : [ [ "0", "PSC not identified/not present" ], [ "1", "PSC present" ], [ "8", "Not applicable: Information not collected for this case\n(If this information is required by your standard setter, use of code 8 may result in an edit error.)" ], [ "9", "Not documented in medical record\nPSC not assessed or unknown if assessed" ] ], "additional_info" : "**Source documents:** patient history, pathology report, imaging reports\n\n**Other names include** PSC, fibrosing cholangitis, chronic obliterative cholangitis, sclerosing cholangitis", - "coding_guidelines" : "**1)** Code stated diagnosis of PSC either clinically or pathologically as documented in the medical record. This may be by history.\n **2)** **Code 0** when primary sclerosing cholangitis is not present\n**3)** **Code 1** when primary sclerosing cholangitis is present\n**4)** **Code 9** when \n * No information in the medical record\n * Pathology report is not available\n * Primary sclerosing cholangitis is not evaluated (not assessed) \n * Unknown if primary sclerosing cholangitis is evaluated (assessed)\n * No mention of primary sclerosing cholangitis on the pathology report or in the medical record", + "coding_guidelines" : "**1)** Code stated diagnosis of PSC either clinically or pathologically as documented in the medical record. This may be by history.\n\n**2)** **Code 0** when primary sclerosing cholangitis is not present\n\n**3)** **Code 1** when primary sclerosing cholangitis is present\n\n**4)** **Code 9** when \n * No information in the medical record\n * Pathology report is not available\n * Primary sclerosing cholangitis is not evaluated (not assessed) \n * Unknown if primary sclerosing cholangitis is evaluated (assessed)\n * No mention of primary sclerosing cholangitis on the pathology report or in the medical record", "rationale" : "Primary Sclerosing Cholangitis is a Registry Data Collection Variable in AJCC. This data item was previously collected for Intrahepatic Bile Duct, SSF #11." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/profound_immune_suppression_68178.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/profound_immune_suppression_68178.json index 510094eea..0cf0a5c99 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/profound_immune_suppression_68178.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/profound_immune_suppression_68178.json @@ -5,8 +5,8 @@ "name" : "Profound Immune Suppression", "title" : "Profound Immune Suppression", "description" : "Profound Immune Suppression suppressed immune status that may be associated with HIV/AIDs, solid organ transplant, chronic lymphocytic leukemia, non-Hodgkin lymphoma, multiple conditions, or other conditions, increases the risk of developing Merkel Cell Carcinoma and is an adverse prognostic factor. \n\nProfound immune suppression may greatly increase the risk of developing Merkel cell carcinoma. Immune suppression is suppression of the body's immune system and its ability to fight infections and other diseases. Immune suppression may be deliberately induced with drugs, as in preparation for bone marrow or other organ transplantation, to prevent rejection of the donor tissue. It may also result from certain diseases such as Acquired Immune Deficiency Syndrome (AIDS) or lymphoma, and from the use of anti-cancer drugs.", - "notes" : "**Note 1:** **Physician statement** \n* Physician statement of Profound Immune Suppression must be used to code this data item. \n* Do not assume that a patient is immune suppressed just because the patient has one of the conditions listed below in the table. \n\n**Note 2:** **Two-year limitation and exceptions**\n* Per AJCC experts, this data item is limited to the conditions in the table below occurring within two years of the diagnosis of Merkel cell carcinoma.\n * ***Exceptions***: For the following conditions ONLY, these patients will experience chronic immunosuppression. These are no time limits for these conditions. If a patient has a history (regardless of when diagnosed or treatment status), code as present \n * Human Immunodeficiency Virus (HIV)/acquired immunodeficiency syndrome (AIDS) (Code 1)\n * Solid organ transplant recipient (Code 2)\n * Chronic lymphocytic leukemia (Code 3)", - "last_modified" : "2024-04-30T19:13:19.892Z", + "notes" : "**Note 1:** **Physician statement** \n* Physician statement of Profound Immune Suppression must be used to code this data item. \n* Do not assume that a patient is immune suppressed just because the patient has one of the conditions listed below in the table. \n\n**Note 2:** **Two-year limitation and exceptions**\n* Per AJCC experts, this data item is limited to the conditions in the table below occurring within two years of the diagnosis of Merkel cell carcinoma.\n * ***Exceptions***: For the following conditions ONLY, these patients will experience chronic immunosuppression. There are no time limits for these conditions. If a patient has a history (regardless of when diagnosed or treatment status), code as present \n * Human Immunodeficiency Virus (HIV)/acquired immunodeficiency syndrome (AIDS) (Code 1)\n * Solid organ transplant recipient (Code 2)\n * Chronic lymphocytic leukemia (Code 3)", + "last_modified" : "2025-11-06T18:41:53.559Z", "definition" : [ { "key" : "profound_immune_suppression", "name" : "Code", @@ -18,6 +18,6 @@ } ], "rows" : [ [ "0", "No immune suppression condition(s) identified/not present" ], [ "1", "Human Immunodeficiency Virus (HIV)/Acquired Immunodeficiency Syndrome (AIDS)" ], [ "2", "Solid organ transplant recipient" ], [ "3", "Chronic lymphocytic leukemia" ], [ "4", "Non-Hodgkin lymphoma" ], [ "5", "Multiple immune suppression conditions" ], [ "6", "Profound immune suppression present" ], [ "8", "Not applicable: Information not collected for this case\n(If this information is required by your standard setter, use of code 8 may result in an edit error.)" ], [ "9", "Not documented in medical record\nProfound immune suppression not assessed or unknown if assessed" ] ], "additional_info" : "**Source documents:** patient history, consultation notes, other statement in medical record\n\n**Other names (per AJCC experts) include** immunosuppression, immunocompromised, immunosuppressed, suppressed immune status", - "coding_guidelines" : "**1) Code 0** when there is no evidence of immune suppression at the time of diagnosis OR within 2 years of diagnosis\n**2) Code 1** for HIV diagnosis regardless of when diagnosed or treatment status\n**3) Code 2** for Solid Organ transplant recipient regardless of when transplant was done\n**4) Code 3** for Chronic lymphocytic leukemia regardless of when diagnosed or treatment status\n**5) Code 4** for Non-Hodgkin lymphoma that has been diagnosed within the last two years\n**6) Code 5** when there are multiple immune suppression conditions (Codes 1-4) present at the same time\n**7) Code 6** when documentation states “profound immune suppression,” but no information regarding which condition is given\n**8) Code 9** if conditions (other than those noted above) were not active within 2 years of (or resolved more than 2 years prior to) diagnosis, or if it is unknown when they existed.", + "coding_guidelines" : "**1) Code 0** when there is no evidence of immune suppression at the time of diagnosis OR within 2 years of diagnosis\n\n**2) Code 1** for HIV diagnosis regardless of when diagnosed or treatment status\n\n**3) Code 2** for Solid Organ transplant recipient regardless of when transplant was done\n\n**4) Code 3** for Chronic lymphocytic leukemia regardless of when diagnosed or treatment status\n\n**5) Code 4** for Non-Hodgkin lymphoma that has been diagnosed within the last two years\n\n**6) Code 5** when there are multiple immune suppression conditions (Codes 1-4) present at the same time\n\n**7) Code 6** when documentation states “profound immune suppression,” but no information regarding which condition is given\n\n**8) Code 9** if conditions (other than those noted above) were not active within 2 years of (or resolved more than 2 years prior to) diagnosis, or if it is unknown when they existed.", "rationale" : "Profound Immune Suppression is a Registry Data Collection Variable in AJCC. It was previously collected as Merkel Cell Penis, SSF #22, Merkel Cell Scrotum SSF #22, Merkel Cell Skin, SSF #22, and Merkel Cell Vulva, SSF #22." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/psa_46258.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/psa_46258.json index 79ee6df26..0032bda2d 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/psa_46258.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/psa_46258.json @@ -5,8 +5,8 @@ "name" : "PSA Lab Value", "title" : "PSA (Prostatic Specific Antigen) Lab Value", "description" : "PSA (Prostatic Specific Antigen) is a protein produced by cells of the prostate gland and is elevated in patients with prostate cancer. This data item pertains to PSA lab value.\n\nSerum PSA is the most sensitive tumor marker for monitoring individuals with prostate cancer, including progression of disease and response to therapy. Although originally not intended to be a screening test, this relatively simple blood test has become a very common method of detecting new prostate cancer in its earliest stages. PSA can be totally negative when prostate cancer is found on digital rectal exam. In such cases, PSA will not be helpful in monitoring for recurrence. \n* ***Note:*** Serum PSA is not the same as free PSA or precursor PSA—do not record values from either of these tests in this field.", - "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of prostatic specific antigen (PSA) pre-diagnosis can be used to code this data item when no other information is available.\n\n**Note 2:** **Staging related** \n* PSA is a prognostic factor required for AJCC staging. It affects the stage group in most cases.\n\n**Note 3:** **PSA criteria**\n * Diagnostic biopsy done\n * Record the last PSA lab value done prior to **AND** within 3 months of the diagnostic biopsy\n * No diagnostic biopsy done (or unknown if diagnostic biopsy done)\n * Record the last PSA lab value done within 3 months of the date of diagnosis **or** additional confirmatory testing when no diagnostic biopsy is done, or unknown if diagnostic biopsy done\n\n* ***Note:** **This is a change in the rules for Version 3.3 of the SSDI manual from the PSA had to be within 3 months and prior to the date of diagnosis AND within 3 months of the diagnostic biopsy***\n * *This change can be applied for cases diagnosed 2018+. There is no recommendation or expectation that registrars will review older cases.* \n\n* ***Example 1:*** 5/17/25 PSA, 8.5. Date of diagnosis 6/6/25 based on MRI. Patient seeks a second opinion. Returns to physician in November 2025. 11/19/25 PSA, 8.6. 11/21/25 needle core biopsy.\n * Code PSA 8.6 based on the 11/19/25 PSA which was done prior to and within 3 months of the diagnostic biopsy\n\n\n * ***Example 2:*** 6/4/25 PSA, 12.7. Additional PSA done 7/5/25, 10.6. Date of Diagnosis on 8/4/25 when the diagnostic biopsy was done. \n * Code PSA 10.6 based on the 7/5/25 PSA since that was the last PSA done prior to and within 3 months of the diagnostic biopsy\n\n * ***Example 3:*** 4/15/25 PSA, 6.4. 5/2/25 MRI done, which confirms prostate cancer. No diagnostic biopsy done.\n * Code PSA 6.4 based on the 4/15/25 PSA which was done within 3 months of the date of diagnosis and no diagnostic biopsy was done. \n\n**Note 4:** **PSA Adjustment** \n* A discrepancy between the PSA documented in the lab report and the PSA documented by the clinician may arise due to the clinician's adjusting the PSA value. Certain medications for benign prostatic hypertrophy (BPH) decrease the PSA. \n * If there is documentation by a clinician within the medical record of an adjusted PSA value, record the adjusted value. \n * The registrar does not adjust the PSA value based on BPH medication use. \n * If there is no documentation by a clinician within the medical record of an adjusted PSA value, record the PSA value provided. \n * The fact that an adjusted PSA value is being recorded should be documented in the Dx Proc - Lab Tests text field (NAACCR Item # 2550).", - "last_modified" : "2025-06-05T12:58:25.598Z", + "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of prostatic specific antigen (PSA) pre-diagnosis can be used to code this data item when no other information is available.\n\n**Note 2:** **Staging related** \n* PSA is a prognostic factor required for AJCC staging. It affects the stage group in most cases.\n\n**Note 3:** **PSA criteria**\n * Diagnostic biopsy done\n * Record the last PSA lab value done prior to **AND** within 3 months of the diagnostic biopsy\n * No diagnostic biopsy done (or unknown if diagnostic biopsy done)\n * Record the last PSA lab value done within 3 months of the date of diagnosis **or** additional confirmatory testing when no diagnostic biopsy is done, or unknown if diagnostic biopsy done\n\n* ***Note:** **This is a change in the rules for Version 3.3 of the SSDI manual from the PSA had to be within 3 months and prior to the date of diagnosis AND within 3 months of the diagnostic biopsy***\n * *This change can be applied for cases diagnosed 2018+. There is no recommendation or expectation that registrars will review older cases.* \n\n* ***Example 1:*** 5/17/25 PSA, 8.5. Date of diagnosis 6/6/25 based on MRI. Patient seeks a second opinion. Returns to physician in November 2025. 11/19/25 PSA, 8.6. 11/21/25 needle core biopsy.\n * Code PSA 8.6 based on the 11/19/25 PSA which was done prior to and within 3 months of the diagnostic biopsy\n\n* ***Example 2:*** 6/4/25 PSA, 12.7. Additional PSA done 7/5/25, 10.6. Date of Diagnosis on 8/4/25 when the diagnostic biopsy was done. \n * Code PSA 10.6 based on the 7/5/25 PSA since that was the last PSA done prior to and within 3 months of the diagnostic biopsy\n\n * ***Example 3:*** 4/15/25 PSA, 6.4. 5/2/25 MRI done, which confirms prostate cancer. No diagnostic biopsy done.\n * Code PSA 6.4 based on the 4/15/25 PSA which was done within 3 months of the date of diagnosis and no diagnostic biopsy was done. \n\n**Note 4:** **PSA Adjustment** \n* A discrepancy between the PSA documented in the lab report and the PSA documented by the clinician may arise due to the clinician's adjusting the PSA value. Certain medications for benign prostatic hypertrophy (BPH) decrease the PSA. \n * If there is documentation by a clinician within the medical record of an adjusted PSA value, record the adjusted value. \n * The registrar does not adjust the PSA value based on BPH medication use. \n * If there is no documentation by a clinician within the medical record of an adjusted PSA value, record the PSA value provided. \n * The fact that an adjusted PSA value is being recorded should be documented in the Dx Proc - Lab Tests text field (NAACCR Item # 2550).", + "last_modified" : "2025-11-06T20:41:42.013Z", "definition" : [ { "key" : "psa", "name" : "Code", @@ -17,7 +17,7 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "0.1", "0.1 or less nanograms/milliliter (ng/ml)\n(Exact value to nearest tenth of ng/ml)" ], [ "0.2-999.9", "0.2 - 999.9 ng/ml\n(Exact value to nearest tenth of ng/ml)" ], [ "XXX.1", "1,000 ng/ml or greater" ], [ "XXX.2", "Lab value not available, physician states PSA is negative/normal" ], [ "XXX.3", "Lab value not available, physician states PSA is positive/elevated/high" ], [ "XXX.7", "Test ordered, results not in chart" ], [ "XXX.9", "Not documented in medical record\nPSA lab value not assessed or unknown if assessed" ] ], - "additional_info" : "**Source documents:** clinical laboratory report (blood or serum test), history, clinician note, pathology report\n\n**Other names include** Prostate specific antigen, serum PSA, total PSA\n\n***Normal reference range varies by age and race of patient***. \n * The reference range should be shown on the clinical laboratory report. In general, normal findings are 0 – 4.0 nanograms per milliliter (ng/ml).\n * Optimal normal range is 0 – 2.6 ng/ml. Nanograms per milliliter may be reported as micrograms per liter (g/L or ug/L).", - "coding_guidelines" : "**1)** Record to the nearest tenth in nanograms/milliliter (ng/ml) the last pre-diagnosis PSA lab value **prior to the diagnostic biopsy** of prostate and treatment. \n\n**2)** The lab value may be recorded in the lab report, history and physical, or clinical statement in the pathology report, etc. \n* A lab value expressed in micrograms per liter (ug/L) is e equivalent to the same value expressed in nanograms per milliliter (ng/ml)\n * Record 0.1 when the lab results are stated as less than 0.1 ng/ml with no exact value.\n\n**3)** A known lab value takes priority over codes XXX.2 and XXX.3. \n* The lab value takes priority even if the physician documents the interpretation\n * ***Example:*** Patient noted to have a PSA of 7.6. Physician notes that the value is elevated\n* Code 7.6 instead of XXX.3 (elevated)\n\n***Additional Examples***\n**1) PSA of 11.56**\n* PSA 11.6. Per Coding Guideline #1, PSA is documented in tenths, not hundredths. Follow the general coding rules and round up (see Rounding Rules in the General instructions). \n\n**2) 12/19/2025: PSA 44.3, 3/11/2026: PSA 42.8, 5/1/2026: DRE positive for bilateral palpable nodularity, 5/5/2026: Casodex initiated without needle core biopsy**\n* PSA 42.8: Per Note #3, when diagnostic biopsy is not done, record the last PSA done within three months of the date of diagnosis. \n\n**3) 2/16/2025: PSA 18.6, adjusted PSA value due to patient taking Medication for benign prostatic hypertrophy**\n* PSA 18.6. Record the adjusted PSA value ONLY if documented by the clinician in the record\n* Registrar does not adjust the PSA value due to BPH medication use\n\n**4)\t12/13/25: PSA 8.2, 1/13/2026: PSA 7.3, 5/22/2026: Biopsy positive for adenocarcinoma**\n* PSA XXX.9. Neither PSA was within three months of the diagnostic biopsy and therefore they can't be used.\n\n**5) PSA 1,100 ng/ml**\n* XXX.1: XXX.1 is defined for values of 1,000 or greater", + "additional_info" : "**Source documents:** clinical laboratory report (blood or serum test), history, clinician note, pathology report\n\n**Other names include** Prostate specific antigen, serum PSA, total PSA\n\n***Normal reference range varies by age and race of patient***. \n * The reference range should be shown on the clinical laboratory report. In general, normal findings are 0 – 4.0 nanograms per milliliter (ng/ml).\n * Optimal normal range is 0 – 2.6 ng/ml. Nanograms per milliliter may be reported as micrograms per liter (mg/L or ug/L).", + "coding_guidelines" : "**1)** Record to the nearest tenth in nanograms/milliliter (ng/ml) the last pre-diagnosis PSA lab value **prior to the diagnostic biopsy** of prostate and treatment. \n\n**2)** The lab value may be recorded in the lab report, history and physical, or clinical statement in the pathology report, etc. \n* A lab value expressed in micrograms per liter (ug/L) is e equivalent to the same value expressed in nanograms per milliliter (ng/ml)\n * Record 0.1 when the lab results are stated as less than 0.1 ng/ml with no exact value.\n\n**3)** A known lab value takes priority over codes XXX.2 and XXX.3. \n* The lab value takes priority even if the physician documents the interpretation\n * ***Example:*** Patient noted to have a PSA of 7.6. Physician notes that the value is elevated\n * Code 7.6 instead of XXX.3 (elevated)\n\n***Additional Examples***\n\n**1) PSA of 11.56**\n* PSA 11.6. Per Coding Guideline #1, PSA is documented in tenths, not hundredths. Follow the general coding rules and round up (see Rounding Rules in the General instructions). \n\n**2) 12/19/2025: PSA 44.3, 3/11/2026: PSA 42.8, 5/1/2026: DRE positive for bilateral palpable nodularity, 5/5/2026: Casodex initiated without needle core biopsy**\n* PSA 42.8: Per Note #3, when diagnostic biopsy is not done, record the last PSA done within three months of the date of diagnosis. \n\n**3) 2/16/2025: PSA 18.6, adjusted PSA value due to patient taking Medication for benign prostatic hypertrophy**\n* PSA 18.6. Record the adjusted PSA value ONLY if documented by the clinician in the record\n* Registrar does not adjust the PSA value due to BPH medication use\n\n**4)\t12/13/25: PSA 8.2, 1/13/2026: PSA 7.3, 5/22/2026: Biopsy positive for adenocarcinoma**\n* PSA XXX.9. Neither PSA was within three months of the diagnostic biopsy and therefore they can't be used.\n\n**5) PSA 1,100 ng/ml**\n* XXX.1: XXX.1 is defined for values of 1,000 or greater", "rationale" : "This data item is required for prognostic stage grouping in AJCC 8th edition, Chapter 58 Prostate. It was previously collected as Prostate, CS SSF #1." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ptld_17694.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ptld_17694.json index aaf7bd958..21d1eda66 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ptld_17694.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ptld_17694.json @@ -6,7 +6,7 @@ "title" : "Post Transplant Lymphoproliferative Disorder-PTLD", "description" : "Post Transplant Lymphoproliferative Disorder (PTLD) is a lymphoid proliferation arising in a recipient of a solid organ transplant, allogeneic bone marrow transplantation, or an umbilical cord blood transfusion. The patient must have a history of a solid organ transplant or an allogeneic bone marrow transplant. Both polymorphic and monomorphic PTLD are actually caused by post-transplant immunosuppression. Most cases of PTLD occur within a year of transplantation; however, they can occur any time after the transplant. Monomorphic PTLD may have histology indistinguishable from that of various malignant hematopoietic neoplasms, particularly lymphomas such as Diffuse Large B-cell Lymphoma.", "notes" : "**Note 1:** **Effective years**\n* This SSDI is effective for diagnosis years 2025+\n* For cases diagnosed 2018-2024, this SSDI must be blank\n\n**Note 2:** **Definition of PTLD** \n* Post Transplant Lymphoproliferative Disorder (PTLD) is a lymphoid proliferation arising in a recipient of a solid organ transplant, allogeneic bone marrow transplantation, or an umbilical cord blood transfusion. \n* The development of PTLD is clinically significant and a prognostic indicator\n* See the Hematopoietic database for more information \n\n**Note 3:** **Types of PTLD**\n* **Polymorphic PTLD**: This is a PTLD by itself, there is no accompanying lymphoma, plasmacytoma or other type of Hematopoietic neoplasm. This type of PTLD is NOT collected in this data item.\n* **Monomorphic PTLD (Code 1)**: This is the most common PTLD and is associated with a malignant hematopoietic neoplasm. Most common, but not limited to, diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma \n* **(Classic Hodgkin lymphoma-PTLD type (Code 2)**: Under the microscope, Reed-Sternberg cells, which are associated with Hodgkin lymphoma are present\n* **PTLD, NOS (Code 4)**: Used when only PTLD (NOS) is documented and there is no mention of monomorphic or Hodgkin like type", - "last_modified" : "2024-05-02T19:46:40.016Z", + "last_modified" : "2025-11-06T21:39:58.312Z", "definition" : [ { "key" : "ptld", "name" : "Code", @@ -17,6 +17,6 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "0", "PTLD not documented on the pathology report or in the medical record" ], [ "1", "Monomorphic PTLD \n* PTLD WITH a specified histology (lymphoma, plasmacytoma, plasma cell myeloma)" ], [ "2", "Classic Hodgkin lymphoma-PTLD type \nPTLD, Hodgkin like" ], [ "4", "PTLD not specified as monomorphic or Hodgkin lymphoma-PTLD type\n• WITH a specified histology (lymphoma, plasmacytoma, plasma cell myeloma)\n• Includes Burkitt type PTLD" ], [ "8", "Not applicable: Information not collected for this case\n(If this item is required by your standard setter, use of code 8 will result in an edit error)" ], [ "", "Diagnosis year prior to 2025" ] ], - "coding_guidelines" : "**See the Hematopoietic manual (Rules M14 and PH1. Hematopoietic Project - SEER Registrars (cancer.gov))**\n\n**1.** Code 0 when there is no mention of PTLD on the pathology report or medical record\n**2.** Code 1 when the pathology report describes monomorphic PTLD with a lymphoma\n**3.** Code 2 when the pathology report describes Classic Hodgkin lymphoma-PTLD type\n**4.** Code 4 when the pathology report describes a Burkitt like PTLD or doesn’t specify what type of PTLD\n\n***Examples (Courtesy of Ask a SEER Registrar)***\n\n**1.** Staining supports the diagnosis of PTLD, monomorphic type, EBV+ diffuse large b-cell lymphoma (non-germinal center) *(Code histology 9680/3, PTLD data item-1)*\n**2.** Monomorphic post-transplant lymphoproliferative disorder (Plasma cell myeloma), EBV negative. Monoclonal kappa plasmacytosis (estimated 20% by CD138 IHC). *(Code histology, 9732/3, PTLD data item: 1)*\n**3.** Per Physician, Stage IIA (bulk) PTLD - Hodgkin-like morphology, Intermediate risk. *(Code histology 9650/3, PTLD data item: 2)*\n**4.** High grade b cell lymphoma/Burkitt like post-transplant lymphoproliferative disorder. *(Code histology 9687/3, PTLD data item-4)*\n**5.** Non-Hodgkin malignant lymphoma with plasmablastic features. Represents a post-transplant/immunodeficiency-related malignant lymphoma. *(Code histology 9590/3, PTLD data item: 4)*\n**6.** Colonoscopy w/bx showed diffuse large B-cell lymphoma w/PTLD. *(Code histology 9680/3, PTLD data item 4)*\n**7.** Right inguinal lymph node biopsy that shows a CD20+ polymorphic PTLD *(Not collected in this schema. Effective 2025+, this would be abstracted as 9971/3 and collected in the HemeRetic schema)*", + "coding_guidelines" : "**See the Hematopoietic manual (Rules M14 and PH1. Hematopoietic Project - SEER Registrars (cancer.gov))**\n\n**1)** **Code 0** when there is no mention of PTLD on the pathology report or medical record\n\n**2)** **Code 1** when the pathology report describes monomorphic PTLD with a lymphoma\n\n**3)** **Code 2** when the pathology report describes Classic Hodgkin lymphoma-PTLD type\n\n**4)** **Code 4** when the pathology report describes a Burkitt like PTLD or doesn’t specify what type of PTLD\n\n***Examples (Courtesy of Ask a SEER Registrar)***\n\n**1.** Staining supports the diagnosis of PTLD, monomorphic type, EBV+ diffuse large b-cell lymphoma (non-germinal center) *(Code histology 9680/3, PTLD data item-1)*\n\n**2.** Monomorphic post-transplant lymphoproliferative disorder (Plasma cell myeloma), EBV negative. Monoclonal kappa plasmacytosis (estimated 20% by CD138 IHC). *(Code histology, 9732/3, PTLD data item: 1)*\n\n**3.** Per Physician, Stage IIA (bulk) PTLD - Hodgkin-like morphology, Intermediate risk. *(Code histology 9650/3, PTLD data item: 2)*\n\n**4.** High grade b cell lymphoma/Burkitt like post-transplant lymphoproliferative disorder. *(Code histology 9687/3, PTLD data item-4)*\n\n**5.** Non-Hodgkin malignant lymphoma with plasmablastic features. Represents a post-transplant/immunodeficiency-related malignant lymphoma. *(Code histology 9590/3, PTLD data item: 4)*\n\n**6.** Colonoscopy w/bx showed diffuse large B-cell lymphoma w/PTLD. *(Code histology 9680/3, PTLD data item 4)*\n\n**7.** Right inguinal lymph node biopsy that shows a CD20+ polymorphic PTLD *(Not collected in this schema. Effective 2025+, this would be abstracted as 9971/3 and collected in the HemeRetic schema)*", "rationale" : "The presence of PTLD, either polymorphic or monomorphic, has clinical significance and prognostic value, especially in the Pediatric and Adolescence and Young Adult (AYA) populations." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/residual_cancer_burden_62520.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/residual_cancer_burden_62520.json index d269f4aea..c2eaadc05 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/residual_cancer_burden_62520.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/residual_cancer_burden_62520.json @@ -6,7 +6,7 @@ "title" : "Residual Cancer Burden (RCB)", "description" : "Residual Cancer Burden (RCB) is a score that measures the amount of cancer remaining in the breast and the regional lymph nodes after neoadjuvant therapy and surgical resection. The RCB score is based on 4 independent prognostic factors measuring the primary tumor bed and 2 independent factors measuring the lymph nodes. \n\nThe RCB score combines these 6 independently prognostic factors from the surgical specimen after neoadjuvant therapy into a single continuous score. This score is prognostic across breast cancer subtypes, different treatments, and within existing stage groups. \n\nThe independent prognostic factors include\n* Primary Tumor Bed\n * Primary Tumor Bed area (measured in millimeters)\n * Includes the largest two dimensions\n * Overall Cancer Cellularity (as percentage of area)\n * Percentage of cancer that is invasive disease\n * Percentage of cancer that is in situ disease\n* Lymph nodes\n * Number of positive lymph nodes\n * Diameter of largest metastasis", "notes" : "***Any questions regarding this SSDI are to be posted in the AJCC CAnswer Forum***\n\n**Note 1:** **Effective years**\n* This SSDI is effective for diagnosis years 2026+. \n* For cases diagnosed 2018-2025, this SSDI must be blank.\n\n**Note 2:** **Criteria for coding**\n* Neoadjuvant therapy **AND** a surgical resection must be done to determine score\n* Leave data item blank if neoadjuvant therapy and a surgical resection are not done\n\n**Note 3:** **CAP Protocol or Synoptic Pathology Report**\n* Only record the information from the CAP Protocol or synoptic pathology report.", - "last_modified" : "2025-05-05T13:50:37.693Z", + "last_modified" : "2025-11-06T18:56:10.558Z", "definition" : [ { "key" : "residual_cancer_burden", "name" : "Code", @@ -17,7 +17,7 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "0.000-9.999", "0.000 – 9.999 score" ], [ "X.777", "Patient had no neoadjuvant therapy, but surgical resection done\nPatient had neoadjuvant therapy, but no surgical resection" ], [ "X.888", "Not applicable: information not collected for this case \n(If this item is required by your standard setter, use of code X.8 will result in an edit error)." ], [ "X.999", "Post neoadjuvant surgery completed and RCB burden not documented in CAP Protocol or synoptic pathology report" ], [ "", "Must be blank if diagnosis year is before 2026" ] ], - "additional_info" : "**Source documents:** pathology report, CAP synoptic report\n\nFor further information, refer to the **Breast Resection cancer protocol** published by the College of American Pathologists for the AJCC Staging System *Breast.*", - "coding_guidelines" : "**1)** Record the Residual Cancer Burden score to the nearest one thousandth. **All three digits beyond the decimal point must be filled in.**\n*Example:* CAP synoptic report states Residual Cancer Burden score 3.151\n* Code 3.151\n*Example:* CAP synoptic reports states Residual Cancer Burden score is 3. \n* Code 3.000\n\n**2)** **Code X.777** when the patient did not have neoadjuvant therapy or did not have surgery. The patient did not meet the criteria for an RCB Score.\n\n**3)** **Code X.999** when a patient has neoadjuvant therapy and post neoadjuvant surgery and information concerning the RCB score is not available. \n* Pathologist does not document the RCB score in the synoptic pathology report or CAP protocol after patient had neoadjuvant therapy followed by surgical resection. \n* Surgical pathology report is not available", + "additional_info" : "**Source documents:** pathology report, CAP synoptic report\n\nFor further information, refer to the **Breast Resection cancer protocol** published by the College of American Pathologists for the AJCC Staging System *Breast*.", + "coding_guidelines" : "**1)** Record the Residual Cancer Burden score to the nearest one thousandth. **All three digits beyond the decimal point must be filled in.**\n\n* *Example:* CAP synoptic report states Residual Cancer Burden score 3.151\n * Code 3.151\n\n* *Example:* CAP synoptic reports states Residual Cancer Burden score is 3. \n * Code 3.000\n\n**2)** **Code X.777** when the patient did not have neoadjuvant therapy or did not have surgery. The patient did not meet the criteria for an RCB Score.\n\n**3)** **Code X.999** when a patient has neoadjuvant therapy and post neoadjuvant surgery and information concerning the RCB score is not available. \n* Pathologist does not document the RCB score in the synoptic pathology report or CAP protocol after patient had neoadjuvant therapy followed by surgical resection. \n* Surgical pathology report is not available", "rationale" : "Neoadjuvant therapy is now standard of care for HER2+ and triple negative breast carcinoma. Quantification of residual disease after neoadjuvant therapy determines further patient management in this setting. The Residual Cancer Burden (RCB) is the most validated measure of volume of residual disease post neoadjuvant for breast cancer and has prognostic value." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/residual_tumor_volume_post_cytoreduction_90653.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/residual_tumor_volume_post_cytoreduction_90653.json index f4a3470de..ff3d58d19 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/residual_tumor_volume_post_cytoreduction_90653.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/residual_tumor_volume_post_cytoreduction_90653.json @@ -6,7 +6,7 @@ "title" : "Residual Tumor Volume Post Cytoreduction", "description" : "Gross residual tumor after primary cytoreductive surgery is a prognostic factor for ovarian cancer and residual tumor volume after cytoreductive surgery is a prognostic factor for late-stage ovarian cancers.\n\nThe amount of ovarian tumor and the location of tumor remaining in the patient after initial ovarian or peritoneal cancer surgery are the most important prognostic factors for advanced disease. The intent of cytoreductive or debulking surgery—particularly for Stage III cancer—is to remove as much of the cancer in the pelvis and abdomen as possible so that chemotherapy will be more effective. The less tumor left behind, the more likely the patient will respond well to adjuvant hemotherapy. Information about residual tumor volume will be in the operative report.", "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of residual tumor status after primary cytoreduction surgery can be used to code this data item when no other information is available.\n\n**Note 2:** **Optimal debulking surgery** \n* Optimal debulking is described as removal of all tumor except for residual nodules that measure no more than 1 centimeter (cm) in maximum diameter.\n\n**Note 3:** **Purpose of surgery** \n* The surgery to remove as much cancer in the pelvis and/or abdomen as possible, reducing the \"bulk\" of the cancer, is called **\"debulking\"** or **\"cytoreductive\"** surgery. \n * It is performed when there is widespread evidence of advanced stage of ovarian cancer with obvious spread to other organs outside the ovary, typically in the upper abdomen, intestines, the omentum (the fat pad suspended from the transverse colon like an apron), the diaphragm, or liver. \n\n**Note 4:** **Gross residual tumor** \n* Gross residual tumor after primary cytoreductive surgery is a prognostic factor that has been demonstrated in large studies. The best prognostic category after surgery includes those who are left with no gross residual tumor.\n* Physicians should record the presence or absence of residual disease, if residual disease is observed, the size of the largest visible lesion should be documented", - "last_modified" : "2024-04-08T20:47:22.516Z", + "last_modified" : "2025-11-05T21:47:50.378Z", "definition" : [ { "key" : "resid_tumor_vol_post_cyto", "name" : "Code", @@ -17,6 +17,6 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "00", "No gross residual tumor nodules" ], [ "50", "Residual tumor nodule(s) 1 centimeter (cm) or less" ], [ "60", "Residual tumor nodule(s) greater than 1 cm" ], [ "70", "Macroscopic residual tumor nodule(s), size not stated" ], [ "80", "Procedure described as optimal debulking and size of residual tumor nodule(s) not given" ], [ "97", "No cytoreductive surgery performed\nNon-invasive neoplasm (behavior /2)" ], [ "98", "Not applicable: Information not collected for this case\n(If this item is required by your standard setter, use of code 98 will result in an edit error.)" ], [ "99", "Not documented in medical record\nResidual tumor status after cytoreductive surgery not assessed or unknown if assessed" ] ], - "additional_info" : "* **Source documents:** operative report, discharge summary, chemotherapy records (inpatient and outpatient)\n\n* **Other names include** debulking, cytoreduction, residual tumor volume\n\nFor further information, refer to the **Ovary, Fallopian Tube, or Peritoneum** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Ovary, Fallopian Tube, and Primary Peritoneal Carcinoma*", + "additional_info" : "* **Source documents:** operative report, discharge summary, chemotherapy records (inpatient and outpatient)\n\n* **Other names include** debulking, cytoreduction, residual tumor volume\n\nFor further information, refer to the **Ovary, Fallopian Tube, or Peritoneum** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Ovary, Fallopian Tube, and Primary Peritoneal Carcinoma*.", "rationale" : "Residual Tumor Volume Post Cytoreduction is a Registry Data Collection Variable listed in AJCC. It was previously collected as Ovary, CS SSF # 3." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/response_to_neoadjuvant_therapy_57695.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/response_to_neoadjuvant_therapy_57695.json index 6221d6a51..8fb23ddc2 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/response_to_neoadjuvant_therapy_57695.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/response_to_neoadjuvant_therapy_57695.json @@ -6,7 +6,7 @@ "title" : "Response to Neoadjuvant Therapy", "description" : "This data item records the physician’s statement of response to neoadjuvant chemotherapy.\n\nNeoadjuvant therapy is defined as systemic, or radiation treatment administered prior to surgery in an attempt to shrink the tumor or destroy regional metastases. This data item documents whether that neoadjuvant therapy was successful. \n\nThis data item is coded based on the clinician’s statement regarding response to neoadjuvant therapy. Do not try to interpret or infer a response based on the medical record. As a guide for the clinician, the definitions below are from the AJCC Cancer Staging Manual, 8th edition. \n\nThe registrar should not use these definitions to code this field \n* Complete Response (CR) – absence of invasive carcinoma in breast and lymph nodes; must be determined by microscopic evaluation of tissues; residual in situ cancer at primary site\n* Partial Response (PR) – a decrease in T and/or N category compared to pretreatment value and no increase, using same method of evaluation as baseline value, residual tumor in lymph nodes of any size\n* No Response (NR) – no apparent change in the T or N category compared to pretreatment value, or an increase in T or N value at time of y pathological examination", "notes" : "**Note 1:** **Physician Statement**\n* A statement from the managing physician for Response to Neoadjuvant Therapy (\"treatment effect\") **must be used to code this data item**.\n\n**Note 2:** **Criteria for coding** \n* This data item should not be coded based on the following pathological, radiological, and imaging findings \n* **This data item should only be coded based on the managing physician's overall interpretation of the results**.\n\n**Note 3:** **SEER Data Item Neoadjuvant Therapy-Treatment effect**\n* The rules for this data item from SEER are different to Response to Neoadjuvant Therapy\n* **Do not use the rules from SEER's Neoadjuvant Therapy-Treatment effect [NAACCR ID# 1634] to code Response to Neoadjuvant therapy**", - "last_modified" : "2025-02-24T14:54:40.962Z", + "last_modified" : "2025-11-05T21:02:01.697Z", "definition" : [ { "key" : "response_neoadjuv_therapy", "name" : "Code", @@ -17,7 +17,7 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "0", "Neoadjuvant therapy not given\nNon-invasive neoplasm (behavior /2)" ], [ "1", "Stated as complete response (CR)" ], [ "2", "Stated as partial response (PR)" ], [ "3", "Stated as response to treatment, but not noted if complete or partial" ], [ "4", "Stated as no response (NR)" ], [ "8", "Not applicable: Information not collected for this case\n(If this item is required by your standard setter, use of code 8 will result in an edit error.)" ], [ "9", "Not documented in medical record\nResponse to neoadjuvant therapy not assessed or unknown if assessed\nUnknown if neoadjuvant therapy given" ] ], - "additional_info" : "**Source documents:** physician statement \n\n**Other names include** treatment effect\n\nFor further information, refer to the **Breast or Breast Biomarker Reporting** cancer protocols published by the College of American Pathologists for the AJCC Staging System *Breast*", + "additional_info" : "**Source documents:** physician statement \n\n**Other names include** treatment effect\n\nFor further information, refer to the **Breast or Breast Biomarker Reporting** cancer protocols published by the College of American Pathologists for the AJCC Staging System *Breast*.", "coding_guidelines" : "**1)** Code 0 if there is no neoadjuvant therapy given\n* This includes in situ (behavior /2) cases\n\n**2)** Code 1 for a Residual Cancer Burden (RCB) result of '0' or an RCB Class of pCR (pathological complete response).\n* Code 1 is to be used only when the managing physician states the response is \"total\" or \"complete\"\n\n**3)** Code 9 when\n* There is no statement of complete, partial or no response by the clinician or when the response is not documented in the medical record\n* Only the post neoadjuvant surgical pathology report is available", "rationale" : "Response to Neoadjuvant Therapy is a Registry Data Collection Variable in AJCC. It was previously collected as Breast, CS SSF #21." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/s_category_clinical_19191.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/s_category_clinical_19191.json index 4e0e354ed..9698a940c 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/s_category_clinical_19191.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/s_category_clinical_19191.json @@ -5,8 +5,8 @@ "name" : "S Category Clinical", "title" : "Testis Serum Markers (S) Clinical (pre orchiectomy)", "description" : "S Category Clinical combines the results of pre-orchiectomy Alpha Fetoprotein (AFP), Human Chorionic Gonadotropin (hCG) and Lactate Dehydrogenase (LDH) into a summary S value.\n\nIn addition to T, N, and M, the S category is collected to stage Testicular cancers. There are three factors that make up the S stage: alpha-fetoprotein (AFP), beta-human chorionic gonadotropin (beta-hCG), and lactase dehydrogenase (LDH). These play an important role as serum tumor markers in the staging and monitoring of germ cell tumors and should be measured prior to removing the involved testicle. For patients with nonseminomas, the degree of tumor-marker elevation after the cancerous testicular has been removed is one of the most significant predictors of prognosis. Serum tumor markers are also very useful for monitoring all stages of nonseminomas and for monitoring metastatic seminomas because elevated marker levels are often the earliest sign of relapse.\n\nThere are several related data items pertinent to the collection of these variables.\n\nFor clinical staging \n* 3807: AFP Pre-Orchiectomy Lab Value\n* 3808: AFP Pre-Orchiectomy Range\n* 3848: hCG Pre-Orchiectomy Lab Value\n* 3849: hCG Pre-Orchiectomy Range\n* 3868: LDH Pre-Orchiectomy Range\n* 3923: S Category Clinical", - "notes" : "**Note 1:** **Physician Statement** \n* Code the S category as described by the physician. If the S category determined by available lab values or calculated by vendor software differs from the physician statement of the S category, the physician's statement takes precedence. \n\n**Note 2:** **Pre-orchiectomy S category** \n* Code the pre-orchiectomy S category (Clinical S) according to the table below. This table is also available in AJCC 8th edition, Chapter 59, Testis.\n* For AFP, a lab value expressed in micrograms per liter (ug/L) is equivalent to the same value expressed in nanograms per milliliter (ng/ml).\n\n**Note 3:** **Clinical Stage** \n* Clinical stage values are those based on physician statement or lab values at diagnosis, prior to orchiectomy, and prior to any systemic treatment.\n\n**Note 4:** **AFP, hCG, LDH** \n* All three lab values are needed for S0-S1. Only one elevated test is needed to assign S2-3. If any individual test is not available and none of the available tests results meets the S2-3 criterion for that test, assign code 9 (SX).", - "last_modified" : "2024-03-30T23:55:45.273Z", + "notes" : "**Note 1:** **Physician Statement** \n* Code the S category as described by the physician. If the S category determined by available lab values or calculated by vendor software differs from the physician statement of the S category, the physician's statement takes precedence. \n\n**Note 2:** **Pre-orchiectomy S category** \n* Code the pre-orchiectomy S category (Clinical S) according to the table below. This table is also available in AJCC 8th edition, Chapter 59, Testis.\n* For AFP, a lab value expressed in micrograms per liter (ug/L) is equivalent to the same value expressed in nanograms per milliliter (ng/ml).\n\n**Note 3:** **Clinical Stage** \n* Clinical stage values are those based on physician statement or lab values at diagnosis, prior to orchiectomy, and prior to any systemic treatment.\n\n**Note 4:** **AFP, hCG, LDH** \n* All three lab values are needed for S0-S1. Only one elevated test is needed to assign S2-3. If any individual test is not available and none of the available test results meet the S2-3 criterion for that test, assign code 9 (SX).", + "last_modified" : "2025-11-06T20:59:27.459Z", "definition" : [ { "key" : "s_category_clin", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/s_category_pathologic_34448.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/s_category_pathologic_34448.json index be6f386dc..04ad9c0be 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/s_category_pathologic_34448.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/s_category_pathologic_34448.json @@ -5,8 +5,8 @@ "name" : "S Category Pathological", "title" : "Testis Serum Markers (S) Pathological (post-orchiectomy )", "description" : "S Category Pathological combines the results of post-orchiectomy Alpha Fetoprotein (AFP), Human Chorionic Gonadotropin (hCG) and Lactate Dehydrogenase (LDH) into a summary S value.\n\nIn addition to T, N, and M, the S category is collected to stage Testicular cancers. There are three factors that make up the S stage: alpha-fetoprotein (AFP), beta-human chorionic gonadotropin (beta-hCG), and lactase dehydrogenase (LDH). These play an important role as serum tumor markers in the staging and monitoring of germ cell tumors and should be measured prior to removing the involved testicle. For patients with nonseminomas, the degree of tumor-marker elevation after the cancerous testicular has been removed is one of the most significant predictors of prognosis. Serum tumor markers are also very useful for monitoring all stages of nonseminomas and for monitoring metastatic seminomas because elevated marker levels are often the earliest sign of relapse.\n\nThere are several related data items pertinent to the collection of these variables.\n\nFor pathological staging \n* 3805: AFP Post-Orchiectomy Lab Value\n* 3806: AFP Post-Orchiectomy Range\n* 3846: hCG Post-Orchiectomy Lab Value\n* 3847: hCG Post-Orchiectomy Range\n* 3867: LDH Post-Orchiectomy Range\n* 3924: S Category Pathological", - "notes" : "**Note 1:** **Physician Statement** \n* Code the S category as described by the physician. If the S category determined by available lab values or calculated by vendor software differs from the physician statement of the S category, the physician's statement takes precedence. \n\n**Note 2:** **Post-orchiectomy S Category** \n* Code the post-orchiectomy S category (Pathological S) according to the table below. This table is also available in AJCC 8th edition, Chapter 59, Testis.\n* For AFP, a lab value expressed in micrograms per liter (ug/L) is equivalent to the same value expressed in nanograms per milliliter (ng/ml).\n\n**Note 3:** **Timing** \n* Pathological stage values are those based on physician statement or lab values **after orchiectomy and prior to adjuvant therapy**. \n\n**Note 4:** **Lab values elevated after orchiectomy** \n* If the initial post-orchiectomy lab values remain elevated, review the subsequent tests and use the lowest lab values (normalization or plateau) prior to adjuvant therapy or before the value rises again.\n\n**Note 5:** **AFP, hCG, LDH** \n* All three lab values are needed for S0-S1. Only one elevated test is needed to assign S2-3. If any individual test is not available and none of the available tests results meets the S2-3 criterion for that test, assign code 9 (SX).\n\n**Note 6:** **Normal Serum Tumor Markers (pre-orchiectomy)** \n* When all the serum tumor markers are normal pre-orchiectomy and they are not repeated post-orchiectomy, code 5.", - "last_modified" : "2024-03-30T23:58:36.472Z", + "notes" : "**Note 1:** **Physician Statement** \n* Code the S category as described by the physician. If the S category determined by available lab values or calculated by vendor software differs from the physician statement of the S category, the physician's statement takes precedence. \n\n**Note 2:** **Post-orchiectomy S Category** \n* Code the post-orchiectomy S category (Pathological S) according to the table below. This table is also available in AJCC 8th edition, Chapter 59, Testis.\n* For AFP, a lab value expressed in micrograms per liter (ug/L) is equivalent to the same value expressed in nanograms per milliliter (ng/ml).\n\n**Note 3:** **Timing** \n* Pathological stage values are those based on physician statement or lab values **after orchiectomy and prior to adjuvant therapy**. \n\n**Note 4:** **Lab values elevated after orchiectomy** \n* If the initial post-orchiectomy lab values remain elevated, review the subsequent tests and use the lowest lab values (normalization or plateau) prior to adjuvant therapy or before the value rises again.\n\n**Note 5:** **AFP, hCG, LDH** \n* All three lab values are needed for S0-S1. Only one elevated test is needed to assign S2-3. If any individual test is not available and none of the available test results meet the S2-3 criterion for that test, assign code 9 (SX).\n\n**Note 6:** **Normal Serum Tumor Markers (pre-orchiectomy)** \n* When all the serum tumor markers are normal pre-orchiectomy and they are not repeated post-orchiectomy, code 5.", + "last_modified" : "2025-11-06T20:59:50.104Z", "definition" : [ { "key" : "s_category_path", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/sarcomatoid_features_99558.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/sarcomatoid_features_99558.json index 96d704750..16646bfb0 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/sarcomatoid_features_99558.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/sarcomatoid_features_99558.json @@ -4,9 +4,9 @@ "version" : "3.3", "name" : "Sarcomatoid Features", "title" : "Sarcomatoid Features", - "description" : "Sarcomatoid features: present or absent and percentage refers to the observation of sheets and fascicles of malignant spindle cells in a kidney tumor which can occur across all histologic subtypes. The percentage of sarcomatoid component has been shown to correlate with cancer-specific mortality. \n\nThe presence of sarcomatoid or spindle cell features in a kidney tumor is a strong adverse prognostic factor. There is a specific ICD-O morphology code for renal cell carcinoma, sarcomatoid or spindle cell (8318/3), but this data item documents any sarcomatoid or spindle cell features in any renal cell cancer. \n* Note: This data item applies to carcinomas only; rare sarcomas of the kidney should not be coded in this field\n* Code the percentage of sarcomatoid features documented anywhere in the pathology report", + "description" : "Sarcomatoid features: present or absent and percentage refers to the observation of sheets and fascicles of malignant spindle cells in a kidney tumor which can occur across all histologic subtypes. The percentage of sarcomatoid component has been shown to correlate with cancer-specific mortality. \n\nThe presence of sarcomatoid or spindle cell features in a kidney tumor is a strong adverse prognostic factor. There is a specific ICD-O morphology code for renal cell carcinoma, sarcomatoid or spindle cell (8318/3), but this data item documents any sarcomatoid or spindle cell features in any renal cell cancer. \n* **Note:** This data item applies to carcinomas only; rare sarcomas of the kidney should not be coded in this field\n* Code the percentage of sarcomatoid features documented anywhere in the pathology report", "notes" : "**Note 1:** **Physician Staging** \n* Physician statement of Sarcomatoid Features (spindle cell features) can be used to code this data item when no other information is available.\n\n**Note 2:** **Criteria for coding** \n* Surgical resection of primary site must be done\n * If no surgical resection of primary site, code unknown (code 9)\n* Do not use imaging findings to code this data item.\n\n**Note 3:** **Sarcomatoid morphology/features** \n* Sarcomatoid morphology may be manifested by any renal cell carcinoma. The presence of sarcomatoid component in a renal cell carcinoma may be prognostically important. \n\n* Sarcomatoid features is mostly seen with renal cell carcinoma (all variants); however, if it’s seen with other carcinoma histologies, it can be coded.", - "last_modified" : "2025-02-24T15:48:53.342Z", + "last_modified" : "2025-11-06T21:19:18.826Z", "definition" : [ { "key" : "sarcomatoid_features", "name" : "Code", @@ -17,7 +17,7 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "000", "Sarcomatoid features not present/not identified " ], [ "001-100", "Sarcomatoid features 1-100%" ], [ "R01", "Sarcomatoid features stated as less than 10%" ], [ "R02", "Sarcomatoid features stated as range 10%-30% present" ], [ "R03", "Sarcomatoid features stated as a range 31% to 50% present" ], [ "R04", "Sarcomatoid features stated as a range 51% to 80% present" ], [ "R05", "Sarcomatoid features stated as greater than 80%" ], [ "XX5", "Sarcomatoid features present from metastatic site only AND\nSarcomatoid features not present, or unknown if present, in primary site" ], [ "XX6", "Sarcomatoid features present, percentage unknown" ], [ "XX7", "Not applicable: Not a renal cell carcinoma morphology" ], [ "XX8", "Not applicable: Information not collected for this case\n(If this information is required by your standard setter, use of code XX8 may result in an edit error.)" ], [ "XX9", "Not documented in medical record\nSarcomatoid features not assessed or unknown if assessed\nNo surgical resection of primary site is performed" ] ], - "additional_info" : "**Source Documents:** Surgical pathology report\n\nFor further information, refer to the **Kidney** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Kidney*", - "coding_guidelines" : "**1)** Record whether sarcomatoid features are present or absent as documented in the surgical pathology report\n* Surgical resection of primary site must be done\n* Do not use imaging findings to code this data item.\n\n**2)** **Code 000** when the surgical pathology report states that there are no sarcomatoid features\n**3)** **Code 001-100** code exact percentage of sarcomatoid features appropriately [1% (001) to 100% (100)]\n**4)** **Code R01-R05** when only range documented (specific percentage not available)\n**5)** **Code XX5** when the only information available about Sarcomatoid features is from a metastatic site\n**6)** **Code XX6** when sarcomatoid features present, percentage unknown\n**7)** **Code XX7** when histology is not renal cell carcinoma (includes other carcinomas that are not renal cell and sarcomas)\n**8)** **Code XX9** when\n* There is no documentation in the medical record\n* Clinical diagnosis only\n* Evaluation of sarcomatoid features not done or unknown if done\n* Surgical resection of the primary site is performed and there is no mention of sarcomatoid features", + "additional_info" : "**Source Documents:** Surgical pathology report\n\nFor further information, refer to the **Kidney** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Kidney*.", + "coding_guidelines" : "**1)** Record whether sarcomatoid features are present or absent as documented in the surgical pathology report\n* Surgical resection of primary site must be done\n* Do not use imaging findings to code this data item.\n\n**2)** **Code 000** when the surgical pathology report states that there are no sarcomatoid features\n\n**3)** **Code 001-100** code exact percentage of sarcomatoid features appropriately [1% (001) to 100% (100)]\n\n**4)** **Code R01-R05** when only range documented (specific percentage not available)\n\n**5)** **Code XX5** when the only information available about Sarcomatoid features is from a metastatic site\n\n**6)** **Code XX6** when sarcomatoid features present, percentage unknown\n\n**7)** **Code XX7** when histology is not renal cell carcinoma (includes other carcinomas that are not renal cell and sarcomas)\n\n**8)** **Code XX9** when\n* There is no documentation in the medical record\n* Clinical diagnosis only\n* Evaluation of sarcomatoid features not done or unknown if done\n* Surgical resection of the primary site is performed and there is no mention of sarcomatoid features", "rationale" : "Sarcomatoid features for Kidney is a Registry Data Collection Variable in AJCC. It was previously collected as Kidney, CS SSF #4." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_bile_ducts_intrahepat.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_bile_ducts_intrahepat.json index 92898baaa..a4d03c867 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_bile_ducts_intrahepat.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_bile_ducts_intrahepat.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Schema Selection BileDuctsIntraHepat", "title" : "Schema selection for BileDuctsIntraHepat", - "last_modified" : "2025-07-07T18:43:50.443Z", + "last_modified" : "2025-09-24T15:41:43.295Z", "definition" : [ { "key" : "site", "name" : "Primary Site", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_bone.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_bone.json index e0c82aad3..cfaa32317 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_bone.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_bone.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Schema Selection Bone", "title" : "Schema selection for Bone", - "last_modified" : "2025-07-08T19:18:50.367Z", + "last_modified" : "2025-09-24T15:39:04.703Z", "definition" : [ { "key" : "site", "name" : "Primary Site", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_bone_appendicular_skeleton.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_bone_appendicular_skeleton.json index d73f1851f..7aedab221 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_bone_appendicular_skeleton.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_bone_appendicular_skeleton.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Schema Selection Bone Appendicular Skeleton", "title" : "Schema selection for Bone Appendicular Skeleton", - "last_modified" : "2025-07-07T18:48:09.384Z", + "last_modified" : "2025-09-24T15:39:07.847Z", "definition" : [ { "key" : "site", "name" : "Primary Site", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_bone_spine.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_bone_spine.json index a8f9befb2..cf84d50a6 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_bone_spine.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_bone_spine.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Schema Selection Bone Spine", "title" : "Schema selection for Bone Spine", - "last_modified" : "2025-07-07T18:50:48.346Z", + "last_modified" : "2025-09-24T15:39:01.551Z", "definition" : [ { "key" : "site", "name" : "Primary Site", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_breast.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_breast.json index bd458c517..52beeecac 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_breast.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_breast.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Schema Selection Breast", "title" : "Schema selection for Breast", - "last_modified" : "2025-09-15T20:31:10.514Z", + "last_modified" : "2025-09-26T20:23:37.614Z", "definition" : [ { "key" : "site", "name" : "Primary Site", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_buccal_mucosa.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_buccal_mucosa.json index 508c9d48e..c397ba5f2 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_buccal_mucosa.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_buccal_mucosa.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Schema Selection BuccalMucosa", "title" : "Schema selection for BuccalMucosa", - "last_modified" : "2025-09-15T19:31:55.660Z", + "last_modified" : "2025-09-25T14:06:59.350Z", "definition" : [ { "key" : "site", "name" : "Primary Site", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_cervical_lymph_nodes_occult_head_and_neck.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_cervical_lymph_nodes_occult_head_and_neck.json index 8bc6d215f..22015b9c5 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_cervical_lymph_nodes_occult_head_and_neck.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_cervical_lymph_nodes_occult_head_and_neck.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Schema Selection Cervical Lymph Nodes, Occult Head and Neck", "title" : "Schema selection for Cervical Lymph Nodes, Occult Head and Neck", - "last_modified" : "2025-09-15T19:31:16.447Z", + "last_modified" : "2025-09-25T14:11:41.865Z", "definition" : [ { "key" : "site", "name" : "Primary Site", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_cervix_9th_2021.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_cervix_9th_2021.json index 98cd4e5ec..2ec611177 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_cervix_9th_2021.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_cervix_9th_2021.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Schema Selection Cervix [9th: 2021+]", "title" : "Schema selection for Cervix [9th: 2021+]", - "last_modified" : "2025-09-15T20:42:56.333Z", + "last_modified" : "2025-09-24T16:29:55.329Z", "definition" : [ { "key" : "site", "name" : "Primary Site", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_cervix_sarcoma.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_cervix_sarcoma.json index 7e08ba4be..76b802c21 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_cervix_sarcoma.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_cervix_sarcoma.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Schema Selection Cervix Sarcoma", "title" : "Schema selection for Cervix Sarcoma", - "last_modified" : "2025-09-15T20:09:16.754Z", + "last_modified" : "2025-09-24T16:29:58.418Z", "definition" : [ { "key" : "site", "name" : "Primary Site", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_chronic_lymphocytic_leukemia_small_lymphocytic_lymphoma_cll_sll.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_chronic_lymphocytic_leukemia_small_lymphocytic_lymphoma_cll_sll.json index 5f9f4cffd..7bb57b927 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_chronic_lymphocytic_leukemia_small_lymphocytic_lymphoma_cll_sll.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_chronic_lymphocytic_leukemia_small_lymphocytic_lymphoma_cll_sll.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Schema Selection Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)", "title" : "Schema selection for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)", - "last_modified" : "2025-09-15T20:25:25.243Z", + "last_modified" : "2025-09-25T14:47:05.781Z", "definition" : [ { "key" : "site", "name" : "Primary Site", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_colon.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_colon.json index 2e0970916..5c76d6797 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_colon.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_colon.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Schema Selection Colon", "title" : "Schema selection for Colon", - "last_modified" : "2025-09-15T19:53:14.794Z", + "last_modified" : "2025-09-25T14:25:44.800Z", "definition" : [ { "key" : "site", "name" : "Primary Site", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_corpus_adenosarcoma.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_corpus_adenosarcoma.json index a241b0165..fea468149 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_corpus_adenosarcoma.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_corpus_adenosarcoma.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Schema Selection CorpusAdenosarcoma", "title" : "Schema selection for CorpusAdenosarcoma", - "last_modified" : "2025-09-15T20:09:19.418Z", + "last_modified" : "2025-09-24T16:30:01.671Z", "definition" : [ { "key" : "site", "name" : "Primary Site", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_corpus_carcinoma.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_corpus_carcinoma.json index 8cc941022..cd7b5d06b 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_corpus_carcinoma.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_corpus_carcinoma.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Schema Selection CorpusCarcinoma", "title" : "Schema selection for CorpusCarcinoma", - "last_modified" : "2025-09-15T20:09:21.600Z", + "last_modified" : "2025-09-24T16:30:05.173Z", "definition" : [ { "key" : "site", "name" : "Primary Site", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_corpus_sarcoma.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_corpus_sarcoma.json index dad220aa3..1a7ed72ab 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_corpus_sarcoma.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_corpus_sarcoma.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Schema Selection CorpusSarcoma", "title" : "Schema selection for CorpusSarcoma", - "last_modified" : "2025-09-15T20:09:23.974Z", + "last_modified" : "2025-09-24T16:30:09.230Z", "definition" : [ { "key" : "site", "name" : "Primary Site", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_cutaneous_squamous_cell_carcinoma_head_and_neck.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_cutaneous_squamous_cell_carcinoma_head_and_neck.json index 7072f32ec..091bbf73f 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_cutaneous_squamous_cell_carcinoma_head_and_neck.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_cutaneous_squamous_cell_carcinoma_head_and_neck.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Schema Selection Cutaneous Squamous Cell Carcinoma Head and Neck", "title" : "Schema selection for Cutaneous Squamous Cell Carcinoma Head and Neck", - "last_modified" : "2025-09-15T19:37:19.890Z", + "last_modified" : "2025-09-25T14:04:32.629Z", "definition" : [ { "key" : "site", "name" : "Primary Site", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_fallopian_tube.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_fallopian_tube.json index 2ff4bcccb..88fb1d53e 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_fallopian_tube.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_fallopian_tube.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Schema Selection Fallopian Tube", "title" : "Schema selection for Fallopian Tube", - "last_modified" : "2025-09-15T20:09:26.433Z", + "last_modified" : "2025-09-24T21:11:49.232Z", "definition" : [ { "key" : "site", "name" : "Primary Site", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_floor_mouth.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_floor_mouth.json index 90d36ab4c..fa56d1b45 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_floor_mouth.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_floor_mouth.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Schema Selection FloorMouth", "title" : "Schema selection for FloorMouth", - "last_modified" : "2025-09-15T19:31:41.627Z", + "last_modified" : "2025-09-25T14:06:46.815Z", "definition" : [ { "key" : "site", "name" : "Primary Site", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_gum_lower.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_gum_lower.json index 40a09ce59..0514a36d5 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_gum_lower.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_gum_lower.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Schema Selection GumLower", "title" : "Schema selection for GumLower", - "last_modified" : "2025-09-15T19:31:35.142Z", + "last_modified" : "2025-09-25T14:06:52.153Z", "definition" : [ { "key" : "site", "name" : "Primary Site", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_heart_mediastinum.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_heart_mediastinum.json index 4eeb64674..761d30e8b 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_heart_mediastinum.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_heart_mediastinum.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Schema Selection HeartMediastinum", "title" : "Schema selection for HeartMediastinum", - "last_modified" : "2025-09-15T19:59:03.964Z", + "last_modified" : "2025-09-24T16:19:49.703Z", "definition" : [ { "key" : "site", "name" : "Primary Site", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_heme_retic.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_heme_retic.json index b75981bcd..a74ce4b64 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_heme_retic.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_heme_retic.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Schema Selection HemeRetic", "title" : "Schema selection for HemeRetic", - "last_modified" : "2025-09-08T17:33:48.223Z", + "last_modified" : "2025-09-26T16:07:27.133Z", "definition" : [ { "key" : "site", "name" : "Primary Site", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_hypopharynx.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_hypopharynx.json index d6e1b1138..05dd89660 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_hypopharynx.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_hypopharynx.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Schema Selection Hypopharynx", "title" : "Schema selection for Hypopharynx", - "last_modified" : "2025-09-15T19:35:23.883Z", + "last_modified" : "2025-09-25T14:06:24.568Z", "definition" : [ { "key" : "site", "name" : "Primary Site", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_kidney_parenchyma.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_kidney_parenchyma.json index 45444b287..b325f547d 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_kidney_parenchyma.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_kidney_parenchyma.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Schema Selection KidneyParenchyma", "title" : "Schema selection for KidneyParenchyma", - "last_modified" : "2025-09-15T20:22:41.618Z", + "last_modified" : "2025-09-25T14:30:15.343Z", "definition" : [ { "key" : "site", "name" : "Primary Site", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_lacrimal_gland.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_lacrimal_gland.json index acadf146b..5382e89c4 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_lacrimal_gland.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_lacrimal_gland.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Schema Selection LacrimalGland", "title" : "Schema selection for LacrimalGland", - "last_modified" : "2025-09-15T20:23:21.517Z", + "last_modified" : "2025-09-24T15:56:13.405Z", "definition" : [ { "key" : "site", "name" : "Primary Site", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_larynx_glottic.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_larynx_glottic.json index 86be203ea..5d4d67502 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_larynx_glottic.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_larynx_glottic.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Schema Selection LarynxGlottic", "title" : "Schema selection for LarynxGlottic", - "last_modified" : "2025-09-15T19:35:32.721Z", + "last_modified" : "2025-09-25T14:06:28.379Z", "definition" : [ { "key" : "site", "name" : "Primary Site", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_larynx_other.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_larynx_other.json index 583339333..d150e969b 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_larynx_other.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_larynx_other.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Schema Selection LarynxOther", "title" : "Schema selection for LarynxOther", - "last_modified" : "2025-09-15T19:35:35.073Z", + "last_modified" : "2025-09-25T14:06:31.869Z", "definition" : [ { "key" : "site", "name" : "Primary Site", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_larynx_subglottic.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_larynx_subglottic.json index 5708aca0d..37a258328 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_larynx_subglottic.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_larynx_subglottic.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Schema Selection LarynxSubglottic", "title" : "Schema selection for LarynxSubglottic", - "last_modified" : "2025-09-15T19:35:38.161Z", + "last_modified" : "2025-09-25T14:06:35.892Z", "definition" : [ { "key" : "site", "name" : "Primary Site", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_larynx_supraglottic.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_larynx_supraglottic.json index 19472ba31..36f815a92 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_larynx_supraglottic.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_larynx_supraglottic.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Schema Selection LarynxSupraglottic", "title" : "Schema selection for LarynxSupraglottic", - "last_modified" : "2025-09-15T19:35:40.982Z", + "last_modified" : "2025-09-26T19:33:45.012Z", "definition" : [ { "key" : "site", "name" : "Primary Site", @@ -13,10 +13,14 @@ "key" : "hist", "name" : "Histology", "type" : "INPUT" + }, { + "key" : "year_dx", + "name" : "Year of Diagnosis", + "type" : "INPUT" }, { "key" : "result", "name" : "Result", "type" : "ENDPOINT" } ], - "rows" : [ [ "C101,C321", "8000-8700", "MATCH" ] ] + "rows" : [ [ "C321", "8000-8700", "*", "MATCH" ], [ "C101", "8000-8700", "2018-2025", "MATCH" ] ] } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_lip_lower.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_lip_lower.json index 983a4358c..ffc51291f 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_lip_lower.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_lip_lower.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Schema Selection LipLower", "title" : "Schema selection for LipLower", - "last_modified" : "2025-09-15T19:31:23.028Z", + "last_modified" : "2025-09-25T14:06:42.826Z", "definition" : [ { "key" : "site", "name" : "Primary Site", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_liver.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_liver.json index 00e28c8da..5e3b49187 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_liver.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_liver.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Schema Selection Liver", "title" : "Schema selection for Liver", - "last_modified" : "2025-07-07T19:33:39.470Z", + "last_modified" : "2025-09-24T15:41:55.194Z", "definition" : [ { "key" : "site", "name" : "Primary Site", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_lung.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_lung.json index 5d18f6beb..a8761428e 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_lung.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_lung.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Schema Selection Lung", "title" : "Schema selection for Lung", - "last_modified" : "2025-09-15T19:55:54.724Z", + "last_modified" : "2025-09-25T14:49:38.187Z", "definition" : [ { "key" : "site", "name" : "Primary Site", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_lung_v9_2025.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_lung_v9_2025.json index e6ef074d6..60771901d 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_lung_v9_2025.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_lung_v9_2025.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Schema Selection Lung [V9: 2025+]", "title" : "Schema selection for Lung [V9: 2025+]", - "last_modified" : "2025-09-15T19:55:22.154Z", + "last_modified" : "2025-09-26T20:22:06.166Z", "definition" : [ { "key" : "site", "name" : "Primary Site", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_lymphoma.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_lymphoma.json index 07f6fda1a..5ecb852ef 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_lymphoma.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_lymphoma.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Schema Selection Lymphoma", "title" : "Schema selection for Lymphoma", - "last_modified" : "2025-09-15T20:25:21.890Z", + "last_modified" : "2025-09-26T16:03:38.689Z", "definition" : [ { "key" : "site", "name" : "Primary Site", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_lymphoma_ocular_adnexa.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_lymphoma_ocular_adnexa.json index 13eefdb7a..eebc7d89d 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_lymphoma_ocular_adnexa.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_lymphoma_ocular_adnexa.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Schema Selection LymphomaOcularAdnexa", "title" : "Schema selection for LymphomaOcularAdnexa", - "last_modified" : "2025-09-05T22:16:47.868Z", + "last_modified" : "2025-09-26T16:00:27.120Z", "definition" : [ { "key" : "site", "name" : "Primary Site", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_major_salivary_glands_v9_2026.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_major_salivary_glands_v9_2026.json index 3573983df..84c7e8831 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_major_salivary_glands_v9_2026.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_major_salivary_glands_v9_2026.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Schema Selection Major Salivary Glands [V9: 2026+]", "title" : "Schema selection for Major Salivary Glands [V9: 2026+]", - "last_modified" : "2025-09-15T19:32:23.189Z", + "last_modified" : "2025-09-25T14:06:16.157Z", "definition" : [ { "key" : "site", "name" : "Primary Site", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_melanoma_buccal_mucosa.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_melanoma_buccal_mucosa.json index 63fd2ace8..4352e9233 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_melanoma_buccal_mucosa.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_melanoma_buccal_mucosa.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Schema Selection MelanomaBuccalMucosa", "title" : "Schema selection for MelanomaBuccalMucosa", - "last_modified" : "2025-09-15T19:36:11.780Z", + "last_modified" : "2025-09-25T14:11:38.166Z", "definition" : [ { "key" : "site", "name" : "Primary Site", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_melanoma_ciliary_body.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_melanoma_ciliary_body.json index a94d02e9a..ca4056820 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_melanoma_ciliary_body.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_melanoma_ciliary_body.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Schema Selection MelanomaCiliaryBody", "title" : "Schema selection for MelanomaCiliaryBody", - "last_modified" : "2025-09-16T14:29:48.961Z", + "last_modified" : "2025-09-24T14:54:59.865Z", "definition" : [ { "key" : "site", "name" : "Primary Site", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_melanoma_skin.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_melanoma_skin.json index c0dc99aa4..46121b0b4 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_melanoma_skin.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_melanoma_skin.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Schema Selection MelanomaSkin", "title" : "Schema selection for MelanomaSkin", - "last_modified" : "2025-09-15T20:01:44.399Z", + "last_modified" : "2025-09-25T14:54:50.197Z", "definition" : [ { "key" : "site", "name" : "Primary Site", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_merkel_cell_skin.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_merkel_cell_skin.json index 50e371259..24924ec02 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_merkel_cell_skin.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_merkel_cell_skin.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Schema Selection MerkelCellSkin", "title" : "Schema selection for MerkelCellSkin", - "last_modified" : "2025-09-15T20:00:25.758Z", + "last_modified" : "2025-09-25T14:35:47.309Z", "definition" : [ { "key" : "site", "name" : "Primary Site", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_mouth_other.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_mouth_other.json index c2a72365a..c062b4cf8 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_mouth_other.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_mouth_other.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Schema Selection MouthOther", "title" : "Schema selection for MouthOther", - "last_modified" : "2025-09-15T19:32:03.010Z", + "last_modified" : "2025-09-25T14:06:20.371Z", "definition" : [ { "key" : "site", "name" : "Primary Site", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_myeloma_plasma_cell_disorder.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_myeloma_plasma_cell_disorder.json index ac229b793..3c1404ea6 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_myeloma_plasma_cell_disorder.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_myeloma_plasma_cell_disorder.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Schema Selection MyelomaPlasmaCellDisorder", "title" : "Schema selection for MyelomaPlasmaCellDisorder", - "last_modified" : "2025-07-07T20:10:09.237Z", + "last_modified" : "2025-09-24T14:28:24.149Z", "definition" : [ { "key" : "site", "name" : "Primary Site", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_nasal_cavity.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_nasal_cavity.json index 1f5638f70..6eb8e1287 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_nasal_cavity.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_nasal_cavity.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Schema Selection NasalCavity", "title" : "Schema selection for NasalCavity", - "last_modified" : "2025-09-15T19:35:30.441Z", + "last_modified" : "2025-09-25T14:04:35.912Z", "definition" : [ { "key" : "site", "name" : "Primary Site", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_nasopharynx.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_nasopharynx.json index 89446ce01..a717be84b 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_nasopharynx.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_nasopharynx.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Schema Selection Nasopharynx", "title" : "Schema selection for Nasopharynx", - "last_modified" : "2025-09-15T19:32:36.540Z", + "last_modified" : "2025-09-25T14:05:18.742Z", "definition" : [ { "key" : "site", "name" : "Primary Site", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_nasopharynx_v9_2025.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_nasopharynx_v9_2025.json index 0a79d529a..b75597e58 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_nasopharynx_v9_2025.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_nasopharynx_v9_2025.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Schema Selection Nasopharynx [V9: 2025+]", "title" : "Schema selection for Nasopharynx [V9: 2025+]", - "last_modified" : "2025-09-15T19:32:48.322Z", + "last_modified" : "2025-09-25T14:04:44.161Z", "definition" : [ { "key" : "site", "name" : "Primary Site", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_oropharynx.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_oropharynx.json index 7457cc04f..a02fa9416 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_oropharynx.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_oropharynx.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Schema Selection Oropharynx", "title" : "Schema selection for Oropharynx", - "last_modified" : "2025-09-15T19:35:17.240Z", + "last_modified" : "2025-09-25T14:05:41.212Z", "definition" : [ { "key" : "site", "name" : "Primary Site", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_oropharynx_hpv_associated_v9_2026.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_oropharynx_hpv_associated_v9_2026.json index ac6bfb8a8..61b037c84 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_oropharynx_hpv_associated_v9_2026.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_oropharynx_hpv_associated_v9_2026.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Schema Selection Oropharynx HPV-Associated [V9: 2026+]", "title" : "Schema selection for Oropharynx HPV-Associated [V9: 2026+]", - "last_modified" : "2025-09-15T19:35:19.311Z", + "last_modified" : "2025-09-26T19:39:35.059Z", "definition" : [ { "key" : "site", "name" : "Primary Site", @@ -26,5 +26,5 @@ "name" : "Result", "type" : "ENDPOINT" } ], - "rows" : [ [ "C019, C024, C051-C052, C090-C091, C098-C099, C100, C102-C104, C108-C109", "8000-8700", "2", "2026-9998,9999,", "MATCH" ] ] + "rows" : [ [ "C019, C024, C051-C052, C090-C091, C098-C099, C100-C104, C108-C109", "8000-8700", "2", "2026-9998,9999,", "MATCH" ] ] } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_ovary.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_ovary.json index 6584746d2..d016c2752 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_ovary.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_ovary.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Schema Selection Ovary", "title" : "Schema selection for Ovary", - "last_modified" : "2025-09-15T20:09:29.029Z", + "last_modified" : "2025-09-24T21:11:46.348Z", "definition" : [ { "key" : "site", "name" : "Primary Site", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_palate_hard.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_palate_hard.json index e0308e1a4..015dad5a3 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_palate_hard.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_palate_hard.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Schema Selection PalateHard", "title" : "Schema selection for PalateHard", - "last_modified" : "2025-09-15T19:31:49.082Z", + "last_modified" : "2025-09-25T14:05:56.793Z", "definition" : [ { "key" : "site", "name" : "Primary Site", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_parotid_gland.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_parotid_gland.json index e3e3fc4c0..6bdb2362d 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_parotid_gland.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_parotid_gland.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Schema Selection ParotidGland", "title" : "Schema selection for ParotidGland", - "last_modified" : "2025-09-15T19:32:13.600Z", + "last_modified" : "2025-09-25T14:06:09.844Z", "definition" : [ { "key" : "site", "name" : "Primary Site", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_peritoneum.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_peritoneum.json index 986ea69d2..cb282611c 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_peritoneum.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_peritoneum.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Schema Selection Peritoneum", "title" : "Schema selection for Peritoneum", - "last_modified" : "2025-09-15T19:59:08.579Z", + "last_modified" : "2025-09-24T16:19:54.524Z", "definition" : [ { "key" : "site", "name" : "Primary Site", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_placenta.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_placenta.json index 4abcc6f57..0f7a0c813 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_placenta.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_placenta.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Schema Selection Placenta", "title" : "Schema selection for Placenta", - "last_modified" : "2025-09-15T20:09:01.900Z", + "last_modified" : "2025-09-24T16:30:13.014Z", "definition" : [ { "key" : "site", "name" : "Primary Site", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_plasmacytomas.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_plasmacytomas.json index 9c6b524cd..2ab27b7f6 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_plasmacytomas.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_plasmacytomas.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Schema Selection Plasmacytomas", "title" : "Schema selection for Plasmacytomas", - "last_modified" : "2025-07-07T20:09:30.420Z", + "last_modified" : "2025-09-25T13:11:46.151Z", "definition" : [ { "key" : "site", "name" : "Primary Site", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_pleural_mesothelioma_v9_2025.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_pleural_mesothelioma_v9_2025.json index f1fdf31e0..f22ca1344 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_pleural_mesothelioma_v9_2025.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_pleural_mesothelioma_v9_2025.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Schema Selection Pleural Mesothelioma [V9: 2025+]", "title" : "Schema selection for Pleural Mesothelioma [V9: 2025+]", - "last_modified" : "2025-07-07T20:11:56.721Z", + "last_modified" : "2025-11-06T16:09:17.073Z", "definition" : [ { "key" : "site", "name" : "Primary Site", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_primary_cutaneous_lymphoma_non_mf_ss.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_primary_cutaneous_lymphoma_non_mf_ss.json index e22530a9c..6778ea950 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_primary_cutaneous_lymphoma_non_mf_ss.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_primary_cutaneous_lymphoma_non_mf_ss.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Schema Selection Primary Cutaneous Lymphoma-non MF/SS", "title" : "Schema selection for Primary Cutaneous Lymphoma-non MF/SS", - "last_modified" : "2025-09-05T22:15:58.443Z", + "last_modified" : "2025-09-26T16:02:07.365Z", "definition" : [ { "key" : "site", "name" : "Primary Site", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_primary_peritoneal_carcinoma.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_primary_peritoneal_carcinoma.json index ad0e66a79..3fefb539e 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_primary_peritoneal_carcinoma.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_primary_peritoneal_carcinoma.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Schema Selection Primary Peritoneal Carcinoma", "title" : "Schema selection for Primary Peritoneal Carcinoma", - "last_modified" : "2025-09-15T20:09:31.745Z", + "last_modified" : "2025-09-24T21:11:52.898Z", "definition" : [ { "key" : "site", "name" : "Primary Site", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_prostate.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_prostate.json index 4161225eb..d0a25f985 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_prostate.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_prostate.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Schema Selection Prostate", "title" : "Schema selection for Prostate", - "last_modified" : "2025-09-15T20:12:42.194Z", + "last_modified" : "2025-09-24T21:02:38.637Z", "definition" : [ { "key" : "site", "name" : "Primary Site", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_retroperitoneum.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_retroperitoneum.json index dcae2215b..2d155a965 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_retroperitoneum.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_retroperitoneum.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Schema Selection Retroperitoneum", "title" : "Schema selection for Retroperitoneum", - "last_modified" : "2025-09-15T19:59:01.617Z", + "last_modified" : "2025-09-24T16:19:47.175Z", "definition" : [ { "key" : "site", "name" : "Primary Site", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_sinus_maxillary.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_sinus_maxillary.json index 7f6afaf76..3dd28f553 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_sinus_maxillary.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_sinus_maxillary.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Schema Selection SinusMaxillary", "title" : "Schema selection for SinusMaxillary", - "last_modified" : "2025-09-15T19:35:27.958Z", + "last_modified" : "2025-09-25T14:04:25.435Z", "definition" : [ { "key" : "site", "name" : "Primary Site", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_soft_tissue_heart_and_mediastinum.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_soft_tissue_heart_and_mediastinum.json index 94063b7da..e3763c8a7 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_soft_tissue_heart_and_mediastinum.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_soft_tissue_heart_and_mediastinum.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Schema Selection Soft Tissue Heart and Mediastinum", "title" : "Schema selection for Soft Tissue Heart and Mediastinum", - "last_modified" : "2025-09-15T19:58:58.805Z", + "last_modified" : "2025-09-24T16:19:43.970Z", "definition" : [ { "key" : "site", "name" : "Primary Site", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_soft_tissue_rare.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_soft_tissue_rare.json index a34a484d1..e3206f6f8 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_soft_tissue_rare.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_soft_tissue_rare.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Schema Selection Soft Tissue Rare", "title" : "Schema selection for Soft Tissue Rare", - "last_modified" : "2025-09-15T19:59:11.181Z", + "last_modified" : "2025-09-24T16:19:57.125Z", "definition" : [ { "key" : "site", "name" : "Primary Site", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_soft_tissue_sarcoma_head_and_neck.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_soft_tissue_sarcoma_head_and_neck.json index 0cf6604b7..8e65b6f78 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_soft_tissue_sarcoma_head_and_neck.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_soft_tissue_sarcoma_head_and_neck.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Schema Selection Soft Tissue Sarcoma Head and Neck", "title" : "Schema selection for Soft Tissue Sarcoma Head and Neck", - "last_modified" : "2025-09-15T19:59:06.292Z", + "last_modified" : "2025-09-24T16:19:52.033Z", "definition" : [ { "key" : "site", "name" : "Primary Site", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_soft_tissue_trunk_and_extremities.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_soft_tissue_trunk_and_extremities.json index 9d0b9d213..d00e5b84b 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_soft_tissue_trunk_and_extremities.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_soft_tissue_trunk_and_extremities.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Schema Selection Soft Tissue Trunk and Extremities", "title" : "Schema selection for Soft Tissue Trunk and Extremities", - "last_modified" : "2025-09-15T19:59:14.091Z", + "last_modified" : "2025-09-24T16:20:00.111Z", "definition" : [ { "key" : "site", "name" : "Primary Site", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_testis.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_testis.json index c869dc259..5e4756dbe 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_testis.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_testis.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Schema Selection Testis", "title" : "Schema selection for Testis", - "last_modified" : "2025-09-15T20:14:40.597Z", + "last_modified" : "2025-09-24T16:16:45.286Z", "definition" : [ { "key" : "site", "name" : "Primary Site", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_tongue_anterior.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_tongue_anterior.json index 856940a60..40f0485b7 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_tongue_anterior.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_tongue_anterior.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Schema Selection TongueAnterior", "title" : "Schema selection for TongueAnterior", - "last_modified" : "2025-09-15T19:31:28.599Z", + "last_modified" : "2025-09-25T14:06:01.781Z", "definition" : [ { "key" : "site", "name" : "Primary Site", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_tongue_base.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_tongue_base.json index 2b659f184..879585442 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_tongue_base.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_tongue_base.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Schema Selection TongueBase", "title" : "Schema selection for TongueBase", - "last_modified" : "2025-09-15T19:35:21.592Z", + "last_modified" : "2025-09-26T19:52:19.736Z", "definition" : [ { "key" : "site", "name" : "Primary Site", @@ -30,5 +30,5 @@ "name" : "Result", "type" : "ENDPOINT" } ], - "rows" : [ [ "C019,C024,C051-C052,C090-C091,C098-C099,C100,C102-C104,C108-C109", "8000-8700", "*", "1,9", "*", "MATCH" ], [ "C111", "8000-8700", "2", "1,9", "2018-2024", "MATCH" ] ] + "rows" : [ [ "C019,C024,C051-C052,C090-C091,C098-C099,C100,C102-C104,C108-C109", "8000-8700", "*", "1,9", "*", "MATCH" ], [ "C111", "8000-8700", "2", "1,9", "2018-2024", "MATCH" ], [ "C101", "8000-8700", "*", "1,9", "2026-9998,9999,", "MATCH" ] ] } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_vagina.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_vagina.json index 0dfc1f4b1..68705c289 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_vagina.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_vagina.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Schema Selection Vagina", "title" : "Schema selection for Vagina", - "last_modified" : "2025-09-15T20:42:58.706Z", + "last_modified" : "2025-09-24T16:29:50.391Z", "definition" : [ { "key" : "site", "name" : "Primary Site", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_vulva.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_vulva.json index a7524dc9b..3dad50d09 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_vulva.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_vulva.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Schema Selection Vulva", "title" : "Schema selection for Vulva", - "last_modified" : "2025-09-15T20:43:01.271Z", + "last_modified" : "2025-09-24T14:59:47.247Z", "definition" : [ { "key" : "site", "name" : "Primary Site", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_vulva_v9_2024.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_vulva_v9_2024.json index 712f9105d..4f37a2af6 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_vulva_v9_2024.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/schema_selection_vulva_v9_2024.json @@ -4,7 +4,7 @@ "version" : "3.3", "name" : "Schema Selection Vulva [V9: 2024+]", "title" : "Schema selection for Vulva [V9: 2024+]", - "last_modified" : "2025-09-15T20:43:04.920Z", + "last_modified" : "2025-09-24T14:59:18.130Z", "definition" : [ { "key" : "site", "name" : "Primary Site", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_mets_21628.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_mets_21628.json index 1bf8e36b3..3f032bb23 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_mets_21628.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_mets_21628.json @@ -6,7 +6,7 @@ "title" : "EOD Mets", "notes" : "**Note 1:** **Bone mets WITH other mets** \n* Use code 50 only when there are bone metastasis WITH other metastatic involvement. \n + If there are multiple distant mets but bone is not one of them, code 30.\n\n**Note 2:** **Distant metastasis** \n* Use code 70 when the only information is “distant metastasis, NOS,” and there is no documentation regarding the specific metastases. \n+ If there are specific metastasis documented that are not listed in codes 10, 20, or 30, assign code 30 for “other specified distant metastasis.”", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions,** National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05.** American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Jimenez, C., Perrier, N.D., et al. **Adrenal - Neuroendocrine Tumors**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:32.800Z", + "last_modified" : "2025-11-14T20:05:20.992Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_mets_32413.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_mets_32413.json index 26e41e4e0..adc5322ff 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_mets_32413.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_mets_32413.json @@ -6,7 +6,7 @@ "title" : "EOD Mets", "notes" : "**Note:** **Trilateral retinoblastomas** \n* Code 50 does not include \"trilateral retinoblastomas.\" The presence of \"trilateral retinoblastomas\" is coded in the data item Heritable Trait. [NAACCR Data Item #3856]", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Mallipatna, A.C., Finger, P.T., et al. **Retinoblastoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:42:09.262Z", + "last_modified" : "2025-11-14T20:05:13.315Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_mets_4721.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_mets_4721.json index 044944b5b..97fca018a 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_mets_4721.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_mets_4721.json @@ -6,7 +6,7 @@ "title" : "EOD Mets", "notes" : "**Note:** **Distant metastasis** \n* Use code 70 when the only information is “distant metastasis, NOS,” and there is no documentation regarding the specific metastases. \n * If there are specific metastasis documented that are not listed in codes 10, 30, or 50, assign code 50 for “other specified distant metastasis.”", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Detterbeck, F.C., Marom, E.M. **Thymus**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:42:11.335Z", + "last_modified" : "2025-11-14T20:05:21.787Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_mets_48348.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_mets_48348.json index a27ca7077..9a2ab9910 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_mets_48348.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_mets_48348.json @@ -5,7 +5,7 @@ "name" : "EOD Mets", "title" : "EOD Mets", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)", - "last_modified" : "2025-09-18T20:41:28.788Z", + "last_modified" : "2025-11-14T20:05:07.180Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_mets_57075.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_mets_57075.json index 741a9a2a7..2d6940a96 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_mets_57075.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_mets_57075.json @@ -6,7 +6,7 @@ "title" : "EOD Mets", "notes" : "**Note 1:** **Lesser sac** \n* The lesser sac of the peritoneum, or omental bursa, is the cavity in the abdomen formed by the lesser and greater omentum; the pancreas forms part of the posterior wall of the lesser sac.\n\n**Note 2:** **Mesenteric nodes** \n* The specific location of the mesenteric nodes determines whether they are regional or distant. If the specific location is not described, code in EOD Regional Nodes.\n\n**Note 3:** **Porta hepatic nodes** \n* Porta hepatic nodes are distant for Body and Tail and should be coded in EOD Mets. If the specific location for hepatic nodes is not described, code in EOD Regional Nodes.\n\n**Note 4:** **Liver mets WITH other metastatic involvement** \n* Use code 60 only when there are liver metastasis WITH other metastatic involvement. \n* If there are multiple distant mets but liver is not one of them, code 50.\n\n**Note 5:** **Distant metastasis, NOS** \n* Use code 70 when the only information is “distant metastasis, NOS,” and there is no documentation regarding the specific metastases. \n * If there are specific metastasis documented that are not listed in codes 10, 20, 40, or 50, assign code 50 for “other specified distant metastasis.”", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Bergsland, E.K., Woltering, E.A., Klimstra, D.S., et al. **Neuroendocrine Tumors of the Pancreas**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) **Neuroendocrine Tumors of the Pancreas**, from the AJCC Cancer Staging System Version 9 (2023). Used with permission of the American College of Surgeons, Chicago, Illinois.", - "last_modified" : "2025-09-18T20:41:33.134Z", + "last_modified" : "2025-11-14T20:05:22.806Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_mets_61487.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_mets_61487.json index 52c16c3d3..0bfe1f042 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_mets_61487.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_mets_61487.json @@ -6,7 +6,7 @@ "title" : "EOD Mets", "notes" : "**Note 1:** **Liver mets WITH other metastatic involvement** \n* Use code 50 only when there are liver metastasis WITH other metastatic involvement. \n * If there are multiple distant mets but liver is not one of them, code 30.\n\n**Note 2:** **Distant metastasis, NOS** \n* Use code 70 when the only information is “distant metastasis, NOS,” and there is no documentation regarding the specific metastases. \n * If there are specific metastasis documented that are not listed in codes 10, 20, or 30, assign code 30 for “other specified distant metastasis.”", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Bergsland, E.K., Woltering, E.A., Klimstra, D.S., et al. **Neuroendocrine Tumors of the Duodenum and Ampulla of Vater**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:42:18.444Z", + "last_modified" : "2025-11-14T20:05:49.688Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_mets_66514.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_mets_66514.json index 203084075..6be56e423 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_mets_66514.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_mets_66514.json @@ -5,7 +5,7 @@ "name" : "EOD Mets", "title" : "EOD Mets", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Kakar, S., Pawlik, T.M., Vauthey, J.N., et al. **Exocrine Pancreas**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cacer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:42:05.821Z", + "last_modified" : "2025-11-14T20:05:34.899Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_mets_79245.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_mets_79245.json index 7b5d77fc4..968b38e8a 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_mets_79245.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_mets_79245.json @@ -6,7 +6,7 @@ "title" : "EOD Mets", "notes" : "**Note:** **Peripheral blood or bone marrow involvement**\n* If there is peripheral blood or bone marrow involvement, code 70.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) **Introduction to Hematologic Malignancies**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Rosen, S.T., Jaffe, E.S., Leonard, J.P., et al. **Primary Cutaneous Lymphomas**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:55.169Z", + "last_modified" : "2025-11-14T20:06:00.422Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_mets_84419.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_mets_84419.json index 89982fa90..c519a1d80 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_mets_84419.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_mets_84419.json @@ -6,7 +6,7 @@ "title" : "EOD Mets", "notes" : "**Note 1:** **Liver mets WITH other metastatic involvement** \n* Use code 50 only when there are liver metastasis WITH other metastatic involvement. \n * If there are multiple distant mets but liver is not one of them, code 30.\n\n**Note 2:** **Distant metastasis, NOS** \n* Use code 70 when the only information is “distant metastasis, NOS,” and there is no documentation regarding the specific metastases. \n * If there are specific metastasis documented that are not listed in codes 10, 20, or 30, assign code 30 for “other specified distant metastasis.”", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Bergsland, E.K., Woltering, E.A., Klimstra, D.S., et al. **Neuroendocrine Tumors of the Duodenum and Ampulla of Vater**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) **Neuroendocrine Tumors of the Duodenum and Ampulla of Vater,** from the AJCC Cancer Staging System Version 9 (2023). Used with permission of the American College of Surgeons, Chicago, Illinois.", - "last_modified" : "2025-09-18T20:41:47.275Z", + "last_modified" : "2025-11-14T20:05:22.289Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_mets_90003.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_mets_90003.json index 0506042c2..72c9a8818 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_mets_90003.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_mets_90003.json @@ -6,7 +6,7 @@ "title" : "EOD Mets", "notes" : "**Note 1:** **Distant lymph node involvement** \n* Distant lymph node involvement is coded in EOD Regional Nodes.\n\n**Note 2:** **Peripheral blood or bone marrow involvement** \n* If there is peripheral blood or bone marrow involvement, code 30 or 50.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Heegaard, S., Finger, P.T., et al. **Ocular Adnexal Lymphoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:42:22.288Z", + "last_modified" : "2025-11-14T20:05:59.975Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_mets_90643.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_mets_90643.json index ca1f06256..be2adba5f 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_mets_90643.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_mets_90643.json @@ -6,7 +6,7 @@ "title" : "EOD Mets", "notes" : "**Note:** **Nodal basins** \n* Nodes in contiguous (secondary) and bidirectional (cephalad/caudal) primary nodal basins are coded in EOD Regional Nodes.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)", - "last_modified" : "2025-09-18T20:41:30.271Z", + "last_modified" : "2025-11-14T20:05:10.276Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_mets_lip_lower_28596.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_mets_lip_lower_28596.json index 45606a020..7b99c7b5b 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_mets_lip_lower_28596.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_mets_lip_lower_28596.json @@ -5,7 +5,7 @@ "name" : "EOD Mets", "title" : "EOD Mets", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Lydiatt, W.M., Patel, S.G., Shah, J.P., et al. **Staging Head and Neck Cancers**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Ridge, J.A., Lydiatt, W.M., Shah, J.P., et al. **Oral Cavity**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:39.526Z", + "last_modified" : "2025-11-14T20:05:17.557Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_mets_melanomachoroid_55264.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_mets_melanomachoroid_55264.json index bc98a462b..b6f78bd38 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_mets_melanomachoroid_55264.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_mets_melanomachoroid_55264.json @@ -6,7 +6,7 @@ "title" : "EOD Mets", "notes" : "**Note 1:** **Multiple metastatic sites** \n* If there are multiple metastatic sites, code based on the largest metastasis. \n\n**Note 2:** **Distant metastases, NOS** \n* Use code 70 when the only information is “distant metastasis, NOS,” and there is no documentation regarding the specific metastases. \n + If there are specific metastasis documented that are not listed in codes 10, 20, or 30, assign code 30 for “other specified distant metastasis.”", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Kivelä, T., Finger, P.T., et al. **Uveal Melanoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:42:07.907Z", + "last_modified" : "2025-11-14T20:05:50.434Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_mets_nasopharynx_46629.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_mets_nasopharynx_46629.json index cdbb6d5f4..6bfb78676 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_mets_nasopharynx_46629.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_mets_nasopharynx_46629.json @@ -5,7 +5,7 @@ "name" : "EOD Mets", "title" : "EOD Mets", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Lydiatt, W.M., Patel, S.G., Shah, J.P., et al. **Staging Head and Neck Cancers**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Lee, A.W.M., Lydiatt, W.M., Shah, J.P., et al. **Nasopharynx**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:42:20.016Z", + "last_modified" : "2025-11-14T20:06:04.201Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_mets_sinus_othervs2_15755.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_mets_sinus_othervs2_15755.json index 15fecaf2e..51d18a221 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_mets_sinus_othervs2_15755.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_mets_sinus_othervs2_15755.json @@ -5,7 +5,7 @@ "name" : "EOD Mets", "title" : "EOD Mets", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)", - "last_modified" : "2025-09-18T20:41:27.047Z", + "last_modified" : "2025-11-14T20:05:14.150Z", "definition" : [ { "key" : "eod_mets", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_25824.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_25824.json index d1bdb58ef..5c9b0391f 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_25824.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_25824.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **Definition of Parathyroid tumors** \n* Parathyroid tumors are defined as left or right and superior (upper) or inferior (lower).\n\n**Note 2:** **Atypical parathyroid neoplasms** \n* Atypical parathyroid neoplasms (code 050) are defined as tumors that are histologically or clinically worrisome but do not fulfill the more robust criteria [i.e., invasion metastasis] for carcinoma.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Landry, C.S., Wang, T.S., Perrier, N.D., et al. **Parathyroid**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:52:04.460Z", + "last_modified" : "2025-11-14T20:05:21.216Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_31838.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_31838.json index e34d5b313..a982fe0ca 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_31838.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_31838.json @@ -5,7 +5,7 @@ "name" : "EOD Primary Tumor", "title" : "EOD Primary Tumor", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Pollock, R.E., Maki, R.G. **Introduction to Soft Tissue Sarcoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Yoon, S.S., Maki, R.G., Pollock, R.E., et al. **Soft Tissue Sarcoma of the Trunk and Extremities**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:51:58.740Z", + "last_modified" : "2025-11-14T20:05:27.564Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_36538.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_36538.json index 5484cce54..9e65f92b3 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_36538.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_36538.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note:** **Extrathyroid extension** \n* Extrathyroidal extension includes minor (microscopic) extension through the thyroid capsule which is identified only on microscopic examination (see code 200) to gross (macroscopic) extrathyroidal extension, which is documented in the operative report and involves major structures (see codes 300, 400, 600, and 700). \n* If the only information available is \"extrathyroidal extension\" and cannot determine whether it is microscopic or gross, code 200.\n* If the only information is \"gross extrathyroidal extension\" and the involvement of major structures cannot be determined, code 750.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Rosen, J.E., Lloyd, R.V., Perrier, N.D., et al. **Thyroid - Medullary**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:52:10.558Z", + "last_modified" : "2025-11-14T20:05:23.077Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_38025.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_38025.json index 01f1f4f2c..0f2c77c87 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_38025.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_38025.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note:** **Cortex of the bone**\n* The cortex of a bone is the dense outer shell that provides strength to the bone; the spongy center of a bone is the cancellous portion. \n* The periosteum of the bone is the fibrous membrane covering of a bone that contains the blood vessels and nerves; the periosteum is similar to the capsule on a visceral organ.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Kneisl, J.S., Rosenberg, A.E., et al. **Bone**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:52:05.537Z", + "last_modified" : "2025-11-14T20:06:13.807Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_42176.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_42176.json index 8d3329100..92c29625d 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_42176.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_42176.json @@ -5,7 +5,7 @@ "name" : "EOD Primary Tumor", "title" : "EOD Primary Tumor", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Pollock, R.E., Maki, R.G. **Introduction to Soft Tissue Sarcoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) O'Sullivan, B., Maki, R.G., Pollock, R.E., et al. **Soft Tissue Sarcoma of the Head and Neck**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:52:34.189Z", + "last_modified" : "2025-11-14T20:05:40.417Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_42751.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_42751.json index 0f67d55d3..c1ed05db8 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_42751.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_42751.json @@ -5,7 +5,7 @@ "name" : "EOD Primary Tumor", "title" : "EOD Primary Tumor", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Bergsland, E.K., Woltering, E.A., Klimstra, D.S., et al. **Neuroendocrine Tumors of the Duodenum and Ampulla of Vater**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:52:31.727Z", + "last_modified" : "2025-11-14T20:05:49.483Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_43302.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_43302.json index 5c4594780..a4cd7067b 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_43302.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_43302.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **Islets of Langerhans** \n* Islets of Langerhans are distributed throughout the pancreas; an islet tumor is coded according to the subsite of the pancreas in which the tumor arises if the information is available.\n\n**Note 2:** **Abutment, encasement** \n* The terms \"abutment,\" \"abut(s),\" \"encases,\" or \"encasement\" of the major blood vessels can be interpreted as involvement of these structures.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Bergsland, E.K., Woltering, E.A., Klimstra, D.S., et al. **Neuroendocrine Tumors of the Pancreas**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) **Neuroendocrine Tumors of the Pancreas**, from the AJCC Cancer Staging System Version 9 (2023). Used with permission of the American College of Surgeons, Chicago, Illinois.", - "last_modified" : "2025-09-18T20:51:49.913Z", + "last_modified" : "2025-11-14T20:05:22.555Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_44962.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_44962.json index 1862081fc..531c27048 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_44962.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_44962.json @@ -5,7 +5,7 @@ "name" : "EOD Primary Tumor", "title" : "EOD Primary Tumor", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Phan, A.T., Perrier, N.D., et al. **Adrenal Cortical Carcinoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:51:48.250Z", + "last_modified" : "2025-11-14T20:05:12.038Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_52444.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_52444.json index 50b969ca9..bba9cdefd 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_52444.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_52444.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note:** **Pheochromocytoma and Paragangliomas**\n* This is a new schema (2018+) for pheochromocytomas (PHs) and paragangliomas (PGs), which are rare neuroendocrine tumors originating in the paraganglia. \n * Pheochromocytomas originate in the adrenal medulla and sympathetic tumors. \n * Paragangliomas originate either in the parasympathetic or sympathetic autonomous nervous system ganglia, which is outside the adrenal medulla.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions,** National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05.** American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Jimenez, C., Perrier, N.D., et al. **Adrenal - Neuroendocrine Tumors**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:51:49.558Z", + "last_modified" : "2025-11-14T20:05:20.794Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_53926.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_53926.json index 057863495..891baea2d 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_53926.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_53926.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **In situ** \n* Code 000 (in situ) is not applicable for this schema.\n\n**Note 2:** **Multifocal** \n* For this schema, \"multifocal\" means involvement of multiple sites (codes 500-700).", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Pollock, R.E., Maki, R.G. **Introduction to Soft Tissue Sarcoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Raut, C.P., Maki, R.G., Pollock, R.E., et al. **Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:52:29.802Z", + "last_modified" : "2025-11-14T20:06:09.280Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_59317.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_59317.json index e193d7b41..0d689be8c 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_59317.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_59317.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note:** **Multifocal tumors** \n* In case of multifocal papillary noninvasive tumors (code 000) and nonpapillary in situ tumors (code 050), code 050.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Hansel, D.E., Reuter, V.E., McKiernan, J.M., et al. **Urethra**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:52:28.619Z", + "last_modified" : "2025-11-14T20:05:11.485Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_60433.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_60433.json index 34693b9b7..851f7a17a 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_60433.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_60433.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note:** **Left and right extremities** \n* Left and right extremities (e.g. arm, leg) are counted as separate body regions.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) **Introduction to Hematologic Malignancies**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Rosen, S.T., Jaffe, E.S., Leonard, J.P., et al. **Primary Cutaneous Lymphomas**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:52:39.472Z", + "last_modified" : "2025-11-14T20:06:00.227Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_6275.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_6275.json index efa1e9a4f..96f6e7405 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_6275.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_6275.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note:** **Extrathyroidal extension** \n* Extrathyroidal extension includes minor (microscopic) extension through the thyroid capsule which is identified only on microscopic examination (see code 200) to gross (macroscopic) extrathyroidal extension, which is documented in the operative report and involves major structures (see codes 300, 400, 600, and 700). \n* If the only information available is \"extrathyroidal extension\" and cannot determine whether it is microscopic or gross, code 200.\n* If the only information is \"gross extrathyroidal extension\" and the involvement of major structures cannot be determined, code 750.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Tuttle, R.M., Perrier, N.D., et al. **Thyroid - Differentiated and Anaplastic Carcinoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:52:06.872Z", + "last_modified" : "2025-11-14T20:05:13.542Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_68925.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_68925.json index 3ac2da171..fe0fd45cb 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_68925.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_68925.json @@ -5,7 +5,7 @@ "name" : "EOD Primary Tumor", "title" : "EOD Primary Tumor", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Detterbeck, F.C., Marom, E.M. **Thymus**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:52:25.842Z", + "last_modified" : "2025-11-14T20:05:21.589Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_72151.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_72151.json index aca64e61f..ed738be90 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_72151.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_72151.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **In situ not applicable** \n* Code 000 (in situ) is not applicable for this schema.\n\n**Note 2:** **Multifocal** \n* For this schema, \"multifocal\" means involvement of multiple sites (codes 500-700).", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Pollock, R.E., Maki, R.G. **Introduction to Soft Tissue Sarcoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Raut, C.P., Maki, R.G., Pollock, R.E., et al. **Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:51:49.257Z", + "last_modified" : "2025-11-14T20:05:20.387Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_88917.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_88917.json index d185ab570..6b81502a2 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_88917.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_88917.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **Bilateral involvement**\n* If both eyes are involved, code the information for the most extensively involved eye in this field. \n\n**Note 2:** **CLINICAL AND PATHOLOGICAL codes** \n* This schema has extension codes that are defined as “CLINICAL assessment only” or “PATHOLOGICAL assessment only” \n* **CLINICAL** assessment only codes (100, 125, 150, 200, 225, 325, 375, 425, 475, 525, 600, 650, 700) are used when there is a clinical work up only, including physical exam, imaging and biopsy (see **Note 3** for exception)\n* **PATHOLOGICAL** assessment only codes (175, 250, 275, 350, 400, 450, 500, 750) are used when there is a surgical resection of the primary site (enucleation)(see **Note 3** for exception)\n* Remaining codes (no designation of CLINICAL or PATHOLOGICAL only assessment) can be used based on clinical and/or pathological information\n\n**Note 3:** **Enucleation** \n* Pathological staging information from an enucleation always takes precedence over clinical staging \n * *Exception*: cases with neoadjuvant treatment where clinical disease is as extensive as or more extensive than disease at surgery", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Mallipatna, A.C., Finger, P.T., et al. **Retinoblastoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:52:22.364Z", + "last_modified" : "2025-11-14T20:05:13.152Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_9084.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_9084.json index b7c72d6ae..91c5bdbd9 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_9084.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_9084.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **Deep invasion** \n* Deep invasion (code 300) is defined as either invasion beyond the subcutaneous fat, or >6 mm deep (as measured from the granular layer of adjacent normal epidermis to the base of the tumor). \n\n**Note 2:** **Multiple simultaneous tumors** \n* In the case of multiple simultaneous tumors, code the tumor with the greatest extension.\n\n**Note 3:** **Skin ulceration** \n* Skin ulceration does not alter the classification.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Lydiatt, W.M., Patel, S.G., Shah, J.P., et al. **Staging Head and Neck Cancers**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Califano, J.A., Lydiatt, W.M., Shah, J.P., et al. **Cutaneous Carcinoma of the Head and Neck**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:52:27.742Z", + "last_modified" : "2025-11-14T20:06:07.623Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_94875.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_94875.json index df1d9bd47..047413776 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_94875.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_94875.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note:** **Multifocal tumors** \n* In case of multifocal papillary noninvasive tumors (code 000) and nonpapillary in situ tumors (code 050), code 050", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Hansel, D.E., Reuter, V.E., McKiernan, J.M., et al. **Urethra**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:52:33.596Z", + "last_modified" : "2025-11-14T20:05:12.478Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_95193.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_95193.json index f0b03a808..5223256e8 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_95193.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_95193.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **Islets of Langerhans** \n* Islets of Langerhans are distributed throughout the pancreas; an islet tumor is coded according to the subsite of the pancreas in which the tumor arises if the information is available.\n\n**Note 2:** **Abutment, encasement** \n* The terms \"abutment,\" \"abut(s),\" \"encases,\" or \"encasement\" of the major blood vessels can be interpreted as involvement of these structures.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Kakar, S., Pawlik, T.M., Vauthey, J.N., et al. **Exocrine Pancreas**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cacer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:52:12.171Z", + "last_modified" : "2025-11-14T20:05:34.698Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_96082.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_96082.json index 2d73c65fb..098deb14d 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_96082.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_96082.json @@ -5,7 +5,7 @@ "name" : "EOD Primary Tumor", "title" : "EOD Primary Tumor", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Bergsland, E.K., Woltering, E.A., Klimstra, D.S., et al. **Neuroendocrine Tumors of the Duodenum and Ampulla of Vater**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) **Neuroendocrine Tumors of the Duodenum and Ampulla of Vater,** from the AJCC Cancer Staging System Version 9 (2023). Used with permission of the American College of Surgeons, Chicago, Illinois.", - "last_modified" : "2025-09-18T20:52:03.376Z", + "last_modified" : "2025-11-14T20:05:22.035Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_eyeother_64077.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_eyeother_64077.json index 2cfac4e08..338f1e970 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_eyeother_64077.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_eyeother_64077.json @@ -5,7 +5,7 @@ "name" : "EOD Primary Tumor", "title" : "EOD Primary Tumor", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)", - "last_modified" : "2025-09-18T20:52:01.999Z", + "last_modified" : "2025-11-14T20:05:45.776Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_head_neck_melanoma_38698.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_head_neck_melanoma_38698.json index e91155b80..4107845dc 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_head_neck_melanoma_38698.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_primary_tumor_head_neck_melanoma_38698.json @@ -6,7 +6,7 @@ "title" : "EOD Primary Tumor", "notes" : "**Note 1:** **Mucosal melanomas** \n* Mucosal melanomas occur throughout the mucosa of the lip and oral cavity (C003-C005, C008-C069, C090-C148) and the nasal cavity and middle ear (C300-C301), accessory sinuses (C310-C319) and the larynx (C320-C329). \n* For a more detailed description of anatomy, refer to the appropriate EOD schema based on the location of the mucosal melanoma. \n\n**Note 2:** **Localized tumors** \n* Code 100 for localized tumors when no other information is available or for extension involving the mucosa only of adjacent sites.\n\n**Note 3:** **Deep tissue involvement** \n* Extension involving the deeper tissues of the primary or adjacent sites are recorded in codes 300, 500 or 600. \n* Code 300 when the only information available is \"deep tissue involvement.\"\n\n**Note 4:** **Moderately advanced disease** \n* Code 700 (Moderately advanced disease, NOS) only when specific information about moderately advanced disease is not available (see codes 300 and 500).", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Lydiatt, W.M., Patel, S.G., Shah, J.P., et al. **Staging Head and Neck Cancers**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Lydiatt, W.M., Brandwein-Gensler, M., Shah, J.P., et al. **Mucosal Melanoma of the Head and Neck**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:51:55.459Z", + "last_modified" : "2025-11-14T20:06:06.080Z", "definition" : [ { "key" : "eod_primary_tumor", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_regional_nodes_17757.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_regional_nodes_17757.json index 431ab7fc8..8d7354393 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_regional_nodes_17757.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_regional_nodes_17757.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n\n**Note 2:** **Most common area of nodal metastases** \n* Regional lymph node metastases occur primarily in levels VI or VII located near the parathyroid.\n\n**Note 3:** **Lymph nodes, NOS** \n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Kakar, S., Pawlik, T.M., Vauthey, J.N., et al. **Exocrine Pancreas**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:48.441Z", + "last_modified" : "2025-11-14T20:05:21.333Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_regional_nodes_19661.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_regional_nodes_19661.json index 3d9f8e3bd..f520f2cc4 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_regional_nodes_19661.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_regional_nodes_19661.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n\n**Note 2:** **Nodal metastasis rare** \n* Regional lymph node involvement is rare. For this schema, if there is no mention of lymph node involvement clinically, assume that lymph nodes are negative. \n* Code unknown (999) only when there is no available information on the extent of the patient's disease, for example when a lab-only case is abstracted from a biopsy report and no clinical history is available.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Pollock, R.E., Maki, R.G. **Introduction to Soft Tissue Sarcoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Raut, C.P., Maki, R.G., Pollock, R.E., et al. **Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:42:16.261Z", + "last_modified" : "2025-11-14T20:06:09.395Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_regional_nodes_27397.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_regional_nodes_27397.json index a8f070756..9e01da90a 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_regional_nodes_27397.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_regional_nodes_27397.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional and distant lymph nodes** \n* All lymph nodes (regional and distant) involvement is coded in this field.\n\n**Note 2:** **Regional lymph nodes include**\n* Cervical\n* Parotid\n* Preauricular\n* Submandibular\n\n**Note 3:** **Lymph nodes, NOS** \n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Heegaard, S., Finger, P.T., et al. **Ocular Adnexal Lymphoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:42:22.182Z", + "last_modified" : "2025-11-14T20:05:59.880Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_regional_nodes_36710.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_regional_nodes_36710.json index f1e469f07..6f9014db9 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_regional_nodes_36710.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_regional_nodes_36710.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n\n**Note 2:** **Lymph nodes, NOS** \n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) **Introduction to Hematologic Malignancies**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Rosen, S.T., Jaffe, E.S., Leonard, J.P., et al. **Primary Cutaneous Lymphomas**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:55.084Z", + "last_modified" : "2025-11-14T20:06:00.339Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_regional_nodes_67072.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_regional_nodes_67072.json index 462a4f891..5e7ebd29e 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_regional_nodes_67072.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_regional_nodes_67072.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n\n**Note 2:** **Nodal metastasis rare** \n* Regional lymph node involvement is rare. For this schema, if there is no mention of lymph node involvement clinically, assume that lymph nodes are negative. \n* Code unknown (999) only when there is no available information on the extent of the patient's disease, for example when a lab-only case is abstracted from a biopsy report and no clinical history is available.\n\n**Note 3:** **Lymph nodes, NOS** \n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Pollock, R.E., Maki, R.G. **Introduction to Soft Tissue Sarcoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Raut, C.P., Maki, R.G., Pollock, R.E., et al. **Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:32.283Z", + "last_modified" : "2025-11-14T20:05:20.500Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_regional_nodes_69051.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_regional_nodes_69051.json index 3a5af9258..c6cffa872 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_regional_nodes_69051.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_regional_nodes_69051.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n\n**Note 2:** **Lymph nodes, NOS** \n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Bergsland, E.K., Woltering, E.A., Klimstra, D.S., et al. **Neuroendocrine Tumors of the Duodenum and Ampulla of Vater**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:42:18.356Z", + "last_modified" : "2025-11-14T20:05:49.603Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_regional_nodes_69974.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_regional_nodes_69974.json index 0747aba94..2934b0a7e 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_regional_nodes_69974.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_regional_nodes_69974.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n\n**Note 2:** **Nodal metastasis rare** \n* Regional lymph node involvement is rare. For this schema, if there is no mention of lymph node involvement clinically, assume that lymph nodes are negative. \n* Code unknown (999) only when there is no available information on the extent of the patient's disease, for example when a lab-only case is abstracted from a biopsy report and no clinical history is available.\n\n**Note 3:** **Lymph nodes, NOS** \n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Pollock, R.E., Maki, R.G. **Introduction to Soft Tissue Sarcoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Yoon, S.S., Maki, R.G., Pollock, R.E., et al. **Soft Tissue Sarcoma of the Trunk and Extremities**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:41.988Z", + "last_modified" : "2025-11-14T20:05:27.691Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_regional_nodes_83435.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_regional_nodes_83435.json index d5dd6ad22..7d021f12b 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_regional_nodes_83435.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_regional_nodes_83435.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n\n**Note 2:** **Lymph nodes, NOS** \n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Bergsland, E.K., Woltering, E.A., Klimstra, D.S., et al. **Neuroendocrine Tumors of the Duodenum and Ampulla of Vater**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) **Neuroendocrine Tumors of the Duodenum and Ampulla of Vater,** from the AJCC Cancer Staging System Version 9 (2023). Used with permission of the American College of Surgeons, Chicago, Illinois.", - "last_modified" : "2025-09-18T20:41:47.169Z", + "last_modified" : "2025-11-14T20:05:22.175Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_regional_nodes_91716.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_regional_nodes_91716.json index d386a14dd..28c3ffe68 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_regional_nodes_91716.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_regional_nodes_91716.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Definition of Head and Neck Lymph Nodes** \n* For head and neck schemas, this field includes all lymph nodes defined as Levels I-VII and Other by TNM. \n\n**Note 2:** **Laterality** \n* If laterality of lymph nodes is not specified, assume nodes are ipsilateral. Midline nodes are ipsilateral.\n\n**Note 3:** **Supraclavicular lymph nodes** \n* Supraclavicular lymph nodes can be either Level IV or Level V\n * Level IV: deep to the sternocleidomastoid muscle, in the lower jugular chain\n * Level V: in the posterior triangle, inferior to the transverse cervical artery, supraclavicular lymph nodes, NOS\n\n**Note 4:** **Lymph nodes, NOS** \n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Lydiatt, W.M., Patel, S.G., Shah, J.P., et al. **Staging Head and Neck Cancers**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Lydiatt, W.M., Brandwein-Gensler, M., Shah, J.P., et al. **Mucosal Melanoma of the Head and Neck**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:41:39.918Z", + "last_modified" : "2025-11-14T20:06:06.152Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_regional_nodes_93152.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_regional_nodes_93152.json index 845967e02..1b329e7e3 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_regional_nodes_93152.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_regional_nodes_93152.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n\n**Note 2:** **Nodal metastasis rare** \n* Regional lymph node involvement is rare. For this schema, if there is no mention of lymph node involvement clinically, assume that lymph nodes are negative. \n* Code unknown (999) only when there is no available information on the extent of the patient's disease, for example when a lab-only case is abstracted from a biopsy report and no clinical history is available.\n\n**Note 3:** **Lymph nodes, NOS** \n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Pollock, R.E., Maki, R.G. **Introduction to Soft Tissue Sarcoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) O'Sullivan, B., Maki, R.G., Pollock, R.E., et al. **Soft Tissue Sarcoma of the Head and Neck**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:42:19.400Z", + "last_modified" : "2025-11-14T20:05:40.530Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_regional_nodes_copy_24179.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_regional_nodes_copy_24179.json index ac7c887af..b94fb8f4d 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_regional_nodes_copy_24179.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_regional_nodes_copy_24179.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n\n**Note 2:** **Lymph nodes, NOS** \n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Detterbeck, F.C., Marom, E.M. **Thymus**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-09-18T20:42:11.229Z", + "last_modified" : "2025-11-14T20:05:21.702Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_regional_nodes_eyeother_16963.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_regional_nodes_eyeother_16963.json index 1a01b67fd..535d20000 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_regional_nodes_eyeother_16963.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_regional_nodes_eyeother_16963.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n* Regional nodes include bilateral and contralateral involvement of named nodes.\n\n**Note 2:** **Lymph nodes, NOS** \n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)", - "last_modified" : "2025-09-18T20:41:45.414Z", + "last_modified" : "2025-11-14T20:05:45.861Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_regional_nodes_lacrimal_sac_33881.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_regional_nodes_lacrimal_sac_33881.json index 56debff4e..30aebafad 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_regional_nodes_lacrimal_sac_33881.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/seer_regional_nodes_lacrimal_sac_33881.json @@ -6,7 +6,7 @@ "title" : "EOD Regional Nodes", "notes" : "**Note 1:** **Regional nodes and nodes, NOS** \n* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.\n\n**Note 2:** **Lymph nodes, NOS** \n* Code 800 if regional lymph nodes are involved, but there is no indication which ones are involved.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)", - "last_modified" : "2025-09-18T20:41:56.054Z", + "last_modified" : "2025-11-14T20:05:46.231Z", "definition" : [ { "key" : "eod_regional_nodes", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/separate_tumor_nodules_69006.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/separate_tumor_nodules_69006.json index 1ce8dbe92..013f61931 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/separate_tumor_nodules_69006.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/separate_tumor_nodules_69006.json @@ -6,7 +6,7 @@ "title" : "Separate Tumor Nodules", "description" : "“Separate tumor nodules” refers to what is conceptually a single tumor with intrapulmonary metastasis in the ipsilateral (same) lung. Their presence in the same or different lobes of lung from the primary tumor affects the T and M categories.\n\nSeparate tumor nodules are defined as intrapulmonary metastasis identified in the same lobe or same lung (ipsilateral) originating from a single lung primary at the time of diagnosis. Biopsy of tumors may or may not be performed. So long as there is a strong suspicion the multiple lesions are of the same histological type by imaging, physician judgement, or microscopically, this meets the criteria of separate tumor nodules representing intrapulmonary metastases. The presence of metastases to extrathoracic sites does not change this distinction.", "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of Separate Tumor Nodules in the ipsilateral (same) lung can be used to code this data item when no other information is available. See discussion of terminology in Note 3. \n * Separate tumor nodules in the contralateral lung are not coded in this data item.\n\n**Note 2:** **Intrapulmonary Metastasis** \n* Code the presence and location of separate tumor nodules with the same histologic type, also known as intrapulmonary metastasis, at the time of diagnosis in this item. \n * Separate tumor nodules can be defined clinically (by imaging) and/or pathologically. \n * They can be in the same or different lobes of the same lung as the primary tumor. \n * In the case of multiple tumor nodules determined to be the same primary, if not all nodules are biopsies, assume they are the same histology\n\n**Note 3:** **Situations NOT coded in this data item**\n* Other situations that display multiple lesions are NOT coded in this item. Assign code 0 if the multiple lesions belong to one of these other situations. Refer to the AJCC Staging System Lung for standardized and precise definitions of the situations which aren’t separate tumor nodules. They are \n * Second primary tumors, also called synchronous primary tumors (not the same histology as the primary tumor) \n * Multifocal lung adenocarcinoma with ground glass/lepidic features \n * Diffuse pneumonic adenocarcinoma\n\n**Note 4:** **Definition of Synchronous** \n* \"Synchronous\" describes the appearance in time compared to the primary tumor\n* Do not code this item based solely on the word \"synchronous\". \n* If separate nodules are described as \"metachronous,\" the nodules may be evidence of progression of disease in which case they would not be coded here.", - "last_modified" : "2025-02-24T13:56:38.137Z", + "last_modified" : "2025-11-05T21:58:26.403Z", "definition" : [ { "key" : "separate_tumor_nodules", "name" : "Code", @@ -17,7 +17,7 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "0", "No separate tumor nodules; single tumor only\nSeparate tumor nodules of same histologic type not identified/not present\nIntrapulmonary metastasis not identified/not present\nMultiple nodules described as multiple foci of adenocarcinoma in situ or minimally invasive adenocarcinoma\n\nNon-invasive neoplasm (behavior /2)" ], [ "1", "Separate tumor nodules of same histologic type in ipsilateral lung, same lobe" ], [ "2", "Separate tumor nodules of same histologic type in ipsilateral lung, different lobe" ], [ "3", "Separate tumor nodules of same histologic type in ipsilateral lung, same AND different lobes" ], [ "4", "Separate tumor nodules of same histologic type in ipsilateral lung, unknown if same or different lobe(s)" ], [ "7", "Multiple nodules or foci of tumor present, not classifiable based on Notes 2 and 3" ], [ "8", "Not applicable: Information not collected for this case\n(If this item is required by your standard setter, use of code 8 will result in an edit error.)" ], [ "9", "Not documented in medical record\nSeparate Tumor Nodules not assessed or unknown if assessed" ] ], - "additional_info" : "**Source documents:** imaging reports and pathology reports\n\nFor further information, refer to the **Lung** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Lung*", + "additional_info" : "**Source documents:** imaging reports and pathology reports\n\nFor further information, refer to the **Lung** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Lung*.", "coding_guidelines" : "Record the presence of separate tumor nodules within the same ipsilateral lobe and/or different lobes of the same lung which are considered a single primary. The histology of the separate tumors must be the same. Histology may be determined clinically (presumed to be the same based on imaging or physician judgement) or microscopically confirmed.\n\n**1)** **Code 0** when \n* Non-invasive neoplasm (/2 behavior)\n* SINGLE TUMOR nodule only\n* Separate tumor nodules present with DIFFERENT HISTOLOGIES\n* Relevant imaging or resection is performed and there is no mention of separate tumor nodules \n * Multiple histologies with\n * Second primary tumors, also called synchronous primary tumors (not the same histology as the primary tumor)\n * Multifocal lung adenocarcinoma with ground glass/lepidic features\n * Diffuse pneumonic adenocarcinoma\n\n**2)** **Code 1** when \n* Separate tumor nodules present in the SAME LOBE with the SAME HISTOLOGY \n\n**3)** **Code 2** when \n* Separate tumor nodules present in DIFFERENT LOBES of the SAME LUNG (ipsilateral) with the SAME HISTOLOGY.\n\n**4)** **Code 3** when \n* Separate tumor nodules present in SAME LOBE AND DIFFERENT LOBES of the SAME LUNG with the SAME HISTOLOGY.\n\n**5)** **Code 4** when \n* Separate tumor nodules present in SAME LUNG with the SAME HISTOLOGY and it’s UNKNOWN IF they are in the SAME LOBE OR DIFFERENT LOBES.\n\n**6)** **Code 7** when\n* There are multiple tumor nodules or foci and the terminology used is not readily identifiable as one of the situations described in Note 4 and no other information is available (including consulting with physician) is available. (Do not use this information in staging the primary tumor)\n\n**7)** **Code 9** when\n* There is no relevant imaging or resection of the primary site", "rationale" : "This data item was previously collected for Lung, SSF #1 and at least one standard setter is continuing to collect it." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/spread_through_air_spaces_stas_67834.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/spread_through_air_spaces_stas_67834.json index 7ca22e767..adb8b72e4 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/spread_through_air_spaces_stas_67834.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/spread_through_air_spaces_stas_67834.json @@ -6,7 +6,7 @@ "title" : "Lung Spread Through Air Spaces (STAS)", "description" : "Spread Through Air Spaces (STAS) is defined as micropapillary clusters, solid nests, or single cells of tumor extending beyond the edge of the tumor into the air spaces of the surrounding lung parenchyma.", "notes" : "***Any questions regarding this SSDI are to be posted in the AJCC CAnswer Forum***\n\n**Note 1:** **Effective years**\n- This SSDI is effective for diagnosis years 2026+. \n- For cases diagnosed 2018-2025, this SSDI must be blank.\n\n**Note 2:** **Physician Statement**\n- Physician statement of STAS can be used to code this data item when no other information is available.\n\n**Note 3:** **Criteria for coding**\n- A surgical resection must be done to determine if there is STAS.\n - *Exception:* In situ tumors (/2) can be coded 0 based on biopsy or surgical resection\n - If no surgical resection done, see code 9\n\n**Note 4:** **CAP Protocol or Synoptic Pathology Report**\n- Only record the information from the CAP Protocol or synoptic pathology report\n - Codes 0, 1, 7 may not be assigned if they are not included in the CAP Protocol or synoptic pathology report", - "last_modified" : "2025-05-05T13:42:01.766Z", + "last_modified" : "2025-11-06T18:31:48.493Z", "definition" : [ { "key" : "stas", "name" : "Code", @@ -17,7 +17,7 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "0", "Not identified" ], [ "1", "Present" ], [ "8", "Not applicable: information not collected for this case\n(If this item is required by your standard setter, use of code 8 will result in an edit error)." ], [ "9", "No surgical resection done\nSurgical resection done and STAS not documented in the CAP Protocol or synoptic pathology report\nSTAS not assessed or unknown if assessed or cannot be determined" ], [ "", "Must be blank if diagnosis year is before 2026" ] ], - "additional_info" : "**Source documents**: CAP protocol or synoptic pathology report\n\nFor further information, refer to the **Lung Resection cancer protocol** published by the College of American Pathologists for the AJCC Staging System *Lung*\n\n**Any questions regarding this SSDI are to be posted in the AJCC Forum**", - "coding_guidelines" : "**1)** Record the STAS score as stated on the CAP Protocol or synoptic pathology report\n**2)** **Code 9** when\n* Surgical resection of the primary site is performed and the presence/absence of STAS is not documented in the CAP Protocol or synoptic pathology report\n* No surgical resection is done\n* Surgical pathology report is not available", + "additional_info" : "**Source documents**: CAP protocol or synoptic pathology report\n\nFor further information, refer to the **Lung Resection cancer protocol** published by the College of American Pathologists for the AJCC Staging System *Lung*.\n\n**Any questions regarding this SSDI are to be posted in the AJCC Forum.**", + "coding_guidelines" : "**1)** Record the STAS score as stated on the CAP Protocol or synoptic pathology report\n\n**2)** **Code 9** when\n* Surgical resection of the primary site is performed and the presence/absence of STAS is not documented in the CAP Protocol or synoptic pathology report\n* No surgical resection is done\n* Surgical pathology report is not available", "rationale" : "Initial studies have shown that the presence of STAS is associated with an increased incidence of recurrence in tumors that have undergone limited resection (e.g., segmentectomy, wedge resection)." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ss2018_44993.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ss2018_44993.json index ae510eb58..895d8cd66 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ss2018_44993.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ss2018_44993.json @@ -5,9 +5,9 @@ "name" : "SS2018: Myeloma and Plasma Cell Disorders", "title" : "Summary Stage 2018: Myeloma and Plasma Cell Disorders", "subtitle" : "Summary Stage 2018", - "notes" : "**Myeloma and Plasma Cell Disorders**\n\n9671 Lymphoplasmacytic lymphoma (except C441, C690, C695-C696)\n * C700-C729, C751-C753 (2018-2022 only) (See Note 2)\n\n9731 Plasmacytoma, NOS\n9732 Plasma cell myeloma/multiple myeloma\n9734 Plasmacytoma, extramedullary (except C441, C690, C695-C696)\n9761 Waldenstrom Macroglobulinemia \n\n**Note 1:** **Sources used in the development of this chapter**\n* SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998) (https://seer.cancer.gov/archive/manuals/EOD10Dig.3rd.pdf)\n* SEER Summary Staging Manual-2000: Codes and Coding Instructions (https://seer.cancer.gov/tools/ssm/ssm2000/)\n* Collaborative Stage Data Collection System, version 02.05: https://cancerstaging.org/cstage/Pages/default.aspx \n* Chapter 82 *Plasma Cell Myeloma and Plasma Cell Disorder*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois.\n\n**Note 2:** **Histologies moved to Brain, CNS, Intracranial Gland** \n* For the histology listed below, this has moved to the Brain, CNS Other, and Intracranial Gland Summary Stage chapters starting with 2023 diagnoses. If you have one of these cases for 2018-2022, then this is the appropriate chapter. If you have one of these cases diagnosed on January 1, 2023, forward, see the appropriate chapter\n* 9671 \n * **Brain**: C700, C710-C719\n * **CNS Other**: C701, C709, C720-C725, C728-C729\n * **Intracranial Gland**: C751-C753\n\n**Note 3:** **Not applicable codes** \n* Codes 0, 2, and 4 are not applicable for this chapter.\n\n**Note 4:** **Definition of Plasma cell myeloma** \n* Plasma cell myeloma/multiple myeloma (9732) is a widely disseminated plasma cell neoplasm, characterized by a single clone of plasma cells derived from B cells that grows in the bone marrow. It is always coded to 7 for systemic involvement.\n\n**Note 5:** **Lymphoplasmacytic lymphoma** \n* Lymphoplasmacytic lymphoma (9671) and Waldenstrom Macroglobulinemia (9761) are now collected with the plasma cell disorders. \n* These are systemic diseases and should always be coded 7.", + "notes" : "**Myeloma and Plasma Cell Disorders**\n\n**The preferred histology terms listed in this schema are from the 2024 WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition.**\n\n* 9671: Lymphoplasmacytic lymphoma (LPL) *(EXCEPT C441, C690, C695-C696)*\n * C700-C729, C751-C753 (2018-2022 only) (See Note 2)\n* 9731: Solitary plasmacytoma of bone (SPB)\n* 9732: Plasma Cell Myeloma (PCM)\n* 9734: Extramedullary plasmacytoma (EMP) *(EXCEPT C441, C690, C695-C696)*\n* 9761: Waldenstrom macroglobulinemia (WM)\n\n**Note 1:** **Sources used in the development of this chapter**\n* SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998) (https://seer.cancer.gov/archive/manuals/EOD10Dig.3rd.pdf)\n* SEER Summary Staging Manual-2000: Codes and Coding Instructions (https://seer.cancer.gov/tools/ssm/ssm2000/)\n* Collaborative Stage Data Collection System, version 02.05: https://cancerstaging.org/cstage/Pages/default.aspx \n* Chapter 82 *Plasma Cell Myeloma and Plasma Cell Disorder*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois.\n\n**Note 2:** **Histologies moved to Brain, CNS, Intracranial Gland** \n* For the histology listed below, this has moved to the Brain, CNS Other, and Intracranial Gland Summary Stage chapters starting with 2023 diagnoses. If you have one of these cases for 2018-2022, then this is the appropriate chapter. If you have one of these cases diagnosed on January 1, 2023, forward, see the appropriate chapter\n* 9671 \n * **Brain**: C700, C710-C719\n * **CNS Other**: C701, C709, C720-C725, C728-C729\n * **Intracranial Gland**: C751-C753\n\n**Note 3:** **Not applicable codes** \n* Codes 0, 2, and 4 are not applicable for this chapter.\n\n**Note 4:** **Definition of Plasma cell myeloma** \n* Plasma cell myeloma/multiple myeloma (9732) is a widely disseminated plasma cell neoplasm, characterized by a single clone of plasma cells derived from B cells that grows in the bone marrow. It is always coded to 7 for systemic involvement.\n\n**Note 5:** **Lymphoplasmacytic lymphoma** \n* Lymphoplasmacytic lymphoma (9671) and Waldenstrom Macroglobulinemia (9761) are now collected with the plasma cell disorders. \n* These are systemic diseases and should always be coded 7.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) **Introduction to Hematologic Malignancies**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Bergsagel, P.L., Jaffe, E.S., Leonard, J.P., et al. **Plasma Cell Myeloma and Plasma Cell Disorders**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2024-05-16T18:44:10.043Z", + "last_modified" : "2025-09-25T13:11:26.328Z", "definition" : [ { "key" : "ss2018", "name" : "SS2018", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ss2018_hemeretic_3793.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ss2018_hemeretic_3793.json index c389a1878..4ac6f162c 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ss2018_hemeretic_3793.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ss2018_hemeretic_3793.json @@ -5,9 +5,9 @@ "name" : "SS2018: HemeRetic", "title" : "Summary Stage 2018: HemeRetic", "subtitle" : "Summary Stage 2018", - "notes" : "**HemeRetic**\n\n9724, 9727, 9740-9742, 9749, 9762-9809, 9811-9820, 9831-9920, 9931-9993 \n* C700-C729, C751-C753 for 9749, 9766 (2018-2022 only) (See Note 2)\n\nC000-C440, C442-C689, C691-C694, C698-C809: 9591 and Schema Discriminator 1: 1, 2 \n\nC000-C699, C739-C750, C754-C809: 9751, 9755-9759 \n\nC000-C440, C442-C689, C691-C694, C698-C809: 9930 \n\n**Note 1:** **Sources used in the development of this chapter**\n* SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998) (https://seer.cancer.gov/archive/manuals/EOD10Dig.3rd.pdf)\n* SEER Summary Staging Manual-2000: Codes and Coding Instructions (https://seer.cancer.gov/tools/ssm/ssm2000/)\n* Collaborative Stage Data Collection System, version 02.05: https://cancerstaging.org/cstage/Pages/default.aspx \n* Chapter 83 *Leukemia*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois.\n\n**Note 2:** **Histologies moved to Brain, CNS, Intracranial Gland** \n* For the histologies and primary sites listed below, these have moved to the Brain, CNS Other, and Intracranial Gland Summary Stage chapters starting with 2023 diagnoses.\n* If you have one of these cases for 2018-2022, then this is the appropriate chapter. If you have one of these cases diagnosed on January 1, 2023, forward, see the appropriate chapter\n * **9749, 9766** \n * **Brain**: C700, C710-C719\n * **CNS Other**: C701, C709, C720-C725, C728-C729\n * **Intracranial Gland**: C751-C753\n\n**Note 3:** **Other Summary Stage chapters with the listed histologies**\n* **Brain**: 9751, 9755-9759 (C700, C710-C719)\n* **CNS Other**: 9751, 9755-9759 (C701, C709, C720-C725, C728-C729)\n* **Intracranial Gland**: 9751, 9755-9759 (C751-C753)\n* **Lymphoma**: 9591 and Schema Discriminator 1: 3, 9 (C000-C440, C442-C689, C691-C694, C698-C809)\n* **Lymphoma Ocular Adnexa**: 9930 (C441, C690, C695-C696\n\n**Note 4:** **The following histologies can be localized (code 1), systemic (7) or unknown (9)** \n\n9740 Mast cell sarcoma \n9749 Erdheim-Chester disease (2021+ only) (except C700-C729, C751-C753 for 1/1/2023+)\n9751 Langerhans cell histiocytosis, disseminated (except C700-C729, C751-C753)\n9755 Histiocytic sarcoma (except C700-C729, C751-C753)\n9756 Langerhans cell sarcoma (except C700-C729, C751-C753)\n9757 Interdigitating dendritic cell sarcoma (except C700-C729, C751-C753)\n9758 Follicular dendritic cell sarcoma (except C700-C729, C751-C753)\n9759 Fibroblastic reticular cell tumor (except C700-C729, C751-C753)\n9766 Lymphomatoid granulomatosis, Grade 3 (2021+ only) (except C700-C729, C751-C753 for 1/1/2023+)\n9930 Myeloid sarcoma (except C441, C690, C695-C696)\n9971 Polymorphic PTLD (2018-2020 only, nonreportable as of 2021)\n\n**Note 5:** **Lymph node involvement** \n* For histologies listed in **Note 4**, it is possible to have lymph node involvement; however, at this time, lymph node involvement for these histologies is not collected.\n\n**Note 6:** **The following histologies are systemic (code 7)**\n\n9591 Splenic B-cell lymphoma/leukemia, unclassifiable (except C441, C690, C695-C696)\n9724 Systemic EBV-positive T-cell lymphoma of childhood\n9727 Blastic plasmacytoid dendritic cell neoplasm\n9741 Systemic mastocytosis with an associated hematological neoplasm\n9742 Mast cell leukemia\n9762 Heavy chain diseases\n9800 Leukemia, NOS\n9801 Acute undifferentiated leukemia\n9806 Mixed-phenotype acute leukemia with t(9;22)(q34.1;q11.2); *BCR-ABL1*\n9807 Mixed-phenotype acute leukemia with t(v;11q23.3); *KMT2A*-rearranged\n9808 Mixed-phenotype acute leukemia, B/myeloid, NOS\n9809 Mixed-phenotype acute leukemia, T/myeloid, NOS\n9811 B-lymphoblastic leukemia/lymphoma, NOS\n9812 B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2); *BCR-ABL1*\n9813 B-lymphoblastic leukemia/lymphoma with t(v;11q23.3); *KMT2A*-rearranged\n9814 B-lymphoblastic leukemia/lymphoma with t(12;21)(p13.2;q22.1); *ETV6-RUNX1*\n9815 B-lymphoblastic/lymphoma with hyperdiploidy\n9816 B-lymphoblastic/lymphoma with hypodiploidy (hypodiploid ALL)\n9817 B-lymphoblastic/lymphoma with t(5;14)(q31.1;q32.1); IGH/*IL3*\n9818 B-lymphoblastic/lymphoma with t(1;19)(q23;p13.3); *TCF3-PBX1*\n9819 B-lymphoblastic/lymphoma, BCR-ABL1-like (2021+ only)\n9820 Lymphoid leukemia, NOS\n9831 T-cell large granular lymphocytic leukemia\n9832 Prolymphocytic leukemia, NOS\n9833 B-cell prolymphocytic leukemia\n9834 T-cell prolymphocytic leukemia\n9837 T-lymphoblastic leukemia/lymphoma \n9840 Pure erythroid leukemia\n9860 Myeloid leukemia, NOS\n9861 Acute myeloid leukemia, NOS\n9863 Chronic myeloid leukemia\n9865 Acute myeloid leukemia with t(6;9)(p23;q34.1); *DEK-NUP214*\n9866 Acute promyelocytic leukemia with *PML-RARA*\n9867 Acute myelomonocytic leukemia\n9869 Acute myeloid leukemia with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26;2); *RBM15-MKL1*\n9870 Acute basophilic leukemia\n9871 Acute myeloid leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); *CBFB-MYH11*\n9872 Acute myeloid leukemia, minimal differentiation\n9873 Acute myeloid leukemia without maturation\n9874 Acute myeloid leukemia with maturation\n9875 Chronic myeloid leukemia, *BCR-ABL1*-positive\n9876 Atypical chronic myeloid leukemia *BCR-ABL1*-negative\n9877 Acute myeloid leukemia with mutated NPM1 (2021+ only)\n9878 Acute myeloid leukemia with biallelic mutation of CEBPA (2021+ only)\n9879 Acute myeloid leukemia with mutated RUNX1 (2021+ only)\n9891 Acute monoblastic and monocytic leukemia\n9895 Acute myeloid leukemia with myelodysplasia-related changes\n9896 Acute myeloid leukemia with t(8;21)(q22;q22.1), *RUNX1-RUNX1T1*\n9897 Acute myeloid leukemia with t(9;11)(p21.3;q23.3); *KMT2A-MLLT3*\n9898 Myeloid leukemia associated with Down Syndrome\n9910 Acute megakaryoblastic leukemia\n9911 Acute myeloid leukemia (megakaryoblastic) with t(1;22)(p13.3;q13.1); *RBM15-MKL1*\n9912 Acute myeloid leukemia with BCR-ABL1 (2021+ only)\n9920 Therapy-related myeloid neoplasms\n9931 Acute panmyelosis with myelofibrosis\n9940 Hairy cell leukemia\n9945 Chronic myelomonocytic leukemia, NOS\n9946 Juvenile myelomonocytic leukemia\n9948 Aggressive NK-cell leukemia\n9950 Polycythemia vera\n9961 Primary myelofibrosis\n9962 Essential thrombocythemia\n9963 Chronic neutrophilic leukemia\n9964 Chronic eosinophilic leukemia, NOS\n9965 Myeloid/lymphoid neoplasms with *PDGFRA* rearrangement\n9966 Myeloid/lymphoid neoplasm with *PDGFRB* rearrangement\n9967 Myeloid/lymphoid neoplasm with *FGFR1* rearrangement\n9968 Myeloid/lymphoid neoplasm with PCM1-JAK2 (2021+ only)\n9975 Myelodysplastic/myeloproliferative neoplasm, unclassifiable\n9980 Myelodysplastic syndrome with single lineage dysplasia\n9982 Myelodysplastic syndrome with ring sideroblasts and single lineage dysplasia\n9983 Myelodysplastic syndrome with excess blasts\n9985 Myelodysplastic syndrome with multilineage dysplasia\n9986 Myelodysplastic syndrome with isolated del(5q)\n9989 Myelodysplastic syndrome, unclassifiable\n9991 Refractory neutropenia (2018-2020 only, see code 9980/3 for 2021+)\n9992 Refractory thrombocytopenia (2018-2020 only, see code 9980/3 for 2021+)\n9993 Myelodysplastic syndrome with ring sideroblasts and multilineage dysplasia (2021+ only)\n\n**Note 7:** **Only staging system** \n* Summary Stage is the only applicable staging system for this site/histology/schema.\n\n**Note 8:** **Not applicable codes** \n* Codes 0, 2, 3, and 4 are not applicable for this chapter.", + "notes" : "**HemeRetic**\n\n**The preferred histology terms listed in this chapter are from the 2024 WHO Classification of Tumours, Haematolymphoid tumours, 5th edition.**\n\n9724, 9727, 9740-9742, 9749, 9762-9809, 9811-9820, 9831-9920, 9931-9993 \n* C700-C729, C751-C753 for 9749, 9766 (2018-2022 only) (See Note 2)\n\nC000-C440, C442-C689, C691-C694, C698-C809: 9591 and Schema Discriminator 1: 1, 2 \n\nC000-C699, C739-C750, C754-C809: 9751, 9755-9759 \n\nC000-C440, C442-C689, C691-C694, C698-C809: 9930 \n\n**Note 1:** **Sources used in the development of this chapter**\n* SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998) (https://seer.cancer.gov/archive/manuals/EOD10Dig.3rd.pdf)\n* SEER Summary Staging Manual-2000: Codes and Coding Instructions (https://seer.cancer.gov/tools/ssm/ssm2000/)\n* Collaborative Stage Data Collection System, version 02.05: https://cancerstaging.org/cstage/Pages/default.aspx \n* Chapter 83 *Leukemia*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois.\n\n**Note 2:** **Histologies moved to Brain, CNS, Intracranial Gland** \n* For the histologies and primary sites listed below, these have moved to the Brain, CNS Other, and Intracranial Gland Summary Stage chapters starting with 2023 diagnoses.\n* If you have one of these cases for 2018-2022, then this is the appropriate chapter. If you have one of these cases diagnosed on January 1, 2023, forward, see the appropriate chapter\n * **9749, 9766** \n * **Brain**: C700, C710-C719\n * **CNS Other**: C701, C709, C720-C725, C728-C729\n * **Intracranial Gland**: C751-C753\n\n**Note 3:** **Other Summary Stage chapters with the listed histologies**\n* **Brain**: 9751, 9755-9759, (9749, 9766 for 2023+) (C700, C710-C719) \n* **CNS Other**: 9751, 9755-9759, (9749, 9766 for 2023+) (C701, C709, C720-C725, C728-C729) (9749, 9766 for 2023+)\n* **Intracranial Gland**: 9751, 9755-9759, (9749, 9766 for 2023+) (C751-C753)\n* **Lymphoma**: 9591 and Schema Discriminator 1: 3, 9 (C000-C440, C442-C689, C691-C694, C698-C809)\n* **Lymphoma Ocular Adnexa**: 9930 (C441, C690, C695-C696\n\n**Note 4:** **The following histologies can be localized (code 1), systemic (7) or unknown (9)** \n\n* 9740: Mast cell sarcoma (MCS)\n* 9749: Erdheim-Chester disease (ECD) *(2021+ only)*\n* 9755: Histiocytic sarcoma\n* 9756: Langerhans cell sarcoma (LCS) \n* 9757: Interdigitating dendritic cell sarcoma (IDCS) \n* 9758: Follicular dendritic cell sarcoma (FDCS) \n* 9759: Fibroblastic reticular cell tumor \n* 9766: Lymphomatoid granulomatosis, grade 3 *(2021+ only)*\n* 9930: Myeloid sarcoma \n* 9971: Polymorphic PTLD *(2018-2020, 2025+)* \n * **Note:** 9971 is /1 and non-reportable *(EXCEPT for C700-C729, C751-C753)* for 2021-2024, moved back to /3 for 1/1/2025+\n\n**Note 5:** **Lymph node involvement** \n* For histologies listed in **Note 4**, it is possible to have lymph node involvement; however, at this time, lymph node involvement for these histologies is not collected.\n\n**Note 6:** **The following histologies are systemic (code 7)**\n\n* 9591: Splenic B-cell lymphoma/leukemia, unclassifiable\n* 9724: Systemic EBV-positive T-cell lymphoma of childhood (SEBVTCL)\n* 9727: Blastic plasmacytoid dendritic cell neoplasm (BPDC)\n* 9741: Systemic mastocytosis with an associated hematological neoplasm (SM-AHN)\n* 9742: Mast cell leukemia (MCL)\n* 9750: ALK-positive histiocytosis\n* 9751: Langerhans cell histiocytosis (LCH), disseminated\n* 9762: Heavy chain diseases, NOS (HCD)\n* 9800: Leukemia, NOS\n* 9801: Acute undifferentiated leukemia\n* 9805: Acute leukemia of ambiguous lineage with other defined genetic alterations\n* 9806: Mixed-phenotype acute leukemia (MPAL) with *BCR::ABL1* fusion\n* 9807: Mixed-phenotype acute leukemia (MPAL) with *KMT2A-rearranged*\n* 9808: Mixed -phenotype acute leukemia, B/myeloid, NOS\n* 9809: Mixed-phenotype acute leukemia (MPAL), T/myeloid, NOS\n* 9811: B-lymphoblastic leukemia/lymphoma [B-ALL/LBL], NOS\n* 9812: B-lymphoblastic leukemia/lymphoma [B-ALL/LBL] with *BCR::ABL1 fusion*\n* 9813: B lymphoblastic leukemia/lymphoma [B-ALL/LBL] with *KMT2A rearrangement*\n* 9814: B-lymphoblastic leukemia/lymphoma [B-ALL/LBL] with *ETV6::RUNX1 fusion*\n* 9815: B-lymphoblastic leukemia/lymphoma with high hyperdiploidy (B-ALL/LBL with high hyperdiploidy)\n* 9816: B-lymphoblastic leukemia/lymphoma [B-ALL/LBL] with hypodiploidy (Hypodiploid B-ALL/LBL)\n* 9817: B-lymphoblastic leukemia/lymphoma [B-ALL/LBL] with *IGH::IL3 fusion*\n* 9818: B-lymphoblastic leukemia/lymphoma [B-ALL/LBL] with *TCF3::PBX1*\n* 9819: B-lymphoblastic leukemia/lymphoma [B-ALL/LBL] with *BCR::ABL1 like features* (BCR::ABL1-like B-ALL/LBL) *(2021+ only)*\n* 9820: Lymphoid leukemia, NOS\n* 9831: T-large granular lymphocytic leukemia (T-LGLL)\n* 9832: Prolymphocytic leukemia (PPL), NOS\n* 9833: Prolymphocytic leukemia, B-cell type (BLL) \n* 9834: T-cell prolymphocytic leukemia (T-PLL)\n* 9837: T-lymphoblastic leukemia/lymphoma (T-ALL/LBL) \n* 9840: Acute erythroid leukemia (AEL)\n* 9860: Myeloid leukemia, NOS\n* 9861: Acute myeloid leukemia (AML), NOS\n* 9863: Chronic myeloid leukemia (CML), NOS\n* 9865: Acute myeloid leukemia with *DEK::NUP214 fusion*\n* 9866: Acute promyelocytic leukemia with *PML::RARA* fusion (APL with *PML::RARA*)\n* 9867: Acute myelomonocytic leukemia, NOS (AMML)\n* 9869: Acute myeloid leukemia with *MECOM rearrangement*\n* 9870: Acute basophilic leukemia\n* 9871: Acute myeloid leukemia with *CBFB::MYH11 fusion*\n* 9872: Acute myeloid leukemia, minimal differentiation\n* 9873: Acute myeloid leukemia without maturation\n* 9874: Acute myeloid leukemia with maturation\n* 9875: Chronic myeloid leukemia (CML), *BCR::ABL1 positive*\n* 9876: Myelodysplastic/myeloproliferative neoplasm with neutrophilia (MDS/MPN-N)\n* 9877: Acute myeloid leukemia with mutated *NPM1* *(2021+ only)*\n* 9878: Acute myeloid leukemia with *CEBPA mutation* *(2021+ only)*\n* 9879: Acute myeloid leukemia with mutated *RUNX1* *(2021+ only)*\n* 9891: Acute monocytic leukemia\n* 9895: Myelodysplasia-related acute myeloid leukemia (AML-MR)\n* 9896: Acute myeloid leukemia with *RUNX1::RUNX1T1*\n* 9897: Acute myeloid leukemia with *KMT2a rearrangement*\n* 9898: Myeloid leukemia associated with Down Syndrome (ML-DS)\n* 9910: Acute megakaryoblastic leukemia (AMKL)\n* 9911: Acute myeloid leukemia (megakaryoblastic) with *RBMI5::MRTFA*\n* 9912: Acute myeloid leukemia with *BCR::ABL1 fusion* *(2021+ only)*\n* 9920 Therapy-related myeloid neoplasms\n* 9931: Acute panmyelosis with myelofibrosis (APMF)\n* 9940: Hairy cell leukemia (HCL)\n* 9945: Chronic myelomonocytic leukemia, NOS (CMML)\n* 9946: Juvenile myelomonocytic leukemia (JMML)\n* 9948: Aggressive NK-cell leukemia (ANKL)\n* 9950: Polycythemia vera (PV)\n* 9961: Primary myelofibrosis (PMF)\n* 9962: Essential thrombocythemia (ET)\n* 9963: Chronic neutrophilic leukemia (CNL)\n* 9964: Chronic eosinophilic leukemia (CEL)\n* 9965: Myeloid/lymphoid neoplasms with *PDGFRA* rearrangement\n* 9966: Myeloid/lymphoid neoplasm with *PDGFRB* rearrangement\n* 9967: Myeloid/lymphoid neoplasm with *FGFR1* rearrangement\n* 9968: Myeloid/lymphoid neoplasm with *JAK2* rearrangement *(2021+ only)*\n* 9975: Myelodysplastic/myeloproliferative neoplasm, NOS, unclassifiable (MPN/MDS-U)\n* 9980: Myelodysplastic neoplasm with low blasts and single-lineage dysplasia (MDS-LB-SLD)\n* 9982 Myelodysplastic /myeloproliferative neoplasm with low blasts and SF3B1 mutation\n* 9983: Myelodysplastic neoplasm with increased blasts (MDS-IB)\n* 9985: Myelodysplastic neoplasm with low blasts, NOS (MDS-LB)\n* 9986: Myelodysplastic neoplasm with low blasts and 5q deletion (MDS-5q)\n* 9989: Myelodysplastic neoplasm, NOS\n* 9991: Refractory neutropenia *(2018-2020 only, see code 9980/3 for 2021+)*\n* 9992: Refractory thrombocytopenia *(2018-2020 only, see code 9980/3 for 2021+)*\n* 9993: Myelodysplastic syndrome with ring sideroblasts and multilineage dysplasia *(2021+)*\n\n**Note 7:** **Only staging system** \n* Summary Stage is the only applicable staging system for this site/histology/schema.\n\n**Note 8:** **Not applicable codes** \n* Codes 0, 2, 3, and 4 are not applicable for this chapter.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) **Introduction to Hematologic Malignancies**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Radich, J.P., Jaffe, E.S., Leonard, J.P., et al. **Leukemia**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-07-18T12:29:13.770Z", + "last_modified" : "2025-09-26T14:24:33.098Z", "definition" : [ { "key" : "ss2018", "name" : "SS2018", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ss2018_larynx_supraglottic_excluding_melanoma_8720_8790_91429.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ss2018_larynx_supraglottic_excluding_melanoma_8720_8790_91429.json index c0646e27d..5a2a7b4d6 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ss2018_larynx_supraglottic_excluding_melanoma_8720_8790_91429.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ss2018_larynx_supraglottic_excluding_melanoma_8720_8790_91429.json @@ -5,9 +5,9 @@ "name" : "SS2018: Larynx Supraglottic", "title" : "Summary Stage 2018: Larynx Supraglottic", "subtitle" : "Summary Stage 2018", - "notes" : "**Larynx Supraglottic**\n\n8000-8700\n\nC101, C321\nC101 Epiglottis anterior\nC321 Supraglottis\n\n**Note 1:** **Sources used in the development of this chapter**\n* SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998) (https://seer.cancer.gov/archive/manuals/EOD10Dig.3rd.pdf)\n* SEER Summary Staging Manual-2000: Codes and Coding Instructions (https://seer.cancer.gov/tools/ssm/ssm2000/)\n* Collaborative Stage Data Collection System, version 02.05: https://cancerstaging.org/cstage/Pages/default.aspx \n* Chapter 13 *Larynx*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois.\n\n**Note 2:** **Other Summary Stage Chapters with Supraglottic Larynx sites** \n* **GIST**: 8935-8936\n* **Kaposi Sarcoma**: 9140\n* **Melanoma Head and Neck**: 8720-8790\n* **Mycosis Fungoides**: 9700-9701\n* **Soft Tissue**: 8710-8714, 8800-8934, 8940-9138, 9141-9582\n\n**Note 3:** **Impaired vocal cord mobility** \n* Impaired vocal cord mobility, also described as vocal cord paresis, may suggest invasion of intrinsic laryngeal muscle. Fixation of the vocal cord may be described as immobility of the arytenoids noted on endoscopy, vocal cord paralysis, or deviation of larynx to fixed side.\n\n**Note 4:** **Localized tumor** \n* Code 1 for localized tumor only if no information is available to identify further extension.\n\n**Note 5:** **Limited to the larynx** \n* Tumor limited to the larynx (code 1) includes tumor involving, but limited to, the supraglottis, glottis and subglottis.", + "notes" : "**Larynx Supraglottic**\n\n8000-8700\n\nC101, C321\nC101 Epiglottis anterior (2018-2025)\nC321 Supraglottis\n\n**Note 1:** **Sources used in the development of this chapter**\n* SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998) (https://seer.cancer.gov/archive/manuals/EOD10Dig.3rd.pdf)\n* SEER Summary Staging Manual-2000: Codes and Coding Instructions (https://seer.cancer.gov/tools/ssm/ssm2000/)\n* Collaborative Stage Data Collection System, version 02.05: https://cancerstaging.org/cstage/Pages/default.aspx \n* Chapter 13 *Larynx*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois.\n\n**Note 2:** **Other Summary Stage Chapters with Supraglottic Larynx sites** \n* **GIST**: 8935-8936\n* **Kaposi Sarcoma**: 9140\n* **Melanoma Head and Neck**: 8720-8790\n* **Mycosis Fungoides**: 9700-9701\n* **Soft Tissue**: 8710-8714, 8800-8934, 8940-9138, 9141-9582\n\n**Note 3:** **Impaired vocal cord mobility** \n* Impaired vocal cord mobility, also described as vocal cord paresis, may suggest invasion of intrinsic laryngeal muscle. Fixation of the vocal cord may be described as immobility of the arytenoids noted on endoscopy, vocal cord paralysis, or deviation of larynx to fixed side.\n\n**Note 4:** **Localized tumor** \n* Code 1 for localized tumor only if no information is available to identify further extension.\n\n**Note 5:** **Limited to the larynx** \n* Tumor limited to the larynx (code 1) includes tumor involving, but limited to, the supraglottis, glottis and subglottis.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Lydiatt, W.M., Patel, S.G., Shah, J.P., et al. **Staging Head and Neck Cancers**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Patel, S.G., Lydiatt, W.M., Shah, J.P., et al. **Larynx**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2024-05-17T10:39:17.301Z", + "last_modified" : "2025-09-26T19:36:50.217Z", "definition" : [ { "key" : "ss2018", "name" : "SS2018", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ss2018_liver_84469.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ss2018_liver_84469.json index 7ada51b6e..f45361816 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ss2018_liver_84469.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ss2018_liver_84469.json @@ -7,7 +7,7 @@ "subtitle" : "Summary Stage 2018", "notes" : "**Liver**\n\n8000-8700, 8720-8790\n\nC220\nC220 Liver\n\n**Note 1:** **Sources used in the development of this chapter**\n* SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998) (https://seer.cancer.gov/archive/manuals/EOD10Dig.3rd.pdf)\n* SEER Summary Staging Manual-2000: Codes and Coding Instructions (https://seer.cancer.gov/tools/ssm/ssm2000/)\n* Collaborative Stage Data Collection System, version 02.05: https://cancerstaging.org/cstage/Pages/default.aspx \n* Chapter 22 *Liver*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois.\n\n**Note 2:** **Other Summary Stage Chapters with Liver sites**\n* **GIST**: 8935-8936\n* **Kaposi Sarcoma**: 9140\n* **Mycosis Fungoides**: 9700-9701\n* **Soft Tissue**: 8710-8714, 8800-8934, 8940-9138, 9141-9582\n\n**Note 3:** **Segments of the Liver** \n* The liver is divided into several lobes as defined below. In the absence of other tumor involvement (lymph node involvement or distant metastasis), code the lobe or segment involvement as follows: \n* If multiple lobes (such as the Caudate lobe and the Left Lobe) are involved, code 2 (Regional). If multiple segments (such as 5 and 6 in the right lobe) in the same lobe are involved, this would be multiple tumors within one lobe, code 1 (Localized).\n * Caudate lobe: Segment 1\n * Quadrate lobe: Segment 4b\n * Left lobe: Segments 2, 3, 4a\n * Right lobe: Segments 5, 6, 7, 8", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Abou-Alfa, G.K., Pawlik, T.M., Vauthey, J.N., et al. **Liver**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2024-05-17T10:37:03.419Z", + "last_modified" : "2025-09-23T19:09:04.299Z", "definition" : [ { "key" : "ss2018", "name" : "SS2018", @@ -17,5 +17,5 @@ "name" : "Description", "type" : "DESCRIPTION" } ], - "rows" : [ [ "0", "**In situ: noninvasive, intraepithelial**" ], [ "1", "**Localized only (localized, NOS)**\n- Confined to liver, NOS\n- Single tumor (one lobe) WITH or WITHOUT vascular invasion\n- Multiple (satellite) nodules/tumor confined to one lobe WITH or WITHOUT vascular invasion" ], [ "2", "**Regional by direct extension only**\n- Diaphragm\n- Extrahepatic bile duct(s)\n- Extrahepatic blood vessel(s)\n + Hepatic artery\n + Portal vein\n + Vena cava\n- Gallbladder\n- Ligament(s)\n + Coronary\n + Falciform \n + Hepatoduodenal\n + Hepatogastric\n + Round (of liver)\n + Triangular\n- Omentum (lesser and omentum, NOS) (See code 7 for greater omentum)\n- Peritoneum, NOS\n + Parietal \n + Visceral\n- Major vascular invasion, NOS\n- More than one lobe involved by contiguous growth (single lesion)\n + WITH or WITHOUT vascular invasion\n- Multiple (satellite) nodules/ tumors in more than one lobe of liver or on surface of parenchyma \n + WITH or WITHOUT vascular invasion" ], [ "3", "**Regional lymph node(s) involved only**\n- Caval\n- Hepatic, NOS\n + Hepatic artery\n + Hepatic pedicle\n + Inferior vena cava\n + Porta hepatis (portal) (hilar) [in hilus of liver]Hepatoduodenal ligament\n- Periportal\n- Portal vein \n- Regional lymph node(s), NOS\n + Lymph node(s), NOS" ], [ "4", "**Regional by BOTH direct extension AND regional lymph node(s) involved**\n- Codes (2) + (3)" ], [ "7", "**Distant site(s)/lymph node(s) involved**\n- Distant site(s) (including further contiguous extension)\n + Greater omentum (See code 2 for lesser omentum and omentum, NOS)\n + Pancreas\n + Pleura\n + Stomach \n- Distant lymph node(s), NOS\n + Aortic (para-aortic, periaortic)\n + Cardiac\n + Coronary artery\n + Diaphragmatic, NOS\n + Inferior phrenic nodes\n + Lateral (aortic) (lumbar)\n + Pericardial (pericardiac)\n + Peripancreatic (near head of pancreas only)\n + Posterior mediastinal (tracheoesophageal) including juxtaphrenic nodes\n + Renal artery\n + Retroperitoneal, NOS\n- Distant metastasis, NOS\n + Carcinomatosis \n + Distant metastasis WITH or WITHOUT distant lymph node(s)" ], [ "9", "Unknown if extension or metastasis" ] ] + "rows" : [ [ "0", "**In situ: noninvasive, intraepithelial**" ], [ "1", "**Localized only (localized, NOS)**\n- Confined to liver, NOS\n- Single tumor (one lobe) WITH or WITHOUT vascular invasion\n- Multiple (satellite) nodules/tumor confined to one lobe WITH or WITHOUT vascular invasion" ], [ "2", "**Regional by direct extension only**\n- Diaphragm\n- Extrahepatic bile duct(s)\n- Extrahepatic blood vessel(s)\n + Hepatic artery\n + Portal vein\n + Vena cava\n- Gallbladder\n- Ligament(s)\n + Coronary\n + Falciform \n + Hepatoduodenal\n + Hepatogastric\n + Round (of liver)\n + Triangular\n- Omentum (lesser and omentum, NOS) (See code 7 for greater omentum)\n- Peritoneum, NOS\n + Parietal \n + Visceral\n- Major vascular invasion, NOS\n- More than one lobe involved by contiguous growth (single lesion)\n + WITH or WITHOUT vascular invasion\n- Multiple (satellite) nodules/ tumors in more than one lobe of liver or on surface of parenchyma \n + WITH or WITHOUT vascular invasion" ], [ "3", "**Regional lymph node(s) involved only**\n- Caval\n- Celiac axis\n- Hepatic, NOS\n + Hepatic artery\n + Hepatic pedicle\n + Inferior vena cava\n + Porta hepatis (portal) (hilar) [in hilus of liver]Hepatoduodenal ligament\n- Periportal\n- Portal vein \n- Regional lymph node(s), NOS\n + Lymph node(s), NOS" ], [ "4", "**Regional by BOTH direct extension AND regional lymph node(s) involved**\n- Codes (2) + (3)" ], [ "7", "**Distant site(s)/lymph node(s) involved**\n- Distant site(s) (including further contiguous extension)\n + Greater omentum (See code 2 for lesser omentum and omentum, NOS)\n + Pancreas\n + Pleura\n + Stomach \n- Distant lymph node(s), NOS\n + Aortic (para-aortic, periaortic)\n + Cardiac\n + Coronary artery\n + Diaphragmatic, NOS\n + Inferior phrenic nodes\n + Lateral (aortic) (lumbar)\n + Pericardial (pericardiac)\n + Peripancreatic (near head of pancreas only)\n + Posterior mediastinal (tracheoesophageal) including juxtaphrenic nodes\n + Renal artery\n + Retroperitoneal, NOS\n- Distant metastasis, NOS\n + Carcinomatosis \n + Distant metastasis WITH or WITHOUT distant lymph node(s)" ], [ "9", "Unknown if extension or metastasis" ] ] } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ss2018_lymphoma_27031.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ss2018_lymphoma_27031.json index bc93d3a1f..3a0745fb3 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ss2018_lymphoma_27031.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ss2018_lymphoma_27031.json @@ -5,9 +5,9 @@ "name" : "SS2018: Lymphoma", "title" : "Summary Stage 2018: Lymphoma", "subtitle" : "Summary Stage 2018", - "notes" : "**Lymphoma**\n\n9590, 9596-9663, 9673-9699, 9702-9719, 9725-9726, 9735, 9737-9738, 9823, 9826-9827 (varying primary sites and histologies)\n* C700-C729, C751-C753: 9690, 9719 (2018-2022 only) (See Note 2)\n\nC000-C440, C442-C689, C691-C694, C698-C809: 9591 and Schema Discriminator 1: 3, 9 \n\n*See Summary Stage 2018 Manual, Appendix III for a detailed listing of primary site/histology combinations for this schema*\n\n**Note 1:** **Sources used in the development of this chapter**\n* SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998) (https://seer.cancer.gov/archive/manuals/EOD10Dig.3rd.pdf)\n* SEER Summary Staging Manual-2000: Codes and Coding Instructions (https://seer.cancer.gov/tools/ssm/ssm2000/)\n* Collaborative Stage Data Collection System, version 02.05: https://cancerstaging.org/cstage/Pages/default.aspx \n* Chapter 79 *Hodgkin and Non-Hodgkin Lymphomas*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois.\n* Chapter 80 *Pediatric Hodgkin and Non-Hodgkin Lymphomas*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois.\n\n**Note 2:** **Histologies moved to Brain, CNS, Intracranial Gland** \n* For the histologies listed below, these have moved to the Brain, CNS Other and Intracranial Gland Summary Stage chapters starting with 2023 diagnoses. \n* If you have one of these cases for 2018-2022, then this is the appropriate chapter. If you have one of these cases diagnosed on January 1, 2023, forward, see the appropriate chapter\n* 9690, 9719 \n * C700, C710-C719: *Brain*\n * C701, C709, C720-C725, C728-C729: *CNS Other*\n * C751-C753: *Intracranial Gland*\n\n**Note 3:** **Other Summary Stage chapters with the listed histologies**\n* **Brain**: C700, C710-C719 (9680, 9699, 9702-9715)\n* **CNS Other**: C701, C709, C720-C725, C728-C729 (9680, 9699, 9702-9715)\n* **Heme Retic**: 9591 and Schema Discriminator 1: 1, 2 (C000-C440, C442-C689, C691-C694, C698-C809)\n* **Intracranial Gland**: C751-C753 (9680, 9699, 9702-9715)\n* **Lymphoma Ocular Adnexa**: C441, C690, C695-C696 (9590-9699, 9673-9699, 9702-9719, 9725-9726, 9734-9738, 9823, 9826-9827, 9930)\n* **Primary Cutaneous Lymphoma**: C440, C442-C449, C510, C609, C632 (9597, 9680, 9708-9709, 9712, 9718-9719, 9726): *Primary Cutaneous Lymphomas*\n\n**Note 4:** **Chapter includes the preferred terms based on the *2017 WHO Classification of Haematopoietic and Lymphoid Tissues***\n\n9590 Malignant lymphoma, NOS\n9591 Non-Hodgkin lymphoma, NOS\n9596 B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and classic Hodgkin lymphoma\n9597 Primary cutaneous follicle centre lymphoma\n9650 Classical Hodgkin lymphoma\n9651 Lymphocyte-rich classic Hodgkin lymphoma\n9652 Mixed cellularity classic Hodgkin lymphoma\n9653 Lymphocyte-depleted classic Hodgkin lymphoma \n9659 Nodular lymphocyte predominant Hodgkin lymphoma\n9663 Nodular sclerosis classic Hodgkin lymphoma \n9673 Mantle cell lymphoma\n9678 Primary effusion lymphoma \n9679 Primary mediastinal (thymic) large B-cell lymphoma\n9680 Diffuse large B-cell lymphoma (DLBCL)\n9687 Burkitt lymphoma\n9688 T-cell/histiocyte-rich large B-cell lymphoma\n9689 Splenic marginal zone lymphoma\n9690 Follicular lymphoma (except C700-C729, C751-C753 for 1/1/2023+)\n9691 Follicular lymphoma, grade 2\n9695 Follicular lymphoma, grade 1\n9698 Follicular lymphoma, grade 3\n9699 Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)\n9702 Peripheral T-cell lymphoma, NOS\n9705 Angioimmunoblastic T-cell lymphoma\n9708 Subcutaneous panniculitis-like T-cell lymphoma\n9709 Primary cutaneous peripheral T-cell lymphomas\n9712 Intravascular large B-cell lymphoma\n9714 Anaplastic large cell lymphoma, ALK-positive\n9715 Anaplastic large cell lymphoma, ALK-negative (2021+ only)\n9716 Hepatosplenic T-cell lymphoma\n9717 Enteropathy-associated T-cell lymphoma\n9718 Primary cutaneous anaplastic large cell lymphoma\n9719 Extranodal NK/T-cell lymphoma, nasal type (except C700-C729, C751-C753 for 1/1/2023+)\n9725 Hydroa vacciniforme-like lymphoma (2018-2020 only, nonreportable as of 2021)\n9726 Primary cutaneous gamma-delta T-cell lymphoma (2018-2020 only, see code 9687/3 for 2021+)\n9735 Plasmablastic lymphoma\n9737 ALK-positive large B-cell lymphoma\n9738 HHV8-positive DLBCL, NOS\n9766 Lymphomatoid granulomatosis grade 3 (2021+ only)\n9823 Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma\n9826 Burkitt cell leukemia (2018-2020 only, see code 9687/3 for 2021+)\n9827 Adult T-cell leukemia/lymphoma\n\n**Note 5:** **Lymph node involvement** \n* Any mention of the terms including fixed, matted, mass in the hilum, mediastinum, retroperitoneum, and/or mesentery, palpable, enlarged, shotty, lymphadenopathy are all regarded as involvement for lymphomas when determining appropriate code.\n\n**Note 6:** **Peripheral Blood or Bone Marrow** \n* If there is peripheral blood or bone marrow involvement, code 7.\n\n**Note 7:** **Splenic involvement** \n* Splenic involvement is based on splenomegaly and FDG-PET or CT scans that state diffuse uptake, solitary mass, miliary lesions, or enlargement of greater than 13 cm\n * A physician’s statement of splenomegaly may be used \n * FDG uptake in the spleen that is not diffuse is not enough to code as splenic involvement \n\n**Note 8:** **Bilateral sites** Code 7 for involvement of bilateral sites (i.e., breast, eye, kidney, etc.).\n* *Example*: Patient with extranodal non-Hodgkin's Lymphoma, involving bilateral choroids, (single focus both sites), and no lymph node involvement. \n * Code 7 for bilateral involvement of choroids (eye)\n\n**Note 9:** **Not applicable codes**\n* Codes 0, 3, and 4 are not applicable for this chapter.", + "notes" : "**Lymphoma**\n\n9590, 9596-9663, 9673-9699, 9702-9719, 9725-9726, 9735, 9737-9738, 9823, 9826-9827 (varying primary sites and histologies)\n* C700-C729, C751-C753: 9690, 9719 (2018-2022 only) (See Note 2)\n\nC000-C440, C442-C689, C691-C694, C698-C809: 9591 and Schema Discriminator 1: 3, 9 \n\n*See Summary Stage 2018 Manual, Appendix III for a detailed listing of primary site/histology combinations for this schema*\n\n**Note 1:** **Sources used in the development of this chapter**\n* SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998) (https://seer.cancer.gov/archive/manuals/EOD10Dig.3rd.pdf)\n* SEER Summary Staging Manual-2000: Codes and Coding Instructions (https://seer.cancer.gov/tools/ssm/ssm2000/)\n* Collaborative Stage Data Collection System, version 02.05: https://cancerstaging.org/cstage/Pages/default.aspx \n* Chapter 79 *Hodgkin and Non-Hodgkin Lymphomas*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois.\n* Chapter 80 *Pediatric Hodgkin and Non-Hodgkin Lymphomas*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois.\n\n**Note 2:** **Histologies moved to Brain, CNS, Intracranial Gland** \n* For the histologies listed below, these have moved to the Brain, CNS Other and Intracranial Gland Summary Stage chapters starting with 2023 diagnoses. \n* If you have one of these cases for 2018-2022, then this is the appropriate chapter. If you have one of these cases diagnosed on January 1, 2023, forward, see the appropriate chapter\n* 9690, 9719 \n * C700, C710-C719: *Brain*\n * C701, C709, C720-C725, C728-C729: *CNS Other*\n * C751-C753: *Intracranial Gland*\n\n**Note 3:** **Other Summary Stage chapters with the listed histologies**\n* **Brain**: C700, C710-C719 (9680, 9699, 9702-9715) (9690, 9719, 2023+)\n* **CNS Other**: C701, C709, C720-C725, C728-C729 (9680, 9699, 9702-9715) (9690, 9719, 2023+)\n* **Heme Retic**: 9591 and Schema Discriminator 1: 1, 2 (C000-C440, C442-C689, C691-C694, C698-C809)\n* **Intracranial Gland**: C751-C753 (9680, 9699, 9702-9715) (9690, 9719, 2023+)\n* **Lymphoma Ocular Adnexa**: C441, C690, C695-C696 (9590-9699, 9673-9699, 9702-9719, 9725-9726, 9734-9738, 9823, 9826-9827, 9930)\n* **Primary Cutaneous Lymphoma**: C440, C442-C449, C510, C609, C632 (9597, 9680, 9708-9709, 9712, 9718-9719, 9726)\n\n**Note 4:** **The preferred histology terms listed below are from the 2024 WHO Classification of Tumours, Haematolymphoid tumours, 5th edition.**\n\n* 9590: Malignant lymphoma, NOS\n* 9591: Malignant lymphoma, non-Hodgkin, NOS\n* 9596: Mediastinal grey zone lymphoma (MGZL)\n* 9597: Primary cutaneous follicle centre lymphoma (PCFCL)\n* 9650: Classic Hodgkin lymphoma (CHL), NOS\n* 9651: Classic Hodgkin lymphoma, lymphocyte-rich (LR-cHL)\n* 9652: Classic Hodgkin lymphoma, mixed cellularity (MC-cHL)\n* 9653: Classic Hodgkin lymphoma, lymphocyte-depleted, NOS (LD-cHL)\n* 9659: Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL)\n* 9663: Classic Hodgkin lymphoma, nodular sclerosis, NOS (NSCHL) \n* 9673: Mantle cell lymphoma (MCL)\n* 9678: Primary effusion lymphoma (PEL)\n* 9679: Primary mediastinal large B-cell lymphoma (PBML/PMBCL)\n* 9680: Diffuse large B-cell lymphoma (DLBCL)\n* 9687: Burkitt lymphoma (BL), NOS\n* 9688: T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL)\n* 9689: Splenic marginal zone lymphoma (SMZL)\n* 9690 Follicular lymphoma (FL), NOS \n* 9691: Follicular lymphoma, grade 2\n* 9695: Follicular lymphoma, grade 1\n* 9698: Follicular lymphoma, grade 3\n* 9699: Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)\n* 9702: Peripheral T-cell lymphoma, NOS\n* 9705: Nodal T follicular helper cell lymphoma, angioimmunoblastic type\n* 9708: Subcutaneous panniculitis-like T-cell lymphoma (SPTCL)\n* 9709: Primary cutaneous peripheral T-cell lymphomas (pcCTCL)\n* 9712: Intravascular large B-cell lymphoma (IVLBCL)\n* 9714: Anaplastic large cell lymphoma, ALK-positive (ALCL)\n* 9715: Anaplastic large cell lymphoma, ALK-negative (ALK-ALCL) *(2021+ only)*\n* 9716: Hepatosplenic T-cell lymphoma (HSTCL)\n* 9717: Intestinal T-cell lymphoma, NOS (ITCL-NOS)\n* 9718: Primary cutaneous anaplastic large cell lymphoma (C-ALCL)\n* 9719: Extranodal NK/T-cell lymphoma (ENKTL) (except C700-C729, C751-C753 for 1/1/2023+)\n* 9725: Hydroa vacciniforme-like lymphoma *(2018-2020 only, nonreportable as of 2021)*\n* 9726 Primary cutaneous gamma-delta T-cell lymphoma (PCGD-TCL) \n* 9735: Plasmablastic lymphoma (PBL)\n* 9737: ALK-positive large B-cell lymphoma (ALK+LBCL)\n* 9738: KSHV/HHV8-positive diffuse large B-cell lymphoma \n* 9823: Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)\n* 9826: Burkitt cell leukemia *(2018-2020 only, see code 9687/3 for 2021+)*\n* 9827: Adult T-cell leukemia/lymphoma (ATLL)\n\n**Note 5:** **Lymph node involvement** \n* Any mention of the terms including fixed, matted, mass in the hilum, mediastinum, retroperitoneum, and/or mesentery, palpable, enlarged, shotty, lymphadenopathy are all regarded as involvement for lymphomas when determining appropriate code.\n\n**Note 6:** **Peripheral Blood or Bone Marrow** \n* If there is peripheral blood or bone marrow involvement, code 7.\n\n**Note 7:** **Splenic involvement** \n* Splenic involvement is based on splenomegaly and FDG-PET or CT scans that state diffuse uptake, solitary mass, miliary lesions, or enlargement of greater than 13 cm\n * A physician’s statement of splenomegaly may be used \n * FDG uptake in the spleen that is not diffuse is not enough to code as splenic involvement \n\n**Note 8:** **Bilateral sites** \n* Code 7 for involvement of bilateral sites (i.e., breast, eye, kidney, etc.).\n* *Example*: Patient with extranodal non-Hodgkin's Lymphoma, involving bilateral choroids, (single focus both sites), and no lymph node involvement. \n * Code 7 for bilateral involvement of choroids (eye)\n\n**Note 9:** **Not applicable codes**\n* Codes 0, 3, and 4 are not applicable for this chapter.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) **Introduction to Hematologic Malignancies**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Zelenetz, A.D., Jaffe, E.S., Leonard, J.P., et al. **Hodgkin and Non-Hodgkin Lymphomas**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(7) Link, M.P., Jaffe, E.S., Leonard, J.P. **Pediatric Hodgkin and Non-Hodgkin Lymphomas**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2024-05-18T12:59:14.943Z", + "last_modified" : "2025-09-26T14:44:53.099Z", "definition" : [ { "key" : "ss2018", "name" : "SS2018", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ss2018_lymphoma_ocular_adnexa_3583.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ss2018_lymphoma_ocular_adnexa_3583.json index c3dd0d1dc..0cb21bcc6 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ss2018_lymphoma_ocular_adnexa_3583.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ss2018_lymphoma_ocular_adnexa_3583.json @@ -5,9 +5,9 @@ "name" : "SS2018: Lymphoma Ocular Adnexa", "title" : "Summary Stage 2018: Lymphoma Ocular Adnexa", "subtitle" : "Summary Stage 2018", - "notes" : "**Lymphoma Ocular Adnexa**\n\n9590-9699, 9702-9719, 9725-9726, 9734-9738, 9823, 9826-9827, 9930 (C441, C690, C695-C696)\n\n**Note 1:** **Sources used in the development of this chapter**\n* SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998) (https://seer.cancer.gov/archive/manuals/EOD10Dig.3rd.pdf)\n* SEER Summary Staging Manual-2000: Codes and Coding Instructions (https://seer.cancer.gov/tools/ssm/ssm2000/)\n* Collaborative Stage Data Collection System, version 02.05: https://cancerstaging.org/cstage/Pages/default.aspx \n* Chapter 71 *Ocular Adnexal Lymphoma*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois.\n\n**Note 2:** **Not applicable codes** \n* Code 0 is not applicable for this chapter.\n\n**Note 3:** **Ocular adnexal lymphomas** \n* Ocular adnexal lymphomas (OAL) originate in conjunctiva, eyelids, lacrimal gland, lacrimal drainage apparatus, and other orbital tissues surrounding the eye. \n* This chapter should not be used for secondary lymphomatous involvement of ocular adnexa or for intraocular lymphomas.\n\n**Note 4:** **Peripheral blood or bone marrow involvement** \n* If there is peripheral blood or bone marrow involvement, code 7.", + "notes" : "**Lymphoma Ocular Adnexa**\n\n9590-9699, 9702-9719, 9725-9726, 9734-9738, 9823, 9826-9827, 9930 (C441, C690, C695-C696)\n\n**Note 1:** **Sources used in the development of this chapter**\n* SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998) (https://seer.cancer.gov/archive/manuals/EOD10Dig.3rd.pdf)\n* SEER Summary Staging Manual-2000: Codes and Coding Instructions (https://seer.cancer.gov/tools/ssm/ssm2000/)\n* Collaborative Stage Data Collection System, version 02.05: https://cancerstaging.org/cstage/Pages/default.aspx \n* Chapter 71 *Ocular Adnexal Lymphoma*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois.\n\n**Note 2:** **Not applicable codes** \n* Code 0 is not applicable for this chapter.\n\n**Note 3:** **Ocular adnexal lymphomas** \n* Ocular adnexal lymphomas (OAL) originate in conjunctiva, eyelids, lacrimal gland, lacrimal drainage apparatus, and other orbital tissues surrounding the eye. \n* This chapter should not be used for secondary lymphomatous involvement of ocular adnexa or for intraocular lymphomas.\n\n**Note 4:** **Peripheral blood or bone marrow involvement** \n* If there is peripheral blood or bone marrow involvement, code 7.\n\n**Note 5:** **The preferred histology terms in this schema are based on the 2024 WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition.**\n\n* 9590: Malignant lymphoma, NOS\n* 9591: Malignant lymphoma, non-Hodgkin, NOS\n* 9596: Mediastinal grey zone lymphoma (MGZL)\n* 9597: Primary cutaneous follicle centre lymphoma (PCFCL)\n* 9650: Classic Hodgkin lymphoma (CHL), NOS\n* 9651: Classic Hodgkin lymphoma, lymphocyte-rich (LR-cHL)\n* 9652: Classic Hodgkin lymphoma, mixed cellularity (MC-cHL)\n* 9653: Classic Hodgkin lymphoma, lymphocyte-depleted, NOS (LD-cHL)\n* 9659: Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL)\n* 9663: Classic Hodgkin lymphoma, nodular sclerosis, NOS (NSCHL) \n* 9673: Mantle cell lymphoma (MCL)\n* 9678: Primary effusion lymphoma (PEL)\n* 9679: Primary mediastinal large B-cell lymphoma (PBML/PMBCL)\n* 9680: Diffuse large B-cell lymphoma (DLBCL)\n* 9687: Burkitt lymphoma (BL), NOS\n* 9688: T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL)\n* 9689: Splenic marginal zone lymphoma (SMZL)\n* 9690 Follicular lymphoma (FL), NOS (except C700-C729, C751-C753 for 1/1/2023+)\n* 9691: Follicular lymphoma, grade 2\n* 9695: Follicular lymphoma, grade 1\n* 9698: Follicular lymphoma, grade 3\n* 9699: Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)\n* 9702: Peripheral T-cell lymphoma, NOS\n* 9705: Nodal T follicular helper cell lymphoma, angioimmunoblastic type\n* 9708: Subcutaneous panniculitis-like T-cell lymphoma (SPTCL)\n* 9709: Primary cutaneous peripheral T-cell lymphomas (pcCTCL)\n* 9712: Intravascular large B-cell lymphoma (IVLBCL)\n* 9714: Anaplastic large cell lymphoma, ALK-positive (ALCL)\n* 9715: Anaplastic large cell lymphoma, ALK-negative (ALK-ALCL) (2021+ only)\n* 9716: Hepatosplenic T-cell lymphoma (HSTCL)\n* 9717: Intestinal T-cell lymphoma, NOS (ITCL-NOS)\n* 9718: Primary cutaneous anaplastic large cell lymphoma (C-ALCL)\n* 9719: Extranodal NK/T-cell lymphoma (ENKTL) (except C700-C729, C751-C753 for 1/1/2023+)\n* 9725: Hydroa vacciniforme-like lymphoma (2018-2020 only, nonreportable as of 2021)\n* 9726 Primary cutaneous gamma-delta T-cell lymphoma (PCGD-TCL) (2018-2020 only, see code 9687/3 for 2021+)\n* 9734: Extramedullary plasmacytoma (EMP)\n* 9735: Plasmablastic lymphoma (PBL)\n* 9737: ALK-positive large B-cell lymphoma (ALK+LBCL)\n* 9738: KSHV/HHV8-positive diffuse large B-cell lymphoma \n* 9823: Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)\n* 9826: Burkitt cell leukemia (2018-2020 only, see code 9687/3 for 2021+)\n* 9827: Adult T-cell leukemia/lymphoma (ATLL)\n* 9930: Myeloid Sarcoma", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Heegaard, S., Finger, P.T., et al. **Ocular Adnexal Lymphoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2024-05-16T21:49:20.941Z", + "last_modified" : "2025-09-26T14:42:47.444Z", "definition" : [ { "key" : "ss2018", "name" : "SS2018", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ss2018_melanoma_skin_64985.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ss2018_melanoma_skin_64985.json index 8e208f938..d8747d6f6 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ss2018_melanoma_skin_64985.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ss2018_melanoma_skin_64985.json @@ -5,9 +5,9 @@ "name" : "SS2018: Melanoma Skin", "title" : "Summary Stage 2018: Melanoma Skin", "subtitle" : "Summary Stage 2018", - "notes" : "**Melanoma Skin**\n\n8720-8790 (C000-C002, C006, C440-C449, C500, C510-C512, C518-C519, C600-C602, C608-C609, C632)\n\n**Note 1:** **Sources used in the development of this chapter** \n* SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998) (https://seer.cancer.gov/archive/manuals/EOD10Dig.3rd.pdf)\n* SEER Summary Staging Manual-2000: Codes and Coding Instructions (https://seer.cancer.gov/tools/ssm/ssm2000/)\n* Collaborative Stage Data Collection System, version 02.05: https://cancerstaging.org/cstage/Pages/default.aspx \n* Chapter 47 *Melanoma of the Skin*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois.\n\n**Note 2:** **Melanomas of other sites** \n* **Melanoma Conjunctiva**: C690 \n* **Melanoma Choroid and Ciliary Body, or Melanoma Iris**: C693, C694:\n* **Melanoma Head and Neck**: C003-C005, C008-C069, C090-C148, C300-C329\n* **All other sites**: Use the appropriate site-specific schema\n\n**Note 3:** **Clark Level versus pathological description** \n* If there is a discrepancy between the Clark level and the pathological description of extent (invasion into the layers of the dermis), use the higher (more extensive) code.\n\n**Note 4:** **Code greatest extent** \n* Code the greatest extent of invasion from any procedure performed on the lesion, whether it is described as a biopsy or an excision. \n * For example, if a punch biopsy with involvement of Clark level IV is followed by a re-excision with residual tumor involving Clark level II, code 1 (Clark level IV).\n\n**Note 5:** **Breslow's depth only available** \n* If a Breslow’s depth is given in the pathology report and there is no other indication of involvement, the following guidelines may be used \n* (**Note:** If a physician documents a different Clark's Level then provided by these guidelines, go with the physician's Clark Level*)\n+ In situ: Level 1\n+ Localized\n - Level II (< 0.75 mm Breslow’s Depth)\n - Level III (0.76 mm to 1.50 mm Breslow’s Depth)\n - Level IV (> 1.50 mm Breslow’s Depth)\n+ Regional\n - Level V: Through entire dermis\n\n**Note 6:** **Isolated tumor cells** \n* Isolated tumor cells (ITCs) are defined as single tumor cells or small clusters not greater than 0.2 mm, usually detected by immunohistochemical (IHC) or molecular methods. ITCs do not usually show evidence of malignant activity (e.g., proliferation or stromal reaction).\n* Lymph nodes with isolated tumor cells (ITCs) are counted as positive lymph nodes\n\n**Note 7:** **In-transit, satellite, and/or microsatellite metastasis** \n* In-transit, satellite, and/or microsatellite metastasis are metastasis that have occurred via lymphatic or angiolymphatic spread. \n* Satellite nodules are subcutaneous metastasis that occur within 2 cm of the primary tumor. \n* Microsatellite metastasis are microscopic cutaneous metastasis found adjacent or deep to a primary melanoma tumor.\n* In-transit, satellite, and/or microsatellite metastasis are counted as positive nodes\n\n**Note 8:** **Bilateral or contralateral nodes** \n* Bilateral or contralateral nodes are classified as regional nodes for head, neck, and truncal tumors with bidirectional drainage to primary nodal basins, as shown on lymphoscintigraphy. \n* Truncal tumors may also drain to both cephalad and caudal primary nodal basins as shown on lymphoscintigraphy.\n* Clinical assessment of bilateral/contralateral or cephalad/caudal regional nodal involvement is required for tumors where lymphoscintigraphy is not performed\n\n**Note 9:** **Nodal basins** \n* Contiguous or secondary nodal basins are the next nodal drainage basins beyond the primary nodal basins and are coded as regional nodes.", + "notes" : "**Melanoma Skin**\n\n8720-8790 (C000-C002, C006, C440-C449, C500, C510-C512, C518-C519, C600-C602, C608-C609, C632)\n\n**Note 1:** **Sources used in the development of this chapter** \n* SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998) (https://seer.cancer.gov/archive/manuals/EOD10Dig.3rd.pdf)\n* SEER Summary Staging Manual-2000: Codes and Coding Instructions (https://seer.cancer.gov/tools/ssm/ssm2000/)\n* Collaborative Stage Data Collection System, version 02.05: https://cancerstaging.org/cstage/Pages/default.aspx \n* Chapter 47 *Melanoma of the Skin*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois.\n\n**Note 2:** **Melanomas of other sites** \n* **Melanoma Conjunctiva**: C690 \n* **Melanoma Choroid and Ciliary Body, or Melanoma Iris**: C693, C694:\n* **Melanoma Head and Neck**: C003-C005, C008-C069, C090-C148, C300-C329\n* **All other sites**: Use the appropriate site-specific schema\n\n**Note 3:** **Clark Level versus pathological description** \n* If there is a discrepancy between the Clark level and the pathological description of extent (invasion into the layers of the dermis), use the higher (more extensive) code.\n\n**Note 4:** **Code greatest extent** \n* Code the greatest extent of invasion from any procedure performed on the lesion, whether it is described as a biopsy or an excision. \n * For example, if a punch biopsy with involvement of Clark level IV is followed by a re-excision with residual tumor involving Clark level II, code 1 (Clark level IV).\n\n**Note 5:** **Breslow's depth only available** \n* If a Breslow’s depth is given in the pathology report and there is no other indication of involvement, the following guidelines may be used \n *(**Note:** If a physician documents a different Clark's Level than provided by these guidelines, go with the physician's Clark Level)*\n * In situ: Level 1\n * Localized\n * Level II (< 0.75 mm Breslow’s Depth)\n * Level III (0.76 mm to 1.50 mm Breslow’s Depth)\n * Level IV (> 1.50 mm Breslow’s Depth)\n * Regional\n * Level V: Through entire dermis\n\n**Note 6:** **Isolated tumor cells** \n* Isolated tumor cells (ITCs) are defined as single tumor cells or small clusters not greater than 0.2 mm, usually detected by immunohistochemical (IHC) or molecular methods. ITCs do not usually show evidence of malignant activity (e.g., proliferation or stromal reaction).\n* Lymph nodes with isolated tumor cells (ITCs) are counted as positive lymph nodes\n\n**Note 7:** **In-transit, satellite, and/or microsatellite metastasis** \n* In-transit, satellite, and/or microsatellite metastasis are metastasis that have occurred via lymphatic or angiolymphatic spread. \n* Satellite nodules are subcutaneous metastasis that occur within 2 cm of the primary tumor. \n* Microsatellite metastasis are microscopic cutaneous metastasis found adjacent or deep to a primary melanoma tumor.\n* In-transit, satellite, and/or microsatellite metastasis are counted as positive nodes\n\n**Note 8:** **Bilateral or contralateral nodes** \n* Bilateral or contralateral nodes are classified as regional nodes for head, neck, and truncal tumors with bidirectional drainage to primary nodal basins, as shown on lymphoscintigraphy. \n* Truncal tumors may also drain to both cephalad and caudal primary nodal basins as shown on lymphoscintigraphy.\n* Clinical assessment of bilateral/contralateral or cephalad/caudal regional nodal involvement is required for tumors where lymphoscintigraphy is not performed\n\n**Note 9:** **Nodal basins** \n* Contiguous or secondary nodal basins are the next nodal drainage basins beyond the primary nodal basins and are coded as regional nodes.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Gershenwald, J.E., Scolyer, R.A., et al. **Melanoma of the Skin**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2024-05-16T21:30:09.708Z", + "last_modified" : "2025-11-07T15:44:01.723Z", "definition" : [ { "key" : "ss2018", "name" : "SS2018", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ss2018_oropharynx_excluding_melanoma_8720_8790_9999.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ss2018_oropharynx_excluding_melanoma_8720_8790_9999.json index 9bff94c4b..cb2eae0a3 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ss2018_oropharynx_excluding_melanoma_8720_8790_9999.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ss2018_oropharynx_excluding_melanoma_8720_8790_9999.json @@ -5,9 +5,9 @@ "name" : "SS2018: Oropharynx", "title" : "Summary Stage 2018: Oropharynx", "subtitle" : "Summary Stage 2018", - "notes" : "**Oropharynx**\n\n**2018-2024**\nC111 and Schema Discriminator 1: Nasopharynx/PharyngealTonsil: 2 (8000-8700) \n\n**2025+**\nC019, C024, C051-C052, C090-C091, C098-C099, C100, C102-C104, C108-C109 (8000-8700)\n\nC019, C024, C051-C052, C090-C091, C098-C099, C100, C102-C104, C108-C109, C111\nC019 Base of tongue, NOS\nC024 Lingual tonsil\nC051 Soft palate, NOS\nC052 Uvula\nC090 Tonsillar fossa \nC091 Tonsillar pillar\nC098 Overlapping lesion of tonsil \nC099 Tonsil, NOS \nC100 Vallecula\nC102 Lateral wall of oropharynx\nC103 Posterior wall of oropharynx\nC104 Branchial cleft (site of neoplasm)\nC108 Overlapping lesion of oropharynx\nC109 Oropharynx, NOS\nC111 Pharyngeal tonsil\n\n**Note 1:** **Sources used in the development of this chapter**\n* SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998) (https://seer.cancer.gov/archive/manuals/EOD10Dig.3rd.pdf)\n* SEER Summary Staging Manual-2000: Codes and Coding Instructions (https://seer.cancer.gov/tools/ssm/ssm2000/)\n* Collaborative Stage Data Collection System, version 02.05: https://cancerstaging.org/cstage/Pages/default.aspx \n* Chapter 10 *Oropharynx HPV-Mediated (p16+)*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois.\n* Oropharynx-Associated, from the AJCC Cancer Staging System Version 9 (2025). Used with permission of the American College of Surgeons, Chicago, Illinois\n* Chapter 11 *Oropharynx (p16-) and Hypopharynx*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois.\n\n**Note 2:** **Other Summary Stage Chapters with Oropharynx sites**\n* **GIST**: 8935-8936\n* **Kaposi Sarcoma**: 9140\n* **Mycosis Fungoides**: 9700-9701\n* **Nasopharynx (2018-2024)**: C111 and Schema Discriminator 1: Nasopharynx/PharyngealTonsil:1 (8000-8700)\n* **Soft Tissue**: 8710-8714, 8800-8934, 8940-9138, 9141-9582\n* **Melanoma Head and Neck**: 8720-8790\n\n**Note 3:** **Intrinsic and extrinsic muscles** \n* The intrinsic muscles of tongue are four paired muscles within the tongue which control its shape. \n* The extrinsic muscles originate from structures outside the tongue and control its positioning.\n\n**Note 4:** **Parapharyngeal involvement** \n* Parapharyngeal involvement (pharyngeal space invasion) (code 7) denotes postero-lateral infiltration of tumor beyond the pharyngobasilar fascia. \n* The pharyngobasilar fascia is the fibrous layer of the pharyngeal wall between the mucosa and the muscular layer, attached superiorly to the basilar part of the occipital bone and diminishing in thickness as it descends.\n\n**Note 5:** **Masticator space** \n* The masticator space (code 7) primarily consists of the muscles of mastication, the medial and lateral pterygoid, masseter, and temporalis muscles. \n* The space also includes the ramus of the mandible and the third division of cranial nerve V as it passes through the foramen ovale into the suprahyoid neck.", + "notes" : "**Oropharynx**\n\n**2018-2024**\nC111 and Schema Discriminator 1: Nasopharynx/PharyngealTonsil: 2 (8000-8700) \n\n**2018+**\nC019, C024, C051-C052, C090-C091, C098-C099, C100, C102-C104, C108-C109 (8000-8700)\n\n**2026+**\nC101 (8000-8700)\n\nC019, C024, C051-C052, C090-C091, C098-C099, C100-C104, C108-C109, C111\nC019 Base of tongue, NOS\nC024 Lingual tonsil\nC051 Soft palate, NOS\nC052 Uvula\nC090 Tonsillar fossa \nC091 Tonsillar pillar\nC098 Overlapping lesion of tonsil \nC099 Tonsil, NOS \nC100 Vallecula\nC101 Anterior surface of epiglottis\nC102 Lateral wall of oropharynx\nC103 Posterior wall of oropharynx\nC104 Branchial cleft (site of neoplasm)\nC108 Overlapping lesion of oropharynx\nC109 Oropharynx, NOS\nC111 Pharyngeal tonsil\n\n**Note 1:** **Sources used in the development of this chapter**\n* SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998) (https://seer.cancer.gov/archive/manuals/EOD10Dig.3rd.pdf)\n* SEER Summary Staging Manual-2000: Codes and Coding Instructions (https://seer.cancer.gov/tools/ssm/ssm2000/)\n* Collaborative Stage Data Collection System, version 02.05: https://cancerstaging.org/cstage/Pages/default.aspx \n* Chapter 10 *Oropharynx HPV-Mediated (p16+)*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois.\n* Oropharynx-Associated, from the AJCC Cancer Staging System Version 9 (2025). Used with permission of the American College of Surgeons, Chicago, Illinois\n* Chapter 11 *Oropharynx (p16-) and Hypopharynx*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois.\n\n**Note 2:** **Other Summary Stage Chapters with Oropharynx sites**\n* **GIST**: 8935-8936\n* **Kaposi Sarcoma**: 9140\n* **Mycosis Fungoides**: 9700-9701\n* **Nasopharynx (2018-2024)**: C111 and Schema Discriminator 1: Nasopharynx/PharyngealTonsil:1 (8000-8700)\n* **Soft Tissue**: 8710-8714, 8800-8934, 8940-9138, 9141-9582\n* **Melanoma Head and Neck**: 8720-8790\n\n**Note 3:** **Intrinsic and extrinsic muscles** \n* The intrinsic muscles of tongue are four paired muscles within the tongue which control its shape. \n* The extrinsic muscles originate from structures outside the tongue and control its positioning.\n\n**Note 4:** **Parapharyngeal involvement** \n* Parapharyngeal involvement (pharyngeal space invasion) (code 7) denotes postero-lateral infiltration of tumor beyond the pharyngobasilar fascia. \n* The pharyngobasilar fascia is the fibrous layer of the pharyngeal wall between the mucosa and the muscular layer, attached superiorly to the basilar part of the occipital bone and diminishing in thickness as it descends.\n\n**Note 5:** **Masticator space** \n* The masticator space (code 7) primarily consists of the muscles of mastication, the medial and lateral pterygoid, masseter, and temporalis muscles. \n* The space also includes the ramus of the mandible and the third division of cranial nerve V as it passes through the foramen ovale into the suprahyoid neck.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Lydiatt, W.M., Patel, S.G., Shah, J.P., et al. **Staging Head and Neck Cancers**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) O'Sullivan, B., Lydiatt, W.M., Shah, J.P., et al. **Oropharynx HPV-mediated (HPV-Associated) Cancer**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(7) Lydiatt, W.M., Ridge, J.A., Shah, J.P., et al. **Oropharynx (p16-) and Hypopharynx**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(8) **Oropharynx HPV-Associated**, from the AJCC Cancer Staging System Version 9 (2025). Used with permission of the American College of Surgeons, Chicago, Illinois.", - "last_modified" : "2025-06-10T13:04:22.691Z", + "last_modified" : "2025-09-26T19:39:39.111Z", "definition" : [ { "key" : "ss2018", "name" : "SS2018", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ss2018_penis_97065.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ss2018_penis_97065.json index 7e2c04b6f..fb0b158f4 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ss2018_penis_97065.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ss2018_penis_97065.json @@ -5,9 +5,9 @@ "name" : "SS2018: Penis", "title" : "Summary Stage 2018: Penis", "subtitle" : "Summary Stage 2018", - "notes" : "**Penis**\n\n8000-8040, 8042-8180, 8191-8246, 8248-8700\n\nC600-C602, C608-C609\nC600 Prepuce\nC601 Glans penis\nC602 Body of penis\nC608 Overlapping lesion of penis\nC609 Penis, NOS\n\n**Note 1:** **Sources used in the development of this chapter**r\n* SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998) (https://seer.cancer.gov/archive/manuals/EOD10Dig.3rd.pdf)\n* SEER Summary Staging Manual-2000: Codes and Coding Instructions (https://seer.cancer.gov/tools/ssm/ssm2000/)\n* Collaborative Stage Data Collection System, version 02.05: https://cancerstaging.org/cstage/Pages/default.aspx \n* Chapter 57 *Penis*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois.\n\n**Note 2:** **Other Summary Stage Chapters with Penis sites**\n* **GIST**: 8935-8936\n* **Kaposi Sarcoma**: 9140\n* **Melanoma Skin**: 8720-8790\n* **Merkel Cell Skin**: 8041, 8190, 8247: *Merkel Cell Skin* \n* **Mycosis Fungoides**: 9700-9701\n* **Soft Tissue**: 8710-8714, 8800-8934, 8940-9138, 9141-9582: *Soft Tissue*\n\n**Note 3:** **Verrucous carcinoma** \n* Code 0 if a verrucous carcinoma is described as noninvasive or as having a broad pushing border or penetration. \n* If there is destructive invasion of verrucous carcinoma into structures in code 1 or greater, assign the appropriate higher code", + "notes" : "**Penis**\n\n8000-8040, 8042-8180, 8191-8246, 8248-8700\n\nC600-C602, C608-C609\nC600 Prepuce\nC601 Glans penis\nC602 Body of penis\nC608 Overlapping lesion of penis\nC609 Penis, NOS\n\n**Note 1:** **Sources used in the development of this chapter**\n* SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998) (https://seer.cancer.gov/archive/manuals/EOD10Dig.3rd.pdf)\n* SEER Summary Staging Manual-2000: Codes and Coding Instructions (https://seer.cancer.gov/tools/ssm/ssm2000/)\n* Collaborative Stage Data Collection System, version 02.05: https://cancerstaging.org/cstage/Pages/default.aspx \n* Chapter 57 *Penis*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois.\n\n**Note 2:** **Other Summary Stage Chapters with Penis sites**\n* **GIST**: 8935-8936\n* **Kaposi Sarcoma**: 9140\n* **Melanoma Skin**: 8720-8790\n* **Merkel Cell Skin**: 8041, 8190, 8247: *Merkel Cell Skin* \n* **Mycosis Fungoides**: 9700-9701\n* **Soft Tissue**: 8710-8714, 8800-8934, 8940-9138, 9141-9582: *Soft Tissue*\n\n**Note 3:** **Verrucous carcinoma** \n* Code 0 if a verrucous carcinoma is described as noninvasive or as having a broad pushing border or penetration. \n* If there is destructive invasion of verrucous carcinoma into structures in code 1 or greater, assign the appropriate higher code", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Pettaway, C.A., Srigley, J.R., Amin, M.B., et al. **Penis**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2024-05-14T20:35:46.280Z", + "last_modified" : "2025-11-07T16:22:11.624Z", "definition" : [ { "key" : "ss2018", "name" : "SS2018", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ss2018_primary_cutaneous_lymphomas_4605.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ss2018_primary_cutaneous_lymphomas_4605.json index 5f14e51ed..1238461fa 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ss2018_primary_cutaneous_lymphomas_4605.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ss2018_primary_cutaneous_lymphomas_4605.json @@ -5,9 +5,9 @@ "name" : "SS2018: Primary Cutaneous Lymphomas (excluding MF and SS)", "title" : "Summary Stage 2018: Primary Cutaneous Lymphomas (excluding MF and SS)", "subtitle" : "Summary Stage 2018", - "notes" : "**Primary Cutaneous Lymphomas (excluding MF and SS)**\n\n9597, 9680, 9708-9709, 9712, 9718-9719, 9726 \n\nC440, C442-C449, C510, C609, C632\nC440 Skin of lip, NOS\nC442 External ear\nC443 Skin of other and unspecified parts of face\nC444 Skin of scalp and neck\nC445 Skin of trunk\nC446 Skin of upper limb and shoulder\nC447 Skin of lower limb and hip\nC448 Overlapping lesion of skin\nC449 Skin, NOS\nC510 Labium majus\nC609 Penis\nC632 Scrotum, NOS\n\n**Note 1:** **Sources used in the development of this chapter**\n* SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998) (https://seer.cancer.gov/archive/manuals/EOD10Dig.3rd.pdf)\n* SEER Summary Staging Manual-2000: Codes and Coding Instructions (https://seer.cancer.gov/tools/ssm/ssm2000/)\n* Collaborative Stage Data Collection System, version 02.05: https://cancerstaging.org/cstage/Pages/default.aspx \n* Chapter 81 *Primary Cutaneous Lymphomas*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois.\n\n**Note 2:** **Not applicable codes** \n* Code 0 is not applicable for this chapter.\n\n**Note 3:** **Mycosis Fungoides** \n* See the *Mycosis Fungoides* chapter for Mycosis Fungoides (9700) and Sezary syndrome (9701).\n\n**Note 4:** **Chapter includes the preferred terms based on the 2017 *WHO Classification of Haematopoietic and Lymphoid Tissues***\n\n* 9597 Primary cutaneous follicle center lymphoma\n* 9680 Primary cutaneous diffuse large B-cell lymphoma, leg type \n* 9708 Subcutaneous panniculitis-like T-cell lymphoma\n* 9709 Primary cutaneous peripheral T-cell lymphomas\n* 9712 Intravascular large B-cell lymphoma\n* 9718 Primary cutaneous anaplastic large cell lymphoma \n* 9719 Extranodal NK/T-cell lymphoma, nasal type\n* 9726 Primary cutaneous gamma-delta t-cell lymphoma\n\n**Note 5:** **Peripheral blood or bone marrow involvement** \n* If there is peripheral blood or bone marrow involvement, code 7.", + "notes" : "**Primary Cutaneous Lymphomas (excluding MF and SS)**\n\n9597, 9680, 9708-9709, 9712, 9718-9719, 9726 \n\nC440, C442-C449, C510, C609, C632\nC440 Skin of lip, NOS\nC442 External ear\nC443 Skin of other and unspecified parts of face\nC444 Skin of scalp and neck\nC445 Skin of trunk\nC446 Skin of upper limb and shoulder\nC447 Skin of lower limb and hip\nC448 Overlapping lesion of skin\nC449 Skin, NOS\nC510 Labium majus\nC609 Penis\nC632 Scrotum, NOS\n\n**Note 1:** **Sources used in the development of this chapter**\n* SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998) (https://seer.cancer.gov/archive/manuals/EOD10Dig.3rd.pdf)\n* SEER Summary Staging Manual-2000: Codes and Coding Instructions (https://seer.cancer.gov/tools/ssm/ssm2000/)\n* Collaborative Stage Data Collection System, version 02.05: https://cancerstaging.org/cstage/Pages/default.aspx \n* Chapter 81 *Primary Cutaneous Lymphomas*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois.\n\n**Note 2:** **Not applicable codes** \n* Code 0 is not applicable for this chapter.\n\n**Note 3:** **Mycosis Fungoides** \n* See the *Mycosis Fungoides* chapter for Mycosis Fungoides (9700) and Sezary syndrome (9701).\n\n**Note 4:** **The preferred histology terms listed below are from the 2024 WHO Classification of Tumours, Haematolymphoid tumours, 5th edition.**\n\n* 9597: Primary cutaneous follicle center lymphoma (PCFCL)\n* 9680: Primary cutaneous diffuse large B-cell lymphoma, leg type (PCLBCL-LT) \n* 9708: Subcutaneous panniculitis-like T-cell lymphoma (SPTCL)\n* 9709: Primary cutaneous peripheral T-cell lymphoma (NOS) (pcPTCL)\n* 9712: Intravascular (large) B-cell lymphoma (IVLBCL)\n* 9718: Primary cutaneous anaplastic large cell lymphoma (C-ALCL)\n* 9719: Extranodal NK-/T-cell lymphoma (ENKTL)\n* 9726: Primary cutaneous gamma-delta T-cell lymphoma (PCGD-TCL)\n\n**Note 5:** **Peripheral blood or bone marrow involvement** \n* If there is peripheral blood or bone marrow involvement, code 7.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) **Introduction to Hematologic Malignancies**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Rosen, S.T., Jaffe, E.S., Leonard, J.P., et al. **Primary Cutaneous Lymphomas**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2025-06-24T19:38:16.502Z", + "last_modified" : "2025-09-26T14:54:17.144Z", "definition" : [ { "key" : "ss2018", "name" : "SS2018", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ss2018_skin_other_56341.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ss2018_skin_other_56341.json index 697530fc4..2fb91ffb1 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ss2018_skin_other_56341.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ss2018_skin_other_56341.json @@ -5,9 +5,9 @@ "name" : "SS2018: Skin (except Eyelid)", "title" : "Summary Stage 2018: Skin (except Eyelid)", "subtitle" : "Summary Stage 2018", - "notes" : "**Skin (except Eyelid)**\n\n8000-8040, 8042-8180, 8191-8246, 8248-8700, 8940, 8982\n\nC000-C002, C006, C440, C442-C449\nC000 External upper lip\nC001 External lower lip\nC002 External lip, NOS\nC006 Commissure of lip\nC440 Skin of lip, NOS\nC442 External ear \nC443 Skin of other and unspecified parts of face \nC444 Skin of scalp and neck\nC445 Skin of trunk \nC446 Skin of upper limb and shoulder\nC447 Skin of lower limb and hip \nC448 Overlapping lesion of skin\nC449 Skin, NOS\n\n**Note 1:** **Sources used in the development of this chapter**\n* SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998) (https://seer.cancer.gov/archive/manuals/EOD10Dig.3rd.pdf)\n* SEER Summary Staging Manual-2000: Codes and Coding Instructions (https://seer.cancer.gov/tools/ssm/ssm2000/)\n* Collaborative Stage Data Collection System, version 02.05: https://cancerstaging.org/cstage/Pages/default.aspx \n* For primary sites C000-C002, C006, C440, C442-C444*, Chapter 15 *Cutaneous Carcinoma Head and Neck*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois.\n\n**Note 2:** **Other Summary Stage Chapters with Skin sites** \n* **GIST**: 8935-8936\n* **Kaposi Sarcoma**: 9140\n* **Melanoma Skin**: 8720-8790\n* **Merkel cell skin**: 8041, 8190, 8247\n* **Mycosis Fungoides**: 9700-9701\n* **Soft Tissue**: 8710-8714, 8800-8934, 8941-8981, 8983-9138, 9141-9582\n\n**Note 3:** **Only staging system (C445-C449)** \n* Summary Stage is the only applicable staging system for primary sites C445-C449.\n\n**Note 4:** **Bilateral or contralateral nodes** \n* Bilateral or contralateral nodes are classified as regional nodes for head, neck, and truncal tumors with bidirectional drainage to primary nodal basins, as shown on lymphoscintigraphy. \n * Truncal tumors may also drain to both cephalad and caudal primary nodal basins as shown on lymphoscintigraphy.\n* Clinical assessment of bilateral/contralateral or cephalad/caudal regional nodal involvement is required for tumors where lymphoscintigraphy is not performed\n\n**Note 5:** **Nodal basins** \n* Contiguous or secondary nodal basins are the next nodal drainage basins beyond the primary nodal basins and are coded as regional nodes.", + "notes" : "**Skin (except Eyelid)**\n\n8000-8040, 8042-8180, 8191-8246, 8248-8700, 8940, 8982\n\nC000-C002, C006, C440, C442-C449\nC000 External upper lip\nC001 External lower lip\nC002 External lip, NOS\nC006 Commissure of lip\nC440 Skin of lip, NOS\nC442 External ear \nC443 Skin of other and unspecified parts of face \nC444 Skin of scalp and neck\nC445 Skin of trunk \nC446 Skin of upper limb and shoulder\nC447 Skin of lower limb and hip \nC448 Overlapping lesion of skin\nC449 Skin, NOS\n\n**Note 1:** **Sources used in the development of this chapter**\n* SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998) (https://seer.cancer.gov/archive/manuals/EOD10Dig.3rd.pdf)\n* SEER Summary Staging Manual-2000: Codes and Coding Instructions (https://seer.cancer.gov/tools/ssm/ssm2000/)\n* Collaborative Stage Data Collection System, version 02.05: https://cancerstaging.org/cstage/Pages/default.aspx \n* For *primary sites C000-C002, C006, C440, C442-C444*, Chapter 15 *Cutaneous Carcinoma Head and Neck*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois.\n\n**Note 2:** **Other Summary Stage Chapters with Skin sites** \n* **GIST**: 8935-8936\n* **Kaposi Sarcoma**: 9140\n* **Melanoma Skin**: 8720-8790\n* **Merkel cell skin**: 8041, 8190, 8247\n* **Mycosis Fungoides**: 9700-9701\n* **Soft Tissue**: 8710-8714, 8800-8934, 8941-8981, 8983-9138, 9141-9582\n\n**Note 3:** **Only staging system (C445-C449)** \n* Summary Stage is the only applicable staging system for primary sites C445-C449.\n\n**Note 4:** **Bilateral or contralateral nodes** \n* Bilateral or contralateral nodes are classified as regional nodes for head, neck, and truncal tumors with bidirectional drainage to primary nodal basins, as shown on lymphoscintigraphy. \n * Truncal tumors may also drain to both cephalad and caudal primary nodal basins as shown on lymphoscintigraphy.\n* Clinical assessment of bilateral/contralateral or cephalad/caudal regional nodal involvement is required for tumors where lymphoscintigraphy is not performed\n\n**Note 5:** **Nodal basins** \n* Contiguous or secondary nodal basins are the next nodal drainage basins beyond the primary nodal basins and are coded as regional nodes.", "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Lydiatt, W.M., Patel, S.G., Shah, J.P., et al. **Staging Head and Neck Cancers**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Califano, J.A., Lydiatt, W.M., Shah, J.P., et al. **Cutaneous Carcinoma of the Head and Neck**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017", - "last_modified" : "2024-05-16T17:38:52.756Z", + "last_modified" : "2025-11-07T15:39:07.793Z", "definition" : [ { "key" : "ss2018", "name" : "SS2018", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/thyroid_gland_thyroglossal_duct_21498.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/thyroid_gland_thyroglossal_duct_21498.json index 678cf93d0..d27f5a863 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/thyroid_gland_thyroglossal_duct_21498.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/thyroid_gland_thyroglossal_duct_21498.json @@ -5,8 +5,8 @@ "name" : "Schema Discriminator 1", "title" : "Schema Discriminator 1: Thyroid Gland/Thyroglossal Duct", "description" : "Thyroid, NOS and thyroglossal duct have the same ICD-O topography code (C739) However, for purposes of the AJCC Staging Systems Thyroid and Thyroid Medullary stage groupings, Thyroid, NOS is applicable for AJCC staging while thyroglossal duct is not (Summary Stage only). A schema discriminator is necessary to distinguish between these primary sites so that the appropriate system/schema is used.", - "notes" : "**Note:** **Schema Discriminator for C739** \n* A schema discriminator is used to discriminate between thyroid gland and thyroglossal duct tumors with primary site code C739: Thyroid Gland. Code the site in which the tumor arose. \n\n* **Thyroid gland (see code 1)**\nSubsites include Thyroid, NOS\n* **Thyroglossal duct (see code 2)**", - "last_modified" : "2024-04-30T19:21:45.242Z", + "notes" : "**Note:** **Schema Discriminator for C739** \n\n* A schema discriminator is used to discriminate between thyroid gland and thyroglossal duct tumors with primary site code C739: Thyroid Gland. Code the site in which the tumor arose. \n\n* **Thyroid gland (see code 1)**\n\n Subsites include Thyroid, NOS\n\n* **Thyroglossal duct (see code 2)**", + "last_modified" : "2025-11-06T21:36:21.139Z", "definition" : [ { "key" : "discriminator_1", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/tumor_deposits_40070.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/tumor_deposits_40070.json index a460e0915..10fe2e913 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/tumor_deposits_40070.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/tumor_deposits_40070.json @@ -6,7 +6,7 @@ "title" : "Tumor Deposits", "description" : "A tumor deposit is defined as a discrete nodule of cancer in pericolic/perirectal fat or in adjacent mesentery (mesocolic or rectal fat) within the lymph drainage area of the primary carcinoma, without identifiable lymph node tissue or identifiable vascular structure.\n\nTumor deposits are separate nodules or deposits of malignant cells in perirectal or pericolic fat without evidence of residual lymph node tissue. If present, tumor deposits may be found within the primary lymphatic drainage area of the tumor. \n\nThey are different from direct extension from the primary tumor and may be the result of lymphovascular invasion with extravascular extension, a totally replaced lymph node, or discontinuous spread. Nodules of tumor outside the primary lymphatic drainage area of the tumor are distant metastasis.", "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of Tumor Deposits can be used to code this data item when no other information is available, provided the criteria for evaluation has been met (*see Note 2*).\n\n**Note 2:** **Criteria for evaluating Tumor Deposits**\n* A **surgical resection** must be done to evaluate tumor deposits\n* Do not use any evaluation of Tumor Deposits from imaging (MRI), or biopsy\n\n**Note 3:** **Tumor deposits vs Tumor budding**\n* **Tumor deposits** are separate nodules or deposits of malignant cells in perirectal or pericolic fat without evidence of residual lymph node tissue\n* **Tumor budding**: The presence of single cells or small clusters of less than five cells at the advancing front of the tumor is considered as peritumoral tumor budding. Numerous studies have shown that high tumor budding in adenocarcinoma arising in a polyp is a significant risk factor for nodal involvement\n * Information on tumor budding is not currently collected", - "last_modified" : "2025-02-24T13:34:57.537Z", + "last_modified" : "2025-11-06T17:54:19.494Z", "definition" : [ { "key" : "tumor_deposits", "name" : "Code", @@ -17,7 +17,7 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "00", "No tumor deposits" ], [ "01-99", "1-99 Tumor deposits (TD) \n(Exact number of TD)" ], [ "X1", "100 or more Tumor Deposits" ], [ "X2", "Tumor Deposits identified, number unknown" ], [ "X8", "Not applicable: Information not collected for this case\n(If this information is required by your standard setter, use of code X8 may result in an edit error.)" ], [ "X9", "Not documented in medical record\nCannot be determined by the pathologist\nPathology report does not mention tumor deposits\nNo surgical resection done\nTumor Deposits not assessed or unknown if assessed" ] ], - "additional_info" : "**Source documents:** surgical pathology report\n\n**Other names include** discontinuous extramural extension, malignant tumor foci, malignant peritumoral deposits, satellite nodule\n\nFor further information, refer to the **Colon and Rectum** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Colon and Rectum*", - "coding_guidelines" : "**Record the number of Tumor Deposits whether or not there are positive lymph nodes**.\n* Do not count involved lymph nodes in this field, only tumor deposits\n\n**1)** **Code 00** when the pathology report states that there are no tumor deposits.\n**2)** **Code 01-99** (for the exact number of tumor deposits reported in the pathology report) \n**3)** **Code X1** for 100 or more tumor deposits.\n**4)** **Code X2** if tumor deposits are mentioned but a number is not reported.\n**5)** **Code X9** when\n * Not documented in medical record\n * No surgical resection done\n * Pathology report not available\n * Surgical resection of the primary site is performed and there is no mention of tumor deposits\n * Tumor deposits not evaluated (not assessed)\n * Unknown if Tumor Deposits evaluated (assessed)", + "additional_info" : "**Source documents:** surgical pathology report\n\n**Other names include** discontinuous extramural extension, malignant tumor foci, malignant peritumoral deposits, satellite nodule\n\nFor further information, refer to the **Colon and Rectum** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Colon and Rectum*.", + "coding_guidelines" : "**Record the number of Tumor Deposits whether or not there are positive lymph nodes**.\n* Do not count involved lymph nodes in this field, only tumor deposits\n\n**1)** **Code 00** when the pathology report states that there are no tumor deposits.\n\n**2)** **Code 01-99** (for the exact number of tumor deposits reported in the pathology report) \n\n**3)** **Code X1** for 100 or more tumor deposits.\n\n**4)** **Code X2** if tumor deposits are mentioned but a number is not reported.\n\n**5)** **Code X9** when\n * Not documented in medical record\n * No surgical resection done\n * Pathology report not available\n * Surgical resection of the primary site is performed and there is no mention of tumor deposits\n * Tumor deposits not evaluated (not assessed)\n * Unknown if Tumor Deposits evaluated (assessed)", "rationale" : "The presence of tumor deposits is a Registry Data Collection Variable in AJCC. It was previously collected as Colon and Rectum CS SSF #4." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/tumor_growth_pattern_31889.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/tumor_growth_pattern_31889.json index 1cd3c7e3e..b65ea4cc6 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/tumor_growth_pattern_31889.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/tumor_growth_pattern_31889.json @@ -6,7 +6,7 @@ "title" : "Tumor Growth Pattern", "description" : "Tumor Growth Pattern refers to the growth pattern of intrahepatic cholangiocarcinoma.\n\nThe tumor growth patterns of intrahepatic cholangiocarcinoma include the mass forming type, the periductal infiltrating type, and a mixed type. \n* **Periductal infiltrating type** (20%): spreads along the duct in a diffuse manner that may be associated with poorer prognosis. This type of cholangiocarcinoma demonstrates a diffuse longitudinal growth pattern along the bile duct. Limited analyses suggest that the diffuse periductal infiltrating type is associated with a poor prognosis.\n* **Mass-forming** (60% of intrahepatic bile duct cases), which grows outward (radially) from the duct and invades the liver parenchyma in a well-defined mass.", "notes" : "**Note:** **Physician Statement** \n* Physician statement of tumor growth pattern can be used to code this data item when no other information is available", - "last_modified" : "2025-02-24T14:41:44.337Z", + "last_modified" : "2025-11-06T18:15:43.046Z", "definition" : [ { "key" : "tumor_growth_pattern", "name" : "Code", @@ -18,6 +18,6 @@ } ], "rows" : [ [ "1", "Mass-forming" ], [ "2", "Periductal infiltrating" ], [ "3", "Mixed mass-forming and periductal infiltrating" ], [ "8", "Not applicable: Information not collected for this case\n(If this information is required by your standard setter, use of code 8 may result in an edit error.)" ], [ "9", "Not documented in medical record\nRadiology and/or pathology report does not mention tumor growth pattern\nCannot be determined by the pathologist\nTumor growth pattern not assessed or unknown if assessed" ] ], "additional_info" : "**Source documents:** radiology, surgery, or pathology report", - "coding_guidelines" : "**Record the specific type of tumor growth pattern.**\n\n**1)** **Code 1** when documentation describes the tumor as mass-forming only\n**2)** **Code 2** when documentation describes the tumor as periductal infiltrating only\n\n**3)** **Code 3** when documentation mentions mixed, mass forming and periductal infiltrating\n\n**4)** **Code 9** when\n* Not documented in the medical record\n* Tumor growth pattern not evaluated (assessed)\n* Unknown if Tumor Growth Pattern evaluated (assessed)", + "coding_guidelines" : "**Record the specific type of tumor growth pattern.**\n\n**1)** **Code 1** when documentation describes the tumor as mass-forming only\n\n**2)** **Code 2** when documentation describes the tumor as periductal infiltrating only\n\n**3)** **Code 3** when documentation mentions mixed, mass forming and periductal infiltrating\n\n**4)** **Code 9** when\n* Not documented in the medical record\n* Tumor growth pattern not evaluated (assessed)\n* Unknown if Tumor Growth Pattern evaluated (assessed)", "rationale" : "Tumor Growth Pattern is a Registry Data Collection Variable in AJCC. This data item was previously collected for Intrahepatic Bile Duct, SSF #10." } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ulceration_5718.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ulceration_5718.json index e54d17a53..23b969edd 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ulceration_5718.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/ulceration_5718.json @@ -4,9 +4,9 @@ "version" : "3.3", "name" : "Ulceration", "title" : "Ulceration", - "description" : "Ulceration, the absence of an intact epidermis overlying the primary melanoma based upon histopathological examination, is a prognostic factor for melanoma of the skin.\n\nUlceration is the formation of a break on the skin or on the surface of an organ. An ulcer forms when the surface cells die and are cast off. Ulcers may be associated with cancer and other diseases. \n\nPrimary tumor ulceration has been shown to be a dominant independent prognostic factor, and if present, changes the pT stage from T1a to T1b, T2a to T2b, etc., depending on the thickness of the tumor.\nThe presence or absence of ulceration must be confirmed on microscopic examination. Melanoma ulceration is defined as the combination of the following features \n* Full-thickness epidermal defect (including absence of stratum corneum and basement membrane)\n* Evidence of reactive changes (i.e., fibrin deposition, neutrophils); and thinning, effacement, or reactive hyperplasia of the surrounding epidermis in the absence of trauma or a recent surgical procedure\n* Ulcerated melanomas typically show invasion through the epidermis, whereas nonulcerated melanomas tend to lift the overlying epidermis", + "description" : "Ulceration, the absence of an intact epidermis overlying the primary melanoma based upon histopathological examination, is a prognostic factor for melanoma of the skin.\n\nUlceration is the formation of a break on the skin or on the surface of an organ. An ulcer forms when the surface cells die and are cast off. Ulcers may be associated with cancer and other diseases. \n\nPrimary tumor ulceration has been shown to be a dominant independent prognostic factor, and if present, changes the pT stage from T1a to T1b, T2a to T2b, etc., depending on the thickness of the tumor. \n\nThe presence or absence of ulceration must be confirmed on microscopic examination. Melanoma ulceration is defined as the combination of the following features \n* Full-thickness epidermal defect (including absence of stratum corneum and basement membrane)\n* Evidence of reactive changes (i.e., fibrin deposition, neutrophils); and thinning, effacement, or reactive hyperplasia of the surrounding epidermis in the absence of trauma or a recent surgical procedure\n* Ulcerated melanomas typically show invasion through the epidermis, whereas nonulcerated melanomas tend to lift the overlying epidermis", "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of microscopically confirmed ulceration (e.g., based on biopsy or surgical resection) can be used to code this data item when no other information is available. \n\n**Note 2:** **Ulceration defined** \n* Melanoma ulceration is the absence of an intact epidermis overlying the primary melanoma based upon microscopic (histopathological) examination.\n* Ulceration can only be confirmed by microscopic examination. Do not use findings from physical exam. \n* It is possible for a patient to present with an ulcerated lesion noted on physical exam, but this is not the same thing as ulceration seen on a microscopic exam", - "last_modified" : "2025-02-24T16:14:08.701Z", + "last_modified" : "2025-11-06T18:45:44.881Z", "definition" : [ { "key" : "ulceration", "name" : "Code", @@ -17,6 +17,6 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "0", "Ulceration not identified/not present" ], [ "1", "Ulceration present" ], [ "8", "Not applicable: Information not collected for this case\n(If this item is required by your standard setter, use of code 8 will result in an edit error.)" ], [ "9", "Not documented in medical record\nCannot be determined by the pathologist\nPathology report does not mention ulceration\nUlceration not assessed or unknown if assessed" ] ], - "additional_info" : "**Source documents:** pathology report\n\nFor further information, refer to the **Melanoma of the Skin** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Melanoma of the Skin*", + "additional_info" : "**Source documents:** pathology report\n\nFor further information, refer to the **Melanoma of the Skin** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Melanoma of the Skin*.", "coding_guidelines" : "**1)** **Code 0** when\n* There is a statement in the pathology report that no ulceration is present\n* All specimens are negative OR one specimen is negative, and the other is unknown\n\n**2)** **Code 1** when \n* Any biopsy (punch, shave, excisional, etc.) or wide excision is positive for ulceration in the presence of an underlying melanoma\n* Ulceration must be caused by an underlying melanoma. \n * Ulceration caused by trauma from a previous procedure should not be coded as positive for this SSDI \n\n**3)** **Code 9** when\n* No information in the medical record\n* Pathology report is not available\n* Ulceration not evaluated (not assessed) \n* Unknown if Ulceration evaluated (assessed)\n* There is microscopic examination and there is no mention of ulceration.\n * This instruction **does** apply to non-invasive neoplasms (behavior /2)" } \ No newline at end of file diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/urethra_prostatic_urethra_30106.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/urethra_prostatic_urethra_30106.json index 8ba3978bd..d0c806404 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/urethra_prostatic_urethra_30106.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/urethra_prostatic_urethra_30106.json @@ -5,8 +5,8 @@ "name" : "Schema Discriminator 1", "title" : "Schema Discriminator 1: Urethra/Prostatic Urethra", "description" : "Urethra (male and female) and prostatic urethra have the same ICD-O topography code (C680). However, for purposes of stage grouping AJCC 8th edition, they each have different definitions for T or primary tumor extension. A schema discriminator is necessary to distinguish between these primary sites so that the appropriate sub(chapter)/schema is used.", - "notes" : "**Note:** **Schema discriminator for C680** \n* A schema discriminator is used to discriminate between urethra (male and female) and prostatic urethra. Code the site in which the tumor arose.\n\n • **Urethra: Male Penile Urethra and Female Urethra (see code 1)**\n * Subsites include Urethra, NOS, Urethral Gland, Cowper gland\n\n • **Urethra: Prostatic Urethra (see code 2)**\n * Subsites include Prostatic urethra, Prostatic utricle", - "last_modified" : "2024-04-30T19:22:02.284Z", + "notes" : "**Note:** **Schema discriminator for C680** \n* A schema discriminator is used to discriminate between urethra (male and female) and prostatic urethra. Code the site in which the tumor arose.\n\n* **Urethra: Male Penile Urethra and Female Urethra (see code 1)** \n\n Subsites include Urethra, NOS, Urethral Gland, Cowper gland\n\n* **Urethra: Prostatic Urethra (see code 2)**\n\n Subsites include Prostatic urethra, Prostatic utricle", + "last_modified" : "2025-11-06T21:25:02.755Z", "definition" : [ { "key" : "discriminator_1", "name" : "Code", diff --git a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/visceral_pleural_invasion_25940.json b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/visceral_pleural_invasion_25940.json index 8e3d84533..897d7d44b 100644 --- a/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/visceral_pleural_invasion_25940.json +++ b/algorithm-eod/src/main/resources/algorithms/eod_public/3.3/tables/visceral_pleural_invasion_25940.json @@ -6,7 +6,7 @@ "title" : "Visceral and Parietal Pleural Invasion", "description" : "Visceral and Parietal Pleural Invasion is defined as invasion beyond the elastic layer or to the surface of the visceral pleura. \n\nInvasion of one or more layers of the pleura covering the lung (visceral pleura), such as invasion beyond the elastic layer of the pleura. The elastic layer may be identified on hematoxylin and eosin (H&E) stains or by special stains looking for the elastic fibers. An elastic stain is not needed in most cases to assess the pleura for invasion, only in those cases where the distinction between PL0 and PL1 is unclear on H&E sections. Elastic stains may also be helpful in cases where the visceral and parietal pleura are adherent, making it difficult to identify the boundary between the visceral pleural surface and the parietal pleura.\n\nVPI is relevant for peripheral lung tumors. The presence of visceral pleural invasion by tumors smaller than 3 cm changes the T category from pT1 to pT2 and increases the stage from IA to IB in patients with no nodal disease or stage IIA to IIB in patients with peribronchial or hilar nodes. Studies have shown that tumors smaller than 3 cm that penetrate beyond the elastic layer of the visceral pleura behave similarly to similar-size tumors that extend to the visceral pleural surface. Visceral pleural invasion should therefore be considered present not only in tumors that extend to the visceral pleural surface, but also in tumors that penetrate beyond the elastic layer of the visceral pleura. Four to six layers of visceral pleura may be described by the pathologist.", "notes" : "**Note 1:** **Physician Statement** \n* Physician statement of Visceral and Parietal Pleural Invasion can be used to code this data item when no other information is available.\n\n**Note 2:** **Criteria for coding** \n* A surgical resection **must** be done to determine if the visceral and/or parietal pleural is involved. \n * *Exception*: In situ tumors (/2) can be coded 0 based on biopsy or surgical resection\n* Do not use imaging findings to code this data item", - "last_modified" : "2025-02-24T15:57:29.559Z", + "last_modified" : "2025-11-05T21:58:39.742Z", "definition" : [ { "key" : "visceral_pleural_invasion", "name" : "Code", @@ -17,7 +17,7 @@ "type" : "DESCRIPTION" } ], "rows" : [ [ "0", "No evidence of visceral pleural invasion identified\nTumor does not completely traverse the elastic layer of the pleura\nStated as PL0\n\nPrimary tumor is in situ\nNon-invasive neoplasm (behavior /2)\nNo evidence of primary tumor" ], [ "4", "Invasion of visceral pleura present, NOS \nStated as PL1 or PL2" ], [ "5", "Tumor invades into or through the parietal pleura OR chest wall\nStated as PL3" ], [ "6", "Tumor extends to pleura, NOS; not stated if visceral or parietal" ], [ "8", "Not applicable: Information not collected for this case\n(If this item is required by your standard setter, use of code 8 will result in an edit error.)" ], [ "9", "Not documented in medical record\nNo surgical resection of primary site is performed\nVisceral Pleural Invasion not assessed or unknown if assessed or cannot be determined" ] ], - "additional_info" : "**Source documents:** pathology report\n\n**Other names include** VPI, PL (number)\n\nFor further information, refer to the **Lung** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Lung*", + "additional_info" : "**Source documents:** pathology report\n\n**Other names include** VPI, PL (number)\n\nFor further information, refer to the **Lung** cancer protocol published by the College of American Pathologists for the AJCC Staging System *Lung*.", "coding_guidelines" : "**1)** Record results of visceral pleural invasion as stated on pathology report. \n* Do not code separate pleural tumor foci or nodules in this field (discontinuous pleural metastasis). \n\n**2)** **Code 0** when \n* No evidence of visceral and parietal pleural invasion or described as PL0\n* Tumor does not penetrate beyond the elastic layer of the visceral pleura \n* Extends to the elastic layer\n* Non-invasive neoplasm (/2) neoplasms (surgical resection not required)\n\n**3)** **Code 4** when\n* Invasion of pleura without specifying visceral or parietal pleura\n* Uncertain whether elastic stain has been performed to identify visceral pleura invasion\n* Pathology report states PL1 or PL2\n\n**4)** **Code 5** when tumor extends to the parietal pleura (classified as T3) or described as PL3\n\n**5)** **Code 9** when \n* No information in the medical record\n* Only FNA performed (A FNA is not adequate to assess pleural layer invasion)\n* Surgical resection of the primary site is performed and there is no mention of visceral and/or parietal pleural invasion\n* Surgical pathology report is not available", "rationale" : "Visceral and Parietal Pleural Invasion (previously called “pleural/elastic layer invasion (PL)”) is a Registry Data Collection Variable for AJCC. This data item was previously collected for Lung, SSF #2." } \ No newline at end of file diff --git a/algorithm-eod/src/test/java/com/imsweb/staging/eod/EodPublicUpdateFromAPI.java b/algorithm-eod/src/test/java/com/imsweb/staging/eod/EodPublicUpdateFromAPI.java index 5085d462e..22eb48328 100644 --- a/algorithm-eod/src/test/java/com/imsweb/staging/eod/EodPublicUpdateFromAPI.java +++ b/algorithm-eod/src/test/java/com/imsweb/staging/eod/EodPublicUpdateFromAPI.java @@ -13,7 +13,7 @@ public class EodPublicUpdateFromAPI { public static void main(String[] args) throws IOException { - UpdaterUtils.update("eod_public", "3.3", new HashSet<>(Collections.singletonList("STAGING")), Paths.get("c:/tmp")); + UpdaterUtils.update("eod_public", "3.3", new HashSet<>(Collections.singletonList("STAGING")), Paths.get("c:/dev/tmp")); } } diff --git a/algorithm-eod/src/test/java/com/imsweb/staging/eod/EodUpdateFromAPI.java b/algorithm-eod/src/test/java/com/imsweb/staging/eod/EodUpdateFromAPI.java index 61b856a79..349e28f16 100644 --- a/algorithm-eod/src/test/java/com/imsweb/staging/eod/EodUpdateFromAPI.java +++ b/algorithm-eod/src/test/java/com/imsweb/staging/eod/EodUpdateFromAPI.java @@ -13,7 +13,7 @@ public class EodUpdateFromAPI { public static void main(String[] args) throws IOException { - UpdaterUtils.update("eod", "3.3", new HashSet<>(Collections.singletonList("STAGING")), Paths.get("c:/tmp")); + UpdaterUtils.update("eod", "3.3", new HashSet<>(Collections.singletonList("STAGING")), Paths.get("c:/dev/tmp")); } }